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1.1 DIABETES: OVERVIEW 
1.1.1 CLASSIFICATION, DIAGNOSIS, AND ETIOLOGY OF DIABETES  
According to the American Diabetes Association, diabetes mellitus is a common and serious 
metabolic condition that is characterised by deficiency in insulin secretion or resistance to insulin 
action or both, resulting in hyperglycaemia.1  The vast majority of cases of diabetes can be 
categorised as type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM): T1DM 
which accounts for 5–10% of all diabetes mellitus, is an absolute deficiency of the insulin secretion 
resulting from autoimmune destruction of the insulin producing cells in the pancreas.1  It usually 
occurs in childhood or adolescence, but can occur at any age and patients require lifelong insulin 
injections in order to control the levels of glucose in their blood for survival.  Patients with 
uncontrolled T1DM may lead to acute and severe hyperglycaemia with ketoacidosis or coma.   
 
In the other, much more prevalent category, T2DM, which represents 90% - 95% of diabetes cases 
worldwide, is a resistance to insulin action and an inadequate compensation in the secretion of 
insulin.1  It usually occurs in adults, but is increasingly seen in children and adolescents 
concordant with the obesity epidemic.  The pancreas generally retains some ability to produce 
insulin, but this is insufficient due to resistance to the actions of insulin in target tissues, including 
skeletal muscle, adipocytes, blood vessels and liver.  Autoimmune destruction of pancreatic β-
cells does not occur and ketoacidosis is rare, thus insulin therapy may not be required.  A chronic 
elevation of inflammatory biomarkers or abnormal cortisol control is also observed in patients with 
T2DM.  In patients with T2DM, treatment initially consists of a diet to assist with weight loss 
and increased physical activity. 
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Less common forms of diabetes include gestational diabetes mellitus (GDM), a condition which 
poses an increased risk for developing T2DM in the next 5–10 years.2  Prediabetes is defined as a 
condition that occurs when a person's blood glucose levels are above normal, thus greatly 
increasing his or her risk for T2DM.1  In addition, pancreatic disease, surgery, infections, and 
drugs or chemicals can predispose to diabetes.1 
 
Diabetes mellitus is diagnosed by individuals demonstrating any one of the following criteria: a 
fasting plasma glucose ≥7.0 mmol/l (126 mg/dl), or 2-h plasma glucose concentration ≥11.1 
mmol/l (200 mg/dl) during an oral glucose tolerance test using 75 g of glucose, or symptoms of 
hyperglycaemia and casual plasma glucose≥11.1 mmol/l (200 mg/dl) or higher.1  Glycated 
haemoglobin (HbA1c) concentration ≥6.5% is recommended as the cut-off point for diagnosing 
diabetes.  However, a HbA1c value ≤ 6.5% does not exclude the diagnosis of diabetes using 
plasma glucose concentrations described above.3  Prediabetes mellitus is diagnosed by the 
presence of a HbA1c of 5.7– 6.4%, fasting plasma glucose of 5.6–6.9 mmol/l, or 2-h post load 
glucose of 7.8 –11.0 mmol/l.1  Notably, despite diagnosed diabetes reaching epidemic levels 
globally, diabetes remains underdiagnosed, in part because often people do not realize they have 
it until they develop complications.  Once diagnosed, an individual’s condition can be monitored 
through self-monitoring plasma glucose concentration, or through routine blood tests carried out 
by his or her medical practitioner.  It is recommended that individuals with diabetes achieve a 
fasting plasma glucose concentration as close to normal as possible (5.5mmol/L), thus a target 
HbA1c of <7.0% is commonly set, and indicates very good long term control of plasma glucose 
concentrations.4  
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It is well recognized that in people with diabetes, cardiovascular disease (CVD) is the primary 
cause of morbidity and mortality.  Ninety percent of people with T2DM are obese or overweight; 
80% have metabolic syndrome (hypertension, dyslipidaemia, visceral obesity and insulin 
resistance).5  Visceral adipose tissue is the center of the pathogenesis of prediabetes and T2DM,6 
thus the global epidemic of obesity contributes to the rising prevalence of T2DM.7  Visceral 
adipose tissue produces adipokines/cytokines, including tumor necrosis factor-α that can directly 
contribute to insulin resistance in muscles, adipocytes, liver, and endothelial cells.8, 9, 10  
Excessive sedentary behaviour/low physical activity level, leading to increased visceral adiposity, 
may also contribute to the pathogenesis of insulin resistance and ultimately the development of 
T2DM.11   
 
Many of these adipokines are considered to be pro-inflammatory, resulting in a state of chronic 
low-grade systemic inflammation within this cohort, which is linked to both insufficient physical 
activity and visceral obesity.12  Systemic inflammation is an independent predictor of all-cause 
mortality, metabolic syndrome, endothelial dysfunction, myopathy, and even depressive symptoms 
and cognitive dysfunction in older adults with diabetes.13, 14  
 
1.1.2 PREVALENCE OF DIABETES MELLITUS 
The increasing prevalence and incidence of T2DM has been referred to as a global epidemic.  In 
2007-2008, almost 898,800 Australians had diabetes, with 87% of those diagnosed with T2DM.5  
Among those with diabetes, 56% were men and 44% were women.5  It is estimated that 3.5 
million Australians will have diabetes by 2025.15  The global burden of diabetes was 110 million 
in 1994 and is estimated to have more than doubled to 239 million by 2015, with 592 million adults 
26 
 
projected to have diabetes worldwide by 2035.16 
 
The ageing of the population is also related to the diabetes epidemic.  The rate of diabetes 
increases with age from 0.3% among those aged 0–34 years to 15.8% of 65–69 year olds.5  This 
is similar to recent data from the American Diabetes Association report where it was estimated 
that in 2012, 12 million, or 21% of Americans over the age of 60 have diabetes (including T1DM), 
representing 54% of the total cases of diabetes amongst all adults within the US.17  
 
Race/ethnicity/geography is related to diabetes mellitus risk.  According to a Diabetes Australia 
report, 12% of Indigenous Australians are affected by diabetes, compared to 4.1% non-Indigenous 
Australians.18  In the USA, nearly 14% of Hispanics and 12% of African Americans are affected 
by diabetes compared with 7% of non-Hispanic whites.19  It is becoming increasingly common 
in the developing world as well.  In many countries in Asia, the Middle East, and the Caribbean, 
diabetes affects 12-20% of the population, compared to 6-10% of Caucasians in North America, 
Australia or Europe.20 
 
1.1.3 THE IMPACT OF DIABETES MELLITUS 
Chronic diabetes, particularly if control is sub-optimal, leads to an increased risk of a myriad of 
complications, as summarised below: 
 
Diabetic retinopathy 
Individuals with diabetes are at increased risk of developing eye disease, and diabetes is the leading 
cause of blindness in the developed world.  Diabetic retinopathy is a condition affecting the blood 
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vessels of the eye, which is reported to affect greater than 15% of individuals with diabetes.21 
 
Diabetic nephropathy  
Chronically, diabetes damages the blood-filtering capillaries in the kidneys.  Diabetic 
nephropathy presents initially as asymptomatic leakage of protein into the urine (microalbuminuria, 
requiring dialysis or organ transplant).  The prevalence of microalbuminuria and 
macroalbuminuria may affect 21.0% and 4.3% of those with diabetes, respectively.22 
 
Peripheral neuropathy and peripheral vascular disease 
Peripheral neuropathy results from damage to the peripheral nerve (sensory nerves of the lower 
limbs) in combination with atherosclerosis or calcification of small blood vessels (peripheral 
arterial disease) in the lower limbs, can lead to the development of ulcers and infections of the 
lower limb, which in extreme cases can lead to amputation.  Diabetes is the leading cause of non-
traumatic lower limb amputation.22  Nerve damage affects the legs and feet of approximately 13% 
of Australians with known diabetes, while the prevalence of poor circulation in the legs and feet is 
almost 14% in those with known diabetes.21  
 
Cardiovascular and cerebrovascular disease and mortality 
Cardiovascular disease is a common and often severe complication of diabetes, and is the primary 
cause of death.  Cardiovascular problems include conditions such as coronary heart disease 
(myocardial ischemia), heart failure, hypertension, and cerebrovascular disease (stroke).23  Major 
cardiovascular events include myocardial infarction and cerebrovascular accidents (stroke).  
Almost 58% of people with known mellitus diabetes had cardiovascular disease in the Australia 
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National Health Survey.23  People with known diabetes and undiagnosed diabetes had an 
increased risk of cardiovascular disease mortality (3 times and 1.6 times than those with 
prediabetes, respectively).  Among all cardiovascular disease deaths within the 5-year follow-up 
period, diabetes and prediabetes contributed to approximately 65% of deaths.23 
 
Psychosocial problems 
Approximately 40% of people with diabetes also report poor psychological well-being with reports 
of anxiety, stress, depression and feeling burned-out from coping with their diabetes.24  
 
Cognitive impairment 
There is a link between cognitive deficits, dementia prevalence and diabetes.  Individuals with 
diabetes have a 1.2- to 1.5-fold greater rate of decline in cognitive function compared to those 
without diabetes.25 
  
Thus, effective target strategies are required to reduce the severity, or prevent the onset of these 
complications within this cohort in order to reduce the substantial societal and personal financial 
burden of comorbidities linked to T2DM.  Total annual cost for T2DM is estimated to be 14.6 
billion within Australian alone.26  The average annual cost of T2DM for a person without 
complications is $4,025; while this rises to $9645 annually per person if both micro- and macro-
vascular complications are present.16  Elevated glycaemic levels increase the risk of developing 
these complications in diabetes and are associated with comorbidity.  Data from The United 
Kingdom Prospective Diabetes Study (UKPDS) showed that improvement of glucose control can 
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greatly reduce the risk of myocardial infarction and stroke.  Reducing HbA1c from 8%, to the 
target of 7% reduced the risk of end stage kidney disease by 40%, macrovascular complications 
by 37%, amputations by 20% and future myocardial infarction risk by 15%.  Thus, there is 
evidence that modification of diabetic complications and long-term morbidity is possible with 
more intensive treatment strategies.   
As noted above, cognitive impairment and dementia are more common in older patients with 
T2DM than in older adults without diabetes.  As one of the growing list of diabetic comorbidities, 
cognitive impairment and dementia in patients with T2DM has generated a great deal of interest.  
An understanding of the mechanisms of cognitive decline and potential treatment modalities in 
this specific population requires further study.  The background information that underlies this 
emerging field is reviewed briefly below. 
 
1.2 COGNITIVE AGEING IN T2DM 
Diabetes mellitus (DM) is a chronic metabolic condition, and a major contributor to cardiovascular 
disease, comorbidity and mortality.  It has become increasingly evident that DM also affects the 
central nervous system in several ways, a complication sometimes referred to as diabetic 
encephalopathy resulting in cognitive impairment and hippocampal neural loss.27, 28  Recently, it 
has been reported that diabetes is associated with mild to moderate impairments of cognitive 
functioning, with lowered performance on tests of speed of information processing, episodic 
memory and, although less consistently, on tests of mental flexibility.29  Epidemiological 
evidence consistently links diabetes with cognitive impairment, higher risk for dementia, and 
increased pathological changes in the central nervous system.30  A recent meta-analysis including 
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patients with neurodegenerative diseases found that diabetes was associated with an increased risk 
of developing dementia.31  A randomised controlled trial (RCT) found that lower levels of HbA1c 
were associated with an decreased risk of developing cognitive impairment in older adults with 
diabetes.32  n addition, a number of common diabetic comorbidities, such as depression, 
cardiovascular, cerebrovascular disease, and chronic inflammation are also risk factors for 
cognitive deficits.33   Furthermore, obesity, which is present in 90% of older adults with T2DM, 
has been associated with cognitive dysfunction.34  Lower muscle mass is also present in both 
diabetes and Alzheimer disease.35   
 
Moreover, prospective cohort studies have shown that higher levels of physical activity are 
associated with lower rates of cognitive decline in women with T2DM.36  Notably, some previous 
studies did not use age as an independent predictor, and the largest effect of T2DM on cognitive 
function were seen in studies in which patients were older.37  As they age, people with T2DM 
develop other related pathologies such as hypertension, atherosclerosis, and macrovascular and 
microvascular disease that produce further cognitive deficits, which become most apparent in later 
life.  For this reason, prevention of cognitive impairment in older adults with T2DM will be one 
of the most important medical challenges in diabetes-related cognitive treatment in the future.  
Many mechanisms have been considered to underlie the association between diabetes and 
cognitive dysfunction.  This chapter provides a focused discussion of potential causative factors 
linking T2DM with cognitive aging: insulin resistance, glucose homeostasis, pro-inflammation 
and anti-inflammation, central adiposity, and sarcopenia.  Indeed, emerging data suggest that all 
these factors may be significantly associated with various forms of cognitive impairment.38 
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1.2.1 INSULIN ACTION AND BRAIN AND COGNITION OF INDIVIDUALS WITH DIABETES MELLITUS  
Hyperglycaemia in diabetes is due to the insufficient action of insulin, and cognitive impairment 
is not only closely associated with hyperglycaemia, but also with the action of insulin.  Insulin 
enters the brain through the blood–brain barrier where it binds with insulin receptors.  In the brain, 
insulin is involved in various neurological processes.  There are a particularly large number of 
insulin receptors in the hippocampus and cerebral cortex, which play a central role in memory.  
Insulin induces the release of β-amyloid peptide (Aβ) in cells to the cell exterior, and also promotes 
the expression of insulin degrading enzyme (IDE).  As IDE also degrades Aβ, if there is lack of 
insulin or resistance to its action, Aβ will accumulate.39, 40  
 
There is evidence that high levels of amyloid are present in Alzheimer’s disease (AD) and are 
associated with cognitive decline in a dose-dependent fashion.  When hyperinsulinaemia or 
insulin-resistance is present, there is a decrease in insulin receptors in the brain and thus less insulin 
is bound to these sites due to down regulation.  Also, as insulin is degraded by IDE, in the 
hyperinsulinaemic state, IDE is consumed and its amount decreases, thus resulting in an increase 
in Aβ.  Therefore, hyperinsulinaemia due to insulin resistance can potentially cause cognitive 
impairment to progress.  In support of this, a cohort study in middle-aged adults reported an 
association between hyperinsulinaemia and cognitive decline.41  Also, in the Hisayama study, 
autopsy findings showed that hyperinsulinaemia and hyperglycaemia as a result of insulin 
resistance were associated with enhanced neritic plaque formation.42  Furthermore, Ronnemaa et 
al.43 reported that a reduction in insulin secretion, not in insulin sensitivity, was associated with 
the onset of AD, suggesting that improvement in both pancreatic function and insulin resistance 
may potentially mitigate the overall cognitive risk in individuals with T2DM.  Thus, insulin 
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seems to be definitely connected with AD pathology via amyloid accumulation.  In addition to 
this amyloid pathway linked to cognitive decline, insulin resistance is a risk factor for vascular 
dementia, as it is associated with atherosclerosis throughout the circulation, manifesting itself as 
cerebrovascular disease, coronary artery disease, and peripheral vascular disease. 
 
1.2.2 GLUCOSE HOMEOSTASIS AND COGNITION OF INDIVIDUALS WITH T2DM 
There is strong evidence from many cross-sectional studies that patients with hyperglycaemia have 
cognitive impairment compared to normoglycaemic individuals.  One prospective longitudinal 
study observed a 0.14-point lower Mini-mental State Examination (MMS) score for each 1% 
higher HbA1c, and reported that hyperglycaemia impaired aspects of cognitive function such as 
psychomotor speed (Digital Symbol Substitution Test [DSST]), memory (Rey Auditory Verbal 
Learning Test) and executive function (Stroop test), suggesting a significant negative association 
between HbA1c level and cognitive function.44  In another study of elderly patients with diabetes, 
baseline HbA1c level was independently related to cognitive impairment as indicated by DSST, 
Stroop test and word recall performance.45  One potential mechanistic link between 
hyperglycaemia and cognitive impairment is advanced products of glycosylation (AGE).  
Elevated AGE levels are present in those with T2DM due to insulin resistance, which reduces the 
ability of the glucose transport system to effectively transport glucose into the cells of the liver and 
muscle, resulting in a high concentration of AGE.  In a hyperglycaemic environment, tissues 
contain increased AGE and up-regulation of its receptor (RAGE) in animal and human with 
diabetes.46, 47  AGE is known to be related to the traditional microvascular complications of 
T2D.48  Increased expression of RAGE is also observed in later stages of AD,49 and expression 
of RAGE is enhanced in blood vessels near Aβ deposits in advanced AD brains.50  
33 
 
Data from the Informatics in Diabetes Education and Telemedicine Study (IDEATel), a randomised 
trial of telemedicine vs. usual care in 2169 elderly persons with T2DM, showed that persons in the 
intervention group, (who had better T2D control parameters compared to usual care), had less 
global cognitive decline during a maximum of 6 years of follow-up.51  This study suggested that 
metabolic control might have beneficial effects on cognitive function.  Yanagawa et al.52 found 
that after 3 months of treatment with exercise, patients experienced a decrease in HbA1c and 
performed significantly better on tests of verbal memory.  Furthermore, a mediation analysis 
demonstrated that better HbA1c, (which is an AGE), was the main mediator for the association 
between improved control and cognitive performance, providing further evidence for the proposed 
mechanism. 
 
1.2.3 ADIPOSITY AND COGNITION OF INDIVIDUALS WITH T2DM  
The centre of the pathogenesis of prediabetes and T2DM is obesity, and in particular, the 
accumulation of central, or visceral adipose tissue.46  The prevalence of T2DM was found to be 
three times higher amongst obese Australians than those of normal weight.53  There is growing 
evidence that obesity, may be an independent predictor of poor neurocognitive outcomes.  It has 
been estimated that if obesity prevalence were reduced by 10% in midlife, the incidence of AD 
would decrease by 25%.54  As obesity is linked in part to behaviours including diet, physical 
activity and sedentary time, there are potentially lifestyle modifications possible which could 
mitigate this risk.   
 
There are three commonly proposed mechanistic links between excess adiposity and cognitive 
impairment.  First, an increased production of adipokines/cytokines, including tumour necrosis 
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factor-α (TNF- α), may directly contribute to cognitive decline.  Second, the sustained exposure 
of the liver to an increased flux of free fatty acids via the portal circulation from visceral adipose 
tissue may be antecedent to the disturbances in glucose and lipid metabolism.  Given that HbA1c, 
fasting hyperglycaemia, and dyslipidaemia have also been shown to predict cognitive decline, 
reduction in these metabolic parameters may potentially mitigate the overall cognitive risk in 
individuals with T2DM.  Third, deposition of ectopic fat may promote peripheral insulin 
resistance.  This deposition occurs predominantly in the liver, but can also be present within 
skeletal muscle, the largest reservoir for glucose disposal, disrupting insulin-mediated glucose 
transport and exacerbating hyperglycaemia.  Figure 1.1 provides a model of how excessive 
sedentary behaviour/low physical activity level, leading to increased visceral adiposity could result 
in the pathogenesis of insulin resistance and the development of T2DM.  Cytokines secreted from 
visceral adipose tissue (adipokines) have been causally linked to the development of insulin 
resistance within skeletal muscle, adipocytes, hepatocytes, and endothelial cells44, 55, 56 and diabetic 
comorbidities including hypertension, cardiovascular disease and metabolic syndrome,57 which 
are all known to have important roles in cognitive decline.  Adipokines have both 
proinflammatory and antiinflammatory properties including adiponectin, leptin, resistin, as well 
as pro-inflammatory cytokines like TNFα. and Interlukin-6 (IL-6).58  Higher adiponectin levels 
have been associated with better cognitive performance in older individuals.38 
 
Pro-inflammatory cytokines result in a state of chronic low-grade systemic inflammation.12, 59  
Systemic inflammation is thought to be an independent predictor of cognitive impairment, AD, 
and vascular dementia.  However, it has a causal link to cerebrovascular disease in older adults, 
as well as to insulin resistance,60-62 which suggests it may be partially involved in the cerebral 
35 
 
atherosclerosis brain neuropathology, as well as accelerating its progression, thus worsening 
cognitive function.63  Higher levels of C-reactive protein (CRP), a marker of low-grade systemic 
inflammation, have been shown to predict cardiovascular disease and insulin resistance in 
individuals with or without T2DM.61  Patients with T2DM with elevated levels of systemic 
inflammatory markers, like CRP, are more likely to exhibit cognitive dysfunction.64  Longitudinal 
studies have shown that elevated baseline CRP levels are associated with decreased cognition and 
executive function over time.65  In a prospective study of individuals with T2DM, those with a 
high concentration of CRP (>3mg/L) had a higher relative risk of cognitive decline and developing 
cardiovascular disease compared to those with a low concentration of CRP (≤3mg/L) over 7 
years.61, 64  Importantly, CRP concentration has been shown to predict cognitive impairment and 
CVD mortality independently from diabetes and insulin resistance.66  Given that HbA1c66 and 
fasting hyperglycaemia67 have also been shown to predict cognition and CVD mortality within this 
cohort, reduction in both inflammation and glycaemic parameters may potentially mitigate the 
overall cardiovascular risk and cognitive function in individuals with T2DM.  In light of the 
adverse effects of excessive and visceral deposition of adipose tissue on insulin resistance and 
systemic inflammation, effective treatment strategies that reduce adiposity may potentially reduce 
cognitive impairment risk within this vulnerable cohort.  Such an improvement in risk factor 
profile would be predicted to reduce cognitive decline, dementia incidence, other comorbidity, and 
mortality itself, although this hypothesis requires confirmation in long term, prospective trials of 
high-risk individuals.   
 
One of the most important anti-inflammatory adipokines is adiponectin.  Adiponectin is a 
hormone, almost exclusively secreted by adipose tissue, which regulates insulin sensitivity, 
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glucose homeostasis, fatty acid catabolism, the immune system, and has potent anti-inflammatory 
properties effects by inhibiting the expression of IL-6 or TNFα.68, 69  Reduction in circulating 
adiponectin levels has been implicated in the development of insulin resistance syndrome, visceral 
obesity, and elevated levels of TNF-a and IL-6.69-73  In addition, adiponectin also has important 
roles in obesity-related insulin resistance, cardiovascular disease, T2DM, and also 
neurodegenerative disorders.74   
 
It has been suggested that there is a link between adiponectin and cognition, such that if 
adiponectin were increased, cognitive function would be improved.  In a small clinical sample of 
patients with AD, mild cognitive impairment (MCI) and controls, low adiponectin levels were 
significantly associated with cognitive impairment in individuals with MCI and AD as compared 
to elderly controls.38  In a population-based study, higher levels of adiponectin in dementia-free 
individuals were an independent predictor of the risk of all-cause dementia and AD, particularly 
in older adults.75  Animal studies have also shown that higher adiponectin expression is another 
mechanism of neuroprotection again amyloid-beta neurotoxicity in AD.76  Adiponectin 
modulates amyloid β in AD and so improves cognition.  Previous studies demonstrate that the 
insulin sensitizing action of adiponectin may be another mechanism of neuroprotection in AD.77-
79  Thus, adiponectin may be a promising therapeutic target to alleviate neurodegenerative 
pathways related to neurotoxicity or insulin resistance in the brain. 
 
1.2.4 SKELETAL MUSCLE MASS AND COGNITION OF INDIVIDUALS WITH T2DM 
Both sarcopenia and T2DM have been identified as important risk factors for poor cognitive 
function among older adults.  White matter lesions and cerebral atrophy have been found to be 
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more common in adults with T2DM,80, 81 and hyperglycaemia and insulin resistance have been 
shown to predict poor performance on executive function and memory.82, 83  It has also been 
reported that low muscle mass may be linked to cognitive performance.  One study found an 
association between low muscle mass and poorer cognition.84  Other studies have also reported 
loss of muscle quality (higher intramuscular lipid) is independently associated with worse 
cognitive function.85  Additionally, higher muscle mass is associated with a 43% decreased risk 
of AD.35  Given the increased prevalence of T2DM amongst older adults, it is important to 
consider the role of sarcopenia in the development and progression of T2DM with age.  Skeletal 
muscle is responsible for 85% of glucose uptake during a hyperinsulinaemic/euglycaemic clamp, 
and as such, is the largest depot for glucose storage available.86  Given that HbA1c and fasting 
hyperglycaemia44 have also been shown to predict cognitive decline and dementia within this 
cohort, increase in muscle mass may potentially mitigate the overall cognitive risk mediated 
through these metabolic parameters in individuals with T2DM via increased capacity for glucose 
disposal.  Ageing is associated with a loss of skeletal muscle,87, 88 potentially contributing to the 
risk for T2DM,89, 90 separate from that attributable to obesity.91  Sarcopenia, defined by some 
investigators as having skeletal muscle mass 2.5 standard deviations below that of a healthy, 
gender-matched cohort,90, 92 has been shown to be independently associated with insulin resistance 
in individuals with and without T2DM.90, 93-95 
 
In addition to the age-related loss of skeletal muscle mass, it has been suggested that systemic 
inflammation may accelerate this process,96 while insulin resistance within skeletal muscle has 
also been proposed to contribute to anabolic resistance within skeletal muscle.97  Thus, the 
presence of T2DM can accelerate the age-related loss of skeletal muscle mass.  Not only can this 
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reduction in skeletal muscle mass result in reduced capacity for storage of glucose, reductions in 
skeletal muscle mass can impose physical limitations, further reducing physical activity levels, 
contributing to frailty and mobility impairment, all of which will ultimately decrease energy 
expenditure and thereby increase adiposity.  This excess adiposity may lead to further cytokine-
mediated muscle wasting, disrupt endothelial functioning, and impact atherosclerosis.  Insulin 
resistance with obesity may prompt an increase in β-amyloid in the brain,98 which is considered 
one of the earliest detectable signs of AD and is associated with cognitive decline, 
neurodegeneration, and synaptic dysfunction.99  Thus, the development of a vicious cycle of body 
composition shifts contributing to diabetes onset and progression can be observed.100  Breaking of 
this vicious cycle is necessary to appropriately address all components contributing to cognitive 
decline in older adults with T2DM. 
 
1.2.5 VASCULAR DISEASE AND COGNITION OF INDIVIDUALS WITH T2DM 
A large number of studies have shown that macrovascular risk factors, such as elevated total and 
low-density lipoprotein cholesterol, hypertension, and atherosclerosis, are associated with 
cognitive impairment and risk of dementia.101,102,103  Moreover, there are also a large number of 
prospective studies showing that macrovascular risk factors, such as atherosclerosis, 
hyperlipidemia, and hypertension, are associated specifically with development of AD.104, 105 
There is also evidence supporting a role of microvascular disease, such as retinal microvascular 
abnormalities, on risk of cognitive impairment and dementia.106  As patients with diabetes are 
more likely to have atherosclerosis, stroke, hyperlipidemia, hypertension, and retinopathy, 
individuals with diabetes is plausible that in patients with diabetes both of these sets of risk factors 
play a role in the development of dementia, with a resultant increased incidence of dementia in 
39 
 
diabetes.   
Diabetes alters cerebral microvascular structure in a number of ways.  Findings from animal 
models suggest that in uncontrolled diabetes, there are focal changes in the thickness of vascular 
basement membranes and calcium deposits in the microvessel walls.107  Several lines of evidence 
indicate that cerebral microvascular disease increases the risk of AD, 108 and findings from 
pathology studies indicate that cerebral microcirculation and microvessel are affected in AD.109  
More specifically, AD involves cerebral arteriolar narrowing, endothelial cell dysfunction, 
capillary microaneurysms, and breakdown of the blood-brain barrier.110  Although several studies 
have found associations between cerebrovascular risk factors and cognitive functioning,111 only 
one study has examined microvascular risk factors and cognitive functioning.  Also, an 
association between cognitive impairment and retinal microvascular abnormalities or chronic 
kidney disease has been reported in patients without diabetes,108 and it primarily involved cerebral 
small vessel disease.  More specifically, retinal and cerebral small vessels are considered to have 
a similar embryological origin and structures, and share common physiological characteristics, and 
it is thought that damage to retinal and cerebral small vessels as a result of ischemia and so on 
leads to decline in a cognitive function.  In middle-aged adults, those with retinopathy or kidney 
disease, including microaneurysms, retinal haemorrhage, and had significantly lower mean 
cognitive scores as well as a greater risk of cognitive impairment.106   Furthermore, the vascular 
bed of the kidney and cerebral small vessels are structurally similar, and disorders of blood flow 
or shear stress as a result of hypertension and so on cause damage to both the brain and kidney, 
showing the brain and the kidney connection.110  Therefore, in cognitive impairment occurring 
when there are retinal abnormalities and kidney disease, there is more likely to be impairment of 
executive function and processing speed, which stem from cerebrovascular disorders, than memory.  
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Regarding neuropathy, it is thought that nerve sheaths in the brain are damaged by a similar 
mechanism to the one for peripheral neuropathy, and that this leads to a decline in cognitive 
function.  In this connection, it has been suggested that increased activity of the polyol pathway 
and abnormal myo-inositol metabolism, which are closely associated with the development of 
diabetic neuropathy, could alter glucose metabolism in the frontal lobe, as mentioned previously, 
resulting in cognitive impairment.112, 113  Regarding decline in cognitive function, it is important 
to consider the association with cerebral small vessel disease.  Types of cerebral small vessel 
disease usually seen on brain MRI are silent brain infarction, white matter lesions and microbleeds, 
and all of them are reportedly related to cognitive dysfunction.114  Among these, silent brain 
infarction has been found to be more prevalent in diabetes than in non-diabetes.115  Other research 
has shown that the presence, severity and progression of cerebral small vessel disease were 
associated with cognitive impairment in elderly patients with diabetes.116  An association was 
observed between cerebral small vessel disease and frontal lobe impairment, the latter assumed to 
be a result of damage to the prefrontal loop caused by silent brain infarction in the thalamus, and 
deep and periventricular white matter lesions.  Patients with diabetes have a high incidence of 
silent brain infarction in the thalamus and basal ganglia.117 
In general, hypertension plays a major role in the onset of cerebral small vessel disease, but 
hyperglycaemia is also considered aetiologic.  Hyperglycaemia damages the endothelium of 
brain microvessel, resulting in disruption of the blood–brain barrier, which in turn leads to cerebral 
small vessel disease.116  An association between vascular endothelial function and cerebral small 
vessel disease, white matter lesion, and silent brain infarction has been reported, as well as an 
association between a rise in serum levels of intercellular adhesion molecule-1 and a decline in 
cognition.118 
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1.2.6 PHYSICAL PERFORMANCE AND COGNITIVE FUNCTION OF INDIVIDUALS WITH T2DM  
It has been reported that poorer physical performance is related to cognition among community-
dwelling older adults.  Many studies have shown that physical performance, such as 6-minute 
walk distance, muscle strength, balance, habitual gait velocity, and chair stand capacity, are 
associated with cognitive function.35, 119-124  Moreover, there are also a large number of 
prospective studies showing that physical performance, such as balance, mobility, and muscle 
strength, are associated with cognitive impairment and development of AD.121 122, 125, 126  In 
addition, several previous studies have indicated that aspects of physical performance, such as gait 
dysfunction,119,120 reduced postural stability,121 and decline in cardiorespiratory fitness,127 are 
related to structural changes of the brain (e.g., leukoaraiosis, medial temporal lobe atrophy,128  and 
whole-brain volume decline127 in older people.  In addition, a prospective, observational cohort 
study indicated that muscle weakness was associated with an increased risk of developing AD and 
MCI.35, 129 
 
Diabetes and its common complication, peripheral neuropathy, may result in balance impairment, 
reduced mobility capacity, and alternations in gait characteristics.  Patients with diabetes and 
peripheral neuropathy have lower gait velocity, decreased cadence, shorter stride length, increased 
stance time and higher step to step variability compared to healthy individuals in controls.130, 131  
One study found that among younger healthy subjects with T2DM, balance was a predictor of 
global cognitive function and executive function.132  A higher six minute walk distance and gait 
speed have been shown to be an independent predictors of cognition.124  It has been argued that 
a higher gait speed and exercise capacity increases the cerebral blood flow especially in the 
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prefrontal cortex, a brain region that plays a crucial role in executive functions.133  In addition, 
high physical fitness has been shown to be an independent predictor of cognitive and physical 
performance.134  These factors could explain why cognition has been related to habitual gait 
speed, six minute walk distance, and balance. 
 
1.2.7 CLINICAL IMPLICATIONS 
A growing body of research indicates that diabetes-related risk factors pose substantial threats to 
physical health.  Insulin resistance, hyperglycemia, inflammation, obesity, physical inactivity, 
depression, loss of skeletal muscle mass, and worse physical performance may increase risk for 
cognitive decline as well as other comorbidities in older adults with T2DM.  Although advancing 
age is still the most prominent risk factor for cognitive decline and dementia, the escalating 
prevalence of obesity, insulin resistance (including frank diabetes), inflammation, sarcopenia and 
functional problems could create a scenario in which the burden of late-life cognitive disorders 
would actually be far greater than that which would be anticipated by virtue of the demographic 
shifts alone.  Fortunately, these diabetes-related risk factors are potentially modifiable.  Regular 
physical activity and healthy diet promote insulin sensitivity; reduce hyperinsulinaemia, and lower 
levels of inflammatory markers.135  Finally, a more healthful body composition profile has been 
reported to reduce insulin resistance and inflammation.136  Thus, a strategy of decreasing 
adiposity and increasing muscle mass in middle-aged and older adults should be considered the 
cornerstone of diabetes prevention. 
 
Critical to these prevention strategies is the development of a theoretically-grounded exercise 
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intervention that targets the diabetes-related biology outlined above, and thereby potentially offers 
either enhancement or protection of late-life cognitive function in this cohort.   
 
1.3 PHYSICAL ACTIVITY AND T2DM 
Prevention is the best approach to the global epidemic of T2DM.  A healthy lifestyle is 
encouraged to address the issue of obesity, metabolism, and inactivity, and thus reduce or delay 
the incidence of T2DM.  Dietary modifications to reduce total calorie intake and lower glycemic 
load, and increase in physical activity and decrease in sedentary behavior will help to improve 
energy balance, glucose control, as well as weight loss and maintenance.  Many systematic 
reviews and meta-analyses reporting lifestyle interventions and prevention of diabetes have been 
published.137, 138  Diabetes prevention programs have been implemented around the world with 
marked success.  For example, the Diabetes Prevention Program,139 the Finnish Diabetes 
Prevention Study,140 the Indian Diabetes Prevention Programme,141  the Da Qing study in 
China,142 the Vasterbotten Intervention Programme,143 the Asti Diabetes Prevention Program,144 
and the Japanese Diabetes Prevention Programme,145 all significantly reduced the incidence of 
T2DM in high risk cohorts through lifestyle modification.  These lifestyles enhanced insulin 
sensitivity and reduced blood levels of inflammatory markers, such as CRP and IL-6, in persons 
at high risk for the development of T2DM   In particular, one study using lifestyle modification139 
showed that persons with prediabetes were able to restore normal glucose homeostasis without 
medication.  However, in addition to prevention of T2DM, lifestyle modification is required to 
improve glucose control of individuals with T2DM, in order to lower the incidence and severity 
of diabetes complications.  When medications such as oral hypoglycemia or insulin are used to 
control T2DM, lifestyle improvements should always be continued as complementary treatment.  
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In support of this, physical activity has been shown to improve glycaemic control, improve insulin 
sensitivity, decrease adiposity, reduce inflammation, reduce blood pressure, reduce blood lipids,146 
and increase muscle mass and functional performance when added to usual pharmacotherapies in 
T2DM.  Numerous systematic reviews document the significant role of physical activity on 
improvements in glycaemic control.147, 148  Glycaemic benefits are of the same order of magnitude 
as oral hypoglycaemic drugs, as long as the physical activity interventions have been prescribed 
under supervision.149  Furthermore, physical activity has a clinically important effect on other 
chronic diseases in older adults such as depression,150, 151 cognitive function, 152 osteoarthritis,153 
osteopenia/osteoporosis,154 physical frailty,155 etc.  Each one of these conditions is associated 
with increased blood levels of inflammatory markers and imposes its own limitations to exercise 
capacity and habitual levels of physical activity.  Thus, the use of physical activity in the 
treatment of obesity and T2DM is multi-factorial in both its rationale and clinical utility156, 157  The 
appropriate prescriptions for physical activity can improve body composition and metabolic health, 
as well as diabetes-related complications associated with ageing, making it a much more potent 
therapy than any medication alone.  Thus, these health outcomes of physical activity emerge as a 
key component in the management of T2DM, a view that has been supported by many professional 
bodies, including position stands from the Exercise Sport Science Australia (ESSA),158 and 
American College of Sports Medicine (ACSM) and the American Diabetes Association,159 among 
others. 
 
1.4 GENERAL GUIDELINES FOR PHYSICAL ACTIVITY IN T2DM 
For many years, aerobic exercise has been considered a cornerstone of diabetes management, along 
with progressive resistance training, as a means to improve glucose control, and thus minimise 
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diabetic complications, morbidity and mortality.  A summary of these exercise guidelines can be 
found in Table 1.1.  The ACSM/ADA guidelines160 suggest a minimum 150 min of moderate-
intensity aerobic activity, ideally 3 days of the week at a moderate intensity (40-60% of VO2max).  
Individuals with T2DM are also recommended to participate in progressive resistance training 
(PRT) on 2 or 3 non-consecutive days per week.  A moderate to high intensity is suggested from 
50% or 80% of the one repetition maximum (1RM).  Each training session should minimally 
include 5–10 exercises involving the major muscle groups (in the upper body, lower body, and 
core) and involve completion of 10–15 repetitions to near fatigue per set early in training.  Both 
aerobic and resistance training improve insulin action, at least acutely, and can assist with the 
management of glucose levels.  Current guidelines, however, do not yet focus on the potential 
role of exercise for the prevention or treatment of cognitive decline in this cohort.  Given the 
major risk for cognitive decline imposed by diabetes (as reviewed above), this is an area requiring 
further empirical study and clinical application.  The rationale for the use of exercise to improve 
cognition in this cohort is outlined in the sections that follow. 
 
1.5 THE COGNITIVE ADAPTATION TO EXERCISE 
1.5.1 ANIMAL STUDIES 
Research using animal models of exercise training have demonstrated clear beneficial effects on 
cognitive function.  Daily wheel (voluntary) running and forced graded increased exercise 
improved memory performance in mice.161  Rats participating in mentally and physically 
stimulating activities had greater effects on memory compared to either physical or cognitive 
activity alone or sedentary controls rats162  Furthermore, aerobic training has been shown to 
counteract age-related cognitive decline on tasks involving memory and learning compared to 
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sedentary control rats.163  Similar improvements in memory performance occurred after 5 days 
of wheel running164 and 4 weeks of treadmill running in mice.165  Chronic aerobic exercise 
maintained cognitive function in mice exposed to stress induced by cortisone administration or 
immobilisation.166  Finally, animal trials indicated that exercise may improve brain function 
directly through the induction and regulation of neurotrophins, transmitters, vasculature, and/or 
indirectly via the modulation of systemic inflammation.167 
 
1.5.2 HUMAN STUDIES 
Many cross-sectional studies in humans suggest that more physically active individuals have 
decreased cognitive impairment and risk of dementia prevalence and/or incidence.168-169, 170  For 
example, individuals participating in light exercise interventions had a reduced odds ratio for all-
cause and AD compared to those reporting no activity.171  Cognitive decline was more prevalent 
in those reporting no activity versus moderate and high physical exercise in a community-based 
study of persons over 55 years.172  Moreover, higher self-reported activity levels at mid- and late-
life were associated with a reduced odds ratio for mild cognitive impairment (MCI) in late life, 
and physical activity levels at various points across the lifespan (teenage, age 30, age 50, and age 
>65) were associated with reduced risk of cognitive impairment in older adults.173, 174  Self-
reported history of high-intensity exercise was associated with better cognitive performance in 
those over 80 years, but worse cognitive performance in postmenopausal women.175,176  Moderate 
activity levels, however, were correlated with better cognitive performance in postmenopausal 
women.176  Older (>60 years) marathon runners and bicyclists performed better than inactive 
controls on one cognitive task—the Five Point Test—of the Vienna Neurophysiological and 
CERAD Test Batteries.177  A recent meta-analysis of 16 prospective studies including patients 
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with neurodegenerative diseases found that higher physical activity was associated with a 28% 
reduction in incident dementia.178  Frequent exercisers (>3/per week) have been reported to 
exhibit stable or improved cognitive health over 5 years.179  It has been estimated from 
prospective cohort studies such as these that reducing inactivity by 25% would prevent 1 million 
cases of dementia worldwide.180 
 
Experimental trials also indicate that increased physical activity may be associated with better 
cognitive performance, although the average effect size (ES) observed is generally small and there 
is a wide range of ESs for individual studies.  Exercise interventions of as little as one week of 
aerobic exercise can result in improved memory, attention, and reaction time.181  Sustained 
improvements, particularly in executive function, have been shown after aerobic training (ES = 
0.41), combined aerobic and resistance training (ES = 0.59), and resistance training alone (ES = 
0.53), even after exercise was withdrawn in some cases.182 
 
The consistency of the epidemiological literature is not matched by the outcomes of clinical trials 
of exercise and cognition.  This may be explained in part by unmeasured factors differentiating 
physically active and inactive individuals which may underlie some of the cognitive differences 
observed.183  Moreover, one area of difficulty in this literature is the lack of consistency in 
outcome variables measured (i.e., cognitive performance, dementia development, AD risk or 
mortality) and measurement techniques (e.g., cognitive test battery used, criteria for dementia or 
cognitive impairment).  Such differences make it difficult to compare studies and draw firm 
conclusions.  In addition, rigorous clinical trials investigating the central and peripheral 
synergistic benefits of exercise for improved cognitive function in older obese individuals with 
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T2DM or hyperglycaemia or insulin resistance are lacking.114 Existing data will be reviewed in 
Chapter 3.  Unfortunately the largest and longest trial of lifestyle modification in T2DM to date 
the LOOKAHEAD Study)184 did not measure cognitive function at baseline, and did not find 
differences in cognition cross-sectionally at follow-up. 
 
1.6 PROGRESSIVE RESISTANCE TRAINING: AN INTERVENTION POTENTIALLY 
BENEFICIAL FOR BOTH T2DM AND COGNITIVE DECLINE 
Progressive resistance training (PRT) is a unique approach to the treatment of T2DM and metabolic 
syndrome.  This is an anabolic form of exercise, differing substantially from aerobic exercise in 
its ability to induce muscle hypertrophy and associated metabolic and functional changes.147, 185, 
186  Resistance training directly targets the underlying pathophysiology of metabolic syndrome: 
visceral obesity and insufficient skeletal muscle activity, thus dually enhancing insulin sensitivity.  
Given the role of insulin in the brain, disturbances in insulin could negatively affect cognitive 
function.  It has been shown in randomised controlled trials to improve insulin sensitivity, glucose 
homeostasis, blood pressure, dyslipidaemia, markers of inflammation, adiponectin, and catabolism, 
and visceral obesity, thus addressing all of the components of metabolic syndrome in T2DM,187,188, 
189,190,191, 192, 193 those of which when compromised may threaten cognitive integrity.194, 195,196  
Resistance training also improves aerobic capacity, disability, depression, functional status, and 
gait and balance impairments, thus addressing a large spectrum disorders which may all potentially 
translate into better cognitive function in older T2DM.191  Resistance training also specifically 
targets type II muscle fibres associated with age-related sarcopenia, and increases neural 
recruitment,97, 197 a high priority in the context of the negative impact of diabetes on peripheral and 
autonomic nerves, as well as cognitive function.198  This theoretical benefit of PRT on cognition 
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has been studied empirically, although not nearly as extensively as aerobic training.  Resistance 
training has been shown to positively influence executive function, and particularly inhibitory 
capacity.199  Similarly, other studies found that PRT contributed to better cognitive function, using 
the Trail Making Test measure of cognition, in community-dwelling cohorts of older adults.200, 201  
A systematic review indicated that PRT was effective in improving cognition in older adults.202  
A higher intensity and longer intervention duration of resistance training appeared most beneficial, 
but these, along with training frequency, were parameters that required further investigation in 
specifically-designed dose-response trials.202  Notably, high intensity PRT is often feasible even 
when robust aerobic exercise is difficult or impossible due to osteoarthritis, making it particularly 
suitable for the obese elderly individual with diabetes.157  Increasing evidence indicates that PRT 
is a safe and effective intervention that promotes positive effects on metabolic and vascular health 
in T2DM.157  Given the multiple pathways by which PRT may potentially benefit brain 
metabolism and function, there is a need for robust research on the effect of PRT on cognition in 
older adults with T2DM.  Importantly, investigation into the relationships between potential 
mediators (improved body composition, metabolic health, systemic inflammation, adiponectin, 
exercise capacity, and functional performance), and changes in cognitive function following PRT 
in individuals with T2DM is warranted.   
 
1.7 RATIONALE FOR THIS THESIS 
There is strong evidence for a PRT intervention for prevention and management of T2DM; 
however, to date, only two randomised controlled trials investigating the efficacy of PRT 
exclusively within older adults (>60 years) have been published.189, 190  Other published 
investigations, while including older adults, also included middle-aged adults.187-189  The benefits 
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documented in these PRT trials have included improved glycaemic control and insulin resistance, 
systematic inflammation, visceral adiposity, adiponectin, muscle mass, functional performance, 
quality of life, and depressive sympotoms.147, 149, 186-190, 192, 203-206  Much less consideration has 
been given to alterations in cognition after exercise, or factors which may underlie cognitive 
benefits.  Thus, investigations in older adults into the role of PRT on cognition itself, as well as 
in the relationships between modifications in body composition (increases in skeletal muscle mass 
and reductions in adipose tissue), insulin resistance, glycaemic control, systemic inflammation, 
adiponectin, exercise capacity, functional performance, quality of life, depressive symptoms, and 
the effects of these modifications on cognition are warranted.   
 
Among the above exercise-related adaptations, a reduction in visceral adipose tissue (as opposed 
to overall adiposity) has now become a primary target in the management of T2DM.  Such an 
adaptation, which has been thought to underlie much of the improvement in insulin resistance, 
glycaemic control and systemic inflammation after PRT, would theoretically improve cognition as 
well.  Furthermore, increases in skeletal muscle mass after PRT has been shown to improve 
insulin resistance, glycaemic control, systemic inflammation and oxidative stress,96, 129, 207 which 
are all important abnormalities in T2DM that have been associated with a risk of cognitive 
decline.208, 209  As noted earlier, other cross-sectional reports have confirmed that increased the 
muscle mass is associated with a decreased risk of developing AD.35  Thus, PRT has the potential 
to address both of the body composition factors linked to cognition (obesity and sarcopenia), 
making it unique among exercise modalities in this regard. 
 
Diabetes increases the risk of disability and accelerates decline in both physical and cognitive 
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function.  While epidemiologic data suggest that changing these variables can influence health 
and function achieved via lifestyle intervention, experimental data also strongly suggest that 
increased physical activity may contribute to the observed cognitive benefits even when weight 
loss did not occur.  The long-term effects of PRT alone on cognitive function have never been 
evaluated for an at-risk group of older adults with diabetes mellitus, hyperglycaemia or insulin 
resistance.  Also there is no data available within a single cohort on PRT-related modifications in 
body composition (increases in skeletal muscle mass and reductions in adipose tissue), insulin 
resistance, glycaemic control, systemic inflammation, and adiponectin, allowing simultaneous 
exploration of multiple putative mechanisms linking PRT with changes in cognitive function.  
Finally, there is no prior study that has investigated a specific variant of PRT called power training 
(high velocity, high intensity PRT) for its effects on metabolic health, body composition and 
cognition.  Theoretically, power training (POWER) best addresses the selective loss of Type II 
fast twitch fibres that typify skeletal muscle ageing and the profound loss of muscle power 
observed in older adults.97, 210  This loss of muscle power has been linked to functional 
impairment to an even greater extent than losses of muscle strength,211 thus underscoring its 
potential utility of power training in this cohort which is at high risk for functional decline from 
both physical and cognitive deficits. 
 
Given the high prevalence of obesity and diabetes in older adults, there is a clear public health 
imperative to understand the cognitive implications of treatment of this cohort via physical 
exercise.  Our Graded Resistance Exercise And Type 2 Diabetes in Older adults (GREAT2DO) 
study randomized 103 participants with T2DM (men and women, over 60 years old).  The 
intervention group performed high intensity power training (high velocity, high intensity resistance 
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training) 3 times/week for 12 months, and the control group performed low intensity, non-
progressive resistance training (SHAM exercise) for the same duration and frequency.  The aims 
of this GREAT2DO sub-study were to identify cognitive adaptations to exercise training in adults 
with T2DM or impaired glucose tolerance, and to assess the relationship cognition and insulin 
resistance, glucose control, systematic inflammation, adiponectin, abdominal adiposity, and 
muscle mass, and capacity and function following a 12-month high intensity power training in 
older adults with T2DM. 
 
1.8 OUTLINE OF THESIS 
The present chapter provides an introduction to the diagnosis, aetiology, prevalence, and clinical 
presentation of T2DM, as a background to the current problem of increased risk for cognitive 
impairment in patients with T2DM.  It discusses the current intervention treatment guidelines for 
T2DM, potential mechanisms of cognitive impairment in T2DM, role of exercise in both diabetes 
and cognition, and presents the specific rationale for a particular kind of exercise, power training, 
which targets many of the putative pathways elevating the risk of cognitive impairment in T2DM.  
The notable gap in the literature with respect to the evidence that PRT or POWER training will 
benefit cognition in T2DM, and if so, what mechanisms underlie this benefit, is outlined.  
Chapters Two to Three are systematic reviews of literature that were undertaken at the 
commencement of this project in order to establish an understanding of the current evidence for 
any exercise modality for cognitive function in both animal models and human subjects with 
diabetes.  The first review, Chapter Two is a review of RCTs and NRCTs that have examined the 
effect of any exercise modality on cerebral morphology, biochemistry, and function in animal 
models with diabetes, IGT or insulin resistance.  This review using animal models investigates 
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whether improvements in cognitive function following exercise interventions were related to 
concomitant changes in brain structure and biochemistry to provide insight into the possible 
cellular and molecular mechanisms that underlie the effects of physical activity on cognitive 
function for our own studies. 
 
Chapter Three is a review of RCTs, NRCTs and observational studies that have investigated the 
effect of any form of exercise on cognitive function in older adults with T2DM, IGT or insulin 
resistance.  This review compared the evidence for current aerobic exercise treatment guidelines 
to the evidence for alternative modes of exercise for cognitive improvements in this cohort, and 
identified gaps in existing literature, and defines the context within which to view our results. 
 
Chapter Four presents the rationale and methodology of our RCT of POWER training designed as 
treatment for metabolic health and comorbidities including cognitive function entitled 
GREAT2DO.  Cognitive function was one of the pre-specified secondary outcomes of this trial.   
Our methodology is presented for the investigations of the baseline body composition, metabolism, 
systemic inflammation, adiponectin, exercise capacity, functional performance, quality of life, 
depressive symptoms, and cognitive function, as well as adaptations of these characteristics to a 
12-month exercise intervention in the older adults with T2DM enrolled in our clinical trial 
GREAT2DO. 
 
Chapter Five presents baseline characteristics of the cohort, as well as analyses of the relationships 
among body composition, the metabolism, exercise capacity, physical performance, and cognitive 
function of older adults with T2DM. 
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Chapter Six presents the 12-month outcomes of the SHAM-exercise controlled RCT on cognitive 
function in our cohort with T2DM.  Additionally, relationships between physiological 
adaptations and cognitive outcomes are explored to attempt to delineate mechanisms underlying 
any cognitive improvements observed. 
 
Chapter Seven discusses the results of thesis, and places it in context of existing literature.  The 
role of body composition, metabolic health, inflammation, adiponectin, exercise capacity and 
physical performance of older adults with T2DM in relation to their cognitive performance is 
presented.  An assessment of the efficacy of power training for cognition in this trial is presented, 
as well as its ability to beneficially modify body composition, metabolic health and physical 
performance in relation to cognitive health outcomes, in this vulnerable cohort.  Finally, future 
directions for research will also be explored, which will focus on identifying possible mechanistic 
links that require additional investigation, among power training, body composition, metabolic 
health, and cognition of older adults with T2DM.  An emphasis will be placed on the potential 
clinical significance of the results from this thesis, and whether these results can be translated into 
the clinical setting. 
 
1.9 OUTLINE OF THE PROJECT 
1.9.1 AIM 
This thesis aims to first synthesise the evidence base supporting the rationale and utility of current 
exercise treatment guidelines for T2DM, and secondly to provide the rationale and first evidence 
of efficacy of a more novel form of exercise, power training, for cognitive function in this cohort.  
This will be accomplished by 1) systematically reviewing the animal and human literature for 
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current evidence of aerobic exercise as well as various modes and intensities of exercise as 
alternatives to aerobic exercise for improving cognition in this cohort; 2) exploring the relationship 
of cognition to metabolic health and other characteristics in older adults with T2DM at baseline; 
3) investigating the effect of POWER training on cognition in this cohort by conducting a RCT 
over one year to test the efficacy of high intensity POWER versus low intensity non-progressive 
resistance training (SHAM control) in older adults with T2DM; 4) determining possible underlying 
mechanisms as to how exercise may improve cognition in this cohort.  Adaptation to PRT is 
known to be intensity-dependent for many outcomes.  However, to date, there has not been one 
trial to report changes in cognition in response to PRT of any intensity or velocity, in older adults 
with T2DM, nor have there been dose-response relationships described between PRT intensity and 
cognitive adaptation.  Thus, both the efficacy and preferred PRT intensity and velocity for 
cognitive benefit in T2DM is unknown, and requires explicit investigation, which is the primary 
aim of this part of our trial. 
 
The following hypotheses were investigated over the course of this thesis  
The primary hypotheses for this sub-study of the GREAT2DO Trial was that 12 months of 
supervised high intensity power training would improve cognitive outcomes in individuals with 
T2DM compared to supervised low intensity non-progressive resistance training (SHAM exercise). 
 
Secondary hypotheses were: 
1. Better baseline cognitive function will be related to better metabolic health, higher muscle 
mass and lower adiposity. 
2. Increases in skeletal muscle mass (mid-thigh cross-sectional area) in response to high intensity 
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power training will be directly related to improvements in cognitive function. 
3. Decreases in abdominal adipose tissue (computerised tomography and anthropometric 
indices) in response to high intensity power training will be inversely associated with 
improvements in cognitive function. 
4. Improvement in glycaemic control and insulin resistance in response to high intensity power 
training will be directly related to improvements in cognitive function. 
5. Favourable changes in adiponectin and inflammatory markers in response to high intensity 
power training will be directly related to improvements in cognitive function. 
6. Improvements in functional mobility/exercise capacity in response to high intensity power 
training will be directly related to improvements in cognitive function. 
7. Improvements in quality of life and depressive symptoms in response to high intensity power 
training will be directly related to improvements in cognitive function. 
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FIGURE 1.1 POTENTIAL MECHANISMS LINKAGE BETWEEN T2DM, SARCOPENIA, 
AGE, AND COGNITIVE IMPAIRMENT  
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FIGURE 1.2 THEORETICAL MODEL OF MECHANISMS LINKAGE PROGRESSIVE 
RESISTANCE TRAINING AND COGNITIVE AND FUNCTIONAL OUTCOMES 
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TABLE 1.1 SUMMARY OF EXERCISE GUIDELINE FOR THE OPTIMAL THERAPY OF T2DM 
___________________________________________________________________________________________________________ 
Year   Governing Body    Aerobic Training    Guidelines PRT Guidelines    Notes 
___________________________________________________________________________________________________________ 
2012   ESSA154    Moderate intensity   Minimum of 60 min/week,    To be performed  
40-59% of VO2R or HRR to be performed on-top of    with no more than 2 
55-69% HRmax    aerobic exercise      consecutive days  
Minimum of 150min/week          without exercise 
Repetition 12-13   Multi-joint exercises,  
       utilising large muscle groups 
Vigorous Intensity   8-10 exercises 
60-84% of VO2R or HRR 2-4 sets 
70-89% HRmax   70-84% 1RM–equivalent to 8-10RM 
Minimum of 65 min/week 1-2 minute rest intervals 
RPE 14-16     Complete 2 or more times per week 
___________________________________________________________________________________________________________ 
2010  ACSM/ADA155    Minimum least 150 min  To be performed in addition 
          /week of  
Moderate (40-60% VO2max) 
Vigorous >60% VO2max) 
aerobic exercise
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HRmax: Maximum heart rate.  Can be determined by the maximum heart rate achieved during a graded exercise test to exhaustion, or 
via 
estimation using the formula HRmax = 220 – age (years). 
HRR: Heart rate reserve.  Can be calculated using the following formula; HRR = HRmax (bpm) – Resting heart rate (bpm). 
VO2: The rate at which oxygen can be consumed by the body in either litres / minute (absolute; l / min) or millilitres / kilogram/minute 
(relative; m/kg/min) 
VO2max: The maximum rate at which oxygen can be consumed by the body.  It can be determined using indirect calorimetry during a 
graded exercise test to exhaustion, or through estimation using a submaximal exercise test with at least 3 grades. 
RM: Repetition maximum.  This refers to the maximum weight that can be lifted for a given exercise.  In the case of a 1RM, this is 
the maximum weight that can be lifted once. 
ESSA: Exercise and Sports Science Australia 
ACSM: American College of Sports Medicine 
ADA: American Diabetes Association 
RPE: Rating of perceived exertion 
PRT: Progressive resistance training 
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CHAPTER 2 
SYSTEMATIC REVIEW OF EXERCISE AND CENTRAL NERVOUS SYSTEM 
FUNCTION, BIOCHEMISTRY AND MORPHOLOGY IN ANIMAL MODELS OF 
DIABETES MELLITUS, INSULIN RESISTANCE OR HYPERGLYCAEMIA 
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2.1 ABSTRACT 
Objectives - The purpose of this review was to systematically investigate the current knowledge 
on the effects of exercise on morphology, biochemistry, and function in animal models with 
diabetes or insulin resistance or hyperglycemia.   
Methods - A systematic and critical literature search was completed from earliest record until 
February 2014 using computerized databases.  Articles were considered for inclusion in the 
review if they were animal studies, assessed brain morphology, biochemistry, or cognitive function, 
as long as they included an exercise intervention, were conducted in any age animal with diabetes 
or insulin resistance or hyperglycemia.  Seven randomized controlled trials and eight non-
randomized controlled trials were analyzed. 
Results - There were 15 voluntary or forced exercise (thirteen running and two swimming) trials 
conducted for 6 to 84 days in which exercising animal were compared to control animals with 
diabetes.  Seventy-three percent of the studies were in animals with a model of type 1 diabetes 
mellitus (T1DM) and 27% of the studies were in animals with a model of type 2 diabetes mellitus 
(T2DM) or insulin resistance.  Overall, 14/15 trials showed significant improvement in at least 
one cerebral morphological, biochemical, or cognitive process after aerobic exercise compared to 
control animals.  Beneficial adaptations to exercise were seen primarily in cell proliferation, cFos, 
long term potential, pre-synaptic plasticity, lesion size, insulin level, insulin and leptin signalling, 
nerve growth factor, brain-derived neurotropic factor, glucocorticoid levels, and memory. 
Conclusions - Animal studies to date support a role for exercise in beneficial adaptions in central 
nervous system (CNS) outcomes in animals with diabetes, hyperglycaemia or insulin resistance.  
More studies are necessary to clarify cellular and molecular mechanisms underlying improvement 
in memory in response to various modalities and doses of exercise in variations of animal species 
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with models of T2DM. 
Key words: Exercise, Diabetes or Hyperglycaemia or Insulin Resistance, CNS Outcomes, 
Animals 
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2.2 INTRODUCTION 
The prevalence of diabetes is increasing, with estimates that it will affect 435 million adults by 
2030, and it is a leading contributor to premature mortality and morbidity globally.1, 2  Diabetes 
is characterised by deficiency in insulin secretion or resistance to insulin action or both,3 and is 
often accompanied by widespread biochemical, morphological and functional abnormalities which 
may affect central and peripheral nervous systems, cardiovascular and renal function, hepatic 
function, physical performance, and muscle mass, among other characteristics.  There are a 
growing number of studies identifying the brain as a site of possible complications in diabetes; 
indeed, evidence accumulated from animal and human clinical studies suggested a correlation 
between diabetes and cognitive deficits in memory, information processing speed, attention, and 
executive function.4  In addition, individuals with diabetes have identified alterations in brain 
structure, including brain atrophy and greater white matter high-intensity lesion volumes, 
predominantly in the subcortical regions.5  Magnetic Resonance Imaging (MRI) has also 
demonstrated hippocampal and amygdala atrophy relative to control subjects with T2DM.6   
Hippocampus and amygdala regions have also been found to be atrophied in humans with 
Alzheimer’s disease.7  Furthermore, hippocampal function, synaptic plasticity, and neurogenesis 
is critical to learning and spatial memory function, and these capacities have been shown to have 
deteriorated in animals with diabetes as compared to control animals.8  A reduced insulin, insulin-
like-growth factor-1 (IGF-1), leptin, nerve growth factor, brain derived neutrophic factor signaling, 
and increased glucocorticoid expression as occurs in diabetes, and is associated with impaired 
brain functions and with an increased prevalence of Alzheimer’s disease.8-10 
 
There is strong evidence from animal and human cross-sectional and prospective cohort studies 
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that participation in physical activities is associated with decreased prevalent and incident 
cognitive impairment11-14  Epidemiological evidence consistently links physical exercise with 
cognitive benefits, lower risk for dementia, and reduced pathological changes11, 15, 16  A recent 
meta-analysis of 16 prospective studies including patients with neurodegenerative diseases found 
that higher physical activity level was associated with a 28% reduction in incident dementia.17  
Frequent exercisers (>3/wk) have been reported to exhibit stable or improved cognitive health over 
5 years.18  Experimental trials indicate that just one week aerobic training can significantly 
improve performance in healthy adults on a range of cognitive tasks.19  The largest effects on 
cognitive function were found on motor function, auditory attention and delayed memory functions 
(effect sizes of 1.17, 0.52, and 0.50, respectively).11  In one set of clinical studies, Colcombe and 
colleagues provided cross-sectional and prospective brain imaging data to suggest that aerobic 
exercise ameliorates age-related volume loss for older adults, changes that are most striking for 
brain regions that support executive control processes and memory including the hippocampus.20, 
21  In addition, aerobic exercise has improved peripheral metabolism and induced up-regulation 
of hippocampal BDNF, and has also been associated with improvements in cognition and brain 
structure.22-24  Thus, although it has been shown in many studies that exercise can enhance 
cognitive function, morphology, and biochemistry in animal models and human studies, there is as 
yet no systematic review of the effects of exercise on CNS adaptations in animal models at high 
risk of cognitive dysfunction due to diabetes, insulin resistance or hyperglycaemia to our 
knowledge.  The importance of such animal models lies in the ability to explore biochemical and 
morphological changes in the CNS in response to exercise, and their potential relationship to 
cognitive performance in ways that are not possible in human investigations. 
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Therefore, the purpose of this investigation was to systemically review adaptations to exposure to 
any mode of exercise in the domains of central nervous system function, biochemistry, or 
morphology in animals with diabetes, insulin resistance or hyperglycaemia, for the purpose of 
identifying underlying mechanisms which may be targeted in future studies of lifestyle 
interventions to combat this global epidemic.  
 
2.3 METHODS AND PROCEFURES 
2.3.1 LITERATURE SEARCH  
A literature review was conducted from the year 1966 to May 2014 using computerised databases 
performed in Medline (1966-2014), CINAHL (1982-2014), EMBASE (1966-2014), SportDiscus 
(1967-2014), PsycINFO (1966-2014), Cochrane Controlled Trials Registry (1st Quarter 2014), 
Cochrane Dementia and Cognitive Improvement Group (1985-issue 1,2014), Cochrane Reviews 
(1985-issue 1, 2014) with the last search being conducted in Feb 2014.  The searches for the 
following categories were conducted using text words pertaining to cognition, exercise and 
diabetes.  A combination of text-based terms in all fields was used to find records. 
a) Intervention: Exercise, or training, or physical activity, or aerobic, or physical capacity, or 
aerobic capacity, or physical performance, or physical endurance, or motor activity, or 
resistance, or weight lifting, or strength, or power training, or strength training, or weight-
training, or resistance-training, or resistance exercise 
b) Animals: Any animal species/strains with diabetes, insulin resistance, hyperinsulinemia, or 
hyperglycaemia 
c) Outcome: Cognition, or cognitive or mental or mental process, or memory, or brain, or 
neuropsychology, or neurological 
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Searches a, b, and c were combined with ‘AND’ to produce the initial set of retrieved references.  
Reference lists in all eligible papers and review articles were hand-searched for any additional 
papers.  (Figure 1)  
 
2.3.2 INCLUSION AND EXCLUSION CRITERIA  
Studies were included if they met all of the following criteria:  
1. They included animals with diabetes, insulin resistance or hyperglycaemia were diagnosed on 
blood glucose level (≥280mg/dl or ≥14–35 mmol/L) or fasting glucose level (≥6.5-6.6mM). 
2. They included an intervention of any form of exercise training (defined as planned, structured, 
and repetitive physical activity which has as a final or intermediate objective, the improvement 
or maintenance of physical fitness), where clear prescriptive parameters were provided, 
whether supervised (forced) or unsupervised (voluntary), and conducted in a laboratory setting. 
3. Animals were exposed to chronic exercise.  A minimum of one week of exercise was used as 
the definition for chronic exposure.  This was to exclude studies of known acute bout effects 
on attention span and focus on chronic adaptations within the CNS or periphery affecting 
cognition. 
4. Any validated test of cognition, brain morphology, or biochemistry reported at follow-up. 
5. The design of the study must have been set up so that the independent effects of exercise could 
be seen in animals with diabetes, insulin resistance or hyperglycaemia.  Enriched environment 
or dietary co-interventions were allowed, only if the exercise effect could be isolated from the 
dietary effect. 
6. The study was a randomised controlled trial (RCT) and non-randomised controlled trial 
(NRCT). 
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The study was a full-length article published in a peer-reviewed English language journal. 
Trials were excluded if they met any of the following criteria:  
1. Studies included human beings with diabetes, insulin resistance or hyperglycaemia. 
2. No validated test of cognitive function, brain morphology or biochemistry was reported as an 
outcome. 
3. Studies were non-English language articles or unpublished papers; or the articles were reviews 
or abstracts. 
 
2.3.3 STUDY SELECTION AND DATA EXTRACTION 
One author (RRZ) conducted the search and extracted all data.  After eliminating duplicates, all 
papers identified by the search strategy were screened by the author, first by title and then by 
abstract using the above eligibility criteria.  Two authors (RZ and MFS) screened papers accepted 
for inclusion in the review.  Quality assessment of all eligible papers was undertaken separately 
by these two authors using a modified Physiotherapy Evidence Database (PEDro)25 for assessing 
the quality of animal RCTs and NRCTs.  Five additional items (“Exercise supervised, animal 
strain reported, age and weight reported: yes/no; and exercise paradigm reported: 
voluntary/forced”) were included to identify these important components of exercise studies 
relevant to animals, providing a final possible score of 14.  Points were only awarded if the 
criterion was clearly satisfied.  Any disputes were resolved by consensus, or by a third author 
(AOS) if necessary.  Data were extracted regarding study methodology, animal cohort 
characteristics, exercise intervention paradigms, outcomes of cognition, morphology, and 
biochemistry, and any concomitant relationships between changes in cerebral biochemistry or 
cerebral morphology and cognition.  If data were only presented graphically, attempts were made 
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to obtain data from authors; if this was not available, values were measured from the published 
graphs. 
 
2.3.4 DATA ANALYSIS 
Due to the heterogeneity of exercise prescriptions, outcomes assessed and measurement tools used, 
a systematic review was conducted rather than a meta-analytic approach.  Trials were split into 
the following groups: 1) RCTs and 2) NRCTs.  Studies were considered to employ control groups 
if one group was assigned an exercise intervention, and the other group was assigned to non-
exercise control, SHAM exercise control, or an alternate form of exercise intervention.  Study 
characteristics were summarised as mean (SD) or median (range) as appropriate for normal or non-
normally distributed data respectively.  Data that were reported as mean ± SEM were converted 
to mean ± SD.  Relative Effect Size (ES) (mean change Treatment – mean change Control) ÷SD 
Pooled baseline was calculated for controlled trials relevant data were available.26  Effect sizes 
were interpreted according to Cohen’s scale27 of ‘trivial’ (<0.20), ‘small’ (0.20 to <0.50), ‘moderate’ 
(0.50 to <0.80), and ‘large’ (>0.80).  ESs and 95% CIs were graphed as forest plots.  Statistical 
significance level was assumed if p < 0.05, and/or ES 95% CIs were not inclusive of zero. 
Finally, results of statistical associations between any of the cognitive, cerebral morphological, or 
biochemical outcomes were extracted, where such relationships were available. 
 
2.4 RESULTS 
2.4.1 STUDIES RETRIEVED 
Figure 2.1 displays the search results.  The combined search yielded 5578 studies, while hand 
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searching identified a further 3 studies.  After the removal of duplicates, 4435 studies remained. 
Titles and abstracts were examined, and studies not meeting the eligibility criteria were excluded.  
The whole text of 97 studies was examined, and 15 trials were found to meet the criteria for review.  
This included 7 RCTs28-34 (one trial with swimming, four with treadmill, and two with wheel 
running) and 8 NRCTs35-42 (8 with treadmill exercise).  Three of the 15 studies assessed cognitive 
function.30, 38, 39 Eight out of 15 studies had measures of cerebral morphology,28, 30, 31, 35, 37, 39, 40, 42 
and 8 had measures of biochemistry.29, 32-34, 36, 39-41   
 
2.4.2 STUDY QUALITY ASSESSMENT 
Study quality on the basis of a modified version of the Physiotherapy Evidence Database (PEDro) 
is summarised in Table 2.1.  Overall, the quality of the RCT trials28-34 included in this review was 
moderate, with most receiving a score of 7 out of 14, and only one study scoring 10 out of 14.  
Common limitations in quality were: lack of concealed allocation,28-34 lack of blinded assessors in 
7 trials,28-34 lack of interventionists blinded to hypotheses in 6 trials,28, 29, 31-34 absence of intention-
to-treat analysis in 7 trials,28-34 and insufficient available information regarding baseline matching 
between groups in 7 trials.28-34  Exercise interventions were fully supervised in all RCTs28-34 and 
key outcomes were obtained in greater than 85% of animals enrolled in each trial.  Quality of the 
included NRCTs was also only moderate, with, on average, 6 of 14 quality criteria being met (mean 
6.4 ± 1.4, range 5-8/14).  It is recognised that some quality elements such as concealment of 
allocation are minimally relevant to animal models as opposed to human trials for which PEDro 
scale was designed. 
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2.4.3 ANIMAL CHARACTERISTICS  
A variety of animal models were used in the 15 studies (see Table 2.2).28-42  One study reported a 
model of intracerebral hemorrhage.28  Total samples (mean n=15, range: 10 to 20), were divided 
into intervention and control groups varying between 5 and 10 animals in 7 RCTs28-34 (Sprague 
Dawley rats, Wistar rats, and Zucker fatty rats with diabetes) with the larger groups (Wistar rats) 
participating in swimming programs,29 while 108 animals (Sprague Dawley rats, Wistar rats, and 
db/db mouse) were included in 8 NRCT.36-42  The average age of animals across all trial trials 
was 61 days, with age ranging from 30 to 161 days (Weanling: 21-35 days, preadolescent: 35-63 
days, adults: 63-180 days).  Thirteen of 15 publications28-33, 35-39, 41, 42 reported the weight of 
animals (mean 198±53 grams) and two publications34, 40 did not report this variable.   Sex 
breakdown was provided in all studies.  Overall, 13 trials included male only,28-30, 32, 33, 35-42 while 
the remaining 2 trials31, 34 were comprised of mixed male and female animals. 
 
2.4.4 DIAGNOSTIC CRITERIA 
Only 5 out of 15 trials reported diagnostic criteria for T2DM or insulin resistance as either fasting 
glucose > 300mg/dl31, 36, 40 or fed glucose 6.5-6.6mM33 or 30.9±1.7mmol/l.34  While the 
remaining 10 trials28-30, 32, 35, 37-39, 41, 42 reported diagnostic criteria for T1DM or hyperglycemia as 
either fasting glucose >300mg/dl or blood glucose level (BGL) 14–35 mmol/l.   
 
2.4.5 TYPE OF DIABETES 
We also identified four different types/aetiologies of diabetes: 10 out of 15 trials reported 
medication treatment28-30, 32, 35, 37-39, 41, 42 to induce a metabolic state similar to T1DM.  The most 
common medications used for this purpose were Streptozotocin and Alloxan.  The remaining five 
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trials did not employ a diabetes inducing injection agent.31, 33, 34, 36, 40  Instead, they utilised animal 
strains bred (Zucker fatty rats with diabetes31, 33, 34 and db/db mice40) for obesity and development 
of insulin resistance/T2DM or pancreatectomy (Wistar rats)36 to induce models of insulin 
resistance and/or T2DM.   
 
2.4.6 MEASURES OF GLUCOSE LEVEL AND INSULIN SENSITIVITY 
Postprandial blood glucose was used in 4 out of 15 trials as a measure of glucose level of diabetes,30, 
31, 34, 35 while the fasting40 and random glucose36 levels were measured in one trial, respectively.  
Only 1 trial used an oral glucose tolerance test to assess insulin sensitivity.33  A blood glucose 
concentration was used in 9 trials as a measure of diabetes.28, 29, 32, 37-39, 41, 42   
 
2.4.7 THE TIME POINT OF ASSESSMENT FOR COGNITIVE FUNCTION AND BRAIN STRUCTURE AND 
BIOCHEMISTRY 
Assessment of time interval between the last bout exercise session and cognitive function, brain 
structure, and brain biochemical markers.  The majority of studies reported the immediate 
measures for cognitive function, cerebral tissue, and cerebral biochemistry28, 30, 33, 34, 36-40, 42, and 
four studies were between 0.5-48 hours after exercise29, 32, 35, 41 while no report was found in one 
study.31 
 
2.4.8 MEASURES OF CEREBRAL MORPHOLOGY  
Cell proliferation in the hippocampus was most commonly measured (4 publications) via 
immunohistochemistry;28, 30, 35, 39  Plasticity of the dentate gyrus was measured by using a 
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concentric bipolar stimulating electrode and a DAM80 differential amplifier to determine 
extracellular field potentials amplified (100×) and filtered (1 Hz to 3 kHz band pass) in two 
publications.37, 42  One trial utilised the Image-Pro Plus computer-assisted image analysis system 
(Media Cyber-bestics Inc., Sliver Spring, MD, USA) to detect change in cFos as a measure of 
neurogenesis.30  One trial acquired images for analysis of dendritic spine density.40  Nissl 
staining was employed in 1 trial to specifically determine lesion volume in a study of cerebral 
haemorrhage and exercise exposure.28 
 
2.4.9 MEASURES OF CEREBRAL BIOCHEMISTRY 
Two trials measured insulin levels using radioimmunoassay.29, 32  One utilized radioimmunoassay 
and biochemical measurement to calculate insulin growth factor 1 (IGF-1) and glycogen,32  One 
trial utilised immunoblotting analysis to determine insulin and leptin signaling.36  Two trials used 
immunohistochemical staining to detect hyperglucocorticoidemia receptors,33, 34  A Kodak Image 
Station for protein determination of nerve growth factor was measured in one tria.39  One trial 
examined BDNF levels using an enzyme-linked immunosorbent assay.40  One trial used 
chromatography and fluorescence detection to calculate gamma-aminobutyric acid and 
glutamate.41 
 
2.4.10 MEASURES OF COGNITIVE FUNCTION 
Relatively few trials (only 3/15) measured cognitive function in comparison to the central 
morphology and biochemistry measures outlined above.  Amongst animal cognitive ability 
assessments, spatial learning and memory performance,38 while one trial utilised radial arm maze 
task measures to test memory, from which memory was assessed by spatial acquisition, and spatial 
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retention.30  A passive avoidance test apparatus was used in one trial to specifically test memory 
retention.39 
 
2.4.11 INTERVENTION PROTOCOLS 
A summary of the training protocols can be seen in Table 2.3. 
 
Exercise modality 
All studies investigated the effects of the aerobic training.  Among the RCTs, 5 trials utilised 
forced treadmill running compared to non-exercise control groups.28, 30-32, 34  Two examined 
effects of forced swimming compared to non-exercise control groups.29, 32  The remaining trial 
used a voluntary wheel running compared to a non-exercise control group.33, 40  The 7 NRCTs 
compared the effects of forced treadmill training to non-exercise control groups.35-39, 41, 42  
 
Volume of exercise and duration of trial 
Exercise volume varied from 30 to 60 minutes per session, mean 40.8±12.4 minutes.  Seven 
sessions per week was the most common training prescription, utilised in 7/15 trials;28, 30, 35, 37, 38, 
41, 42 but it was as low as four to five sessions per week in the remaining 5 trials.29, 31, 32, 36, 39  Trial 
duration ranged from 1 to 12 weeks, mean 7.7±4.6 weeks; the majority of studies were between 5-
12 weeks,30-34, 36-42 and three studies were between 1-4 weeks.28, 29, 35 
 
Intensity and progression 
Despite all trials utilising a mode of aerobic training, there was a large variation in the protocols 
used to conduct the exercise intervention.  Aerobic exercise intensity in Kim (2003) and Lee 
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(2005) were prescribed at 2 metres per minute for 5 minutes, 7 times per week, which progressed 
from 5 to 8 m/min and the duration increased from 5 to 20 minutes over 1 week exercise.28, 35  
Reishi report workload 5 meter / minute for 10 minutes, which increased 17 metres /minute for 40 
minutes in week 1, workload set 17 meters / minutes for 40 minutes starting from week 2 to week 
12.37, 38, 41, 42  In Park et al (2005),36 aerobic exercise was prescribed at 20 metres per minute for 
30 minutes, 4 times per week..  Aerobic intensity was set at speed of 12 metres/minute for 60 
minutes in daily (5 days a week), for 7 weeks, which speed increased from 1 metre/minute per 
week and the duration was 60 minutes over the course of 5 days from week 1 to week 12.34  You 
et al (2003)30 set the duration of aerobic exercise at 75 minutes/session, 7 times per week for 6 
weeks, and the exercise intensity consisted of running for 5 minutes at a constant speed of 4000 
metres/hour, followed by running for 5 minutes at 5000 metres/hour, and then running for 20 
minutes at 7000 metres/hour.  In Yi et al (2009)31, aerobic exercise was prescribed at 5 to 17 
metres / min for 15 minutes in week 1, which gradually progressed to 22 metres per minute for 45 
minutes, while duration increased from 10 to 40 minutes from week 2 to week 5. Campbell et al 
(2010)33 set the average daily running distances for the exercising animals began at 3.4 ± 0.2 
km/day during week 1, peaked at 6.5 ± 0.5 km/day during week 6, and then slowly declined to 4.5 
± 0.7 km/day during week 10.  Finally, the speed and duration of the treadmill exercise in Chae 
et al (2007)39 were gradually increased from 10 metres/minute for 10 minute (grade 0%) in the 1st 
week to 10 m/min for 20 minutes in the 2nd week, 14–15 metres/minute for 20 minutes (grade 0%) 
in the 3rd week, 14–15 metres/minute for 30 minutes in the 4th week, and 17–18 metres/minute for 
30 minutes from the 5th week.  Swimming exercise was set a 5% body weight for 60 minutes.29  
Similarly, one aerobic exercise included three swimming sessions and set 4%, 5%, and 6% body 
weight, swimming workload is 4% body competed with 90% the maximal lactate steady state from 
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25 to 60 minutes in two week, which is gradually increased workload from 5% to 6% body weight 
interval week.32   
 
Overall, aerobic training intensity was considered to be low in 8 studies,28, 31, 34, 35, 37-39, 41, 42 
moderate in 2 studies,36 and high in 3 studies29, 30, 32 of the 13 studies where prescriptive elements 
were reported.  However, no intensity (speed) were reported in two studies.33, 40  All but two 
trials28-31, 34-38, 40-42 were fully forced, supervised treadmill exercise without any inclination, while 
two studies utilised voluntary unsupervised wheel running exercise.32, 33  
 
2.4.12 OUTCOME MEASURES 
2.4.12.1 MORPHOLOGICAL OUTCOMES 
Results are reported in Table 2.4.  Eight trials investigated the effects of forced treadmill running 
on cell proliferation28, 31, 35, 39 and synaptic plasticity.30, 37, 40, 42  Improved cell proliferation and 
synaptic plasticity were the most consistent positive adaptations observed, and in general, the 
effect sizes were large and moderate. 
 
Neuronal cell proliferation  
Four studies measured neuronal cell proliferation in the hippocampus.28, 31, 35, 39  Compared to 
control groups, neuronal cell proliferation significantly improved in two trials of low and moderate 
intensity exercise, with very large ESs calculated [(ES: 4.64; 95% CI: 2.76, 6.52)35 and (ES: 6.28; 
95% CI: 4.15, 8.42).39  Aerobic training significantly increased Ki67 positive nuclei assessed 
using immunohistochemistry (a marker of cell proliferation) and doublecortin (DCX) 
immunoreactivity (a marker of progenitors differentiating into neurons measured by Western Blot 
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analysis) in one trial of low intensity running, again with very large ESs [(Ki67 ES: 5.99; 95% CI: 
3.70, 8.29), (DCX in the dentate gyrus ES: 2.20; 95% CI: 0.96, 3.44), (DCX with tertiary dendrites 
ES: 17.81; 95% CI: 11.56, 24.08), and DCX without tertiary dendrites ES: 4.97; 95% CI: 2.99, 
6.95) ],31 respectively.  In another trial of low intensity exercise in animals with hyperglycaemic 
complication of cerebral haemorrhage, (60 minutes/session, five session/per week ± 5 weeks), 
increases in cell proliferation were seen following early or later aerobic training [(Early exercise 
ES: 2.50; 95% CI: 0.99, 4.01) and (Later exercise ES: 2.31; 95% CI: 0.85, 3.77)], compared to a 
control group.28  Compared to the control group, early aerobic training also significantly reduced 
lesion size and neuronal apoptosis (ES: -1.96; 95% CI: (-3.34, -0.58), while later exercise (ES: -
2.87; 95% CI: -4.48, -1.26) failed to produce such an effect in this trial. 28 
 
Synaptic plasticity 
Four studies measured the effects of forced treadmill running on synaptic plasticity in the 
hippcampus.30, 37, 40, 42  In two studies, paired pulse index [short-term forms of synaptic plasticity; 
(ES: -3.09; 95% CI: -4.77, -1.42)] and field excitatory post-synaptic potential (ES: -3.36; 95% CI: 
5.12, -1.60)37 as well as long term potential-population spike [a form of activity-dependent 
synaptic plasticity; (ES: 3.02; 95% CI: 1.36, 4.67] and long term potential-field excitatory post-
synaptic potential slope (ES: 1.94; 95% CI: 0.57, 3.31),42 were enhanced in the hippocampus from 
running rats as compared controls.  Mixed results were reported in another study, in which 
aerobic exercise (low intensity voluntary wheel running for 12 weeks) had no effect on dendritic 
spine length using Golgi impregnation and analysis, (ES: 0.40; 95% CI: -0.74,1.55) although a 
significant increase was observed in dendritic spine density (ES: 2.11; 95% CI: 0.70, 3.52)40  In 
another trial aerobic exercise significantly improved hippocampal cFos expression [neuronal 
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immediate-early gene (IEG) cFos expression], which is associated with regulated synaptic activity 
(ES: 0.96; 95% CI: 0.67, 1.25) using the Image-Pro® Plus computer-assisted image analysis 
system, compared to the control group.30  Two trials30, 39 reported that the increased cFos and 
neuronal cell proliferation and enhancement in memory observed after low or high intensity 
running, respectively.  However, no other studies reported whether such relationships existed.   
 
2.4.12.2 BIOCHEMISTRY OUTCOMES 
Three NRCTs compared voluntary or forced aerobic training to a non-exercise control group, with 
aerobic training shown to improve insulin, insulin-like-growth factor-1 insulin signaling, leptin 
signaling, nerve growth factor signaling, BDNF, glutamate, and glucocorticoid receptor, but not 
gamma-amino-butyric acid.  Voluntary wheel running improved both dendritic spine density and 
BDNF levels in another trial.40  Increased nerve growth factor signaling and increased BDNF and 
improved memory were observed following aerobic exercise.  However, no study reported the 
relationships between increased nerve growth factor signaling and increased BDNF and memory.  
  
Insulin/insulin like growth factor 1 (IGF-1) 
When comparing exercise training to a non-exercise control group, one RCT was shown to 
improve insulin level in one trial for high intensity running (ES: 2.12; 95% CI: (0.89, 3.34)29 while 
no effect was seen on insulin (ES: 0.58; 95% CI: -0.31, 1.47) and insulin-like growth factor 1 (ES: 
0.30; 95% CI: -1.18, 0.58) in one RCT trial for high intensity running.32 
 
Insulin and leptin signaling  
Improvements in brain insulin signaling assessed by tyrosine phosphorylation insulin receptor 
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substrate 2 (IRS2) and Akt were seen following aerobic training in one trial [IRS2 cortex (ES: 
3.59; 95% CI: 2.17, 5.01), (IRS2 hypothalamus ES: 4.21; 95% CI: 2.64, 5.79), (Akt cortex ES: 
8.36; 95% CI: 5.62, 11.09), and (Akt hypothalamus ES: 18.87; 95% CI: 12.95, 24.78)].36  Aerobic 
exercise improved leptin signaling measured by STAT3 in one trial [(ES: 3.19; 95% CI: 1.87, 4.51) 
and (ES: 10.90; 95% CI: 7.41, 14.39)].36  One NRCT trial observed a significant increase in 
glycogen synthesis of the cortex and hypothalamus [(ES: 3.19; 95% CI: 1.87, 4.51) and (ES: 10.90; 
95% CI: 7.41, 14.39)],36 while one RCT trial32 and one NRCT36 failed to report such an effect in 
hippocampus.   
 
Neurotrophic factor and neurotransmitters 
Three NRCT trials compared voluntary or forced aerobic training to a non-exercise control group, 
with aerobic training shown to improve nerve growth factor signaling by determined tyrosine 
kinase receptor A (TrkA) (ES: 3.92; 95% CI: 2.43, 5.43) and extracellular signal-regulated kinase 
1/2 (Erk1/2) [(tErk1 ES: 1.85; 95% CI: 0.50, 3.21) and (tErk2 ES: 8.97; 95% CI: 5.21, 12.74)],39 
brain derived neurotrophic factor (ES: 4.77; 95% CI: 2.22, 6.32),40 and glutamate (ES: 2.37; 95% 
CI: 0.90, 3.85),41 but not gamma-amino-butyric acid (ES: 0.34; 95% CI: -0.65, 1.32).41  Voluntary 
wheel running improved dendritic spine density with increased brain derived neurotrophic factor 
levels.40  However, one study reported spin density and BDNF levels improved with aerobic 
exercise,40 a finding that implicates a potential benefit of improved BDNF levels on spin density 
and cognitive processes.   
 
Glucocorticoid receptor (GR) 
Two trials measured GR and reported significant change, and ESs were modest or large.  
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Campbell et al33 reported a net increase ranging from 40.6% and 76.4% in quantification of the 
relative signal intensity of hippocampal GR and hippocampal GR content and the between group 
effect sizes for this trial were large.  The second trial reported34 a net decrease of 136.8, 98.2 and 
48.2 in stratum pyramidal and radiatum, respectively, but not significant changes in stratum orients 
and dentate gyrus, and the between groups effect size we calculated was non-significant.  
However, as there are only two trials33, 34 investigating glucocorticoid receptor and exercise, further 
investigation is required to confirm these findings and assess the relevance to enhanced 
glucocorticoid receptor in different area of hippocampus after exercise. 
 
2.4.12.3 COGNITIVE FUNCTION 
A summary of the results can be found in Table 2.6.  Three studies measured some aspect of 
cognitive function (learning and memory).30, 38, 39, and it was significantly improved in all them.  
Very large ESs were demonstrated after low to high intensity running, with volumes ranging from 
30 to 40 minutes per session, five to seven sessions per week, and duration of interventions ranging 
from 6 to 12 weeks.  For example, exercise improved spatial learning and memory [error number 
(ES: -2.47; 95% CI: -4.12, -0.83)]30 spatial acquisition [(escape latencies ES: -3.43; 95% CI: -4.97, 
-1.89); swim distance (ES: -2.13; 95% CI: -3.35, -0.90); swim speed (ES: 2.01; 95% CI: 0.81, 
3.21)]; spatial retention [(platform located chance % ES: 1.27; 95% CI: 0.20, 2.35) and crossing 
number (ES: 1.83; 95% CI: 0.67, 3.00)38 and retention latency (ES: 1.68; 95% CI: 0.66, 2.70)].39 
 
2.5 DISCUSSION 
This systematic review identified seven RCTs and eight NRCTs of exercise in animal models with 
diabetes or hyperglycemia or insulin resistance.  The quality of this literature was moderate, and 
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the majority of trials had samples too small for sufficient power to detect small effects.  The major 
finding of this review was that there was a significant improvement in cerebral structure, chemistry 
in the majority of these trials after exposure to a variety of doses of chronic aerobic exercise, and 
ESs were generally large to very large.  Limited data were available on improvements in 
cognitive performance itself, but what was reported was significant as well.  This review also 
showed that the elevations in the cell proliferation, cFos expression, and nerve growth factor levels 
in this rodent model of with diabetes or hyperglycemia or insulin resistance were associated with 
increased memory ability, although these data come from only two trials which investigated such 
relationships.  Notably, all but two of the 15 trials used forced exercise, which could theoretically 
have had negative impacts on brain structure and function through elicitation of a stressor 
response,33, 34 but this was not evident.  As no trials to date have directly compared the benefits 
of forced and voluntary exercise on cerebral morphology or function, it is not possible to ascertain 
whether improvements would have been even greater if a voluntary exercise paradigm had been 
utilised. 
 
The literature search only retrieved two investigation that assessed the effects of voluntary and 
forced exercise on glucocorticoid receptor in the hippocampus in zucker rats with diabetes, 
showing different effects.  Given the associations between glucocorticoid receptor, and 
hippocampal degeneration and the emergence of learning and memory deficits,43 this gap in the 
literature should be addressed in future trials.  A better understanding of the interaction between 
the glucocorticoid receptor and changes in cognitive function in response to voluntary and forced 
exercise may lead to the development of mechanisms to beneficially modulate such glucocorticoid 
receptor and thus provides compelling evidence for the need and augment the effect of exercise in 
104 
 
future trials.  
 
Despite the numerous studies performed measures of cerebral morphology and/or biochemistry, 
many failed to report whether any relationships existed between the changes in these variables and 
function, thus making them unable to be conclusion in this particular review.  If functional 
significance related to these variables were able to be reported by future investigations, this would 
provide a very rich pool of data in which to explore potential relationships.  
 
2.5.1 BRAIN MORPHOLOGICAL OUTCOMES 
This review identified seven trials (3 RCT and 4 NRCTs) that measured brain structure.  The 
modest amount of evidence available suggests that aerobic exercise improves neurogenesis, 
synaptic plasticity, and intracerebral lesion size.  Previous reviews have shown that there is a 
positive effect of aerobic exercise on brain neuroplasticity within healthy animals.44,45  It is clear 
from the trials included in this review that significant, large improvements in neurogenesis and 
neuroplasticity occurred with exercise training in these models of diabetes and insulin resistance 
as well.  Specifically, the results showed that increases in neuronal cell proliferation in the 
hippocampus.28, 35, 39  Furthermore, in one randomised controlled trial of aerobic training,31 ki67 
and DCX cells, signifying cell proliferation and cell differentiation, respectively, markedly 
increased in the exercise group in the dentate gyrus.  In this trial,31 doublecortin positive cells 
with or without tertiary dendrites were significant increased.  In addition, cFos,30 hippocampal 
neuronal immediate-early gene, significantly increased after training and there was a significant 
direct association between enhanced cFos levels and increased memory.  Increase in long term 
potential (34-50%),42 and dendritic spine density (10%)40 as well as reduction in pre-synaptic 
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plasticity (301-307%)37 and reduced lesion size (7.6-20%) and neuronal apoptosis (12-32%)28 in 
animal models with diabetes or insulin resistance was also seen.  Given that these cerebral 
benefits occurred across a wide range of exercise doses and intensities, there does not seem to be 
an obvious dose-response relationship between exercise exposure and CNS adaptation.  However, 
as there were no studies that directly compared the benefits of different doses, there is a need for 
future studies to confirm both optimal and minimal exercise exposure for cerebral benefits in 
diabetes or insulin resistance or hyperglycaemia.  There is limited evidence yet that these 
morphological adaptations result in improved cognitive performance.  In the one study to explore 
this question, increase in synaptic plasticity associated with forced exercise occurred in the 
hippocampus, which was concomitantly linked to increased memory performance, suggesting that 
enhancement in new cells and cFos may have a functional role in this process.  Additional studies 
are needed to extend and confirm this finding. 
 
Whether exercise exposure is effective for both prevention and treatment of cerebral pathology in 
diabetes is an important question that has received little empirical study.  In the one trial to 
examine this question, improvements in CNS hemorrhagic lesion volume was related to early 
exercise intervention (12 hours), but no significant benefit was observed when exercise was started 
later (after the lesion).28  It was concluded that regardless of mode or intensity of exercise, later 
intervention was not able to reduce lesion size, nor provide a robust neuroprotective benefit, 
because neuronal cell apoptosis reached the maximum level 72 h after the hemorrhage.   
 
Thus, the timing of exercise with respect to prevention of diabetes-related pathology in the brain 
(such as hemorrhage) may be important.  The animal review suggested that aerobic exercise, in 
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an optimal time window, increased proliferation and reduced haemorrhagic lesion size in the brain, 
and was therefore recommended as a behavioral intervention to promote functional recovery in 
brain diseases in an animal model with hyperglycaemia.  Additionally the finding of beneficial 
cellular changes in brain structures in animal models, brought about by exercise, provides 
compelling evidence for the need for further study of stroke in humans.  However, it is ischemic 
stroke in humans, which occurs with higher prevalence in type 2 diabetes patients.  Ischemic 
stroke is the most common type of stroke, accounting for almost 80 percent of all strokes.77  
Therefore, the relevance of these animal data to ischemic stroke in humans with type 2 diabetes is 
not known at this time, and should be the focus of future epidemiological and experimental 
investigations. 
 
Aerobic exercise in optimal time window increased proliferation and reduced haemorrhagic lesion 
size in the brain, and is also recommended as a behavioral intervention to promote functional 
recovery in brain diseases animal model with hyperglycaemia.  Nevertheless, ischemic stroke in 
human, a severe complication in type 2 diabetes patients, is the most common type of stroke, 
accounting for almost 80 percent of all strokes.  The finding of cellular changes in analogous 
brain structures in animal models, brought about by exercise, provides compelling evidence for 
the need for further study of stroke in humans. 
 
Future studies are needed to delineate the optimal time for initiation of exercise in metabolic 
dysfunction and diabetes for maximum neuroprotection for this and other kinds of pathology 
(ischemic stroke) related to cognitive impairment.  Eight trials (4 RCTs and 4 NRCTs) tested 
cerebral biochemistry.29, 32-34, 36, 39-41  Some benefits were seen in hippocampal molecular 
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pathways and metabolites after aerobic exercise training. 
 
2.5.2 BRAIN BIOCHEMICAL OUTCOMES 
Neurotrophic factor  
BDNF concentrations were elevated significantly in response to aerobic exercise.40  This result 
is in agreement with the findings from healthy animal studies, which have clearly shown that a 
period of aerobic exercise elevates levels of BDNF mRNA and protein in the hippocampus and 
other brain regions in healthy males46-48  However, the study suffered from the limitations in 
terms of the small sample size (6 mice in each group).  More studies are warranted to determine 
the adaptation of hippocampal BDNF in response to long-term voluntary and forced exercise 
training.   
 
One trial reported increases of NGF, TrkA, p-Erk1/2, and p-CREB protein expression,39 which has 
been demonstrated to be low in patients with T1DM compared to control in healthy rats,39 and has 
been reported to increase with aerobic exercise training.39  Notably, all positive adaptations above 
(NGF/TrkA/p-Erk1/2/ p-CREB) are from non-randomised controlled trials.  These results can 
therefore only be considered a weak form of evidence at present, and they require confirmation in 
randomised controlled trials. 
 
Insulin/IGF-1and/or leptin signaling 
Two RCT studies investigated insulin.29, 32  In Leme et al (2011), exercise significantly increased 
in insulin concentration.29  In one case, even though no significant changes in insulin level were 
observed, there is an increase in exercise groups.32  These ranged from 2.3 pmol/kg/wet in the 
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aerobic training group.  However, other than exercise modality, there is no obvious explanation 
for this lack of adaptation for insulin in aerobic training studies.   
While radioimmunoassay analysis for IGF-1 was performed in one trial, swimming increased the 
expression of hippocampal IGF-1 that are decreased in diabetes.32  Glycogen synthesis increases 
in the cerebral cortex and hypothalamus were reported in one aerobic training trial,36 but no 
significant increases were observed in glycogen in hippocampus.32, 36  With the limited data 
available, it is difficult to conclusively determine the specific role of changes in IGF-1 contents 
and glycogen. 
 
One RCT trial tested some parameters of insulin and leptin signaling.36  Some beneficial 
improvements in insulin signaling were seen in the cerebral cortex and hypothalamus after exercise 
training.  One aerobic training trial36 reported increases of insulin receptor substrate 2, Akt 
(protein kinase B), glucose transporter type 2, and signal transducer and activator of transcription 
3, which result in insulin signaling.  Exercise also decreased leptin signaling in the cerebral cortex 
and increased leptin signaling in the hypothalamus.36  However, only one trial reported the 
positive effects of exercise on insulin and leptin signaling, thus more trials is need to confirm other 
insulin and leptin singling outcomes in the regional brain after exercise.   
 
Glucocorticoid receptor (GR) 
Two RCT trials with voluntary and forced aerobic exercise reported significant change in GR.  
One trial reported increased GR,33 but another one reported decreased GR.34  However, no 
consistent pattern has been demonstrated for other GR synthesis outcomes in the regional brain.  
Further investigation is required to confirm these findings and assess the relevance to enhanced 
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glucocorticoid receptor in hippocampus after exercise. 
 
Neurotransmitters 
Glutamate, the most common neurotransmitter in the brain, is an excitatory neurotransmitter 
involved in many aspects of brain function, including learning and memory.49  Animal studies 
have shown that treadmill running significantly increases glutamate levels during and for a short 
while following exercise in healthy rats.50  In rats with diabetes, aerobic training markedly 
improved glutamate, but not GABA.41  The changes of glutamate (93%) after exercise training 
in T1DM rats were similar to those in a healthy control group (82%),41 it is clear from the trials 
included in this review that increases in glutamate was observed in aerobic group,  There is only 
one non-randomised controlled trial , thus more trials should be considered if aerobic exercise 
improves the positive adaptations above in neurotransmitters (glutamate) with various strain and 
species animal models. 
 
2.5.3 COGNITIVE PERFORMANCE 
In three studies (two NRCTs and one RCT) of forced treadmill training,30, 38, 39 significant large 
ESs were reported for learning and memory.  In healthy rodents, a previous review reported both 
voluntary wheel running and forced treadmill training have also been shown to enhance spatial 
learning using different types of mazes (such as water, radial maze).51  Running improved 
memory performance in other hippocampus-dependent tasks in healthy rodents.52  Thus the 
adaptations of the current review of animals with diabetes are in accordance with the adaptations 
observed in healthy animal models, although the extent of the literature is very small at present. 
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2.5.4 FUNCTIONAL SIGNIFICANT OF NEUROGENESIS, NEUROPLASTICITY AND NEUROTROPHIC FACTOR 
Data available suggest that improvements in learning and memory may be partially mediated by 
increases in hippocampal neurogenesis,53-56 although the role of neurogenesis in these functions is 
controversial at present.57  The results in our review showed increases in cell proliferation with a 
concomitant improvement (40.5%) in memory (step-through passive avoidance) (Table 2.7)39.  
Physical activity has also been shown to improve neural cell proliferation in the hippocampus in 
elderly rats with diabetes.39  There is evidence that exercise stimulated proliferation of the neural 
progenitor population, increased the number of new neurons, and promotes survival of these new 
cells.23, 58  New formed neurons can integrate into a neural network and become functional.59  
Exercise has also been reported to induce cell proliferation is associated with enhanced synaptic 
plasticity in key brain areas for learning and memory,52 such as the hippocampus where synaptic 
neurotransmitters and their receptor are responsive to exercise.  In particular, cFos expression in 
the hippocampal is believed to play crucial roles in neuroplasticity and neurogenesis associated 
with spatial learning and memory.  
 
In our review, cell proliferation and cFos expressions were compared in hippocampal slices from 
running and control rats with diabetes.  Increased cell proliferation and cFos were accompanied 
by memory in running group compared to diabetes control rats.  However, there is only two trials 
included in this review that demonstrated improvements in memory were partially dependent on 
increases in cell proliferation and cFos in the hippocampal rats with diabetes.30, 39  Thus, future 
studies should specifically aim to link cognitive performance with potential underlying adaptations 
in cerebral structure and metabolism to further understanding of the most important mediators of 
such functional improvements.  Understanding of this pathway may allow development of more 
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specific exercise interventions designed to maximally stimulate the most relevant components. 
 
Exercise resulted in a greatly increased growth factor in the hippocampus.60  Increases in growth 
factors expression may potentially explain changes in cell proliferation, learning and memory 
(Morris water maze), exercise, and synaptic plasticity.61  Trophic factors that influenced adult 
neurogenesis and synaptic plasticity, included nerve growth factor and BDNF in healthy and 
insulin resistance animal models.60, 62-64  Increases in hippocampal BDNF levels are thought to 
contribute to the upregulation of adult dendritic spine density in hippocampus that is observed 
aerobic treatment.65  Indeed, animal studies have shown that hippocampal BDNF levels are 
decreased in patients with diabetes and exercise intervention can ameliorate this deficit associated 
with synapse plasticity.65  On the basis of the extensive literature linking plasticity among spines 
with synaptic function66, and the relationship between spine and synapse plasticity and 
hippocampus-dependent memory67, it is possible that hippocampal BDNF mediates the efficacy 
of exercise on synapse plasticity hippocampus-dependent memory.  Consistent with these 
previous findings, in one trial, enhanced BDNF level and dendritic spine density were observed 
after aerobic exercise in the mice hippocampus with T2DM. 
 
Much like BDNF, increases in NGF, TrkA, p-Erk1/2, and p-CREB protein levels may explained a 
significant portion of the variance in cell proliferation, synaptic plasticity, and memory.  Previous 
results from available animal studies have strongly demonstrated that decreased NGF and TrkA 
levels are associated with the impaired function of cholinergic neurons.68, 69  Clinical trials have 
shown that patients with mild cognitive impairment had low TrkA and NGF levels.70, 71  Recently 
animal studies have strongly demonstrated that NGF and TrkA is a crucial mediator of exercise-
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induced neuroplasticity and brain function.46, 64, 72  In agreement with this idea, this reviewed 
reported that aerobic exercise as a fitness intervention for the rats with diabetes significantly 
increases the NGF and TrkA while also increasing cell proliferation and improving memory in 
hippocampus of rats with insulin resistance / diabetes.39   
 
Meanwhile, many investigators have contribute to an understanding potential relationships 
between the molecular, cellular, and cognitive behavour after exercise.  Rodents studies 
performed by Shen et al73 has shown that exercise upregulates multiple proteins involved in signal 
transduction (protein kinase C (PKC), calcium-calmodulin-dependent protein kinase II and IV, and 
mitogen-activated extracellular-signal-regulated kinases protein kinase (MAPK), transcriptional 
regulation (cyclic AMP response element binding protein (CREB)), BDNF, and neurotramitters 
(increased glutamate level).  Current study suggests that the molecular mechanisms by which 
exercise stimulates cellular regeneration via the upregulation of growth factors (BDNF and NGF) 
through a calmodulin-dependent protein kinase and CREB.  It is thought that a calcium influx in 
the setting of metabolic demand stimulates the calmodulin-dependent protein kinase, which in 
return phosphorylates CREB.  CREB drives the synthesis of BDNF, providing further activate 
CREB.  Moreover, CREB phosphorylated by MAPK modifies the plasticity of neurons and is 
involved in controlling the formation of long-term memories.74  Impey et al.75 and Russo-
Neustadt et al.76 reported that 1 or 2 days of maximal running increased p-CREB levels in the 
hippocampus, and that these effects lasted for 7 days.  Shen et al. (2001)73 observed that MAPK 
and CREB levels were high in the hippocampus of animals that had exercised for longer periods, 
extending from 1 week to 1 month.  Our review in agreement with our previous study,72 in which 
regular physical exercise activate MAPK/Erk and CREB in the hippocampus, which results in the 
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increased retrograde transport of NGF.  Thus, it is suggested that the improvement of cognitive 
function by exercise in animal models with diabetes, induces phosphorylated CREB and facilitates 
NGF signaling by activity MAPK/Erk1/2  It is clear that growth factors and growth factor 
signaling cascades are central regulatory mechanisms underlying the effects of exercise in the CNS.  
However, the two concomitant relationships reported in this review30, 39 do suggest that increases 
in neurogenesis and synapse plasticity and trophic factors may potentially contribute to the 
improvements in memory in animals with diabetes exposed to aerobic exercise.  Increases in 
neurogenesis and synapse plasticity involved in dependent-hippocampal memory may be mediated 
in part by exercise-induced growth factors and growth factor signaling cascades.  If reproduced, 
these results would confirm that physical exercise induces growth neurotropic effects on brain 
structures and functions at the molecular and structural levels in animal animals with diabetes with 
diabetes, providing a rationale for exploring these pathways in human trials. 
 
2.5.5 IMPLICATIONS FOR EXERCISE INTERVENTIONS AND FUTURE RESEARCH 
The findings from this systematic review support the view that one of the goals of aerobic 
interventions for brain disease in diabetes should be maximisation of neurogenesis, neuroplasticity, 
growth factors, and function.  Factors which may be relevant maintain progressive overload and 
adequate intensity, and/or avoiding plateaus in adaptation through varying exercises, which 
supports cerebral metabolism, neuroplasticity, nerve growth factor, and function.53  With only 15 
trials meeting the criteria for this review, further research is required in order to adequately address 
the relationship between increases in neurogenesis, neuroplasticity, nerve growth factor, and the 
improvements in cognitive function on memory in animal models with T2DM.  In particular, the 
current data presented in these trials were performed primarily in animal models of T1DM, 
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whereas 90% of human diabetes is T2DM.  Thus, the relevance of these animal models to the 
bulk of human diabetes is not known, and future animal trials should focus on models of potentially 
more relevance to human disease.  Additionally, there was not much discussion or exploration of 
the mechanistic links between morphology, biochemistry, and cognitive performance, which future 
studies should focus on.  There is also evidence from human studies that many forms of exercise 
(aerobic exercise, resistance training, combinations of resistance and aerobic exercise,) may have 
a beneficial effect on cognitive impairment and dementia.  As all of the animal studies to date 
have utilised aerobic exercise, exploration of resistance training models is warranted in future 
animal investigations in this field. 
 
Finally, it is possible that heterogeneous outcomes in the trials reviewed may be due to differences 
in species, genetics, age, weight, metabolic condition, specific exercise paradigms (modality, 
voluntary/forced, intensity, dose), and behavioural tasks used, but these influences are poorly 
understood as of yet.  Identifying and addressing the possible reasons why animals are likely to 
be unresponsive to aerobic exercise may improve aerobic training-induced outcomes within future 
trials.  Future studies specifically designed for the investigation of the direct relationships 
between improvements in neurogenesis, neuroplasticity, and signaling pathways and cognitive 
health of animals with models T2DM are particularly warranted. 
 
In conclusion, the limited data available suggest that aerobic exercise improves brain structure, 
biochemistry, and function in animal models with diabetes or insulin resistance or hyperglycaemia, 
while there is insufficient evidence exploring any relationship between improvements in 
hippocampus-dependent memory task and increases of cell proliferation, cFos, and growth factor 
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in animal models of T1DM or T2DM.  Future research in this field should include robust 
measures of hippocampus structure and biochemistry profile, and explore the species, genetic, 
clinical and physiological factors that potentially mediate the relationships between these two 
domains.  Such investigations will lead to a better understanding of the mechanisms underlying 
the exercise-induced cognitive improvements and ultimately to the design of interventions 
specifically targeting cerebral structure plasticity and biochemistry tailored to the mechanisms 
identified and to the unique needs of specific individuals or cohorts.
116 
 
Conflict of interest 
The authors declare that they have no conflict of interest. 
  
117 
 
2.5 REFERENCES 
1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 
2030. Diabetes Res Clin Pract. 2010;87: 4-14. 
2. Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S. Inflammation and insulin 
resistance are independently related to all-cause of death and cardiovascular events in Japanese 
patients with type 2 diabetes mellitus. Atherosclerosis. 2003;169: 317-321. 
3. Yun WJ, Shin MH, Kweon SS, et al. [A comparison of fasting glucose and HbA1c for the 
diagnosis of diabetes mellitus among Korean adults]. J Prev Med Public Health. 2010;43: 451-454. 
4. Kawamura T, Umemura T, Hotta N. Cognitive impairment in diabetic patients: Can diabetic 
control prevent cognitive decline? J Diabetes Investig. 2012;3: 413-423. 
5. Lazarus R, Prettyman R, Cherryman G. White matter lesions on magnetic resonance imaging 
and their relationship with vascular risk factors in memory clinic attenders. Int J Geriatr Psychiatry. 
2005;20: 274-279. 
6. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal 
lobe structures on brain MRI. Diabetologia. 2003;46: 1604-1610. 
7. Lehericy S, Baulac M, Chiras J, et al. Amygdalohippocampal MR volume measurements in the 
early stages of Alzheimer disease. AJNR Am J Neuroradiol. 1994;15: 929-937. 
8. Wang SH, Sun ZL, Guo YJ, Yuan Y, Yang BQ. Diabetes impairs hippocampal function via 
advanced glycation end product mediated new neuron generation in animals with diabetes-related 
depression. Toxicol Sci. 2009;111: 72-79. 
9. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral 
streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers 
Dis. 2006;9: 13-33. 
118 
 
10. Marwarha G, Ghribi O. Leptin signaling and Alzheimer's disease. Am J Neurodegener Dis. 
2012;1: 245-265. 
11. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-
analytic study. Psychol Sci. 2003;14: 125-130. 
12. Hillman CH, Motl RW, Pontifex MB, et al. Physical activity and cognitive function in a cross-
section of younger and older community-dwelling individuals. Health Psychol. 2006;25: 678-687. 
13. Radak Z, Kaneko T, Tahara S, et al. Regular exercise improves cognitive function and 
decreases oxidative damage in rat brain. Neurochem Int. 2001;38: 17-23. 
14. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise 
on synaptic plasticity and cognition. Eur J Neurosci. 2004;20: 2580-2590. 
15. Etgen T, Sander D, Huntgeburth U, Poppert H, Forstl H, Bickel H. Physical activity and 
incident cognitive impairment in elderly persons: the INVADE study. Arch Intern Med. 2010;170: 
186-193. 
16. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident 
dementia among persons 65 years of age and older. Ann Intern Med. 2006;144: 73-81. 
17. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic 
review of prospective evidence. Psychol Med. 2009;39: 3-11. 
18. Middleton LE, Barnes DE, Lui LY, Yaffe K. Physical activity over the life course and its 
association with cognitive performance and impairment in old age. J Am Geriatr Soc. 2010;58: 
1322-1326. 
19. Loprinzi PD, Kane CJ. Exercise and cognitive function: a randomized controlled trial 
examining acute exercise and free-living physical activity and sedentary effects. Mayo Clin Proc. 
2015;90: 450-460. 
119 
 
20. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume 
in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61: 1166-1170. 
21. Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain tissue loss in aging 
humans. J Gerontol A Biol Sci Med Sci. 2003;58: 176-180. 
22. Johnson RA, Rhodes JS, Jeffrey SL, Garland T, Jr., Mitchell GS. Hippocampal brain-derived 
neurotrophic factor but not neurotrophin-3 increases more in mice selected for increased voluntary 
wheel running. Neuroscience. 2003;121: 1-7. 
23. Trejo JL, Carro E, Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-
induced increases in the number of new neurons in the adult hippocampus. J Neurosci. 2001;21: 
1628-1634. 
24. Anderson BJ, Rapp DN, Baek DH, McCloskey DP, Coburn-Litvak PS, Robinson JK. Exercise 
influences spatial learning in the radial arm maze. Physiol Behav. 2000;70: 425-429. 
25. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale 
for rating quality of randomized controlled trials. Phys Ther. 2003;83: 713-721. 
26. Coe R. Effect size calculator, 2006: revised 2006 Sep 13 [online]. Available from URL: 
http://davidmlane.com/hyperstat/effect_size.html [Accessed 2009 Mar 26]. 
27. Cohen J. Statistical power analysis for the behavioural sciences. New York: Academic Press. 
1977. 
28. Lee HH, Shin MS, Kim YS, et al. Early treadmill exercise decreases intrastriatal hemorrhage-
induced neuronal cell death and increases cell proliferation in the dentate gyrus of streptozotocin-
induced hyperglycemic rats. J Diabetes Complications. 2005;19: 339-346. 
29. Leme JA, Gomes RJ, de Mello MA, Luciano E. Moderate physical training increases brain 
insulin concentrations in experimental diabetic rats. Indian J Exp Biol. 2008;46: 443-446. 
120 
 
30. You JS, Kim CJ, Kim MY, et al. Long-term treadmill exercise-induced neuroplasticity and 
associated memory recovery of streptozotocin-induced diabetic rats: an experimenter blind, 
randomized controlled study. NeuroRehabilitation. 2009;24: 291-297. 
31. Yi SS, Hwang IK, Yoo KY, et al. Effects of treadmill exercise on cell proliferation and 
differentiation in the subgranular zone of the dentate gyrus in a rat model of type II diabetes. 
Neurochem Res. 2009;34: 1039-1046. 
32. Gomes RJ, de Oliveira CA, Ribeiro C, et al. Effects of exercise training on hippocampus 
concentrations of insulin and IGF-1 in diabetic rats. Hippocampus. 2009;19: 981-987. 
33. Campbell JE, Kiraly MA, Atkinson DJ, D'Souza A M, Vranic M, Riddell MC. Regular exercise 
prevents the development of hyperglucocorticoidemia via adaptations in the brain and adrenal 
glands in male Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol. 2010;299: 
R168-176. 
34. Hwang IK, Yi SS, Yoo KY, et al. Effect of treadmill exercise on blood glucose, serum 
corticosterone levels and glucocorticoid receptor immunoreactivity in the hippocampus in chronic 
diabetic rats. Neurochem Res. 2011;36: 281-287. 
35. Kim HB, Jang MH, Shin MC, et al. Treadmill exercise increases cell proliferation in dentate 
gyrus of rats with streptozotocin-induced diabetes. J Diabetes Complications. 2003;17: 29-33. 
36. Park S, Jang JS, Jun DW, Hong SM. Exercise enhances insulin and leptin signaling in the 
cerebral cortex and hypothalamus during dexamethasone-induced stress in diabetic rats. 
Neuroendocrinology. 2005;82: 282-293. 
37. Reisi P, Babri S, Alaei H, Sharifi MR, Mohaddes G, Lashgari R. Effects of treadmill running 
on short-term pre-synaptic plasticity at dentate gyrus of streptozotocin-induced diabetic rats. Brain 
Res. 2008;1211: 30-36. 
121 
 
38. Reisi P, Alaei H, Babri S, Sharifi MR, Mohaddes G. Effects of treadmill running on spatial 
learning and memory in streptozotocin-induced diabetic rats. Neurosci Lett. 2009;455: 79-83. 
39. Chae CH, Jung SL, An SH, et al. Treadmill exercise improves cognitive function and facilitates 
nerve growth factor signaling by activating mitogen-activated protein kinase/extracellular signal-
regulated kinase1/2 in the streptozotocin-induced diabetic rat hippocampus. Neuroscience. 
2009;164: 1665-1673. 
40. Stranahan AM, Lee K, Martin B, et al. Voluntary exercise and caloric restriction enhance 
hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus. 2009;19: 
951-961. 
41. Reisi P, Alaei H, Babri S, et al. Effects of treadmill running on extracellular basal levels of 
glutamate and GABA at dentate gyrus of streptozotocin-induced diabetic rats. J Res Med Sci. 
2010;15: 172-174. 
42. Reisi P, Babri S, Alaei H, et al. Treadmill running improves long-term potentiation (LTP) 
defects in streptozotocin-induced diabetes at dentate gyrus in rats. Pathophysiology. 2010;17: 33-
38. 
43. Sanchez MM, Ladd CO, Plotsky PM. Early adverse experience as a developmental risk factor 
for later psychopathology: evidence from rodent and primate models. Dev Psychopathol. 2001;13: 
419-449. 
44. Smith PJ, Blumenthal JA, Hoffman BM, et al. Aerobic exercise and neurocognitive 
performance: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72: 
239-252. 
45. Thomas AG, Dennis A, Bandettini PA, Johansen-Berg H. The effects of aerobic activity on 
brain structure. Front Psychol. 2012;3: 86. 
122 
 
46. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and 
plasticity. Trends Neurosci. 2002;25: 295-301. 
47. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and 
improves memory. Proc Natl Acad Sci U S A. 2011;108: 3017-3022. 
48. Neeper SA, Gomez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature. 
1995;373: 109. 
49. McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. 
Psychopharmacology (Berl). 1993;111: 391-401. 
50. Leung LY, Tong KY, Zhang SM, Zeng XH, Zhang KP, Zheng XX. Neurochemical effects of 
exercise and neuromuscular electrical stimulation on brain after stroke: a microdialysis study using 
rat model. Neurosci Lett. 2006;397: 135-139. 
51. Liu YF, Chen HI, Wu CL, et al. Differential effects of treadmill running and wheel running on 
spatial or aversive learning and memory: roles of amygdalar brain-derived neurotrophic factor and 
synaptotagmin I. J Physiol. 2009;587: 3221-3231. 
52. van Praag H. Neurogenesis and exercise: past and future directions. Neuromolecular Med. 
2008;10: 128-140. 
53. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth 
factor cascades and inflammation. Trends Neurosci. 2007;30: 464-472. 
54. Leuner B, Gould E, Shors TJ. Is there a link between adult neurogenesis and learning? 
Hippocampus. 2006;16: 216-224. 
55. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal 
neurogenesis in aged mice. J Neurosci. 2005;25: 8680-8685. 
56. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, 
123 
 
and long-term potentiation in mice. Proc Natl Acad Sci U S A. 1999;96: 13427-13431. 
57. Llorens-Martin MV, Rueda N, Tejeda GS, Florez J, Trejo JL, Martinez-Cue C. Effects of 
voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a 
model of Down syndrome. Neuroscience. 2010;171: 1228-1240. 
58. Fabel K, Fabel K, Tam B, et al. VEGF is necessary for exercise-induced adult hippocampal 
neurogenesis. Eur J Neurosci. 2003;18: 2803-2812. 
59. van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis 
in the adult hippocampus. Nature. 2002;415: 1030-1034. 
60. Berchtold NC, Chinn G, Chou M, Kesslak JP, Cotman CW. Exercise primes a molecular 
memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. 
Neuroscience. 2005;133: 853-861. 
61. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in 
adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel. 
2006;9: 580-586. 
62. Scardigli R, Capelli P, Vignone D, et al. Neutralization of nerve growth factor impairs 
proliferation and differentiation of adult neural progenitors in the subventricular zone. Stem Cells. 
2014;32: 2516-2528. 
63. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes impairs 
hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat 
Neurosci. 2008;11: 309-317. 
64. Winocur G, Greenwood CE, Piroli GG, et al. Memory impairment in obese Zucker rats: an 
investigation of cognitive function in an animal model of insulin resistance and obesity. Behav 
Neurosci. 2005;119: 1389-1395. 
124 
 
65. Yau SY, Lau BW, Tong JB, et al. Hippocampal neurogenesis and dendritic plasticity support 
running-improved spatial learning and depression-like behaviour in stressed rats. PLoS One. 
2011;6: e24263. 
66. Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. 
Annu Rev Neurosci. 2008;31: 47-67. 
67. Leuner B, Shors TJ. New spines, new memories. Mol Neurobiol. 2004;29: 117-130. 
68. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical 
TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol. 2004;56: 520-531. 
69. Mufson EJ, Conner JM, Kordower JH. Nerve growth factor in Alzheimer's disease: defective 
retrograde transport to nucleus basalis. Neuroreport. 1995;6: 1063-1066. 
70. Granholm AC, Albeck D, Backman C, et al. A non-invasive system for delivering neural 
growth factors across the blood-brain barrier: a review. Rev Neurosci. 1998;9: 31-55. 
71. Niewiadomska G, Baksalerska-Pazera M. Age-dependent changes in axonal transport and 
cellular distribution of Tau 1 in the rat basal forebrain neurons. Neuroreport. 2003;14: 1701-1706. 
72. Chae CH, Kim HT. Forced, moderate-intensity treadmill exercise suppresses apoptosis by 
increasing the level of NGF and stimulating phosphatidylinositol 3-kinase signaling in the 
hippocampus of induced aging rats. Neurochem Int. 2009;55: 208-213. 
73. Shen H, Tong L, Balazs R, Cotman CW. Physical activity elicits sustained activation of the 
cyclic AMP response element-binding protein and mitogen-activated protein kinase in the rat 
hippocampus. Neuroscience. 2001;107: 219-229. 
74. Davis S, Vanhoutte P, Pages C, Caboche J, Laroche S. The MAPK/ERK cascade targets both 
Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent 
gene expression in the dentate gyrus in vivo. J Neurosci. 2000;20: 4563-4572. 
125 
 
75. Impey S, Obrietan K, Storm DR. Making new connections: role of ERK/MAP kinase signaling 
in neuronal plasticity. Neuron. 1999;23: 11-14. 
76. Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW. Physical activity and antidepressant 
treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the 
rat hippocampus. Neuroscience. 2000;101: 305-312. 
77. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with 
acute ischemic stroke: a guideline for healthcare professionals from the American Heart 
Association/American Stroke Association. Stroke. 2013;44: 870-947.
126 
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Original PEDro Scale Additional Modified Criteriac  
Kim, 200335 NRCT 0 0 1 1 0 0 0 1 1 1 1a 0 1 1 8 
Lee, 200528 RCT 1 0 0 1 0 0 0 1 1 1 1a 0 1 1 8 
Park, 200536 NRCT 0 0 0 1 0 0 0 1 1 1 1a 0 1 1 7 
Reisi, 200837 NRCT 0 0 0 1 0 0 0 1 1 1 1a 0 1 0 6 
Leme, 200829 RCT 1 0 0 1 0 0 0 1 1 1 1a 0 1 1 8 
Reisi, 200938 NRCT 0 0 0 1 0 0 0 1 1 1 1a 1 1 0 7 
You, 200930 RCT 1 0 0 1 0 1 0 1 1 1 1a 1 1 1 10 
Yi, 200931 RCT 1 0 0 1 0 0 0 1 1 1 1a 0 1 0 7 
Gomes,200932 RCT 1 0 0 1 0 0 0 1 1 1 1a 0 1 0 7 
Chae, 200939 NRCT 0 0 0 1 0 0 0 1 1 1 1a 0 1 0 6 
Stranhan,200940 NRCT 0 0 0 1 0 0 0 1 1 0 1b 0 1 0 5 
Reisi, 200941 NRCT 0 0 0 1 0 0 0 1 1 1 1a 0 1 0 6 
Reisi, 201042 NRCT 0 0 0 1 0 0 0 1 1 1 1a 0 1 0 6 
Campbell,201033 RCT 1 0 0 1 0 0 0 1 1 0 1b 0 1 1 7 
Hwang,201134 RCT 1 0 0 1 0 0 0 1 1 1 1a 0 1 0 7 
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Notes: 
aForced exercise (supervision) is associated with certain level of stress, involved a slower, more consistent pace for longer periods of 
time. 
bVoluntary exercise (non-supervision) is characterized by rapid pace and short duration, which allows rats/mice to freely use running 
wheel exercise with recorded distance traveled, average speed and time spent daily by computer system. 
cAuthor added 5 criteria related to animal studies. 
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TABLE 2.2 ANIMAL CHARACTERISTICS 
Citation Animal type Metabolic condition Treatments 
 
 
Inclusion Group (n) Total 
n 
Author,  
Year 
Reference 
Species Age  
(day)  
Weight (g) % men 
Kim, 
200335 
SDR 
 
35 150 ± 10g 
 
100 T1DM STZ BGL>300mg/dl  8 / group 
(4 groups) 
8 / CO 
8 / EX, 
8 / DC 
8 / DE 
32 
Lee, 
200528 
SDR  63  250 ± 10 100 T1DM/HG STZ BGL>300mg/dl 6 / group 
(5 groups) 
6 / CO  
6 / DC 1 
6 / DC2 
6 / DE3 
6 / DE4 
30 
Park, 
200536 
SDR  NR  235 ± 16 100 T2DM/IR PAN BGL>9.4 mm (6 groups) 
9 / DC 
8 / DCL 
9 / DCH 
9 / DE 
10 / DEL 
10 / DEH 
55 
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TABLE 2.2 ANIMAL CHARACTERISTICS - CONTINUED 
Citation Animal type Metabolic condition Treatments 
 
 
Inclusion Group (n) Total 
n Author,  
Year 
Reference 
Species Age  
(day)  
Weight (g) % men 
Raise,  
200837 
WR NR 150-180 100 T1DM STZ BGL>300mg/dl 10 / group 
(4 groups) 
10 / CO 
10 / EX 
10 / DC 
10 / DE 
40 
Leme,  
200829 
WR 56  175-200 100 T1DM ALL BGL>600mg/dl 8 / group 
(4 groups) 
8 / CO 
8 / EX 
8 / DC 
8 / DE 
32 
Reisi, 
200938 
WR NR 230 ± 20 100 T1DM STZ BGL>300mg/dl (4 groups) 
11/ CO 
10 / EX 
8 / DC  
8 / DE  
37 
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TABLE 2.2 ANIMAL CHARACTERISTICS - CONTINUED 
Citation Animal type Metabolic 
condition 
Treatments 
 
 
Inclusion Group (n) Total 
n Author,  
Year 
Reference 
Species Age  
(day)  
Weight (g) % men 
You, 
200930 
SDR 84  300 ± 20 100 T1DM STZ BGL≥280mg/dl 5 / group 
3 group 
5 / CO 
5 / DC 
5 / DE 
15  
Yi, 
200931 
ZDF 42  125-150 50 T2DM MM BGL=118.7mg/dl 8 / group 
(4 groups) 
8 / CO 
8 / EX 
8 / DC 
8 / DE 
32 
Gomes, 
200932 
WR 38 175-200 100 T1DM ALL BGL14–35 mmol/l 10 /group 
(4 groups) 
10 / CO 
10 / EX 
10 / DC 
10 / DE 
40 
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TABLE 2.2 ANIMAL CHARACTERISTICS - CONTINUED 
Citation Animal type Metabolic 
condition 
Treatments 
 
 
Inclusion Group (n) Total 
n Author,  
Year 
Reference 
Species Age  
(day)  
Weight 
(g) 
% men 
Chae,  
200939 
  SDR
  
63 250 - 320 100 T1DM STZ BGL>300mg/dl (4 groups) 
10 / CO 
10 / EX 
10 / DC 
10 / DE 
40 
Stranahan, 
200940  
Mice  30  NR 100 T2DM/IR PM BGL>271mg/dl* 6 / group  
6 / DC 
6 / DE 
6 / DCR 
6 / DER 
24 
Reisi,  
200941 
WR NR 230 ± 20 100 T1DM STZ BGL>300mg/dl 6-7/ group  
(4 groups) 
6-7 / CO 
6-7 / EX 
6-7 / DC 
6-7 / DE 
24-28 
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TABLE 2.2 ANIMAL CHARACTERISTICS - CONTINUED 
Citation Animal type Metabolic 
condition 
Treatments 
 
 
Inclusion Group (n) Total 
n Author,  
Year 
Reference 
Species Age  
(day)  
Weight (g) % men 
Reisi,  
200942 
WR NR 160 ± 15 100 T1DM STZ BGL>300mg/dl 6 / group  
(3 groups) 
6 / CO  
6 / DC  
6 / DE  
18 
Campbell, 
201033 
ZDF 42 150-175 100 T2DM MM BGL 6.5-6.6mM (3 groups) 
8 / CO  
8 / DC  
9 / DE  
25 
Hwang, 
201134 
ZDF
  
161 NR 50 T2DM MM BGL 30.9±1.7mmol/l 7/ group  
(4 groups) 
7 / CO 
7 / EX 
7 / DC 
7 / DE 
28 
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Notes: 
Data is presented as mean ± SD or Median (range) 
%men is represented in percent 
Streptozotocin (Streptozocin, STZ, Zanosar®) and alloxan are a naturally occurring chemical that is particularly toxic to destroy the insulin-
producing beta cells of the pancreas in mammals.  It is used to produce an animal model for T1DM in large dose 
Zucker fatty (ZDF) rat with diabetes is considered to be an excellent animal model of T2DM that presents a physiological and metabolic profile 
similar to those seen in humans, and male ZDF rats develop a phenotype of obesity, insulin resistance, and hyperglycemia 
db/db mouse is a model of obesity, diabetes, and dyslipidemia  
* represents the blood glucose level estimated from graphics 
SD: Spregue Dawley rat 
WR: Wistar rat 
db/db Mice: C57Bl/6 mice 
ZDF: Zucker fatty rat with diabetes 
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T1DM: Type 1 diabetes mellitus 
T2DM: Type 2 diabetes mellitus 
IR: Insulin resistance 
HG: Hyperglycemia 
 1DC: Hyperglycemia 
2 DC: Hyperglycemia - hemorrhage 
3DEE: Hyperglycemia – hemorrhage early exercise  
4DLE: Hyperglycemia – hemorrhage later exercise 
CO: Control 
EX: Exercise  
DC: Diabetes control 
DE: Diabetes exercise 
DCR: Diabetes control diet restrict 
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DER: Diabetes control diet restrict exercise 
DCL: Diabetes control- low dexamethasone 
DCH: Diabetes control-high dexamethasone 
DEL: Diabetes exercise- low dexamethasone 
DEH: Diabetes exercise-high dexamethasone 
STZ: Streptozotocin 
ALL: Alloxan 
MM: Missense mutation 
PM: Point mutation 
NR: Not reported  
FBG: Fed glucose level 
BGL: Blood glucose level  
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TABLE 2.3 INTERVENTION CHARACTERISTICS 
Citation Exercise intervention 
Control  
treatment 
Author,  
Year 
Reference 
Type Volume 
(minute 
or meter)  
Frequency 
(day/week) 
Duration 
(weeks) 
Intensity (minute) 
Kim, 
200335 
Aerobic exercise 
(Treadmill) 
Forced and supervised 
30 7 1  0 degree of inclination 
2 m / min × 5 min 
5 m / min × 5 min 
8 m / min × 20 min 
No exercise on 
treadmill for 30 
minutes  
Lee, 
200528 
Aerobic exercise 
(Early treadmill )a 
Forced and supervised  
 
Aerobic exercise 
(Late treadmill) b 
Forced and supervised 
30 7 1 week (early) 
 
 
 
More than one 
week (later) 
0 degree of inclination 
2 m / min × 5 min 
5 m / min × 5 min 
8 m / min × 20 min 
No exercise on 
treadmill for 30 
minutes 
Park, 
200536 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
30 4 8 0o inclination 
20 m / min × 30 min 
 
No exercise on 
treadmill for 30 
minutes 
Reisi, 
200837 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
 
40 7 12 0 degree of inclination 
5-17 m / min × 10 min at initial 
workload until 40 min at 1st week 
17 m / min × 40 min at 2nd week until 
12 week 
No exercise on 
treadmill for 40 
minutes 
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TABLE 2.3 INTERVENTION CHARACTERISTICS - CONTINUED 
Citation Exercise intervention Control  
treatment 
 
Author, 
Year 
Reference 
Type Volume 
(minute 
or meter) 
Frequency 
(day/week) 
Duration 
(weeks) 
Intensity (minute) 
Leme,  
200829   
  
Aerobic exercise 
(swimming) 
Forced and supervised 
60 5 4 5% of the body weight No exercise on 
swimming for 60 
minutes 
Reisi, 
200938 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
 
40 7 12 0o inclination 
(5-17 m) / min × (10-40 min) at initial  
workload for 5 days 
 
17 m / min × 40 min at second week until 
12 weeks 
No exercise on 
treadmill for 40 
minutes 
You, 
200930 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
30 7 6 0 degree of inclination  
4000 m / min for 5 min 
5000 m / min for 5 min 
7000 m / min for 20 min 
No exercise on 
treadmill for 30 
minutes 
Yi, 
200931 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
 
60 5 5 0o inclination 
15 m / min × 15 min 
at initial workload for 1st week 
 
22 m / min × 60 min for 2nd week the speeds 
accelerated 2m / min per-2 week 
No exercise on 
treadmill for 60 
minutes 
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TABLE 2.3 INTERVENTION CHARACTERISTICS - CONTINUED 
Citation Exercise intervention Control  
treatment 
 
Author,  
Year 
Reference 
Type Volume 
(minute or 
meter)  
Frequency 
(day/week) 
Duration 
(weeks) 
Intensity (minute) 
Gomes, 
200932 
Aerobic exercise 
(swimming) 
Forced and supervised  
 
 
60 5 7 90% MLSS x 60 min in load of 4% of body 
weight at 2nd week 
90% MLSS x 60 min in load of 5% of body 
weight at 4th week 
90% MLSS x 60 min in load of 6% of body 
weight at 6th week 
No swimming 
exercise for 60 
minutes 
Chae, 
200939 
Aerobic exercise 
(Treadmill) 
Forced and supervised  
 
30 5 7 0 degree of inclination 
10 m / min × 10 min in 1st week 
20 m / min × 20 min in 2nd week 
10-14 m / min × 20 min in 3rd week 
14-15 m / min × 30 min in 4th week 
17-18 m / min  × 30 min in 5th week 
No exercise on 
treadmill for 30 
minutes 
Stranahan, 
200940 
Aerobic exercise 
(wheel running) 
voluntary and 
nonsupervised  
1800 
meters 
Continuously 
available 
12 NR No exercise and 
diet restriction  
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TABLE 2.3 INTERVENTION CHARACTERISTICS - CONTINUED 
Citation Exercise intervention Control  
treatment 
 
Author,  
Year 
Reference 
Type Volume 
(minute or 
meter)  
Frequency 
(day/week) 
Duration 
(weeks) 
Intensity (minute) 
Reisi, 
200941 
Aerobic exercise 
(Treadmill)  
Forced and supervised  
 
40 7 12 0 degree of inclination 
2 m / min × 5 min 
5 m / min × 5 min 
8 m / min × 20 min 
No exercise on 
treadmill for 40 
minutes 
Reisi, 
200942 
Aerobic exercise 
(Treadmill)  
Forced and supervised  
 
40 7 12 0 degree of inclination 
5-17 m / min × 10 min initial workload until  
40 min at 1st week 
17 m / min × 40 min at 2nd week until 12 
weeks 
No exercise on 
treadmill for 40 
minutes 
Campbell,  
201033 
Aerobic exercise 
(Wheel running)  
Voluntary  
Non-supervised 
3500-6500 
meters 
Continuously 
available 
10 NR No exercise 
 
 
 
Hwang, 
201134 
Aerobic exercise 
(Treadmill)  
Forced and supervised  
 
60 5 7 12 m / min x 60 min initial workload 1st 
week 
13 m / min × 20 min in 3rd week 
14 m / min × 30 min in 5th week 
15 m / min × 30 min in 7th week 
No exercise on 
treadmill for 60 
minutes 
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Notes: 
NR: Not reported 
MLSS: Maximal lactate steady state
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TABLE 2.4 ANIMAL BRAIN MORPHOLOGICAL OUTCOMES 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Kim,  
200335 
30 minutes BrdU-positive cells 
in dentate gyrus 
BrdU Immune- 
histochemistry 
DC 
DE 
40.25 ± 8.20*  
83.25 ± 9.10* 
<0.05 (DE vs DC) +106.8  4.64 (2.76, 6.52) 
Lee,  
200528 
Immediate Lesion volume In 
the striatum 
 
 
The number of 
TUNEL-positive 
cells 
 
Cell proliferation in 
the dentate gyrus 
Nissal Staining, 
Image-pro plus 
image analyzer 
 
TUNEL staining 
 
 
 
BrdU Immune-
histochemistry 
DCa 
DEE 
DEL 
 
D  DCa 
DEE 
DEL 
 
DCa 
DEE 
DEL 
9.90 ± 2.00* 
8.26 ± 1.76* 
9.20 ± 1.27*  
 
138.9 ± 31.5* 
96.7 ± 25.1* 
129.1 ± 33.2*  
 
39.64 ± 21.68* 
126.42 ± 39.70* 
106.57 ± 30.99*  
<0.05 (DEE vs DC) 
NS (DLE vs DC) 
 
 
<0.05 (DEE vs DC) 
NS (DLE vs DC) 
 
 
<0.05 (DEE vs DC) 
<0.05 (DLE vs DC) 
 
-12.0  
-7.6 
 
 
-43.6 
-7.5  
 
 
+317.9 
+268.8 
 
-1.96 (-3.34,-0.58) 
0.57 (-0.59,1.72) 
 
 
-2.87 (-4.48, -1.26) 
-1.32 (-2.56,-0.07) 
 
 
2.50 (0.99, 4.01) 
2.31 (0.85, 3.77) 
Reisi, 
200837 
Immediate Paired pulse index 
(%) 
 
EPSP slope index 
(%) 
Electrophysiological 
recording  
 
Electrophysiological 
recording 
DC 
DE 
 
DC 
DE 
355.50 ± 45.00* 
88.53 ± 24.51*  
 
236.72± 65.71*  
51.33 ± 31.1*  
<0.05 (DE vs DC) 
 
 
<0.05 (DE vs DC) 
-301.5 
 
 
-361.1 
-3.09(-4.77,-1.42) 
 
 
-3.36(-5.12,-1.60) 
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TABLE 2.4 ANIMAL BRAIN MORPHOLOGICAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
You, 
200930 
 
Immediate The number of cFos 
positive cells in the 
hippocampus 
The Image-Pro® 
Plus computer-
assisted image 
analysis system 
DC 
DE 
93.99 ± 82.00*  
181.58±102.50* 
<0.05 (DE vs DC) +93.2 0.96 (0.67,1.25) 
Yi, 
200931 
 
 
 
 
 
 
 
 
 
 
 
NR 
 
 
 
 
 
 
 
 
 
 
 
 
Density of cells in  
the dentate gyrus  
 
Ki67 cells  
 
 
Granule cells 
 
 
DCX positive cells 
with tertiary dendrites 
 
DCX positive cells 
without tertiary dendrites 
Immunohisto-
chemistry 
 
 
 
 
Western Blot  
Analysis 
 
 
 
 
 
DC 
DE 
 
DC 
DE  
 
DC 
DE  
 
DC 
DE 
 
DC 
DE 
104.72 ± 9.52 
200.00 ± 57.12 
 
44.00 ± 12.50 
275.00 ±50.00  
 
229629±29629 
259259±37037 
 
885.00 ± 142.50 
5130.00 ± 885.00 
 
1896.05 ± 172.41 
3625.68 ± 431.00 
<0.05 (DE vs DC) 
 
 
<0.05 (DE vs DC) 
 
 
NS 
 
 
<0.05 (DE vs DC) 
 
 
<0.05 (DE vs DC) 
+90.1 
 
 
+525.0 
 
 
+12.9 
 
 
+479.6 
 
 
+91.2 
2.2 (0.96, 3.44) 
 
 
5.99 (3.70, 8.29) 
 
 
0.84 (-0.19, 0.86) 
 
 
17.81 
(11.56, 24.08) 
 
4.97 (2.99, 6.95) 
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TABLE 2.4 ANIMAL BRAIN MORPHOLOGICAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Chae, 
200939 
  
Immediate The number of  
BrdU-labeled cells 
Immunohisto-
chemistry 
DC 
DE 
176.40 ± 29.40 
335.51 ± 17.64  
<0.01 (DE vs DC) +90.1 6.28 (4.15, 8.42) 
Stranahan, 
200940 
 
Immediate Dendritic spine density 
 
 
Dendritic spine length 
Golgi 
impregnation 
and analysis 
DCb 
DEc 
 
DCb 
DEc 
15.00 ± 0.86 
16.50 ± 0.35 
 
1090 ± 327.24 
1277 ± 489.60 
<0.05 (DE vs DC) 
 
 
NS (DE vs DC) 
+11 
 
 
+11.7 
2.11(0.70,3.52) 
 
 
0.40 (-0.74,1.55) 
Reisi, 
200942 
Immediate Long term potential - 
population spike 
 
Long term potential - 
field excitatory post-
synaptic potential slope 
Power-lab / 4SP, 
AD instruments, 
Australia 
DC 
DE 
 
DC 
DE 
237.80 ± 21.60 
319.00 ± 27.70 
 
236.40 ± 63.10 
355.24 ± 48.97 
<0.01 (DE vs DC) 
 
 
<0.05 (DE vs DC) 
+34.1 
 
 
+50.2 
 
3.02 (1.36, 4.67)  
 
 
1.94 (0.57, 3.31) 
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 Notes: 
Higher BrdU-positive cells in dentate gyrus indicate to increase new nervous cell formation.  
Higher cFos expressions indicate better synaptic plasticity. 
Higher dendritic spine density indicates better synaptic plasticity. 
Higher field excitatory post-synaptic potential (fEPSP) slope and population spike (PS) amplitude indicate better synaptic plasticity. 
Higher number of TUNEL-positive cells indicates to decrease new nervous cell formation. 
Higher paired puLse and excitatory post-synaptic potential values indicate worse synaptic plasticity.  
TUNEL staining detects DNA fragmentation and neurons death. 
cFos is immediate early gene, whose expression is considered as a marker for stimuli-induced changes in the metabolic activity of neurons, and  
cFos upregulation in the hippocampus is known to be associated with enhanced spatial memory capacity. 
Ki67 and doublecortin (DCX) immunoreactivity, which is a marker of cell proliferation expressed during cell cycles and a marker of progenitors 
differentiating into neurons in the subgranular zone of the dentate gyrus, respectively. 
+/- represents increase/decrease. 
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Results reported in Mean +/-SD. 
* SEM were converted from SD. 
Between group effect size = (mean change in treatment –mean change in control)/pooled baseline SD.26 
SD: standard deviation 
EPSP: Excitatory post-synaptic potential 
Brud: Bromodeoxyuridine. 
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling 
TSLEB: Time since last exercise bout 
DE: Diabetes exercise 
DC: Diabetes control 
aDC: Hyperglycemic hemorrhage 
bDC: db/db sedentary 
cDE: db/db sedentary running 
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NR: Not reported 
NS: Not significant 
vs: Versus 
CI: confidence interval 
UTBC: Unable to be calculated; Data was estimated from graphics
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TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Park, 
200536 
Immediate 
 
Biochemical 
Measurement 
 
 
 
 
 
 
 
DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE 
DCa 
DEa  
DCa 
DEa 
18.15 ± 1.89 
19.03 ± 1.83 
NR 
NR 
11.30 ± 1.33 
13.30 ± 1.00 
17.00 ± 1.67 
19.70 ± 1.67 
15.80 ± 1.67 
20.00 ± 2.00 
15.80 ± 1.67 
20.00 ± 2.00 
0.86 ± 0.10 
1.38 ± 0.19 
1.90 ± 0.20 
2.40 ± 0.26 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC)  
 
<0.05 (DE vs DC) 
  
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
+4.8 
 
 
 
+10.4 
 
+11.6 
 
+26.5 
 
+26.5 
 
+60.4 
 
+2.6 
0.45 (-0.49, 1.39)  
 
UTBC 
 
1.62 (0.55, 2.68) 
 
1.55(0.55, 2.55) 
 
2.17 (1.01, 3.34) 
 
2.17 (1.01, 3.34) 
 
3.26 (1.85, 4.67) 
 
2.05 (0.58, 3.19) 
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TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Park, 
200536 
Immediate 
pAkt / Akt (cerebral cortex) 
 
IRS2 / ps85 (Hypothalamus) 
 
IRS2 / PY20 (Hypothalamus) 
 
pAkt / Akt (Hypothalamus) 
 
Levels of glucokinase / p85  
(cerebral cortex) 
GLUT2 (cerebral cortex) 
 
Levels of lucokinase / p85 
(Hypothalamus) 
GLUT2 (Hypothalamus) 
Immunoblot 
 
DCa 
DEa  
DCa 
DEa  
DCa 
DEa  
DCa 
DEa 
DCa 
DEa  
DCa 
DEa  
DCa 
DEa  
DCa 
DEa  
0.48 ± 0.10 
0.95 ± 0.14 
0.48 ± 0.05 
0.69 ± 2.67 
1.33 ± 0.14 
2.50 ± 0.10 
0.19 ± 0.05 
0.64 ± 0.10 
0.89 ± 0.08 
1.33 ± 0.11 
0.25 ± 0.06 
0.49 ± 0.03  
0.93 ±0.14 
1.50 ± 0.18 
0.35 ±0.14 
0.54 ±0.17 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
+97.9 
 
+43.8 
 
+87.9 
 
+236.8 
 
+49.4 
 
+96.0 
 
+50.5 
 
+54.3 
3.68 (2.16, 5.20) 
 
1.52(0.52,  2.52) 
 
9.16(6.03, 12.29) 
 
5.42 (3.42, 7.42) 
 
4.36 (2.66, 6.05) 
 
5.04 (4.47, 5.60) 
 
3.37 (1.93, 4.80) 
 
1.53 (1.22, 1.85) 
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TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES - CONTINUED 
Citation Time 
point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Leme, 
200829 
48 hours Hippocampus insulin 
contents 
Radioimmuno-
assay 
DC 
DE  
1.89 ± 0.89 
6.00 ± 2.44 
<0.05 (DE vs DC) +217.4 2.12 (0.89, 3.34) 
Gomes, 
200932 
48 hours Hippocampus insulin 
levels 
Hippocampus glycogen 
 
Hippocampus insulin-like 
growth factor-I levels  
Radioimmuno-
assay 
Colorimetry 
Immunoradio-
metricassay 
DC 
DE  
DC 
DE  
DC 
DE  
5.20 ± 4.60 
7.60 ± 3.20 
0.058 ± 0.030 
0.052 ± 0.026 
0.80 ± 0.27 
0.88 ± 0.27 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
+46.1 
 
-10.3 
 
+10.0 
0.58 (-0.31, 1.47) 
 
-0.38 (-0.45,1.26) 
 
-0.30 (-0.18,0.58) 
Chae, 
200939 
 
 
 
 
 
 
Immediate 
 
 
 
 
 
 
 
Nerve growth factor 
 
TrkA 
 
P75 receptor protein level 
 
t-PI3-K 
 DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE  
100.00 ± 6.25 
225.00± 37.50 
100.00 ± 0.00 
208.75 ± 37.50 
84.61 ± 7.69 
80.76 ± 3.85 
100.00 ± 2.78 
100.00 ± 1.39 
<0.01 (DE vs DC) 
 
<0.01 (DE vs DC) 
 
N (DE vs DC) 
 
NS (DE vs DC) 
+125.0 
 
+108.8 
 
-4.7 
 
0.00 
4.45 (2.82, 6.09) 
 
3.93 (2.43, 5.43) 
 
0.48 (-0.41, 1.37) 
 
0.00 (-0.88, 0.88) 
150 
 
TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Chae, 
200939 
Immediate p-PI3-K 
 
Caspase-3 protein  
 
t-Erk1 (p44) 
 
t-Erk2 (p42) 
 
p-Erk1(p44) 
 
p-Erk2 (p42) 
 
t-CREB 
 
p-CREB 
Chemical test 
(EDTA,  
SDS-PAGE, TBST) 
DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE 
DC 
DE  
DC 
DE  
DC 
DE  
DC 
DE 
92.00 ± 14.70 
104.00 ± 4.90 
123.48 ± 10.80 
111.72 ± 14.40 
81.39 ± 8.15 
93.70 ± 12.24 
69.93 ± 20.39 
86.58 ± 24.47 
96.57 ± 14.28 
126.54 ± 31.62 
106.56 ± 6.13 
179.82 ± 8.15 
106.40 ± 1.92 
110.02 ± 3.84 
115.54 ± 5.70 
134.61 ± 7.60 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
<0.001(DE vs DC) 
 
<0.001(DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
+13.0 
 
-10.5 
 
+15.1 
 
+23.8 
 
+31.0 
 
+67.8 
 
+3.0 
 
+16.5 
(-0.20, 2.20) 
 
-0.85 (-2.03,0.33) 
 
0.89 (-0.30, 2.07) 
 
0.68 (-0.48, 1.85) 
 
1.85 (0.50, 3.21) 
 
8.97 (5.21, 12.74) 
 
1.14 (0.20, 2.09) 
 
3.29 (1.94, 4.63) 
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TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES - CONTINUED 
Citation Time 
point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise (Mean 
± SD) 
P value 
(Inter-group) 
Stranahan, 
200940 
Immediate Brain-derived 
neurotrophic factor 
ELISA DC 
DE 
3.01 ± 0.15 
3.65 ± 0.13 
<0.05 (DE vs DC) +21.2 4.27 (2.22, 6.32) 
Reisi, 
200941 
Immediate Glutamate 
Gamma-Aminobutyric 
acid  
NR 
NR 
NR 
NR 
DC 
DE  
DC 
DE  
1704.54± 524.23* 
3292.69± 698.37* 
1096.25± 461.31* 
1260.11± 461.18* 
<0.05 (DE vs DC) 
 
NS (DE vs DC) 
+93.1 
 
+14.9 
2.37 (0.90, 3.85) 
 
0.34 (-0.65, 1.32) 
Campbell, 
201033 
Six hours Quantification of the 
relative signal intensity in 
hippocampal GR 
 
Hippocampal GR content 
ICS DC 
DE 
  
 
DC 
DE 
480.00 ± 67.50* 
675.00 ± 52.50* 
 
 
60.71 ± 25.33* 
107.14 ± 21.43* 
<0.05 (DE vs DC) 
 
 
 
<0.01 (DE vs DC) 
+40.6 
 
 
 
+76.4 
1.07(0.05, 2.08) 
 
 
 
1.89 (0.74, 3.03) 
152 
 
TABLE 2.5 ANIMAL BRAIN BIOCHEMICAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics +/- 
Change 
(%) 
Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Hwang, 
201134 
Immediate ROD % at CA1 region 
Stratum orients (GR) 
 
Stratum pyramidal  
 
 
Stratum radiatum  
 
 
ROD % at dentate gyrus    
Polymorphic layer 
 
Granule cell layer 
 
 
Molecular layer 
 
Immunore
-activity 
DC 
DE  
 
DC 
DE  
 
DC 
DE  
 
DC 
DE 
 
DC 
DE 
 
DC 
DE 
110.02 ± 29.33* 
106.12 ± 29.03* 
 
346.15± 122.10* 
146.15 ±50.87* 
 
148.00 ± 48.90* 
74.67 ± 18.52* 
 
216.09 ± 58.34* 
145.53 ± 17.64* 
 
335.16 ± 46.67* 
97.02 ± 23.38* 
 
101.14 ± 35.00* 
92.61 ± 23.23* 
NS (DE vs DC) 
 
 
<0.01(DE vs DC) 
 
 
<0.01 (DE vs DC) 
 
 
<0.01 (DE vs DC) 
 
 
<0.01 (DE vs DC) 
 
 
NS (DE vs D) 
 
-3.7 
 
 
-136.8 
 
 
-98.2 
 
 
-48.4 
 
 
-245.5 
 
 
-9.2 
 
-0.11 (-1.16, 0.94) 
 
 
-1.99 (-3.27, -0.71) 
 
 
-1.86(-3.12, -0.61) 
 
 
-1.52 (-2.71,-0.33) 
 
 
-6.00 (-8.46, -3.54) 
 
 
-0.71 (-1.79, 0.37) 
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Notes: 
aMale Sprague-Dawley rats had 90% of their pancreas removed (Px rats) or received a SHAM pancreatectomy.   
Px rats glucose levels of random fed serum should be greater than 9.4 mM after surgery, thus represents the insulin resistance or T2DM. 
Relative optical densities (ROD) as % values of GR in the dentate gyrus. 
Results reported in Mean +/-SD. 
Between group effect size = (mean change in treatment –mean change in control)/pooled baseline SD.26 
*SEM were converted from SD. 
SD: standard deviation 
GR: Glucocorticoid receptor 
TSLEB: Time since last exercise bout 
IRS2: Insulin receptor substrate 2 
Akt is known as protein kinase B (PKB) 
STAT: Signal transducer and activator of transcription 3, 
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GLUT2: Glucose transporter 2 
Trk: Transforming tyrosine kinase protein 
PI3K: Phosphatidylinositol-4, 5-bisphosphate 3-kinase  
p75: Neurotrophin receptor   
Erk:  Extracellular-signal-regulated kinases 
CREB: cAMP response element-binding protein 
ICS: Immunohistochemical staining 
DE: Diabetes exercise 
DC: Diabetes control 
NR: Not reported 
NS: Not significant 
vs: Versus 
CI: confidence interval
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TABLE 2.6 ANIMAL BRAIN FUNCTIONAL OUTCOMES 
Citation Time 
point 
 (TSLEB) 
Outcomes 
 
Results Statistics Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
Reisi,  
200938 
24 hours cSpatial acquisition 
Escape latencies (sec) 
Swim distance (cm) 
 
Swim speed (cm/sec) 
 
dSpatial retention  
Time spent (%) in each zone 1  
Time spent (%) in each zone 2 
  
Time spent (%) in each zone 3 
  
Time spent (%) in each zone 4 
  
Time spent (%) in quadrantzone  
 
The number of crossing  
in exact place 
Morris water 
maze 
 
 
 
 
 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
DC 
DE 
49.98 ± 7.34*  
23.36 ± 7.34*  
796.43±138.01* 
485.32±138.01* 
 16.06 ± 7.30*  
26.20 ± 2.28*  
33.36 ± 20.13* 
54.29 ± 20.13* 
30.5 ± 10.13* 
20.12 ± 10.13* 
16.02 ± 10.06* 
14.24 ± 10.06* 
17.8 ± 10.06* 
14.24 ± 10.06* 
25.02 ± 13.69*  
54.29 ± 27.54* 
0.19 ± 0.37* 
1.50 ± 0.88* 
<0.001 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.01 (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
NS (DE vs DC) 
 
<0.05 (DE vs DC) 
 
<0.05 (DE vs DC) 
 
-3.43 (-4.97, -1.89) 
 
-2.13 (-3.35, -0.90) 
 
2.01 (0.81, 3.21) 
 
0.97(-0.06, 2.01) 
 
-0.97 (-2.00, 0.07) 
 
-0.17 (-1.15, 0.81) 
 
-0.37(-1.32, 0.65) 
 
1.27 (0.20, 2.35) 
 
1.83 (0.67, 3.00) 
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TABLE 2.6 ANIMAL BRAIN FUNCTIONAL OUTCOMES - CONTINUED 
Citation Time point 
 (TSLEB) 
Outcomes 
 
Results Statistics Effect size 
(95%, CI) 
Author,  
Year 
Reference 
Variable Method Group Post-exercise 
(Mean ± SD) 
P value 
(Inter-group) 
You,  
200930 
Immediate bThe number of errors  
in the spatial memory  
Radial arm maze 
test 
DC 
DE 
11.00 ± 2.21  
6.50 ± 0.71 
<0.05 (DE vs DC) 
 
-2.47 (-4.12, -0.83) 
Chae,  
200939 
Immediate aRetention latency  
(cognitive function) 
The passive 
avoidance test 
DC 
DE 
213.5 ± 70.00 
300.00 ± 0.00 
< 0.05 (DE vs D) 1.68 (0.66, 2.70) 
Notes: 
aHigher retention latency represents better memory. 
bThe decreased number of error indicates better the spatial memory. 
SD: standard deviation 
TSLEB: Time since last exercise bout 
DE: Diabetes exercise 
DC: Diabetes control 
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CI: confidence interval 
vs: Versus
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TABLE 2.7 CONCOMITANT RELATIONSHIP BETWEEN MORPHOLOGY AND COGNITION 
Citation Brain Morphology Cognition Change% 
Morphology/cognition 
Relationship Comments 
Author, 
Year 
Reference 
You,  
200930 
cFos Memory 93.2 / 69.2  Increase in cFos with 
concomitant 
improvements in 
memory 
Aerobic exercise group only 
Chae,  
200939 
Cell proliferation Memory 90.1 / 40.5 Increase in cell 
proliferation with 
concomitant 
improvements in 
memory 
Aerobic exercise group only 
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FIGURE 2.1 FLOW CHART OF SEARCH STRATEGY 
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160 
 
RCTs: Randomised Controlled trials 
NRCT: Non- randomised Controlled trials
161 
 
CHAPTER 3 
SYSTEMATIC REVIEW OF EXERCISE OR PHYSICAL ACTIVITY AND COGNITVE 
FUNCTION IN ADULTS WITH TYPE 2 DIABETES MELLITUS OR INSULIN 
RESISTANCE OR IMPAIRED GLUCOSE TOLERANCE 
  
162 
 
3.1 ABSTRACT 
Objectives - The purpose of this review was to systematically evaluate the effects of exercise or 
physical activity on cognitive function in adults with type 2 diabetes mellitus (T2DM) or insulin 
resistance (IR) or impaired glucose tolerance (IGT). 
Methods - A systematic search of studies published from 1966 to the last update in Dec 2014 was 
conducted using Medline, EMBASE, SportDiscus, CINAHL, PsycINFO, PubMed, and Cochrane 
Controlled Trials Registry.  Any experimental or observational study was included if it evaluated 
the relationship between exercise or physical activity exposure/intervention on any measure of 
cognition function in adults with T2DM, IR or IGT.   
Results - Six trials including 1767 subjects met the eligibility criteria.  Only four of the five 
studies (80%) reported significant benefits of exercise/physical activity for at least one cognitive 
outcome.  Exercise was associated with improved cognition in these studies, explaining 12% of 
improvements in delayed memory, 14% of improvements in global cognition, and 30% of 
improvements in executive function.  Overall, only 18% of cognitive outcomes were significantly 
improved across all trials.  Three trials examined any association between insulin, glucose control, 
and cognitive function.  Increased insulin levels were related to worse delayed memory (r=-0.52, 
p=0.047).  Clinical improvements in HbA1c and glucose fasting control were related to 
improvements in delayed memory (r=-0.627, p=0.029) and executive function (r=0.611, p=0.035), 
respectively.  In addition, higher glucose infusion rate values were correlated with better delayed 
word list scores (r=0.614, p=0.024) at baseline and follow-up.  One trial investigated the 
relationship between changes in cognition and changes in cerebral amyloid or intra-abdominal fat 
after exercise training, and neither of these adaptations was related to changes in cognition. 
Conclusions - The limited data available suggest that exercise may contribute to improvements in 
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cognitive function in T2DM or IR or IGT, but the results of these trials to date are heterogeneous, 
and most cognitive outcomes showed no significant benefit after exposure to exercise/physical 
activity.  With only one trial meeting review criteria, there is insufficient evidence to document 
any potential mechanisms of exercise-related cognitive benefits such as changes in cerebral 
amyloid or intra-abdominal fat.  Large-scale, high quality randomised controlled trials are 
required to determine if exercise improves cognition in this high risk cohort, and investigate 
putative mechanistic links between cognition, body composition, metabolism, and inflammation.   
Key words: Exercise, T2DM or IR or IGT, Cognitive Outcomes 
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3.2 INTRODUCTION 
Diabetes mellitus (DM) is projected to affect 435 million adults by 2030,1 and as the prevalence 
rises with age from 12% in people aged 65 to 70 to 15% in people over age 80, older adults will 
continue to be disproportionately affected.2  T2DM, accounting for 85% to 90% of patients with 
DM, is a progressive decline in insulin sensitivity with insulin deficiency that results in sustained 
hyperglycaemia.3  DM is the leading cause of cardiovascular disease, kidney disease, vision loss, 
and neuropathy.4  Patients with T2DM have been found to present cognitive deficits, associated 
with reduced performance on multiple domains of cognitive function.5-8  Higher levels of HbA1c 
have been negatively associated with cognitive performance on a number of tests in elderly and 
middle aged individuals.5, 9 Additionally, in elderly patients with T2DM, cognitive deficits in 
working memory and attention have been observed in the hyperglycaemic state during a glucose 
clamp.10 
 
Diet and exercise represent the initial treatment approaches in clinical practice to slow progression 
of metabolic disturbance associated with prediabetes and to assist with pharmacological treatment 
in established T2DM.  Increased physical activity has clear beneficial physiological effects for 
older adults with T2DM or glucose intolerance or insulin resistance,11, 12 and more recently has 
been shown to benefit cognition as well.13-15  Epidemiological evidence consistently links 
physical exercise with better cognitive performance,13 lower risks for dementia, and reduced 
pathological changes in the central nervous system (CNS).14-16  Experimental studies have also 
reported benefits of aerobic and resistance training on cognitive function in older adults.17, 18  
Furthermore, regular physical exercise has also potent therapeutic effects on glucose regulation 
and cardiovascular health, both of which when compromised may threaten cognitive integrity.18-20  
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Positive effects of aerobic exercise on cognition have been well documented in animal models and 
in aging clinical populations21-23  There is evidence from cross-sectional and prospective brain 
imaging studies to suggest that aerobic exercise may reduce brain atrophy in older adults, changes 
that are most striking for brain regions that support executive control processes and memory.23, 24 
 
Although it has been shown that exercise can enhance cognitive function, most studies have been 
in healthy elderly, and thus the applicability of these findings to older adults at high risk for 
cognitive decline are less well defined.  Indeed, there are recent reviews of the cognitive benefits 
of physical activity,25, 26 but there is no systematic review of the effects of exercise on cognitive 
function in people with T2DM or impaired glucose tolerance or insulin resistance to our 
knowledge.  Given the increased risk for dementia posed by T2DM, it is important to define the 
utility of exercise or physical activity for this outcome in this cohort specifically. 
 
Therefore, our objective was to systematically review the literature to identify the relative efficacy 
of various modes of structured exercise or habitual physical activity level in individuals of any age 
with T2DM or IR or IGT on any measure of cognition, including attention, visuo-spatial 
performance, memory, information processing speed, executive control processes, or global 
cognitive function.  Our secondary aim was to identify the potential mechanisms underlying any 
cognitive benefits by examining relationships between changes in metabolism, body composition, 
markers of cerebral pathology including amyloid deposition, and cognitive changes after exposure 
to chronic exercise or physical activity in this cohort.   
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3. 3 METHODS 
3.3.1 LITERATURE SEARCH 
A systematic review of published literature investigating the effects of chronic exercise or physical 
activity exposure on cognition (including attention, visuo-spatial performance, memory, 
information processing speed, executive function, or global cognitive function) in individuals with 
T2DM, IR or IGT was conducted.  An electronic database search was performed from 1966 to 
Dec 2013 using computerised databases including Medline (1966-2013), EMBASE (1966-2013), 
SportDiscus (1967-2013), CINAHL (1982-2013), PsycINFO (1966-2013), and Cochrane 
Controlled Trials Registry (3rd Quarter 2013) with the last search being conducted on 21 Dec 2013.  
The searches for the following categories were conducted using text words pertaining to cognition, 
exercise and diabetes.  A combination of text-based terms in all fields was used to find records.   
 Intervention: exercise, or training, or physical activity, or aerobic, or physical capacity, or 
aerobic capacity, or physical performance, or physical endurance, or motor activity, or 
resistance, or weight lifting, or strength, or power training, or strength training, or weight-
training, or resistance-training, or resistance exercise 
and 
 Populations: individuals with diabetes, or insulin resistance, or hyperglycaemia, or impaired 
glucose tolerance. 
and 
 Outcome: cognition, or cognitive or mental or mental process, or memory, or brain, or 
neuropsychological, or neurological. 
Finally, reference lists in all eligible papers and review articles identified from database searches 
were hand-searched for any additional papers missed by database searches for potential inclusion.  
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Non-English literature and unpublished theses were not included in the literature search. 
 
3.3.2 INCLUSION AND EXCLUSION CRITERIA 
Studies, regardless of design, were included if they met the following criteria:   
1) The study design was a randomised controlled trial (RCT), non-randomised controlled trial 
(NRCT), or observational study    
2) Full-length article published in a peer-reviewed English language journal.   
3) All studies in human subjects of any age and of either sex diagnosed with T2D or IR or IGT 
with a valid measure of insulin resistance or glucose homeostasis, including fasting glucose 
or insulin, glycosylated haemoglobin (HbA1c), Homeostatic model of assessment (HOMA-
IR or HOMA2-IR), glucose clamp, intravenous glucose tolerance test, oral glucose tolerance 
test variables or meal tolerance test.  
4) The intervention or exposure was any form of exercise training (defined as planned, structured, 
and repetitive physical activity which has as a final or intermediate objective, the improvement 
or maintenance of physical fitness) or reported participation in various levels of physical 
activity.  If the study was an experimental trial, the exercise intervention did not need to be 
fully supervised but must have been prescribed, and quantifiable including self-administered 
questionnaires or activity monitors.  If the study was observational, then it had to report level 
of physical activity of the cohort.  Physical activity is defined as any bodily movements 
produced by skeletal muscles that result in energy expenditure.27 
5) The design of the study must have been such that the independent effects of exercise or 
physical activity could be analysed.  In the case of multiple interventions (e.g., diet + 
exercise), one group must have been treated with diet/other intervention, another with 
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diet/other intervention + exercise, and both must have included individuals with T2DM, IGT 
or IR. 
6) Any validated neuropsychological test of cognition reported at baseline and follow-up after 
exposure to exercise or physical activity for a minimum of 12 weeks. 
7) Papers must have directly analysed the effects of changes in insulin resistance or other 
metabolic on the changes in cognitive function outcomes.  Analyses included insulin 
resistance or other metabolic or other body composition as a independent variables using 
simply or in multiple regression models, unless the independent effects of changes in skeletal 
muscle could be determined from the statistical models presented. 
8) Control group: For experimental studies, any kind of control group was eligible, including no 
contact, no treatment, waiting list, attention control, SHAM exercise, or alternative active 
treatment.  For observational studies, cohorts had to be stratified by level of physical activity, 
with the least active stratum considered the control/low exposure group. 
9) Control groups may have included participants who were healthy, or who had T2DM, IR, or 
IGT. 
Trials were excluded for the following reasons:   
1) Only animals were investigated. 
2) Individuals without T2DM, IR, or IGT were enrolled. 
3) The study reported only the effect of acute exposure to exercise or physical activity, acute 
exposure to exercise or physical activity is defined as less strenuous exercises for a shorter 
amount of time.  For instance it could be half an hour on the cross trainer or a few minutes 
skipping (it may include studies of one bout, 2 bouts, 2 weeks, 4 weeks). 
4) No validated test of cognitive function was reported as an outcome. 
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5) They were non-English language articles or unpublished papers; or the articles were reviews 
or abstracts. 
 
3.3.3 SELECTION OF DTUDIES AND DATA EXTRACTION 
One author (RRZ) conducted the search and extracted all data.  After eliminating duplicates, all 
papers identified by the search strategy were screened by the author, first by title and then by 
abstract.  Two authors (RRZ and MF) determined final eligibility by reading the full text of 
potentially relevant studies.  Trials were split into four groups:  
1) Randomised controlled trials (RCTs),  
2) Non-randomised controlled trials (NRCTs),  
3) Cross-sectional studies, and  
4) Prospective cohort studies.   
Experimental studies were considered to employ control groups if one group was assigned an 
exercise intervention, and the other group was assigned to either non-exercise control, SHAM 
exercise control or an alternate form of exercise intervention. Quality assessment of all eligible 
papers was undertaken separately by these two authors, using an adapted Physiotherapy Evidence 
Database (PEDro),28 with the addition of one quality assessment item deemed pertinent to this 
review, namely ‘full supervision of exercise program’, which formed criterion point 12  Points 
were only awarded if the criterion was clearly satisfied.  Any disputes were resolved by 
consensus, or by a third author (AOS) when necessary.  Data were extracted regarding 
methodology of the study, cohort characteristics, exercise intervention or physical activity 
exposure, cognitive outcomes, and any relationships between changes in cognition and metabolism 
or other cohort characteristics.  Data in this review are reported as mean ± SD.  Data that were 
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reported as mean ± SEM were converted to mean ± SD.  Authors were contacted for missing data 
whenever possible. 
 
3.3.4 DATA ANALYSIS 
A quantitative meta-analysis across studies was not carried out due to the heterogeneity of exercise 
interventions, outcomes assessed and measurement tools used.  In experimental studies, between-
group ESs (adjusted via Hedges’ bias-correction for small sample sizes) and 95% confidence 
intervals (CIs) were calculated for each outcome measure where applicable using formula 1: 
between-group ES = (change in treatment - change in control)/pooled baseline standard deviation 
(SD).29  Formula 2: intra-group ES =(post-score - pre-score)/baseline SD.29  
 
Final sample sizes excluding dropouts were used to calculate ESs, unless there had been imputation 
of missing data from dropouts.  ES were interpreted according to the method of Cohen as: ‘trivial’ 
(≤ 0.20), ‘small’ (≥ 0.20 to < 0.50), ‘moderate’ (≥ 0.50 to < 0.80) and ‘large’ (≥ 0.80).30  
Significant level was set at p < 0.05 unless otherwise indicated. 
 
3.4 RESULTS 
3.4.1 STUDIES RETRIEVED  
Figure 3.1 displays the detailed results of the search process at each step.  The search strategy 
identified 5759 studies while hand searching identified a further two studies. After the removal of 
duplicates, 3866 studies remained.  Literature titles and abstracts were examined, and studies not 
meeting the eligibility criteria were excluded.  The whole text of 47 studies was examined, and 
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five trials, reported in six citations (all aerobic exercise),31-35 were found to meet the criteria for 
review.  This included two RCTs,31, 34  one NRCT,35  one prospective cohort study33 and two 
cross-sectional studies.32, 33   
 
3.4.2 STUDY QUALITY ASSESSMENT 
An evaluation of the study quality checklist items based on a modified PEDro is summarised in 
Table 3.1.  Overall, the quality of the two RCTs31, 34 included in this review was moderate-high, 
receiving scores of 7 and 9 out of 12.  The blinding of assessors and participants were common 
deficiencies,31, 34 exercise interventions were fully supervised in two31, 34 of the three trials, but one 
trial removed supervised training after 6 months and continued with a home-based program.31  
Key outcomes were obtained in greater than 85% of participants enrolled in each trial.  The non-
randomised controlled trial,35 prospective,33and cross-sectional32, 33 and studies were of a low 
standard on the PEDro scale,32, 33, 35 with an average study quality was 5/12, (range 4 to 6). 
 
3.4.3 STUDY DESIGN/COHORT CHARACTERISTICS 
A summary of study design and cohorts characteristics for each trial is shown in Table 3.2.1-3.2.4. 
 
3.4.4 DEMOGRAPHICS 
A total of 72 participants were enrolled across 5 studies, ranging from 16 to 1769 participants.  
Pooled sample size amongst RCTs was 58 (n= 28 and 30),31, 34 while 1711 participants were 
enrolled in non-randomised controlled trial,35 and prospective33 and cross-sectional studies.32, 33  
The average age of cohorts across all trials was 65.9 years, with age ranging from 58.5 to 74 years.  
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Sex breakdown was provided in 4/5 study cohorts.  Overall, one study included women only,33 
while another one did not report sex.31  The remaining 3 studies32, 34, 35 were comprised of mixed 
cohorts.  Body Mass Index (BMI) was reported in all but one cross-sectional study.32  
Participants were overweight or obese with BMI ≥ 25 kg/m2,31, 33, 34 except for the NRCT where 
BMI was 22.9±2.5 kg/m2.35 
 
3.4.5 DIAGNOSTIC CRITERIA FOR T2DM AND IGT 
Only 1 out of 5 studies (6 citations) reported diagnostic criteria for T2DM, as either fasting 
glucose≥126 mg/dL, or insulin resistant 100 to 125 mg/dL, or diagnosed diabetes.32  Among the 
remaining 4 studies, one study recruited participants registered as prediabetes, a fasting plasma 
glucose level <7.8 mmol /L and a plasma glucose level≥7.8 and <11.1mmol/L two hours after 
carbohydrate loading.31  One study reported subjects meeting glucose tolerance criteria for 
prediabetes (140 mg/dL≥2-h glucose < 200 mg/dL) or newly diagnosed (at the time of study 
screening) T2DM (2-h glucose ≥ 200 mg/dL).34  Participants were diagnosed as diabetes using 
euglycemic clamp in one study,35 while one study reported revised criteria of the American 
Diabetes Association with T2DM medical records.33 
 
3.4.6 MEDICATIONS AND DISEASE BURDEN 
In general, medication usage and disease burden reporting were sub-optimal or important elements 
missing in most studies.  Two out of five studies32, 33 reported the participants’ diabetic 
medications,31-35 however these studies did not report if there were any changes in medications 
during the trial.  Among these studies, one trial included some participants with insulin 
treatment.33  Participants in the 5 studies reported in 6 citations were only treated with oral agents33 
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or didn’t take diabetic medications.31, 32, 34, 35  One study explicitly excluded participants on oral 
hypoglycaemia therapy.34  Duration of diabetes was reported in one study and ranged from 1 to 
15 years.33 
 
Only 2 studies published in 6 citations33, 34 reported medications other than diabetic medications, 
and only 1 study reported chronic diseases other than T2DM which included hypertension, 
cardiovascular disease, or exercise limitations.33  One cross-sectional study reported habitual 
physical activity level as “sedentary”, although precise definitions were not given.32  One study 
reported the treatment of anti-hypertensive34 and anti-depression medications.33 
 
3.4.7 NEUROPSYCHOLOGICAL ASSESSMENT 
There was considerable heterogeneity in the cognitive outcome assessment tools employed across 
these studies, as shown in Table 3.3.1-3.34 making it difficult to directly compare outcomes 
between them.  For example, global cognitive function was measured with the Telephone 
Interview for Cognitive Status forms of the Mini-Mental State Examination (TICS-MMS) in one 
trial published in two citations.33 Another study used both the MMS and the Saint Louis University 
Mental Status exam (SLUMS), defining cut-off points for MMS scores (>24) and SLUMS (>20 
final as normal cognitive function).  These definitions categorised participants as cognitively 
normal with the exception of 5 participants (6.8%) in the cross-sectional study who were 
considered to have mild to moderate cognitive impairment.32  Participant score on the MMS who 
was 23 or lower were excluded.35  In addition, one trial used Story Recall and Attention Visual 
Retention, as well as Trail Making Test (TMT) and Stroop Interference Tests to assess the memory 
and attention;31  Another trial utilsed Story Recall, Learning List, TMT, Task Switching, Stroop 
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Color-Word Interference, Verbal Fluency, and Self-Ordered Pointing measures to assess memory 
and executive function.34  Finally, one trial measured Word List, a subtest of the Alzheimer’s 
disease Assessment Scale (ADAS), Digit Symbol Test, a subtest of the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R), Digit Symbol Test, a subtest of the Wechsler Adult Intelligence Scale-
Revised (WAIS-R), and TMT to evaluate the memory, complex psychomotor skills, and 
attention.35 
 
A total of 28 different cognitive outcome measures were administered (average 5/study, range: 2-
7).  Data from non-significant findings were not always provided.31, 34  General cognitive 
function was measured using MMS, SLUMS, TICS-MMS, or overall global score32, 33, 35  The 
majority of trials administered standardized neuropsychological tests with attention/executive 
function the most frequently measured domain,31, 34, 35 followed by memory31, 33-35 and information 
processing.31, 35 
 
3.4.8 MEASURES OF GLUCOSE HOMEOSTASIS AND INSULIN RESISTANCE 
A summary of the results can be found in Table 3.4 to 3.5.  One trial utilised fasting glucose 126 
mg/dL.32  The hyperinsulinaemic euglycaemic clamp (the gold standard measurement for insulin 
resistance) was only used in two trials,34, 35 while only one trial used an oral glucose tolerance test 
to assess glucose tolerance and insulin sensitivity.31  One trial (2 citations) failed to report any 
measurement of insulin or glucose metabolism.33  
 
3.4.9 MEASURES OF BODY COMPOSITION 
A summary of the results can be found in Table 3.6.  Body composition was reported in all but 
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one cross-sectional study.32  One trial used computed tomography to measure intra-abdominal 
fat.31  Two studies reported measures to calculate %fat using computed tomography.34, 35  The 
remaining one study (two citations) reported that 36% of participants were overweight or obese, 
with body mass index (BMI) mean of >30 kg/m2.33 
 
3.4.10 MEASURES OF EXERCISE CAPACITY 
A summary of the results can be found in Table 3.7.  Exercise capacity and changes in response 
to exercise/physical activity exposure were not reported in the majority of studies.  Only 2 trials 
included measures of cardiorespiratory fitness,31, 34 as measured by treadmill measures of VO2 peak.  
One trial measured the Vo2peak (L/min),
34 while the remaining one trial did report the detailed 
measurement of Vo2peak (ml/kg/minute).
31  No studies reported other non-aerobic domains of 
exercise capacity such as muscle strength, muscle power, six minute walk distance, gait speed, 
chair stand, or balance. 
 
3.4.11 MEASURES OF AΒ42 METABOLISM 
A summary of the results can be found in Table 3.8.  Only 1 trial34 included measures of Aβ42, 
which were aging- and AD related biomarkers. 
 
3.4.12 INTERVENTION CHARACTERISTICS  
Table 3.2 provide an overview of the exercise training interventions among the experimental trials.  
For the cross sectional and prospective studies, physical activity exposure was also assessed by 
self-report questionnaires, including observational studies. 
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Modality:  
Among the two RCTs, one trial investigated the effects of a combination of aerobic exercise and 
dietary restriction compared to a diet restriction plus stretching control group,31 and another 
prescribed aerobic exercise compared to a stretching control group.34  The single NRCT 
compared the effects of horseback riding therapeutic equipment (JOBA) aerobic training compared 
to a maintaining usual level of activity (walking) control group.35  This horseback riding 
therapeutic equipment (JOBA Matsushita Electric Works, Ltd., Japan), was developed as an 
attempt to imitate the passive movement of bending down and straighten up during a horse riding.  
The characteristic of the JOBA equipment is that it produces a simple movement which is enough 
to experience the feeling of a real horse riding and it also effectively provides place for muscular 
relaxation.  Therefore, it is considered as a way to maintain muscular power and strength.  In 
addition, this equipment causes an elevation of heart rate (55 69% of maximal heart rate,), and is 
thus proposed to be able to improve aerobic fitness.36  However, no reports of improved aerobic 
capacity, muscle function or balance after JOBA interventions have been published to our 
knowledge.  The single prospective cohort study compared the effects of highest habitual 
physical activity level to lowest physical activity level,33 while the cross-sectional study, derived 
from the same cohort, examined the difference between the highest and the lowest physical activity 
groups.33  Finally, another cross-sectional compared the cognitive function of regular exercise in 
a healthy group to exercise in a group with T2DM.32 
 
Intensity: 
There was one trial of low intensity aerobic training,35 and two trials of moderate or high intensity 
aerobic training.31, 34  One RCT study used diet control plus aerobic exercise and a non-exercise 
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diet restrict control group over 52 weeks.  Aerobic exercise in Watson et al (2006) set the exercise 
intensity at 50% to 70% HRR over 12 week training intervention.31  One study prescribed high 
intensity aerobic exercise, consisting of 45-60 minutes of multiple modalities of aerobic training 
(stationary bicycle, elliptical trainer, or treadmill walking) with a gradual increase in exercise 
intensity during the first 6 weeks, which progressed to 60 minutes at 70-85% heart rate reserve 
during 11-26 weeks.34  One NRCT employed either jogging or walking on a treadmill with low 
intensity at 50% of maximum heart rate (heart rate max), which progressed to 70% of maximum 
heart rate reserve (HRR) over 12 weeks, and would be considered low intensity.35  Only Devore 
et al (2009) used one modality of exercise (metabolic equivalent),33 while the study of Colberg et 
al (2008) used multiple modalities of aerobic training (e.g. usual exertion, usual walking pace, 
stairs climbed, and city blocks walked).32 
  
Volume and Frequency:  
In the aerobic training or combined aerobic training with diet control studies, the volume varied 
from 45 to 60 minutes per session of continuous exercise,31, 34, 35 mean 50±9 minutes.  Frequency 
ranged from 3 to 4 days per week.31, 34, 35  One self-report study was 180±18 minutes of moderate 
aerobic exercise 3 times a week.32  One did not report the volume and frequency.33 
 
Duration: 
Trial duration ranged from 12 to 52 weeks in the experimental studies,31, 34, 35  Supervision was 
removed during the maintenance phase in one study and participants were advised to continue 
exercise at home for the final 6 months.31  Two studies were between 12 to 26 weeks.34, 35  Two 
cross-sectional studies reported a minimum duration of 1 years.32, 33  In longitudinal studies, for 
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classification of physical exercisers, duration were defined as 4.2 years using questionnaire.33 
 
3.4.13 CONTROL CONDITIONS 
Control conditions were highly variable and included diet,31 or stretching or balance,34 or usual 
activities.35  Three trials had active or SHAM control conditions including diet controls and low 
intensity aerobic exercise,31 stretching and balance,34 or normal walking.35  Two of the 
experimental trials reported supervision during the control condition.31, 34  The one prospective 
and two cross-sectional and studies described the control condition as a low level of habitual 
aerobic exercise/physical activity which was compared to the higher activity level condition, all 
unsupervised.32, 33 
 
3.4.14 FOLLOW-UP FOR OUTCOME ASSESSMENT 
Results are reported in Table 3.2 All details and documents related to recruitment and screening 
are presented in the Appendix.  Measurements were taken at baseline, midpoint, and post-training 
in two studies31, 34 and pre-post only in the 12-week JOBA study.35  However, the midpoint 
measure in the 26-week treadmill than others was not report.34  Only one longitudinal study had 
follow-up after exercise intervention at 4.2 years.33 
 
3.4.15 ADVERSE EVENTS 
Not reporting adverse events is considered a quality deficiency in terms of consort reporting 
requirements. 
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3.4.16 OUTCOMES MEASURES  
A complete summary of outcomes, ESs (95%, CIS) is found in tables in Tables 3.3-3.9. 
 
3.4.17 EFFECT OF EXERCISE INTERVENTIONS ON COGNITIVE FUNCTION 
A summary of the results can be found in Table 3.3.  Compared to a control group, aerobic was 
shown to improve executive function, while no effect was seen on memory in one RCT.34  
Increases in delayed memory score was seen following aerobic training combined with diet control 
compared to a diet control group, while no beneficial improvement was found in executive 
function compared to diet control.31  Aerobic exercise was not found to have an effect on 
cognitive domain in one NRCT.35  Compared to the low activity level group, higher physical 
activity level had significantly better global cognitive function in two cross-sectional studies.32, 33  
However, no effects were reported for memory and global cognitive function in one longitudinal 
studies.33 
 
Effect sizes were calculated for all cognitive outcome measures, as detailed below.  Twenty-six 
weeks of high intensity supervised treadmill walking has a small but positive significant effect on 
tests of cognitive flexibility (TMTB ES: 0.36; p=0.04), response inhibition (SCWI ES: 0.38; 
p=0.04), and Task Switching (ES: 0.39; p=0.03), but not Verbal Fluency (ES: 0.25; p=0.11) nor 
Self-Ordered Pointing Test (ES: 0.29; p=0.10) in older adults with impaired glucose tolerance.  
Similarly, there were no significant effects on verbal memory (ES=0.11).34   
 
The combined aerobic exercise and American Heart Association Step 2 Eucaloric Diet 
(AHAS2ED) resulted in large significant effects on one of two memory tests (Story Recall ES: 
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1.35; 95% CI: 0.48, 2.22), while no significant results were found for attention/executive function 
on the Traill Making Test and Stroop Interface Test.31  By contrast, no significant effects were 
revealed for memory (Word List Memory Immediate and Word List Memory Delayed), 
information processing speed (Wechsler Adult Intelligence Scale - Digit Symbol and Trail Making 
Test A), attention/executive function (Stroop Color-Word Test and Trail Making Test B), and 
global cognitive function in a trial of low intensity supervised JOBA exercise for 12 weeks.35   
 
In summary, four of the five studies (6 citations) reported significant benefits for at least one 
outcome; no significant effects were found in the two trials.33, 35  However, exercise was reported 
to result in improved delayed memory,31 executive function,34 and global cognition.32, 33  Overall, 
only 22% of outcomes were significant across all trials.31-35  
 
3.4.18 EFFECT OF PHYSICAL ACTIVITY EXPOSURE/EXERCISE INTERVENTIONS ON INSULIN SENSITIVITY 
Results are summarised in Table 3.4.  Among the experimental trials, one RCT compared a 
combined moderate intensity aerobic exercise and dietary restriction (American Heart Association 
step 2 eucaloric diet) to dietary restriction (American Heart Association step 1 eucaloric diet) and 
stretching, with aerobic exercise/diet found to have a greater effect on insulin sensitivity (ES: -
3.28; 95% CI: -4.41, -2.14; p=0.02) than diet and stretching, determined by 2-hour-OGTT glucose 
levels and 2-hour-OGTT insulin levels.31  High intensity aerobic training alone tended to improve 
glucose disposal rate (ES: 0.47; 95% CI: -0.33, 1.28; p=0.05),34 but not for fasting plasma insulin 
in aerobic group.  There was no significant difference in metabolic clearance rate (ES: 0.97; 95 
CI: -0.07, 2.02; p=0.24) or glucose infusion rate (ES: 0.66; 95 CI: -0.36, 1.67; p=0.99) between 
low intensity JOBA aerobic exercise compared to normal physical activity groups.35  Limited 
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data were available from the observational studies.  In one cross-sectional study,32 higher physical 
activity levels (high daily stairs, flights and walking pace) were inversely related to insulin 
resistance (r=-0.27, p<0.01).  Similarly, high weekday vigorous and weekend vigorous improved 
fasting insulin.  However, the observational cohort study did not report any insulin metabolic data 
from either cross-sectional33 or prospective analyses.33   
 
3.4.19 EFFECT OF PHYSICAL ACTIVITY EXPOSURE/EXERCISE INTERVENTIONS ON GLUCOSE 
HOMEOSTASIS  
Results are reported in Table 3.5.  None of the experimental studies reported a significant 
improvement in glucose homeostasis after any exercise intervention.  A combined aerobic 
exercise and dietary intervention was not reported to be beneficial compared to diet and stretching 
group in one study.31  Comparing aerobic exercise to a stretch or balance as control group, aerobic 
exercise did not improve fasting plasma glucose (ES: -0.31; 95% CI: -1.10, 0.49; p=0.44) in one 
trial.34  There was also no difference in HbA1c (ES: -0.19; 95 CI: -1.18, 0.80; p=0.72) or fasting 
blood glucose (ES:-0.17; 95 CI: -1.15, 0.82; p=0.21) between low intensity JOBA aerobic exercise 
compared to usual physical activity groups.35  However, high levels of Daily stairs, flights in one 
cross-sectional study had a low glucose level as measured by HbA1c%.32  Moreover,  fasting 
glucose was reversely related to weekend sitting, hours (r=0.27, p<0.01), weekday sitting, hours 
(r=0.19, p=0.03), and weekday light, hours (r=0.17, p=0.04).32  The other observational studies 
did not include data on glucose homeostasis.33   
 
3.4.20 EFFECT OF EXERCISE INTERVENTIONS ON BODY COMPOSITION 
A summary of the results can be found in Table 3.6.  In the experimental trials, aerobic training 
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alone was not found to decrease percent body fat in either of two trials compared to control 
groups.34, 35  The combination of aerobic training and diet did not report a significant effect on 
BMI compared to diet control (p=0.16).31  Moreover, there was no difference between JOBA 
aerobic exercise compared to normal physical activity on BMI and percent body fat.35  In addition, 
high physical activity in cross-sectional and prospective studies was not reported to have any 
significant effect on body mass index compared to low physical activity.33  Effect sizes were trivial 
and non-significant for body mass index and percent body fat.31, 34  The remaining one study 
reported a moderate ES for percent body fat, although non-significant.35  Together, these results 
suggest aerobic exercise had no significant beneficial effect on BMI and percent body fat. 
 
3.4.21 EFFECT OF EXERCISE INTERVENTIONS ON PEAK OXYGEN UPTAKE 
A summary of the results can be seen in Table 3.7.  A trend for an increase in relative peak oxygen 
uptake was observed in a combined aerobic training and diet program compared to a diet/stretching 
control group.31  Compared to non-exercise control group, aerobic exercise was shown to 
improve absolute peak oxygen uptake in one trial, with a small ES calculated (ES: 0.41; 95% CI; 
-0.39, 1.21; p=0.03).34 
 
3.4.22 EFFECT OF EXERCISE INTERVENTIONS ON AΒ42 METABOLISM 
A summary of the results can be found in Table 3.8.  In a RCT, aerobic exercise tended to decrease 
plasma levels of Aβ42 compared to a non-exercise control group (ES: -0.62; 95% CI; -1.43, 0.19; 
p=0.07).34 
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3.4.23 RELATIONSHIP BETWEEN CHANGES IN MEASURES OF COGNITIVE FUNCTION AND INSULIN 
RESISTANCE 
A summary of the results can is shown in Table 3.9.  Significant relationships between changes 
in cognition and changes in insulin resistance were seen in all 3 out of 5 studies, and were only 
present amongst the RCT’s,31 the NRCT,35 and cross-section study,32 but not for prospective 
study.33  Specifically, increases in delayed memory were inversely related to changes in 2 hour 
OGTT insulin levels (r=-0.52; p<0.05) in the aerobic exercise plus diet group only, while no 
relationship was seen in the diet and stretching control group.31  Changes in delayed memory 
were correlated with improvements in glucose infusion rates (r=0.64; p=0.024) during a 
euglycaemic clamp, with a trend for metabolic clearance rate (r=0.575; p=0.051) in those who 
performed JOBA exercise, as well as in the usual physical activity control group.35  Changes in 
global cognitive function in participants performing aerobic training were inversely related to 
HOMA-IR (r=-0.19; p=0.02) and insulin level (r=-0.13; p=0.03).32  In the Thus, there is some 
evidence to suggest that improvements in insulin sensitivity are potentially contributory to 
cognitive adaptations or at least modified proportionally by exercise. 
 
3.4.24 RELATIONSHIP BETWEEN CHANGES IN MEASURES OF COGNITIVE FUNCTION AND GLUCOSE 
HOMEOSTASIS 
A summary of the results can be found in Table 3.10.  A significant inverse association with 
changes in word recall and changes in HbA1c (r =-0.627; p=0.029) reported in one trial compared 
to stretch or balnce.35  Higher fasting blood glucose was directly related to worse executive 
function (r=0.611; p=0.035) in this same trial.35  However, no such relationships between 
cognition and glucose changes were reported in those who performed aerobic training or aerobic 
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training plus diet control only, or in the control groups of these two trials.31, 34  Thus, there is little 
support for improvements in glucose homeostasis as a mechanism for cognitive benefits of 
exercise in this cohort. 
 
3.4.25 RELATIONSHIP BETWEEN CHANGES IN MEASURES OF COGNITIVE FUNCTION AND BODY 
COMPOSITION 
A summary of the results can be found in Table 3.11.  Change in intra-abdominal fat was inversely 
correlated with changes in delayed memory within control participants who received diet and 
stretching, while no significant relationship was observed in those who received aerobic training 
and dietary intervention.31  No significant relationship was reported between changes in percent 
body fat and changes in cognition.34, 35 in the 2 trials examining this.  Thus, there is no evidence 
support for changes in body fat contributing to cognitive benefits of exercise.  In addition, no 
relationships between cognition and VO2peak and biomarker were reported in two trials (Table 
3.12 to 3.13).31, 34 
 
3.5 DISCUSSION 
The purpose of this review was to evaluate published research investigating the effects of exercise 
on cognitive outcomes in individuals with T2DM or IGT or IR.  This was done to increase our 
understanding of the potential role that exercise may play in cognitive capacity in this specific 
cohort, given their increased risk of cognitive decline.  This systematic review identified 2 RCTs, 
one NRCT, two cross-sectional and one prospective cohort studies of exercise or physical activity 
exposure in individuals with T2DM or IGT or IR.  The quality of this literature was only moderate, 
and the majority of trials had samples too small for sufficient power to detect small effects.  Only 
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one trial34 fulfilled most of the recommended PEDro criteria for trial internal validity.  The lack 
of blinding of assessors, participants, and trainers in all trials reviewed is a serious limitation of 
this literature.  The vast majority of cognitive outcomes (78%) were non-significant, thus 
providing no strong or consistent evidence that aerobic exercise or lifestyle intervention or higher 
levels of habitual physical activity improve cognition or are associated with less risk of decline in 
individuals with T2DM or IGT or IR. 
 
3.5.1 EFFECT OF AEROBIC INTERVENTION ON COGNITIVE FUNCTION 
The major finding of this review is that in three out of the five studies identified, physical exercise 
or lifestyle intervention was associated with beneficial effects on 14% of memory, 33% of 
executive function, and 11% of general cognition tests in individuals with T2DM or IR or IGT.  
Prior studies in non-diabetes cohorts have mainly focused on aerobic exercise and linked it to 
improved executive function.22  In one study, moderate intensity aerobic exercise plus diet 
significantly improved delayed memory, even no significant change in tasks of executive function 
including selective and divided a attention, cognitive flexibility, and working memory in older 
adults with glucose intolerance.31  Moderate to high intensity aerobic exercise were related to 
improve executive function and information processing speed, but not for verbal memory.34  
Notably, participants were performed high physical activity were related to better global cognitive 
function, with data from both groups pooled for analysis.32  Similarly, results from Devore et al 
(2009),33 showed that high physical activity had better cognitive function within the highest 
physical activity group, and this relationship remained a significant after adjusting for age, 
education, and disability indicators.  The lack of relationship reported within the one prospective 
study may be due to the chronic conditions such as brain pathology.33 The intervention delivered 
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during this particular trial was JOBA exercise,35 and it was concluded that the intervention was not 
of a sufficient intensity (55-69% maximal heart rate or 40–59% of VO2max) to induce significant 
improves in cognition.  In summary, this small body literature about the efficacy of aerobic 
exercise for cognition in older adults with T2DM or IR or IGT is mixed and inconclusive.  Much 
more information is needed about other modalities of exercise, as well as confirmation of any 
clinically relevant and sustained benefits of aerobic exercise.   
 
The potential role of progressive resistance training (PRT) and cognitive function is of interest for 
a variety of reasons.  First, reduction in adiposity and increase in muscle mass, which is targeted 
by PRT, has been specifically associated with improved insulin sensitivity, glucose control, and 
inflammation, 37-40 which are in turn associated with a decreased risk of cognitive decline.  
Secondly, PRT may improve hypertension, dyslipidemia, and insulin and glucose regulation, 
which are important comorbidities of T2DM associated with cognitive impairment.20, 41  Third, 
PRT results in a range of positive benefits for neurobiological outcomes in animal and human 
studies, such as increased insulin-like growth factor-1 (IGF-1),42 increased brain derived 
neurotrophic factor (BDNF),43-45 neurogenesis,45 functional plasticity,46 decreased inflammatory 
cytokines,47, 48 decreased cortisol response to stressors, and improved cognitive function.45, 49  
Specifically, PRT can increase IGF-1 levels, which may lead to improved neurogenesis and vessel 
remodeling in the brain.42  Currently, the inconsistent efficacy of aerobic training for cognitive 
outcomes in this review suggests that this modality may not be optimal or sufficient for targeting 
cognitive impairment in this cohort.  Resistance training is theoretically uniquely grounded as an 
alternative exercise modality which may improve brain health and cognitive function by increasing 
growth factors and reducing the systemic risk factors. 
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3.5.2 RELATIONSHIP BETWEEN CHANGES IN COGNITION AND CHANGES IN INSULIN RESISTANCE 
The small amount of evidence available suggests that better memory is partially explained by 
reductions in insulin resistance.  Specifically, the results show that increases in insulin sensitivity 
(2-hour OGTT insulin levels) (Table 3.9) were related to a significant improvement in delayed 
memory.31  Furthermore, the improvements of memory were explained by increases metabolic 
clear rate and glucose infusion rate indicating improved peripheral insulin resistance (via 
hyperinsulinaemic-euglycaemic clamp).35  One study has shown the concomitant improvements 
in cognition and insulin resistance with individuals with T2DM or impaired glucose tolerance after 
aerobic exercise,34 again suggesting this as a potential mechanism of the cognitive benefit.  In 
one case, improvements in IR during a hyperinsulinaemic-euglycaemic clamp were related to 
better memory, although no significant change in either measure was observed post-intervention.35  
Low insulin resistance had better global cognitive function.32  The intervention delivered during 
this particular trial was JOBA exercise, and it was concluded that the intervention was not of a 
sufficient intensity to induce significant improvements in delayed memory, information processing 
speed, executive function, and global cognitive function, nor provide robust metabolic benefit.  
However, what the results do suggest is that improvements in insulin resistance were explained a 
portion of the cognitive changes.  By contrast, this review did not provide support for reductions 
in hyperglycaemia as a mechanism of cognitive benefit in this cohort.  However, it is 
acknowledge that this literature is small, and only of modest quality, and many other putative 
factors which could contribute to cognitive adaptation such as reductions in systemic inflammation 
or changes in growth factors were not measured in these trials.  Thus, future robustly-designed 
studies should incorporate such mechanistic measures to substantively advance knowledge in this 
field. 
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3.5.3 RELATIONSHIP BETWEEN CHANGES IN COGNITION AND CHANGES IN GLUCOSE HOMEOSTASIS 
Much like insulin resistance, decreases in glucose homeostasis explained a significant portion of 
the variance in cognitive function.  Specifically, they explained the reductions in HbA1c within 
2 trials31, 32 and the reduction in FBG35 (Table 3.10).  With the limited data available, it is difficult 
to conclusively determine the specific role of changes in glucose homeostasis on cognition.  
However, the few relationships observed do suggest that increases in glucose homeostasis are 
independently related to improvements in memory, executive function, and global cognitive 
function. 
 
3.5.4 IMPLICATIONS FOR EXERCISE INTERVENTIONS AND FUTURE RESEARCH 
Previous reviews have suggested that aerobic exercise and resistance training should form part of 
any lifestyle intervention aimed at improving the cognitive function and metabolic profile in 
healthy adults,16, 50  However, much of the focus has been on cellular and molecular adaptations 
in the brain.21, 51  This is the first review to focus on neurocognitive adaptations in response to 
exercise in older adults with T2DM, and attempt to identify any mechanic links between changes 
in cognition and changes in metabolism, body composition, neurtophic factor, and inflammation.  
The data from these trials presented in this review indicate that improvements in cognitive health 
not as consistently seen as in healthy elders, and those that do occur are partly explained by 
improvements in insulin sensitivity, with less evidence for links with glucose homeostasis or body 
composition changes or neutrophic factor or inflammation.   
 
The findings from this systematic review support the view that one of the goals of exercise 
interventions for metabolic disease should be maximisation of cognitive benefits, but the exact 
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prescription to achieve this aim consistently remains elusive.  Theoretically, optimal nutrition 
plus exercise may best influence insulin signaling, neurogenesis, neurotrophic factors, and 
plasticity in brain regions directly relevant to memory, and there is a need for more studies 
comparing isolated and combined lifestyle interventions to identify the most beneficial strategy.   
 
With only six studies meeting the criteria for this review to date, further research is required in 
order to adequately address the relationship between the improvements in metabolic health and 
improvements in cognition in individuals with T2DM.  In particular, the data analyses presented 
in these trials were performed as secondary analyses, and as such, there was not much discussion 
or exploration of the mechanistic link between the exercise and cognitive change.  For example, 
although results of our review suggest that aerobic exercise decreased circulating levels of Aβ42 
and increased VO2peak for subjects with better cognitive function in the aerobic exercise group 
relative to controls, this finding requires replication and extension, and its clinical relevances needs 
to be determined.  Many other putative mechanistic factors remain to be studied in this regard as 
well.  Additionally, little is known regarding the persistence of putative therapeutic effects on 
cognition following the termination of exercise.  The training regimes were relatively short and 
some lacked sufficient intensity to optimise neurophysiological or neuropsychological change.  
Dose-response relationships between exercise dose (both volume and intensity) and cognitive 
outcomes in this cohort are completely lacking, and should also be a focus of additional 
investigation.  Given that many risk factors such as insulin resistance, hyperglycemia, 
inflammation, obesity, and dyslipidemia exist in this cohort, it is possible that improvement in 
these risk factors is implicated in delayed cognitive decline after exercise exposure.  Future 
studies should focus on controlled trials of aerobic exercise that include metabolism, body 
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composition, growth factors, and inflammation, and a broad range of cognitive domains, to address 
the gaps we have identified. 
 
Importantly, all of the literature we have reviewed to date is focused on aerobic exercise and 
cognition in adults with metabolic disease.  Notably, resistance training may directly target 
insulin sensitivity, glucose homeostasis, inflammation and catabolism, muscle mass and reduced 
adiposity, thus having many potential links to cognition as well.  Additionally, it must be 
considered that other factors involved in the cognitive process response to PRT may play an 
independent role.  However, rigorous clinical trials investigating the central and peripheral 
synergistic benefits of resistance training for improved cognitive function are lacking.  Thus, PRT 
should be directly compared to aerobic training benefits for cognition in future trials in this cohort.  
Additionally, by identifying those who are likely to be unresponsive to an aerobic intervention, 
PRT interventions may be prescribed that are more likely to bring about improvements in cognitive 
health.  Future investigations should therefore be specifically designed for the investigation of 
the isolated benefits of resistance training, and to provide novel, comprehensive data on possible 
proposed links between cognitive improvement, metabolism, inflammation, and whole-body-
adaptation to resistance training in older individuals with T2DM. 
 
Furthermore, future studies will also need to use cognitive measures which are comprehensive and 
more sensitive to longitudinal change, and provide long-term follow up to assess sustainability of 
any gains achieved during clinical trials.  Arguably the most salient issue for the field is the 
expansion of outcomes to assess transfer of cognitive gains to activities of daily living, quality of 
life, and psychological well-being. 
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In conclusion, the limited data available suggest that exercise or lifestyle intervention improved 
some aspects of cognition in adults with T2DM, including executive function and delayed memory.  
Exercise-induced improvements in insulin sensitivity in particular were associated with the 
observed cognitive benefits, while there is insufficient evidence exploring any relationship with 
other physiological adaptations at this time.  Future research in this field should include robust 
measures of body composition, metabolic profile, growth factors, and explore the genetic, 
inflammatory markers, clinical and physiological factors that potentially mediate the cognitive 
process.  Such investigations will lead to a better understanding of the mechanisms underlying 
the direct relationship between cognition, body composition, and metabolic health, and ultimately 
to the design of interventions specifically targeting the need of specific individuals and cohorts, 
contribute to their physical, cognitive and psychological health, and ultimately improve quality of 
life 
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Author,  
Year 
Reference 
Watson, 200631 RCT Yes Yes No Yes No No No Yes No Yes Yes Yes 7 
Colberg, 200832 CS Yes N/A N/A No N/A N/A N/A Yes N/A Yes Yes No 4 
Devore, 200933 CS Yes N/A N/A No N/A N/A N/A Yes N/A Yes Yes No 4 
Devore, 200933 LS Yes N/A N/A No N/A N/A N/A Yes N/A Yes Yes No 4 
Baker, 201034 RCT Yes Yes No Yes No Yes No Yes Yes Yes Yes Yes 9 
Yanagawa, 201135 
NRCT Yes No No Yes No No No Yes No Yes Yes Yes 6 
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Points are only awarded when a criterion is clearly satisfied within a modified PEDro Scale 
PEDro Scale: Physiotherapy Evidence Database Scale 
CSS: Cross-sectional study 
LS: Longitudinal study 
N/A: Not applicable 
Yes = 1 
No or N/A = 0 
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TABLE 3.2 STUDY DESIGN AND SUBJECT CHARACTERISTICS  
TABLE 3.2.1 STUDY DESIGN AND SUBJECT CHARACTERISTICS (RANDOMISED CONTROLLED TRIALS)  
Citation Study 
subjects 
Metabolic 
Condition 
(Medication) 
 
Total 
n 
Control 
condition 
Training 
modality 
Active Treatment Inclusion Criteria 
Author, 
Year 
Reference 
% male 
Age (y) 
 
Intensity Volume 
(min) 
Frequency 
(times/wk) 
Duration 
(days/wk) 
Watson, 
200631 
NR 
AT:  
58.0± 9.7 
CO: 
60.6 ± 9.0 
IGT (NR) 
 
n=28 
AT=15 
CO=13 
Stretching 
plus 
AHAS1ED  
 
Aerobic 
exercise 
(treadmill 
plus 
AHAS2ED 
supervised 
50% of 
HRR (over 
12 wk) 
increasing 
to 70% of 
HRR (13-
26 wk) 
60 3 52 Subjects met WHO criteria for 
impaired glucose tolerance, a 
fasting plasma glucose level <7.8 
mmol/L and a plasma glucose 
level≥7.8 and<11.1mmol/L two 
hours after a 75-gram oral glucose 
tolerance test.  Normal cognitive 
function was assessed by 
neuropsychological examination 
Baker, 
201034 
35.7% 
AT: 
71.0±7.5 
CO: 
66.0±6.0 
IGT/T2DM 
(Oral HG) 
n=28 
AT=19 
CO=9 
Stretching 
or balance 
Aerobic 
exercise 
(Treadmill, 
stationary 
bicycle, or 
elliptical 
trainer.) 
supervised 
Workload 
gradually 
increased 
to 75–85% 
of HRR 
(over 1-6 
wk) 
45-60 4 26 Subjects met glucose tolerance 
criteria for prediabetes (140 
mg/dL≥2-h glucose <200 mg/dL) 
or newly diagnosed (at the time of 
study screening) T2DM (2-h 
glucose ≥ 200 mg/dL).  Normal 
cognitive status was determined by 
neuropsychological assessment. 
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Data is presented as Mean ± SD or Median (interquartile or range) or (±SD). 
AHAS1ED: American Heart Association Step 1 Eucaloric Diet (total calories 30% fat, 50% carbohydrate, and 20% protein) 
AHAS2ED: American Heart Association Step 2 Eucaloric Diet (total calories 30% fat, 7% saturated fat, 55% carbohydrate, and 15% protein)  
HRR: heart rate reserve ((0.5 × [maximal heart rate-resting heart rate] + resting heart rate)) 
y: year 
min: minute 
wk: week 
NR: Not reported  
IGT: Impaired glucose tolerance 
T2DM: Type 2 diabetes mellitus 
HG: Hypoglycaemia  
AT: Aerobic training  
CO: Control 
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TABLE 3.2.2 STUDY DESIGN AND SUBJECT CHARACTERISTICS ((NON-RANDOMISED CONTROLLED TRIALS)  
Citation Study 
subjects 
Metabolic 
Condition 
(Medication) 
 
Total 
n 
Control 
condition 
Training 
modality 
Active Treatment Inclusion Criteria 
Author, 
Year 
Reference 
% male 
Age (y) 
 
Intensity Volume 
(min) 
Frequency 
(times/wk) 
Duration 
(days/wk) 
Yanagawa 
201135 
68.9% 
AT: 
71.6±3.8 
CO: 
70.1±3.7 
T2DM (NR) n=16 
AT=9 
CO=7 
 
 
 
 
 
Maintain usual 
level of activity 
(walking) 
Aerobic 
exercise 
(JOBA) and 
maintain 
usual level 
of activity 
(walking) 
supervised 
55-69% of 
maximal 
heart rate, 
40–59% of 
VO2max 
45 4 12 All participants were 
outpatients diagnosed 
with T2DM using 
euglycemic clamp.  
Score on Mini-Mental 
State Examination 
(cutoff>23) was used 
as the diagnosis of 
normal cognitive 
function. 
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Data is presented as Mean ± SD or Median (interquartile or range) or (±SD) 
y: year 
min: minute 
wk: week 
NR: Not reported  
T2DM: Type 2 diabetes mellitus  
AT: Aerobic training  
CO: Control  
JOBA: Joba horseback riding simulation equipment 
VO2: oxygen consumption  
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TABLE 3.2.3 STUDY DESIGN AND SUBJECT CHARACTERISTICS (CROSS-SECTIONAL STUDIES) 
Citation Study 
subjects 
Metabolic 
Condition 
(medication
) 
Total 
n 
Physical 
activity 
assessmen
t method 
Physical activity category Inclusion Criteria 
Author, 
Year 
Reference 
%male 
Age (y) 
Group 
Low Active 
(T2DM) 
High Active 
(Control) 
Colberg, 
200832 
33.8% 
HA: 
55.5±1.0 
LA: 
57.5±1.3 
 
 
 
 
T2DM 
(NR) 
 
145 
HA=74 
LA=71 
Modified 
(diabetes) 
version of 
the 
HAPAQ52 
(One year 
recall) 
aRegular exercise, %     55.4  
Days of exercise/week,   0.2±0.3 
City blocks walked/day,  1.2±1.5  
Stairs climbed/day, flights 3.5±0.6 
Usual walking pace,     2.0±0.1  
Usual exertion,         3.9±0.2 
Weekday, hours / day 
Vigorous activity       0.8±0.2  
Moderate activity       3.0±0.3  
Light activity          5.5±0.4  
Sit activity          7.1±0.5  
Sleep/recline activity    7.6±0.2 
Weekend (hours / day) 
Vigorous activity       1.0±0.2  
Moderate activity       3.2±0.3  
Light activity          4.5±0.3  
Sit activity          7.1±0.4 
Sleep/recline activity    8.2±0.2 
aRegular exercise, %    71.8 
Days of exercise/week   2.2±0.3 
City blocks walked/day  0.3±2.4  
Stairs climbed/day flights 0.6±0.8  
Usual walking pace     0.5±0.1  
Usual exertion         4.3±0.2 
Weekday, hours / day 
Vigorous activity       0.8±0.1  
Moderate activity       3.2±0.4  
Light activity          6.9±0.3  
Sit activity            5.4± 0.4  
Sleep/recline activity    7.6±0.2  
Weekend (hours / day) 
Vigorous activity       0.2±0.2  
Moderate activity       4.2±0.3  
Light activity          5.4±0.3  
Sit activity            5.3±0.4 
Sleep/recline activity    7.9±0.2 
American diabetes 
association criteria 
for diagnosis of 
T2DM, fasting 
glucose≥126 mg/dL; 
insulin resistant 
between 100 to 125 
mg/dL or diagnosed 
diabetes 
The cut-off points 
for MMS scores 
(>24) and SLUMS 
(>20 for high school 
educated, <15 for 
less education) were 
used as the diagnosis 
of normal cognitive 
function in 
Community samples 
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Physical activity category classified according to the HAPAQ where possible (regular exercisea is defined as subjects involving in at least 30 
minutes of moderate aerobic exercise 3 times a week for a minimum of 1 year, while sedentary subjects engaged in 2 or fewer days of activity or 
activities of daily living (ADL) alone)  
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
Gender is presented as % 
Mean ± SD or Median (IQR or range)  
Y: Year  
NR: Not reported  
T2DM: Type 2 diabetes mellitus  
HA: Highest active  
LA: Lowest physical active level  
HAPAQ: Harvard Alumni Physical Activity Questionnaire 
MMS: Mini-mental State Examination 
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SLUMS: Saint Louis University Mental Status Exam 
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TABLE 3.2.4 STUDIES DESIGN AND SUBJECT CHARACTERISTICS (CROSS-SECTIONAL AND PROSPECTIVE STUDIES) 
Citation Study 
subjects 
Metabolic 
Condition 
(medication) 
Total 
n 
Physical 
activity 
assessment 
method 
Physical activity category a Inclusion Criteria 
Author, 
Year 
Reference 
%male 
Age (y) 
Group 
Low active 
 
Moderate active High active 
Median no. of MET-hours b (range) 
Devore, 
200933 
0% 
HA: 
(74±2.3) 
LA: 
(74±2.4) 
T2DM 
(insulin 
treatment and 
oral 
hypoglycaemia) 
n=1550 
 
LA=512 
MA=520 
HA=518 
 
SAPAQc  
(cross-
sectional) 
 
 
3.38 (0.13-6.76) 10.70 (6.77-15.50) 24.39 (15.54-112.23) T2DM was diagnosed 
by a physician 
according to American 
diabetes association. 
Normal cognitive 
status was measured 
by neuropsychological 
assessment 
Devore, 
200933 
0% 
HA: 
(74±2.3) 
LA: 
(74±2.4) 
T2DM 
(insulin 
treatment and 
oral 
hypoglycaemia) 
n=1352 
 
LA=NR 
MA=NR 
HA=NR 
 
SAPAQc  
(prospective) 
 
 
3.38 (0.13-6.76) 10.70 (6.77-15.50) 24.39 (15.54-112.23) T2DM was diagnosed 
by a physician 
according to American 
diabetes association. 
Normal cognitive 
status was measured 
by neuropsychological 
assessment 
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Physical activity categorya was classified according to the SAPAQ where (the average amount of time per week spent in the following activities 
during the past year: running (< 10 minutes/mile); jogging (>10 minutes/mile); walking or hiking outdoors; racquet sports; lap swimming; 
bicycling; aerobic dancing or use of exercise machines; other vigorous activities; and low-intensity exercise (e.g., yoga, stretching, toning)). 
1 MET-hour b is the amount of energy expended by sitting quietly for 1 hour. (MET values assigned were: 12 for running; 8 for stair-climbing; 7 
for jogging, racquet sports, lap swimming, and bicycling; 6 for aerobic dancing, use of exercise machines, and other vigorous activities; and 4 for 
yoga, tretching, or toning.  
An average of 5 reportsc was used to calculate the primary exposure over a median time period of 13.3 years (interquartile range, 12.3–13.8) 
between the first activity assessment and the initial cognitive interview. 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
Gender is presented as % 
Y: Year 
SD: Standard deviation 
MD: Mean difference 
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NR: Not reported 
T2DM: Type 2 diabetes mellitus 
MET: Metabolic equivalent  
HA: Highest active  
MA: Moderate active 
LA: Lowest physical active  
SAPAQ: Self-administered physical activity questionnaire   
210 
 
TABLE 3.3 COGNITIVE OUTCOMES  
TABLE 3.3.1 COGNITIVE OUTCOMES (RANDOMIZED CONTROLLED TRIALS) 
Citation Time point 
(wk) 
Outcomes Results Calculation 
Statistics 
Author, 
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%,CI) 
 
Between group 
ES (95%,CI) 
 
Between 
group 
p value 
Watson,  
200631 
26 
 
 
52 
 
 
26-52 
 
 
26-52 
 
 
 
26-52 
Memory 
(delayed) 
 
 
 
 
 
 
 
Attention/
Executive 
function 
 
SRb 
 
 
BVRb 
 
 
BVRb 
 
 
TMTb 
  
 
 
SITb 
Exercise 
Control 
 
Exercise 
Control  
 
Exercise 
Control 
 
Exercise 
Control 
 
 
Exercise 
Control 
6.30 ± 1.15* 
6.25 ± 1.10* 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
 
NR 
NR 
3.65 ± 1.15* 
5.05 ± 1.10* 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
 
NR 
NR 
-1.45 (-2.35,-0.55) 
 
 
UTBC 
 
 
UTBC 
 
 
UTBC 
 
 
 
UTBC  
1.35 (0.48, 2.22) 
 
 
UTBC 
 
 
UTBC 
 
 
UTBC 
 
 
 
UTBC 
0.01 
 
 
NSa 
 
 
NS 
 
 
NS 
 
 
 
NS 
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TABLE 3.3.2 COGNITIVE OUTCOMES (RANDOMIZED CONTROLLED TRIALS) 
Citation Time 
point 
(wk) 
Outcomes Results Calculation Statistics 
Author, 
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%,CI) 
 
Between group 
Effect size 
(95%,CI) 
Between 
group p 
value 
Baker,  
201034 
12-26 
 
 
 
 
 
 
 
 
 
 
 
Attention/Executiv
e function 
 
 
 
 
 
 
 
 
 
 
 
 
Memory  
Short memory 
 
 
Memory recall 
VFc 
 
 
TMTBb 
 
 
TSb 
 
 
SCWIb 
 
 
SOPTc 
 
 
SRc 
 
 
LLc 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control  
 
Exercise 
Control 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR  
 
NR 
NR 
NR 
NR 
 
-0.21 (-0.28,-0.14) 
 
 
-54.49 (-68.25,-40.73) 
 
 
-121.88 (-155.66,-88.10) 
 
 
1.3 (-0.28,2.88) 
 
 
UTBC 
UTBC 
 
UTBC 
UTBC 
0.25 
 
 
0.36 
 
 
0.39 
 
 
0.38 
 
 
0.29 
 
 
UTBC 
 
 
UTBC 
0.11 
 
 
=0.04 
 
 
=0.03 
 
 
=0.04 
 
 
=0.10 
 
 
NS 
 
 
NS 
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aNS was determined from p-value provided or confidence interval 
bHigher scores indicate poorer function 
cHigher scores indicate better function 
Data with asterisk were estimated from graphs  
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
wk: Week  
SD: Standard deviation  
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
NR: Not reported 
NS: Not significant 
UTBC: Unable to be calculated 
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Between group effect size = (Change in Treatment – Change in Control) / Pooled baseline SD,29 where D indicates change. 
Intra-group effect size = (post-exercise - pre-exercise) / pooled baseline SD29 
SR: Story Recall (immediate recall (maximal score=12) and Delayed Recall (maximal score=12))  
BVR: Benton Visual Retention   
TMT: Trail Making Test 
SIT: Stroop Interface Test  
VF: Verbal Fluency 
DST: Digit Symbol Test (score=0-93), a subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-R)  
TMTB: Trail Making Test B 
TS: Task Switching 
SCWI: Stroop Color-Word Interference 
SOPT: Self-Ordered Pointing Test 
SR: Story Recall 
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LL: Learning Recall
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TABLE 3.3.2 COGNITIVE OUTCOMES (NON-RANDOMIZED CONTROLLED TRIALS) 
Citation Time 
point 
(wk) 
Outcomes Results Calculation Statistics 
Author, 
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%,CI) 
 
Between group 
Effect size 
(95%,CI) 
Between 
group p 
value 
Yanagawa, 
201135 
12 Verbal 
memory 
 
 
 
Information 
processing 
speed 
 
 
Attention/ 
Executive 
function 
 
 
 
Global 
cognitive 
function 
WLIMa 
 
 
WLDMa 
 
WAISR- 
DSTa 
 
 
 
TMTAb 
SCWTb 
TMTBb 
 
 
 
MMSa 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
 
Exercise 
Control 
21.67 ± 1.80 
22.29 ± 1.38 
 
8.22 ± 1.86 
7.57 ± 1.90 
 
42.44 ± 9.15 
46.43 ± 15.30 
 
 
53.44 ± 48.24 
39.76 ± 12.57 
 
20.54 ± 11.22 
22.57 ± 9.26 
 
112.56 ± 37.08 
134.06 ± 0.19 
 
26.33 ± 2.24 
26.56 ± 1.99 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
1.27 (-0.92,3.46) 
 
 
0.13 (-1.45,1.71) 
 
 
4.40 (-.39,14.19) 
 
 
 
12.86 (-27.55, 53.27) 
 
 
0.71 (-4.32,5.74) 
 
 
17.90 (-12.55, 48.35) 
 
 
0.04 (-.34,1.24) 
0.59 (-0.42, 0.60) 
 
 
0.08 (-0.90, 1.07) 
 
 
0.38 (-0.62, 1.38) 
 
 
 
0.46 (-0.54, 1.46) 
 
 
0.14 (-0.84, 1.13) 
 
 
0.60 (-0.41, 0.41) 
 
 
0.02 (-0.97, 1.00)  
0.31 
 
 
1.00  
 
 
0.27  
 
 
 
0.53  
 
 
0.79  
 
 
0.27  
 
 
0.96  
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aHigher scores indicate better function 
bHigher scores indicate poorer function 
Data is presented as Mean ± SD or Median (interquartile or range) or (±SD) 
wk: Week 
NR: Not reported 
SD: Standard deviation 
MD: mean difference 
ES: Effect size 
CI: Confidence interval 
WLIM: Word List (immediate memory), a subtest of the Alzheimer’s disease Assessment Scale  
WLDM: Word List (delayed memory), a subtest of the Alzheimer’s disease Assessment Scale  
DST: Digit Symbol Test (score=0-93), a subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-R)  
TMTA: Trail Making Test A  
TMTB: Trail Making Test B 
SCWT: Stroop Color-Word Test  
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MMS: Mini-mental State Examination (maximal score=0-30)
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TABLE 3.3.3 COGNITIVE OUTCOMES (CROSS-SECTIONAL STUDIES)  
Citation Time 
point 
(wk) 
Outcomes Results Calculation Statistics 
Author, 
Year 
Reference 
Domain Method Group Physical 
activity 
levels 
Between group  
MD (95%, CI) 
 
Between 
group  
ES (95%, CI) 
 
Between 
group 
p value 
(HA 
versus LA) 
aColberg, 
200832 
Cross-
sectional 
 
Global 
cognitive 
function 
MMSd 
 
 
SLUMSd 
HA (control) 
LA (diabetes) 
 
HA (control) 
LA (diabetes) 
NR 
NR 
 
NR 
NR 
NR 
NR 
 
NR 
NR 
NR 
NR 
 
NR 
NR 
0.04b 
 
 
<0.05b 
aDevore, 
200933 
Cross-
sectional 
Global 
cognitive 
function g 
 
Global 
cognitive 
functionf, g  
 
 
 
 
Verbal 
Memory g 
TICSd 
 
 
 
Global (TICSd, 
EBMT- IRd, 
EBMT-DRd, 
CFd, TICS-
WLDRd, 
DSBd) 
 
EBMT-IRd, 
EBMT-DR d 
TICS-IR, and 
TICS-DR d 
HA 
LA 
 
 
HA 
LA 
 
 
 
 
 
HA 
LA 
NR 
NR 
 
 
NR 
NR 
 
 
 
 
 
NR 
NR 
0.37 (0.02±0.72) 
 
 
 
0.07 (-0.01±0.15) 
 
 
 
 
 
 
0.06 (-0.03±0.15) 
 
NR 
NR 
 
 
NR 
NR 
 
 
 
 
 
NR 
NR 
0.03 
 
 
 
0.06 
 
 
 
 
 
 
0.20 
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TABLE 3.3.4 COGNITIVE OUTCOMES (PROSPECTIVE STUDY) 
Citation Time point 
(wk) 
Outcomes Results Calculation Statistics 
Author, 
Year 
Reference 
Domain Method Group Physical 
activity 
levels 
Between group  
MD (95%, CI) 
 
Between 
group  
ES (95%, CI) 
 
Between 
group 
p value 
(HA versus 
LA) 
aDevore, 
200933 
Prospective d 
 
Global 
cognitive 
function g 
 
Global 
cognitive 
functione, g  
 
 
 
 
Verbal 
Memoryf, g 
TICSc 
 
 
 
Global score 
(TICSc, EBMT- 
IMc, EBMT-
DRc, CFc,  
TICS-WLDRc, 
DSBc) 
 
EBMT-IRc, 
EBMT-DRc  
TICS-IR, c and 
TICS-DRc 
HA 
LA 
 
 
HA 
LA 
 
 
 
 
 
HA 
LA 
NR 
NR 
 
 
NR 
NR 
 
 
 
 
 
NR 
NR 
0.21 (-0.15± 0.57) 
 
 
 
0.05 (-0.03±0.12) 
 
 
 
 
 
 
0.02 (-0.03±0.16) 
 
UTBC 
 
 
 
UTBC 
 
 
 
 
 
 
UTBC 
0.2 
 
 
 
0.2 
 
 
 
 
 
 
0.2 
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aSignificant difference in baseline measures was noted in paper and in our quality assessment of this trial.  
bSignificance was determined from p-value provided or confidence interval. 
cHigher scores indicate poorer function. 
dHigher scores indicate better function. 
eAnalyses of cognitive decline over 2 interviews included 1,352 women who additionally participated in the second cognitive assessment 
(follow-up exceeded 90% in the second and third cognitive interviews as well (mean time span over 3 interviews = 4 years) 
fAn overall global score averaged together scores from all 6 of our cognitive tests (TICSd, EBMTd,  CFd, TICS-WLDRd, DSBd). 
gA verbal memory score averaged together scores from all 4 of our cognitive tests (EBMT d and TICS-WLDRd). 
hAdjusted for age, education, initial cognitive score, time between cognitive interviews, disability indicators, use of antidepressant 
medication (yes/no), alcohol intake (none, 1–14 g/day, or 15 g/day), smoking (never, past, current), duration of diabetes (<5, 5–9, 10–
14, or 15 years prior to initial cognitive interview), use of diabetes medication (none, oral medication only, insulin), body mass index 
(weight (kg)/height (m)2; <25, 25–29, or 30), and vascular factors (high blood pressure, high cholesterol, myocardial infarction, coronary 
artery bypass graft, transient ischemic attack, carotid surgery, and congestive heart failure—yes/no) 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
Wk: Weeks 
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NR: Not reported 
HA: Highest active 
LA: Lowest active 
CI: Confidence interval 
NR: Not reported 
NS: Not significant 
ES: Effect size 
EBMT: East Boston Memory Test 
EBMT: East Boston Memory Test of the Immediate Recalls and the Delayed Recalls  
CF: Category Fluency 
TICS: Telephone Interview for Cognitive Status + Immediate Recall  
RR: Relayed Recall  
DSB: Digital-Spam Backwards  
TICS: Telephone Interview for Cognitive Status (maximal score=41) 
MMS: Mini-mental State Examination (maximal score=30) 
SLUMS: Saint Louis University Mental Status Exam  
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TABLE 3.4 INSULIN RESISTANCE OUTCOMES 
TABLE 3.4.1 INSULIN RESISTANCE OUTCOMES (RANDOMISE CONTROLLED TRIALS) 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group  
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group  
p value 
Watson,  
200631 
26 Insulin 
sensitivity  
2-hour OGTT 
insulin levels 
(pmol/l) a 
Exercise 
Control 
NR 
NR 
-107 ± 36 a 
123 ± 92 
-230.00  
(-282.85,-177.15) 
-3.29 (-4.43,-2.15) 0.02 
Baker, 
201034 
26 Insulin 
sensitivity 
bGDR 
(mg/kgFFM/m
in) 
 
Fasting plasma 
insulin 
(mU/mL) 
Exercise 
Control 
 
 
Exercise 
Control 
5.90 ± 3.30 
7.60 ± 2.50 
 
 
11.1±9.0 
9.8±3.9 
6.50 ± 3.00 
6.70 ± 2.70 
 
 
9.0±4.4 
8.4±5.0 
1.50 (-1.06, 4.06) 
 
 
 
-0.70 (-7.18, 5.78) 
 
0.47(-0.33, 1.28) b 
 
 
 
-0.09 (-0.88, 0.71) 
0.05 
 
 
 
0.62 
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aValue in 6 month adjusted for baseline 
bGDR= mean 30-miute glucose disposal rate 120 minute into the hyperinsulinemic-euglycemic clamp (HEC), adjusted for fat free mass 
in mg/kgFFM/min).Negative values represent high insulin sensitivity and glycemia control 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
Wk: Weeks  
NR: Not reported 
SD: Standard deviation 
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
OGTT: Oral glucose tolerance test 
GDR: Glucose disposal rate  
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TABLE 3.4.2 INSULIN RESISTANCE OUTCOMES (NON-RANDOMISE CONTROLLED TRIALS). 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group  
p value 
Yanagawa, 
201135  
12  Insulin 
sensitivity  
GIR 
(mg/kg/
min)  
 
MCR 
(mL/kg/
min)  
Exercise  
Control  
 
 
Exercise  
Control  
4.79 ± 1.35  
4.00 ± 1.56  
 
 
2.08 ± 1.07  
2.26 ± 0.93  
NR  
NR  
 
 
NR  
NR  
1.18 (-0.06, 2.42)  
 
 
 
0.59 (-0.33, 1.51)  
0.97 (-0.07, 2.02) 
  
 
 
0.66 (-0.36, 1.67)  
0.24  
 
 
 
0.99  
Data is presented as Mean ± SD or Median (IQR or range) or (±SD). 
Wk: Weeks  
SD: Standard deviation 
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
NR: Not reported 
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TABLE 3.5 GLUCOSE HOMEOSTASIS OUTCOMES  
TABLE 3.5.1 GLUCOSE HOMEOSTASIS OUTCOMES (RANDOMISED CONTROLLED TRAILS) 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
 
Between group  
ES (95%,CI) 
Between 
group  
p value 
Watson,  
200631  
26  Glucose 
tolerance  
2-hour OGTT 
glucose levels 
(mmol/l)  
Exercise  
Control  
9.40 ± 1.10  
9.40 ± 0.90  
NR  
NR  
NR  
NR  
Unable 
to be calculated  
NR  
Baker,  
201034 
26  Glucose 
homeostasis  
FBG (mg/dL)  Exercise  
Control  
105.0±30.0  
91.0±8.2  
100.0±20.0  
94.0±11.4  
-8.0 (-29.1, 13.1)  -0.31 (-1.10, 0.49)  0.44  
Data is presented as Mean ± SD or Median (IQR or range) or (±SD). 
wk: Weeks  
NR: Not reported 
SD: Standard deviation 
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
OGTT: Oral glucose tolerance test 
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FBG: Fasting blood sugar 
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TABLE 3.5.2 GLUCOSE HOMEOSTASIS OUTCOMES (NON-RANDOMISED CONTROLLED TRAILS) 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group  
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group  
p value 
Yanagawa  
201135 
12  Glucose 
homeostasis  
HbA1c 
(%)  
 
FBS 
(mg/dl)  
Exercise  
Control  
 
Exercise  
Control  
7.29 ± 0.56  
7.14 ± 0.61  
 
128.44 ± 22.57  
129.86 ± 24.72  
NR  
NR  
 
NR  
NR  
-0.07 (-0.45, 0.31)  
 
 
-2.49 (-7.86,12.88)  
-0.19 (-1.18, 0.80) 
  
 
-0.17 (-1.15,0.82)  
0.72  
 
 
0.21  
          
Data is presented as Mean ± SD or Median (IQR or range) or (±SD). 
wk: Weeks  
NR: Not reported 
SD: Standard deviation 
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
HbA1c: Glycosylated haemoglobin 
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FBS: Fasting blood sugar  
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TABLE 3.6 BODY COMPOSITION 
TABLE 3.6.1 BODY COMPOSITION (RANDOMISED CONTROLLED TRAILS) 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Referen
ce 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group  
p value 
Watson,  
200631 
26 
 
IAFA (cm2) 
 
Computer 
Tomography 
Exercise 
Control 
NR 
NR 
NR 
NR 
NR 
NR 
UTBC NR 
BMI  
(kg/m2) 
Anthropometry Exercise 
Control 
24.7 ± 3.2  
26.7 ± 4.3  
23.6 ± 2.9  
26.4 ± 4.1 
-0.50 (-2.93, 1.93) -0.13 (-0.75, 0.49) 0.16 
Baker, 
201034 
26 Fat (%) 
 
 
Dual energy  
X-ray 
absorptiometry 
Exercise 
Control 
 
37.7 ±  6.6  
42.6 ± 7.1 
 
36.1 ± 6.0 
41.0 ± 7.6  
 
 
0.00 (-5.62, 5.62) 0.00 (-0.79, 0.79) 
 
 
1.00 
 
 
 
          
Data is presented as Mean ± SD or Median (IQR or range) or (±SD). 
Fat% presented as percent fat distributed across the body. 
IAFA: Intra-abdominal fat area 
BMI:  Body mass index 
wk: weeks  
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SD: standard deviation  
MD: mean difference 
NR: not reported 
ES: Effect size 
CI: confidence interval 
UBC: Unable to be calculated
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TABLE 3.6.2 BODY COMPOSITION (NON-RANDOMISED CONTROLLED TRAILS) 
Citation Time 
point 
(wk) 
Outcomes Results  Calculation Statistics 
Author  
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group  
p value 
Yanagawa, 
201135 
12 Fat (%) 
 
NR 
 
Exercise 
Control 
16.24 ± 1 4.04 
21.47 ± 1 6.48 
 
NR 
NR 
 
NR 
NR 
 
0.67 (-0.34, 1.69) 
 
0.18 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD). 
Fat% presented as percent fat distributed across the body. 
IAFA: Intra-abdominal fat area 
wk: weeks  
SD: standard deviation  
MD: mean difference 
NR: not reported 
ES: Effect size 
CI: confidence interval 
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TABLE 3.7 EXERCISE CAPACITY OUTCOMES 
Citation Time 
point 
(wk) 
Outcomes Results Calculation 
 
Statistics 
Author,  
Year 
Reference 
Domain Method Group  Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
 
Between group 
ES (95%,CI) 
Between 
group p 
value 
Watson,  
200631 
26 
 
 
52 
Peak 
oxygen 
uptake 
(ml/kg/min) 
 
 
Submaximal 
aerobic 
exercise 
(treadmill 
test) 
 
Exercise 
Control 
 
Exercise 
Control 
29.50 ± 7.10 
27.40 ± 5.60 
 
NR 
NR 
33.80 ± 6.30 
27.30 ± 5.50 
 
NR 
NR 
4.40 (-0.62, 9.42) 0.66 (-0.10, 1.42) 
 
 
NR 
NR 
0.08 
 
 
NR 
Baker,  
201034 
26 Peak 
oxygen 
uptake 
(L/min) 
Maximal 
aerobic 
exercise 
(treadmill 
test, 
stationary 
bicycle, or 
elliptical 
trainer) 
Exercise 
Control 
1.79 ± 0.60  
1.69 ± 0.30  
1.97± 0.70 
1.65 ± 0.30 
0.22 (-0.22, 0.66) 0.41 (-0.39, 1.21) a 0.030 
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aEffect size model was adjusted for β-blocker use. 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
wk: weeks 
MD: Mean difference 
SD: Standard deviation 
ES: Effect size 
CI: Confidence interval 
NR: Not reported 
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TABLE 3.8 PLASMA AΒ42 METABOLIC OUTCOMES 
Citation Time 
point 
(wk) 
Outcomes Results Calculation Statistics 
Author, 
Year 
Reference 
Domain Method Group Pre-exercise 
(Mean ± SD) 
Post-exercise 
(Mean ± SD) 
Between group 
MD (95%, CI) 
Between group 
ES (95%, CI) 
Between 
group 
p value 
Baker,  
201034 
26 Aβ42a ELISA Exercise 
Control 
87.1 ± 64.9 
58.9 ± 66.6 
66.0 ± 42.7 
79.9 ± 43.8 
-42.10 (-96.52, 12.32) -0.62 (-1.43, 0.19)b 0.07 
a Higher Aβ42 represents the worse function. 
bNegative effect size favor high active group in all cases, as expected lower Aβ42. 
Data is presented as Mean ± SD or Median (IQR or range) or (±SD) 
wk: Weeks  Plasma levels of Aβ42 
SD: Standard deviation 
MD: Mean difference 
ES: Effect size 
CI: Confidence interval 
ELISA: Enzyme-linked immunosorbent assay 
Aβ42: Amyloid β42  
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TABLE 3.9 RELATIONSHIP BETWEEN CHANGES IN COGNITION AND CHANGES IN INSULIN RESISTANCE 
Citation  Cognitive 
measurement 
IR measurement Time since last 
exercise bout 
Relationship r p Comments 
Author,  
Year 
Reference 
Watson, 
200631 
Delayed 
memory 
2-h oral glucose 
tolerance test insulin 
level (pmol/L) 
 
NR Change in delayed 
memory and 
change 2-hour oral 
glucose tolerance 
test insulin level 
r=-0.52  
 
 
 
r=0.02 
p=0.047 
 
 
 
p=0.946 
AT plus 
AHAS2ED 
group only 
 
Control group 
(AHAS1ED) 
Colberg,  
200832 
General 
cognitive 
function 
HOMA-IR 
 
Insulin (IU/mL) 
NR 
 
NR 
 r=-0.19 
 
r=-0.13 
p=0.02 
 
p=0.03 
Pooled 
sample 
Yanagawa, 
201135 
Delayed 
memory 
Euglycaemic 
Clamp (glucose 
infusion rate 
(mg/kg/min) and 
metabolic clearance 
rate (mL/kg/min)) 
 Change in word 
recall (immediate) 
and change in 
glucose infusion 
rate 
 
Change in word 
recall (immediate) 
and change in 
metabolic 
clearance rate 
r=0.64  
 
 
 
 
 
r=0.575  
p=0.024 
 
 
 
 
 
p=0.051 
Pooled 
sample 
AHAS1ED: American Heart Association Step 1 Eucaloric Diet 
AHAS2ED: American Heart Association Step 2 Eucaloric Diet 
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HOMA: Homeostatic Model Assessment  
IR:  Insulin resistance 
NR: not report  
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TABLE 3.10 RELATIONSHIP BETWEEN CHANGES IN COGNITION AND CHANGES IN GLUCOSE HOMEOSTASIS 
Citation  Cognitive 
measurement 
Glucose 
Homeostasis 
Time since last 
exercise bout 
Relationship r p Comments 
Author,  
Year 
Reference 
Watson,  
200631 
NR Fasting 
Glucose 
(mmol/l) 
NR NR NR NR NR 
Yanagawa, 
201135 
Delayed memory 
 
 
Executive function 
HbA1c (%) 
 
 
Fasting blood 
sugar (mg/dL) 
NR 
 
 
NR 
Change in word recall 
and change in HbA1c 
 
Change in Trail 
Making Test B and 
change in fasting 
blood sugar 
r=-0.627  
 
 
r=0.611  
p=0.029 
 
 
p=0.035 
Pooled 
sample 
HbA1c: glycosylated hemoglobin 
NR: not reported 
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TABLE 3.11 RELATIONSHIP BETWEEN CHANGES IN COGNITION AND CHANGES IN BODY COMPOSITION 
Citation  Cognitive 
measurement 
Body composition Time since last 
exercise bout 
Relationship r p Comments 
Author,  
Year  
Reference 
Watson,  
200631 
Delayed 
memory 
Intra-abdominal fat 
(cm2) 
NR NR r=0.62,  P=0.024 Control group 
(AHAS1ED) 
Baker,  
201034 
NR 
 
Fat% NR NR NR NR NR 
Yanagawa, 
201135 
NR 
 
Fat% NR 
 
NR NR NR NR 
AHAS1ED: American Heart Association Step 1 Eucaloric Diet 
NR: Not reported 
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FIGURE 3.1 FLOW CHART OF PAPERS IDENTIFIED FROM SEARCH STRATEGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention 
n=1,269,586 
 
Condition 
n=682,149 
Outcome 
n=2,132,265 
Combined Search 
n=5754 
Papers excluded   n = 27 
Reasons: 
No cognitive outcomes n = 9 
Animal trials   n = 18 
 
 
 
 
 
   
Potentially Eligible Papers 
n=32 
 
Included Papers 
n=5 
 
 Randomised Controlled Trials 
n=3 
 
Observational Studies 
n=2 
 
Nonrandomised Controlled Trials  
n=1 
 
Excluded on basis of title or abstract 
n=5722 
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CHAPTER 4 
RATIONALE AND METHODOLOGY OF THE GREAT2DO TRIAL: A RANDOMISED 
DOUBLE-BLIND, SHAM-EXERCISE CONTROLLED TRIAL OF POWER TRAINING 
IN OLDER INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS 
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4.1 ABSTRACT 
OBJECTIVES - The objective of the study was to assess the efficacy of power training as a 
therapeutic intervention in older adults with type 2 diabetes mellitus (T2DM), as well as its effects 
on comorbidities and physical function.  This chapter provides the detailed rationale and 
methodology of a randomised double-blind, SHAM-exercise controlled trial of the Graded 
Resistance Exercise and T2DM in Older adults (GREAT2DO) Study.  The cognitive function 
outcomes, which are the primary focus of this thesis, were secondary outcomes of the overall trial. 
METHODS - Community dwelling men and women were recruited into a randomised controlled 
trial (RCT).  Primary inclusionary criteria were sedentary, stable disease, and aged 60 years or 
older, with previously diagnosed T2DM.  Exclusionary criteria included uncontrolled or fasting 
glucose consistently > 11.1mmol/L, significant cognitive impairment, non-ambulatory status or 
lower extremity amputation other than toes, current alcohol or substance abuse, contraindications 
to performance of resistance training or rapidly progressive or terminal illness. The study enrolled 
103 subjects from July 2006 to December 2009, concluding the 12-month RCT phase in January 
2011.  Participants were randomly allocated using a 1:1 ratio via computer-generated blocks of 
4, stratified by sex and use or non-use of insulin to either a supervised experimental group or 
SHAM-exercise control group (3 days/week × 12 moths).  The experimental POWER training 
group performed high intensity high velocity power training (at 80% of maximal strength) of 8 
major muscle groups, 3 days per week for 12 months.  The SHAM-exercise group performed 3 
sets of 8 repetitions on the same machines, but with no loading beyond the bar of the machine and 
the loads were non-progressive.  Primary outcomes measured at baseline and 12 months were 
insulin resistance and glucose homeostasis.  Secondary outcomes were neuropsychological test 
scores, psychological well-being, quality of life, cardiovascular and musculoskeletal function, 
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body composition, adipokines, and systemic and cytokine inflammation. 
CONCLUSIONS - This study included all design and reporting requirements for RCTs, adhering 
precisely to Consolidated Standards of Reporting Trials (CONSORT) guidelines.  The specific 
aim of this sub-study of the GREAT2DO trial was to determine whether the P training intervention 
in diabetes, a major risk factor for Alzheimer’s disease and vascular dementia, can reduce early 
decline in cognitive function and also identify the potential underlying mechanisms of adaptation 
in older adults at risk of further cognitive decline. 
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4.2 INTRODUCTION 
The prevalence of T2DM increases with age1, 2  This disease and associated comorbidities and 
complications such as cardiovascular disease, nephropathy, retinopathy, neuropathy, peripheral 
vascular disease and depression have a substantial negative impact on cerebral structure and 
function, quality of life, and higher mortality rates.  Organ damage is a serious consequence of 
inflammation, abnormal glucose and lipid metabolism, and cardiovascular disease is the leading 
cause of morbidity and mortality in T2DM.  Similarly, cognitive impairment can advance to 
dementia, a major challenge to sufferers, their caregivers, and the health care system.3 Clearly 
there is a continuing and urgent need to reduce this burden and define the best strategies to achieve 
this. 
 
Recent studies suggest that T2DM is a risk factor for cognitive deficits in older adults.4, 5  The 
underlying mechanisms are multifactorial.  In older individuals with T2DM, the presence of 
much comorbidity likely contributes to this increased risk of cognitive impairment.  Previous 
studies have reported that transient ischemic attacks (TIAs), stroke, or atherosclerosis are strong 
predictors of cognitive decline.6  Associations between high glycosylated haemoglobin (HbA1c) 
and cognitive decline have been demonstrated in older and middle aged individuals.7  Also, in 
older patients with T2DM, acute deficits in working memory and attention have been observed in 
the hyperglycaemic state during a glucose clamp.8, 9 are some of the central abnormalities linking 
T2DM and dementia, and loss of muscle mass has been recently potentially implicated as well.10  
A sedentary lifestyle is associated with increased risk of dementia, and it has been observed that 
regular moderate exercise during midlife is related to higher cognitive performance in later life.11  
Physical inactivity also results in a chronic elevation of inflammatory biomarkers,12 which are also 
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observed in patients with dementia and T2DM13  Furthermore, inflammatory mediators such as 
tumour necrosis factor alpha (TNF-α) are secreted from abdominal adipose tissue14 and previous 
findings have shown that abdominal obesity (more than whole body obesity) is associated with 
risk of cognitive decline in late life.15  In addition, higher muscle mass is associated with a 43% 
decreased risk of Alzheimer disease.16  Each of these diabetes-related comorbidities is potentially 
modifiable, and therefore an appropriate target for interventions. 
 
The management of T2DM often includes a combination of dietary modifications, medications 
and the prescription of exercise.  Specifically, the benefits of exercise include improved 
glycaemic control, increased insulin sensitivity, decreased adiposity, decreased inflammation, 
decreased blood pressure and decreased blood lipids,17 as well as treatment for many of the 
common comorbidities of T2DM, including obesity, cardiovascular disease, osteoarthritis, 
peripheral vascular disease, and depression, among others.18-20  Notably, these risk factors have 
been shown to improve cognitive function in other cohorts, although data on the effects of 
modifying them in T2DM specifically in relation to cognitive risk are lacking.   
 
Current exercise guidelines for the management of T2DM encourage the use of aerobic or 
endurance training, as well as progressive resistance training (PRT) or weight lifting.17  PRT 
holds a unique advantage over endurance training in its ability to simultaneously decrease 
adiposity and increase skeletal muscle mass and associated metabolic and functional changes.9, 20-
22  PRT can address all components of the progression of type 2 diabetes.  It has positive effects 
on performance tasks including muscle strength,23 6-minute walk distance,24 aerobic capacity,25 
balance,26 gait speed,23 chair stand,24 stair-climbing speed and power,24 and physical function,24, 25 
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Improvements in body composition following PRT are likely to contribute to the improvements in 
insulin sensitivity, glucose homeostasis, blood pressure, dyslipidaemia, physical performance, and 
markers of inflammation and catabolism, ultimately leading to improvements in cognitive function 
and quality of life in older adults with T2DM.12 
 
PRT has been shown to have positive effects on growth factors [e.g., brain-derived neural growth 
factor (BDNF) and insulin-like growth factor 1 (IGF-1)]27, 28 and the regulation of systemic 
inflammation,29, 30 so addressing multiple components related to brain function of older adults.  
Notably, PRT may sometimes be a more realistic exercise option in this cohort, as it is more 
feasible in elders with severe mobility impairment related to obesity, osteoarthritis, peripheral 
vascular disease, peripheral neuropathy or balance problems, accordingly having the potential for 
long-term adherence.  In addition, PRT may be an appropriate and effective tool for the 
management of T2DM, and the beneficial whole body adaptation to PRT may lead to 
improvements in the cognitive health of individuals with T2DM.  
  
A variant of PRT, power training (POWER), involves maximal velocity concentric (shortening) 
contractions and slow velocity eccentric (lengthening) contractions.  The rationale for this type 
of training lies in the optimal recruitment of Type II muscle fibres induced by high velocity 
training,31, 32 and the knowledge that these are the specific fibres most atrophied with ageing and 
inactivity.33-36  In addition, losses of muscle power occur earlier and more precipitously than 
losses of muscle strength in older adults.37  Finally, muscle power has been more closely linked 
to functional disability and fall risk than muscle strength, thus building a rationale for POWER 
training in older adults as the specific modality of resistance training to employ. 
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As reviewed in Chapter 3, there have been two randomised controlled trials (RCTs), one non-
randomised controlled trial, and two observational studies investigating physical activity or 
aerobic exercise in adults with T2DM or impaired glucose tolerance examining cognitive 
outcomes.  However, no published rigorous clinical trials have investigated the central and 
peripheral benefits of power training for improved cognitive function in this cohort.   
 
At the time of initiation of this trial the effects of resistance training in older adults with T2DM 
were just beginning to emerge.  These studies were comprised of cohorts of29, 38, 39 participants, 
and only lasted for 3 and 4 months respectively.  More recent studies also reported PRT has 
demonstrated benefits including improved fasting plasma glucose,38 HbA1C,38, 40-45 insulin 
sensitivity40, 46 as well as decreased abdominal adiposity and increased lean tissue in older adults 
with T2DM.31, 47  These studies had some design flaws, including small sample sizes  limiting 
conclusions.  The aim of the overall GREAT2DO study was to rigourously investigate the effects 
of a 12-month power training program in older adults with T2DM.  The hypothesised adaptations 
(see Figure 1) included changes in fitness, body composition, glucose homeostasis, insulin 
resistance, inflammation, body composition, physical performance, exercise capacity, and 
neuropsychological function.  The GREAT2DO trial provided a unique opportunity, in the 
context of an RCT, to further address the relationship between cognitive function and T2DM, 
associated risk factors, and the ability to alter the trajectory of cognitive decline in this high risk 
cohort. 
 
The remainder of this chapter will outline the methodology of the components of the GREAT2DO 
study specific to this thesis.  A detailed description of this methodology can be found in the 
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Appendix A, Appendix B, and Appendix C. 
 
4.3 METHODS 
4.3.1 Study Design 
The GREAT2DO trial is a longitudinal double-blind randomised, SHAM-exercise controlled 
clinical trial.  Participants (n=103) were randomised to the experimental (high intensity, high 
velocity power training (POWER), or control condition (SHAM low intensity, non-progressive 
resistance training), for 12 months, in addition to usual medical care, with participants blinded to 
investigators’ hypotheses as to which was the experimental group.  Blinded outcome assessments 
were conducted at 0, 6 and 12 months in all participants regardless of adherence level.  Only 
baseline and 12-month outcomes were analysed for this thesis.  Follow-up was continued for a 
total of 6 years, which is on-going, and is outside of the scope of this thesis. 
 
The trial was registered with the Australian Clinical Trials Registry (ACTR) (ACTR No: 
ACTRN12606000436572).  Ethical approval was obtained from Ethics Review Committee 
(Royal Prince Alfred Hospital (RPAH) Zone), Sydney South West Area Health Service (Ethics 
Committee Protocol No: X04-0096) and written informed consent was obtained from all 
participants.  The assessments were conducted at Cumberland Campus of University of Sydney 
in Lidcombe New South Wales (NSW) Australia.  Computerised Tomography (CT) Scans were 
performed at the Radiology Department of RPAH in Camperdown NSW Australia.  The exercise 
training was conducted at either the Harbord Diggers Memorial Club (Freshwater Rehabilitation) 
in Manly NSW Australia or the Centre for STRONG Medicine, Balmain Hospital in Balmain NSW 
Australia. 
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Objectives and hypothesis 
The primary objective of the GREAT2DO trial was to determine the efficacy of high intensity, 
high velocity progressive resistance training (POWER) on insulin resistance and glucose 
homeostasis in older adults with T2DM and metabolic syndrome, as measured by Homeostatic 
Model of Assessment of Insulin Resistance (HOMA2-IR)48 and HbA1c, as well as its effects on 
many secondary outcomes, including the focus of this thesis, cognitive function.  Our secondary 
aim was to identify potential mechanisms of benefit for hypothesised cognitive function 
improvements, in particular modulation of cardiovascular risk profile, systemic inflammatory 
cytokines, growth factors, fitness levels and physical performance, and body composition.   
Primary hypotheses of the GREAT2DO Study 
Twelve months of supervised power training will significantly improve glucose homeostasis and 
insulin sensitivity relative to a SHAM exercise control condition (low intensity, slow velocity, non-
progressive training). 
 
Secondary hypotheses of the GREAT2DO  
1. Power training will improve cognitive outcomes in the POWER training group in the domains 
of memory, information processing speed, attention, and executive function, relative to the 
SHAM control condition. 
2. Power training will improve body composition, ambulatory blood pressure, cardiovascular 
risk profile including systemic and adipose tissue inflammation, resting metabolic rate, 
skeletal muscle morphology and metabolism, aerobic and musculoskeletal exercise capacity, 
habitual activity levels, sleep quality, psychosocial function, quality of life, gait and balance 
and physical function compared to the SHAM exercise control group. 
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3. Improvements in insulin sensitivity and glucose homeostasis, body composition, systemic 
inflammation and adipokines will be related to cognitive improvements at 12 months. 
 
4.3.2 Sample Size Estimates 
Sample size estimates were driven by hypothesised differences between participants randomised 
to receive POWER, compared to those randomised to receive SHAM exercise for the primary 
outcomes of the GREAT2DO trial:  insulin sensitivity and HbA1c.  Effect sizes (ESs) were 
calculated based on an average of published studies of PRT in diabetes/obesity22, 38, 49 (Table 4.1), 
and the largest available standard deviations used for conservative estimates of ES, as no previous 
studies of power training in this cohort exist.  For these calculations, β was set at 90%, and α at 
0.05, and a 10% loss to follow-up was assumed.  Effect sizes were calculated using G*Power 
3.1.2 (Kiel, Germany).50 Sample size estimates for this cognitive sub study of GREAT2DO (α 0.05, 
β 0.20) were based on planned comparisons for the main effects of POWER compared to SHAM 
exercise on our primary cognitive outcome: global cognitive function.  Meta-analyses51 and 
review of published RCTs52 in older adults report ESs for a range of cognitive outcomes of 
approximately 0.59 for PRT, compared to 0.15 for control groups.  Thus, we had sufficient power 
based on our primary outcome calculations to show an ES of 0.59 for the main effects of POWER 
vs. SHAM exercise (n 47/group × 2 = 94) for this secondary cognitive outcome as well.  
According to our estimates, and assuming a dropout 10% over one year, we inflated sample size 
needs for approximately 10% drop out rate to account for anticipated attrition (n =103). 
 
4.3.3 Study Population 
Between July 2006 and November 2009, 103 participants were recruited and randomised to receive 
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either 12 months of high intensity, high velocity power training (POWER) or SHAM exercise (low 
intensity, slow velocity, non-progressive exercise; SHAM).  Participants were given no dietary or 
pharmacological treatment or counselling, but continued to be under their usual medical care and 
nutritional advice from their usual health care providers for the duration of the study. 
 
4.3.4 Inclusion and Exclusion Criteria 
Inclusionary criteria 
Inclusionary criteria were based on diagnosed T2DM, age, and physical activity level.  
Participants were community-dwelling persons aged 60 or above and insufficiently active (no PRT; 
structured exercise ≤ 1/week; less than 150 min / week low or moderate-intensity walking or other 
aerobic exercise).  Participants could be treated with diet alone, oral medications or insulin or 
combination at the time of enrolment.   
 
Exclusionary criteria  
Exclusionary criteria included significant cognitive impairment (dementia diagnosed or inability 
to understand informed consent), non-ambulatory status or lower extremity amputation other than 
toes, current alcohol or substance abuse, inability to comply with study requirements over the 
course of one year due to travel plans or other commitments, and specific contraindications to 
resistance training exercise, such as unstable cardiovascular disease, unrepaired aortic aneurysm, 
symptomatic hernias, proliferative diabetic retinopathy, or rapidly progressive or terminal illness.  
Temporary exclusions (any change in dosage or type of diabetic medications within the past 3 
months, retinal laser surgery within 6 weeks, uncontrolled hypertension) were resolved prior to 
study enrolment and screening procedures.  All inclusionary and exclusionary criteria were 
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determined by telephone screening questionnaire, review of medical records, and in-person history, 
physical exam, and maximal exercise tolerance testing by the study physician prior to enrolment.   
 
4.3.5 Recruitment and Screening 
Participants were recruited from newspaper advertisements, Diabetes Australia newsletter 
pamphlets, and direct communication to general practitioners and University of Sydney databases 
of volunteers.  Subjects were screened for eligibility via initial telephone questionnaire, and the 
study enrolled 103 participants from July 2006 to December 2009, completing in January 2011.  
After confirming interest with eligible participants, an introductory letter was sent with 
information for assessment dates.  A request for permission to access medical records was 
included and a medical release letter was sent to the general practitionser (GP) requesting patient 
assessment information.  If there were no reasons for exclusion reported from the GP, a patient 
assessment information pack was given to each participant including all the details and dates of 
assessments.  Confirmation letters were also sent at 6- and 12-months for follow-up assessments.  
All details and documents related to recruitment and screening are presented in the Appendix A. 
 
4.3.6 Randomisation, Allocation and Concealment 
Randomisation was at the level of the individual patient, stratified by sex and use or non-use of 
insulin, in blocks of 4 via a computer-generated randomisation scheme.  The sequential treatment 
assignments were based on a computer-generated randomisation scheme 
(http://www.randomization.com, created by Dr Gerard E. Dallal, Tufts University).  
Randomization occurs at the completion of the entire baseline assessment.  Where randomization 
occurs in person, assignments would be placed in sealed opaque envelopes and delivered to 
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subjects by an independent researcher with subjects designated to 12 month of an experimental 
POWER group (blue group) or SHAM exercise group (green group). 
 
An investigator not involved in the study performed randomisation.  Randomisation was 
concealed by emailing the randomisation assignment to the blinded study assessor at the 
conclusion of all baseline testing, who disclosed this information to the participant via telephone 
call.  Two groups had an equal volume and frequency of contact with trainers in the 12 months 
of the study.  All primary and secondary outcomes were obtained and analyzed by blinded 
assessors on different days to the training programs 
 
4.3.7 INTERVENTION 
Experiment intervention protocol: power training (POWER) 
Experimental participants received high intensity power training of 8 major muscle groups 3 days 
per week under full supervision of research staff, using pneumatic resistance equipment (Keiser 
Sports Health Equipment, Ltd.  Fresno, CA, USA).  All trainers were Exercise and Sport 
Science Australia approved exercise physiologists, other allied health professionals with expertise 
in exercise and chronic disease treatment, or postgraduate students in exercise physiology at the 
University of Sydney.  All exercise was supervised in the clinic/gym and overseen by onsite and 
offsite physicians via weekly case conferences.  The exercises targeted large symmetrical muscle 
groups of the arms, legs, and trunk: seated row, chest press, leg press, knee extension, hip flexion, 
hip extension and hip abduction.  A version of PRT known as power training was employed, in 
which the concentric contraction (lifting) was done as quickly as possible, while the eccentric 
contraction (lowering) was done over 4 seconds.  The choice of power training as opposed to 
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traditional slow velocity PRT was based on a number of important factors: 
1. Power training has never been investigated in older adults with T2DM. 
2. Loss of muscle power is more precipitous than loss of muscle strength in older adults37   
3. Low muscle power is more closely related to functional impairment than low muscle strength 
in older adults53 
4. High intensity power training improves muscle strength, power and endurance and improves 
power more than slow velocity progressive resistance training.54  
5. The recruitment of atrophied Type II fibres (which are most closely related to losses of power 
and muscle mass in sarcopenia)55 is optimised by the requirement for both high velocity and 
high force contractions which define power training.54  
6. The cognitive requirements of generating maximal velocity with each contraction in power 
training may theoretically engage central nervous system (CNS) mechanisms that would 
stimulate neural and well as muscular adaptations better than slow velocity PRT. 
For each exercise, participants performed 3 sets of 8 repetitions (2 sets of 8 on each leg for hip 
flexion, hip extension and hip abduction).  The intensity was set at 80% of the most recently 
determined peak strength (one repetition maximum, 1RM), re-assessed every 4 weeks.  Where 
1RM testing was not feasible, resistances were increased by targeting a Borg scale 56 rating of 
perceived exertion between 15 and 18, which approximates 80% of the 1RM. 
 
As we age, muscle power fades even more swiftly than strength does.  Using heavy loads during 
explosive resistance training (known power training) has been shown to be a safe and effective 
method for improving neuromuscular power and other physical performance outcomes in older 
adults compared to low velocity strength training alone.125  Although there are non-cognitive 
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reasons to study this form of training in older adults with diabetes, high speed power training had 
a positive effects on metabolic health in this cohort.   
 
Power training was based on the fact that the attempt to contract at high velocity force contractions 
specifically is known126 to target a greater recruitment of type 2 fibers and increase neural 
stimulation than slow velocity contractions.  Moreover, training novices to contract rapidly 
against a heavy load includes a cognitive component to the training session as the participant thinks 
about and plans for each maximal velocity contraction, which is more focused, difficult, and 
engaging than slow velocity training. 
 
Control group intervention: SHAM 
The SHAM exercise group trained on the same equipment, 3 times a week, under full supervision 
from the same trainers at different times of the day so as to remain blinded to the investigators’ 
hypotheses, with both interventions offered as potentially beneficial.  These participants 
performed 3 sets of 8 repetitions on the same machines, but with no loading beyond the bar of the 
machine, using 1-2 second concentric and eccentric contraction speed.  No interim 1RM testing 
and no progression took place.  This regimen has been shown to produce minimal change in 
muscle function or mass, functional status, mobility, depression, aerobic capacity, or other clinical 
outcomes.54 
 
4.3.8 Adverse Events 
A weekly questionnaire administered by a trainer, in person or by phone was used to monitor 
adverse events.  Furthermore, any changes in health status, medication, or health care utilisation 
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and the reasons for any missed sessions were determined in all participants.  Any musculoskeletal 
or cardiovascular event attributable to testing or training was defined a priori as an adverse event.57 
 
4.3.9 Outcome Measures 
The primary outcomes of this study were HOMA2-IR, measured 96 hours after the last exercise 
bout in each participant, and HbA1c.  The time interval of 96 hours was chosen to minimize any 
potential residual effects of the last bout of resistance training on insulin sensitivity,58-60 as we were 
primarily interested in long-term training adaptations.  The secondary outcome that was the focus 
of this thesis was cognitive function, including domains of memory, information processing speed, 
attention/executive function, and global cognitive function.  Other secondary outcomes included 
all of the components of metabolic syndrome, body composition, cardiovascular profile, exercise 
capacity, functional performance, health status, measures of energy expenditure, physical activity 
and quality of life.  It was hypothesised that improvements in cognitive function would be related 
to the chronic changes in insulin sensitivity and glucose homeostasis, as well as changes in 
adiposity, skeletal muscle mass, exercise capacity, and inflammatory profile of participants. 
All measurements were completed at baseline, 6 and 12 months in the POWER and SHAM 
participants by blinded assessors at a laboratory facility separate from the training site, to prevent 
un-blinding of assessors.  A 24-hour food recall was performed on the day of the baseline 
assessment, and participants were asked to follow the same diet prior to subsequent assessments 
at 12 months.  The domains of assessment of the GREAT2DO trial at each time-point were the 
following: 
 
Insulin Resistance and Glucose Homeostasis:  
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HOMA2 computer model for insulin resistance (HOMA2-IR), insulin sensitivity (HOMA2-%S) 
and beta cell function (HOMA2-%B), fasting glucose, HbA1c, insulin and c-peptide levels, 
diabetic medication inventory and dosages. 
 
Cardiovascular Disease Profile:  
Heart rate variability, pulse wave velocity, pulse wave analysis, ankle-brachial index (ABI), blood 
pressure (24-hr ambulatory, brachial, central, and postural). 
 
Lipid Metabolism:  
Intramuscular lipid content estimated from CT scan attenuation of thigh muscle, total, low density, 
high density cholesterol, triglycerides. 
 
Muscle Metabolism:  
Heat Shock Protein 72 (HSP72), phospho-Jun N-terminal Kinase (pJNK), Tumour Necrosis 
Factor-α (TNF-α), Insulin-like Growth Factor-1 (IGF-1), Interleukin-6 (IL-6) in vastus lateralis 
muscle biopsies. 
 
Adipokines, Inflammatory Markers: 
High Molecular Weight (HMW) Adiponectin, total Adiponectin, Adiponectin ratio, TNF-α, and 
IL-6 in adipose tissue biopsies.  C-reactive protein (CRP), HMW Adiponectin, total Adiponectin, 
and Adiponectin ratio in serum. 
 
Exercise Capacity and Functional Status:  
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Muscle strength, power, and endurance, habitual and maximal gait speed, static and dynamic 
balance, six-minute walk distance (6WMD), chair stand time, and stair climb power. 
 
Body Composition:  
Anthropometry, total fat mass and skeletal muscle mass via bioelectrical impedance, waist 
circumference, neck circumference, BMI, sagittal diameter, abdominal visceral and subcutaneous 
adipose tissue area, thigh muscle area, mid-thigh muscle subcutaneous adipose tissue area, mid-
thigh muscle intermuscular adipose tissue area, and mid-thigh muscle attenuation by CT scan. 
 
Resting Metabolic Rate:  
Assessed over a 30-min steady-state period via indirect calorimetry.61 
 
Energy Balance:  
Habitual physical activity, sleep, and sedentary behavior via the Physical Activity Scale for the 
Elderly (PASE)62 and accelerometry (Actigraph; ActiGraph LLC, Pensacola, FL, USA) and dietary 
intake (Food Frequency Questionnaire of Bloch).63  
 
Psychosocial Function and Quality of Life:  
Geriatric depression scale,64 Ewart's Self-efficacy Scale,65 Pittsburg Sleep Quality Index,66 and 
Medical Outcomes Survey Short Form-36 (SF-36) version two questionnaires.67 
 
Cognitive Function:  
Word List subtests of the Consortium to Establish a Registry for Alzheimer’s disease (CERAD),68, 
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69 Trial Making Test A & B,70 and Modified Mini-mental State Examination (3MS).71 
 
The following methodology relates to the domains of assessment specific to this thesis.  A more 
detailed methodology for these outcomes can be found in Appendix B. 
 
Anthropometry 
Morning fasting stretch stature (wall-mounted Holtain stadiometer, Holtain Limited, Crymych 
Pembs., UK) was measured in triplicate to the nearest 0.1cm.  The participant was barefoot with 
the feet together and heels, buttocks, and shoulder blades against the wall, or as close to this 
position as possible (if the vertical position of the body was distorted due to skeletal pathology it 
may have been just the buttocks against the wall mount).  The head of the participant was 
positioned in the Frankfort plane.  The participant was asked to take a deep breath, and the 
investigator applied upward pressure using a pistol grip to achieve maximal elongation of the 
spinal column.  The headboard was then lowered onto the participant’s head to attain the height 
measurement.  The average of the three values was used. 
 
Naked weight [weight in gown (kg) – weight of gown (kg)] was measured in the morning, with 
the patient fasting, in triplicate to the nearest 0.01kg.  The average of the three values was used.  
The gown was weighed prior to being worn by the participant.  Participants were instructed to 
change into the gown, removing all clothing (except underwear), jewellery and accessories where 
possible. 
 
Waist circumference (WC) was obtained with Lufkin (W606PM) flexible steel tape measure by a 
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number of methods for data collection and the ISAK protocol72 was used for this analysis.  
Measures were recorded by an experienced anthropometrist with technical measurement errors 
<1%. 
 
Demographics, Health status, Medications and Treatment Plan 
Participants were asked routine questions to obtain demographic information, as well as their 
current health status relating to the presence of other chronic diseases.  Participants also provided 
a list of all their current medication and dosages.  Medical records were also hand-searched to 
extract any information not provided by the participant.  Each participant’s treatment plan in 
individual with diabetes was then determined and scored as either diet only, oral hypoglycaemic 
only, insulin only or oral hypoglycaemic and insulin. 
 
Whole Body Measures of Body Composition 
Total fat mass and skeletal muscle mass were determined using bioelectrical impedance analysis 
(BIA; RJL Systems, Inc., Clinton, MI, USA).73, 74 All participants were fasting and BIA was 
performed at a similar time of day for all participants, after a minimum 12-hour fast.  BIA was 
performed on the right side for all participants, with the participant supine, wearing only the gown 
(as described for naked weight).  The signal electrode of the right hand was placed on the 
proximal interphalangeal joint of the middle finger, while the detecting electrode was placed on 
the dorsal aspect of the wrist along an imaginary line bisecting the styloid process of the ulna.  
The signal electrode of the right foot was placed over the base of the proximal phalange of the 
second toe.  The detecting electrode was placed on the edge on the anterior aspect of the ankle 
along an imaginary line bisecting the medial malleolus.  Participants were instructed to have their 
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arms by their side and their legs apart so their thighs were not touching if possible.  The presence 
of a pacemaker is a contraindication for the use of BIA, and thus, participants with pacemakers 
were excluded from this measurement.  Percent body fat and fat-free mass were estimated using 
bioelectrical impedance (BIA-101: RJL Systems.  Detroit, MI, USA).  The average of 3 
measurements taken early in the morning after a 12-hour fast, was used to calculate fat mass and 
fat-free mass using the formula developed by Lukaski and colleagues for older adults.74 Skeletal 
Muscle Mass was calculated from the following formula.73 
Skeletal Muscle Mass = 0.401 (Height2 / Resistance) + 3.825 (sex) + age (-0.071) + 5.102 
Height is in cm; Resistance is in Ohms; Sex: men = 1 and Women = 0; Age is in years 
 
Total fat mass was determined by using BIA, by subtracting lean body mass from naked weight to 
determine total fat mass.  Lean body mass was determined using the following equation:74 
Lean Body Mass = -4.03 + 0.734(Ht2/BIA) + 0.116(BW) + 0.096(Xc) + 0.984(sex) with height 
(Ht) in cm, BIA resistance in ohms (average of 3 measures), naked body weight (BW) in kg, Xc 
reactance in ohms and sex coded 1 for men and 0 for women. 
 
Regional Measures of Body Composition 
Computed tomography (CT) (GE High Speed CTI Scanner, MIL, USA at the Royal Prince Alfred 
Hospital, Sydney) was used to quantify visceral adipose tissue (cm2) (VAT), mid-thigh muscle 
cross sectional area (cm2) (CSA) and mid-thigh muscle attenuation (an index of intramyocellular 
lipid content).  For CT scans of the abdomen, a 1-mm slice was performed at the mid-point of the 
iliac crest and lowest rib.  This was located by palpation with the patient supine and arms rose 
above the head.  A marker placed at the site was visible on the scout image to set up scanning 
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coordinates.  A line was drawn from the femoral notch to the marker and the linear distance was 
recorded.  This was designed to enable replication of follow-up scans.  Settings were kV: 100 
and mA: 170 (depending on participant’s abdominal mass) with displayed field of view (DFOV) 
45-48 (depending on participant size).  For CT scans of the mid-thigh, a 1-mm slice was 
performed at the mid-point of the inguinal crease to the proximal pole of the patella measured with 
the participant supine and knee flexed.  A marker placed at the site was visible on the scout image 
and a linear distance from the femoral notch to this marker was recorded to replicate follow-up 
scans.  Settings were kV: 100 and mA: 170 with displayed field of view (DFOV) 25 (depending 
on participant size). 
 
Scan Images 
Scan images were analysed according to optical density by a blinded investigator using NIH Image 
software (Version 1.63, National Institutes of Health) programmed with specific macros to 
quantify cross-sectional adipose tissue.  To determine VAT, macros were programmed to select 
the outer perimeter extending from the paraspinal muscles to the anterior abdominal muscles.  
The program calculated this measure by summing the area within the selected perimeter occupied 
by pixels with optical density in the range of 140 to 240.  Mid-thigh muscle density (unitless 
measure) was calculated according to a specific optical density range (10-113) chosen to best 
discriminate muscle from fat and bone.  Co-efficient of repeatability, determined using a Bland-
Altman plot on a subset of 10 scans was found to be excellent at 0.49 for VAT and 0.44 for mid-
thigh CSA.75  CT scan data were not available in one participant due to body mass exceeding the 
specifications of the scanner bed. 
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Exercise Capacity and Functional Status 
Dynamic Muscle Strength  
Lower extremity peak strength was assessed using digital K400 Keiser pneumatic resistance 
machines (Keiser Sports Health Equipment, Inc., Fresno, CA). One Repetition Maximum (1 RM) 
tests were performed according to de Vos and colleagues54 on chest press, seated row, bilateral 
knee extension, bilateral knee flexion, bilateral leg press. Strength tests were performed twice at 
baseline approximately 10 days part, and the higher of the 2 results was recorded as the 1RM.  
 
Muscle Power 
Muscle power was assessed approximately one hour after the second muscle strength test. 
Participants were instructed to push the load once as fast as possible at 20%, 30%, 40%, 50%, 60%, 
70%, 80%, 90% and 100% of their baseline 1RM. The force, average velocity, work and average 
power during the concentric phase of each contraction were recorded. The highest average power 
produced using the loads tested was recorded as the peak power. 
 
Six-minute Walk Distance 
Walking endurance was assessed using the six-minute walk test, which is a proxy for overall 
cardiovascular endurance capacity (aerobic capacity) and in older adults it may be determined by 
muscle strength and endurance, balance, orthopaedic or neurologic abnormalities, and other 
problems.76  Participants were instructed that they were to “cover as much ground as possible in 
six minutes” by “walking as fast as they can the entire time”.  They were encouraged and 
reminded of the task at least every 30 seconds during the test to minimise slowing down.  The 
number of metres travelled at the end of 6 minutes was recorded to the nearest cm from the wheel.   
Gait Speed  
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Gait speed was recorded as the normal walking speed of the participant in an open path of at least 
10 metres using an ultrasonic transmitting device (Ultra-timer Glasgow, Scotland) attached to the 
participant with a belt.  The average of the two trials was recorded and distance walked over two 
metres was converted to velocity (m/s).77  Maximal gait speed velocity was recorded as the 
maximal walking speed over 2 metres.  The better of two trials was recorded.   
 
Balance  
Balance was assessed in progressively more challenging positions, gradually narrowing the base 
of support and then removing visual input.78  The conditions were:   Wide Stance, Narrow 
Stance, Semi-tandem Stance, Tandem Stance, One-Leg, Eyes open, One-Leg and Eyes Closed.  
The success of each test was recorded over 15 seconds, recording the time of balance maintained, 
with higher scores indication better balance. 
 
Stair Climb 
Stair climb was used as an indicator of lower extremity power.79  Two trials were conducted on a 
9-step stair climb with a one-minute rest between trials.  The faster of two tests was recorded 
using vertical stair height and body mass to convert to Watts.  Power was calculated from the 
formula: P (watts) = (M × D) × 9.8/t Where: M = Body mass (kg), D= Vertical distance (m), t = 
Time (s) and, D = vertical height of the staircase = height of 1 step in metres × number of steps. 
 
Chair Stand 
Chair stand test is used as a proxy for lower extremity power, or the ability to generate high forces 
rapidly, primarily utilising the hip extensor and knee extensor muscle groups.77  Participants were 
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asked to attempt 5 complete sit-to-stand repetitions from seated to fully erect without the use of 
hands if possible.  The time and the number completed were recorded, as well as any use of hands 
required. 
 
Neuropsychological Assessments 
All cognitive questionnaires were administrated privately by a blinded trained interviewer using 
visual prompts at baseline where necessary.  Each test was chosen because of excellent 
psychometric properties to screen for cognitive impairment and minimal sensitivity to changes in 
cognitive function over time.  Cognitive testing took place in a fed state (after breakfast), and 
before any physical testing on that day to standardise known effects of fasting and acute exercise 
on cognitive performance.  The tests represent memory, processing speed, executive function, 
and global cognitive 
Function.  Administration time was approximately 30 to 45 minutes to complete all tests 
described in more detail below. 
 
Word List Subset of CERAD 
Word List subset of Consortium to Establish a Registry for Alzheimer’s disease (CERAD) 
neuropsychological battery is composed of Word List memory,68 Word List Recall,69 and Word 
List Recognition.68  It would provide an easy-to-use, normativebased summary score of memory 
performance that could be used to identify level of cognitive impairment and aid in differentiating 
AD, mild cognitive impairment (MCI), and normal aging. 
 
Description 
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The Word List Memory task was administrated privately by a trained interview to test the 
participant’s ability to remember newly learned information.68  The participant was asked to read 
10 common nouns printed on separate cards in the CERAD flipbook.  The 10 words were 
presented at a constant rate of one word every two seconds and then participants were asked to 
recall as many words as possible.  Three trials were given with alternate order of words.  Score 
was the total number correctly recalled words after all three trials.  The score ranges from 0-30.  
Administration time was about 5 minutes. 
 
The second memory test was Word List Recall.69  The Word List Recall determines how well 
participants remember the words from the original list after a distraction task (the medication 
review).  Participants were asked to recall as many words as possible from the previously 
presented 10-word memory task.  Administration time was about 5 minutes and the score range 
for each trial ranges from 0-10.   
 
The Word List Recognition task tests the participant’s ability to remember words that were 
previously included in the word list and words that were not in the list.  Participants were asked 
to identify the word they had seen before.  The score consists of the number of correct “yes” 
responses and “no” responses.  Administration time was approximately 5 minutes.  Best control 
score (yes) is 10.68 
 
Word List Subset of CERAD: Psychometric Properties 
Validity 
An earlier study showed a correlation between CERAD Word List Memory with 60 seniors (14 
266 
 
with initial AD and 46 without AD) with the Screening Test for Alzheimer’s Disease with Proverbs 
(r=0.61; p=0.000).80  These data agree with those of Bertolucci et al,81 who found the Word List 
Memory tests to be sensitive and specific for the diagnosis of cognitive impairment.  Moreover, 
Morris et al68 showed the CERAD Word List Memory (r=0.85), word recall (r=0.85), and word 
list recognition (r=0.74) were related to MMS in 350 patients with a diagnosis of AD and 275 
control participants.82   
 
Reliability 
For Word List Memory (subset of CERAD), a correlation between duplicate measurements was 
reported to range from 0.80 to 0.91 in 238 patients with mild or moderate AD.68  Reliability was 
determined in the same study.  The correlation between test 1 and test 2 was lower for Word List 
Memory (r=0.68-0.83), Word List Recall (r=0.43-0.63), and for Word List Recognition (r=0.44-
0.52) due to ceiling effects.  On all measures, correlations were lower for control participants than 
for AD patients because of ceiling effects.68  Inter-rater reliability of Word List Recall was high, 
assessed by intraclass correlation coefficients (r=1.0).83  Similarly, a correlation between 
duplicate measurements was reported to range from 0.64 to 0.74 in 20 patients with mild or 
moderate AD.84  Finally, it discriminates between individuals with dementia or these without; its 
sensitivity ranged from 74.2 to 85.7 (85.7% for Word List Memory, 74.2% for Word List Word 
List Recall, and 87.1 for Word List Recognition) and its specificity ranged from 82.4 to 87.1 
(87.1% for Word List Memory, 82.4% for Word List Word List Recall, and 87.1 for Word List 
Recognition),  Bertolucci et al81 suggest that the cognitive tests (CERAD Word List Memory, 
Word List Word List Recall, and Word List Recognition) is as effective as the Mini-mental State 
Examination  when used to screen for dementia.  However, Clark reported that the influence of 
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age and educational levels on the word list subset of CERAD contributes to higher variability in 
memory and delayed recall in cognitive impairment and AD patients than in normal control groups, 
resulting in a weak correlation of 0.33 for test-retest reliability.  Given the lack of any significant 
cognitive impairment at baseline in our participants, these tests were considered to have very 
acceptable validity and reliability. 
 
Trail Making Test 
The Trail Making Test85 is a neuropsychological test of visual attention and task switching. It 
consists of two parts (Trail Making Test Part A and Trail Making Test Part B) in which the subject 
is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. It can 
provide information about visual search speed, scanning, speed of processing, mental flexibility, 
as well as executive functioning.  It is also sensitive to detecting several cognitive impairments 
such as Alzheimer's disease and dementia.86 
 
Description 
The Trail Making Test (TMT) is one of the most widely used instruments in neuropsychological 
assessment as an indicator of speed of cognitive processing and executive functioning.87, 88  The 
test consists of two parts (test A and B).  The direct score of each part is represented by the time 
of completion of the tasks.  In addition to direct scores, the B-A difference score have been used 
for clinical proposals as the purest indicators of certain cognitive operations or specific markers of 
brain damage.86, 89  Both parts of the TMT consist of 25 circles distributed over a sheet of paper.   
In Trail Making Test Part A (TMTA), the circles are numbered 1 – 25, and the participants draw 
lines to connect the numbers in ascending order.  In Trail Making Test Part B (TMTB), the circles 
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include both numbers (1 – 13) and letters (A – L); as in TMTA, and the participant draws lines to 
connect the circles in an ascending pattern, but with the added task of alternating between the 
numbers and letters (i.e., 1-A-2-B-3-C, etc.).  The participant was instructed to connect the circles 
as quickly as possible, without lifting the pen or pencil from the paper while being timed.  If the 
participant makes an error, it was pointed out immediately and the participant allowed to correct 
it.  Errors affect the participant's score only in that the correction of errors is included in the 
completion time for the task.  It is unnecessary to continue the test if the participant has not 
completed both parts after five minutes have elapsed.  Administration of the each trial requires 
approximately 5 minutes.  Higher score represents worse information processing speed and 
executive function.  Apart from these two direct scores, Lezak90 has proposed additional indexes 
to better describe the cognitive skills required to complete the TMT.  The difference score (B–A) 
is meant to remove the speed component from the test evaluation, representing pure executive 
function.90  Higher score represents worse information processing speed and executive function 
 
TMTA, TMTB, and Difference Score (Psychometric Properties) 
Validity: 
Trial Making Tests A & B have been validated for assessment of healthy normal cognitive function, 
cognitive impairment and dementia, and appear to have high validity.  Performance on the TMT 
has been shown to be significantly correlated with a variety of other tests that measure information 
processing speed in young and older healthy populations.  For example, scores on the TMT-A 
significantly correlated with the GO/no GO Task (r=-0.34)91 and Adjusting-Paced Serial Addition 
Test (r=0.33)92 in young healthy people.  Significant associations between TMT-A and Digit 
Symbol (r=-0.29), Controlled Word Association Test (r=-0.26), efficiency of alphabet (r=0.44), 
269 
 
and finger tapping (r=-0.45) have been demonstrated in older people.93  Moreover, correlations 
between TMT-A and Objects Finding Test have been reported in five groups of brain injury patients 
(r=−0.41, r=−0.93, r=−0.68, r=−0.60, r=−0.70, respectively) and with Hidden Patterns Test only 
in nonaphasic patients (r=−0.61, r=−0.58, r=−0.54).94  The TMT-A score has also been correlated 
with IQ (measured with WAIS-R; r values between r=−0.37 and r=−0.49) in traumatic brain injury 
and neuropsychiatric groups.95  The TMT-B score has been correlated with MMS (r=−.027), 
Controlled Word Association Test (COWAT; r=-0.31), Boston Naming Test (BNT; r =-0.23), and 
Animal Naming (r=-0.31) in healthy controls.96  Performance on TMT-B has also been shown to 
be strongly correlated with IQ measured with Wechsler Adult Intelligence Test-Revised (r=-0.37 
to 0.49) in patients with brain injury.95  Furthermore, TMT-B has been correlated with MMS (r=-
0.40), COWAT (r=-0.33), and Boston Naming Test (r=−0.41) in neurologically impaired patients.96  
Score on TMT-B-A correlated with Stroop Color-Word (r=0.55, r=0.49), Controlled Word 
Association Test (r=0.38, r=0.32) and Wisconsin Card Sorting Test Percent Error (r=0.34, r=0.32) 
in neurologically impaired patients.97  
 
Reliability 
The inter-rater reliability of TMT scores has been examined in one report by having two pairs of 
examiners record the performance in 18 healthy participants.98  The inter-rater reliability for the 
TMT-A and B sum scores was very high at 0.94 and 0.90, respectively.98  One study has shown 
that the inter-rater reliability coefficients for the TMT-A five subsections ranged from 0.933 to 
0.994 and the Part B five subsections ranged from 0.881 and 0.997, and the TMT-B five 
subsections ranged from 0.881 and 0.997, and the difference score between TMT-B and TMT-A 
ranged from 0.94 to 0.96 in healthy older adults.98  Neuropsychological battery assessed the twice 
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tests to a sample of 29 medical students and reported modest correlation coefficient values; 0.46 
for TMT Part A and 0.44 for TMT Part B.99  Charter also administrated the TMT to healthy 
subjects on two occasions using a retest period, the overall stability scores using a coefficient of 
concordance was 0.95 for TMT Part A and 0.94 for TMT Part B in a sample of over 300 subjects 
that included 123 normal control subjects.100  In normal 487 participants, test-retest reliability 
and inter-rater reliability coefficients for time scores of Parts A and B were shown as 0.78, 0.99 
and 0.73, 0.93, respectively.101  In a samples of 15 cerebral injury patients reliability values were 
0.79 for TMT Part A and 0.85 for TMT Part B.102  Retest reliability of TMT A and B in recruited 
patients with depression was between 0.76 and 0.89 and between 0.86 and 0.94, respectively.103  
 
3MS 
The Mini Mental State Examination (MMS) was designed to provide a brief, standardized 
assessment of cognitive status that would serve to differentiate between organic and functional 
disorders in older patients.104  The test has moderate to high levels of test-retest and interrater 
reliability in clinical and community populations and adequate to good sensitivity and specificity 
for detecting and tracking the progression of cognitive impairment associated with 
neurodegenerative disorders such as Alzheimer’s disease in patient samples.  However, its 
validity is weaker in detecting mild dementia.  The revised test, known as the 3MS,71 was 
significantly better than the MMS in identifying cognitive impairment and dementia among older 
persons in the population-based Canadian Study of Health and Aging.71, 105-108 
 
Description 
A summary form for the administration and scoring of the 3MS is presented in the Appendix C 
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and can be reproduced on one side of a standard (8.5 in. x 11 in.) sheet of paper.  3MS is a revision 
of the MMS that includes four additional items (date and place of birth, word fluency, similarities, 
and delayed recall of words) to sample a wider range of cognitive abilities an expended range of 
scores from 0-30 to 30-100.  On the back side of the same sheet, CLOSE YOUR EYES (all in 
capital letters, approximately 12 in. high) can be printed in the upper part, and two intersecting 
pentagons (each side 1 in, long) can be drawn in the lower part.  Enough blank space is left to 
record the participant's drawing and writing.  
  
Compared with the MMS, the 3MS has more standardized administration and more graded 
scoring; it also assesses a broader variety of cognitive domains and covers a wider range of 
difficulty levels.  The 3MS can extract more information about the subject's cognitive status than 
the MMS; it is also more sensitive than the MMS in detecting within-individual changes over time. 
 
3MS Score (Psychometric Properties) 
Validity 
Three studies that proposed higher 3MS cutoff scores of between 77 and 78 found sensitivity 
ranged from 69 to 88% specificity ranged from and 76 to 90 % for the detection of clinically 
diagnosed dementia or cognitive impairment individuals with dementia and 1092 participants 
without dementia.71, 107, 109, 110  Performance on the 3MS has been shown to be significantly 
correlated with a variety of other tests that measure global cognition including the Brief Interview 
of Mental Status (r=0.74-0.79),110  Cognitive Performance Scale (r=0.62-0.65),110 MMS 
(r=0.94),111 and other aspects of cognitive functioning107 in a wide variety of populations. 
Reliability 
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The 3MS is a highly reliable measures of global cognitive function.  Several studies examining 
the reliability of the 3MS suggest that it has adequate reliability, with internal consistency ranged 
from 0.72 to 0.91,106, 107, 111-113 and test-retest from 0.48 to 0.87,107, 111, 114, 115 and interrater 
reliability ranged from 0.81 to 0.98.111, 116  One study reported the internal consistency of the 3MS 
obtained Cronbach’s alphas of 0.82 and 0.88 in older patients with no mild cognitive impairment 
(n=406) and AD (n=119) stratified for two age groups (65-79 and 80-89) and two educational 
levels (0-8 and 9+ years), respectively.112  Two studies that examined the internal consistency of 
the 3MS obtained Cronbach’s alphas of 0.91 and 0.87 in older patients living in community 
(n=885) and older adults from community and institution residents (n=1166), respectively.106, 111  
Grace et al reported stability of the 3MS in a hospitalized stroke population and found that the 
3MS was a significantly better predictor of functional independence than the MMS.107  In elderly 
individuals without dementia, the test-retest reliability of the 3MS was found to be 0.78 over a 3 
year interval in patients with older adults (n=228)111 and 0.67–0.47 over a 5- to 10-year interval in 
patients in community-dwelling elderly people (n=3255).114  The interrater reliability for the 3MS 
was high in one study,  and reported the overall pairwise intraclass correlation coefficient 
estimate was 0.98 (95% CI 0.97–0.99), and intraclass correlation coefficient estimates for 
individual rater pairs ranged from 0.95 to 0.99 in older people without cognitive impairment.111  
Graham et al reported slightly high inter-rater reliability of the 3MS in in a sample of 2,914 elderly 
(age 65 years+) Canadians from the Canadian Study of Health and Aging for screening a 
community prevalence study of dementia and cognitive impairment (Inter-rater reliability was 
high: kappa = 0.81 for dementia/no dementia; kappa = 0.74 for normal/cognitive impairment, not 
dementia/ dementia).116  Performance on the 3MS is significantly related to age and education for 
individuals with and without cognitive impairment or dementia.  Individuals with 8 or fewer 
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years of formal education perform more poorly than those with more than 8 years of education.112, 
117  Age and education influence performance on the 3MS independent of other condition, such 
as medical conditions.106, 107, 111, 117  Some authors112, 117 suggest that the 3MS should be adjusted 
so that a cutoff points of 77-78/100 or below is used for those with 8 years of education or less and 
a score of 80 or below for well-educated individuals.  Finally, it discriminated between with 
dementia or cognitive impairment and those without; it had high sensitivity and specificity, 
suggesting that 3MS test is as effective as the MMS when used to screen for dementia or cognitive 
impairment. 
 
Questionnaires 
All questionnaires were interviewer-administered by a trained interviewer, in a private room using 
visual prompts.  All questionnaires including habitual physical activity, psycho-social and quality 
of life were widely used, previously validated questionnaires in cohorts similar to this one.  
 
Psychological Assessment 
The Geriatric Depression Scale is used to assess an older person’s level of depression with simple 
yes/no response set,64 and the thirty item screening test has been reported to be satisfactory.118  
Overall this self-report assessment depressive symptoms can be calculated by summing scores 
ranging from 0-30, with higher scores indicating higher distress.64  Administration time typically 
ranges from 5 to 10 min. 
 
Quality of Life  
The SF-36® Health Survey version 2 (SF-36v2)67 is a generic outcome measure designed to 
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examine a person’s perceived health status.  The Physical & Mental Health Summary Scales 
include eight generic health concepts, selected from the Medical Outcomes Study (MOS), and 
MOS researchers selected and adapted questionnaire items and developed new measures for a 36-
item Functioning and Well-Being Profile the source for SF-36® items.119  The SF-36v2 consists 
of eight scaled scores, which are the weighted sums of the questions in their section.  Each scale 
is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. 
Higher scores represent better health status.  Additionally, the scale scores can be aggregated into 
two distinct higher-order summary scores: a physical component summary (PCS) and a mental 
component summary (MCS).  The component summary scores are standardized using normative 
data from the 1998 America general population with a mean score of 50 and a standard deviation 
of 10. 
 
Physical Activity 
Habitual physical activity levels were assessed using the Physical Activity Scale for the Elderly 
(PASE) questionnaire,62 where higher scores reflect increasing amounts of habitual structured and 
unstructured physical activity. 
 
Systemic Inflammation 
During blood sampling, extra blood was sampled and the serum stored for future analysis of high-
sensitivity CRP.  CRP was measured in duplicate by enzyme-linked immunosorbent assay 
(ELISA) (eBIOSCIENCE, Camarillo, CA), with the average value used in statistical analyses.  
The lowest detectable concentration was 0.01mg/L. Co-efficient of variation was required to be 
less than 20%, otherwise a third measurement was performed.  The average intra-assay co-
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efficient of variation was 6.4%. 
 
Adiponectin 
During blood sampling, extra blood was sampled and the serum stored for future analysis of serum 
adiponectin.  Serum adiponectin was measured in duplicate by enzyme-linked immunosorbent 
assay (ELISA) (eBIOSCIENCE, Camarillo, CA), with the average value used in statistical 
analyses.  The lowest detectable concentration was 0.01mg/L.  Co-efficient of variation was 
required to be less than 15%, otherwise a third measurement was performed.  The average intra-
assay co-efficient of variation was 7.2%. 
 
4.3.10 COVARIATES 
Covariates specified a priori for all cognitive test analyses were age, sex, and educational history.  
This was because extensive literature suggests that these factors may influence performance on 
some of these tests.86, 112, 120 
 
4.3.11 STATISTICAL ANALYSIS 
The intention-to-treat (ITT) strategy was used as our primary analytic treatment of the data without 
imputation for missing time points.  Normally distributed data were described as mean ± SD; 
non-normally distributed data as median (range) or frequencies.  Non-normally distributed data 
were log-transformed for use with parametric statistics.  Nonparametric tests were used if 
assumptions of normality were not met despite transformation.  Comparisons of baseline 
characteristics between groups were made using Chi Square tests for categorical data and a one-
way ANOVA for normally distributed continuous data.  The Mann-Whitney U test was used for 
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non-normally distributed continuous data. 
 
Mixed models of baseline and 12-month outcomes, adjusted for baseline values and a priori or 
potential confounders identified after inspection of baseline correlations were constructed to test 
our primary and secondary hypotheses.  We included the main effects of TIME, GROUP, as well 
as for the interaction term (Group × Time) to identify isolated training arm significance.  Baseline 
age, sex, years of education, and baseline cognitive scores were used as covariates in these mixed 
models.   
 
Relationships of interest and predictors of changes in cognitive function and other secondary 
outcomes were analysed with simple and multivariate linear regression models as appropriate. 
Relative ESs were calculated for all outcomes.  Calculations of ES were adjusted via Hedges’ 
bias-corrected ES121 for small sample sizes, and interpreted as ‘trivial’ (<0.20), ‘small’ (≥0.20 
<0.50), ‘moderate’ (≥0.50 <0.80), or ‘large’ (≥0.80).  Ninety-five percent CIs for the relative ES 
were calculated.  The following formula was used: Mean differences and between-group and/or 
intra-group effect sizes (ESs) were calculated for both groups.  For group 1, between-group ES 
adjusted via Hedges’ bias-corrected for small sample sizes and 95% confidence intervals (CIs) 
were calculated for each outcome measure where applicable using formula 1: between-group ES 
= (D treatment –D control)/pooled baseline standard deviation (SD), where D indicates change.122  
For group 2, an intra-group ES was calculated for each treatment arm using formula 2: intra-group 
ES = (post-score - pre-score)/baseline SD.122  For group 2, a between-group ES was also 
calculated using formula 1 outlined above.  Final sample sizes excluding dropouts were used to 
calculate ESs, unless there had been imputation of missing data from dropouts.  Prior to 
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calculating ESs, data were manipulated if necessary to derive means and SDs as follows: 
1. When sample size exceeded 25 and the mean was not reported, the median was substituted for 
the mean. In sample sizes <25, means were calculated using the following formula: x ≈ (a + 2m + 
b)/4, where m= median, a = the smallest/minimum value, and b = the largest/maximum value.123 
2. If data were presented as mean and range or interquartile range then SDs were calculated using 
the following formulae: SD= one quarter of the range or SD= four fifths of the interquartile range  
3. Values reported as standard error (SE) were converted to SD using the following formula: SD= 
SE√n, where n = number of subjects.  SPSS (Version 20 for Windows, Cary NC: SAS Institute 
Inc) was used for all data analysis.  All two-tailed p values less than 0.05 and/or ES 95% CIs 
exclusive of 0 were accepted as statistically significant.   
 
4.4 CONCLUSIONS 
The GREAT2DO trial conformed to all design and reporting requirements for randomised 
controlled trials recommended by the CONSORT group 124.  This was the first RCT of power 
training as a potential non-pharmacological intervention that targets the pathophysiology of T2DM 
and multiple associated comorbidities in older adults.  It was also the first study of anabolic 
exercise for cognitive improvement in older adults with T2DM.  Through this investigation, we 
aimed to contribute to better treatment for physical and cognitive health, and ultimately improve 
quality of life for older adults with T2DM.
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CHAPTER 5 
THE GREAT2DO STUDY: BASELINE CHARACTERISTICS OF OLDER ADULTS 
WITH TYPE 2 DIABETES MELLITUS IN A RANDOMISED CONTROLLED TRIAL 
OF POWER TRAINING
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5.1 ABSTRACT 
Objectives – Diabetes is associated with cognitive impairment and dementia.  However, 
mechanisms and mitigating factors require further study.  We explored some potential factors 
related to baseline cognitive function of older adults with type 2 diabetes mellitus (T2DM) who 
were enrolled in the Graded Resistance Exercise and T2DM in Older adults (GREAT2DO) study, 
a randomised double-blind, SHAM-exercise controlled trial.  The overall purpose of the study 
was to assess the efficacy of a one-year power training intervention compared to a SHAM-exercise 
control on metabolic profile, comorbidities, and health outcomes associated with T2DM.  The 
specific focus of this chapter is to explore any relationships between baseline cognitive function 
and metabolic profile, inflammatory markers, body composition, physical performance and 
exercise capacity in the cognitive sub-study of the GREAT2DO study. 
Methods – Cross-sectional data in 103 older adults over 60 years of age with T2DM participating 
in a clinical trial of exercise were analysed.  Primary characteristics of interest were cognitive 
measures (memory, processing speed, executive function, and global cognitive score) and fasting 
glucose, glycosylated haemoglobin (HbA1c), fasting insulin, and insulin resistance and 
pancreatic beta cell function assessed by the Homeostasis Model Assessment 2 (HOMA 2) 
computer model.  Secondary characteristics of interest were to investigate health status, including 
chronic diseases, body composition, pro-inflammatory factor C-reactive protein (CRP), adipokines, 
depressive symptoms, quality of life, and habitual physical activity level, and physical 
performance (chair stand, stair climb, gait velocity, balance, and 6-minute walk distance). 
Results - The health status of our cohort was generally more impaired than reported averages for 
older adults with T2DM in Australia.  Specifically, they had higher levels of abdominal obesity 
and BMI, prevalence of hypertension, higher triglycerides, and lower high-intensity lipoprotein 
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(HDL) cholesterol than reported for this cohort.  Additionally, the use of insulin and oral diabetic 
medications were all higher compared to adults with T2DM in Australia.  Notably, their physical 
performance was lower than healthy people of similar age.  Multiple linear regression models 
adjusted for age, sex and years of education were constructed for all potential predictors of each 
cognitive test.  In these analyses, higher 6-minute walk distance (β=0.22, p=0.04) and lower 
sagittal abdominal diameter (β=-0.21, p=0.03), and higher total adiponectin (r=0.25, p=0.04) were 
related to better memory (a higher score on Word List Recall.), as hypothesised.  Lower 6-minute 
walk distance (β=-0.21, p=0.05), slower chair stand time (β=0.34, p=0.001), lower stair climb 
power (β=-0.29, p=0.02), and higher CRP (β=-0.30, p<0.001) were related to a worse information 
processing speed score (Trail Making Test A), again as hypothesised.  Contrary to our hypotheses, 
however, overall muscle mass, thigh muscle area, thigh subcutaneous adipose tissue area, 
intramuscular adipose tissue area, thigh muscle lipid density, total abdominal adipose tissue area, 
visceral adipose tissue, abdominal subcutaneous adipose tissue area, HbA1C, fasting insulin, insulin 
resistance (IR), beta cell function, and depressive symptoms, quality of life, and habitudinal 
physical activity were not associated with any cognitive domains (memory, information processing 
speed, pure executive function, and global cognitive function) (p>0.05), and higher fasting glucose 
was paradoxically associated with better memory (Word List Recall; β=0.20, p=0.02). 
Conclusions – Better physical performance, lower central adiposity, higher adiponectin levels and 
lower systemic inflammation were each related to better cognitive function in some domains in 
this cohort of older adults with T2DM, after adjustment for age, sex and education.  Thus, 
exercise interventions targeting improvements in body composition and inflammatory profile in 
obese older adults with T2DM should be explicitly tested as a strategy to improve cognition and 
reduce dementia risk in this cohort and may result in better physical performance as well,.  Such 
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improvements may be independent of, or not dependent upon, changes in metabolic profile 
including glucose homeostasis and insulin resistance. 
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5.2 INTRODUCTION  
The prevalence of diabetes is increasing, with estimates that it will affect 435 million adults by 
2030, and it is a leading contributor to premature mortality and morbidity globally.1  The most 
common form, T2DM is characterised by insulin resistance and relative insulin deficiency that 
results in sustained hyperglycaemia.2,3  The aim of treatment is to maintain normal glucose levels 
in order to prevent comorbidities and complications.  Comorbidities and complications of T2DM 
such as retinopathy, neuropathy, nephropathy, and cardiovascular disease, amputation, depression, 
low physical performance, increased adiposity and decreased muscle mass, and inflammation, lead 
to profound psychological consequences, reduced quality of life, and increased economic burden.  
In patients with T2DM, this treatment initially consists of dietary restrictions and exercise.  Oral 
hypoglycemic medications or insulin injections are prescribed in later stages.  
 
Diabetes is associated with cardiovascular comorbidity and mortality and is associated with a 
higher risk of cognitive dysfunction due to both vascular dementia and Alzheimer’s disease (AD).4-
8  Individuals with diabetes are more likely to present with early cognitive impairment and frank 
dementia than individuals without diabetes.9  Precise mechanisms for this diabetes-related 
cognitive decline remain unclear; however, many studies have demonstrated that previous transient 
cerebral ischemia, stroke, myocardial infarction, or atherosclerosis are all strong predictors of 
cognitive dysfunction.10   
 
Increasing evidence has demonstrated that a link between some of the features of diabetes (e.g., 
fasting glucose, HbA1C, fasting insulin, insulin resistance and beta cell function) also exists.  
Some cross-sectional and longitudinal studies have found a negative association between HbA1c 
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and cognitive function,11-13 while others have found no association14, 15  Acute hyperglycaemia 
has been shown to impair cognitive function,16, 17  Other studies have shown no effect of acute 
hyperglycemia on cognitive function.13, 18, 19  Paradoxically, associations between high HbA1c 
and better cognitive function have been demonstrated in elderly individuals with or without 
diabetes.20, 21  Thus, evidence about metabolic profile and risk of cognitive impairment are mixed 
and require further study. 
 
Body composition has also been shown to predict cognition in some cohorts.  Several cross-
sectional studies showed that higher obesity up to a mean age of 72 years was negatively associated 
with cognition,22-25 whereas two studies (mean age > 73) reported a positive association between 
obesity and cognitive performance in older individuals without diabetes.22, 25, 26  Prospective 
studies show similar results to cross-sectional studies, findings being somewhat age dependent and 
contradictory.  One study found that obesity was related to cognitive decline.27  The other two 
studies showed that higher obesity levels predicted better cognitive performance28 or less decline 
in cognitive function.26  There is also recent data demonstrating that weight loss is associated 
with poor cognitive performance in older adults,29-32 which reflects a large literature about the 
negative associations of unintended weight loss in old age, including excess morbidity, frailty, and 
mortality compared to those with stable or increasing weight.  Overweight in middle age has been 
strongly linked to later-life cognitive decline,33, 34 although again data are not consistent.  For 
example, data from the Framingham studies showed that higher BMI was an independent predictor 
of cognitive decline.23, 27, 35  By contrast, higher BMI in non-demented middle-aged adults was 
shown to be unrelated to cognitive function.36  Finally, a recent analysis of the Health, Aging and 
Body Composition (ABC) Study cohort investigating the effects of total fat and visceral adiposity 
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has shown that total fat and sagittal abdominal diameter had a significant and inverse relationship 
with global cognitive function as measured by Modified Mini-mental State Examination (3MS).37  
Additionally, higher muscle mass has been associated with a decreased risk of Alzheimer’s disease 
(AD).38  Several studies have shown a greater risk of cardiovascular disease and metabolic 
disorders with overweight and obesity.8, 39, 40  Several cardiovascular risk factors and diseases are 
linked to risk of dementia.8, 39, 41  Therefore, the relationships between body composition, 
comorbidity, and cognition are complex and inconsistent across demographic cohorts, and there is 
little information specifically in diabetes, where the cognitive risks are higher than average. 
 
Another feature of T2DM which is relevant to cognitive risk is systemic inflammation.  C-
reactive protein (CRP) is a marker of chronic inflammation that has been shown in epidemiological 
studies to predict future cardiovascular disease and neurodegenerative diseases42, 43 and has been 
associated with T2DM and metabolic syndrome components in a cohort of healthy women.44  
Inflammation may also be observed in older people with T2DM and dementia.45  Many previous 
studies have shown the relationship between cardiovascular disease, metabolic syndrome, T2DM, 
and cognitive dysfunction10, 46-48  Emerging evidence suggests that CRP may be a cognitive 
decline and AD biomarker,49-52 although no association has been found in other studies.51, 53, 54  
Two longitudinal studies showed associations between increased levels of inflammatory 
biomarkers and decreased cognitive ability in the cognitively healthy ageing population.50, 55  Few 
studies have investigated the association between inflammation and cognition specifically in 
patients with T2DM.  However, a cross-sectional study published in 2010 found that raised 
plasma levels of interleukin-6, tumor necrosis factor-alpha and CRP were associated with poorer 
cognitive ability in people with T2DM.56  These associations persisted after adjustment for the 
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patients prior cognitive ability.  However, evidence of causality remains speculative from such 
investigations.   
 
Adiponectin modulates the sensitivity to insulin, glucose homeostasis and fatty acid catabolism, 
and has potent anti-inflammatory properties.57, 58  Reduction in circulating adiponectin levels has 
been implicated in the development of insulin resistance syndrome and visceral obesity.  Reduced 
adiponectin levels have been related to many clinical and psychological disorders, such as obesity, 
diabetes and depression.59-61  The presence of insulin resistance, hyperglycemia, pro-
inflammatory cytokines in the brain adjacent to amyloid plaques may contribute to the progression 
and acceleration of AD-related neurodegeneration.62, 63  Despite its theoretical relevance, few 
studies have evaluated the relationship between circulating levels of adiponectin and cognitive 
function.  In small clinical sample of patients with AD, mild cognitive impairment (MCI) and 
controls, adiponectin levels were significantly decreased in individuals with MCI and AD as 
compared to elderly controls64  Chan et al reported that high concentrations of adiponectin (10 
μg/ml) were protective against amyloid beta induced neurotoxicity in Sw-APP transfected SH-
SY5Y cells exposed to oxidative stress conditions, further supporting adiponectin might be 
protective against AD.65  However, other studies did not find significant differences in circulating 
adiponectin levels between AD and healthy elderly controls66 and also did not found an association 
between adiponectin levels and higher risk of cognitive decline and dementia in dementia-free 
older adults.67  Thus, evidence about adiponectin and risk of cognitive impairment are mixed and 
require further study. 
 
Better physical function has also been related to cognition in cohorts not selected for T2DM.  The 
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6-minute walk distance (6WMD) test, originally designed to be a proxy for cardiovascular 
endurance capacity (aerobic capacity), is associated with grey matter volume in the left middle 
temporal gyrus, middle occipital gyrus, and hippocampus in older adults with mild cognitive 
impairment,42  in addition to being related to muscle strength and endurance, balance, orthopedic 
or neurologic abnormalities, and other problems in older adults.68  In this study, a better 6MWD 
was also related to better memory.69  Recently, a positive association was observed between the 
6WMD and MMS score in older outpatients with chronic heart failure.70  Similarly, a significant 
association between memory and 6WMD was seen in older individuals with multiple 
commorbidities.71  These findings from epidemiological studies are supported by randomised 
controlled trials (RCTs) that have shown that older adults (both healthy and with chronic 
conditions) who begin exercise programs may have significant improvement in both physical 
function and cognition72,73  Such studies have reported associations between physical functional 
performance such as balance,74-76 gait speed,76-78 chair stand time,76 stair climber power,79 and 
cognitive function in older individuals, but not to date in older individuals with T2DM.   
 
Thus, despite the above supportive evidence across varied cohorts, there are no published data to 
our knowledge that simultaneously examine glucose homeostasis and insulin resistance, regional 
fat and muscle distribution, inflammation, adiponectin, and physical function within a single 
cohort.  Perhaps more importantly, these relationships have not been examined exclusively within 
a metabolically-compromised cohort, such as older individuals with T2DM, in whom a more 
complete understanding of these relationships might have significant therapeutic relevance.  
Therefore, the primary purpose of this sub-study cross-sectional analysis was to examine measures 
of glucose homeostasis (glycosylated haemoglobin, HbA1c) and insulin resistance (HOMA2-IR) 
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in relation to cognition at baseline in a cohort of older adults with T2DM enrolled in a randomised 
clinical trial of resistance training.  Secondary analyses included the relationships between 
measures of visceral adipose tissue (VAT), total abdominal adipose tissue (TAAT), subcutaneous 
(abdominal) adipose tissue (SCAT), sagittal diameter (SAD), skeletal muscle mass, thigh muscle 
area, total fat mass, serum CRP, serum adiponectin, and 6MWD, balance, gait speed, chair stand, 
stair climb power, and cognition.  Consistent with recently published data, our hypotheses were 
as follows: 
1) Metabolic profile (fasting glucose, HbA1c, fasting insulin and IR) would be inversely related 
to cognitive function at baseline 
2) Adiposity (TAAT, VAT, SCAT, SAD and total fat mass) would be inversely related to cognitive 
function at baseline 
3) Muscle mass (mid-thigh CSA and whole body skeletal muscle mass) would be positively 
related to cognitive function at baseline 
4) Low-grade systemic inflammation (CRP) would be inversely related to cognitive function at 
baseline 
5) Serum adiponectin would be positively related to cognitive function at baseline 
6) Physical performance (total balance time, 6MWD, gait speed, chair stand and stair climb 
performance, and muscle strength) would be related to better cognitive function 
 
5.3 METHODS 
5.3.1 STUDY DESIGN  
Participants for this cross-sectional investigation consisted of 103 older adults with T2DM who 
were recruited for the on-going GREAT2DO study.  The GREAT2DO study is a randomised, 
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double-blind, SHAM exercise controlled trial investigating the effects of one year of power 
training (high velocity, high intensity progressive resistance training) on a number of outcome 
measures.  These included HOMA2-IR, HbA1c, body composition, lipid profile, systemic 
inflammation, neuropsychological status, exercise capacity, physical performance, health status, 
and quality of life.  The data used for the purpose of this investigation were collected at baseline.  
The trial was registered with the Australian Clinical Trials Registry (ACTR) (ACTR No: 
ACTRN12606000436572).  The study protocol was approved by Ethics Review Committee 
(Royal Prince Alfred Hospital (RPAH) Zone), Sydney South West Area Health Service (Ethics 
Committee Protocol No: X04-0096) and written informed consent was obtained from all 
participants.  The assessments were conducted at Cumberland Campus of the University of 
Sydney in Lidcombe New South Wales (NSW) Australia.  Computerised Tomography (CT) 
Scans were performed at the Radiology Department of RPAH in Camperdown NSW Australia.  
The exercise training was conducted at Freshwater Rehabilitation in Manly NSW Australia or the 
Centre for STRONG Medicine, Balmain Hospital in Balmain NSW Australia by research staff at 
each site.  A description of the overall study design is provided in Chapter 4. 
 
5.3.2 ELIGIBILITY AND EXCLUSIONARY CRITERIA 
Inclusionary criteria were: sedentary (no resistance training; structured exercise ≤ 1/week; less 
than 150min/week low or moderate-intensity walking or other aerobic exercise), aged 60 years or 
older, previously diagnosed T2DM and stable glucose control with no significant changes in 
medications for the previous 3 months.  Exclusionary criteria included: significant cognitive 
impairment, non-ambulatory status or lower extremity amputation other than toes, current alcohol 
or substance abuse, inability to comply with study requirements over the course of one year due to 
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travel plans or other commitments, and specific contraindications to resistance training exercise, 
such as unstable cardiovascular disease, unrepaired aortic aneurysm, symptomatic hernias, 
proliferative diabetic retinopathy, or rapidly progressive or terminal illness.  Temporary 
exclusions (any change in dosage or type of diabetic medications within the past 3 months, acute 
illnesses, retinal laser surgery within 2 weeks, uncontrolled hypertension or newly diagnosed 
coronary artery disease) were resolved prior to study enrolment and baseline assessments.  
Participants could be treated with diet alone, oral medications, insulin or a combination at the time 
of their enrolment. 
 
5.3.3 RECRUITMENT 
Participants were recruited from July 2006 until December 2009 from publicity in media, 
advertisements in local newspapers, General Practitioner (GP) lists, Diabetes Australia newsletters 
and pamphlets, completing the 12-month RCT phase in 2011. 
 
5.3.4 SAMPLE SIZE 
Sample size estimates were driven by hypothesised differences between the experimental and 
control participants in the primary outcomes of the trial: insulin sensitivity and HbA1c, based on 
an average of published studies of progressive resistance training in diabetes/obesity.80-83  This 
sample size was also sufficient for testing secondary hypotheses regarding all components of 
metabolic syndrome as well, with > 90% power, alpha of 0.05, assuming 10% loss to follow-up 
(See Table 5.1).  Largest available standard deviations (SDs) were used for conservative 
estimates of effect size (ES).  In our experience in fully supervised training of older adults with 
frailty/chronic disease, dropout averages 10-15% over 12 months.  Therefore, we inflated sample 
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size needs for approximately10% drop out rate to account for anticipated attrition (n =103).  In 
addition, sample size estimates (alpha 0.05, beta 0.20) were also calculated for the secondary 
planned comparisons for the main effects of power training on our cognitive outcome: global 
cognitive function as assessed by 3MS.  The assumptions were as follows: our meta-analyses84 
and review of published RCTs in older adults85 revealed ESs for a range of cognitive outcomes of 
approximately 0.59 for resistance training compared to 0.15 for control groups.  Thus, we had 
approximately 60% power to show a relative ES of 0.44 for the main effect of power training vs. 
control on global cognition.   
 
5.3.5 SCREENING PROCEDURE 
Potential participants underwent initial telephone interview and screening using questionnaire 
followed by a physician history and physical examination.  If eligible after physician screening, 
the remainder of the baseline physical performance testing was completed, followed by baseline 
cognitive tests and CT scan.  If following screening a participant was temporarily excluded for 
abnormal stress test or other acute illness, he or she may have entered the study following 
appropriate treatment and medical review.   
 
5.3.6 DEMOGRAPHICS, HEALTH STATUS, MEDICATIONS AND TREATMENT PLAN 
Participants were asked routine questions to obtain demographic information, as well as their 
current health status relating to the presence of other chronic diseases.  Participants also provided 
a list of all their current medication and dosages.  Medical records were also hand searched to 
extract any information not provided by the participant.  Each treatment plan in patients with 
diabetes was then determined and scored as either diet only, oral hypoglycemic only, insulin only 
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or oral hypoglycemic and insulin.   Participants remained under the usual care of their physicians, 
and were asked not to alter their habitual dietary intake and report any changes in physical activity 
outside of that prescribed in study. 
 
5.3.7 OUTCOMES 
Primary Outcomes 
Blood samples were taken at Cumberland of University of Sydney in Lidcombe, NSW Australia, 
and were sent to Douglass Hanley Moir, Sydney, Australia (www.dhm.com.au) for analysis.  
Fasting blood tests were analysed for HbA1c, glucose, insulin, C-peptide, inflammatory profile, 
and lipids.  Homeostatic Model of Assessment of Insulin Resistance (HOMA2-IR) was 
calculated with glucose and c-peptide values using the validated calculator (accessed at 
http://www.dtu.ox.ac.uk).86  Sixteen participants with insulin treatment were deleted from HOMA 
calculations only, as recommended by Wallace et al (2004).  HOMA2-IR was calculated using C-
peptide and glucose because of the effects of long-acting insulin use and of fatty liver on insulin 
clearance in participants.  HOMA2-IR has been shown in multiple studies to correlate with the 
hyperinsulinemic/euglycemic clamp,87, 88 however, due to its feasibility; it is a far more clinically 
accessible index of IR.  Complete details of methods are described in Chapter 4.   
 
Secondary Outcomes 
Cognitive Assessment 
All measures were administered by blinded assessors at baseline at a laboratory facility separate 
from the training site, to prevent un-blinding of assessors.  Each test was chosen because of 
excellent psychometric properties and minimal sensitivity to practice effects.  Cognitive testing 
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took place in a fed state (after breakfast), and before any physical testing on that day to standardise 
known effects of fasting and acute exercise on cognitive performance.  The tests represent 
memory, processing speed, executive function, and global cognitive function.  All assessments 
were administered by the same exercise physiologist trained in administering the included tests.   
 
The tests have been described in Chapter 4.  In brief, the Word List is a subtest of the Consortium 
to Establish a Registry for Alzheimer’s disease, which assesses immediate and delayed memory.  
It has been used extensively to measure cognitive function in cognitively intact individuals, and 
its score is well correlated with measures of physical function and future cognitive decline. 
 
Word List subtest of the Consortium to Establish a Registry for Alzheimer’s disease  
To investigate verbal memory we used three different tests: Word List Memory, Word List Recall, 
and Word List Recognition, which were a subtest of the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD).89, 90  It has been used extensively to measure cognitive function in 
cognitively intact individuals and in AD.  The participant was required to read 10 words and then 
asked to repeat as many words as they could recall in any order (immediate memory).  The range 
of scores is 0-30.  After a distracting task, lasting at least 5 minutes, the participants were asked 
to recall the 10-word list again (delayed memory).  The words were evaluated as either correct or 
incorrect by the tester.  The word list recognition task tests the participant’s ability to remember 
words that were previously included in the word list and words that were not in the list.  
Participants were asked to identify the word they have seen before.  Score consists of the number 
of correct “yes” responses and “no” responses.  Administration time is approximately 5 minutes.  
Normal control score (yes) is 10.  For all 3 tests, higher scores indicate better memory. 
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Trail Making Test Part A & B and difference score (Trail Making Test Part B minus Trail Making 
Test Part A) 
Trail Making Test Part A91 was administered to test information processing speed.  Trail Making 
Test Part A (TMTA) consists of 25 numbers, which must be connected in arithmetic order.  This 
test presumably reflects speed of information and motor ability.  Attention and Executive 
functions were assessed with Trail Making part B (TMTB),91 consisting of numbers and letters, 
which must be connected by alternating 1-A-2-B etc.  TMTB minus TMTA is a more pure 
measure of executive function than TMT-B because it minimizes visuo-perceptual and working 
memory demand.92 
 
3MS 
The 3MS is a screening tool to assess global cognitive function.93  It can also identify changes in 
cognitive function for elderly individuals without dementia and may identify individuals in the 
prodromal phase of dementia.  Complete details of methods are described in Chapter 4.  
 
Muscle Function and Physical Performance 
Muscle Strength 
Lower extremity peak strength was assessed in Newtons (N) or Newton-metres (M-m) using 
digital K400 Keiser pneumatic resistance machines (Keiser Sports Health Equipment, Ltd., Fresno, 
CA, USA).  One Repetition Maximum (1 RM) tests were performed at baseline approximately 
10 days apart, and the higher of the 2 results was recorded as the 1RM according to de Vos and 
colleagues.94  Muscle strength was tested bilaterally on chest press, seated row, knee extension, 
and knee flexion and unilaterally on hip abduction and hip extension.  Previous randomised 
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controlled trials from our research lab have reported a coefficient of variation (CV) for these 
exercises as mean 13.1%, range 9.8% – 21.7%.95 
 
Muscle Power 
Muscle power was assessed approximately one hour after the second muscle strength test.  
Participants were instructed to push the load once as fast as possible at 20%, 30%, 40%, 50%, 60%, 
70%, 80%, 90% and 100% of their baseline 1RM (the higher of the 2 days of strength testing).  
The force, average velocity, work and average power during the concentric phase of each 
contraction were recorded.  The highest average power produced using the loads tested was 
recorded as the peak power. 
 
Walking Endurance 
The 6-minute walk test was chosen as a measure of walking endurance, as it has been shown to be 
strongly associated with physical activity levels and overall cardiovascular endurance capacity 
(aerobic capacity).  In the older adult, it may be determined by muscle strength and endurance, 
balance, orthopedic or neurologic abnormalities, and other problems.68  Each participant was 
instructed to cover as much ground as possible within the 6 minutes and notified that they were 
allowed to sit down and rest if needed, however to start walking again as soon as possible.  If 
participants needed to stop during the test for any reason and the total distance covered in 6 minutes 
was recorded to the nearest 0.1 metre.  Each participant completed the 6-minute walk twice at the 
baseline assessment, with each test scheduled 10 days apart.  The better of 2 trials was recorded 
at baseline to allow for learning effects.  Previous RCTs from our research lab have reported at 
the coefficient of variation for this test as mean 3.0%, (range 0.0 % – 13.0%).95 
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Static Balance 
Static balance test performed using Rossiter-Fornoff and colleagues96 was used to assess static 
balance.  Standing static balance test was assessed for up to 15 second in six different positions 
without the use of an assistive device in the following order: (1)  Wide stance (feet parallel and 
hip width apart), (2)  Narrow stance (feet side by side and touching), (3)  Semi-tandem stance 
(feet parallel and the toes of one foot at the level of the in-step and touching the other foot), (4)  
Tandems stance (toes of the foot touching the heel of the other foot), (5)  Single leg stance eyes 
open, (6)  Single leg stance eyes closed.  Total static balance was calculated by summing the 
time recorded for each of the 6 stances.96 
 
Gait Velocity 
Gait velocity was measured using an Ultra-timer (DCPB Electronics, Glasgow, Scotland, UK).  
Participants were asked to walk with any habitual assistive devices at their self-selected normal 
and maximal speed for 2-3 trials.  Gait velocity was defined as the mean of the 2 closest trials for 
habitual speed, and the highest value for maximal speed. 
 
Stair Climb 
Maximal stair climb was used as a proxy for lower extremity power.97  Two trials were conducted 
of the 9-step stair climb with 60 seconds rest between each trial.   The time taken for each test 
was recorded to the nearest 0.01 a second and the best of the 2 test results was used to calculated 
stair power using following formula.97, 98 
Power (Watts) = Body Weight (N) × Height of Stairs (m) /Ascent Time (s) 
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Chair Stand 
The five chair stand test, performed according to Guralnik and colleagues99 was used as an index 
for lower extremity power/balance.  Participants were instructed to sit in a chair with arms folded 
at chest level and to complete 5 stands consecutively as quickly as possible.  At the completion 
of each stand, legs were to be straight, and with each return to siting, the back was to touch the 
back of the chair.  The assessor used a handheld stopwatch and timing was commenced after the 
assessor said ‘go’ and was stopped the participant achieved a full erect standing position for the 5th 
time.  Time taken, as well as numbers of stands completed and whether arms were used were 
recorded. 
 
Body Composition 
Anthropometry 
Morning fasting stretch stature (wall-mounted Holtain stadiometer, Holtain Limited, Crymych 
Pembs., UK) and naked weight [weight in gown (kg) – weight of gown (kg)] were measured in 
triplicate to the nearest 0.1cm and 0.01kg respectively.  Body mass index (BMI) was calculated 
from fasting naked weight and stretched stature measurements.100  
 
Waist circumferences were measured with a Lufkin flexible steel tape by a number of methods for 
data collection and International Society for the Advancement of Kinanthropometry (ISAK) 
protocol100 was used for analysis.  Measures were recorded by an experienced anthropometrist 
with technical measurement errors < 1%. 
 
Bioelectrical Impedance Analysis  
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Total fat mass and skeletal muscle mass were determined using bioelectrical impedance analysis 
BIA); RJL Systems, Inc., Clinton, MI, USA).  All participants were fasting and BIA was 
performed in the morning, at a similar time of day for all participants. 
Skeletal Muscle Mass (SMM) was calculated from the following formula.101  
SMM = 0.401 × (Height2 / Resistance) + 3.825 (sex) + age × (-0.071) + 5.102  
Height is in cm; Resistance is in Ohms; Sex: men = 1 and Women = 0; Age is in years. 
 
Total fat mass was determined using BIA, by subtracting fat free mass from naked weight to 
determine total fat mass.  Fat free mass was determined using the following equation.102 
Fat Free Mass = -4.03 + 0.734(Ht2/BIA) + 0.116(BW) + 0.096(Xc) + 0.984(sex) with height (Ht) 
in cm, BIA resistance in ohms (average of 3 measures), naked body weight (BW) in kg, Xc 
reactance in ohms and sex coded 1 for men and 0 for women. 
 
Computed Tomography  
Computed tomography (CT) (GE High Speed CTI Scanner, MIL, USA at the Royal Prince Alfred 
Hospital, Sydney) was used to quantify total abdominal adipose tissue (TAAT), abdominal 
subcutaneous adipose tissue (SCAT), visceral adipose tissue area (VAT), sagittal abdominal 
diameter, total thigh muscle, thigh subcutaneous adipose tissue area, mid-thigh muscle cross 
sectional area (CSA), intramuscular adipose tissue, and thigh muscle lipid density. 
For CT scans of the abdomen, a 1-mm slice was performed at the mid-point of the iliac crest and 
lowest rib.  This was located by palpation with the participant supine and arms raised above the 
head.  A marker placed at the site was visible on the scout image to set up scanning coordinates.  
A line was drawn from the femoral notch to the marker and the linear distance was recorded.  This 
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was designed to enable replication of follow-up scans.  Settings were kV: 100 and mA: 170 
(depending on participant’s abdominal mass) with displayed field of view (DFOV) 45-48 
(depending on participant size).   
 
For CT scans of the mid-thigh, a 1-mm slice was performed at the mid-point of the inguinal crease 
to the proximal pole of the patella measured with the participant supine and knee flexed.  A 
marker placed at the site was visible on the scout image and a linear distance from the femoral 
notch to this marker was recorded to replicate follow-up scans.  Settings were kV: 100 and mA: 
170 with displayed field of view (DFOV) 25 (depending on participant size). 
 
Image Analysis 
Scan images were analysed according to optical density on a Macintosh iBook G4 (Apple; 
Sunnyvale, CA, USA), by a trained investigator in a blinded manner.  NIH Image software 
(Version 1.63, National Institutes of Health) was programmed via specific macros to quantify 
cross-sectional areas of muscle, bone and adipose tissue.  To determine VAT, macros were 
programmed to select the outer perimeter extending from the paraspinal muscles to the anterior 
abdominal muscles. The program calculated this measure by summing the area within the selected 
perimeter occupied by pixels with optical density in the range of 140 to 240.  Thigh muscle 
attenuation (an index of intramuscular lipid) was calculated using a template set up in Excel 
(Microsoft) based on the ‘average’ density for thigh pixels in a specific optical density range (10-
113) chosen to best discriminate muscle from fat and bone.  Higher numbers reflect more 
intramuscular lipid (less dense muscle).  Co-efficient of repeatability, determined using a Bland-
Altman plot on a subset of 10 scans was found to be excellent at 0.49 for VAT and 0.44 for mid-
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thigh CSA.103  CT scan data were not available in 1 participant due to body mass exceeding the 
specifications of the scanner bed. 
 
Questionnaires 
All questionnaires were interviewer-administered by a trained interviewer, in a private room using 
visual prompts.  Participants were asked routine questions to obtain demographic information, as 
well as their current health status relating to the presence of other chronic diseases.  All 
questionnaires including habitual physical activity, psycho-social and quality of life were widely 
used, previously validated questionnaires in cohorts similar to this one.   
 
Physical Activity  
Habitual physical activity levels were assessed using the Physical Activity Scale for the Elderly 
(PASE) questionnaire,104 valid instruments for the assessment of physical activity in epidemiology 
studies of older people.104  Higher scores reflect increasing amounts of habitual structured and 
unstructured physical activity.   
 
Quality of Life 
Health-related quality of life was assessed using Version 2 of the Medical Outcomes Survey 36-
item Short-Form (SF-36v2) questionnaire.105  which was constructed to stratify minimum 
psychometric standards necessary for group comparisons involving health concepts that are not 
specific to any age, disease, or treatment group. 
 
Depressive Symptoms 
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Depressive symptoms were assessed using Geriatric Depression Scale (GDS).106  The GDS is a 
self report mood symptom checklist with simple yes/no response set.  The directionality of the 
answers scored for depression changes randomly and the questionnaire itself has been well 
validated in older adults.107  All participants were also asked to complete the Geriatric Depression 
Scale (GDS), which is a screening test for depression with scores ranging from 0 to 30. 
 
Systemic Inflammation 
High-sensitivity CRP was measured in duplicate by enzyme-linked immunosorbent assay (ELISA) 
(eBIOSCIENCE, Camarillo, CA), with the average value used in statistical analyses. The lowest 
detectable concentration was 0.01mg/L, and the intraassay co-efficient of variation was 6.4%. CRP 
analysis was available in 89 participants. 
 
Adiponectin 
During blood sampling, extra blood was sampled and the serum stored for future analysis of serum 
adiponectin.  Serum levels of adiponectin (eBioscience, San Diego, CA, USA) and human SAA 
(BioSource, amarillo, CA, USA) were measured in duplicate with enzyme-linked immunosorbent 
assay kits according to instructions of the respective manufacturers, with the average value used 
in statistical analyses.  The lowest detectable concentration was 0.01mg/L.  Co-efficient of 
variation was required to be less than 15%, otherwise a third measurement was performed.  The 
intra-assay coefficient of variations of the adiponectin were 10%. 
 
5.3.8 COVARIATES 
Covariates for cognitive outcome models specified a priori were age, sex, and educational history.  
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In addition, other factors considered for inclusion as confounders were occupational history, 
burden of chronic disease (medications and diagnoses), nutritional supplements, and habitual 
physical activity level. 
 
5.3.9 STATISTICAL ANALYSIS 
Outcomes were measured by blinded assessors and analysed using Statview (Version 5.0 for 
Windows, Cary NC: SAS Institute Inc).  Data were inspected for normally visually and 
statistically.  A sample was considered skewed if the standard error of the mean was ≤-1 or ≥1.  
All distributed data are expressed as mean ± standard deviation or median and range or frequencies, 
as appropriate.  Non-normally distributed data were log transformed if possible for use with 
parametric statistics.  Any value of zero was treated as 0.0001 for the purpose of statistical 
analysis.  Comparisons of variables between groups were performed using a one-way ANOVA.  
The Mann-Whitney U test was used for non-normally distributed continuous data.  Multiple 
linear regressions were used to estimate the independent relationship between either each of the 
cognitive measures and other variables after controlling for age, sex, and education.  These 
relationships were evaluated the other variables and cognitive domain separately by sex when 
adjusted age and years of education, as appropriate.  All p values of less than 0.05 were 
considered statistically significant. 
 
5.4 RESULTS 
Details of recruitment are included in the study recruitment flow chart (Figure 5.1). 
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5.4.1 DEMOGRAPHICS  
The characteristics of the study participants are summarized in Table 5.1.  The average age of the 
participants was 67.9±5.5 years (ranging from 60 to 83), and consisted of 52 men (50.5%) and 51 
women (49.5%).  Participants were predominantly Caucasian, married, and had completed high 
school or tertiary level education.  Approximately 80% of participants reported alcohol 
consumption and nearly one-third on a daily basis.  Nearly 62% of the cohort had a smoking 
history, but less than 5% were current smokers.   
 
5.4.2 HEALTH STATUS  
This cohort of adults with T2DM was more obese than the general Australia population in similar 
age ranges,108 and they were characterised by a higher number of chronic diseases ranged from 2 
to 11 with an average of 5.1±1.9.  The medications used in our cohort (75% of the participants 
took oral diabetic medications, 16% were on insulin, and 11% used both) were similar to recent 
data from diabetes treatment in Australia where 17% of Australians with diabetes aged 55 or over 
were prescribed insulin, and 74% of them were prescribed oral diabetic medications, 15.5% were 
on insulin, and 5% used both.108  
 
5.4.3 METABOLIC MEASURES  
Glucose Level and HbA1c 
Measures of glucose level in our group (7.3±2.4 mmol/L) were similar to two studies,109, 110 or 
better than other previous studies.12, 111  Glucose were generally well controlled by medications 
in this cohort.  Glucose was generally well controlled by medications in this cohort.  Glycaemic 
control, as indicated by %HbA1c (7.1 ±1.1), was similar to other studies,112-114  or better,81, 83, 115, 
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116 in all but one prior study of exercise and T2DM.117  Our findings may be viewed according to 
relatively well-controlled glycaemia in this cohort, which may have blinded potential relationships 
cognitive domains with improvements in glucose homeostasis after power training. 
 
Insulin Sensitivity 
The average insulin level for this cohort (9.4±4.9 mU/L) was higher than reported for some 
populations in resistance or aerobic exercise studies118, 119 but similar to others.120  Compared to 
other studies of adults with T2DM, this cohort had lower insulin level than younger,118 but similar 
to another study121 in similar age normal groups.  Beta cell function (%B: 110.8±4.5) was 
higher122 or lower123 than other reported measures for these studies with T2DM cohorts.  Our 
group had a lower insulin resistance index (2.9±1.1) to younger,114, 124, 125 older120 and similar age 
groups,126 compared to other cognitive studies with T2DM.  The mean HOMA insulin resistance 
for our cohort was lower than reported for older population without T2DM 
 
5.4.4 PHYSICAL PERFORMANCE  
Muscle Strength and Power 
Total muscle strength of our cohort was 25198.6±836.1 N, which was 27% higher than the total 
strength reported in people in the same age group (over 60 years old, 1899±644 N).94  Total 
muscle power of our cohort was 1549.2±653.4W, similar to that reported in de Vos’ study94 
(1708±643 W), whose participants were not specifically selected for diabetes, but enrolled in a 
power training study. 
 
Walking Endurance  
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Average 6MWD for the cohort was 547.6±86.3 m, which was approximately 17% lower than the 
distance reported in healthy people in a similar age group (55-75 years old, 659±62 m),127 and 13% 
lower than another study which recruited healthy people in a similar age group (50-85 years old, 
631±93 m).128   These findings are consistent with reported impairments in physical function in 
older adults with T2DM compared to age-matched peers.129, 130  The average 6MWD for men 
(569.3±92.6 m) and women (523.0±89.1 m) in our study was lower than that reported for men 
(647.9±201.8 m) and women (579.3±159.8 m) with healthy older adults.131   
 
Gait Speed 
Seventy-six percent of our cohort was below the normal habitual gait velocity for healthy older 
adults in the same age group of 1.3 m/s33.132  In addition, 18% of our cohort was below the 1.0 
m/s threshold for elevated risk of health-related outcomes (persistent and severe lower extremity 
limitation, death, and hospitalisation within 1 year).133   
 
Chair Stand 
Our cohort had worse chair stand time (12.1±2.7 sec) compared to older healthy populations134-137 
but similar to other studies.138-140  Compared to other chair stand studies of adults with T2DM 
this, our cohort were similar in chair stand to some,141, 142 or lower than others.143-146   
 
Stair Climb Power 
Compared to other stair physical performance studies of healthy adults, our cohort had similar stair 
climber power to older,147 or lightly lower than similar age group.148  Our sample for stair climb 
power (370.4±126.6 w) was lower than the values described in other cohort with diabetes (434±72 
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w) and diabetes neuropathology (407±88 w).149   
 
5.4.5 BODY COMPOSITION 
The baseline descriptive statistics for body composition are presented in Table 5.1.   
BMI 
The average BMI for our cohort was similar to some studies81, 112, 150 or higher than others.151-153  
Compare to other body composition studies of adults with T2DM, this cohort had similar BMI to 
younger,154-156 older157 and similar age group158 and for women also.159  BMI values for both men 
(30.3±4.4 kg/m2 ) and women (32.9±6.0 kg/m2) in our study was comparable to reported values 
for men and women with diabetes.160  
 
Total Abdominal Adipose Tissue 
The average total abdominal adipose tissue area for our cohorts (421.6±117.6 cm2) was lower than 
other reports in the cohorts with T2DM.157  The mean values of total abdominal adipose tissue 
for both men (56.8±20.0 cm2) and women (113.1±50.5 cm2) in our study was comparable to 
reported values for men and women with older adults with T2DM and impaired glucose 
tolerance.157 
  
Visceral Adipose Tissue 
Compared to other resistance or combined exercise studies or body composition analysis of adults 
with T2DM, for our cohort in our study, the average visceral adipose tissue (215.0±89.2 cm2) was 
similar to other reports at L4-L5112, 161 and L2-L3.155  The visceral adipose tissue of men in our 
study (258.7±83.4 cm2) was higher than other groups of men with T2DM154, 157, 162 whereas the 
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women (169.6±70.9 cm2) in our study had similar visceral adipose tissues to these groups,154, 157, 
162 or slightly lower than others.114  Two women in our study had very low visceral adipose tissue 
values of 33.86 cm2 and 26.44 cm2. 
 
Abdominal Subcutaneous Adipose Tissue 
The combined sex sample mean for abdominal subcutaneous adipose tissue area (206.7±90.4cm2) 
was much less than the values described in other cohorts with diabetes.112, 158  The mean of the 
combined sample of our cohort for thigh muscle area was much lower than slightly more obese 
adults with T2DM selected over wider age groups who were slightly older.112  The values 
reported for similarly aged women by Cuff and colleague were much higher than ours.114 
 
Thigh Muscle Area 
The mean of the combined sample of our cohort for thigh muscle area was much lower than slightly 
more obese adults with T2DM selected over wider age groups who were slightly older.157  The 
values reported for similarly aged women by Cuff and colleague were much higher than our.114 
 
5.4.6 QUALITY OF LIFE, PSYCHO-SOCIAL STATUS AND PHYSICAL ACTIVITY LEVEL 
Total SF-36 MCS scores were slightly higher (48.8±10.8, 45.1±9.2), than those reported in healthy 
people in the same age group in Australia (45.86 ± 9.03, 44.57 ± 10.75, respectively).163  Physical 
Activity Scale for the Elderly (PASE) score of our cohort was 116±60, similar to that reported in 
Cinzia (111.91 ± 50.39), whose participants were selected for obesity.163  Average GDS for the 
cohort was normal at 6.9±5.3, which was approximately 4% lower (better) than reported in healthy 
people in a similar age group (71-75 years old, 7.2±5.6),130 and 13% higher than another study 
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which recruited healthy people in a similar age group (50-85 years old, 5.75±4.34).128   
 
5.4.7 RECRUITMENT RESULTS 
A total of 427 people were assessed for eligibility, and 103 (24.1%) of those were eligible for 
randomisation, see Figure 5.1.  Reasons for exclusion were not meeting study criteria (5.6%), 
medical reasons (2.1%), too young (1.2%), too physically active (16.4%), too far to travel (8.2%), 
inability to commit to the study protocol (33.3%), no longer interested in participating (3.5%), 
work commitments (2.6%) and other (3.0%).  One hundred and three participants recruited 
provided data for these baseline analyses. 
 
5.4.8 INFLAMMATION AND ADIPOKINES 
The average of our cohort for CRP (3.9±4.2) was similar to one,164 or much less than values than 
other reports in older adults with T2DM,165 but had higher CRP than younger without diabetes164  
Measures of High Molecular Weight adiponectin were similar to166 or lower than one study with 
T2DM167 and total adiponectin were similar to one study,166 lower than measures values reported 
coronary heart disease in young group.168 
 
5.4.9 COGNITIVE FUNCTION TESTS 
The average score in Word List Memory for our cohorts (21.3±3.9) was lower than other reported 
for intact cognitive older adults with combined exercise studies,169 but similar to others.90, 170  
Word List Recall was similar to one,89 or lower170 than the reported measures for these exercise 
studies without T2DM cohorts.  Our group was similar in Word List Recognition to some140 or 
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slightly lower than cohorts.90 
 
Our combined cohort had TMTA (40.6±12.6) higher than another170 but similar to that reported in 
a slightly more obese group with T2DM.111  The average TMTB in our study (95.2±42.5) was 
higher than one study170, 171 or slightly lower than that reported 111 but similar values172 reported 
for aged people.  Pure executive function in our cohorts was lower values reported111, 172 in older 
adults with T2DM but higher than one reported without diabetes and dementia.170  Measures of 
3MS (94.1±4.8) was higher than other reported in same age group with diabetes,173 but similar to 
values in one study who were slightly older.37 
 
5.4.10 RELATIONSHIP BETWEEN COGNITION AND AGE, EDUCATION, AND SEX OR HEALTH STATUS OR 
COMPLIANCE 
Results are presented in Table 5.2 and 5.3.  We adjusted the analyses for several factors that may 
confound the association of the variable of interest and cognitive function, including age, sex and 
educational level, as detailed below. 
 
The decline of cognitive domains most frequently seen with advancing age is a reduction of verbal 
memory, attention, and executive function.  In our study, we found that older age was associated 
with more impaired cognitive function, including Word List Memory (r=-0.33; p<0.01), Word List 
Recall (r=-0.34; p<0.01), information processing speed (r=0.29; p<0.003), executive function 
(r=0.22; p=0.028), and global cognitive score (r=-0.24; p=0.02).  Moreover, every one year 
increase in age was also associated with a 0.33-point lower Word List Memory score (p<0.01), a 
0.34-point lower Word List Recall score (p<0.01), a 0.12-point lower Word List Recognition score, 
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a worse score (i.e., 0.29 seconds) on the Trail Making Test A (p<0.003), a worse score (0.22 
seconds, p<0.05) on Trail Making Test B, and 0.24-point lower on 3MS.  These findings are in 
general agreement with the findings reviewed by Singh-Manoux and Beeri.174, 175  Therefore, in 
order to assess the relationships among cognitive domains and metabolism, physical performance 
and body composition; age was added to these models to minimise confounding.  Educational 
level is well known to be related to cognitive function.85, 176, 177  In our cohort, higher years of 
education was related to Word List Recall (r=0.22; p=0.03) and Word List Recognition (r=0.21; 
p=0.03), pure executive function (r=-0.25; p=0.01), with a trend for Word List Memory (r=0.18; 
p=0.08), information processing speed (r=-0.18; p=0.07), executive function (r=-0.18; p=0.08) and.  
Health status such as duration of diabetes was associated with pure executive function (Trail 
Making Test B minus Trail Making Test A) (r=0.20; p=0.04).  Total no. of Medications was 
significantly associated with Word List Recall (r=-0.30; p<0.01) and Word List Recognition (r=-
0.31; p<0.01))  No association between global cognition (3MS) and education was found in our 
cohort.  There were also nosignificant relationships between total no of diseases and any 
cognitive domain tests.  Subsequent regressions were adjusted for educational level based on 
these relationships therefore. 
 
Sex differences related to cognitive function, body composition, and inflammatory markers178, 179 
have been established.  In our trial, there were significant sex differences between Word List 
Memory (p=0.001), Word List Recall (p=0.002).  A trend for Word List Recognition (p=0.08) 
and 3MS (p=0.06) were present.  Women have higher Word List Memory, Word List Recall, and 
global cognitive scores than men.  For this reason, sex differences should be considered for a 
clear understanding of the mechanisms related to body composition and metabolic abnormalities 
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of T2D associated with cognitive decline not confounded by sex differences in all these variables.   
Healthy status and compliance were not related to any domains of cognition (p=0.19-0.99).   
 
All analytic models were thus adjusted for age, and years of education and sex, in view of pre-
existing literature and our own data presented above.  In addition, due to the major differences 
between men and women in many variables, we also performed regressions stratified by sex, and 
adjusted for age and education, in order to look at relationships within each sex separately. 
 
5.4.11 RELATIONSHIPS BETWEEN MEASURES OF METABOLISM AND OF COGNITION 
Fasting glucose 
There was a significant unexpected positive relationship between higher fasting glucose and better 
delayed memory (r=0.26, p<0.01) (Table 5.3).  The relationship between fasting glucose and 
Word List Recall remained after controlling for age, sex, and education in a multiple regression 
model (β=0.23, p=0.02) (Table 5.4 and Figure 5.2).  When stratified by sex, however, no 
relationship was found between fasting glucose and any of the cognitive domains.  No other 
cognitive tests were related to fasting glucose.  Therefore, this may be a spurious finding. 
 
HbA1c 
Contrary to our expectations (Table 5.4), HbA1c was not related to Word List Memory (β=-0.02, 
p=0.82), Word List Recall (β=0.16, p=0.08), Word List Recognition (β=0.10, p=0.32), information 
processing speed (β=0.14, p=0.16), attention (β=0.13, p=0.20), executive function (β=0.08, 
p=0.41), or global cognitive function (β=0.04, p=0.71), adjusting for age, sex, and educational 
history.  When stratified by sex, there were still nosignificant relationships found. 
329 
 
Fasting insulin 
Unexpectedly (Table 5.4), fasting insulin was also not related to any of the cognitive tests (p>0.05).  
When stratified by sex, there was still no association between fasting insulin and any of the 
cognitive tests. 
 
Beta cell function  
There were no significant relationships between HOMA2-%Beta and memory, information 
processing speed, executive function, and global cognitive function, again contrary to our 
hypotheses.  When stratified by sex, HOMA 2 % Beta remained unrelated to any of the cognitive 
domain tests (Table 5.4). 
 
Insulin resistance 
Contrary to our hypotheses (Table 5.4), HOMA2-IR was not related to Word List Memory (n=86, 
β=-0.02, p=0.80), Word List Recall (n=86, β=-0.07, p=0.51), information processing speed (n=86, 
β=-0.15, p=0.18), attention (n=86, β=-0.18, p=0.09), executive function (n=86, β=-0.12, p=0.26), 
or global cognitive function (n=86, β=0.13, p=0.25) adjusted for age, sex, and education.  
Stratification by sex did not alter these non-significant results.   
 
5.4.12 RELATIONSHIPS BETWEEN PHYSICAL PERFORMANCE AND COGNITIVE FUNCTION  
Associations between measures of exercise capacity and cognition are presented in Table 5.5.  As 
expected, for the whole cohort, longer 6 Minute Walking Distance (6MWD) was related to better 
Word List Recall (β=0.22, p=0.04; Figure 5.3), with a nearly significant trend for information 
processing speed (β=-0.21, p=0.05; Figure 5.5).  The relationship between 6WMD and Word List 
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Recall persisted only in men (men; n=52, β=0.29, p<0.05, women; n=50, β=0.11, p=0.16) when 
stratified by sex.  Consistent with expectations, information processing speed was significantly 
associated with stair climb power (β=0.34, p=0.001; Figure 5.6) and chair stand time (β=-0.29, 
p=0.02; Figure 5.7).  However, when stratified by sex, the significant relationship between 
information processing speed and chair stand was only significant in women (women; n=50, 
β=0.51, p=0.000; men; n=52; β=0.26, p=0.13).  No significant associations muscle strength, 
muscle power, balance, gait speed with any cognitive domains was found. 
  
5.4.13 RELATIONSHIPS BETWEEN MEASURES OF BODY COMPOSITION AND COGNITION  
Associations between measures of body composition and cognition are presented in Table 5.6.  
As expected, sagittal abdominal diameter was inversely related to Word List Recall (β=-0.21 
p=0.03; Table 5.11 and Figure 5.4).  When stratified by sex, sagittal abdominal diameter remained 
significant for men (men; n=52, β=-0.35, p=0.009; women; n=49, β=-0.12, p=0.39), with no 
relationship seen in women.  There was a trend towards an association between total abdominal 
adipose tissue (β=-0.17, p=0.06) and subcutaneous abdominal adipose tissue (β=-0.20, p=0.08) 
and Word List Recall.  Contrary to our hypotheses, no significant relationships between visceral 
adipose tissue, thigh subcutaneous adipose tissue, intramuscular adipose tissue, mid-thigh cross-
sectional area, thigh muscle lipid density, skeletal muscle mass,, or fat mass and any of the 
cognitive tests was observed in the multiple regression analyses after adjusting for age, sex, and 
years of education, nor when stratified by sex.   
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5.4.14 RELATIONSHIPS BETWEEN PSYCHOSOCIAL STATUS, PHYSICAL ACTIVITY AND COGNITIVE 
FUNCTION 
Results are presented in Table 5.7.  Using multiple linear regression models, unexpectedly, higher 
physical activity level (PASE) was positively related to pure executive cognitive tests (β=0.29, 
p=0.01; Table 5.7 and Figure 11).  However, the gender effects relationship between cognitive 
function and PASE remained a trend in men (n=39, β=0.29, p=0.06), with no relationship seen in 
women (p=0.10). 
 
Depression and SF-36 MCS and PCS scores were not significantly related to any cognitive 
domains (p=0.17-0.97) in the overall cohort.  However, when stratified by sex, there was a 
significant relationship between depression score and executive function in women (TMT-B; n=48, 
β=0.30, p=0.04, and TMT-B minus A; n=48, β=0.32, p=0.03,) but not in men.  As hypothesised, 
more depressive symptoms were associated with worse executive function on these tests of 
executive function in the women. 
 
5.4.15 RELATIONSHIP BETWEEN INFLAMMATION AND ADIPOKINES AND COGNITION 
As expected, for the whole cohort (Table 5.8 and 5.15), higher serum CRP was related to slower 
information processing speed (n=88, β=0.30, p<0.01; Figure 5.8).  However, when stratified by 
sex, the relationship between CRP and information processing speed was stronger in women (n=42, 
β=0.35, p=0.05), and attenuated and no longer significant in men (n=46, β=0.27, p=0.06).  
Contrary to our expectations, however, serum CRP was not related to Word List Memory (n=88, 
β=-0.01, p=0.97), Word List Recall (n=88, β=-0.11, p=0.28), Word List Recognition (n=88, β=-
0.13, p=0.44), attention/executive function (n=88, β=-0.02, p=0.87), pure executive function (n=88, 
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β=-0.13, p=0.21), or global cognitive function (n=88, β=-0.04, p=0.87).   
 
As hypothesised, serum total adiponectin was directly related to Word List Recall (n=39, β=0.25, 
p=0.04; Table 5.16; Figure 5.9), but not related to other tests of cognitive function (p=0.11-0.91).  
When stratified by sex, the relationship between high serum adiponectin and Word List Recall was 
stronger in women (n=19, β=0.59, p<0.01) but not present in men (n=20, β=0.12, p=0.53).  
Higher serum HMW adiponectin: adiponectin ratio was related to better pure executive function 
(n=39, β=-0.43, p=0.01; Table 5.17 and Figure 5.10), but no other cognitive tests (p=0.25-0.78).  
When stratified by sex, this remained significant for men (men; n=20, β=-0.49, p=0.02) and was 
slightly attenuated in women (n=19, β=-0.44, p=0.08).   
 
5.5 DISCUSSION 
To our knowledge, this is the first investigation examining the relationship of indices of insulin 
resistance and glucose homeostasis, physical performance, body composition, and systemic 
inflammation to a wide range of cognitive  tests including immediate memory, delayed memory, 
information processing speed, attention/executive function, and global cognitive function 
specifically in a clinical cohort of older adults with T2DM.  Furthermore, it is the first 
investigation to simultaneously examine glucose hemostasis, insulin resistance, physical 
performance, body composition, and systematic inflammation within the same cohort, and 
measure adipose tissue and muscle mass using two distinct body composition techniques (BIA and 
CT scan).  Previous investigations have used only abdominal fat, or measures of muscle mass or 
6MWD or muscle strength, or glucose control and insulin resistance, or CRP in healthy 
participants.50, 69, 120, 180-182  Our comprehensive assessment of multiple physiological 
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characteristics represents a major advance over previously published investigations.  We have 
demonstrated that 6MWD, stair climb power, sagittal abdominal diameter, systematic 
inflammation, adipokines (adiponectin) are related to specific cognitive domains in this cohort.   
 
In general, our baseline cognitive test results suggest that a ceiling effect was present for some 
cognitive domains in our cohort, which might have obscured some relationships between insulin 
resistance, glucose homeostasis, physical performance, body composition, CRP, adiponectin, and 
cognitive capacity. 
 
5.5.1 HEALTH STATUS 
Our cohort was primarily overweight or obese, and this percentage (97%) was higher than a similar 
age group (approximately 71% in people aged 55 or over not selected for diabetes) reported by 
Australian Bureau of Statistics.183  The medications used in our cohort (67% of the participants 
took oral diabetic medications, 16% were on insulin, and 14% used both) were very similar to 
medications used by older adults with diabetes in Australia.  For example, 18% of people with 
diabetes and aged 55 or over in Australia are prescribed insulin, and 72% of them take oral diabetic 
medications.183 
Generally speaking, the health status of our cohort (97% overweight or obese; 44% high total 
cholesterol; 79% raised triglycerides; 77% reduced HDL cholesterol; 74% hypertension, 3% stroke, 
18% cardiovascular disease) was worse than the health status of people with diabetes in Australia 
(59.6% overweight or obese; 51.2% high total cholesterol; 20.5% raised triglycerides; 23.1% 
reduced HDL cholesterol; 28.8% hypertension.184, 185  However, this comparative data is from 
AusDiab (The Australian Diabetes, Obesity and Lifestyle Study), which included a representative 
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sample of those aged 25 or over with diabetes. This broader age range likely explains the lower 
prevalence of comorbidity.   
 
Our cohort is comparable to other resistance training or combined resistance and aerobic exercise 
studies that have analysed Caucasian populations.  Other reports have included Latino,81 Asian 
Indian,151, 152 Japanese153 population with T2DM.  Sample sizes of these intervention were 
typically small in two randomised controlled trial which included combined training and combined 
versus single mode trial in participants with T2DM.112, 150  Another non-randomised controlled 
trial which included aerobic training in 16 participants with T2DM reported age, education, 
cognitive function, and glucose control similar to our cohort.186  The age, BMI, and general health 
status of our cohort was similar to other studies of adults with T2DM participating in resistance 
training alone187 and similar to another Australian sample.115 
 
5.5.2 MEASURES OF METABOLISM AND COGNITIVE FUNCTION  
Glucose control and cognitive function 
We hypothesised that metabolic disturbance would also be related to lower cognitive performance, 
but the associations we found for one test of memory were unexpectedly positive between higher 
fasting glucose level and better delayed memory, even after adjusting for age, sex, and educational 
level.  Given that it was not present when stratified by sex, and no other cognitive tests were 
related to glucose, it may be a spurious finding.   
 
We did not see any relationship of HbA1c and cognition, contrary to our hypotheses.  Others have 
shown that glucose level was negatively related to cognitive decline.120  Another study 
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demonstrated that a cognitive benefit is achievable in reasonably well-controlled T2DM adults 
(mean age of 60 years; glycated hemoglobin levels less than 8.0%) with no evidence of dementia 
(using the MMS) or depression, who further improve their blood glucose control through use of 
diabetic medications (ie, insulin sensitizers).172, 188  For those subjects, treatment-induced 
reductions in fasting plasma glucose levels were accompanied by improvements in cognition (ie, 
working memory).  The lack of relationship in our cohort is not fully understood at this time, but 
there are several possibilities.  It is possible that the lack of association of cognitive function with 
HbA1c could be attributed to the tight level of glycaemic control (7.1±1.1%) with glucose-
lowering drugs in the cohort, which was much lower than earlier diabetes exercise studies.  
Secondly, cognitive function was relatively intact in our subjects for many of the tests.  Thus, the 
combination of relatively intact cognitive function and good metabolic control in this cohort may 
have obscured potential relationships between cognition and glucose homeostasis seen in some 
previous literature.   
 
Insulin resistance and cognitive function 
It was also hypothesised that higher beta cell function would be related to better cognitive 
performance, but no associations were found between HOMA2-%beta and any cognitive domains.  
The role of insulin and insulin resistance on cognition in patients with diabetes is obscure, 
especially in the elderly.  Previous studies that investigated the relationship between insulin 
resistance and cognitive function suggested a number of possible biological mechanisms that could 
be involved, including accumulation of oxidative stress with advanced glycation end products120, 
121 and also decreased cortical glucose utilisation, particularly in the hippocampus and entorhinal 
cortex.  Insulin resistance may also cause Tau phosphorylation and neurofibrillary tangle 
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formation, and increased beta amyloid aggregation.122   Although it is difficult to address the role 
of these suggested mechanisms, the current literature suggests that insulin resistance and 
hyperinsulinemia are important for cognitive decline, especially in elderly women.189   
Our results were inconsistent with the current literature supporting the evidence for insulin 
resistance resulting in cognitive dysfunction.189  It is possible that our cohort had cognitive 
function which was too well preserved, precluding demonstration of such relationships.  In 
addition, most previous studies established the mean values to assess insulin resistance in adults 
with T2DM ranging from 3.875 to 5.825 for the HOMA index.120,190  When compared with our 
data, these insulin resistance indices were much higher.  Thus, in our study, the relationships 
between insulin and insulin resistance and cognition may have been obscured by intensive 
medication management, which may both control glycaemia and improve insulin sensitivity 
(metformin).  Moreover, the effect of insulin resistance on cognition might be long-term, as 
others have reported the effects of higher insulin level on global cognition and verbal memory up 
to 10 years later.191  Additionaly the HOMA2 calculation will estimate lower insulin resistance 
than the gold standard euglycaemic clamp.  The HOMA2 model has been validated as a measure 
of fasting insulin resistance reflective of hepatic insulin sensitivity87, 88  However, one of the 
limitations of this methodology is that it does not directly reflect whole body or peripheral 
sensitivity in skeletal muscle.192  Thus, additional studies are needed to clarify the association 
between insulin resistance and cognition, using precise measures of whole body insulin resistance 
and a broader range of metabolic control and cognitive function, as well as via long term follow-
up. 
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5.5.3 RELATIONSHIP BETWEEN PHYSICAL PERFORMANCE AND COGNITIVE FUNCTION 
It has been reported that poorer physical fitness and low physical activity are related to cognitive 
decline in people at risk for diabetes.193, 194  Our study showed that cognitive function (Word List 
Recall and Trail Making Test A ) was negatively related to 6MWD, chair stand time, and stair 
climb power.  To our knowledge, this is the first evidence to show that cognition in older people 
who have already developed T2DM is associated with poor physical function and low exercise 
capacity.  The physical function and exercise capacity tasks which were related to worse 
cognitive decline are composite measures of mobility, lower extremity, strength and power, 
balance, aerobic capacity, underlining the clinically important impact of cognitive function on 
ability to function independently in this cohort.   
 
T2DM and its common complication, central and peripheral neuropathy, may lead to sensory and 
motor deficits, which can result in mobility-related dysfunction, alterations in gait characteristics 
and balance impairments.195  Patients with peripheral neuropathy of diabetes have lower gait 
velocity, decreased cadence, shorter stride length, increased stance time and higher step to step 
variability compared to healthy controls.196  Moreover, these patients have less ankle moment and 
ankle power, as well as a different onset and cessation time of muscle activity.197  In addition, 
reductions in exercise capacity, sit to stand, and stair climb power in T2DM complications have 
been related to impaired physical function, neurologic abnormalities, impaired muscle mass, 
strength, aerobic capacity and balance.198  Gait speed or strength or muscle mass or aerobic 
capacity are the components of exercise capacity most strongly associated with cognitive function 
in the literature, while the executive function and attention domains of cognition are most 
consistently related to exercise capacity.  Additionally, in our cohort, higher insulin resistance 
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was related to worse physical performance, including 6MWD, habitual gait speed, and chair stand 
power.   
 
Mechanisms linking these factors to cognition may include changes in muscle metabolism.  For 
example, contracting muscles secrete so-called myokines that mediate an anti-inflammatory 
effect,199, 200 and have been related to increased brain blood flow volume, increased insulin level 
in the brain, higher brain derived neurotrophic factor (BDNF), and improved neuroplasticity, as 
well as improved.200-206  This may be one explanation for the link between exercise capacity, 
physical function and cognition.  The mechanisms of this association will need to be investigated 
by subsequent intervention trials.   
 
5.5.4 RELATIONSHIP BETWEEN MEASURES OF BODY COMPOSITION AND COGNITIVE TEST SCORES 
This analysis of 103 individuals with established T2DM demonstrated a clear inverse relationship 
between cognitive function and central obesity as measured by the SAD and other measures after 
adjusting for age, educational history, and sex.  This is in agreement with Kanaya et al,37 who 
showed the same relationship amongst the health ABC cohort.  Their investigation however 
involved a cohort that included older adults with and without diabetes (average 3MS score 90).  
Our study was the first to include exclusively older men and women, all with T2DM.  Kanaya 
(2009) reported that this relationship was weakened when those with overt diabetes were included 
in the analyses,37 but our data by contrast show a strong inverse relationship between central 
obesity measure SAD and Word List Recall still exists within this particular cohort.  In fact, our 
multiple regression models suggest that contribution of SAD to Word List Recall among this cohort 
is greater than that of other measures of central obesity, supporting the fact that SAD is closely 
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linked with the amount of metabolically unfavorable depots of abdominal fat and thus may become 
a good predictor of risk of cognitive decline.   
 
Several studies have examined the effect of overweight on cognitive function.23, 207  Some 
longitudinal studies have found that a higher BMI is associated with increased risk of developing 
dementia,33, 36, 208 while others have found no association.34, 209  Fewer studies have evaluated the 
association between adiposity and cognitive function or decline in intact cognitive older adults 
with T2DM.  We found 2 prospective studies that evaluated the effect of BMI on cognitive 
function.23, 210  The first observed 1423 individuals in the Framingham Heart Study for 4 to 6 
years and found that higher BMI was associated with worse cognitive function scores in men,23, 27  
The second study was performed in 5607 postmenopausal Danish women observed for 7 years; it 
examined baseline body weight, yearly change in weight, and central fat mass by whole-body dual 
x-ray absorptiometry.210  The authors found a protective association of body fat mass with 
cognitive impairment in the elderly women and showed that those who lost the most weight had 
the worst cognitive performance at follow-up.210  Neither of these studies had baseline measures 
of cognitive function or more precise measures of regional adiposity.  Our findings that sagittal 
abdominal diameter as a mark of visceral adipose tissue have greater cognitive decline is consistent 
with the Framingham results, and our finding that men show an inverse associations with visceral 
adipose tissue, sagittal abdominal diameter, and subcutaneous abdominal adipose tissue and 
cognitive change is consistent with the Danish study.  We have extended the literature by 
observing that total body fat and subcutaneous abdominal fat are the 2 adiposity measures that 
have the strongest effect on cognitive change in men. 
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Our study is the first to more closely examine regional adiposity measured computed tomography.  
Surprisingly, our direct measure of visceral fat, which has been most closely tied to poor metabolic 
outcomes, had only a borderline significant association with cognitive change.  There were 
effects of VAT in men.  This may be because only the men had high enough VAT to show 
relationships with cognition.   
 
Our findings demonstrate that increasing levels of sagittal diameter abdominal diameter are 
strongly associated with worsening cognitive function in older persons with diabetes.  Men show 
inverse associations between adiposity and cognitive change.  Future studies should confirm 
these longitudinal associations with adiposity and cognitive change and investigate why adiposity 
has inverse associations in men but not in women. 
 
5.5.5 RELATIONSHIP BETWEEN PSYCHOSOCIAL STATUS, PHYSICAL ACTIVITY, QUALITY OF LIFE AND 
COGNITIVE FUNCTION 
Physical Activity 
Previous studies have examined the effect of physical activity level on cognitive function.  Some 
longitudinal studies have found that a higher physical activity is associated with better cognitive 
function,211, 212 while others have found no association.213  Fewer studies have evaluated the 
association between physical activity and cognitive function or decline in adults with T2DM.  We 
found 2 experimental studies that evaluated the effect of physical activity on cognitive function.214, 
215  The first study for 26 week intervention and found that higher physical activity was associated 
with better cognitive function scores.214  The second study was performed higher physical 
exercise for 26 weeks; it examined the effects of exercise on cognition.215  Unexpectedly, there 
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was a significant positive association between Physical Activity Scale for the Elderly and 
executive domain of cognition in the multiple regression model.  The relationship remained 
unexplained by other variables.  Although literature was mixed with regard to the association 
physical activity levels with cognitive function, particularly in cross-sectional studies, the majority 
of physiological data would suggest that higher levels of physical activity was beneficial for 
cognitive function according to our original hypothesis.  The results of the intervention in our 
trial would hopefully clarity the role of anabolic interventions such as power training on cognitive 
function in this cohort with T2DM. 
 
Geriatric Depression Scale  
T2DM has been linked to an increased risk of cognitive impairment and shown higher prevalence 
of depressive symptoms, and depressive symptoms might be related to cognitive impairment.216-
222  Although it is known that depression, mild cognitive impairment (MCI), and dementia are 
highly prevalent chronic conditions associated with social support, biomedical factors, and 
economic burdens, since it has been reported that depressive symptoms are related to white matter 
and lacunae abnormalities223 and severity of diabetic complications.224  There is less literature 
that evaluates the effects of depression on cognitive function with T2DM.  Recent studies in 
health maintenance organization populations examined whether depression was associated with an 
increase in the risk of all-cause dementia among patients with diabetes.221, 222  One study, among 
nearly 4000 patients with T2DM, found a doubling of the risk of dementia diagnosis for patients 
with depression after 3 to 5 years of follow-up.221  The another one study of nearly 20 000 patients 
with T2DM also found a doubling of the risk of a dementia diagnosis for patients with depression 
after 3 to 5 years of follow-up.222  These studies were limited by their reliance on medical record 
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diagnoses of dementia, which lack sensitivity and are prone to ascertainment bias.  Our study is 
the first to more closely examine depression measured GDS.  Surprisingly, our direct measure of 
depression, which has been most closely tied to poor metabolic outcomes, had no significant 
association with cognitive change.  It is possible that our sample size for depression is too small 
to identify the negative benefits. 
 
Quality of Life 
Cognitive dysfunction in older adults with T2DM is relatively well described.  Cognitive 
impairment may subsequently contribute to reduced fulfilment in work life and social life as well 
as in a reduction in health-related quality of life (QoL).225-227  To our knowledge, there is less 
literature that evaluates the effects of quality of life identified only in the context of the mental and 
physical health limitations domain on change in cognitive function.  
 
Prior studies examining the relationship between cognitive impairment and QoL have revealed 
inconsistent results.  One study have examined the effect of quality of life on cognition, using 
either Mental or physical health composites of the MSQOL-54 were not predicted by cognitive 
functions in Benedict’s report.147  Cognitive status was not identified as a quality of life predictive 
factor by Amato et al.148  Similarly, results of other investigations indicated an absence of 
significant relations between cognitive measures (i.e., memory, executive function, and global 
cognitive function) and the PCS and MCS scales of the SF-36.231-233  In contrast, in Montel’s study, 
a negative impact of cognitive impairment was identified only in the context of the mental health 
limitations domain of the SEP-59 questionnaire.149  Other authors have reported a more obvious 
association between cognitive deficits and self-reported quality of life outcomes.  Benito-Leon’s 
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study reported associations between lower cognitive scores (MMS) and lower quality of life levels.  
Therefore, the relationships between QoL and cognitive function are complex and contradictory.  
These relationships may be sensitive to the method used to measure and define relative deficiencies 
of quality of life, as well as the specific cognitive impairment.   
 
T2DM are at greater risk for reduced functional abilities and poorer quality of life.150  Cognitive 
impairment may have a profound effect in the treatment management of T2DM in older patients 
(i.e., poorer adherence to medication; dietary and physical activity recommendations).  Other 
work showed greater cognitive impairment among older adults with T2DM is related with poorer 
disease care management and adherence.151  Previous animal studies have shown physical 
activity to improve insulin resistance and attenuate neuroautonomic dysregulation and improve 
cognitive function among rats.  Similarly, other studies have shown that lower scores on clinical 
neuropsychological tests of memory, executive function and global cognitive function have been 
associated with lower scores on measures of QoL among those with chronic disease.225, 228-230  
The lack of relationship in our cohort is not fully understood at this time, but there are several 
possibilities.  Our cohort with diabetes are likely to have less advanced brain pathology and 
relatively intact cognitive function assessed by the stranded cognitive test battery we used, possibly 
due to their good glucose control.  Another possibility for their preserved cognitive function 
could be the generally low levels of depression in the group with diabetes, possibly due to their 
high social support.234-238   Both social support positive affect could potentially blunt any 
potential negative effects of cognition on the emotional and physical domains of health-related 
QoL.  However, we were unable to confirm the impact of social support because this data was 
not collected in our study. 
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5.5.6 SYSTEMATIC INFLAMMATION AND COGNITION 
We have shown for the first time that CRP level and cognitive function in the older adults with 
T2DM were inversely related.  In agreement with our data, Mariono et al239 concluded in an 
Edinburgh T2DM Study that elevated CRP levels were positively related to worse information 
processing speed.  Others have shown CRP to be associated with cognitive decline in healthy 
individuals.55, 56  Our findings also support previous studies that have demonstrated deleterious 
effects of inflammation on cognition.240  It is known that CRP is an independent risk factor for 
cardiovascular disease, and previous studies have also suggested a relationship with cognitive 
decline.241,242  These findings are not fully understood at this time, but a possible explanation as 
to why CRP seems to be particularly detrimental to information processing speed during diabetes 
may be linked to the damage to cerebral small vessels.243 Low grade systemic inflammation 
mediated by CRP may lead to increased blood–brain barrier permeability, impairment of 
endothelial function, toxic elevations of intracellular calcium,163 and local inflammation in the 
brain.  Moreover, associations of the low-grade inflammatory CRP with frontal white matter 
changes were found by others.244-246  This may be why we found an association with poorer 
information processing speed in our study.   
 
Cognitive dysfunction can have a significant impact on quality of life including disability, daily 
care, exercise capacity, and mortality247 and has been associated with metabolic syndrome and 
diabetes-comorbidities such as hypertension, hyperlipidemia, and even obesity, which lead to 
increase low-grade inflammatory levels that ultimately impaired in cognition.248  Thus, serum 
CRP is inflammatory biomarker for cognitive diseases that warrant validation in future 
intervention studies.   
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5.5.7 SERUM ADIPOKINES AND COGNITION  
As hypothesised, higher circulating adiponectin levels and HMW adiponectin relative to total 
adiponectin ratio showed a significant correlation with scores on Word List Recall (delayed 
memory) difference score between Trail Making Test B minus Trail Making Test A (measure of 
pure executive function), after controlling for age, sex, and educational levels.   Others have 
shown that plasma total adiponectin was positively related to cognitive function.249   
 
Adiponectin is the most abundant anti-inflammatory adipokine.  Several studies have reported 
that high levels of adiponectin are related to decreases in the expression of inflammatory cytokines, 
such as TNF-ɑ and NF-kB activation.58  Increased adiponectin levels also induce the production 
of other anti-inflammatory molecules like IL-10 and IL-1 receptor antagonist.250  The presence of 
pro-inflammatory cytokines in the brain tissue adjacent to amyloid plaques may contribute to the 
progression and acceleration of AD-related neurodegeneration.63  Conversely, elevated levels of 
TNF-a and IL-6 are able to inhibit adiponectin transcription in the adipocyte.251  Therefore, it is 
possible that lower adiponectin levels may have a dual effect on the physiopathology of cognitive 
impairment by stimulating pro-inflammatory cascades and inhibiting anti-inflammatory cascades, 
thus favoring the higher pro-inflammatory state observed in MCI and AD.252  In addition, as 
adiponectin regulates brain metabolism and sensitivity to insulin,253 its reduction may contribute 
to the deregulated glucose metabolism and mitochondrial dysfunction observed in AD.254  
 
In a previous prospective epidemiological study, increased adiponectin levels were associated with 
increased risk of dementia and AD in participants with no evidence of cognitive decline, 
particularly in women.64  However, another population-based study did not find a significant 
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association between adiponectin levels and cognitive impairment in older individuals.66, 67  
Differences in the sample size, characterisation of cognitive status of included participants, and 
presence of clinical comorbidities might explain discrepant results observed among current 
available studies.  In addition, these distinct results observed for adiponectin levels may be, in 
part, due to the heterogeneous nature of the pathologic changes in the preclinical stages of dementia 
and AD.255 Therefore, additional studies, preferentially including participants across multiple 
cohorts, are needed to help to disambiguate the relationship between circulating adiponectin levels 
and the risk of cognitive function.  Thus, the consistency and clinical relevance of adiponectin 
findings remains speculative and requires further study.   
  
Implications and future direction  
Notably, the main implication from the current investigation is that when considering the cognitive 
health of an individual, it is important to consider sex, age, exercise capacity, physical function, 
central adipose tissue, systemic inflammation, and anti-inflammation.  While physical inactivity, 
central obesity, and inflammation are well-known contributors to cognitive decline, our multiple 
regression model suggests that exercise capacity, physical function, central adipose tissue, and 
systemic pro- and anti-inflammatory profile are related to cognitive function, independent of age, 
sex and years of education.  Furthermore, lower exercise capacity was related to higher CRP, 
insulin resistance, and sagittal adipose diameter, as well as lower muscle mass in our cohort, 
suggesting these factors may confound or mediate associations with cognition observed in this and 
other studies.  Similarly, inflammatory mediators such as CRP are related to adipose tissue as 
well as insulin resistance, and may be potentially mediators of the relationship to cognition.  
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Given the above findings, the use of resistance training, or other anabolic interventions which lead 
to improvements in exercise capacity, body composition, CRP, insulin resistance, and adiponectin 
would thus be theoretically beneficial for cognition.  This unique form of exercise has the ability 
to reduce adipose tissue and systematic inflammation, and increase skeletal muscle mass while 
concomitantly increasing exercise capacity.  Indeed, clinical trials utilizing PRT show this to be 
true.187,122-256  Furthermore, improvements in health outcomes following an exercise program can 
be seen in patients with T2DM257 due to improvements in body composition (decreased fat, 
increased skeletal muscle), insulin resistance, inflammation, and exercise capacity.  Importantly, 
hypothesised pathways linking cognitive impairment to T2DM are multiple and complex, 
including insulin resistance in brain,258,259 decreased neuroplasticity260 and cerebral 
atherosclerosis,261 among others.35  Improvements in systemic inflammation, insulin resistance, 
exercise capacity, and body composition are possible with PRT, and could be ultimately beneficial 
to preservation of cognitive function in this cohort therefore. 
 
The cross-sectional nature of this investigation doesn’t allow for the determination of causality.  
In theory, it is possible that low cognitive function causes lower physical activity and therefore 
leads to metabolic deteriorations, low-grade inflammation, and increased fat and reduced muscle 
mass.  Anabolic interventions would still be indicated in this case, as they may serve to combat 
lower exercise capacity associated with insulin resistance, inflammation, and increased fat and 
reduced muscle mass.  To verify our results, large-scale prospective and mechanistic studies are 
needed to examine this important issue of etiology vs. consequence of body composition and 
exercise capacity relationships to cognition.  It is quite likely that bi-directional relationships 
exist between exercise capacity and cognition.  Theoretically higher exercise capacity may be 
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involved in the pathogenesis of cognitive protection mediated by higher physical activity level, 
leading to reduced insulin resistance, inflammation, and reduced fat and increased muscle mass.  
If such causality is determined, development of optimal therapeutic strategies may minimise 
progression of cognitive decline associated with T2DM. 
 
One major limitation of this study is the cross-sectional design; thus causal inferences about these 
relationships cannot be made.  Secondly, due to participant burden constraints, our analyses were 
restricted to the use of the HOMA2-IR, an estimate of fasting hepatic insulin resistance.  Whole 
body insulin sensitivity measures such as a the hyperinsulinaemic/euglycaemic clamp would have 
provided more specific data related to skeletal muscle and adipose tissue insulin sensitivity and 
glucose disposal.  Thirdly, the total fat mass and skeletal muscle mass were measured using BIA.  
Finally, CRP has been shown to independently predict cognitive deficit within this cohort, 52, 262 
and thus its relationship to body composition, insulin resistance and glucose homeostasis is of 
significant interest.  However, it must be considered that other pro-inflammatory cytokines such 
as TNF-α and interleukins 1 and 6 (IL-1 and IL-6) are known to independently be associated with 
cognitive function.263,264  To verify our results, prospective analyses between cognition and 
circulating cytokines are warranted, to establish a better understanding of body composition, 
inflammation, insulin resistance and glycemic control, physical function and exercise capacity in 
relation to cognitive function within individuals with T2D. 
  
5.6 CONCLUSIONS 
Generally speaking, the health status of our cohort was worse than people with diabetes in 
Australia.  They were more obese, and the prevalence of hypertension, raised triglycerides, 
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reduced HDL cholesterol and the use of insulin and oral diabetic medications were all higher than 
people with diabetes in Australia, substantiating the potential generalisability of our clinical trial 
outcomes to this cohort or other Caucasians or other international populations with T2DM 
(external validity).   
 
The muscle strength and power of our cohort were higher than people in the same age group, which 
could be explained by the larger body weight and consequently large fat free mass.  However, the 
overall exercise capacity, represented by 6MWD and physical function assessed by stair climb 
power, of our cohort was more limited than healthy people of a similar age.   
 
Our results suggest the importance of lower exercise capacity and stair climb power for worse 
memory and information processing speed in older adults with T2DM.  We have shown that the 
predictive value of sagittal adipose diameter was independent of, and stronger than that of visceral 
adipose tissue for memory in this cohort.  Our data also demonstrate an association between 
increases in low-grade inflammation assessed by CRP and reductions in total adiponectin and 
HMW adiponectin relative to total adiponectin ratio and poorer cognitive function.  Overall, these 
data expand evidence from animal models and healthy individuals, showing for the first time in 
older adults with T2DM that physical performance, body composition, inflammation, and 
adiponectin are related to cognitive function.  Multiple regressions model included all of these 
factors showed that they were all independently and still significantly related to cognitive function 
adjusted for age, sex, education level, and physical activity level.  Understanding how chronic 
exercise exposure may modify these factors is crucial to advance our understanding and 
optimisation of the physical activity prescription for cognitive health.  
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TABLE 5.1 SAMPLE SIZE CALCULATIONS 
Outcome Experimental 
Mean Change 
(SD) 
Control Mean 
Change (SD) 
 
Effect 
Size (ES) 
Beta Alpha Sample 
Size 
Estimate 
(total 
study) 
Insulin Sensitivity 
(HOMA2-IR) 
-0.6(0.8) 0(0.8) 0.75 0.10 0.05 78 
HbA1c (%) -1.2(1.7) 0(0.2) 0.71 0.1 0.05 86 
Cognition   0.59 0.2 0.05 94 
HOMA2: Homeostasis Model Assessment 2 
IR: Insulin Resistance 
HbA1c: Glycosylated Haemoglobin A1c 
Sample size estimates were driven by hypothesised differences between the experimental and 
control participants in the primary outcomes of the trial: insulin sensitivity and HbA1c, based on 
an average of published studies of in diabetes/obesity.80-83, 85, 116
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS 
______________________________________________________________________________ 
Variable      Total   Men   Women   p-value 
        n=103   n=52   n=51 
______________________________________________________________________________ 
Demographics 
Age (years)      67.9±5.5  68.9±6.0  66.9±4.8  0.070 
Education  
Primary School     3 (2.9 %)  1(1%)   2 (1.9%)  0.546 
High sSchool     46 (44.6%)  19 (18.4%)  27 (26.2%)  0.094 
Tertiary       45 (43.7%)  25 (24.3%)  20 (19.4%)  0.365 
Post-Graduate Study    9 (8.7%)  7 (6.8%)  2 (1.9%)  0.086 
Ethnicity 
Caucasian      99 (96.1%)  49 (47.6%)  50 (48.5%)  0.097 
Asian       4 (3.9%)  2 (1.9%)  2 (1.9%)  0.984 
Marital status  
Married/Defector    59 (57.3%)  35 (34.0%)  24 (23.3%)  0.038 
Widowed      12 (11.7%)  4 (3.9%)  8 (7.8%)  0.206 
Divorced      19 (18.5%)  8 (7.8%)  11 (10.7%)  0.419 
Never Married     11 (10.7%)  5 (4.9%)  6 (5.8%)  0.750 
Separated      2 (1.9%)  0 (0.0%)  2 (1.9%)  0.149 
Smoking-Current    6 (5.8%)  2 (1.9%)  4 (3.9%)  0.387 
Drinking Habit 
None       25 (24.2%)  7 (6.7%)  18 (17.5%)  0.010 
Once a Month     7 (6.8%)  1 (1%)   6 (5.8%)  0.047
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
______________________________________________________________________________ 
Variable      Total   Men   Women   p-value 
        n=103   n=52   n=51 
______________________________________________________________________________ 
Two or Three Times a Month  11 (10.7%)  4 (3.9%)  7 (6.8%)  0.322 
Once or Twice a Week   21 (20.4%)  11(10.7%)  10 (9.7%)  0.846 
Three to Four Times a Week  13 (12.6%)  7 (6.8%)  6 (5.8%)  0.795 
Almost Every Day    25 (24.2%)  21 (20.4%)  4 (3.9%)  0.001 
Health Status 
Normal Weight 
BMI: 18.5 – 24.9 kg/m2   3 (2.9%)  1 (1%)   (1.9%)   0.546 
Overweight 
BMI: 25.0 – 29.9 kg/m2   33 (32.0%)  21(20.4%)  12(11.6%)  0.067 
Obese: 
BMI ≥30kg/m2     67 (65.0%)  30 (29.1%)  37 (35.9%)  0.114 
Cerebral Vascular Disease  3 (2.9%)  3 (2.9%)  0 (0.0%)  0.082 
Depression Score >10   18 (17.5%)  5 (3.9%)  13 (12.6%)  0.034 
Previous history of CVD   19 (18.4%)  14 (13.6%)  5 (4.9%)  0.025 
Hypertension     76 (73.8%)  38 (36.9%)  38 (36.9%)  0.869 
Hyperlipidaemia     45 (43.7%)  17 (16.5%)  28 (27.2%)  0.003 
Diabetes Duration (years)   7.0 (28)   6.3 (25)   7.5 (28)   0.047 
Metabolic Syndrome  
Central Obesity     100 (97.1%)  50 (96.1%)  50 (98.0%)  0.323 
Raised Triglycerides    81 (78.6%)  41 (39.8%)  40 (38.8%)  0.950
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
______________________________________________________________________________ 
Variable      Total   Men   Women   p-value 
        n=103   n=52   n=51 
______________________________________________________________________________ 
Reduced HDL Cholesterol  77 (74.8%)  39 (37.9%)  38 (36.9%)  0.954 
Hypertension     101 (98.0%)  50 (48.5%)  51(49.5%)  0.157 
Diabetes/Raised Fasting   103 (100 %)  52 (50.5%)  51 (49.5%)  0.982 
Plasma Glucose  
IDF Diagnosis of Metabolic  100 (97.0%)  50 (48.5%)  50 (48.5%)  0.569 
Syndrome  
Sedentary (hour/day)    10.9±1.3  11.2±1.2  10.6±1.3  0.046 
Number of Chronic Diseases (n) 5.1±1.9   5.1±2.1   5.1±1.7   0.560 
Number of Medications (n)   6±3    6±3    5±3    0.187 
Number on Insulin     16 (15.5%)  10 (9.7%)  6 (5.8%)  0.296 
Metformin Users     74 (70%)  42 (19%)   32 (31%)  0.040 
Metformin Dosage (mg/day)   1545±659   1504±651   1598±676  0.543 
Glicazide      26 (25.2%)  11 (10.7%)  15 (14.5%)  0.335 
Glicazide Dosage (mg/day)  85.1±61.2  74.5±42.9  92.9±82.7  0.509 
Diet Controlled      18 (17.5%)  5 (4.9%)   13 (12.6%)  0.060 
Exercise Capacity  
Total Muscle Strength (N)  2533.5±854.2 2803.8±870.6 2236.7±702.7 <0.001 
Leg Press (N)     1616.4±464.7 1720.7±474.2 1499.5±428.7 0.459 
Chest Press (N)     326.1±109.3  388.3±106.1  255.9±59.0  <0.0001 
Seated Row (N)     158.4±57.4  183.0±56.8  124.0±35.5  <0.0001
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
______________________________________________________________________________ 
Variable      Total   Men   Women   p-value 
        n=103   n=52   n=51 
______________________________________________________________________________ 
Knee Extension (Nm)   240.8±74.6  288.2±72.6  200.0±53.0  <0.0001 
Knee Flexion (Nm)    191.8±148.2  223.6±160.9  157.3±126.5  <0.0001 
Total Muscle Power (W)   1494.1±447.3 1790.8±796.2  1072.3.3±630.1 <0.0001 
Leg Press      528.0±237.1  675.0±352.9  378.1±243.8  <0.0001 
Chest Press      191.0±114.1  253.5±115.9  127.5±68.6  <0.0001 
Seated Row      312.0±145.0  402.8±130.5  220.2±91.6  <0.0001 
Knee Extension     305.0±144.0  295.8±126.8  204.5±84.0  <0.0001 
Knee Flexion     158.1±16.1  173.7±170.1  141.9±154.7  <0.0001 
Six Minute Walk Distance (m) 545.9±93.2  569.3±92.6  523.0±89.1  0.030 
Physical Performance 
Normal Gait Speed (m/sec)  1.2±0.2   1.2±0.2   1.2±0.2   0.210 
Maximal Gait Speed (m/sec)  1.9±0.3   1.9±0.3   1.8±0.3   0.360 
Chair Stand (sec)    12.1±2.7  11.7±1.9  12.0±3.0  0.350 
Stair Climb Power (W)   370.4±126.6  430.0±129.3  314.9±96.1  <0.001 
Static Balance Total Time (sec) 74.7±7.1  76.2±6.1  74.9±5.7  0.450 
Body Composition 
Stretched Stature (m)    1.69±0.09  1.74±0.06  1.62±0.07  <0.0001 
Body Mass Index (kg/m2)   31.6±5.4   30.3±4.4   32.9±6.0  0.001 
Wait Circumstance (cm)   107.2±11.9  109.1±11.4  105.1±12.2  0.092  
Total Abdominal Adipose   421.6±117.6  412.3±113.4  431.3±110.1  0.416 
Tissue (cm2)
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
______________________________________________________________________________ 
Variable       Total   Men   Women  p-value 
         n=103   n=52   n=51 
______________________________________________________________________________ 
Visceral Adipose Tissue (cm2)   215.0±89.2  258.7±83.4  169.6±70.9  <0.0001 
Subcutaneous Abdominal    206.7±90.4  153.662.4 261.8±82.0  <0.0001 
Adipose Tissue (cm2) 
Sagittal Abdominal Diameter (cm)  27.6±3.9  28.3±3.7  26.8±4.0 <0.0001 
Mid-Thigh Cross Section Area (cm2) 109.4±24.1  127.6±16.8   90.5±13.8  <0.0001 
Thigh Subcutaneous     84.4±47.4  56.8±20.0  113.1±50.5 <0.0001 
Adipose Tissue (cm2) 
Intermuscular Adipose Tissue (cm2) 13.3±6.5  14.0±6.8  12.5±6.2 0.262 
Mid-Thigh Muscle Attenuation  84.1±2.3   84.0±2.2   84.3±2.4  0.480 
Total Fat Mass (kg)     31.8±11.4   28.6±8.9   35.1±12.8 <0.010 
Free Fat Mass (kg)     57.0±10.0  63.3±7.7  50.7±7.8 <0.0001 
Skeletal Muscle Mass (kg)    30.4±4.1   32.0±3.8   28.7±3.6 <0.0001 
Body Fat (%)      35.7±7.2  30.6±5.7  40.0±6.6 <0.0001 
Muscle Mass (%)     34.6±4.0  35.1±3.4  34.2±45.6 0.258 
Habitual Physical Activity Level 
PASE (score)      116±60   121±70   112±48  0.480 
Quality of Life  
SF-36 (0-100) 
SF-36 Physical Component Summary 45.1±9.2  46.8±8.0  43.4±10.1 0.060 
SF-36 Mental Components Summary 48.8±10.8  50.0±9.0  47.5±12.5 0.060
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
______________________________________________________________________________ 
Variable      Total   Men   Women   p-value 
        n=103   n=52   n=51 
______________________________________________________________________________ 
Depressive symptoms 
Geriatric Depression Scale (0/30) 6.90 ± 5.3  6.3 ± 4.6  7.6 ±6.0   0.204 
Cognitive Function 
Word List Memory Score (0/20) 21.3±3.9  19.8±3.7  22.8±3.4  <0.001  
Word List Recall Score (0/10)  7.0±1.8   6.5±1.8   7.6±1.7   0.002 
Word List Recognition Score  10.0 (4.0)   10.0 (4.0)   10.0 (3.0)  0.080 
(0/10) 
Trail Making Test A Score (sec) 40.6±12.6  41.4±12.8  39.8±12.5  0.540 
Trail Making Test B Score (sec) 95.2±42.5  97.6±38.7  93.0±46.2  0.480 
DIFFBA Score (sec)    45.1(267.1)  45.4 (223.6)  44.1(254.8)  0.750 
Modified Mini-Mental State  94.1 ± 4.8  92.2±5.2  95.0±4.0  0.058 
Score (0/100) 
Glucose Metabolism 
Fasting Glucose (mmol/L)  7.3±2.4   7.2±2.3   7.3±2.4   0.850 
HbA1c (%)       7.1±1.1   7.0±1.0   7.2±1.2   0.340 
Fasting Insulin (mU/L)   9.4±4.9   8.7±3.5   10.0±6.0  0.20 
(n=87)    (n=42)   (n=45) 
HOMA2-IR     2.9±1.1   2.8±1.1   3.0±1.1   0.310 
HOMA2-%Beta     110.8±4.5  106.9±39.4  114.5±50.7  0.440 
(n=87)    (n=42)   (n=45) 
Total Cholesterol (mmol/L)  4.4±11.1  4.1±0.8   4.7±1.2   <0.010
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TABLE 5.2 BASELINE CHARACTERISTICS OF GREAT2DO PARTICIPANTS - CONTINUED 
________________________________________________________________________________ 
Variable      Total   Men    Women   p-value 
        n=103   n=52    n=51 
________________________________________________________________________________ 
Serum Triglycerides (mmol/L) 1.7±0.9   1.8±1.1    1.6±0.8   0.121 
Serum High Density Lipoprotein 1.2±0.3   1.1±0.3    1.3±0.4   0.016 
(mmol/L) 
Serum High Density Lipoprotein 2.4±0.9   2.2±0.8    2.6±0.9   0.018 
(mmol/L) 
Low-Grade Systematic Inflammation 
C - Reactive Protein (mg/L)  3.9±4.2   2.9±3.0    5.0±4.9   0.110 
Adipokines 
Serum HMW Adiponectin (ng/ml) 5020.6±4717.7 5346.6±6017.2  4660.1±2780.7 0.652 
Serum Total Adiponectin(ng/ml) 6446.8(18540.0) 6403.2 (16307.7) 6526.5(16998.0) 0.193 
Adiponectin Ratio    0.4 (4.3)  0.4 (4.3)   0.43 (2.9)  0.874 
________________________________________________________________________________ 
Normally distributed data presented as mean ± SD.  Non-normally distributed data presented as 
median (range).  Difference between men and women was assessed via one way ANOVA.  Non-
normally distributed data were log-transformed before use with parametric statistics.  Categorical 
variables we assessed using a Chi-square.  Participants taking insulin were excluded from analyses 
for HOMA2-IR and %Beta 
Participants taking insulin were excluded from analyses for fasting insulin, HOMA 2 Insulin 
Resistance and %Beta. 
CVD: Cardiovascular disease including ischemic heart disease, myocardial infarction and angina 
HOMA2-IR: Homeostatic Model of Assessment 2 of Insulin Resistance  
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HbA1c: Glycosylated haemoglobin 
PASE: Physical Activity Scale for the Elderly 
SF-36: The Short Form (36) Health Survey 
DIFFBA: Difference score Trail Making Test B minus Trail Making Test A 
HMW: High-molecular weight 
% represents percentage 
M: Metre 
Sec: Second 
N: Newton 
W: Watt 
Kg: Kilograms
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TABEL 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
————————————————————————————————————————————————————————— 
Demographics 
Age (year)    -0.33 (<0.01) -0.34 (<0.01) -0.36 (<0.01) 0.29 (<0.01)  0.21 (0.03)  0.14 (0.15)  -0.24 (0.02) 
Education (year)   0.18 (0.08)  0.22 (0.03)  0.21 (0.03)  -0.18 (0.07)  -0.18 (0.08)  -0.25 (0.01)  0.06 (0.55) 
Duration of Diabetes  0.05 (0.61)  0.07 (0.55)   0.04 (0.68)  0.06 (0.55)  0.21 (0.13)  0.20 (0.04)  0.15 (0.19) 
(year) 
Total no of Diseases  -0.05 (0.63)  0.18 (0.08)  0.19 (0.06)  0.01 (0.91)  -0.05 (0.61)  -0.05(0.62)  -0.10 (0.44) 
Total no of Medications -0.19 (0.06)  -0.30 (<0.01) -0.31 (<0.01) 0.04(0.68)  -0.18 (0.11)  0.01 (0.63)  0.07 (0.42) 
SF-36 (0-100) 
Physical Component  0.02 (0.72)  0.16 (0.11)  0.17 (0.10)  -0.13 (0.26)  -0.04 (0.70)  0.05 (0.72)  0.03 (0.79) 
Summary Score (log) 
Mental Component  -0.11 (0.19)  0.06 (0.67)  0.07 (0.51)  -0.10 (0.39)  0.03 (0.71)  0.08 (0.55)  0.20(0.04) 
Summary Score (log) 
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TABLE 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
————————————————————————————————————————————————————————— 
Physical Activity Level 
PASE (score) (log)  0.15 (0.17)  0.01 (0.91)  0.01 (0.92)  0.04 (0.71)  0.14 (0.17)  0.24 (0.03)  0.01 (0.91) 
Depressive symptom 
Geriatric Depression  0.04(0.71)  0.04 (0.67)  -0.03 (0.81)  0.16 (0.10)  0.07 (0.49)  0.11 (0.28)  -0.11 (0.27) 
Scale (0/30) 
Exercise capacity 
Muscle Strength (kg)  -0.21 (0.07)  -0.20 (0.09)  0.17 (0.12)  -0.14 (0.18)  -0.01(0.92)  -0.02 (0.85)  0.24 (0.13) 
Muscle Power (W)  -0.19 (0.11)  -0.14 (0.17)  0.13 (0.25)  -0.13 (0.26)  -0.06 (0.53)  -0.02 (0.73)  0.09 (0.48) 
6 Minute Walk Distance 0.11 (0.29)  0.21 (0.04)  0.10 (0.37)  -0.27 (<0.01) -0.14 (0.22)  -0.04 (0.70)  0.03 (0.69) 
(m)  
Physical Performance 
Balance (sec)   0.11 (0.27)  0.12 (0.24)  0.11 (0.28)  0.13 (0.18)  -0.19 (0.61)  -0.14(0.17)  0.16 (0.17) 
Average Gait Speed  -0.01 (0.86)  0.04 (0.67)  0.06 (0.59)  0.01 (0.88)  0.07 (0.42)  0.12 (0.30)  0.07 (0.51) 
(m/sec) 
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TABLE 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
__________________________________________________________________________________________________________________ 
Maximal Gait Speed  0.11 (0.28)  0.17 (0.10)  0.12 (0.26)  -0.23 (<0.01) -0.21 (0.04)  -0.12 (0.23)  0.13 (0.19) 
(m/sec) 
Stair Climb Power (W) 0.02 (0.81)  0.02 (0.82)  0.04 (0.73)  -0.28 (<0.01) -0.11 (0.25)  -0.05 (0.61)  0.03 (0.78) 
Chair Stand (sec)  0.05 (0.69)  0.01 (0.89)  0.05 (0.63)  0.38 (<0.01)  0.14 (0.17)  -0.09 (0.39)  0.08 (0.44) 
Body Composition 
Body Mass Index  0.12 (0.27)  -0.03 (0.78)  0.05 (0.69)  0.15 (0.19)  -0.11 (0.27)  -0.10 (0.31)  0.19 (0.08) 
(kg/m2) 
Waist Circumstance(cm) -0.20 (0.06)  -0.17 (0.08)  0.07 (0.52)  -0.03 (0.76)  -0.03 (0.76)  -0.04 (0.72)  0.12 (0.26) 
Abdominal Total   -0.01 (0.88)  -0.15 (17)  0.12 (0.24)  -0.05 (0.65)  -0.04 (0.71)  -0.04 (0.70)  0.09 (0.39) 
Adipose Tissue (cm2) 
Visceral Adipose   0.23 (0.02)  -0.26 (0.02)  0.04 (0.71)  0.04 (0.67)  0.03 (0.75)  0.07 (0.47)  0.02 (0.89) 
Abdominal Subcutaneous 0.21(0.04)  0.06 (0.56)  0.10 (0.31)  0.10 (0.32)  -0.08 (0.42)  -0.02 (0.83)  0.01 (0.90) 
Adipose Tissue (cm2)
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TABLE 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
————————————————————————————————————————————————————————— 
Sagittal Adipose   -0.22 (0.02)  -0.28 (0.02)  0.22 (0.03)  -0.04 (0.67)  0.03 (0.75)  -0.07 (0.49)  0.01 (0.89) 
Diameter (cm) 
Mid-thigh Muscular  -0.13 (0.20)  -0.15 (0.16)  0.13 (0.25)  -0.05 (0.60)  0.02 (0.80)  0.07 (0.47)  0.03 (0.76) 
Area (cm2) 
Thigh Subcutaneous  0.19 (0.05)  0.12 (0.19)  0.13 (0.19)  -0.07 (0.54)  0.02 (0.82)  0.03 (0.68)  0.05 (0.60) 
Adipose Tissue (cm2) 
Imtermuscular   -0.12 (0.18)  0.03 (0.74)  0.03 (0.76)  -0.02 (0.87)  -0.02 (0.89)  0.01 (0.92)  0.10 (0.29) 
Adipose Tissue (cm2) 
Mid-thigh Muscle  -0.09 (0.35)  -0.10 (029)  0.11 (0.29)  0.04 (0.72)  0.11 (0.31)  0.13 (0.19)  0.08 (0.55) 
Attenuation 
Body Fat (%)   0.05 (0.64)  0.13 (0.28)  0.12 (0.25)  0.04 (0.72)  0.06 (0.56)  0.01 (0.91)  0.05 (0.64) 
Body Muscle (%)  0.18 (0.08)  0.13 (0.28)  -0.12 (0.24)  -0.03 (0.74)  -0.01 (0.90)  -0.01 (0.92)  0.09 (0.40) 
Free Fat Mass (kg)  -0.15 (0.12)  0.13 (0.20)  0.08 (0.44)  -0.08 (0.44)  0.07 (0.49)  0.14 (0.17)  0.11 (0.30) 
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TABLE 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
————————————————————————————————————————————————————————— 
Skeletal Muscle Mass -0.03 (0.76)  -0.13 (0.20)  0.06 (0.55)  -0.11 (0.28)  0.02 (0.82)  0.09 (0.39)  0.09 (0.39) 
Mass (kg) 
Total Fat Mass (kg) (log) 0.07 (0.48)  -0.08(0.49)  0.02 (0.81)  -0.08(0.49)  -0.06 (0.59)  -0.00 (0.96)  0.15 (0.12) 
Metabolism  
Fasting Glucose   0.12 (0.24)  0.26 (0.01)  0.15 (0.18)  0.11 (0.30)  0.08 (0.43)  0.06 (0.55)  0.09 (0.40) 
(mmol/L) (log) 
HbA1c (%)    0.03 (0.76)  0.19 (0.07)  0.17 (0.10)  0.18 (0.08)  0.10 (0.20)  0.08 (0.49)  0.00 (0.96) 
Fasting Insulin (uM/L) -0.05 (0.64)  0.01 (0.91)  0.08 (0.48)  0.04(0.71)  -0.07(0.48)  -0.05 (0.64)  0.03(0.76) 
(log) 
HOMA 2-IR    0.04 (0.71)  0.10 (0.20)  0.07 (0.48)  -0.04 (0.71)  -0.12 (09.18) -0.06 (0.55)  0.07 (0.48) 
HOMA 2-%Beta   0.04 (0.70)  -0.06 (0.55)  0.09 (0.35)  0.10 (0.20)  -0.18 (0.09)  -0.14(0.18)  0.08 (0.44) 
Inflammation 
C-Reactive Protein  0.08 (0.48)  -0.07 (0.48)  0.12 (0.24)  0.23 (0.04)  -0.00 (0.96)  -0.05 (0.64)  0.00 (0.96) 
(mg/L) (log)
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TABLE 5.3 COGNITION VS. BASELINE CHARACTERISTICS 
————————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS 
r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r (p value)  r(p value) 
————————————————————————————————————————————————————————— 
Adipokines 
Serum HMW   -0.13 (0.25)  -0.17 (0.10)  0.11 (0.28)  -0.07 (0.48)  -0.09 (0.40)  -0.17 (0.10)  0.15 (0.12) 
Adiponectin (ng/ml) (log)  
Serum Total Adiponectin 0.07 (0.50)  0.34(0.01)  0.03 (0.76)  -0.17 (0.13)  -0.03 (0.76)  0.18 (0.09)  -0.07 (0.48) 
(ng/ml) (log) 
Serum HMW/Total  0.01 (0.91)  -0.23(0.91)  0.12 (0.26)  -0.06(0.55)  -0.29(0.13)  -0.42 (0.01)  0.12(0.24) 
Adiponectin Ratio (log)
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HOMA2-IR: Homeostatic model of assessment of insulin resistance 2 
HbA1c: Glycosylated hemoglobin 
WIM: Word List Memory score (0/20) 
WLR: Word List Recall score (0/10) 
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec) 
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score 
3MS: Modified Mini Mental State score (0/100) 
PASE: Physical Activity Scale for the Elderly 
HMW: High-Molecular Weight 
% represents percentage 
M: Meter 
Sec: Second 
N: Newton 
W: Watt 
Kg: Kilograms 
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TABLE 5.4 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND METABOLISM: SUB-STUDY OF GREAT2DO TRIAL 
———————————————————————————————————————————————————————— 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
———————————————————————————————————————————————————————— 
Fasting Glucose (mmol/L) 
Men    0.22 (0.82)  0.17 (0.15)  -0.14 (0.40)  -0.07 (0.62)  0.05(0.74)  0.03 (0.86)  -0.14 (0.33)  
Women    0.15 (0.28)  0.26 (0.07)  0.18 (0.29)  0.33 (0.02)  0.19 (0.18)  0.00 (0.99)  -0.17 (0.25) 
Men and Women  0.06 (0.47)  0.23 (0.02)  0.03 (0.83)  0.17 (0.08) - 0.09 (0.35)  0.09 (0.35)  -0.14 (0.16) 
HbA1c (%) 
Men    -0.13 (0.33)  0.16 (0.20)  0.14 (0.34)  0.04 (0.76)  -0.03 (0.86)  0.04 (0.79)  -0.12 (0.40) 
Women    0.13 (0.38)  0.20 (0.18)  0.04 (0.82)  0.22 (0.13)  0.26 (0.07)  0.00 (0.35)  0.06 (0.71) 
Men and Women  -0.02 (0.82)  0.16 (0.08)   0.10(0.32)  0.14 (0.16)  0.13 (0.20)  0.08 (0.41)  0.04 (0.71) 
HOMA-%Beta  
Men    0.06 (0.60)  -0.05 (0.72)  0.01 (0.99)  0.04 (0.98)  -0.19 (0.24)  -0.23 (0.17)  0.06 (0.70) 
Women    -0.04 (0.75)  -0.09 (0.58)  0.06 (0.55)  -0.21 (0.19)  -0.15 (0.31)  -0.04 (0.75)  0.10 (0.51) 
Men and Women  0.01 (0.92)  0.06 (0.51)  0.06 (0.60)  0.05 (0.63)  -0.04 (0.72)  -0.00 (0.9)  -0.02 (0.89) 
HOMA-IR  
Men    -0.02 (0.88)  0.01 (0.90)  0.26 (0.07)  -0.02 (0.87)  0.01 (0.94)  0.44 (0.78)  -0.07 (0.66) 
Women    0.10 (0.49)  0.10 (0.53)  0.26 (0.07  0.10 (0.52)  -0.08 (0.58)  -0.04 (0.78)  0.03 (0.87) 
Men and Women  -0.02 (0.80)  -0.07 (0.51)  0.26 (0.07)  -0.15 (0.18)  -0.18 (0.09)  -0.12 (0.26)  -0.13 (0.25)
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β-coefficients for relationship between cognitive test scores and metabolic variables after adjusting for age, sex, and years of education for 
combined men and Women: GREAT2DO-substudy 
All baseline metabolism measures were stratified by sex after controlling age and highest years of education: in men and Women: GREAT2DO-
substudy 
HbA1c: Glycated hemoglobin 
HOMA: The Homeostasis Model Assessment  
IR: Insulin resistance 
WIM: Word List Memory score (0/20)   
WLR: Word List Recall score (0/10)    
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec)  
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score  
3MS: Modified Mini Mental State score (0/100) 
% represents percentage 
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TABLE 5.5 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND EXERCISE CAPACITY AND PHYSICAL 
PERFORMANCE: SUB-STUDY OF GREAT2DO TRIAL 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Total Muscle Strength (N) 
Men    -0.17 (0.66)  -0.65 (0.06)  -0.67 (0.06)  0.33 (0.20)  0.17 (0.65)  0.15 (0.68)  -0.17 (0.65) 
Women    -0.43 (0.10)  -0.14 (0.62)  -0.14 (0.64)  -0.33 (0.25)  0.24 (0.37)  0.31 (0.27)  -0.61 (0.06) 
Men and Women  -0.31 (0.20)  -0.42 (0.09)  -0.40 (0.10)  -0.11 (0.62)  0.25 (0.26)  0.30 (0.19)  -0.41 (0.08) 
Total Muscle Power (W) 
Men    -0.03 (0.85)  0.01 (0.98)  0.03 (0.81)  -0.17 (0.19)  -0.05 (0.71)  0.02 (0.86)  0.20 (0.15) 
Women    -0.18 (0.19)  -0.13 (0.34)  -0.13 (0.38)  -0.14 (0.33)  0.11 (0.42)  0.20 (0.16)  -0.18 (0.21) 
Men and Women  -0.07 (0.47)  -0.04 (0.68)  -0.02 (0.88)  -0.18 (0.11)  <0.01 (0.99)  0.09 (0.46)  0.12 (0.38) 
Six Minute Walk Distance (m) 
Men    0.14 (0.40)  0.29 (0.049)  0.20 (0.08)  -0.12 (0.49)  0.22 (0.21)  0.18 (0.25)  -0.03 (0.84) 
Women    -0.00 (0.98)  0.11 (0.46)  0.03 (0.85)  -0.29 (0.06)  -0.24 (0.12)  -0.05 (0.72)  -0.04 (0.87) 
Men and Women  0.07 (0.51)  0.22 (0.04)  0.19 (0.12)  -0.21 (0.05)  -0.02 (0.88)  0.09(0.45)  0.01 (0.93)
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TABLE 5.5 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND EXERCISE CAPACITY AND PHYSICAL 
PERFORMANCE: SUB-STUDY OF GREAT2DO TRIAL - CONTINUED 
___________________________________________________________________________________________________________________ 
Variable     WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
___________________________________________________________________________________________________________________ 
Static Balance (sec)    
Men     -0.00 (0.95  0.04 (0.83)  0.13 (0.41)  0.11 (0.78)  0.11(0.50)  0.13(0.42)  -0.12 (0.45) 
Women     -0.10 (0.52)  0.11 (0.51)  0.03 (0.83)  0.11 (0.51)  0.04 (0.78)  -0.07(0.64)  0.31 (0.04) 
Men and Women   -0.05 (0.60)  0.00 (0.95)  0.09 (0.41)  0.08 (0.49)  0.03 (0.80)  0.03(0.82)  0.07 (0.55) 
Average Gait Speed (m/sec) 
Men     -0.13 (0.43)  0.31 (0.02)  0.17 (0.24)  -0.05 (0.71)  -0.21 (0.19)  -0.24 (0.12)  0.00 (0.96) 
Women     -0.15 (0.33)  -0.10 (0.53)  0.08(0.85)  -0.12 (0.43)  0.01 (0.95)  0.14 (0.36)  0.17 (0.25) 
Men and Women    0.00 (0.97)  0.11 (0.26)  0.14 (0.19)  -0.09 (0.40)  -0.11 (0.31)  -0.05 (0.61)  0.07 (0.52) 
Maximal Gait Speed (m/sec) 
Men     0.07 (0.62)  0.31 (0.02)  -0.14 (0.38)  -0.14 (0.35)  -0.13 (0.42)  0.10 (0.49)  0.03 (0.85) 
Women     0.08 (0.62)  0.04 (0.81)  -0.05 (0.74)  -0.10 (0.59)  -0.08 (0.62)  -0.15 (0.93)  0.04 (0.81) 
Men and Women   0.07 (0.50)  0.17 (0.10)  -0.10 (0.37)  -0.12 (0.27)  -0.09 (0.84)  -0.08 (0.49)  0.04 (0.75)
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TABLE 5.5 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND EXERCISE CAPACITY AND PHYSICAL 
PERFORMANCE: SUB-STUDY OF GREAT2DO TRIAL - CONTINUED 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Chair Stand (sec) 
Men    0.06 (0.73)  -0.07 (0.68)  0.08 (0.65)  0.26 (0.13)  0.12 (0.52)  -0.22 (0.26)  0.02 (0.92) 
Women    0.17 (0.26)  0.17 (0.31)  0.06 (0.51)  0.51 (0.01)  0.12 (0.47)  0.17 (0.31)  0.14 0.31) 
Men and Women  0.10 (0.36)  0.06 (0.60)  0.10 (0.39)  0.34 (0.00)  0.13 (0.30)  -0.15 (0.22)  0.09 (0.43) 
Stair Climb Power (w) 
Men    0.20 (0.22)  0.08 (0.58)  0.08 (0.62)  -0.29 (0.06)  0.05 (0.79)  0.12 (0.49)  0.05 (0.80) 
Women    -0.02 (0.87)  0.12 (0.46)  0.09 (0.69)  -0.21 (0.18)  -0.11(0.50)  0.06 (0.70)  -0.00 (0.99) 
Men and Women  0.12 (0.32)  0.11 (0.36)  0.07 (0.62)  -0.29 (0.02)  -0.03 (0.80)  0.10 (0.45)  0.02 (0.85) 
_________________________________________________________________________________________________________________ 
β-coefficients for relationship between cognitive test scores and exercise capacity and physical performance variables after adjusting for age, 
sex, and years of education for combined men and Women: GREAT2DO-substudy 
All baseline exercise capacity and physical performance measures were stratified by sex after controlling age and highest years of education in 
men and Women: GREAT2DO-substudy 
WLM: Word List Memory score (0/20) 
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WLR: Word List Recall score (0/10)    
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec)*  
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score  
3MS: Modified Mini Mental State score (0/100) 
M: Meter 
Sec: second 
W: Watt 
Min: Minute 
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TABLE 5.6 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND BODY COMPOSITION: SUB-STUDY OF GREAT2DO 
TRIAL  
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Total Abdominal Adipose Tissue (cm2)  
Men    -0.17 (0.29)  -0.16 (0.11)  0.05 (0.67)  -0.04 (0.74)  -0.16 (0.16)  -0.06 (0.58)  0.11 (0.33) 
Women    0.10 (0.50)  -0.04 (0.00)  -0.01 (0.92)  -0.06 (0.69)  -0.05 (0.75)  0.03 (0.83)  0.22 (0.18) 
Men and Women  -0.02 (0.85)  -0.17(0.06)  0.05 (0.29)  0.01 (0.95)  -0.22 (0.14)  0.13 (0.42)  0.22 (0.14) 
Visceral Adipose Tissue (cm2) 
Men    -0.24 (0.12)  -0.32 (0.02)  -0.17 (0.27)  0.10 (0.95)  0.05 (0.78)  0.11 (0.51)  0.25 (0.12) 
Women    -0.24 (0.07)  0.09 (0.52)  -0.19 (0.28)  0.08 (0.61)  -0.12 (0.43)  -0.07 (0.63)  0.02 (0.87) 
Men and Women  0.02 (0.88)  -0.12 (0.26)  -0.11 (0.30)  0.03 (0.81)  0.21 (0.09)  0.00 (0.98)  -0.05 (0.68) 
Subcutaneous Abdominal Adipose Tissue (cm2) 
Men    0.01 (0.92)  -0.30 (0.03)  -0.07 (0.62)  -0.12 (0.41)  -0.15 (0.36)  -0.07 (0.65)  0.07 (0.65) 
Women    -0.09 (0.55)  -0.01 (0.94)  -0.04 (0.77)  -0.06 (0.69)  -0.23 (0.13)  0.12 (0.44)  -0.05 (0.76) 
Men and Women  -0.06 (0.63)  -0.20 (0.08)  -0.11 (0.29)  0.02 (0.40)  -0.13 (0.34)  0.10 (0.34)  -0.05 (0.72)
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TABLE 5.6 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND BODY COMPOSITION: SUB-STUDY OF GREAT2DO 
TRIAL - CONTINUED  
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Sagittal Abdominal Diameter (cm)  
Men    -0.36 (0.00)  -0.35(0.00)  -0.22 (0.12)  0.16 (0.32)  0.14 (0.40)  0.10 (0.56)  0.23 (0.17) 
Women     0.04 (0.76)  0.12(0.39)  -0.04 (0.76)  0.05 (0.74)   0.14 (0.35)  -0.09 (0.54)  0.07 (0.62) 
Men and Women  -0.11(0.19)  -0.21(0.03)  -0.12 (0.72)  -0.06 (0.58)  0.09 (0.43)  -0.01 (0.90)  0.15 (0.17) 
Thigh Muscle Area (cm2) 
Men    0.20 (0.24)  0.00(0.96)  0.13 (0.41)  -0.19 (0.28)  0.04 (0.80)  0.12 (0.51)  0.21 (0.25) 
Women    0.06 (0.67)  -0.08(0.62)  -0.12 (0.49)  0.12 (0.46)  0.03 (0.84)  0.02 (0.71)  0.07 (0.66) 
Men and Women  -0.23 (0.12)  0.00 (0.97)  0.12 (0.49)  -0.06 (0.69)  0.06 (0.68)  0.10 (0.58)  0.16 (0.30) 
Subcutaneous Adipose Tissue (Thigh) (cm2) 
Men    -0.10 (0.52)  0.18 (0.15)  0.08 (0.57)  -0.13 (0.34)  0.04 (0.77)  0.09 (0.24)  0.10 (0.96) 
Women    -0.18 (0.75)  -0.04 (0.92)  -0.05 (0.83)  0.04 (0.82)  0.11 (0.47)  0.18 (0.67)  0.14 (0.62) 
Men and Women  -0.05 (0.68)  0.05 (0.67)  0.02 (0.86)  -0.05 (0.67)  0.10 (0.43)  0.14 (0.26)  0.09 (0.45)
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TABLE 5.6 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND BODY COMPOSITION: SUB-STUDY OF GREAT2DO 
TRIAL - CONTINUED  
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Intramuscular Thigh Fat Area (cm2) 
Men    0.09 (0.51)  0.25 (0.04)  -0.17 (0.23)  -0.02 (0.28)  0.08 (0.59)  0.09 (0.54)  0.23 (0.09) 
Women    0.05 (0.71)  -0.08 (0.58)  -0.23 (0.12)  <0.01 (0.98)  0.06 (0.67)  0.11 (0.46)  -0.07 (0.63) 
Men and Women  -0.04 (0.62)  0.12 (0.17)   -0.04 (0.72) -0.01 (0.93)  -0.02 (0.86)  <0.00 (0.98)  0.13 (0.21) 
Thigh Muscle Density 
Men    -0.24 (0.09)  0.19 (0.18)  0.03 (0.85)  -0.19 (0.28)   0.05 (0.80)  0.04 (0.81)  0.19 (0.22) 
Women     0.02 (0.11)  0.24 (0.19)  0.18 (0.13)    0.12 (0.46)  -0.05 (0.23)  0.16 (0.28)  0.05 (0.75) 
Men and Women  -0.04 (0.66)  0.01 (0.95)  0.12 (0.26)     -0.06 (0.69)  0.03 (0.91)  0.11 (0.29)  0.12 (0.24) 
Skeletal Muscle Mass (kg)  
Men    -0.23 (0.12)  0.00 (0.97)  -0.24 (0.15)  -0.06 (0.69  0.06 (0.68)  0.10 (0.58)  0.16 (0.30) 
Women    -0.23 (0.12)  0.00 (0.97)  0.09 (0.57)  -0.06 (0.69)  0.06 (0.68)  0.10 (0.58)  0.16 (0.30) 
Men and Women  0.08 (0.50)  0.11 (0.35)  0.11 (0.36)  0.12 (0.34)  0.05 (0.66)  0.12 (0.32)  0.20 (0.10) 
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TABLE 5.6 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND BODY COMPOSITION: SUB-STUDY OF GREAT2DO 
TRIAL - CONTINUED  
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Free Fat Mass (kg) 
Men    0.18 (0.28)  -0.08 (0.58)  -0.20 (0.21)  -0.20 (0.25)  0.19 (0.33)  0.07 (0.25)  0.03 (0.04) 
Women    -0.09 (0.57)  -0.14 (0.38)  -0.04 (0.80)  -0.04(0.80)  0.19 (0.23)  0.26 (0.09)  0.03 (0.84) 
Men and Women  0.58 (0.53)  -0.12 (0.35)  -0.10 (0.37)  -0.16 (0.27)  0.02 (0.87)  0.12 (0.41)  0.21(0.15) 
Total Fat Mass (kg)  
Men    0.20 (0.26)  -0.07 (0.64)  -0.18 (0.29)  -0.18 (0.30)  -0.17 (0.35)  -0.07 (0.69)  0.36 (0.04) 
Women    -0.07 (0.66)  -0.15 (0.33)  -0.12 (0.50)  -0.03 (0.85)  0.23 (0.14)   0.29 (0.06)  0.10 (0.54) 
Men and Women  -0.23 (0.12)  0.00 (0.97)  -0.09 (0.41)  -0.06 (0.69)  0.06 (0.68)  0.10 (0.58)  0.16 (0.30) 
%Muscle 
Men    0.12 (0.38)  0.19 (0.12)  0.07 (0.61)  0.09 (0.50)  0.03 (0.79)  -0.04 (0.79)  -0.13 (0.36) 
Women    0.02 (0.86)  0.36 (0.03)  -0.11 (0.48)  -0.06 (0.68)  0.09 (0.55)  06 (0.69)  0.07(0.66) 
Men and Women  0.08 (0.39)  0.13 (0.14)  0.09 (0.37)  0.01 (0.92)  0.06 (0.54)  0.01 (0.91)  -0.03 (0.74) 
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TABLE 5.6 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND BODY COMPOSITION: SUB-STUDY OF GREAT2DO 
TRIAL - CONTINUED  
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Body Mass Index 
Men    0.14 (0.33)  -0.15 (0.13)  0.02 (0.82)     -0.03 (0.77)    -0.11 (0.50)  -0.02(0.88)  0.21(0.25) 
Women    0.03 (0.81)  -0.16 (0.06)    -0.16 (0.32)     0.03 (0.81)  0.10 (0.53)  0.11 (0.44)  0.07 (0.66) 
Men and Women  -0.02 (0.83)  -0.10 (0.50)     0.14 (0.32)     0.20 (0.28)  0.01 (0.93)  0.05 (0.63)  0.16 (0.30) 
Body Weight (kg) 
Men    -0.02 (0.87)  -0.15 (0.27)  0.22 (0.15)  0.17 (0.26)  0.12 (0.42)  0.04 (0.93)  0.31 (0.04) 
Women    0.02 (0.93)  0.11 (0.26)  0.04 (0.91)  0.04 (0.67)  0.02 (0.82)  0.08(0.27)  0.04 (0.80) 
Men and Women  0.02 (0.85)  0.11 (0.26)  0.01 (0.91)  -0.04 (0.67)   0.02 (0.82)  0.08 (0.42)  0.11 (0.29) 
Waist Circumstance (cm) 
Men    0.18 (0.19)  -0.28 (0.03)  -0.22 (0.14)  0.05 (0.72)  -0.03 (0.86)  0.02 (0.88)  0.24 (0.11) 
Women    -0.09 (0.52)  0.01 (0.92)  0.19 (0.19)  0.05 (0.71)  0.09 (0.56)  0.05 (0.75)  0.08 (0.52) 
Men and Women  0.03 (0.77)  -0.13 (0.16)  -0.02 (0.89)  0.02 (0.89)  -0.06 (0.51)  -0.02 (0.84)  0.16 (0.12)
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β-coefficients for relationship between cognitive test scores and exercise capacity and physical performance variables after adjusting for age, 
sex, and years of education for combined men and Women: GREAT2DO-substudy 
All baseline body composition measures were stratified by sex after controlling age and highest years of education in men and Women: 
GREAT2DO-substudy 
WIM: Word List Memory score (0/20)   
WLR: Word List Recall score (0/10)    
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec)*  
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score  
3MS: Modified Mini Mental State score (0/100) 
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TABLE 5.7 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND PSYCHO-SOCIAL, QUALITY OF LIFE, AND PHYSICAL 
ACTIVITY: SUB-STUDY OF GREAT2DO TRIAL 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Physical Activity Scale  
for the Elderly Score (log)   
Men    -0.16 (0.30)  -0.05 (0.71)  0.04 (0.81)  -0.09 (0.55)  0.23 (0.14)  0.30 (0.06)  -0.03 (0.85) 
Women    0.05 (0.77)  0.12 (0.51)  -0.05 (0.76)  0.02 (0.89)  0.25 (0.11)  0.27 (0.10)  0.09 (0.60) 
Men and Women  -0.08 (0.45)  -0.04 (0.70)  0.01 (0.93)  0.04 (0.74)  -0.16 (0.27)  0.29 (0.01)  0.02 (0.85) 
SF-36 PCS (score) (log) 
Men    -0.16 (0.21)  -0.14 (0.29)   0.06 (0.60)  0.24 (0.08)  -0.04(0.81)  -0.11 (0.46)  0.01 (0.98) 
Women    0.10 (0.51)  -0.16 (0.30)  0.05 (0.77)  -0.09 (0.56)  -0.01 (0.51)  -0.08 (0.60)  0.04 (0.81) 
Men and Women  -0.02 (0.85)  -0.13 (0.18)  0.06 (0.52)  0.07 (0.48)  0.07 (0.53)  0.10 (0.35)  0.02 (0.85) 
SF-36 MCS (score) (log)  
Men    -0.06 (0.67)  -0.12 (0.36)  -0.22 (0.13)  0.17 (0.21)  0.19(0.16)  0.17 (0.23)  -0.08 (0.58) 
Women    0.12 (0.37)  0.20 (0.16)  0.16 (0.29)  0.11 (0.49)  0.17 (0.23)  0.25 (0.08)  0.09 (0.55) 
Men and Women  0.04 (0.63)  0.06 (0.50)  -0.04 (0.73)  0.13 (0.17)  0.01 (0.97)  0.07 (0.51)  -0.03 (0.78) 
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TABLE 5.7 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND PSYCHO-SOCIAL, QUALITY OF LIFE, AND PHYSICAL 
ACTIVITY: SUB-STUDY OF GREAT2DO TRIAL - CONTINUED 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Geriatric Depression Scale (0/30) 
Men    -0.10 (0.47)  -0.11(0.41)  -0.20 (0.17)  0.21 (0.12)  0.06 (0.65)  0.06 (0.92)  -0.17 (0.23) 
Women    0.23 (0.10)  0.08 (0.58)  -0.20 (0.14)  0.09 (0.55)  -0.30 (0.04)  -0.32 (0.03)  -0.03 (0.87) 
Men and Women  -0.04 (0.41)  -0.01 (0.99)  0.03 (0.78)  0.15 (0.14)  -0.12 (0.22)  -0.12 (0.09)  -0.10 (0.52) 
_________________________________________________________________________________________________________________
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β-coefficients for relationship between cognitive test scores and exercise capacity and physical performance variables after adjusting for age, 
sex, and years of education for combined men and Women: GREAT2DO-substudy 
All baseline body composition measures were stratified by sex after controlling age and highest years of education in men and Women: 
GREAT2DO-substudy 
WIM: Word List Memory score (0/20)   
WLR: Word List Recall score (0/10)    
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec)*  
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score  
3MS: Modified Mini Mental State score (0/100) 
SF-36: Short Form-36 
PCS: Physical Component Summary 
MCS: Mental Component Summary
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TABLE 5.8 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND INFLAMMATION AND ADIPOKINES: SUB-STUDY OF 
GREAT2DO TRIAL 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
CRP (mg/L) (log) 
Men    -0.01 (0.91)  -0.24 (0.09)  0.10 (0.90)  0.27 (0.06)  0.05(0.72)  -0.05 (0.72)  -0.08 (0.58) 
Women    0.15 (0.38)  -0.02 (0.92)    -0.02 (0.92)  0.34 (0.05)  -0.09 (0.59)  -0.18 (0.28)  0.04 (0.60) 
Men and Women  0.02 (0.83)  -0.15 (0.15)  0.13 (0.44)  0.30 (<0.01)  -0.02 (0.87)  -0.10 (0.35)  0.04 (0.71) 
HMW Adiponectin (ng/ml) 
Men    -0.09 (0.66)  0.49 (0.02)   0.04 (0.84)  0.20 (0.33)  -0.15 (0.50)  0.10 (0.99)  0.02 (0.95)   
Women    0.02 (0.94)  0.17 (0.51)  -0.25 (0.26)  -0.16 (0.52)  0.30 (0.22)  0.41 (0.10)   0.36 (0.15) 
Men and Women  -0.04 (0.73)  0.04 (0.78)  0.06 (0.69)  -0.16 (0.27)  -0.17 (0.27)  0.08 (0.60)  0.19 (0.25)    
Total Adiponectin (ng/ml) (log)  
Men    -0.07 (0.70)  0.12 (0.53)  0.04 (0.87)  -0.23 (0.26)  0.17 (0.41)  0.01 (0.99)  0.14 (0.53) 
Women    0.05 (0.83)  0.59 (<0.01)  -0.26 (0.25)  0.19 (0.44)  0.27 (0.26)  0.41 (0.10)  -0.41 (0.11) 
Men and Women  -0.02 (0.85)  0.25 (0.04)  0.18 (0.11)  -0.21 (0.17)  -0.02 (0.91)  -0.20 (0.90)  0.10 (0.55)
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TABLE 5.8 MULTIPLE REGRESSION OF COGNITIVE TEST SCORES AND INFLAMMATION AND ADIPOKINES: SUB-STUDY OF 
GREAT2DO TRIAL 
_________________________________________________________________________________________________________________ 
Variable    WLM   WLR   WLRE   TMTA   TMTB   DIFFBA  3MS  
β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value)  β (p value) 
_________________________________________________________________________________________________________________ 
Adiponectin Ratio (ng/ml) (log) 
Men    -0.04 (0.83)   -0.15 (0.47) 0.27 (0.22)  0.05 (0.80)  -0.30 (0.15)  -0.49 (0.02)  0.31 (0.15) 
Women    0.02 (0.93)  0.47 (0.05)  -0.14 (0.56)  0.17 (0.51)  -0.24 (0.36)  -0.44 (0.08)  0.01 (0.95) 
Men and Women  -0.04 (0.77)  0.14 (0.15)  -0.16 (0.30)  0.06 (0.80)  -0.25 (0.11)  -0.43 (0.01)  0.06 (0.70) 
_________________________________________________________________________________________________________________
411 
 
 
β-coefficients for relationship between cognitive test scores and CRP variables after adjusting for age, sex, and years of education for combined 
men and women: GREAT2DO-substudy 
All baseline CRP and adiponectin measures were stratified by sex after controlling age and highest years of education in men and women: 
GREAT2DO-substudy 
WIM: Word List Memory score (0/20)   
WLR: Word List Recall score (0/10)    
WLRE: Word List Recognition score (0/10)  
TMTA: Trail Making Test A score (sec) 
TMTB: Trail Making Test B score (sec)*  
DIFFBA score (sec): Difference score between Trail Making Test B score minus Trail Making Test A score  
3MS: Modified Mini Mental State score (0/100) 
CRP: C-reactive protein 
HMW: High Molecular Weight
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TABLE 5.9 MULTIPLE REGRESSIONS OF WORD LIST RECALL AND SERUM 
GLUCOSE FASTING 
____________________________________________________________________
Variable         Standard Co-efficient   p-value 
Age          -0.23       0.01 
Sex           -0.30      0.001 
Years of Education       0.24      0.007 
Serum Glucose Fasting (log unit)   0.23      0.02 
Word List Recall      r2=0.26      p<0.0001 
____________________________________________________________________
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TABLE 5.10 MULTIPLE REGRESSIONS OF WORD LIST RECALL AND SIX 
MINUTE WALK DISTANCE 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.35       0.09 
Sex           -0.24      0.01 
Years of Education      0.24      0.01 
6 Minute Walk Distance     0.22      0.04 
Word List Recall      r2=0.29      p<0.0001 
_____________________________________________________________________ 
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TABLE 5.11 MULTIPLE REGRESSIONS OF TRAIL MAKING TEST A AND SIX 
MINUTE WALK DISTANCE 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.21      0.051 
Sex           -0.03      0.80 
Years of Education       0.19      0.052 
6 Minute Walk Distance     -0.21      0.052 
Trail Making Test A      r2=0.15      p=0.003 
_____________________________________________________________________ 
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TABLE 5.12 MULTIPLE REGRESSIONS OF TRAIL MAKING TEST A AND 
STAIR CLIMB POWER 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.19       0.08 
Sex           -0.15      0.20 
Years of Education      0.15      0.13 
Stair Climb Power      -0.29      0.02 
Trail Making Test A      r2=0.17      p=0.001 
_____________________________________________________________________ 
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TABLE 5.13 MULTIPLE REGRESSIONS OF TRAIL MAKING TEST A AND 
CHAIR STAND  
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.21       0.04 
Sex           -0.02       0.84 
Years of Education       0.20      0.05 
Chair Stand         0.34      0.001 
Trail Making Test A      r2=0.24      p=0.0002 
_____________________________________________________________________ 
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TABLE 5.14 MULTIPLE REGRESSIONS OF TRAIL MAKING TEST A AND C-
REACTIVE PROTEIN 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.30      0.006 
Sex           -0.02      0.88 
Years of Education       0.19      0.07 
C - reactive Protein (log units)   -0.30      0.006 
Trail Making Test A      r2=0.18      p=0.003 
_____________________________________________________________________ 
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TABLE 5.15 MULTIPLE REGRESSIONS OF WORD LIST RECALL AND SERUM 
TOTAL ADIPONECTIN  
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          0.22       0.16 
Sex           -0.24      0.36 
Years of Education       -0.26      0.08 
Serum Total Adiponectin (log)   -0.59      0.005 
Word List Recall      r2=0.33      p=0.01 
_____________________________________________________________________ 
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TABLE 5.16 MULTIPLE REGRESSIONS OF DIFFBA AND SERUM 
ADIPONECTIN RATIO 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          -0.08       0.52 
Sex           0.59      <0.0001 
Years of Education       0.26      0.08 
Serum Total Adiponectin (log)   -0.43      0.01 
DIFFBA        r2=0.33      p<0.0001 
_____________________________________________________________________ 
DIFFBA: Difference score between Trail Making Test B minus Trail Making Test A 
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TABLE 5.17 MULTIPLE REGRESSIONS OF DIFFBA AND PHYSICAL ACTIVITY 
SCALE FOR THE ELDERLY  
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          -0.67       0.51 
Sex           0.07      0.95 
Years of Education       0.26      0.08 
Serum Total Adiponectin (log)   -0.38      0.006 
Scores of PASE       r2=0.210     p=0.002 
_____________________________________________________________________ 
PASE: Physical Activity Scale for the Elderly 
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TABLE 5.18 MULTIPLE REGRESSIONS OF WORD LIST RECALL AND 
SAGITTAL ABDOMINAL DIAMETER 
_____________________________________________________________________ 
Variable         Standard Co-efficient   p-value 
Age          -0.30       0.00 
Sex           0.23      0.02 
Years of Education       0.23      0.01 
Sagittal Abdominal Diameter    -0.21      0.03 
Word List Recall      r2=0.22      p<0.0001 
_____________________________________________________________________ 
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FIGURE LEGENDS 
Figure 5.1: Study Recruitment Flow Chart 
n=sample size 
Figure 5.2: The Relationship between Glucose Fasting and Word List Recall.  
Simple linear regression between glucose fasting and word list recall was analysed.  
Low glucose fasting was significantly associated with be worse Word List Recall.  
Cognitive function was significantly associated with age, years of education, and 
men had lower cognitive function on immediate and delayed memory, information 
processing speed, executive function, pure executive function, and global cognitive 
function than women, age, years of education, and sex were added to the model.  
This relationship remained after for age, sex, and years of education in a multiple 
regression model (r=0.26; p<0.0001).  r and p values were calculated by linear 
regression analysis. 
 
Figure 5.3: The Relationship between Six-Minute Walk Distance and Word List 
Recall.  Simple linear regression between six-minute walk distance and word list 
recall was analysed.  Low six-minute walk distance was significantly associated 
with worse Word List Recall.  Cognitive function was significantly associated with 
age, years of education, and men had lower cognitive function on immediate and 
delayed memory, information processing speed, executive function, pure executive 
function, and global cognitive function than women, age, years of education, and sex 
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were added to the model.  This relationship remained after for age, sex, and years 
of education in a multiple regression model (r=0.54; p<0.0001).  r and p values 
were calculated by linear regression analysis. 
Figure 5.4: The Relationship between Sagittal Abdominal Diameter and Word 
List Recall.  Simple linear regression between sagittal abdominal diameter and 
word list recall was analysed.  Low sagittal abdominal diameter was significantly 
associated with higher delayed memory (word list recall).  Cognitive function was 
significantly associated with age, years of education, and men had lower cognitive 
function on immediate and delayed memory, information processing speed, executive 
function, pure executive function, and global cognitive function than women, age, 
years of education, and sex were added to the model, age, years of education, and sex 
were added to the model.  This relationship remained after for age, sex, and years of 
education in a multiple regression model (r=-0.47; p<0.0001).  r and p values were 
calculated by linear regression analysis. 
Figure 5.5: The Relationship between Six-Minute Walk Distance and 
Information Processing Speed.  Simple linear regression between six-minute walk 
distance and information processing speed was analysed.  Low six-minute walk 
distance was significantly associated with decreased information processing speed.  
Cognitive function was significantly related to age, years of education, and men had 
lower cognitive function on immediate and delayed memory, information processing 
speed, executive function, pure executive function, and global cognitive function than 
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women, age, years of education, and sex were added to the model, age, years of 
education, and sex were added to the model.  This relationship remained after for 
age, sex, and years of education in a multiple regression model (r=-0.39; p=0.003).  
r and p values were calculated by linear regression analysis.   
Figure 5.6: The Relationship between Stair Climb Power and Information 
Processing Speed.  Simple linear regression between stair climb power and 
information processing speed was analysed.  Low stair climb power was 
significantly associated with decreased information processing speed.  Cognitive 
function was significantly associated with age, years of education, and men had lower 
cognitive function on immediate and delayed memory, information processing speed, 
executive function, pure executive function, and global cognitive function than 
women, age, years of education, and sex were added to the model.  This relationship 
remained after for age, sex, and years of education in a multiple regression model (r=-
0.41; p=0.001).  r and p values were calculated by linear regression analysis. 
Figure 5.7: The Relationship between Chair Sand and Information Processing 
Speed.  Simple linear regression between chair stand and information processing 
speed was analysed.  Fast chair stand was significantly associated with higher 
information processing speed.  Cognitive function was significantly associated with 
age, years of education, and men had lower cognitive function on immediate and 
delayed memory, information processing speed, executive function, pure executive 
function, and global cognitive function than women, age, years of education, and sex 
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were added to the model.  This relationship remained after for age, sex, and years of 
education in a multiple regression model (r=0.49; p=0.0002). r and p values were 
calculated by linear regression analysis. 
Figure 5.8: The Relationship between C-reactive Protein and Information 
Processing Speed.  Simple linear regression between C-reactive protein and 
information processing speed was analysed.  High C-reactive protein was 
significantly associated with decreased information processing speed.  Cognitive 
function was significant associated with age, years of education, and men had lower 
cognitive function on immediate and delayed memory, information processing speed, 
executive function, pure executive function, and global cognitive function than 
women, age, years of education, and sex were added to the model.  This relationship 
remained after for age, sex, and years of education in a multiple regression model 
(r=0.42; p=0.003).  r and p values were calculated by linear regression analysis. 
Figure 5.9: The Relationship between Serum Total Adiponectin and Word List 
Recall.  Simple linear regression between serum total adiponectin and Word List 
Recall was analysed.  Lower serum total adiponectin was significantly associated 
with decreased Word List Recall scores.  Cognitive function was related to age, 
years of education, and men had lower cognitive function on immediate and delayed 
memory, information processing speed, executive function, pure executive function, 
and global cognitive function than women, age, years of education, and sex were 
added to the model.  This relationship remained after for age, sex, and years of 
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education in a multiple regression model (r=0.57; p=0.01).  r and p values were 
calculated by linear regression analysis. 
Figure 5.10: The Relationship between serum HMW Adiponectin Relative to 
Total Adiponectin Ratio and Pure Executive Function.  Simple linear regression 
between serum HMW adiponectin relative to total adiponectin ratio and pure 
executive function was analysed.  Lower serum total adiponectin was significantly 
associated with worse pure executive function.  Cognitive function was associated 
with age, years of education, and men had lower cognitive function on immediate and 
delayed memory, information processing speed, executive function, pure executive 
function, and global cognitive function than women, age, years of education, and sex 
were added to the model.  This relationship remained after for age, sex, and years of 
education in a multiple regression model (r=0.57; p<0.0001).  r and p values were 
calculated by linear regression analysis.   
Figure 5.11: The relationship between Physical Activity Scale for the Elderly and 
pure executive function. Simple linear regression between Physical Activity Scale 
for the Elderly and pure executive function was analysed.  Higher s Physical 
Activity Scale for the Elderly was significantly associated with worse pure executive 
function.  Cognitive function was associated with age, years of education, and men 
had lower cognitive function on immediate and delayed memory, information 
processing speed, executive function, pure executive function, and global cognitive 
function than women, age, years of education, and sex were added to the model.  
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This relationship remained after for age, sex, and years of education in a multiple 
regression model (r=0.45; p=0.002). r and p values were calculated by linear 
regression analysis.  
A lower score in word list memory, word list recall, Trail making Test A, Trail 
Making test B, Trail Making test B minus Trial Making Test A, and global cognitive 
function equals poorer function
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FIGURE 5.1 STUDY RECRUITMENT FLOW CHART 
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FIGURE 5.2 SERUM GLUCOSE FASTING VERSUS WORD LIST RECALL 
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FIGURE 5.3 SIX MINUTE WALK DISTANCE VERSUS WORD LIST RECALL 
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FIGURE 5.4 SAGITTAL ABDOMINAL DIAMETER VERSUS WORD LIST 
RECALL 
1
2
3
4
5
6
7
8
9
10
11
W
o
rd
 L
is
t 
R
e
c
a
ll 
(/
1
0
) 
b
a
s
e
lin
e
15 17.5 20 22.5 25 27.5 30 32.5 35 37.5 40 42.5
Abdominal Sagittal Diameter (cm)_Baseline
n=101, r=-0.47, r2=0.22, p<0.0001 
432 
 
FIGURE 5.5 SIX MINUTE WALK DISTANCE VERSUS TRAIL MAKING TEST A 
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FIGURE 5.6 STAIR CLIMB POWER VERSUS TRAIL MAKING TEST A 
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FIGURE 5.7 CHAIR STAND VERSUS TRAIL MAKING TEST A 
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FIGURE 5.8 CRP VERSUS TRAIL MAKING TEST A 
 
CRP: C-reactive protein 
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FIGURE 5.9 SERUM TOTAL ADIPONECTIN VERSUS WORD LIST RECALL 
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FIGURE 5.10 SERUM HMW ADIPONECTIN RELATIVE TO TOTAL ADIPONECTIN RATIO 
VERSUS PURE EXECUTIVE FUNCTION 
 
 
HMW: High–Molecular Weight 
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FIGURE 5.11 PHYSICAL ACTIVITY SCALE FOR THE ELDERLY VERSUS PURE 
EXECUTIVE FUNCTION 
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CHAPTER 6 
THE EFFECTS OF POWER TRAINING ON COGNITION IN OLDER ADULTS WITH 
TYPE 2 DIABETES MELLITUS: A RANDOMISED SHAM EXERCISE CONTROLLED, 
DOUBLE-BLIND TRIAL 
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6.1 ABSTRACT 
Objectives - T2DM has been associated with an increased risk of cognitive impairment and 
dementia.  Our aim of this GREAT2DO sub-study was therefore to assess whether 12 months of 
high intensity, high velocity, progressive resistance training (POWER training) could slow 
cognitive decline in older adults with T2DM.  Our secondary aim was to identify potential 
mechanisms linking POWER training with improved cognitive function in this at-risk group of 
older adults, including changes in metabolic profile, body composition, physical activity levels, 
psychological status, or other clinical characteristics. 
Methods - One-hundred and three participants were randomised to receive either supervised 
POWER training or SHAM exercise 3 days per week for 12 months.  The primary cognitive 
outcomes of this sub-study included measures of memory performance (Word List Memory, Word 
List Recall, and Word List Recognition), information processing speed (Trail Making Test A), 
executive function (Trail Making Test B), pure executive function (Difference scores between Trail 
Making Test B minus Trail Making Test A), and global cognitive function (3MS), analysed via 
repeated measures mixed models adjusted for age, sex, years of education, duration of diabetes, 
Short Form-36 (SF-36) MCS, HbA1c, and cognitive function.  The potential mediators/correlates 
of the hypothesised cognitive changes included measures of insulin resistance and glucose 
homeostasis obtained via Homeostatic Model of Assessment 2 (HOMA2-IR) and glycosylated 
haemoglobin (HbA1c), total fat mass and skeletal muscle mass assessed using bioelectrical 
impedance (BIA), total abdominal adipose tissue, subcutaneous abdominal adipose tissue, visceral 
adipose tissue, sagittal diameter, thigh muscle area, thigh subcutaneous adipose area, intramuscular 
adipose area, and thigh muscle density quantified using computed tomography, serum levels of 
adiponectin and C-reactive protein (CRP), physical performance, depressive symptoms via 
Geriatric Depression Scale (GDS) and physical activity levels via Physical Activity Scale for the 
Elderly (PASE). 
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Results: There were improvements over time in immediate and delayed memory (Word List 
memory and Word List Recall); information processing speed, attention/executive function, and 
global cognitive function.  No significant improvements were found in Word List Recognition or 
pure executive function.  Unexpectedly, POWER training did not significantly improve the 
scores for any cognitive outcomes relative to the SHAM exercise condition.  Instead, SHAM 
exercise significantly improved executive function (TMT-B; p=0.03) and global cognitive function 
(3MS; p=0.04) compared to POWER training.  As hypothesised, but only within the POWER 
group, changes in skeletal muscle mass and thigh muscle area were positively related to better 
scores in Word List Memory and information processing speed (β=0.36, p=0.04, β=-0.34, p<0.05, 
respectively) while no body composition relationships with cognition change were found in Word 
List Recognition, information processing speed, executive function, or global cognitive function.  
Again as expected, increasing serum levels of adiponectin were associated with better global 
cognitive function (β=0.57, p=0.03) in the POWER group, but not in the SHAM group (β=0.10, 
p=0.59). Measurements of HOA2-IR tended to be associated with information processing speed 
(β=-0.36, p=0.06) in POWER group, and were significantly associated with global cognitive 
function (β=-0.40, p<0.01) in SHAM group, as hypothesized.  Measurements of glucose fasting, 
HbA1c, fasting insulin, and HOMA 2 beta function were not associated with any tests of cognition 
in our cohorts.  Improved physical performance, including static balance, chair stand time, stair 
power and gait speed were all significantly related to cognitive improvements, but not in the 
POWER group, and may have been linked to a common mediator or potentially even a result of 
improved cognition after exercise. 
Conclusions - Contrary to our expectations, the results of our study suggest that 12 months of 
POWER training is not better than low intensity SHAM exercise for cognitive outcomes in older 
adults with T2DM.  In fact, both types of exercise significantly improved memory, information 
processing speed, executive function, and global function, and low intensity SHAM exercise was 
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superior to high intensity POWER training for executive function and global function.   
Improvements in cognitive function were associated with skeletal muscle mass, thigh muscle area, 
and physical performance as hypothesised, but only in the POWER group.  Adiponectin increases 
and improved insulin sensitivity were related to better cognition in some domains in both groups.  
Unexpectedly, changes in visceral adiposity did not predict cognitive improvements.  Future 
studies enrolling adults with more cognitive impairment at baseline and non-exercise control 
groups are needed to identify the precise roles of exercise modality and intensity, as well as body 
composition and metabolic adaptations to exercise, on cognitive function in T2DM.   
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6.2 INTRODUCTION 
The prevalence of diabetes mellitus is rising with age, and this condition is projected to affect 435 
million adults globally by 2030.1  T2DM is the most common type of diabetes and represents 90-
95% of all diabetes mellitus.2 Especially in conjunction with obesity, T2DM is characterized by 
resistance to the actions of insulin in target tissues, including skeletal muscle, adipose tissue and 
liver.  Older adults with T2DM have an increased risk of cognitive decline and dementia.3 
Evidence from prospective studies indicates that cognitive function and insulin resistance are 
closely associated.4, 5  Relationships between high HbA1c and cognitive dysfunction have been 
demonstrated in older6 and middle aged7 individuals.  Also, in older patients with T2DM, acute 
deficits in working memory and attention have been observed in the hyperglycaemic state during 
a glucose clamp.8  
 
Many physiological abnormalities associated with T2DM may play a role in the higher risk of 
cognitive impairment in this cohort.  For example, skeletal muscle, the largest reservoir for 
glucose disposal, is important for the maintenance of cognitive function,9 and muscle mass is lower 
in T2DM compared to age-matched controls.10  A previous study in older diabetes adults has 
shown that central obesity is linked to risk of cognitive decline in late life,11 and central obesity is 
a key feature of T2DM.  In addition, anti-inflammatory mediators such as adiponectin are 
secreted from adipose tissue,12 and are known to be lower than normal in T2DM.13  Adiponectin 
plays a role as a regulator of glucose homeostasis and insulin signaling14, 15  Previous findings 
have shown that insulin resistance increases the risk of Alzheimer’s disease (AD), amyloid plaques, 
neurofibrillary tangles and brain atrophy.15-19  By enhancing insulin sensitivity, adiponectin might 
reduce brain pathology and AD risk.  Furthermore, at the cellular level, Chan et al20 reported that 
high concentrations of adiponectin (10 μg/ml) were protective against amyloid beta-induced 
neurotoxicity in Sw-APP transfected SH-SY5Y cells exposed to oxidative stress conditions, 
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further supporting putative cognitive protection related to adiponectin.  Thus, many pathways 
exist for modulation of cognitive function in T2DM. 
 
Exercise is recommended by all consensus panels as central to the treatment of T2DM.21-24  The 
benefits of exercise in T2DM include improved glycaemic control, increased insulin sensitivity, 
decreased adiposity, decreased inflammation, decreased blood pressure, decreased blood lipids, 
physical function (gait speed and balance), and treatment of many common comorbidities, 
including peripheral vascular disease, osteoarthritis, sarcopenia, depression, and cognitive 
impairment.24-27  Thus, it is important to understand and optimise adaptations to exercise in T2DM, 
as well as to identify the physiological mechanisms linking exercise adaptation with improved 
cognitive function in this cohort. 
 
Resistance exercise offers a unique and relatively novel approach to the exercise treatment of 
T2DM and metabolic syndrome.  Progressive resistance training (PRT) is an anabolic form of 
exercise, differing substantially from aerobic exercise in its ability to induce muscle hypertrophy 
and associated metabolic and functional changes.26, 27 Skeletal muscle hypertrophy is thought to 
mediate the metabolic benefits of PRT, by increasing the quality and quantity of skeletal muscle 
available for glucose storage.  It has been shown in randomised controlled trials (RCTs) to 
improve insulin sensitivity, glucose homeostasis, blood pressure, dyslipidaemia, adiponectin, 
markers of inflammation and catabolism, muscle mass, and visceral obesity, which are important 
factors in T2DM that have been associated with a reduced risk of cognitive decline.28-30  Our 
systematic review of the limited evidence available (Chapter 2 and Chapter 3) has shown that 
aerobic exercise has positive cognitive benefits in animals and humans with diabetes mellitus, and 
that improvements in insulin resistance after aerobic exercise were inversely related to improved 
cognitive function in older adults with T2DM.  However, we identified no previous studies 
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investigating the role of anabolic exercise such as PRT on cognitive function in older adults with 
T2DM. 
 
In Chapter 5, we have shown cross-sectional relationships between body composition and 
cognitive function.  Specifically, we have shown that sagittal abdominal diameter best predicted 
cognitive impairment in our older adults with T2DM, while visceral adipose tissue, subcutaneous 
abdominal fat and waist circumference were also inversely related to various cognitive domains in 
men.  In addition, higher fat-free mass was positively related to better cognition in women.  
Given that sarcopenia has been related to both T2DM31 and cognitive impairment,32 and that we 
reported in Chapter 5 better cognition in those with better functional performance partially 
dependent on muscle mass and function (stair climb power, chair stand time, and 6MWD), further 
study of the role of muscle mass and function,  as well as central obesity and cognitive decline in 
T2DM is warranted.  Additionally, we showed in Chapter 5 that higher inflammatory marker C-
reative protein (CRP) and lower adiponectin was related to worse cognitive performance.  Thus, 
identification of potential pro- and anti-inflammatory mediators of cognitive adaptation to exercise 
is needed.  For example, adiponectin improves insulin sensitivity14,15 and vascular function,29 and 
has anti-atherogenic, anti-inflammatory actions30 and cardio-protective effects.33  Thus, reduced 
adiponectin in obesity and diabetes could indirectly influence AD risk through modulation of 
several interrelated systemic factors.   
 
Although recent reports suggest that PRT can attenuate normal age-related cognitive changes and 
deficits associated with mild cognitive impairment34, 35 and dementia,36-38  it has not been 
established whether PRT improves cognition for cognitively normal or near-normal older adults 
with T2DM who are at increased risk of cognitive decline.  The purpose of this report was to 
investigate the effects of a 12-month high velocity PRT program (POWER training) on cognitive 
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function, and the relationship of changes in physical performance, body composition, psychosocial 
status, physical activity, metabolic profile, and inflammatory milieu to changes in cognitive 
function in older adults with T2DM. 
 
6.3 METHODS 
6.3.1 STUDY DESIGN 
The GREAT2DO study is an ongoing double blind randomised, SHAM-exercise controlled 
clinical trial on the insulin resistance and glucose homeostasis effects of 12 months of power 
training versus SHAM exercise, with 5 years of follow-up after the RCT phase.  This 
GREAT2DO sub-study was designed to investigate the effects of power training on cognitive 
function.  Between July 2006 and December 2009, 103 participants were randomised to receive 
12 months of high-intensity, high-velocity power training (POWER) or low intensity, non-
progressive exercise (SHAM training) in addition to usual care.  Study personnel involved in 
collection of outcome measures were unaware of each participant’s assigned group, and 
participants were presented with both forms of exercise as potentially beneficial for health 
outcomes.  Written informed consent was obtained from all participants and Study protocol 
(Ethics Committee Protocol No: X04-0096) was approved by the Sydney South West Area Health 
Service and the University of Sydney Human Research Ethics Committees.  The trial was 
registered with the Australian Clinical Trials Registry (ACTR) (ACTR No: 
ACTRN12606000436572).  The assessments were conducted at Cumberland Campus of the 
University of Sydney in Lidcombe New South Wales (NSW) Australia.  Computerised 
Tomography (CT) Scans were performed at the Radiology Department of RPAH in Camperdown 
NSW Australia.  The exercise training was conducted at Freshwater Rehabilitation in Manly 
NSW Australia or the Centre for STRONG Medicine, Balmain Hospital in Balmain NSW 
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Australia by research staff at each site. 
 
6.3.2 INCLUSIONARY AND EXCLUSIONARY CRITERIA 
Inclusionary criteria were for the GREAT2DO study required participants to be community 
dwelling, 60 years of age or above and sedentary (no progressive resistance training; structured 
exercise ≤ 1/week; less than 150 min/week low or moderate intensity walking or other aerobic 
exercise), and to have been diagnosed with both T2DM and metabolic syndrome.  Participants 
could be treated with diet alone, oral medications, insulin or combination at the time of enrolment, 
without recent changes in medication (<3 months).  Exclusionary criteria for the study were the 
presence of unstable chronic diseases or significant cognitive impairment (defined as diagnosed 
dementia or inability to understand study protocols and sign informed consent), or any 
contraindications to PRT, or being un-willing to commit to a 12-month exercise training program, 
3 times per week.   
 
6.3.3 RECRUITMENT 
Participants were recruited from July 2006 until December 2009 from publicity in media, 
advertisements in local newspapers, General Practitioner (GP) lists, Diabetes Australia newsletters 
and pamphlets, completing the 12-month RCT phase in 2011.  
 
6.3.4 SAMPLE SIZE ESTIMATES 
Sample size estimates were driven by hypothesised differences between the experimental and 
control participants in the primary outcomes of the trial: insulin sensitivity and glycosylated 
hemoglobin A1c (HbA1c), based on an average of published studies of progressive resistance 
training in diabetes/obesity.39-43  Sample size was also sufficient for testing secondary hypotheses 
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regarding all components of metabolic syndrome as well, with > 90% power, alpha of 0.05, 
assuming 10% loss to follow-up (See Table 5.1).  Largest available standard deviations (SDs) 
were used for conservative estimates of effect size (ES).  In our experience in fully supervised 
training of older adults with frailty/chronic disease, dropout averages 10-15% over 12 months.  
Therefore, we inflated sample size needs for approximately 10% drop out rate to account for 
anticipated attrition (n =103).   
 
6.3.5 SCREENING PROCEDURE 
Potential participants underwent initial telephone interview and screening using a questionnaire as 
well as a complete physician history and physical examination.  If eligible after physician 
screening, the remainder of the baseline physical performance testing was completed, followed by 
baseline cognitive tests and CT scan.  If following screening a participant was excluded for an 
abnormal stress test or other acute illness, he or she entered the study following appropriate 
treatment and medical review.  Participants were randomised at the completion of all baseline 
assessments. 
 
6.3.6 RANDOMISATION/ALLOCATION/CONCEALMENT 
Randomisation was at the level of the individual patient, stratified by sex and use or non-use of 
insulin, in blocks of 4 via on a computer-generated randomisation scheme 
(www.randomization.com).  Opaque sealed envelopes were prepared by an independent 
researcher, containing sequential treatment assignments.  Envelopes were opened by each 
participant after completion of all baseline testing or read to participant via telephone. 
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6.3.7 ASSESSMENTS 
Participants were randomised using a 1:1 ratio to a high-intensity resistance exercise (POWER) or 
low-intensity SHAM exercise control group.  Cognitive testing occurred between 8 am and 10 
am at baseline and at 6 and 12 months.  Study personnel involved in collection of outcome 
measures were blinded to randomisation assignment at 0, 6 and 12 months.   
 
6.3.8 DEMOGRAPHICS, HEALTH STATUS, MEDICATIONS AND TREATMENT PLAN 
Participants were asked routine questions to obtain demographic information, as well as their 
current health status relating to the presence of other chronic diseases.  Participants also provided 
a list of all their current medication and dosages.  Each participant’s individual treatment plan 
was then determined and scored as either diet only, oral hypoglycemic only, insulin only or oral 
hypoglycemic and insulin. 
 
6.3.9 INTERVENTION  
Experiment intervention protocol: power training 
The POWER group trained 3 days per week under supervision using pneumatic resistance 
equipment (Keiser Sports Health Equipment, Ltd, Fresno, CA, USA) at two sites.  A version of 
PRT known as power training was used, in which the concentric contraction (lifting) was 
performed as quickly as possible, whereas the eccentric contraction (lowering) was performed over 
4 seconds.  Participants in the POWER group exercised for approximately 45- 60 minutes per 
session. 
 
The exercises targeted large symmetrical muscle groups of the arms, legs, and trunk: seated row, 
chest press, leg press, knee extension, hip flexion, hip extension, and hip abduction.  For each 
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exercise, participants performed three sets of eight repetitions (two sets of eight on each leg for 
hip flexion, hip extension, and hip abduction).  The intensity was set at 80% of the most recently 
determined one repetition maximum (1RM), reassessed every 4 weeks.  When 1RM testing was 
not feasible, resistances were increased by targeting a Borg scale rating of perceived exertion 
between 15 and 18, which approximates 80% of the 1RM. 
 
Control group intervention: SHAM exercise 
SHAM exercise participants were supervised by the same trainers in the same facility, but at 
different hours to avoid contamination and unblinding.  The exercises were presented as 
potentially beneficial and participants were blinded to the investigators’ hypotheses regarding 
efficacy.  These participants performed 3 sets of 8 repetitions on the same machines, but with no 
loading beyond the bar of the machine, using 1-2 second concentric and eccentric contraction 
speed.  No interim 1RM testing and no progression took place.  This regimen has been shown 
to produce minimal changes in muscle function or mass, functional status, mobility, depression, 
aerobic capacity, or other clinical outcomes.43  Low intensity power training has also been shown 
to have no effect on visceral fat, adiponectin, glucose homeostasis, insulin sensitivity, blood 
pressure or bone density, thus providing an ideal SHAM exercise control condition.44, 45 
 
6.3.10 USUAL CARE 
Participants in both groups were given no dietary or pharmacological treatment or counseling, but 
continued to be under the care of their own GPs and consultant physicians for the duration of the 
study.  Any abnormalities uncovered during study assessments were communicated to these 
physicians, but recommendations for treatment adjustments were not made. 
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6.3.11 ADVERSE EVENTS 
Monitoring of adverse events were achieved by weekly questionnaire/interview and proxy 
information was obtained whenever necessary to minimise missing data.  Adverse events 
included any exacerbation of underlying disease, or new onset musculoskeletal, cardiovascular, or 
metabolic abnormality attributed directly to study protocols.   Specific adverse events which 
were routinely monitored included: falls, cardiac events during physical testing and exercise 
training (angina, arrhythmias, blood pressure excursions, clinically significant electrocardiogram 
changes); fatigue, muscle soreness or musculoskeletal injury after resistance or SHAM physical 
training; anxiety during CT scan; pain, bruising, or infection at the venipuncture and biopsy site.  
In addition, participants were asked to report all changes in medications, health care professional 
visits, new diagnoses, acute illnesses, or any new symptoms throughout the 12 months. 
 
6.3.12 OUTCOME MEASURES 
All outcome measures at baseline were administered by blinded assessors.  Each test was chosen 
because of excellent psychometric properties and minimal sensitivity to practice effects of aging 
or early neurodegenerative disease.  Cognitive testing took place in a fed state (after breakfast), 
and before any physical testing on that day to standardize known effects of fasting and acute 
exercise on cognitive performance.  If a participant was acutely ill, the assessment was delayed 
until health stabilised. 
 
Primary Outcomes 
Assessment of global cognitive score 
Global cognition was evaluated using the Modified Mini-mental State Examination (3MS).46  
The 3MS retains the brevity, ease of administration, and objective scoring of the MMS but 
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broadens the range of items and scores from 0-30 to 0-100; a higher score indicates better function. 
 
Assessment of processing speed, attention, and executive function  
The Trail Making Test (TMT)47 is extensively used in neuropsychological assessment of visual 
attention and task switching.  It can provide information about visual search speed, scanning, 
speed of processing, mental flexibility, as well as executive functioning.1 It is also sensitive to 
detecting brain damage and several cognitive impairments such as Alzheimer's disease and 
dementia.48   
 
The test consists of two parts (A and B) 46 that must be performed as quickly and accurately as 
possible.  Trail Making Test A (TMT-A) assesses attention and information processing speed, and 
requires the examinee to draw a line connecting the numbers 1 through 25 in order.  Trail Making 
Test B (TMT-B) consists of encircled numbers and letters; participants were instructed to draw a 
line as quickly and as accurately as possible from 1 to A, A to 2, 2 to B, and so on, until they 
completed the task.  It is considered to assess elements of attention, information processing speed, 
and executive function.  The score on each part represents the amount of time required to 
complete the task.  We recorded the amount of time (s) required to complete each task; a higher 
score indicates worse function. 
 
Apart from these two direct scores, other studies have proposed additional indexes to better 
describe the cognitive skills required to complete the Trail Making Test.  The Trail Making Test 
index score, subtracting Trail Making Test A time from Trail Making Test B time, is meant to 
remove the speed component from the test evaluation49 as an indicator of pure executive function. 
 
Assessment of memory 
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Immediate and delayed memory were assessed using the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) neuropsychological tests.50, 51  Word List Memory tests the ability 
to recall immediately learned lists of words.  Ten printed words are presented to the participant 
who reads them, and afterwards recalls as many as possible.  Three trials are given with alternate 
order of words.  Scores is the total number of correctly recalled words after all three trials.  
Administration time is approximately 5 minutes.  Word List recall is a test of delayed recall.  
After a 5-minute distracting cognitive task, participants are asked to recall as many words as 
possible from previously presented ten word memory task, within a maximum period of 90 seconds, 
with a maximum score of 10 points.  Finally, the Word List Recognition test was performed as an 
additional test of delayed memory.  This is a test of ability to recognize previously presented 
words from distractor words presented at same time.  The 10 original words were randomly 
presented visually, mixed with 10 new words.  Participants were asked to identify the words they 
had seen before.  Score consists of the number of correct “yes” responses and “no” responses, 
with a maximum score of 10 points.  A higher score indicates better function.  Administration 
time requires approximately 5 minutes. 
 
Insulin sensitivity and glucose homeostasis 
We tested HbA1c, C-peptide levels, fasting glucose, and fasting insulin levels in the morning after 
a 12 hour fast.  The Homeostatic Model Assessment 2 computer model52 was used to calculate 
beta cell function (%Beta), insulin sensitivity (IS, %S), and insulin resistance.  C-peptide was 
used for Homeostatic Model Assessment 2 calculations due to the use of long-acting insulin in 16 
participants.  However, ultimately the sixteen participants were omitted from Homeostatic Model 
Assessment 2 calculations because of insulin therapy, because it has not yet been validated in this 
cohort.  Blood samples were taken at Cumberland Campus of University of Sydney in Lidcombe 
NSW Australia, and sent to Douglass Hanly Moir Pathology (DHM) (Macquarie Park, NSW, 
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Australia, www.dhm.com.au) for analysis.   
 
Secondary Outcomes 
The secondary outcomes for this cognitive sub-study included serum results for physical 
performance, body composition, as well as glucose homeostasis, insulin sensitivity, systemic 
inflammation, and adiponectin levels.  These factors were chosen for inclusion based on 
relationships in published literature as well as in our cross-sectional analyses (Chapter 5) with 
cognitive performance. 
 
Physical Performance 
Static Balance 
Six-position static balance test, performed according to Rossiter-Fornoff and colleagues53 was used 
to assess both static and dynamic balance.  The series of static balance stands were done in the 
following order: (1) Wide Stance, (2) Narrow Stance, (3) Semi-tandem Stance, (4) Tandem Stance, 
(5) One Leg, Eyes Open, (6) One Leg, Eyes Closed.  The number of seconds to the nearest 0.01 
seconds was recorded for each position, up to a maximum of 15 seconds, and the sum of all 6 
stances was used in analyses. 
 
Gait Velocity 
Gait velocity was performed using an Ultra-timer (DCPB Electronics, Glasgow, Scotland, UK).  
Participants were asked to walk with any habitual assistive devices at their self-selected normal 
and maximal speed for 2-3 trials.  Gait velocity was defined as the mean of the 2 closest trials. 
 
Walking Endurance 
Six-minute walk distance is used to assess the walking endurance to the nearest 0.1m.  The better 
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of 2 trials 10 days apart was recorded.  The six minute walk test is a proxy for predicting overall 
cardiovascular endurance capacity (aerobic capacity) and in the elderly participant it may be 
determined by muscle strength and endurance, balance, orthopaedic or neurologic abnormalities, 
and other problems.54 
 
Stair Climber 
Maximal stair climb55 was used as a proxy for lower extremity power. Two trials were conducted 
of the 9-step stair climb with 30-60 seconds rest between each trial.  The best of the 2 test results 
was used. 
Power (W) = Body Weight (N) × Height of Stairs (m) / Ascent Time (s) 200 
 
Chair stand  
The five chair stand (sit to up) test, performed according to Guralnik56 and colleagues was used as 
an index for lower extremity power/balance.  Time taken, as well as numbers of stands completed 
were recorded. 
 
Body Composition 
Anthropometry 
Morning fasting stretch stature (wall-mounted Holtain stadiometer, Holtain Limited, Crymych 
Pembs., UK) and naked weight [weight in gown (kg)–weight of gown (kg)] were measured in 
triplicate to the nearest 0.1cm and 0.01kg respectively.  Body mass index (BMI) was calculated 
from fasting naked weight and stretched stature measurements.57  
 
Waist Circumference 
Waist Circumference was obtained with a Lufkin (W606PM) flexible steel tape measure by a 
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number of methods for data collection and the ISAK protocol57 was used for this analysis.  
Measures were recorded by an experienced anthropometrist with technical measurement 
errors<1%. 
 
Bioelectrical Impedance Assessment (BIA)  
All participants were fasting and BIA was performed at a similar time of day for all participants.  
Skeletal muscle mass was determined using the following equation.58 
 Skeletal muscle mass = [0.401 x (height2/BIA + (3.825 x sex) + (0.071 x age)] + 5.102 with 
height in cm, BIA resistance in ohms (average of 3 measures), sex coded 1 for men and 0 for 
women, and age in years.  Total fat mass was determined by using BIA by subtracting lean body 
mass from total mass to determine total fat mass.  Lean body mass was determined using the 
following equation.59   
Lean Body Mass= -4.03 + 0.734(Ht2/BIA) + 0.116(BW) + 0.096(Xc) + 0.984(sex) with height 
(Ht) in cm, BIA resistance in ohms (average of 3 measures), body weight (BW) in kg, X 
 
Computed tomography (CT)  
Scanning (GE High Speed CTI Scanner, Milwaukee, WI) was carried out at the Royal Prince 
Alfred Hospital, Sydney) to quantify total abdominal adipose tissue (cm2) (TAAT), visceral 
adipose tissue (cm2) (VAT), mid-thigh muscle cross sectional area (cm2) (CSA), and mid-thigh 
muscle attenuation (an index of intramyocellular lipid content).   
 
CT scans of the abdomen 
A 1-mm thick slice was taken at the mid-point between the iliac crest and lowest rib (determined 
with the participant supine).   This scan location is concordant with the standing waist 
circumference measurement site used by the International Diabetes Federation (IDF), which is a 
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criteria used by the IDF to classify metabolic syndrome.60 Settings were kV: 100 and mA: 170 with 
a displayed field of view (DFOV) 45 – 48, depending on participant size. 
   
CT scans of the mid-thigh 
A 1-mm slice was performed at the mid-point between the inguinal crease and the proximal pole 
of the patella (measured with the participant supine and hip and knee flexed).  The non-dominant 
leg was then scanned with the leg fully extended and relaxed.  Settings were kV: 100 and mA: 
170 with a field of view (DFOV) optimised to the size of each leg. 
 
Image analysis 
Scan images were analysed according to optical density by a blinded investigator using NIH Image 
software (Version 1.63, National Institutes of Health) programmed with specific macros to 
quantify regional cross-sectional adipose tissue, and muscle area and muscle density.  To 
determine VAT, macros were programmed to select the outer perimeter extending from the 
paraspinal muscles to the anterior abdominal muscles.  The program calculated this measure by 
summing the area within the selected perimeter occupied by pixels with optical density in the range 
of 140 to 240.  Mid-thigh muscle density (unitless measure) was calculated according to a 
specific optical density range (10-113) chosen to best discriminate muscle from fat and bone.  
Bland-Altman coefficient of repeatability, determined using a high level of reliability for intra-
tester and inter-tester analyses using these protocols with no evidence of systematic bias (Chapter 
4). 
 
Assessment of inflammatory markers and adipokines 
High-sensitivity CRP was measured in duplicate by enzyme-linked immunosorbent assay (ELISA) 
(eBIOSCIENCE, Camarillo, CA), with the average value used in statistical analyses. The lowest 
458 
 
detectable concentration was 0.01mg/L, and the intraassay co-efficient of variation was 6.4%. CRP 
analysis was available in 89 participants. 
 
Adiponectin 
During blood sampling, extra blood was sampled and the serum stored for future analysis of serum 
adiponectin.  Serum adiponectin was measured in duplicate by enzyme-linked immunosorbent 
assay (ELISA) (eBIOSCIENCE, Camarillo, CA), with the average value used in statistical 
analyses.  The lowest detectable concentration was 0.01mg/L.  Co-efficient of variation was 
required to be less than 15%, otherwise a third measurement was performed.  The average intra-
assay co-efficient of variation was 7.2%. 
 
Questionnaires 
All questionnaires were interviewer-administered by a trained interviewer, in a private room using 
visual prompts.  All questionnaires were widely used, previously validated questionnaires in 
cohorts similar to this one.  Habitual physical activity levels were assessed using the Physical 
Activity Scale for the Elderly (PASE) questionnaire,61 where higher scores reflect increasing 
amounts of habitual structured and unstructured physical activity.  Depressive symptoms were 
assessed by the Geriatric Depression Scale.62  Health-related quality of life was assessed using 
Version 2 of the Medical Outcome Survey 36-item Short-Form (SF-36) questionnaire.63  
 
6.3.13 COVARIATES 
Covariates specified a priori for inclusion in models of cognitive outcomes were age, sex, 
educational history, as these have been linked to cognitive performance in published literature.64  
Additional covariates were identified from baseline comparisons between treatment groups, with 
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factors that were different between groups by a statistical or clinically relevant amount, and 
potentially related to the dependent cognitive outcome of interest selected for inclusion in 
cognitive outcome models as potential confounders. 
 
6.3.14 STATISTICAL ANALYSES 
Normally distributed data are presented as mean ± SD; non-normally distributed data as median 
(range) or frequencies.  Non-normally distributed data were transformed for use with parametric 
statistics.  Comparisons of baseline characteristics between groups were made using Chi Square 
tests for categorical data and unpaired t-tests for normally distributed continuous data.  For 
primary outcomes, the effect of intervention (POWER vs. SHAM) over time on the cognitive 
functions was investigated in intention-to-treat (ITT) analyses.   
 
Repeated measures mixed models of 6- and 12-month outcomes adjusted for baseline cognitive 
values, age, sex and educational level, and any potential confounders identified were constructed 
to test our primary hypotheses.  We tested for main effects of time and a group × time interaction.  
The post hoc analyses were made between times and groups using the Bonferroni method.  
Relationships of interest and risk factors for changes in cognitive function and other secondary 
outcomes were analysed with simple and multiple linear regression models as appropriate.   
 
All available data from participants who were randomised and received at least one dose of the 
intervention, regardless of compliance, were used for analysis, resulting in an n of 100 for the 
assessment of cognitive changes over time.  The 3 participants who withdrew prior to the first 
intervention session were not included in mixed models, as is the protocol for pharmacological 
studies.  Participants with missing cognitive data were included as long as one cognitive 
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assessment was available, as the mixed models allow for inclusion of these participants without 
imputation.  For regression models, only participants who had data from both of the variables in 
the regression were included, resulting in variable numbers for these analyses, as indicated in 
Tables and Figures.   
 
Relative effect sizes (ES) were calculated as: 
Effect Size = Δ Treatment – Δ Control/Pooled (Treatment + Control) Baseline SD.  Calculations 
of ES were adjusted via Hedges’ bias-corrected effect size for small sample sizes using Coe’s on-
line calculator.65  Effect sizes were interpreted according to Cohen’s interpretation of ‘trivial’ 
(<0.20), ‘small’ (≥0.20 <0.50), ‘moderate’ (≥0.50 <0.80), and ‘large’ (≥0.80) effect size.66  Ninety-
five percent confidence intervals (CIs) for the relative ES were calculated.  For non-normally 
distributed data, median was substituted for mean, and range/4 was substituted for SD.67  The 
statistical analyses were conducted using SPSS software (Version 21; SPSS Inc., Chicago, IL, 
USA).  All statistical significance tests were two-sided, and an alpha-level of 0.05 was considered 
statistically significant. 
 
6.4 RESULTS 
Figure 6.1 with Consolidated Standards of Reporting Trials (CONSORT) flowchart shows the flow 
of participants from the time of screening to study completion at 12 months.  A total of 427 people 
were assessed for eligibility, and 103 (24.1%) of those were eligible for randomisation.  Reasons 
for exclusion were not meeting study criteria (5.6%), medical reasons (2.1%), too young (1.2%), 
too physically active (16.4%), too far to travel (8.2%), inability to commit to the study protocol 
(33.3%), no longer interested in participating (3.5%), work commitments (2.6%) and other (3.0%).  
As shown in Figure 6.1, among 103 study participants, 100 began the intervention, 86 completed 
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their 12-month follow-up, and 14 dropped out (defined as not completing their 12-month 
assessment).   
 
6.4.1 ADVERSE EVENTS 
There were eight adverse events in five participants adjudicated to be related to study procedures, 
seven in the POWER training group and one in SHAM exercise group.  These included three 
syncopal episodes in a man with known syncope, one hamstring strain, one back pain leading to 
dropout, one exacerbation of pre-existing umbilical hernia requiring surgical repair, one 
subscapularis tear in a woman with pre-existing grade IV osteoarthritis/rotator cuff disease 
requiring surgery and partial thickness tear of a rotator cuff muscle managed conservatively.  
Three of the four participants in the POWER group who experienced adverse events did not change 
their training mode and the POWER group had higher attendance than the SHAM group overall.   
No significant difference between the POWER training and the SHAM group in terms of number 
of adverse events was observed (p=0.25).  In addition, data analysis in these participants with 
adverse events did not show an significant differences with any cognitive outcomes compared to 
participants without adverse events (Word List Memory: 3.0±3.6 vs 2.9±3.5, p=0.96, Word List 
Recall: 1.2±1.7 vs 0.98 ±1.5, p=0.25, Word List Recognition 1.0+0.02 vs 1.0+0.03, p=0.56, Trail 
Making Test A:, 1.3±0.21 vs 1.4±0.17, p=0.53, Trail Making Test B: -24.8±25.5 vs 0.7±30.8, 
p=0.26, DIFFBA: -22.8±25.3 vs -2±29.8, p=0.18, 3MS: 1.67±2.08 vs 2.35±4.21, p=0.78).  
Moreover, there were no significant differences in any cognitive domains within the POWER 
group with or without adverse events (Word List Memory: 2.0±3.6 vs 3.0±3.8, p=0.23, Word List 
Recall: 2.0±1.7 vs 1.3±1.5, p=0.46, Word List Recognition: 1.0±0.02 vs 1.0±0.03, p=0.14, Trail 
Making Test A: 1.24±1.78 vs 1.36±1.78, p=0.28, Trail Making Test B:15.9±22.4 vs 6.0±30.3, 
p=0.23, DIFFBA: -17.7±28.4 vs 10.4±30.0, p=0.13, 3MS: 1.67±2.08 vs 0.78±3.09, p=0.63).  
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There is no evidence that the small number of adverse events observed were related the outcomes 
of the study. 
 
6.4.2 BASELINE CHARACTERISTICS AND ADHEREnce 
Participant characteristics are reported in Table 6.1.  Baseline relationships among metabolic 
profile, body composition, exercise and functional performance, inflammation and cognition have 
been previously reported in Chapter 5.  There were no statistically significant or clinically 
meaningful differences between the two groups at baseline for homeostatic model assessment - 
insulin resistance (p=0.14) or any body composition parameters (p=0.30-0.99).  The SHAM 
group had a higher income (p=0.01), and tended to have older age (p=0.09), higher HbA1c 
(p<0.05), higher F-36 Mental Component Summary (p=0.06), and longer duration of T2DM 
(p=0.07).  Conversely, the POWER group had a significantly higher Modified 3MS score 
(p=0.02), and tended to have higher GDS (p=0.10) and higher chest press (muscle strength) 
(p=0.06).  Overall, annual median and range of training adherence for the POWER group 
(including dropouts) was 77.8% (11.2-97.2%), while the median adherence for the SHAM group 
was 83.2% (14.6-98.6%), tending to be higher in the SHAM group (p = 0.09).  Adherence was 
not related to any domains of cognition at baseline (p=0.19-0.99). 
 
6.4.3 CHANGE IN COGNITIVE FUNCTION  
Results of the repeated-measures mixed-effect models across the seven neuropsychological 
assessments are shown in Table 6.2, with significance levels indicated for time effect or time-by-
group interactions.  Contrary to our hypotheses, 3MS increased significantly in the SHAM group 
compared to the POWER group (p=0.04).  In the post hoc analysis, the POWER group showed 
no significant increase in the 3MS score at 12 months compared to at baseline and 6 months 
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(p>0.05) and the SHAM group showed significant increase at 6 months and 12 months compared 
to at baseline (p<0.05) (Figure 6.2).  At 6 months and 12 months, the between-group difference 
in 3MS scores was not significant.  Between-group effect size showed a trivial effect between 
POWER and SHAM group [Effect size -0.06 (-0.45, 0.33)].  Trail Making Test B score improved 
in the SHAM compared to the POWER groups (p=0.03) adjusted for age, sex, education, SF-36 
MCS, and HbA1c.  SHAM group decreased Trail Making Test B score at 6 months and 12 months 
compared to at baseline with post-hoc analysis revealing a significant difference (Figure 3), but no 
difference in the POWER group between baseline, 6 months, and 12 months.  There was a 
significant difference between the groups at 12 months (p<0.05).  Effect size was small between 
POWER and SHAM groups [Effect size 0.44 (0.05, 0.84)]. 
 
Contrary to our hypotheses, there were no differences between the POWER and SHAM group for 
changes in Word List Memory, Word List Recall, Word List Recognition, Trail Making Test A, or 
DIFFBA (p=0.19-0.73) (Table 6.2).  In the post hoc analysis, the POWER group showed 
significant increase in the Word List Memory score at 12 months compared to at baseline and 6 
months (p<0.05) and the SHAM group showed significant increase at 6 months and 12 months 
compared to at baseline (p<0.05).  There were no significant differences between the groups at 
each timepoints (Table 6.2).  The POWER group improved Word List Recall at 6 months and 12 
months compared to at baseline (p<0.05) and SHAM group improved at 6 months compared at 
baseline.  There were no significant differences between the groups at each time points.  Again, 
SHAM group showed a significant decreased Trail Making Test A score at 6 months and 12 months 
compared to at baseline, but no significant difference between at baseline, 6 months, and 12 months. 
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6.4.4 CHANGES IN METABOLIC PROFILE  
Metabolic profile changes are shown in Table 6.3.  Contrary to our hypotheses, there were no 
significant differences in fasting serum glucose, HbA1c, fasting insulin, HOMA2 beta cell function, 
or HOMA2-IR in the POWER group compared to the SHAM group (p=0.13-0.99).  In the post 
hoc analysis, both groups showed similar, significant reductions in HbA1c level at 6 months and 
12 months compared to at baseline (p<0.05).  There were no significant differences between the 
groups at each time points. 
 
6.4.5 CHANGES IN PHYSICAL PERFORMANCE 
Results are presented in Table 6.4.  Using a mixed model, as expected, total muscle strength 
significantly increased in the POWER group compared to the SHAM group (p=0.000).  Over 
time, total muscle strength significantly increased at 6 months and 12 months in POWER group 
compared to at baseline.  There had a significant difference in total muscle strength in POWER 
group compared to SHAM group at 6- and 12- months.  Contrary to our hypotheses, there were 
no differences in any physical performance variables between groups (p=0.11-0.86).  Over time, 
however, there were similar, significant improvements in total strength, habitual gait speed, 
maximal gait speed, chair stand time and stair climb power in both groups.  In the post hoc 
analysis, the POWER group showed significant increase in the habitudinal gait speed at 6 months 
and 12 months compared to at baseline (p<0.05) and the SHAM group showed significant increase 
at 12 months compared to at a baseline (p<0.05).  There were no significant differences between 
the groups at each time points.  SHAM group improved maximal gait speed at 6 months and 12 
months compared to at baseline (p<0.05).  Stair climb power significantly increased in POWER 
group at 12 months compared to at baseline.  At each time points, no between-group difference 
in stair climb power approached statistical significance.  SHAM group also significantly 
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increased in chair stand at 6 months and 12 months compared to at baseline (p<0.05) (Table 6.4).  
In the post hoc analysis, chair stand time significantly declined in both treatment groups at 6 
months compared to at baseline, but there was no difference between POWER and SHAM at each 
time points.  The POWER group increased 6 minute walk distance at 12 months compared to at 
baseline, and SHAM group increased 6 minute walk distance at 6 months compared to at baseline 
(p<0.05).  There were no consistent group differences by POWER and SHAM for either 6 minute 
walk distance at each time points. 
 
6.4.6 CHANGES IN BODY COMPOSITION 
Results are shown in Table 6.5.  As expected, thigh muscle area significantly increased in the 
POWER group compared to the SHAM group (p=0.03), which was the only significant group 
difference in body composition, and was one of our primary hypotheses in this regard.  However, 
there was a trend for a reduction in total abdominal adipose tissue in the POWER group compared 
to the SHAM group (p=0.10), and a similar pattern for reductions in visceral adipose tissue 
(p=0.16) was also present, again suggesting that POWER training may be beneficial as we 
hypothesised, although the study may have been underpowered to show a statistically significant 
difference.   
 
No differences were seen between the POWER and SHAM group for changes in body mass index, 
body weight, skeletal muscle mass, total fat mass, percent muscle mass, subcutaneous thigh 
adipose tissue, sagittal abdominal diameter, subcutaneous thigh fat area, intermuscular fat area, or 
thigh muscular density (p=0.10-0.92).  In post hos analysis, POWER group showed significant 
increase in the mid-thigh muscle at 6 months and 12 months compared to at baseline (p<0.05).  
There were no significant difference between the groups at each timepoints (Table 6.5).  
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Moreover, POWER group showed significant decline in visceral adipose tissue and abdominal 
subcutaneous adipose tissue at 6 months compared to at baseline (p<0.05).  Similarly, POWER 
group also improved total abdominal adipose tissue at 6 months and 12 months compared to at 
baseline (p<0.05).  There was no difference between treatments at each time points.  In post hos 
analysis, Total fat mass declined significant in the POWER group, but there was no difference 
between treatments at each time points (Table 6.5).  POWER and SHAM groups significantly 
decreased body mass index at 6 months compared to at baseline (p<0.05).  There were no 
significant differences between the groups at each time points.  In post hos analysis, Waist 
circumstance significantly declined in both treatment groups at 12 months compared to at baseline 
(p<0.05), the between-group difference in waist circumstance did not approach statistical 
significance at each time point (Table 6.5). 
 
6.4.7 CHANGES IN QUALITY OF LIFE, PSYCHOSOCIAL FUNCTION AND PHYSICAL ACTIVITY LEVEL 
Results are shown in Table 6.6.  Using a mixed model, no significant group differences were 
found for changes in SF-36 MCS (p=0.41), PASE (p=0.30) or GDS (p=0.88), while a trend for 
increases in SF-36 PCS was present, unexpectedly favoring the SHAM group (p=0.06).  In post 
hoc analysis, depressive scores declined in the POWER group at 6 months compared to at baseline 
(p<0.01).  Depressive scores decreased in SHAM group at 6 months and 12 months compared to 
at baseline.  By contrast, there were no significant differences between the groups at each time 
points (p>0.05). 
 
6.4.8 CHANGES IN ADIPONECTIN AND SYSTEMATIC MARKER OF INFLAMMATION 
Results are shown in Table 6.7.  There were no significant differences in the change in HMW 
adiponectin, total adiponectin, ratio of HMW-to-total adiponectin, or CRP in the POWER group 
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compared to the SHAM group (p=0.40, p=0.54, p=0.91, p=0.82, p=0.14, respectively), and all ESs 
were negligible to small.  Neither were there time effects for HMW adiponectin (p=0.66), total 
adiponectin (p=0.54), nor adiponectin ratio (p=0.51), while SHAM group improved CRP at 6 
months compared to at baseline CRP (p<0.05).  There were no consistent group differences by 
POWER and SHAM at each time points. 
 
6.4.9 RELATIONSHIPS BETWEEN CHANGES IN BODY COMPOSITION VARIABLES  
Results are shown in Table 6.8.  Changes in total abdominal adipose tissue and changes in thigh 
muscle area were not related in the POWER group (n=37, r=0.26, p=0.13), but were significantly 
related in the SHAM group (n=43, r=0.35, p=0.02), with both muscle and fat deposts changing in 
direct proportion to each other.  Such a direct relationship might be expected due to generalised 
weight gain from increased dietary intake, for example, whereas an inverse relationship would be 
hypothesised if the changes were related to exercise exposure.  Changes in thigh muscle area 
were not related to changes in subcutaneous abdominal adipose tissue in the POWER group (n=37, 
r=0.25, p=0.11) nor in the SHAM group (n=43, r=0.25, p=0.11).  Finally, total abdominal adipose 
tissue was positively related to changes in subcutaneous abdominal adipose tissue in the POWER 
group (n=37, r=0.67, p<0.0001) and in the SHAM group (n=44, r=0.74, p<0.0001). 
 
6.4.10 CHANGES IN METABOLIC PROFILE AND CHANGES IN COGNITION 
Results are presented in Table 6.9.  Findings were mixed.  Using multiple regression models, 
higher HOMA2-IR tended to be related to worse information processing speed in the POWER 
(n=32, β=0.34, p=0.07), and in the SHAM group (n=36, β=-0.28, p=0.11).  Also, higher 
HOMA2-IR was associated with worse global cognitive function in the SHAM group (n=37, β=-
0.40, p<0.01), but not in the POWER group (n=32, β=-0.10, p=0.55) adjusted for age, sex, years 
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of education, duration of diabetes, SF-36 MCS, cognitive score, and HbA1c. 
 
6.4.11 CHANGES IN PHYSICAL PERFORMANCE AND CHANGES IN COGNITION 
Results are presented in Table 6.10.  Using multiple regression models, as expected, there was a 
direct relationship between increases in total static balance and better global cognitive function 
within the POWER group (β=0.27, p=0.03) (Figure 6.10.1) but this was not present in the SHAM 
group (β=0.02, p=0.89) (Figure 6.10.2), after controlling for age, gender, education, SF-36 MCS 
score, duration of diabetes, and HBA1c.  Similarly, changes in habitual gait speed also tended to 
be directly related to changes in Word List Recall in the POWER group (β=0.35, p=0.06), but 
again, no relationship was present in the SHAM group (n=48, β=-0.09, p=0.54).  Higher stair 
climb power also tended to be related to better pure executive function (n=33, β=0.16, p=0.09) in 
the POWER group (n=37, β=0.12, p=0.50), but not in the SHAM.  By contrast, increased total 
static balance tended to related to better information processing speed in the SHAM group only 
(n=45, β=-0.32, p=0.06), and not in the POWER group (n=35, β=-0.24, p=0.16).  Chair stand 
time was also unexpectedly related to better delayed memory in the SHAM group (n=38, β=0.39, 
p=0.02) (Figure 6.11.2), but again, no relationship was present in the POWER group (n=30, β=0.16, 
p=0.53) (Figure 6.11.2).  Finally, higher total muscle strength was related to better information 
processing speed in the POWER group (n=35, β=-0.41, p=0.03) (Figure 6.28.1), no relationships 
was found in SHAM group (n=44, β=-0.06, p=0.73) (Figure 6.28.2). 
 
Unexpectedly, higher maximal gait speed tended to be associated with worse Word List 
Recognition in the POWER group (β=-0.36, p=0.08).  No 6MWD changes were related to 
changes in any cognitive domains in either the POWER or SHAM group.  Moreover, our data 
did not find any associations physical performance with and executive function in both POWER 
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and SHAM exercise groups (p>0.05). 
 
6.4.12 CHANGES IN BODY COMPOSITION AND CHANGES IN COGNITION 
Results from multiple linear regression models testing explanatory body composition variables on 
cognitive function changes, adjusted for age, sex, educational level, duration of diabetes, HbA1c, 
and cognitive function, are presented in Tables 6.11.  Most muscle compartment changes 
exhibited hypothesised relationships with better cognitive outcomes in the POWER group.  
Higher skeletal muscle mass was positively related to better Word List Memory in the POWER 
group (β=0.36, p=0.03; Figure 6.12.1).  Furthermore, in the POWER group, better information 
processing speed was directly related to higher thigh muscle area (β=-0.34, p<0.05; Figure 6.13.1), 
also as hypothesised.  Similarly, increased free fat mass tended to be related to better Word List 
Memory and Word List Recall (n=36, β=0.32, p=0.08;, n=36, β=0.38, p=0.06, respectively) in the 
POWER group.  The only significant relationship in the SHAM group was that skeletal muscle 
mass was directly related to better global cognitive function (n=44, β=0.20, p<0.05; Figure 6.14.2).   
 
Relationships between changes in adiposity and changes in cognition were contrary to our 
hypotheses.  Unexpectedly, decreased total abdominal adipose tissue area was significantly 
related to worse attention/executive function in the POWER group (TMT- B: n=36, β=-0.40, 
p=0.04; Figure 6.15.1) but not in the SHAM group (TMT- B: n=36, β=-0.40, p=0.04; Figure 
6.15.2).  Similarly, total abdominal adipose tissue area tended to be inversely related to changes 
in pure executive function in the POWER group (n=36, β=-0.34, p=0.09), but again, no 
relationship was present in the SHAM group (n=41, β=-0.05, p=0.78).  Similarly, worse Word 
List Recall was related to decreased subcutaneous abdominal adipose tissue, weight, and body 
mass index in the POWER group (n=37, β=0.39, p=0.03; n=36,  β=0.48, p=0.03; n=36, β=0.44, 
470 
 
p=0.01, respectively; Figure 6.16.1-6.18.1), but again, no such relationships were present in the 
SHAM group (n=44, β=-0.04, p=0.76; n=46, β=-0.20, p=0.13; n=46, β=-0.19, p=0.16, 
respectively; Figure 6.16.2-6.18.2).  Finally, lower total abdominal adipose tissue, visceral 
adipose tissue, body weight, and body mass index were directly related to worse Word List 
Memory (n=42, β=0.35, p=0.01; n=44, β=0.31, p=0.01; n=45, β=0.34, p=0.01; n=46, β=0.38, 
p=0.03; n=47, β=0.41, p=0.03, respectively; Figure 6.19.2-6.22.2) in the SHAM group, but no 
relationships were present in the POWER group (n=37, β=-0.12, p=0.51;  n=37, β=0.14, p=0.44; 
n=37, β=-0.22, p=0.26; n=36, β=-0.11, p=0.56; n=36, β=0.07, p=0.72, respectively; Figure 6.19.1-
6.22.1).  No other body composition relationships with any tests of cognition were observed. 
 
Given the observed correlations between individual body composition parameters (see sections 
above); we identified the body composition outcomes (BMI, total abdominal adipose tissue, 
visceral adipose tissue, abdominal subcutaneous adipose tissue, sagittal abdominal diameter, thigh 
muscle area, and skeletal muscle mass that were related to cognitive outcomes of memory and 
information processing speed in multiple regression models.  To do this, separate multiple 
regression models were constructed with cognitive function (memory and information processing 
speed) as the dependent variable, and with skeletal muscle mass, thigh muscle area and either total 
abdominal adipose tissue, sagittal abdominal diameter, visceral adipose tissue, BMI or abdominal 
subcutaneous adipose tissue as the second independent variable, to investigate whether portion of 
the variance in cognitive function attributed to skeletal muscle mass was independent of BMI, total 
abdominal adipose tissue, abdominal subcutaneous adipose tissue, sagittal abdominal diameter, 
and visceral adipose tissue. 
 
When individual body compartment parameters were added into these multiple regression models, 
change in skeletal muscle mass explained a significant portion of the variance in the change in 
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memory, independently of changes in total abdominal adipose tissue (p=0.66), visceral adipose 
tissue (p=0.35), subcutaneous abdominal adipose tissue (p=0.73), sagittal abdominal diameter 
(p=0.59), and body mass index (p=0.80), none of which retained their original relationship to 
memory observed in univariate regression models.  Thus, the unexpected direct relationships 
between adipose tissue gain and cognitive improvements appeared to have been a spurious finding 
due to the fact that changes in muscle and fat depots were directly associated, and it was only the 
increase in muscle mass that explained the improvement in cognition. 
 
6.4.13 RELATIONSHIPS BETWEEN CHANGES IN PSYCHOSOCIAL, QUALITY OF LIFE, AND PHYSICAL 
ACTIVITY CHANGE IN COGNITION 
Results are presented in Table 6.12 Contrary to our hypotheses, no clear relationships of the 
cognitive scores to either SF-36 MCS and PCS or GDS were observed (p=0.17-0.97).   
 
6.4.14 RELATIONSHIPS BETWEEN CHANGES IN ADIPONECTIN AND INFLAMMATION AND CHANGES IN 
COGNITION 
Results are presented in Table 6.13.   As hypothesised, higher serum total adiponectin 
concentrations were directly related to better global cognitive function, in the POWER group 
(β=0.57, p=0.03; Figure 6.23.1), adjusted for age, sex, years of education, duration of diabetes, 
SF-36 MCS, and HbA1c.  Also in the POWER group, increased total adiponectin expression 
tended to be associated with better Word List Recall (β=0.66, p=0.09).  Results for the SHAM 
group were mixed however.  Increased HMW adiponectin was related to better 
attention/executive function (TMT-B) and pure executive function (n=16, β=-0.65, p=0.03; n=16, 
β=-0.68, p=0.04, respectively; Figure 6.24.2-6.25.2) in the SHAM group.  Unexpectedly; 
however, increased adiponectin ratio was associated with worse Word List Memory in the SHAM 
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group (n=16, β=-0.33, p=0.01; Figure 6.26.2). 
 
Systemic inflammation was also inconsistently related to cognitive changes. Increased CRP was 
related to worsened Word List Recognition in the SHAM group only (n=36, β=0.35, p=0.02; 
Figure 6.27.2), but this relationship was not present in the POWER group (n=29, β=-0.17, p=0.51; 
Figure 6.27.1). 
 
6.5 DISCUSSION 
To our knowledge, this sub-study of GREAT2DO is the first RCT in older people with T2DM to 
test the effect of high intensity, high velocity POWER training compared with low intensity SHAM 
exercise on cognitive function.  Overall, there was no evidence in this cohort that POWER 
training provided additional benefit to cognitive function over that of SHAM exercise, as both 
groups improved over 12 months in most cognitive outcomes.  Unexpectedly, in fact, SHAM 
exercise resulted in significantly greater benefits than POWER training for executive function and 
global cognition.  We have also shown that clinically relevant improvements in cognition in older 
adults with T2DM were predicted by improvements in muscle mass, primarily if achieved via high 
intensity POWER training.  Additionally, increases in adiponectin levels achieved via POWER 
training were related to better cognition, but mixed results were seen for SHAM exercise.  
Reduced inflammation did not improve cognitive outcomes, and in fact was related to worse 
memory in the SHAM group.  The relationship of insulin resistance changes to cognitive 
improvements was inconsistent. 
 
6.5.1 ROLE OF POWER TRAINING ON COGNITION 
A large body of evidence indicates that aerobic training and resistance training enhance healthy 
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brain aging, including cognition, among healthy older adults.68, 69   Previous studies observed that 
12 months of twice-weekly resistance training were strongly associated with better cognitive 
function in cognitively healthy women aged 65–75 years old.70  In contrast to these earlier studies, 
we show no significant improvements in any cognitive domains associated with POWER at 12 
months which were greater than those seen after SHAM exercise.  However, all of the previous 
studies included only young and healthy people,68, 71, 72 and there were no studies looking at the 
cognitive changes after exercise of any type in older adults with or without T2DM. 
 
Several factors might have attenuated intervention differences in cognitive scores in our study 
groups.  Trends for higher baseline quality of life (mental health score), and higher study exercise 
adherence may have contributed to controls performing better than expected.  Most importantly, 
baseline cognition was higher for Word List Memory, Word List Recognition, Trail Making Test, 
and 3MS values in the POWER group compared with SHAM, and that may have limited the ability 
to increase cognitive scores in this group and minimised the difference between groups.   
 
However, we agree that even stability would have been better than what might have been predicted 
from an older cohort with T2DDM and multiple other risk factors for cognitive decline.  Age has 
been related to cognitive function on Word List Memory (r=-0.33, p<0.001), Word List Recall (r=-
0.32, p<0.001), Trail Making Test A (r=0.29, p<0.003), Trail Making Test B (r=0.22, p=0.028), 
and the Modified Mini-mental State Exam (r=-0.24, p=0.02), as reported on page 323 of Chapter 
5.  A statistically significant association was observed between age and the score on all seven 
cognitive tests.  Compared to other previous studies in cognitively intact healthy older individuals, 
the reported cognitive deterioration per year varies from -0.56 to -0.9 for 3MS score,144 0.55 to 
1.56 for Trail Making Test A score (seconds),145 1.1 to 3.2 for Trail Making Test B score 
(seconds),145 -1.3 to -2.5 for Trail Making: B-A Difference score (seconds),145 -1.6 to -1.9 score 
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for CERAD Word List Memory score,50 -0.15 to -0.7 scores for CERAD Word List Recall score,50, 
70 -0.3 to-1 score for Word List Recognition score.50 
 
Therefore, in a 12-month study of persons with clinically diagnosed T2DM, we might have 
expected this degree of decline in performance.  Instead, after 12 months of either low intensity 
SHAM exercise or high intensity POWER training, the performance on these tests improved by 
0.90 to 0.3.4 in 3MS score, -4.30 to -5.55 in Trail Making Test A score (seconds), -0.03 to -0.05 in 
Trail Making Test B score (seconds), 0.04 to -0.04 in Trail Making: B-A Difference score (seconds), 
0.87-1.45 in Word List Memory score, 0.31 to 0.78 in Word List Recall score, 0.01 to 0.04 in Word 
List Recognition score.  It has been shown that in randomised controlled trials that improvements 
in cognitive function may delay onset of cognitive impairment and dementia.146  Therefore, 
improvements in cognitive scores in 3MS, Trail Making Test A score (seconds), Trail Making Test 
B score (seconds), Trail Making: B-A Difference score (seconds), Word List Memory score, Word 
List Recall score, Word List Recognition score in our study corresponds to a reduction of cognitive 
ageing of approximately 1 to 3 years.  
 
6.5.2 ASSOCIATIONS OF METABOLIC PROFILE AND COGNITIVE FUNCTION 
It was expected in the context of previous metabolic research, that metabolic profile changes would 
be prominently related to cognitive outcomes.  Regression analyses (Figure 6.9), notably, show 
that higher insulin resistance tended to be related to worse information processing speed within 
the POWER group only (β=0.34, p=0.07).  Similar findings were reported by Yanagawa et al73 
who found that improvements in HOMA-insulin resistance were related to better cognitive 
function in those who participated in aerobic training (p<0.0.5), with no relationship observed in 
those randomised to a non-exercise control group.  Interestingly, both groups in that trial showed 
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similar significant improvements in global cognitive function (β=-0.32).  This is in agreement 
with our data, which suggest that maintaining, or improving insulin resistance through the use of 
high or low intensity power training may be related to improved cognitive health of older adults 
with T2DM.  These findings suggest that improvements in cognitive function are dependent on 
the improvements in hepatic insulin resistance.  As HOMA2-IR is a measure of hepatic insulin 
resistance, reductions in HOMA2-IR seem to play a modulator role in synaptic transmission, and 
animal models have found insulin to be linked to feeding behavior as well as learning and 
memory.74   In an experimental animal model, rats, after training in a water maze, had increased 
insulin mRNA levels in the hippocampus, as well as increased accumulation of insulin receptor 
proteins.75, 76  There is evidence that insulin plays a role in cerebral glucose utilisation.77, 78  
Insulin may also function as a neuromodulator directing the secretion and reuptake of 
neurotransmitters and affecting learning and memory.79,80  It is thought that impairments in the 
insulin signaling pathway play a role in AD and aging overall.  The HOMA index is clinically 
relevant as it has been shown to reflect whole body insulin sensitivity as measured in clamp 
studies81, 82 and insulin resistance is predictive of cognitive impairments.83  Therefore, further 
investigations into the mechanism by which increases in insulin resistance lead to reductions in 
any tests of cognitive function are needed.  Insulin resistance has been shown to directly cause a 
decrease in insulin degrading enzyme (IDE) in AD,84 potentially contributing to the development 
degradation of amyloid beta, a major part of the AD process, which generates neurofibrillary 
plaques in an animal model, while improvement in insulin resistance through exercise has been 
shown to ameliorate insulin degrading enzyme associated with a greater extent of cerebral amyloid 
beta.83-85  However, we found no associations between HOMA2-%beta function and fasting 
insulin in our participants.  Although our data were widely distributed for most variables, both 
groups were generally near normal for both cognitive function and metabolic values of fasting 
insulin and %Beta function (floor effects), which may have weakened any potential associations.   
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Unexpectedly, insulin sensitivity did not change over time or between groups.  However, glucose 
homeostasis did improve significantly and similarly in both groups over time.  Insulin resistance 
index and glycosylated haemoglobin at baseline were relatively well controlled compared to 
previous studies, which may have attenuated any possible benefits of the intervention on metabolic 
profile (floor effect).  These relationships may be clarified by including a broader range of 
participant characteristics including leaner, obese, inflammation, and adipokines.  
 
There were some other physiological changes in this study which may be beneficial for cognition 
and deserve further exploration. Specifically, POWER training increased skeletal muscle mass and 
adiponectin levels over 12 months.  We have previously reported that skeletal muscle mass plays 
a significant role in insulin resistance, glucose homeostasis and systemic inflammation.6  
Improvement in insulin sensitivity (r=-0.38, p=0.04) and glucose hemostasis may be in part 
mediated by increasing skeletal muscle mass achieved via high intensity power training, as 
described in this GREAT2DO substudy.147  In addition, we are the first to show (in this thesis, see 
p 478)  a relationship between increases in total adiponectin level and reductions in glucose 
control (r=-0.35, p<0.05) after exercise exposure. 
 
Thus, POWER training may improve insulin sensitivity, adiponectin, and glucose level in older 
adults with T2DM.  However, these benefits are not uniform in the intervention group, but appear 
to be associated with robust adaptations of skeletal muscle mass.  Importantly, we have shown 
for the first time that improved executive function was related to increased skeletal muscle mass.  
As not all individuals exposed to POWER increased skeletal muscle mass to the extent required to 
see associated improvements in metabolic profile and cognitive function, there was no group 
difference in cognitive outcomes.  Future studies with a non-exercise control group would likely 
magnify the group differences in muscle mass over time, and potentially result in greater 
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improvements in other physiological factors (e.g., adiponectin, insulin resistance, glucose 
homestasis) which could contribute to better cognition as well. 
 
In contrast to earlier studies, our data demonstrated that neither fasting glucose nor HbA1c were 
related to cognitive changes over 12 months in our cohort, despite the fact had considerably lower 
baseline HbA1c values (7.11%; 54mmol/mol) compared to previous investigations (7.8%; 62 
mmol/mol45 and 8.5%; 69 mmol/mol40, 86), which may have precluded our ability to assess 
relationships between improvements in glucose control and cognitive benefits. 
 
6.5.3 ROLE OF PHYSICAL PERFORMANCE AND COGNITION  
It has been reported that poorer physical fitness and low physical activity are related to cognitive 
impairment in people at risk for diabetes.87  We showed many changes in physical performance 
in both groups, but relationships with cognition were predominantly seen within the POWER 
group.  Regression analyses in our study (Figure 6.10.1) showed that increases in total static 
balance time were related to improvements in global cognitive function within the POWER group 
only (β=0.27, p=0.03), while this relationship was not significant in the SHAM group (Figure 
6.10.2).  Moreover, Higher total physical strength and power was associated the better 
information processing speed and delayed memory (β=0.41, p=0.03) (Figure 6.28.1), but not for 
the SHAM group (β=-0.06, p=0.73).  To our knowledge, this is the first evidence to show that 
improving cognitive function in older people who have already developed type T2DM is 
associated with improved physical performance.  The physical performance tasks which were 
related to better cognition are composite measures of mobility, lower extremity, strength and power, 
balance, and aerobic capacity, underlining the potentionally clinically important impact of 
cognitive function on ability to function independently in this cohort.   
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It is not precisely known how these domains of physical performance and cognition are linked.  
T2DM and its common complication, peripheral neuropathy, may lead to sensory and motor 
deficits, which can result in mobility-related dysfunction, alterations in gait characteristics and 
balance impairments.88  Patients with diabetes and peripheral neuropathy have lower gait velocity, 
decreased cadence, shorter stride length, increased stance time and higher step to step variability 
compared to healthy controls.88  Additionally, cardiorespiratory fitness was an independent 
predictor of balance and cognitive performance in that study.  Similar findings were reported by 
Yoo et al89 who found that an intervention combining cognitive training with physical exercise 
improved balance, which was related to memory.  After the 12-week intervention, the group 
showed significant improvement, compared to the control group, in all the measures studied.   
Furthermore, other studies found that a high level of physical activity during life reduces the risk 
of dementia90  Since physical activity also increases physical performance, such as muscle 
strength, gait speed, functional mobility, and balance,91  it is not surprising that there is a positive 
relationship between physical performance and cognition.92  More specifically, older people with 
better physical performance levels, for example, mobility,93 balance,69 strength,93,94 and aerobic 
fitness,95 have better cognitive functions, such as cognitive flexibility or global cognition.  
Moreover, similar to physical activity, better physical performance, such as balance96 and 
strength,9, 94 also decreases the risk of dementia.100 
 
This longitudinal data extends the baseline cross-sectional associations reported in Chapter 5, and 
suggests that the physical and cognitive benefits change in proportion to each other.  This could 
be because the improved cognition contributes to the improved physical performance.  However, 
it could also be that both adaptations are related to another underlying factor, such as anabolic 
hormone profile or reduction in inflammatory cytokines after POWER training.  Future studies 
are needed to explore the mechanisms underlying this relationship between cognitive and physical 
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function improvements after exercise. 
 
6.5.4 ROLE OF SKELETAL MUSCLE MASS AND COGNITION 
This investigation was also the first to examine the relationships between changes in the expression 
of skeletal muscle bulk and change in cognitive domains.  Multiple regression analyses, notably, 
showed that increases in skeletal muscle mass and thigh muscle area were related to better scores 
in Word List Memory (β=0.38, p=0.03; Figure 6.12.1) and information processing speed (β=-0.34, 
p<0.05; 6.13.1) within the POWER group, respectively.  Similar findings were reported by 
Nourhashemiet al96 who found an association between cognitive impairment and reduced muscle 
mass in women without dementia.  Our data suggest that cognition-related improvements in body 
composition may be predominantly related to the amount of increase in skeletal muscle mass. 
 
Our findings also suggest that skeletal muscle mass may be a more sensitive measure to relate 
body composition to cognitive outcomes than measures of adiposity.  Skeletal muscle mass was 
increased in individuals compared with sham controls and was associated with cognition.  Thus, 
our data present the importance of assessing specific measures of body composition and suggest 
the hypothesis that change in skeletal muscular mass and thigh muscle area may underlie previous 
relationships of specific measures of body composition (lean muscle) with cognitive decline.103  
It should be noted that there was a direct relationship between skeletal muscle mass change and 
global cognitive change in the SHAM group as well, but these muscle-cognitive relationships were 
more extensive in the POWER trainers. 
 
Sarcopenia in the normal ageing process is most strongly linked with age-related reductions in 
muscle mass and physical activity97, 98  Physical inactivity results in a chronic elevation of 
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inflammatory biomarkers,99 which are also observed in patients with dementia and T2DM.100  
Additionally, lower physical activity level is associated with less lean mass.  Skeletal muscle 
mass is the primary site for glucose disposal, and thus it is possible that decreases in skeletal muscle 
simply decrease the available storage depot for glucose and increased insulin resistance, suggesting 
that behavioral changes associated with AD may result in loss of lean mass.   
 
On the other hand, the benefits of exercise in cohorts with T2DM may include improved structural 
and functional changes such as glycaemic control, increased insulin sensitivity, decreased body fat 
content, decreased inflammation, decreased blood pressure, and decreased blood lipids, and 
treatment of many common comorbidities associated with cognitive impairment and ageing.25, 101  
Even after controlling for physical activity levels, however, skeletal muscle mass remained 
independently associated with cognition, suggesting that the decline in physical activity observed 
in our cohort is unlikely to fully explain our results. 
 
An alternative explanation for our observations is that cognitive improvements and muscle 
hypertrophy share common underlying mechanisms.  Cognitive impairment is associated with 
systemic inflammatory abnormalities that are also implicated in sarcopenia.102-105  Although our 
measures of inflammatory processes are limited in this study, we observed an independent 
relationship between skeletal muscle mass and insulin (p<0.05), a well-known anabolic 
hormone106 that may have neurotrophic107 and neuroprotective properties.108  A previous study 
has reported that insulin levels are associated with cognition in early AD.109  Muscle is our largest 
metabolically active organ, thus improving skeletal muscle mass through anabolic exercise may 
improve the metabolic health of older adults with T2DM, and thereby cognition.  Exercise 
enhances insulin sensitivity, an effect which tended to be related to improvements in cognition in 
our POWER group.  Thus, our observation that skeletal muscular mass and insulin levels are 
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interrelated suggests that increased anabolic support to both the muscle and brain may be a 
potential mechanism underlying cognitive benefits.   
 
Progressive resistance training may boost the activity of antioxidant enzymes within skeletal 
muscle and thus be an anti-inflammatory stimulus through this process, enhancing defense against 
damage caused by oxygen reactive specimens and CRP,39, 149  in the long run, modify the function 
of central systems, particularly the hippocampus, amygdala, medial septum, and entorhinal cortex 
(important regions related to memory processed such as consolidation, storage, and recall),109, 110 
as inflammation is known to be damaging to neuronal structure and metabolism.110，   
 
Skeletal muscle is the primary site for glucose disposal, and thus it is possible that increases in 
skeletal muscle mass after POWER training simply increased the available storage depot for 
glucose in our study,147 which could ultimately lead to improved brain plasticity and cognition.  
In addition, part of the hypertrophic stimulus resulting from PRT or POWER training is attributable 
to increases in IGF-1.149  Mechanical stimulation of skeletal muscle results in the local production 
of two isoforms of IGF-1; IGF-1E, which is similar to that derived from hepatocytes and 
contributes to increases circulating IGF-1.150  IGF-1 management may play a role in cognitive 
function.  It is therefore possible that a potential link between augmentation of skeletal muscle 
mass and better cognitive function exists.   
 
6.5.5 ROLE OF ADIPOSE TISSUE ON COGNITIVE PERFORMANCE 
This investigation was also the first to examine the relationships between detailed measurements 
of adiposity and relative deficits in cognitive function after resistance training in older people with 
T2DM.  We unexpectedly found that decreased total abdominal adipose tissue subcutaneous 
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abdominal adipose tissue were significantly associated with worse executive function and Word 
List Recall within the POWER group.  Reductions in total abdominal adipose tissue (Figure 
6.19.2), visceral adipose tissue (Figure 6.20.2), and sagittal diameter were also related to worse 
Word List Memory within the SHAM group.  It is likely that this was mediated through reduction 
in body mass index within the POWER and SHAM group.  This probably reflects the fact that 
our participants with higher BMI also had higher amounts of muscle in addition to higher amounts 
of fat, either from the increased thigh muscle required to support increased weight, or from fatty 
infiltration of muscle.  Supporting this hypothesis, we found no associations between total 
abdominal adipose, visceral adipose tissue, and sagittal diameter and memory when controlling 
for BMI or skeletal muscle mass.  To our knowledge no other studies have examined these 
relationships in such detail between regional and whole body adiposity, skeletal muscle and 
cognitive function in older adults with T2DM, and these findings require replication and further 
investigation. 
 
6.5.6 RELATIONSHIP BETWEEN PSYCHOSOCIAL STATUS, PHYSICAL ACTIVITY LEVEL AND COGNITION 
Unexpectedly, reductions depressive symptoms were not related to improvements in cognitive 
function.  Others have shown that depression may be associated with cognitive deficits.111  
Depression has also been reported to result in greater cognitive impairment in individuals with 
diabetes than in participants without diabetes,112 with the greatest differences in 
attention/information processing speed and executive functioning.  Our cohort had normal scores 
on the GDS on average, likely precluding such relationships however.  
 
Changes in SF-36 MCS were not related to changes in cognitive function, and did not change 
significantly over time or between groups.  This is contradictory to previous cross-sectional data 
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showing a direct relationship between SF-36 MCS and cognition in older adults with T2DM,113 
suggesting that reductions in SF-36 MCS could either lead to, or result from, cognitive dysfunction.  
It is likely that in our study, as quality of life was close to normal at baseline, it may have not 
improved or been linked to cognition due to ceiling effects.  Similarly, changes in SF-36 PCS 
were not associated with changes in cognitive function, likely for similar reasons. 
 
A large body of evidence indicates that higher physical activity levels are associated with healthy 
brain ageing, including cognition, among healthy older adults.114, 115  In a previous study,116 
greater levels of physical activity, including walking, were strongly associated with better 
cognitive function in 18,000 Nurses’ Health Study participants who were generally healthy.  
However, we did not find positive effects of our interventions on physical activity level or 
relationships to cognitive function in either study group of GREAT2DO.  It is possible that the 
self-report PASE tool was insufficiently sensitive to change or precise enough to delineate such 
changes or relationships, particularly in a cohort as sedentary as ours.  Accelerometry data would 
be better suited to testing these hypotheses in longitudinal studies of older adults, particularly if 
memory impairment may cause recall bias in the cohort.  Therefore, additional studies are needed 
to investigate the potentially bi-directional relationship between physical activity levels and 
cognitive function, and define the mechanistic pathways linking these two domains. 
 
6.5.7 RELATIONSHIP BETWEEN ADIPONECTIN AND CRP LEVELS AND COGNITION 
This is the first report of increased circulating levels of adiponectin after power training in older 
people with T2DM.  Multiple regression models showed that higher circulating levels of total 
adiponectin independently predicted better global cognitive scores within the POWER group 
(β=0.57, p=0.03).  This is in agreement with cross-sectional data,116 showing strong positive 
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relationships between total adiponectin levels and cognition. 
Increases in HMW adiponectin also predicted improvements in executive function.  This is 
contradictory to a previous cross-sectional data showing a relationship between higher HMW 
adiponectin and worse cognition in older adults with mild cognitive impairment.116, 117  However, 
consistent with our data, previous investigations into the effects of exercise in older adults have 
shown adiponectin to have positive effects on neurogenesis and cognitive function.6, 117, 118  
Several mechanisms could explain our observations.  Adiponectin has a neuroprotective effect 
on hippocampal neurons.6, 117, 118  Treatment with adiponectin preserves the integrity of the 
blood–brain barrier and has a neuroprotective effect on hippocampal neurons.118  Moreover, 
adiponectin plays a direct protective role against atherosclerotic vascular change, and loss of 
effects enhances endothelial dysfunction in the brain.  Circulating adiponectin is strongly linked 
to protection against endothelial cell damage.119  In addition, adiponectin plays a role in the 
pathogenesis of multiple sclerosis and AD.120, 121  Taken together, these findings suggest that the 
brain, vascular factors, and adiponectin interact and reinforce each other through mechanisms that 
may be associated with neural and vascular protective effects related to cognitive function.   
 
Adiponectin is a protein hormone secreted predominantly by adipose tissue and modulates insulin-
sensitizing, glucose control, anti-inflammatory and anti-oxidant properties.122, 123   Our data 
showed that the change in serum circulating levels of total adiponectin in the POWER groups 
tended to be associated with improved executive function (p=0.09).  Increase in total adiponectin 
levels was associated with improved %beta cell (r=0.3, p<0.05) and reduced HbA1c (r=-0.35, 
p<0.05) in our cohort.  Insulin resistance in particular has been studied124 and may mediate, 
cognitive function through modulation of hippocampal synaptic plasticity,125 neuroinflammation 
and subsequent protein deposition.20   Insulin resistance has been implicated in cognitive 
dysfunction in neurologically normal older adults, even in the absence of silent microvascular 
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disease on MRI.126, 127  In addition, we are the first to show a relationship between increases in 
total adiponectin level and reductions in glucose control (r=-0.35, p<0.05) and increase in %beta 
cell (r=0.3, p<0.05) after exercise exposure, as well as between increases in adiponectin and 
improvements in cognition (β=0.57, p=0.03).  In our study, those in the POWER group who 
increased skeletal muscle mass increased their total adiponectin compared to those who decreased 
their skeletal muscle mass in the SHAM group (p=0.10).  It appear to be associated with robust 
adaptations of skeletal muscle mass although there were no significant difference between change 
in skeletal muscle mass and adiponectin.  Adaptations of skeletal muscle mass may potentially 
mediate metabolic profile and adiponectin which contribute to better cognition as well.  
 
Another potential mediating factor is that POWER can result in a decrease in adiposity.  Adipose 
tissue is a metabolically active tissue and source of a variety of hormones, such as leptin and 
adiponectin.  Adiponectin is an effective insulin sensitizer; and circulating levels are inversely 
correlated to insulin resistance, metabolic syndrome, obesity, type 2 diabetes, cardiovascular, and 
inflammation.  BMI is inversely related to circulating adiponectin.  Reducing adiposity may 
increase adiponectin levels, thus mediating effects of insulin, inflammation, and glucose control 
on cognitive function.  In agreement with this, as shown in our own data, increases in adiponectin 
were related to reductions in HbA1c. 
 
It is possible that decreased adiponectin level in T2DM is a medicator of cognitive decline in this 
cohort therefore.  Thus, increase in total adiponectin and HMW adiponectin through exercise may 
be a promising therapeutic target to alleviate Alzheimer's disease pathologies such as apoptosis 
and cognitive decline and dysfunctional brain insulin system.  In our study, adiponectin was not 
improved significantly by exercise, although other studies have been positive in this regard.  
Future studies should compare the relative efficacy of different modes, intensities, and doses of 
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exercise on this factor which may provide a strong link between central obesity, insulin resistance, 
and cognition in the older adult. 
 
After 12 months, no significant relationship between reduced CRP and better cognitive function 
was observed after controlling for potential confounding factors.  Some previous literature has 
shown PRT to be an effective mode of exercise to reduce systemic inflammation,86,128 and this is 
also true in adults with T2DM, and may be related to cognitive processes.129  However, there is 
also a report of no reduction in systemic inflammation in response to PRT , reviewed here.129 
Although some longitudinal studies have found associations specifically between increased CRP 
level and incident cognitive decline,129 others have revealed conflicting results, including minimal 
or no overall association with incident decline in memory,130-132 dementia,133 or 
neuropsychological test performance.134, 135  Figure 7.1.1 shows that improvements in Word List 
Recognition following POWER training were related to reductions in CRP.  Compared with other 
studies of cognition and CRP, our median CRP level at baseline within participants in the POWER 
group of 2.5 mg/L was much higher than in some other studies of dementia and memory, 
suggesting its potential relevance in high risk cohorts with cardiovascular disease, for example.  
Our findings support the utility of further refining an anti-inflammatory intervention to reduce 
overall cardiovascular risk and cognitive decline within individuals with T2DM.  This possibility 
requires further exploration. 
 
6.5.8 LIMITATIONS AND FUTURE DIRECTIONS 
Contrary to our expectations, power training did not result in beneficial changes in any cognitive 
domains relative to the SHAM group.  Similarly, glucose homeostasis, insulin sensitivity, 
physical performance, psychosocial status, physical activity, and systemic inflammation and 
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adipokines did not change between groups.  It remains unclear why participants randomised to 
the SHAM group had significantly greater improvements in executive function and global 
cognitive performance compared to POWER training.  It is possible that unprescribed dietary 
restrictions, higher SF-36 Mental Component Summary, higher adipokine levels (higher serum 
HMW adiponectin), lower depression score, and/or changes in habitual levels of physical activity 
outside of the study interventions may explain these findings.  While data regarding changes in 
dietary intake and habitual physical activity by accelometry were collected, these data were not 
available at the time of writing, and were thus beyond the scope of the present analyses. 
Another factor might have attenuated treatment differences in cognitive scores.  Higher training 
intensity and velocity were the only differences between the POWER training and SHAM exercise 
control group, and not all participants in POWER training group reached the intended high 
intensity training range. Thus, the differences in training modality between the two groups were 
not quite as distinct as planned, and adherence was high and equivalent in both groups.  This 
could have minimised the group differences observed.  Our SHAM exercise control design, 
although more robust and ethically justified than if a waitlist control group or advice-only control 
group had been used instead, may have led to an actual underestimation of POWER training 
efficacy.  Future trials may need to include a non-exercise control group as well, although this 
raises ethical concerns of clinical equipoise in a year-long trial of T2DM, as exercise is considered 
part of the standard care of this cohort, as reported on page 479 of Chapter 6. 
 
Sample size limitations could have contributed to Type II errors for some analyses, however, in 
our study, this cohort was a random sample of the population.  Sample size estimates were 
determined for differences between participants randomised to receive high intensity POWER 
training, compared to those randomised to receive SHAM exercise for the primary and secondary 
outcomes of the study.  All participants (47 in the POWER group and 53 in the SHAM group) 
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were included in the statistical models, we has sufficient power to detect a statistically significant 
difference in secondary outcomes.  Moreover, effect size were all negligible and small, 
suggesting that Type II error was not a major case of negative findings.  On a population level, 
even small changes in cognition may be very relevant to the prevention of dementia over time 
however.  Therefore, future larger studies should be powered to detect changes in cognition of 
this magnitude. 
 
The most interesting finding from this investigation is that despite similar changes in skeletal 
muscle mass and thigh muscle area in the participants within the POWER groups, improvements 
in Word List Memory and information processing speed were only present in those randomised to 
the POWER group.  Similarly, improvement 3MS scores were seen in the SHAM.  The low 
intensity exercise within the SHAM group was likely sufficient to promote hypertrophy, and so 
gains in skeletal muscle mass within these participants would be attributed to cognitive 
improvement.  Increase in lean mass and decrease in adiposity may be sensitive measure to relate 
body composition to cognitive outcomes and dementia.  Higher skeletal muscle had better 
cognitive function in the POWER group and the SHAM group.  In addition, increase in adiposity 
may resulted in cognitive improvement.  Thus, favorable alterations in both skeletal muscle mass 
and adiposity mediated through low and high intensity power training can result in improvements 
in the metabolic health of individuals with T2DM contributed to the observed cognitive benefits.   
 
The data presented within this report clearly show that increasing adipokine level and improving 
physical performance result in improvements in serum total adiponectin level and total static 
balance, respectively, and consequently, improvements in global cognitive function in the POWER 
and the SHAM group.  Additionally, it remains unclear why participants randomised to the 
SHAM group with low intensity, who reductions in insulin resistance showed improvements in 
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global cognitive function but not in the POWER group (Figure 6.9.2).  Serum adiponectin could 
be another important mediator.  High serum adiponectin has been reported to mediate insulin 
resistance and cognition.136-138  In the present study, insulin resistance was independently 
associated with cognitive function adjusted age, sex, years of education, duration of diabetes, SF-
36 Mental Component Summary, cognitive function, and HbA1c.  However, the relationships 
between insulin resistance and global cognitive function was attenuated after controlled for age, 
sex, years of education, duration of diabetes, SF-36 MCS, cognitive function, HbA1c, and High 
Molecule Mass adiponectin / total adiponectin ratio.  It is possible that un-prescribed dietary 
restrictions, and/or changes in habitual levels of physical activity and mental activity outside of 
the study interventions may explain these findings.  While data regarding changes in dietary 
intake and habitual physical activity were collected, the data was not available at the time of 
writing, and were thus beyond the scope of the present analyses.   
However, the mechanistic pathways require further examination and were beyond the scope of this 
investigation.  An alternative explanation for our observations is that cognitive function and 
sarcopenia (loss of lean tissue) share common underlying mechanisms.  Alzheimer’s disease is 
associated with systemic anabolic and inflammatory abnormalities that are also implicated in 
sarcopenia.139  Although our measures of inflammatory processes are limited in this study, we 
observed an independent relationship between lean mass and insulin, a well-known anabolic 
hormone140 that may have neurotrophic141 and neuroprotectiveproperties.141  Previous study 
reported that insulin levels are associated with cognition and brain volume in early Alzheimer’s 
disease.  Lean mass and insulin levels are interrelated suggests that reduced anabolic support to 
both the muscle and brain may be a potential mechanism underlying the observed relationships.  
Additionally, adiponectin stimulates glucose utilisation, fatty acid oxidation, and inhibits 
intramuscular fat lipid deposition, finally improves insulin resistance contributed to glucose 
control, thus both improved insulin resistance and glucose level may predict cognitive changes.  
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Furthermore, balance is also significantly associated with global cognitive function in the present 
study.  Balance is dependent on the functioning of the frontocerebellar and frontostriatal 
connections,142 connections between, respectively, the cerebellum and the striatum and the frontal 
cortex, for example, dorsolateral prefrontal cortex (DLPFC).142  Since the DLPFC is also involved 
in cognitive function,143 it is not surprising that in older people with T2DM, balance is significantly 
related to global cognitive function, because both performances appeal to the same neural circuits. 
 
The mechanism behind the reductions in total abdominal adipose tissue and abdominal adipose 
tissue within the POWER group, and why this was associated with worse score in cognition is 
unclear.  It is possible that the association of high adiposity to cardiovascular risk factor 
(triglyceride) is attenuated in older age groups.  Adipose tissue produces (adipokines) many 
mediated insulin resistance and inflammation linked to structural brain abnormalities and cognitive 
impairments.  In addition, leptin was associated with improved cognitive deficits and 
inflammation in the brain.   
 
Due to funding constraints and equipment availability, exercise-induced improvements in insulin 
resistance, cytokines (Tumor Necrosis Factor-ɑ and Interlukines-6), neurotropic, and other 
metabolic parameters (Aβ42) related to cognitive decline were not measured.  Furthermore, IR 
was determined using HOMA2-IR, reflective of hepatic IR as opposed to being a whole body 
measure.  Appropriately powered studies of similar design should be employed that utilize more 
direct measures of whole-body composition (such as dual-energy X-ray absorptiometry), IR 
(hyperinsulinaemic-euglycaemic clamp), and cognition.  In addition, there is lack of control 
group without exercise because exercise intensity in SHAM is too higher than expect.  Finally, 
exercise-induced cognitive benefits may relate to the type of tests administered or the specific task 
demands that rely more heavily on brain regions.  Future controlled trials of resistance exercise 
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that include brain imaging measures of glucose metabolism and blood flow and other cognitive–
related biomarkers will likely help to identify specific mechanisms to account for cognition-
enhancing effects in older adults with T2DM. 
 
In conclusion, this clinical trial in 103 older adults with a intact cognition, a mean HbA1c level of 
7.1%, and  long-term T2DM shows no overall reduction of the rate of T2DM-related cognitive 
decline though high intensity resistance training compared to low intensity resistance training.  
However, increases in skeletal muscle mass and free fat mass, adiponectin level, and total static 
balance achieved through high intensity power training improved cognition in a cohort of older 
adults with T2DM.  
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT  
________________________________________________________________________ 
Variable       Total  POWER  SHAM  p-value 
         (n=100)  (n=47)   (n=53) 
________________________________________________________________________ 
Demographics 
Age (years)       68.1±5.5  67.1±4.8  68.9±6  0.09 
Men, Women (n)      50, 50   24, 23   26, 27  0.84 
Marital Status (n)    
Married        56   25    31 
Widowed       12   5    7 
Divorced       19   13    6 
Never Married      11   3    8 
Separated       2   1    1   0.24 
Ethnic Origin (n)    
Caucasian       96   47    49 
Indian Sub-Continent     2   0    2 
Other        2   0    2   0.16 
Residential Status (n)     
House (own)      63   29    34 
House (rented)      3   1    2 
Unit (own)       16   8    8 
Unit (rented)      17   9    8 
Retirement Village     1   0    1   0.84 
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
_________________________________________________________________________ 
Variable       Total  POWER  SHAM  p-value 
         (n=100)  (n=47)   (n=53) 
_________________________________________________________________________ 
Living Situation (n) 
Alone        34   14    20 
Spouse/Partner      47   22    25  
Family        19   11    8   0.50 
Educational Level (years)    13.7±3.6 13.4±3.6  13.7±3.7 0.65 
Work (n)       28   11    17   0.34 
Volunteer Work (n)     34   15    19   0.68 
Annual Income Distribution (n)     
<$15,000       31   21    10  
$15,000-$30,000      26   8    18  
>$30,000       43   18    25   0.01 
Current Smoker (n)     6   3    3   0.86 
Previous Smoker (n)     63   30    33   0.87 
Drinking Habit (n) 
Almost every day     23   11    12  
Two to Three Times a Week   13   9    4  
Once or Twice a Week    21   8    13  
Two or Three Times a Month   11   3    8  
Once a Month      8   4    4  
None        24   12    12   0.41
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
_________________________________________________________________________ 
Variable       Total  POWER  SHAM  p-value 
         (n=100)  (n=47)   (n=53) 
_________________________________________________________________________ 
Health Status 
Number of Chronic Diseases (n)  5.1±1.9  5.2±2.0   5.0±1.8  0.67 
Adverse Event (n)     5/100  4/47   1/53  0.13 
Depression (n)      18   10    8   0.46 
Duration of Diabetes (years)   8.0 ± 6.0 7.0 ± 5.0  9.0 ± 7.0 0.07 
High Cholesterol (n)     45   24    21   0.25 
Hypertension (n)      73   35    38   0.76 
History of Stroke (n)     3   0    3   0.10 
History of IHD, MI and Angina (n) 19   8    11   0.60 
Osetoarthritis (n)      66   33    33   0.40 
Peripheral Neuropathy (n)   5   1    4   0.37 
Peripheral vascular disease (n)  21   10    11   0.99 
Sleep Apnoea (n)     19   7    12   0.30 
Metabolic Syndrome (n)  
Central Obesity       99   47    52   0.34 
Raised Triglycerides     78   34    44   0.20 
Reduced HDL Cholesterol   75   33    42   0.30 
Hypertension      98   46    52   0.93 
Diabetes/Raised  
Fasting Plasma Glucose    100   47    53   0.99
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
_________________________________________________________________________ 
Variable       Total  POWER  SHAM  p-value 
         (n=100)  (n=47)   (n=53) 
_________________________________________________________________________ 
IDF Diagnosis of Metabolic  
Syndrome       97   47    50   0.10 
Medication 
Total No. of Medications/Day (n)  5.7±2.9  5.3±2.8   6.1±3.0  0.15 
Insulin Users (n)      16   7    9   0.78 
Metformin Users (n)     68   35    33   0.19 
Metformin Dosage (mg/day) 1544.6±659.0 1526.4±618.9 1561.8±703.3 0.82 
Glibenclamide Users (n)    2   0    2   0.17 
Glicazide Users (n)     25   13    12   0.56 
Glicazide Dosage (mg/day)   60.0   64.0    60.0  0.98 
Glimepiride Users (n)    3   1    2   0.62 
Glipzide Users (n)     1   0    1   0.34 
Acarbose Users (n)     2   1    1   0.95 
Diet control Users (n)    15   7    8   0.95 
Obesity Categories (n)     
Normal (18.5<BMI<24.9)   5   3    2   0.55 
Overweight (25<BMI<29.9)   38   15    23   0.24 
Obese I (30<BMI<34.9)    35   19    16   0.28 
Obese II (35<BMI<39.9)    13   7    6   0.63 
Obese III (BMI≥40)     8   3    5   0.58 
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
________________________________________________________________________________ 
Variable       Total   POWER  SHAM   p-value 
         (n=100)   (n=47)   (n=53) 
________________________________________________________________________________ 
Quality of Life  
SF-36 (0-100) 
SF-36 Physical Component Summary 46.3 (61.7)  47.3 (61.8)  46.0 (41.6)  0.49 
SF-36 Mental Component Summary 0.8 (65.3)  50.5 (60.2)  52.2 (38.7)  0.06 
Habitual Physical Activity Level  
Physical Activity Scale    574.4 (7891.0) 556.7 (7803.0) 601.2 (6344.0) 0.30 
for the Elderly (score) 
Cardiovascular Profile 
Systolic Blood Pressure (mm Hg)  146.1±17.8  147±17.9  145±17.9  0.56 
Diastolic Blood Pressure (mm Hg)  79.1±9.0  78.9±7.5  77.3±10.1  0.39 
Physical Performance 
Physical Function  
Static Balance Total Time (sec)  74.8±7.1  75.1±7.4  74.5±7.0  0.70 
Normal Gait Velocity (m/s)   1.20±0.19  1.18±0.19  1.21±0.18  0.39 
Maximal Gait Velocity (m/s)   1.86±0.31  1.87±0.32  1.85±0.32  0.80 
Six-Minute Walk (m)     544.7±95.7  552.8±95.7  539.3±96.2  0.56 
Fastest Chairstand (sec)    12.1±2.7  12.2±2.8  11.9±2.6  0.48 
Stair Climb Power (W)    364.4±126.7  367.8±137.0  361.6±118.6  0.81 
Muscle Strength 
Leg Press (N)      1605.5±456.1 1655.8±479.9 1569.4±44  0.95
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
_____________________________________________________________________________ 
Variable      Total   POWER  SHAM   p-value 
        (n=100)   (n=47)   (n=53) 
_____________________________________________________________________________ 
Chest Press (N)     332.3±108.5  349.0±130.8  302.7±84.7  0.06 
Knee Extension (Nm)    157.0±56.9  167.1±65.3  148.4±47.7  0.12 
Seated Row (N)     239.1±74.7  243.9±86.3  234.7±63.0  0.56 
Knee Flexion (Nm)    141.0 (715)  141.0 (713)  143.0 (565)  0.70 
Power (W) 
Leg Press      515.7±330.6  473.0±337.8  553.4±332.6  0.17 
Chest Press      155.7±76.8  170.4.4±88.9 144.5±64.9  0.40 
Knee Extension     310.6±143.0  307.6±169.1  313.2±116.7  0.85 
Seated Row      295.2±160.3  316.2±18.5  276.5±138.9  0.22 
Knee Flexion     116.2±53.5  109.4±49.3  122.2±57.2  0.37 
Overall Body Composition 
Stretched Stature (m)    1.68±0.89  1.68±0.94  1.67±0.85  0.62 
Naked Body Weight (kg)   89.0±17.3  89.5±15.3  88.6±18.9  0.78 
Body Mass Index (BMI (kg/m2) 31.5±5.4   31.3±4.6   31.6±6.1   0.79 
Skeletal Muscle Mass (kg)  30.4±4.1   30.7±4.3   30±3.9    0.40 
Fat Free Mass (kg)     56.1±10.7  56.7±11.3  55.6±10.1  0.59 
Fat Mass (kg)     31.8±11.6   31.8±10.0   31.8±12.9  0.99 
Body Fat (%)     36.4±8.4  36.5±8.2  36.3±8.7  0.93 
Regional Body Composition 
Waist Circumference    107.2±11.9  107.9±10.8  106.6±12.9  0.57 
(ISAK) (cm)
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
____________________________________________________________________________ 
Variable      Total   POWER  SHAM   p-value 
        (n=100)   (n=47)   (n=53) 
____________________________________________________________________________ 
Regional Body Composition 
Sagittal Abdominal Diameter  26.8±3.5  26.9±3.2  26.9±3.9  0.64 
Total Abdominal Adipose   418.9±118.36 428.3±112.2  410.5±124.1  0.46 
Tissue (Without Skin) (cm2) 
Visceral Fat Area (cm2)    212.6±88.0  220.7±84   205.2±91.7  0.38 
Subcutaneous Abdominal   206.4±90.6  207.6±92.9  205.3±89.5  0.90 
Adipose tissue (cm2) 
Thigh Muscle Density   84.2±2.3   84.2±2.2   84.1±2.4  0.79  
Total Thigh Fat Area (cm2)  97.5±50.0  92.5±42.9  102.2±55.5  0.42 
Subcutaneous Thigh Fat   84.3±47.6  78.6±40.2  89.5±53.3  0.30 
Area (cm2) 
Intermuscular Thigh Fat   13.2±6.6  13.8±7.3  12.6±5.9  0.38 
Area (cm2) 
Thigh Muscle Area (cm2)   109.0±24.1  110.4±26.3  107.6±22.1  0.57 
Relative Thigh Muscle Area (%) 0.52±0.13  0.54±0.13  0.51±0.14  0.45 
Cognitive Function 
Word List Memory (0/30)   21.3 ± 3.9  21.4±3.5  21.2±4.2  0.68 
Word List Recall (0/10)   7.0 ± 1.8  6.9±1.4   7.2±2.1   0.46 
Word List Recognition (0/10)  10 (4)   10 (4)    10 (2)   0.64 
Trial Making Test A (s)   40.7 ± 12.6  40.4±12.2  41.0±13.3  0.84 
Trial Making Test B (s)   85.1 (254.7)  82.7 (241.0)  85.9 (254.8)  0.44 
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
____________________________________________________________________________ 
Variable      Total   POWER  SHAM   p-value 
        (n=100)   (n=47)   (n=53) 
____________________________________________________________________________  
Cognitive Function 
DIFFBA (s)      45.1 (267.1)  42.7 (267.1)  47.5 (208.9)  0.43 
Modified Mini-mental State  94.2 ± 4.7  95.3±3.9  93.3±5.2  0.02 
Examination (0/100)  
Depression Score (0/30)   6.8±5.3   7.7±4.9   6.1±4.6   0.13 
Metabolism 
Total Cholesterol (mmol/L)  4.3±1.1   4.5±1.1   4.2±1.0   0.28 
Triglycerides (mmol/L)   1.5 (4.4)  1.5 (4.4)  1.5 (4.1)  0.62 
High Density Lipoprotein   1.22±0.54  1.21±0.29  1.23±0.38  0.84 
Low Density Lipoprotein   2.2(4.7)   2.3(3.9)   2.0 (4.7)  0.15 
(mmol/L) 
Fasting Glucose Levels   6.5 (13.4)  6.4 (13.0)  6.6 (12.2)  0.49 
(mmol/L) 
HbA1c (%)      7.1±1.1   6.9±0.9   7.3±1.3   <0.05 
Fasting Insulin (mU/L)   9.8 (34.1)  9.1 (33.3)  10.0(34.0)  0.20 
(n=87)   (n=42)    (n=45) 
HOMA2-%B     110.0±48.0  105.0±37.9  114.5±55.7  0.49 
(n=87)   (n=42)   (n=45) 
HOMA2-IR    2.9±1.1   2.6±1.0   3.0±1.2   0.14  
(n=87)   (n=42)   (n=45) 
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TABLE 6.1 BASELINE CHARACTERISTICS OF STUDY COHORT - CONTINUED 
_____________________________________________________________________________ 
Variable      Total   POWER  SHAM   p-value 
        (n=100)   (n=47)   (n=53) 
_____________________________________________________________________________ 
C - reactive Protein (CRP) (mg/L) 2.5 (21.1)  2.4 (13.0)  2.8 (21.1)  0.98 
Serum HMW Adiponectin (ng/ml) 3781.1(23121.1) 4026.6(13690.6) 3448(23121.1) 0.58 
Serum Total Adiponectin (ng/ml) 7969.5±4738.7 7174.7±4114.4 8061.1±5230 0.54 
Serum Adiponectin Ratio   0.40 (4.27)  0.45 (1.19)  0.37 (1.29)  0.20 
_____________________________________________________________________________
Normally distributed data presented as mean ± SD.   
Non-normally distributed data presented as median (range).   
Difference between groups was assessed via one-way ANOVA continuous data.   
Non-normally distributed data were log-transformed before use with parametric statistics.   
Non-normally distributed data after log-transformation were analyzed using Mann-Whitney 
U test of raw data.   
Categorical variables we assessed using a Chi Square tests for categorical data.   
Word list subset of the Consortium to Establish a Registry for Alzheimer’s disease is a 
measure immediate memory and delayed memory, higher score indicates better memory 
function.  Trail Making Test A is a measure of information processing speed, higher score 
(second) indicates worse information processing speed.  Trail Making Test B is a measure 
of executive function, higher score (second) indicates worse executive function.  DIFFBA 
(Trial Making Test B minus Trail Making Test A) (second) is a measure of pure executive 
function.  High score indicates worse executive function.  Modified Mini-mental State 
Examination (3MS) is used to assess general cognitive function; higher score indicates better 
global cognitive function. 
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16 participants were excluded from HOMA2-IR analyses due to insulin therapy.   
HbA1C = Hemoglobin A1c 
HOMA2 = Homeostasis Model Assessment 2 
HMW: High-Molecule Weight 
N: Newtons 
Nm: Newton Meters 
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TABLE 6.2 COMPARISON OF COGNITIVE FUNCTIONS BETWEEN POWER AND SHAM GROUPS  
_________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months    Relative ES (95% CIs) T   T×G 
_____________________________  ______________________________       ______  _____ 
POWER (n=47)  SHAM (n=53)  POWER (n=47)  SHAM (n=53)        p value  p value 
_________________________________________________________________________________________________________________________________ 
Cognitive Outcomes 
Word List Memory (/30) 1.35 (0.17, 1.53)  2.07 (0.95, 3.19)  2.80 (1.51, 4.08)  2.94 (1.71, 4.16)  -0.04 (-0.43, 0.35) 0.000a, b, c, d, e  0.54 
Word List Recall (/10) 0.51 (-0.01, 1.03) 0.47 (-0.80, 1.03) 1.29 (0.65, 193)  0.78 (0.27, 1.30)  0.34 (-0.06, 0.73) 0.000b, c, e  0.19  
Word List Recognition -0.02 (-0.24, 0.23) 0.01 (-0.21, 0.22) 0.02 (0.10, 0.50)  0.02 (-0.23, 0.28) 0.31 (-0.09, 0.71) 0.75   0.33 
(/10) (log) 
Trial Making Test A (sec) -0.01 (-4.48, 4.29) 0.23 (-3.85, 4.32) -4.31 (-9.03, 0.41) -5.78 (-9.12, -2.45) 0.13 (-0.26, 0.52) 0.000e, f    0.73 
Trial Making Test B (sec) 0.01 (-0.05, 0.05) -0.02 (-0.06, 0.05) -0.02 (-0.06, 0.02) -0.07 (-0.11, 0.03) 0.44 (0.05, 0.84)  0.02e, f, h    0.03 
(log) 
DIFFBA (sec) (log)  -0.01 (-1.01, 0.12) -0.03 (-0.12, 0.06) 0.03 (-0.09, 1.44) -0.07 (-0.16, 0.03) 0.35 (-0.04, 0.75) 0.83    0.43 
Modified Mini-Mental 0.004 (-0.004, 0.011) 0.009 (0.003, 0.016) 0.004 (-0.002, 0.010) 0.015 (0.008, 0.023) -0.06 (-0.45, -0.33) 0.000d, e,   0.04 
State Examination (0/100) (log)
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Non-normally distributed data were transformed before use with parametric statistics. 
Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.65   Ninety-five percent confidence  
intervals (CIs) for the relative ES were calculated.  Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline 
SD.   
Time effect and group and time interaction between groups were both adjusted for age, sex, and educational levels, SF-36 mental 
component score, HbA1c, and baseline cognitive score of the dependent cognitive outcome of interest. 
Word List Memory, Word List Recall, and Word List Recognition are measures of immediate memory and delayed memory; higher score  
indicates better immediate memory and delayed memory.  Trail Making Test A is a measure of attention/information processing speed; 
higher score (seconds) indicates worse attention/information processing speed.  Trail Making Test B is a measure of 
attention/information processing speed and executive function; higher score (seconds) indicates worse attention/information processing 
speed and executive function.  DIFFBA (seconds) is calculated by subtracting Trail Making Test A from Trail Making Test B, and is 
considered a purer measure of executive function; higher score indicates worse executive function.  3MS is a measure of global 
cognitive function; higher score indicates better global cognitive function. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bp<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
significant differences between baseline and 6 months in the SHAM group, e P<0.05; significant differences between baseline and 12 
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months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h P<0.05; significant differences between the POWER and SHAM 
groups at 12 months. 
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
ES: Effect Size 
POWER: Power training group 
SHAM: Control group 
CIs: Confidence intervals 
T: Time 
G×T: Group and time interaction  
Sec: Second
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TABLE 6.3 COMPARISON OF METABOLISM BETWEEN POWER AND SHAM GROUPS 
________________________________________________________________________________________________________________________________ 
Outcomes   Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months   Relative ES (95% CIs) T   T×G 
_____________________________  ______________________________        ______  _____ 
POWER (n=47)  SHAM (n=53)  POWER (n=47)  SHAM (n=53)         p value  p value 
________________________________________________________________________________________________________________________________ 
Glucose Homeostasis  
Serum Glucose  -0.42 (-1.15, 0.30) -0.30 (-0.83, 0.23) -0.38 (-1.04, 0.29) -0.39 (-1.01, 0.22) -0.01 (-0.04, 0.38)  0.14  0.83 
Fasting (mmol/L) 
HbA1c (%)   -0.18 (-0.37, 0.01) -0.19 (-0.4, 0.01)  -0.07 (-0.32, 0.19) -0.16 (-0.42, 0.10) -0.10 (-0.30, 0.49)  0.04  0.85 
Serum Insulin    0.69 (-0.64, 2.02) 0.59 (-0.84, 2.02) 1.06 (-0.40, 2.51) -1.14 (-2.89, 0.61) 0.39 (-0.01, 0.79)  0.29  0.13 
Fasting (mU/L) 
HOMA2-Beta  0.03 (-0.03, 0.09) 0.07 (-0.04, 0.18) 0.04 (-0.03, 0.10) 0.08 (-0.04, 0.20) -0.21 (-0.60, 0.19)  0.17  0.99 
Cell Function (%Beta) 
HOMA2-IR   -0.15 (-0.40, 0.10) -0.10 (-0.43, 0.23)  0.02 (-0.27, 0.30) -0.15 (-0.27, 0.56) -0.10 (-0.50, 0.29)  0.15  0.23 
________________________________________________________________________________________________________________________________ 
Non-normally distributed data were log-transformed before use with parametric statistics. 
Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.65  Ninety-five percent confidence  
intervals (CIs) for the relative ES were calculated.  Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline. 
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16 participants were excluded from HOMA2-IR analyses due to insulin therapy. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bP<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
significant differences between baseline and 6 months in the SHAM group, e P<0.05; significant differences between baseline and 12 
months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h P<0.05; significant differences between the POWER AND SHAM 
groups at 12 months. 
ES: Effect Size 
HOMA 2-IR: Homeostatic Model of Assessment 2 
POWER: power training group 
SHAM: Control group 
IR: Insulin resistance 
HbA1c: Glycosylated hemoglobin 
CI: Confidence interval 
T: Time 
G×T: Group and time interaction
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TABLE 6.4 COMPARISON OF PHYSICAL PERFORMANCE BETWEEN POWER AND SHAM GROUPS 
________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)    Mean Difference (95% CI)     
between baseline and 6 months   between baseline and 12 months    Relative ES (95% CIs) T   T×G 
______________________________  ______________________________        ______  _____ 
POWER (n=47)  SHAM (n=53)  POWER (n=47)  SHAM (n=53)         p value  p value 
________________________________________________________________________________________________________________________________ 
Physical Function and Exercise Capacity 
Total Muscle strength (N) 536.5 (105.2, 967.8) 43 (-251.2, 337.2) 860.5 (413.8, 1307.2) 18.4 (-277.8, 314.5)  0.62 (0.20, 1.03)  0.000a, b, g, h 0.000 
Total Muscle Power (W) 216.6 (-103.4, 536.6) -112.7 (-437.4212.0) 205.3 (-516, 6106.0) -207.3 (-134.0, 548.7) 0.44 (-0.01, 0.90) 0.74  0.11 
Statics Balance (sec)  0.01 (-0.02, 0.03) 0.00 (-0.00, 0.02) 0.00 (-0.01, 0.02) -0.01 (-0.02, 0.00)  0.05 (-0.35, 0.44) 0.06  0.33 
Habitual Gait Speed  0.10 (0.02, 0.17)  0.04 (-0.01, 0.09) 0.10 (0.02, 0.18)  0.07 (0.02, 0.11)   0.28 (-0.11, 0.68) 0.000a, b, e 0.28 
(m/sec) 
Maximal Gait Speed  0.08 (-0.04, 0.19) 0.10 (0.01, 0.20)  0.11 (-0.03, 0.20) 0.15 (0.04, 0.25)   -0.13 (-0.53, 0.26) 0.000d, e  0.86 
(m/sec) 
Stair Climb Power (w)   -25.52 (-52.38, 1.35) -35.81 (-60.18, -11.44) -24.43 (-48.39,-0.48) -30.01 (-55.52,-4.51) 0.47 (0.07, 0.87)  0.000b, d, e 0.79 
Chair Stand (sec)   -2.32 (-4.27, -0.37) -1.54 (-3.08,-0.01) -0.79 (-1.66, 0.09) -0.63 (-1.50, 0.25)  -0.04 (-0.43, 0.36) 0.000a, d  0.73    
Six Minute Walk   6.94 (-25.62, -11.75) -9.56 (-25.22, 6.10) -13.57 (-13.74, 8.60)  0.58 (-17.86, 19.03)  -0.05 (-0.44, 0.35) 0.01b, d  0.28 
Distance (m) 
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Normally distributed data presented as mean ± SD.  Non-normally distributed data were log-transformed before use with parametric statistics. 
Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.65  Ninety-five percent confidence  
intervals (CIs) for the relative ES were calculated.  Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bp<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
significant differences between baseline and 6 months in the SHAM group, e p<0.05; significant differences between baseline and 12 
months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h p<0.05; significant differences between the POWER and SHAM 
groups at 12 months. 
ES: Effect Size 
POWER: power training group 
SHAM: Control group 
CI: Confidence interval 
T: Time 
G×T: Group and time interaction 
m: meter 
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Sec: second
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TABLE 6.5 COMPARISON OF BODY COMPOSITION BETWEEN POWER AND SHAM GROUPS 
________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months   Relative ES (95% CIs) T   T×G 
______________________________  ______________________________        ______  _____ 
POWER (n=47)  SHAM (n=53)  POWER (n=47)  SHAM (n=53)         p value  p value 
 
________________________________________________________________________________________________________________________________ 
Overall Body Composition 
Body Mass Index (kg/m2) -0.37 (-1.66, 0.92) -0.05 (-1.06, 1.16) -1.26 (-3.03, 0.51) -0.76 (-2.26, 0.75) -0.06 (-0.42, 0.36)  0.05  0.84 
Waist Circumference  -1.68 (08.61, 5.25) -1.94 (-5.96, 5.57) -7.06 (-15.25, 1.13) -4.41 (-11.25, 2.63) -0.15 (-0.54, 0.25)  0.02  0.84 
(cm) (ISAK) 
Body Weight (kg)  -0.90 (-1.98, 0.18) 0.10 (-3.00, 3.20) -1.062 (-2.63, 0.51) -2.12 (6.40, 2.20) -0.08 (-0.48, 0.31)  0.16  0.39 
Skeletal Muscle    0.10 (-4.02, 0.59) 0.17 (-3.36, 0.667) 0.23 (-0.28, 0.73) 0.18 (-0.35, 0.72) 0.00 (-0.39, 0.39)  0.39  0.92 
Mass (kg) 
 Free Fat Mass (kg)  0.14 (-0.68, 0.96) 0.27 (-0.58, 1.13) 0.42 (-0.52, 1.35) 0.27 (-0.68, 1.1)  0.02 (-0.38, 0.41)  0.45  0.85  
Total Fat Mass (kg)  -1.03 (-2.23, 0.16) -0.00 (-0.89, 0.88) 1.33 (2.78, 0.12)  -0.00 (-0.00, 0.01) -0.07 (-0.46, 0.32)  0.03 b  0.38 
% Muscle    0.14 (-0.01, 0.029) -0.00 (-0.006, 0.006) 0.01 (-0.01, 0.03) -0.01 (-0.01, 0.03) 0.21 (-0.18, 0.61)  0.53  0.19 
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TABLE 6.5 COMPARISON OF BODY COMPOSITION BETWEEN POWER AND SHAM GROUPS-CONTINUED 
________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)     Mean Difference (95% CI)      
between baseline and 6 months     between baseline and 12 months    Relative ES(95% CIs) T   T×G 
_________________________________  _______________________________       ______  _____ 
POWER (n=47)   SHAM (n=53)  POWER (n=47)  SHAM (n=53)       p value  p value 
________________________________________________________________________________________________________________________________ 
Regional Body Composition  
Total Abdominal   -30.86 (-46.95, -14.77) -5.48 (-24.25, 13.38) -24.66 (-46.43, -2.89) -7.60 (-24.60, 9.40) -0.15 (-0.55, 0.25) 0.01a, b    0.10   
Adipose Tissue (cm2) 
Visceral Adipose Tissue -17.26 (-29.33, -5.19) -1.31 (-13.98, 11.36) -13.18 (-29.05, 2.68) -1.50 (-13.41, 10.41) -0.02 (-0.41, 0.37) 0.03 a  0.16 
(cm2) 
Subcutaneous Abdominal -13.53 (-24.84,-2.12)  -2.97 (-12.78, 6.34) -11.24 (25.02, 2.55) -4.39 (-14.42, 5.64)  -0.08 (-0.47, 0.31) 0.02 a  0.37 
Adipose Tissue (cm2) 
Sagittal Abdominal  -0.05 (-0.82, 0.72)  -0.71 (-1.28, -0.14) -0.12 (-0.84, 0.60) -0.53 (-1.17, 0.11) -0.11 (-0.50, 0.28) 0.12  0.24  
Diameter (cm) 
Thigh Muscle Area  5.33 (1.22, 9.44)   1.57 (-3.00, 6.14) 5.32 (1.57, 9.28)  -3.37 (-3.70, 2.96) 0.41 (0.02, 0.80)  0.01 a, b  0.03
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TABLE 6.5 COMPARISON OF BODY COMPOSITION BETWEEN POWER AND SHAM GROUPS-CONTINUED 
________________________________________________________________________________________________________________________________ 
Outcomes     Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months   Relative ES (95% CIs) T   T×G 
_____________________________  ______________________________        ______  _____ 
POWER (n=47) SHAM (n=53)  POWER (n=47)  SHAM (n=53)        p value  p value 
________________________________________________________________________________________________________________________________ 
Subcutaneous Thigh  -1.84 (-5.00, 1.31) 1.56 (-3.66, 6.77) 0.82 (-5.27, 3.63) -3.18 (-8.10, 1.73) 0.05 (-0.34, 0.44)  0.23  0.10 
Adipose Tissue (cm2) 
Intermuscular Thigh  -0.12 (-1.34, 1.10) 1.07 (-2.64, 4.77) 0.09 (-1.62, 1.80) 2.52 (-1.80, 6.84) -0.60 (-1.54, 0.33)  0.64  0.36 
Adipose Tissue (cm2)  -0.86 (-1.41, -0.30) -0.99 (-1.49, -0.48) -1.34 (-2.05, -0.63) -1.10 (-1.76, -0.44) 0.08 (-0.31, 0.48)  0.00 a  0.51 
Thigh Muscle Density -0.86 (-1.41, -0.30) -0.99 (-1.49, -0.48) -1.34 (-2.05, -0.63) -1.10 (-1.76, -0.44) 0.08 (-0.31, 0.48)  0.00 a  0.51 
(cm2) 
Normally distributed data presented as mean ± SD.  Non-normally distributed data were log-transformed before use with parametric statistics. 
Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.65  Ninety-five percent confidence intervals  
(CIs) for the relative ES were calculated.  Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline. 
Normally distributed data presented as mean ± SD.  Non-normally distributed data were log-transformed before use with parametric statistics. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bP<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
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significant differences between baseline and 6 months in the SHAM group, e P<0.05; significant differences between baseline and 12 
months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h P<0.05; significant differences between the POWER and SHAM 
groups at 12 months. 
ES: Effect Size 
POWR: power training 
SHAM: Control group 
SD: Standard deviation  
CIs: Confidence interval 
T: Time 
G×T: Group and time interaction  
529 
 
TABLE 6.6 COMPARISON OF QUALITY OF LIFE, PSYCHOSOCIAL STATUS, AND PHYSICAL ACTIVITY BETWEEN POWER AND 
SHAM GROUPS 
________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months   Relative ES (95% CIs) T   T×G 
______________________________  _____________________________        ______  _____ 
POWER (n=47) SHAM (n=53)   POWER (n=47)  SHAM (n=53)        p value  p value 
________________________________________________________________________________________________________________________________ 
Quality of Life 
SF-36 Physical   -1.21 (-3.78, 1.36) 2.44 (-0.68, 5.57) -2.37 (-5.29, 3.87) 1.18 (-1.95, 4.32) -0.44 (-0.83, -0.04)  0.39  0.06 
Component Summary (score)    
 SF-36 Mental   2.98 (-0.07, 6.03) 0.92 (-2.80, 4.62) 3.45 (-0.15, 7.05) 0.72 (-3.34, 4.78) 0.30 (-0.10, 0.69)  0.10  0.41 
Component Summary (score)  
Psychosocial Status 
Geriatric Depression  -1.45 (-2.85, 0.006) -1.60 (-2.78, -0.42) -1.28 (-2.76, 0.19) -1.11 (-2.41, 0.20) -0.06 (-0.45, 0.34)  0.00a, d, e  0.88  
Scale (0/30) 
Physical Activity  
Physical Activity Scale  5.50 (-13.46, 24.46) -4.48 (-28.93, 19.24) 9.95 (-33.91, 14.02) 1.06 (-23.54, 25.66) -0.06 (-0.46, 0.33)  0.72  0.30 
For the Elderly (score)
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Normally distributed data presented as mean ± SD.  Non-normally distributed data were log-transformed before use with parametric statistics. 
Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.65  Ninety-five percent confidence  
intervals (CIs) for the relative ES were calculated.  Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bp<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
significant differences between baseline and 6 months in the SHAM group, e p<0.05; significant differences between baseline and 12 
months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h p<0.05; significant differences between the POWER and SHAM 
groups at 12 months. 
ES: Effect Size 
POWR: power training 
SHAM: Control group 
SF-36: Short Form-36 
SD: Standard deviation,  
CI: Confidence interval 
T: Time 
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G×T: Group and time interaction  
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TABLE 6.7 COMPARISON OF ADIPOKINES AND SYSTEMATIC MARKER BETWEEN POWER AND SHAM GROUPS 
________________________________________________________________________________________________________________________________ 
Outcomes    Mean Difference (95% CI)    Mean Difference (95% CI)      
between baseline and 6 months    between baseline and 12 months   Relative ES (95% CIs) T   T×G 
______________________________  ______________________________        ______  _____ 
POWER (n=47)  SHAM (n=53)  POWER (n=47)  SHAM (n=53)        p value  p value 
________________________________________________________________________________________________________________________________ 
C – Reactive Protein  0.22 (-0.78, 1.22) -0.64 (-1.66, 0.38) -0.01 (-1.18, 0.98) -1.08 (-1.89, -0.26) 0.28 (-0.11, 0.68)  0.25d  0.14 
(mg/L) 
Serum HMW   -1104.541   9.77     -370.72    -239.14    -0.01 (-0.41, 0.38)  0.66  0.54 
Adiponectin (ng/ml)  -3575.63, 1366.55) (-1955.57, 1995.12) (-3713.09, -2971.65) (-2709.40, 2231.11)     
Serum Total Adiponectin 551.96    273.85    241.64    -382.70    0.07 (-0.32, 0.47)  0.54  0.91 
(ng/ml)      (-2032.59, 3136.50) (-796.37, 1344.06) (-3095.48, 3578.76) (-1690.29, 1924.88)   
 
Serum HMW/Total  0.00 (-0.11, 0.11) -0.01 (-0.07, 0.05) -0.02 (-0.08, 0.12) -0.05 (-0.13, 0.03) 0.02 (-0.37, 0.42)  0.51  0.53 
Adiponectin Ratio 
________________________________________________________________________________________________________________________________ 
Normally distributed data presented as mean ± SD.  Non-normally distributed data were log-transformed before use with parametric  
statistics.  Calculations of effect size were adjusted via Hedges’ bias-corrected effect size for small sample sizes.62 Ninety-five percent confidence  
intervals (CIs) for the relative ES were calculated.   
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Effect Size = (Δ Treatment – Δ Control) / Pooled (Treatment + Control) Baseline. 
a P<0.05; significant differences between baseline and 6 months in the POWER group, bp<0.05; significant differences between baseline 
and 12 months in the POWER group, c P<0.05; significant differences between 6 months and 12 months in the POWER group, d P<0.05; 
significant differences between baseline and 6 months in the SHAM group, e p<0.05; significant differences between baseline and 12 
months in the SHAM group, f P<0.05; significant differences between 6 months and 12 months in the SHAM group, g P<0.05; significant 
differences between the POWER and SHAM groups at 6 months, h p<0.05; significant differences between the POWER and SHAM 
groups at 12 months. 
ES: Effect Size 
POWR: power training 
SHAM: Control group 
CRP: C-reactive protein 
HMW: High-Molecular-Weight 
SD: Standard deviation,  
CIs: Confidence interval 
T: Time 
G×T: Group and time interaction 
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TABLE 6.8 RELATIONSHIPS BETWEEN CHANGES IN BODY COMPOSITION VARIABLE  
_______________________________________________________________________________________________________________________ 
Changes in Body    Changes in Body       POWER Group       SHAM Group 
Composition Variable  Composition Variable   n Standard Coefficient β p   n Standard Coefficient β p 
_______________________________________________________________________________________________________________________ 
Total Abdominal Adipose  Visceral Adipose Tissue   37   0.78   <0.0001  43   0.79   <0.0001 
Tissue      Subcutaneous Abdominal   37   0.67   <0.0001  43   0.74   <0.0001 
Adipose Tissue 
Sagittal Abdominal Diameter  37   0.49   0.002  43   0.71   <0.0001 
Thigh Muscle Area    37   0.26   0.13  42   0.32   0.04 
Body Mass Index    36   0.77   <0.0001  43   0.67   <0.0001 
Body Weight     36   0.78   <0.0001  43   0.67   <0.0001 
Skeletal Muscular Mass   36   0.11   0.54  42   0.36   0.02 
Total Fat Mass     36   0.74   <0.0001  42   0.44   0.004 
Visceral Adipose Tissue  Subcutaneous Abdominal   37   0.06   0.73  43    0.17   0.27 
Adipose Tissue 
Sagittal Abdominal Diameter  37   0.61   <0.0001  43   0.59   <0.0001 
Thigh Muscle Area    37   0.13   0.45  44   0.21   0.47
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TABLE 6.8 RELATIONSHIPS BETWEEN CHANGES IN BODY COMPOSITION VARIABLE - CONTINUED 
______________________________________________________________________________________________________________________ 
Changes in Body    Changes in Body       POWER Group       SHAM Group 
Composition Variable  Composition Variable   n Standard Coefficient β p   n Standard Coefficient β p 
______________________________________________________________________________________________________________________ 
Visceral Adipose Tissue  Body Mass Index    36   0.71    <0.0001  45   0.50   0.0005 
Body Weight     36   0.78   <0.0001  45   0.67   <0.0001 
Skeletal Muscular Mass   36   0.11   0.54  44   0.36   0.02 
Total Fat Mass     36   0.69   <0.0001  44    0.25   0.10 
Subcutaneous Abdominal  Sagittal Abdominal Diameter  37   0.06   0.74  43   0.39   0.01 
Adipose Tissue     Thigh Muscle Area    37   0.25   0.13  42   0.24   0.13 
Body Mass Index    36   0.37   0.03  43   0.47   0.001 
Body Weight     36   0.39   0.02  43   0.48   0.001 
Skeletal Muscular Mass   36   0.09   0.51  42   0.21   0.17 
Total Fat Mass     36   0.35   0.03  42   0.38   0.01 
Sagittal Abdominal Diameter Thigh Muscle Area    37   -0.10   0.55  44   0.31   0.04 
Body Mass Index    36   0.45   0.86  45   0.71   <0.0001 
Body Weight     36   0.45   0.53  45   0.71   <0.0001
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TABLE 6.8 RELATIONSHIPS BETWEEN CHANGES IN BODY COMPOSITION VARIABLE - CONTINUED 
______________________________________________________________________________________________________________________ 
Changes in Body    Changes in Body       POWER Group       SHAM Group 
Composition Variable  Composition Variable   n Standard Coefficient β p   n Standard Coefficient β p 
______________________________________________________________________________________________________________________ 
Sagittal Abdominal Diameter Skeletal Muscular Mass   36   0.14   0.43  43   0.31   0.04 
Total Fat Mass     36   0.37   0.03  43   0.49   0.0008 
Thigh Muscle Area   Body Mass Index    36   0.28   0.10  45   0.01   0.93 
Body Weight     36   0.28   0.19  45   <0.01   0.99 
Skeletal Muscular Mass   36   0.03   0.84  43   0.32   0.04 
Total Fat Mass     36   0.25   0.15  43   -0.20   0.19 
Body Mass Index   Body Weight     36   0.99   <0.0001  47   0.99   <0.0001 
Skeletal Muscular Mass   36   0.35   0.03  45   0.45   0.02 
Total Fat Mass     36   0.79   <0.0001  45   0.66   <0.0001 
Body Weight    Skeletal Muscular Mass   36   0.34   0.04  45    0.46   0.01 
Total Fat Mass     36   0.80   <0.0001  45    0.66   <0.0001 
Skeletal Muscular Mass  Total Fat Mass     36   -0.29   0.09  45   -0.36   0.02 
______________________________________________________________________________________________________________________ 
β coefficient represents the correlation.
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TABLE 6.9 RELATIONSHIPS BETWEEN CHANGE IN METABOLISM AND CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Metabolism    Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Serum Glucose Fasting (mmol/L) Word List Memory   36   -0.25   0.23  47   0.08   0.60    
Word List Recall    36   -0.12   0.59  47   0.05   0.70 
Word List Recognition  36   0.30   0.21  47   0.17   0.24  
Trail Making Test A   36   -0.16   0.46  43   -0.08   0.68 
Trail Making Test B   36   -0.25   0.26  43   0.08   0.66 
DIFFBA     36   -0.28   0.21  43   0.05   0.79 
3MS      36   -0.04   0.79  44   0.09   0.41 
HbA1c (%)      Word List Memory   36   0.01   0.96  45   -0.20   0.21 
Word List Recall    36   0.05   0.84  45   0.04   0.80 
Word List Recognition  36   0.01   0.96  45   -0.07   0.70 
Making Test A    36   0.30   0.14  43   0.22   0.29 
Trail Making Test B   36   -0.03   0.88  43   -0.14   0.49 
DIFFBA     36   0.05   0.83  43   -0.08   0.70 
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TABLE 6.9 RELATIONSHIPS BETWEEN CHANGE IN METABOLISM AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Metabolism  Changes in Cognitive Scores    POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
HbA1c (%)     3MS       36   0.12   0.44  44   0.10   0.40 
Serum Insulin Fasting  Word List Memory    32   -0.09   0.66  38   0.02   0.92 
(mU/L) (log)    Word List Recall     32   0.16   0.47  38   -0.04   0.83 
Word List Recognition   32   -0.05   0.85  38   <-0.01   0.98 
Trail Making Test A    32   -0.18   0.38  37   -0.23   0.22 
Trail Making Test B    32   -0.03   0.88  37   -0.10   0.60 
DIFFBA      32   0.02   0.92  37   -0.19   0.29 
3MS        32   -0.09   0.60  38   <-0.01   0.99 
HOMA2-Beta Cell    Word List Memory    32   -0.06   0.79  32   -0.27   0.10 
Function (%B)    Word List Recall     32   0.21   0.38  32   -0.24   0.10 
Word List Recognition   32   -0.11   0.60  32   -0.26   0.14 
Trail Making Test A    32   -0.10   0.65  31   -0.12   0.57 
Trail Making Test B    32   -0.10   0.68  31   -0.04   0.85
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TABLE 6.9 RELATIONSHIPS BETWEEN CHANGE IN METABOLISM AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Metabolism  Changes in Cognitive Scores    POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
HOMA2-Beta Cell Function DIFFBA      32   -0.16   0.48  31   -0.06   0.80 
(%B)      3MS       32   -0.09   0.61  31    0.06   0.66 
HOMA2-Insulin Resistance Word List Memory    32   -0.06   0.73  37   0.08   0.63 
Word List Recall     32   -0.06   0.80  37   0.05   0.78 
Word List Recognition   32   0.23   0.28  37   -0.11   0.58 
Trail Making Test A    32   0.34   0.07  36   -0.14   0.46 
Trail Making Test B    32   -0.09   0.64  36   -0.10   0.61 
DIFFBA      32   0.04   0.86  36   -0.15   0.42 
3MS       32   -0.08   0.64  37   -0.40   <0.01 
____________________________________________________________________________________________________________________ 
β coefficient represents the correlation. 
For Word List memory, Word List Recall, 3MS, a negative change value represents a worsening score (worse function). 
For the Trail Making Test A, Trail Making Test B, and DIFFBA, a positive change value represents a worsening score(worse function).   
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Difference scores calculated (DIFFBA) as Trail Making Test B minus Trail Making Test A, a positive change value represents a worsening score 
(worse function).  
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
3MS: Modified Mini-mental State Examination
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TABLE 6.10 RELATIONSHIPS BETWEEN CHANGE IN PHYSICAL PERFORMANCE AND CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Physical   Changes in Cognitive Scores    POWER Group       SHAM Group 
Function Exercise Capacity         n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Total Muscle Strength (N) Word List Memory    35   -0.41   0.09  44   -0.13   0.38 
Word List Recall     35   0.23   0.22  44   -0.12   0.48 
Word List Recognition   35   -0.30   0.24  44   -0.08   0.88 
Better Trail Making Test A  35   -0.41   0.03  44   -0.26   0.22 
Trail Making Test B    35   0.25   0.40  44   0.20   0.34 
DIFFBA      35   -0.41   0.15  44   0.13   0.51 
3MS       35   -0.33   0.16  44   0.13   0.50 
Total Muscle Power (w)  Word List Memory    32   -0.15   0.43  44   0.03   0.85 
Word List Recall     32   -0.01   0.98  44   -0.17   0.23 
Word List Recognition   32   0.16   0.32  44   0.13   0.34 
Trail Making Test A    32   -0.18   0.36  44   0.18   0.31  
Trail Making Test B    32   0.09   0.68  44   -0.24   0.15 
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TABLE 6.10 RELATIONSHIPS BETWEEN CHANGE IN PHYSICAL PERFORMANCE AND CHANGE IN COGNITION - CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Physical   Changes in Cognitive Scores    POWER Group       SHAM Group 
Function Exercise Capacity         n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Total Muscle Power (w)  DIFFBA      32   0.02   0.93  44   -0.20   0.23 
Better 3MS      32   0.13   0.33  44   0.01   0.91 
Total Static Balance (sec)  Word List Memory    36   -0.05   0.76  47   0.09   0.48 
Word List Recall     36   -0.21   0.26  47   -0.09   0.53 
Word List Recognition   36   0.08   0.57  47   -0.09   0.51 
Trail Making Test A    35   -0.24   0.16  45   -0.32   0.06  
Trail Making Test B    35   -0.12   0.51  45   -0.20   0.22 
DIFFBA      35   -0.07   0.70  45   -0.08   0.61 
Better 3MS      35   0.27   0.03  46   0.02   0.89 
Habitual Gait Speed (m/sec) Word List Memory    37   -0.08   0.95  48   -0.06   0.85 
Word List Recall     37   0.35   0.06  48   0.09   0.54 
Word List Recognition   37   -0.06   0.59  48   -0.11   0.52 
Trail Making Test A    36   0.03   0.37  46   -0.01   0.95 
Trail Making test B    36   -0.14   0.65  46   -0.07   0.61
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TABLE 6.10 RELATIONSHIPS BETWEEN CHANGE IN PHYSICAL PERFORMANCE AND CHANGE IN COGNITION - CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Physical   Changes in Cognitive Scores    POWER Group       SHAM Group 
Function Exercise Capacity         n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Habitual Gait Speed (m/sec) DIFFBA      36   -0.17   0.47  46   -0.05   0.75 
3MS       36   0.03   0.74  47   -0.11   0.29 
Maximal Gait Speed (m/sec) Word List Memory    37   -0.10   0.66  45   -0.08   0.57 
Word List Recall     37   -0.34   -0.10  45   0.15   0.26 
List Recognition     37   -0.36   0.08  45   0.02   0.88 
Trail Making Test A    36   -0.17   0.39  43   0.05   0.78 
Trail Making test B    36   -0.03   0.89  43   -0.04   0.82 
DIFFBA      36   -0.09   0.65  43   -0.03   0.86 
3MS        36   0.16   0.28  44   0.08   0.45 
Stair Climb Power (w)  Word List Memory    34   -0.31   0.10  39   -0.10   0.95 
Word List Recall     34   0.30   0.54  39   -0.07   0.64 
Word List Recognition   34   0.25   0.24  39   -0.10   0.51 
Trail Making Test A    33   -0.08   0.70  37   0.33   0.10
544 
 
TABLE 6.10 RELATIONSHIPS BETWEEN CHANGE IN PHYSICAL PERFORMANCE AND CHANGE IN COGNITION - CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Physical   Changes in Cognitive Scores    POWER Group       SHAM Group 
Function Exercise Capacity         n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Stair Climb Power (w)  Trail Making test B    33   0.33   0.11  37   -0.02   0.90 
DIFFBA      33   -0.16   0.09  37   0.12   0.50  
3MS       33   -0.03   0.82  38   -0.05   0.12 
Chair Stand (sec)   Word List Memory    30   -0.06   0.76  38   0.05   0.73 
Word List Recall     30   0.02   0.95  38   0.11   0.52 
Better Word List Recognition  30    0.16   0.53  38   0.39   0.02 
Trail Making Test A    29    0.01   0.97  36   -0.15   0.48  
Trail Making test B    29   -0.19   0.47  36   0.06   0.77 
DIFFBA      29   -0.17   0.52  36   -0.01   0.99 
3MS       29   -0.15   0.39  37   -0.13   0.38 
Six Minute Walk Distance Word List Memory     35   -0.05   0.82  45   -0.08   0.55 
(meter)      Word List Recall     35   -0.11   0.58  45   -0.15   0.30 
Word List Recognition   35   <0.01   0.97  45   0.03   0.83 
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TABLE 6.10 RELATIONSHIPS BETWEEN CHANGE IN PHYSICAL PERFORMANCE AND CHANGE IN COGNITION - CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Physical   Changes in Cognitive Scores    POWER Group       SHAM Group 
Function Exercise Capacity         n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Six Minute Walk Distance Trail Making Test A    34   0.01   0.96  44   -0.23   0.21 
(meter)      Trail Making test B    34   -0.07   0.74  44   -0.20   0.27 
DIFFBA      34   -0.07   0.74  44   -0.13   0.48 
3MS       34   0.04   0.80  44   0.10   0.39 
____________________________________________________________________________________________________________________ 
β coefficient represents the correlation. 
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
For Word List memory, Word List Recall, 3MS, a negative change value represents a worsening score (worse function).   
For the Trail Making Test A, Trail Making Test B, and DIFFBA, a positive change value represents a worsening score (worse function).   
Difference scores calculated (DIFFBA) as Trail Making Test B minus Trail Making Test A, a positive change value represents a worsening  
score (worse function). 
3MS: Modified Mini-mental State Examination
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Total Abdominal Adipose   Worse Word List Memory 37   -0.12   0.51  42    0.35   0.01 
Tissue (cm2)      Word List Recall    37   0.33   0.09  42   0.11   0.45 
Word List Recognition  37   0.06   0.76  42   0.01   0.98  
Trail Making Test A   36   -0.11   0.95  41   0.05   0.80 
Worse Trail Making Test B  36   -0.40   0.04  41   0.04   0.81 
Worse DIFFBA    36   -0.34   0.09  41   0.05   0.78 
3MS      36   -0.04   0.79  42   0.07   .54 
Visceral Adipose Tissue (cm2)  Worse Word List Memory 37   0.14   0.44  44   0.31   0.01 
Word List Recall    37   0.08   0.69  44   0.05   0.74 
Worse Word List Recognition 37   -022   0.28  44   -0.06   0.64 
Trail Making Test A   36   <0.01   0.99  44   0.02   0.93 
Trail Making Test B   36   -0.22   0.26  44   -0.04   0.80 
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Visceral Adipose Tissue (cm2)  DIFFBA     36   -0.17   0.38  44   -0.04   0.83  
3MS      36   0.04   0.77  44    0.13   0.20 
Subcutaneous Abdominal   Word List Memory   37   -0.02   0.90  44   0.22   0.11 
Adipose Tissue (cm2)    Worse Word List Recall  37   0.39   0.03  44   0.04   0.76 
Worse Word List Recognition 37   0.14   0.45  44   0.06   0.57 
Trail Making Test A   37   0.02   0.93  42   -0.11   0.55 
Trail Making Test B   37   -0.32   0.08  42   0.20   0.27 
DIFFBA     37   -0.29   0.12  42   0.16   0.35 
3MS      37   -0.10   0.47  42   -0.06   0.60 
Sagittal Adipose Diameter (cm) Worse Word List Memory 37   -0.22   0.26  45   0.34   0.01 
Word List Recall    37   -0.27   0.19  44   0.18   0.24 
Word List Recognition  37   -0.30   0.15  44   0.10   0.95 
Trail Making Test A   36   <0.01   0.99  44   0.14   0.45 
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
_______________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
_______________________________________________________________________________________________________________________ 
Sagittal Adipose Diameter (cm) Trail Making Test B   36   -0.20   0.34  44   -0.21   0.23 
DIFFBA     36   -0.14   0.50  44   0.18   0.30 
3MS      36   -0.20   0.21  44   0.01   0.98 
Thigh Muscle Area (cm2)   Word List Memory   37    0.16   0.38  45   0.05   0.69 
Word List Recall    37   0.25   0.18  45   0.02   0.89 
Word List Recognition  37   0.24   0.21  45   -0.06   0.70 
Better Trail Making Test A 36   -0.34   <0.05  44   0.13   0.47 
Trail Making Test B   36   -0.13   0.50  44   -0.09   0.60 
DIFFBA     36   0.15   0.27  44   0.06   0.61 
3MS      36   -0.23   0.23  44   -0.06   0.73 
Subcutaneous Thigh Fat   Word List Memory   37   0.03   0.87  45   -0.11   0.39 
Area (cm2)      Word List Recall    37   0.27   0.16  45   -0.08   0.56 
Word List Recognition  37   -0.24   0.24  45   -0.03   0.84 
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
_______________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
_______________________________________________________________________________________________________________________ 
Subcutaneous Thigh Fat   Trail Making Test A   36   -0.18   0.32  44   -0.04   0.81 
Area (cm2)      Trail Making Test B   36   -0.19   0.32  44   -0.16   0.36 
DIFFBA     36   -0.23   0.23  44   -0.19   0.28 
3MS      36   0.09   0.54  44   <-0.01   0.99 
Intermuscular Thigh    Word List Memory   37   0.18   0.30  45   -0.06   0.67 
Fat Area (cm2)     Word List Recall    37   -0.05   0.81  45   -0.12   0.42 
Word List Recognition  37   -0.31   0.11  45   0.06   0.68 
Trail Making Test A   36   0.03   0.85  44   -0.10   0.57 
Trail Making Test B   36   0.17   0.40  44   -0.24   0.16 
DIFFBA     36   0.15   0.45  44   -0.28   0.10 
3MS       36   -0.09   0.55  44   0.12   0.29
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Thigh Muscle Density (cm2)  Word List Memory   37   0.18   0.69  45   0.24   0.1 
Word List Recall    37   0.05   0.42  45   -0.11   0.48 
Word List Recognition  37   0.13   0.51  45   0.03   0.85 
Trail Making Test A   36   -0.28   0.14  44   0.03   0.86 
Trail Making Test B   36   -0.07   0.72  44   0.09   0.60 
DIFFBA     36   0.03   0.90  44   0.09   0.60 
3MS      36   -0.22   0.11  44   0.18   0.08 
Body Mass Index (kg/height2)  Worse Word List Memory 36   -0.11   0.56  46   0.38   0.03 
Worse Word List Recall  36   0.48   0.03  46   -0.20   0.13 
Word List Recognition  36   0.01   0.95  46   -0.15   0.30 
Trail Making Test A   36   -0.04   0.85  45   0.06   0.75 
Trail Making Test B   36   0.28   0.15  45   0.18   0.29 
DIFFBA     36   0.28   0.15  45   0.17   0.31
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Body Mass Index (kg/height2)  3MS      36   -0.03   0.81  45   -0.10   0.35 
Waist Circumference (cm)  Word List Memory   34   -0.02   0.91  44   0.12   0.12 
Word List Recall    34   0.36   0.06  44   0.13   0.34 
Word List Recognition  34   -0.06   0.76  44   0.03   0.83 
Trail Making Test A   34   -0.10   0.63  43   -0.26   0.13 
Trail Making Test B   34   -0.11   0.63  43   -0.25   0.14 
DIFFBA     34   -0.07   0.73  43   -0.17   0.30 
3MS      34   0.01   0.93  43   0.08   0.44 
Naked Weight (kg)    Worse Word List Memory 36   0.07   0.72  47   0.41   <0.01 
Worse Word List Recall  36   0.44   0.01  46   0.19   0.16 
Word List Recognition  36   <0.01   0.97  46   0.13   0.34 
Trail Making Test A   36   0.03   0.87  46   -0.10   0.57 
Trail Making Test B   36   -0.31   0.09  46   -0.22   0.18
552 
 
TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Naked Weight (kg)    DIFFBA     36   -0.31   0.09  46   -0.21   0.21 
3MS      36   0.05   0.74  46   0.08   0.42 
Skeletal Muscular Mass (kg)  Better Word List Memory  36    0.36   0.04  45   0.13   0.34 
Better Word List Recall  36   0.34   0.09  45   0.02   0.89 
Word List Recognition  36   <0.01   0.99  45   -0.01   0.92 
Trail Making Test A   36   0.23   0.22  44   0.12   0.47 
Trail Making Test B   36   0.06   0.78  44   -0.11   0.57 
DIFFBA     36   -0.02   0.92  44   <0.01   0.98 
Worse 3MS     36   -0.06   0.65  44   0.20   <0.05 
Free Muscular Mass (kg)   Word List Memory   36    0.32   0.08  44   0.15   0.26 
Word List Recall    36   0.38   0.06  44   0.04   0.78 
Word List Recognition  36   0.06   0.79  44   -0.02   0.89 
Trail Making Test A   36   -0.24   0.20  44    0.14   0.40 
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Free Muscular Mass (kg)   Trail Making Test B   36   -0.04   0.84  44   0.07   0.67 
DIFFBA     36   -0.11   0.57  44   -0.05   0.78 
3MS      36   -0.03   0.82  44   0.20   0.06 
Total Fat Mass (kg)    Worse Word List Memory 36   -0.19   0.30  43   0.28   0.03 
Word List Recall    36   0.24   0.22  43   0.06   0.67 
Word List Recognition  36   -0.07   0.71  43   0.05   0.74 
Trail Making Test A   36   -0.17   0.37  42   -0.11   0.48 
Trail Making Test B   36   -0.34   0.06  42   -0.18   0.28 
DIFFBA     36   -0.27   0.14  42   -0.16   0.35 
3MS      36   0.06   0.67  42   -0.09   0.39 
%Muscle Mass     Word List Memory   36   0.29   0.11  45   0.11   0.49 
Word List Recall    36   -0.09   0.64  45   -0.06   0.69 
Word List Recognition  36   0.03   0.90  45   <-0.01   0.99 
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TABLE 6.11 RELATIONSHIPS BETWEEN CHANGE IN BODY COMPOSITION AND CHANGE IN COGNITION – CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Body Composition Changes in Cognitive Scores   POWER Group       SHAM Group 
n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
%Muscle Mass     Trail Making Test A   36   -0.13   0.50  44   0.03   0.85 
Trail Making Test B   36   0.32   0.11  42   0.11   0.51 
DIFFBA     36   0.25   0.22  42   0.12   0.49 
3MS      36   -0.05   0.71  42   0.17   0.10 
____________________________________________________________________________________________________________________ 
β coefficient represents the correlation. 
For Word List memory, Word List Recall, 3MS, a negative change value represents a worsening score (worse function). 
For the Trail Making Test A, Trail Making Test B, and DIFFBA, a positive change value represents a worsening score (worse function). 
Difference scores calculated (DIFFBA) as Trail Making Test B minus Trail Making Test A, a positive change value represents a worsening  
score (worse function). 
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
3MS: Modified Mini-mental State Examination
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TABLE 6.12 RELATIONSHIPS BETWEEN CHANGE IN PSYCHOSOCIAL STATUS, QUALITY OF LIFE, AND PHYSICAL ACTIVITY 
CHANG IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Psychosocial  Changes in Cognitive Scores    POWER Group       SHAM Group 
Status, Quality of Life and        n  Standard Coefficient β p  n  Standard Coefficient β p 
Habitudinal Physical Activity 
____________________________________________________________________________________________________________________ 
 
Physical Health Summary Word List Memory   377   -0.15   0.45  46   0.09    0.50  
   Scales SF-36® (score)  Word List Recall    37    <-0.01   0.97  46   -0.03    0.81 
Word List Recognition  37   0.02   0.91  46   -0.03    0.85 
Trail Making Test A   36   <0.01   0.96  44   0.12    0.52 
Trail Making Test B   36   -0.04   0.86  44   0.14    0.30 
DIFFBA     36   -0.09   0.68  44   0.24    0.16 
3MS      36   0.15   0.34  44   -0.01    0.90 
Mental Health Summary  Word List Memory   37   0.11   0.67  46   -0.15    0.30 
Scales SF-36® (score)  Word List Recall    37   0.33   0.25  46    0.21    0.15 
Word List Recognition  37   -0.06   0.83  46   0.12    0.42 
Trail Making Test A   36   -0.06   0.82  44   -0.06    0.76
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TABLE 6.12 RELATIONSHIPS BETWEEN CHANGE IN PSYCHOSOCIAL STATUS, QUALITY OF LIFE, AND PHYSICAL ACTIVITY  
CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Psychosocial  Changes in Cognitive Scores    POWER Group       SHAM Group 
Status, Quality of Life and        n  Standard Coefficient β p   n Standard Coefficient β p 
Habitudinal Physical Activity 
____________________________________________________________________________________________________________________ 
Mental Health Summary  Trail Making Test B   36   -0.05   0.86   44   0.15   0.45 
Scales SF-36® (score)  DIFFBA     36   0.13   0.55   44   -0.03   0.80 
3MS       36   -0.05   0.87   44   0.14   0.47 
Physical Activity Scale   Word List Memory   28   0.07   0.72   35   0.23   0.14 
for The Elderly (score)  Word List Recall    28   0.11   0.60   35   0.18   0.25 
Word List Recognition  28   -0.45   0.06   35   -0.09   0.63 
Trail Making Test A   28   <0.01   0.99   33   -0.15   0.49 
Trail Making Test B   28   -0.30   0.21   33   -0.30   0.18 
DIFFBA     28    -0.24   0.32   33   -0.27   0.11 
3MS      28   0.36   0.13   33   -0.23   0.22 
Geriatric Depression   Word List Memory   36   -0.33   0.07   46   0.12   0.32 
Scale (/30)     Word List Recall    36   <-0.01   0.99   46   -0.12   0.37 
Word List Recognition  36   0.19   0.37   46   0.01   0.94 
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TABLE 6.12 RELATIONSHIPS BETWEEN CHANGE IN PSYCHOSOCIAL STATUS, QUALITY OF LIFE, AND PHYSICAL ACTIVITY  
CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Psychosocial  Changes in Cognitive Scores    POWER Group       SHAM Group 
Status, Quality of Life and        n  Standard Coefficient β p   n Standard Coefficient β p 
Habitudinal Physical Activity 
____________________________________________________________________________________________________________________ 
Geriatric Depression   Trail Making Test B   36   0.11   0.59   45   -0.14   0.37 
Scale (/30)     DIFFBA     36   0.16   0.55   45   -0.16   0.31 
3MS      36   0.11   0.43   46   0.02   0.87 
____________________________________________________________________________________________________________________ 
β coefficient represents the correlation.  
For Word List memory, Word List Recall, 3MS, a negative change value represents a worsening score (worse function). 
For the Trail Making Test A, Trail Making Test B, and DIFFBA, a positive change value represents a worsening score (worse function). 
Difference scores calculated (DIFFBA) as Trail Making Test B minus Trail Making Test A, a positive change value represents a worsening  
score (worse function). 
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
3MS: Modified Mini-mental State Examination
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TABLE 6.13 RELATIONSHIPS BETWEEN CHANGE IN INFLAMMATION AND ADIPOKINES AND CHANGE IN COGNITION 
____________________________________________________________________________________________________________________ 
Changes in Inflammation  Changes in Cognitive Scores    POWER Group       SHAM Group 
and Adiponectin            n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________  
C-reactive Protein (mg/L)  Word List Memory    29   0.23   0.31  36   -0.15   0.32 
Word List Recall     29   0 .26   0.30  36    0.07   0.69 
Worse Word List Recognition  29   0.17   0.51  36   -0.35   0.02 
Trail Making Test A    29   -0.13   0.59  36   -0.01   0.99 
Trail Making Test B    29   0.16   0.51  36   -0.14   0.60 
DIFFBA      29   0.11   0.64  36   -0.16   0.67 
3MS       29   -0.16   0.22  36   -0.10   0.92  
Serum High Molecule  Word List Memory    17   -0.31   0.34  16   -0.24   0.16 
Weight Adiponectin (ng/ml) Word List Recall     17   -0.52   0.14  16   0.06   0.84 
Word List Recognition   17   -0.40   0.18  16   0.05   0.85 
Trail Making Test A    17   0.22   0.46  16   -0.03   0.92 
Better Trail Making Test B  17   -0.12   0.75  16   -0.65   0.03
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TABLE 6.13 RELATIONSHIPS BETWEEN CHANGE IN INFLAMMATION AND ADIPOKINES AND CHANGE IN COGNITION – 
CONTINUED 
____________________________________________________________________________________________________________________ 
Changes in Inflammation  Changes in Cognitive Scores    POWER Group       SHAM Group 
and Adiponectin            n Standard Coefficient β p   n Standard Coefficient β p 
____________________________________________________________________________________________________________________ 
Serum High Molecule  Better DIFFBA     17   -0.14   0.69  16   -0.68   0.04 
Weight Adiponectin (ng/ml) 3MS       17   -0.24   0.44  16   0.13   0.524 
Serum Total Adiponection Word List Memory    17   0.27   0.47  16   0.05   0.77 
(ng/ml)      Word List Recall     17   0.66   0.09  16   0.35   0.28 
Word List Recognition   17   0.21   0.56  16   0.06   0.79 
Trail Making Test A    17   -049   0.16  16   -0.12   0.72 
Trail Making Test B    17   0.30   0.45  16   -0.49   0.11 
DIFFBA       17   0.37   0.35  16   -0.54   0.09 
Better 3MS      17   0.57   0.03  16   0.10   0.59 
Serum High-Molecular  Word List Memory    17   0.47   0.11  16   -0.33   0.01 
Weight/Total Adiponectin  Word List Recall     17   0.20   0.52  16    0.42   0.10 
Ratio      Word List Recognition   17   -0.24   0.39  16   0.09   0.69 
Trail Making Test A    17   0.05   0.86  16   0.24   0.39
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TABLE 6.13 RELATIONSHIPS BETWEEN CHANGE IN INFLAMMATION AND ADIPOKINES AND CHANGE IN COGNITION – 
CONTINUED 
________________________________________________________________________________________________________________ 
Changes in Inflammation  Changes in Cognitive Scores   POWER Group       SHAM Group 
and Adiponectin           n Standard Coefficient β p   n Standard Coefficient β p 
________________________________________________________________________________________________________________ 
Serum High-Molecular  Trail Making Test B   17   -0.20   0.53  16   0.40   0.17 
Weight/Total Adiponectin  DIFFBA     17   -0.02   0.96  16    0.44   0.11 
Ratio      3MS      17   -0.24   0.28  16   -0.02   0.90 
________________________________________________________________________________________________________________ 
β coefficient represents the correlation. 
For Word List memory, Word List Recall, 3MS, a negative change value represents a worsening score (worse function). 
For the Trail Making Test A, Trail Making Test B, and DIFFBA, a positive change value represents a worsening score (worse function). 
*Difference scores calculated (DIFFBA) as Trail Making Test B minus Trail Making Test A, a positive change value represents a worsening score 
(worse function). 
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score. 
3MS: Modified Mini-mental State Examination
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FIGURE LEGENDS 
Figure 6.1: Consort Flow Diagram 
n=sample size 
Figure 6.2-6.8: Changes in the Word List Memory, Word List Recall, Word List Recognition, Trail Making Test A, Trail Making Test B, 
DIFFBA (Difference score between Trail Making Test B minus Trail Making Test A), and Modified Mini-mental State Examination (3MS) 
score 
Figures showed change in the Word List Memory, Word List Recall, Word List Recognition, Trail Making Test A, Trail Making Test B, DIFFBA 
(Difference score between Trail Making Test B minus Trail Making Test A), and 3MS scores at baseline, 6 month, and 12 month intervention.  
Blue and red lines indicate the PRT and SHAM groups, respectively.  Group mean and standard difference are shown in older adults with T2DM.  
Models are adjusted for age, gender, years of education, duration of diabetes, SF-36 Mental Component Summary, HbA1c, and cognitive score 
Figure 6.9 Changes in HOMA 2-IR vs Change in 3MS (score) 
Figure 6.9.1 Change in HOMA 2-IR vs Change in 3MS (score) in the POWER group 
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Figure 6.9.2 Change in HOMA 2-IR vs Change in 3MS (score) in the SHAM group 
Figure 6.10 Change in Total Static Balance (sec) vs Change in 3MS (score） 
Figure 6.10.1 Change in Total Static Balance (sec) vs Change in 3MS (score) in the POWER group 
Figure 6.10.2 Change in Total Static Balance (sec) vs Change in 3MS (score) in the SHAM group 
Figure 6.11 Change in Chair Stand (sec) vs Change in Word List Recognition (score) 
Figure 6.11.1 Change in Chair Stand (sec) vs Change in Word List Recognition (score) in the POWER group 
Figure 6.11.2 Change in Chair Stand (sec) vs Change in Word List Recognition (score) in the SHAM group 
Figure 6.12 Change in Skeletal Muscle Mass (kg) vs Change in Word List Memory (score) 
Figure 6.12.1 Change in Skeletal Muscle Mass (kg) vs Change in Word List Memory (score) in the POWER group 
Figure 6.12.2 Change in Skeletal Muscle Mass (kg) vs Change in Word List Memory (score) in the SHAM group 
Figure 6.13 Change in Thigh Muscle Area (cm2) vs Change in Trail Making Test A (score) 
Figure 6.13.1 Change in Thigh Muscle Area (cm2) vs Change in Trail Making Test A (score) in the POWER group 
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Figure 6.13.2 Change in Thigh Muscle Area (cm2) vs Change in Trail Making Test A (score) in the SHAM group 
Figure 6.14 Change in Skeletal Muscle Mass (kg) vs Change in 3MS (score) 
Figure 6.14.1 Change in Skeletal Muscle Mass (kg) vs Change in 3MS (score) in the POWER group 
Figure 6.14.2 Change in Skeletal Muscle Mass (kg) vs Change in 3MS (score) in the SHAM group 
Figure 6.15 Change in Total Abdominal Adipose tissue (cm2) vs Change in Trail Making Test B (score) 
Figure 6.15.1 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Trail Making Test B (score) in the POWER group 
Figure 6.15.2 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Trail Making Test B (score) in the SHAM group 
Figure 6.16 Change in Subcutaneous Adipose Tissue (cm2) vs Change in Word List Recall (score) 
Figure 6.16.1 Change in Subcutaneous Adipose Tissue (cm2) vs Change in Word List Recall (score) in the POWER group 
Figure 6.16.2 Change in Subcutaneous Adipose Tissue (cm2) vs Change in Word List Recall (score) in the SHAM group 
Figure 6.17 Change in Body Mass Index and Change in Word List Recall (score) 
Figure 6.17.1 Change in Body Mass Index and Change in Word List Recall (score) in the POWER group 
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Figure 6.17.2 Change in Body Mass Index and Change in Word List Recall (score) in the SHAM group 
Figure 6.18 Change in Body Weight (kg) vs change in Word List Recall (score) 
Figure 6.18.1 Change in Body Weight (kg) vs change in Word List Recall (score) in the POWER group 
Figure 6.18.2 Change in Body Weight (kg) vs change in Word List Recall (score) in the SHAM group 
Figure 6.19 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Word List Memory (score) 
6.19.1 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Word List Memory (score) in the POWER group 
Figure 6.19.2 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Word List Memory (score) in the SHAM group 
Figure 6.20 Change in Visceral Adipose Tissue (cm2) vs Change in Word List Memory (score)  
Figure 6.20.1 Change in Visceral Adipose Tissue (cm2) vs Change in Word List Memory (score) in the POWER group 
Figure 6.20.2 Change in Visceral Adipose Tissue (cm2) vs Change in Word List Memory (score) in the SHAM group 
Figure 6.21 Change in Body Mass Index vs Change in Word List Memory (score) 
Figure 6.21.1 Change in Body Mass Index vs Change in Word List Memory (score) in the POWER group 
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Figure 6.21.2 Change in Body Mass Index vs Change in Word List Memory (score) in the SHAM group 
Figure 6.22 Change in Body Weight (kg) vs Change in Word List Memory (score) 
Figure 6.22.1 Change in Body Weight (kg) vs Change in Word List Memory (score) in the POWER group 
Figure 6.22.2 Change in Body Weight (kg) vs Change in Word List Memory (score) in the SHAM group 
Figure 6.23 Change in Total Adiponectin (ng/ml) vs Change in 3MS (score) 
Figure 6.23.1 Change in Total Adiponectin (ng/ml) vs Change in 3MS (score) in the POWER group 
Figure 6.23.2 Change in Total Adiponectin (ng/ml) vs Change in 3MS (score) in the SHAM group 
Figure 6.24 Change in HMW Adiponectin (ng/ml) vs Change in Trail Making Test B (score) 
Figure 6.24.1 Change in HMW Adiponectin (ng/ml) vs Change in Trail Making Test B (score) in the POWER group 
Figure 6.24.2 Change in HMW Adiponectin (ng/ml) vs Change in Trail Making Test B (score) in the SHAM group 
Figure 6.25 Change in HMW Adiponectin (ng/ml) vs Change in Pure Executive Function (difference score between Trail Making Test B minus 
Trail Making Test A) 
566 
 
Figure 6.25.1 Change in HMW Adiponectin (ng/ml) vs Change in Pure Executive Function (difference score between Trail Making Test B 
minus Trail Making Test A) in the POWER group 
Figure 6.25.2 Change in HMW Adiponectin (ng/ml) vs Change in Pure Executive Function (difference score between Trail Making Test B 
minus Trail Making Test A) in the SHAM group 
Figure 6.26 Change in C - reactive protein (mg/L) vs Change in Word List Recognition (score) 
Figure 6.26.1 Change in C - reactive protein (mg/L) vs Change in Word List Recognition (score) in the POWER group 
Figure 6.26.2 Change in C - reactive protein (mg/L) vs Change in Word List Recognition (score) in the SHAM group 
Figure 6.27 Change in Change in Total Muscle Strength (N) vs Change in Word List Recognition (score) 
Figure 6.27.1 Change in Total Muscle Strength (N) vs Change in Trail Making Test A (score) in the POWER group 
Figure 6.27.2 Change in Total Muscle Strength (N) vs Change in Trail Making Test A (score) in the SHAM group
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FIGURE 6.1 CONSORT FLOW DIAGRAM 
Enrolment 
 
 
 
 
 
 
 
Allocation 
                                
 
      
 
  Follow-up 
 
 
 
 
Analysis 
 
Assessed for eligibility 
(n=427) 
SHAM Group 
Allocated to intervention (n=54) 
 Withdrew prior to commencing 
intervention (n=1) 
 Received allocated intervention 
(n=53) 
POWER Group 
Allocated to intervention (n=49) 
 Withdrew prior to commencing 
intervention (n=2) 
 Received allocated intervention 
(n=47) 
 Excluded (n=324) 
 Not meeting inclusion criteria 
(n=285) 
 Declined to participate (n=15) 
 Other reasons (n=24) 
 
 
47 Included in primary analysis 
Randomized (n=103) 
Lost to follow-up (n=4) 
Medical, (n=2),  
Commitment issue (n=2) 
Discontinued intervention (n=1) 
Lost to follow-up (n=10) 
Medical (n=2), 
Commitment issue (n=1),  
Too hard (n=5),  
Disinterest (n=1),  
Adverse event (n=1) 
Discontinued intervention (n=4) 
53 Included in primary analysis 
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FIGURE 6.2 CHANGES IN THE WORD LIST MEMORY SCORES OVER 12 
MONTHS 
 
Panels showed change in Word List Memory scores at baseline, 6 month, and 12 month 
intervention.  Blue and red lines indicate the POWER and SHAM groups, respectively.  
Group mean and standard deviation are shown in older adults with T2DM.  The linear 
mixed models revealed significant time effect (p<0.001) only, but not group × time 
interactions in Word List Memory (p=0.54).  I bar note the standard  
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FIGURE 6.3 CHANGES IN THE WORD LIST RECALL SCORES OVER 12 
MONTHS 
 
Panels showed change in Word List recall scores at baseline, 6month, and 12 month 
intervention.  Blue and red lines indicate the POWER and SHAM groups, respectively.  
Group mean and standard deviation are shown in older adults with T2DM.  The linear 
mixed models revealed significant time effect (p<0.001) only, but not group × time 
interactions in Word List Recall (p=0.19).  I bar note the standard deviation.  
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FIGURE 6.4 CHANGES IN THE WORD LIST RECOGNITION SCORES OVER 12 
MONTHS 
 
Panels showed change in Word List recognition scores at baseline, 6 month, and 12 
month intervention.  Blue and red lines indicate the POWER and SHAM groups, 
respectively.  Group mean and standard deviation are shown in older adults with 
T2DM.  The linear mixed models revealed insignificant time effect (p=0.75) and 
group × time interactions in Word List Recognition (p=0.33).  I bar note the standard 
deviation.   
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FIGURE 6.5 CHANGES IN THE TRIAL MAKING TEST A SCORES OVER 12 
MONTHS 
 
Panels showed change in Trial Making Test A scores at baseline, 6 month, and 12 month 
intervention.  Blue and red lines indicate the POWER and SHAM groups, respectively.  
Group mean and standard deviation are shown in older adults with T2DM.  The linear 
mixed models revealed significant time effect (p<0.001) only, but not group × time 
interactions in Trail Making Test A (P=0.73).  I bar note the standard deviation.
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FIGURE 6.6 CHANGES IN THE TRAIL MAKING TEST B SCORES OVER 12 
MONTHS 
 
Panels showed change in Trail Making Test B scores at baseline, 6 month, and 12 month 
intervention.  Blue and red lines indicate the POWER and SHAM groups, respectively.  
Group mean and standard deviation are shown in older adults with T2DM.  The linear 
mixed models revealed significant time effect (p=0.02) and group × time interactions 
in Trail Making Test B (P=0.03).  I bar note the standard deviation.   
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FIGURE 6.7 CHANGES IN THE DIFFBA SCORES OVER 12 MONTHS 
 
DIFFBA; difference scores between Trail Making Test B minus Trail Making Test A.  
Panels showed change in DIFFBA scores at baseline, 6 month, and 12 month 
intervention.  Blue and red lines indicate the POWER and SHAM groups, respectively.  
Group mean and standard deviation are shown in older adults with T2DM.  The linear 
mixed models did not revealed significant group × time interactions in DIFFBA 
(P=0.83) and significant time effect (p=0.43).  I bar note the standard deviation.   
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FIGURE 6.8 CHANGES IN THE MODIFIED MINI-MENTAL STATE 
EXAMINATION SCORES OVER 12 MONTHS 
 
Panels showed change in 3MS scores at baseline, 6 month, and 12 month intervention.  
Blue and red lines indicate the POWER and SHAM groups, respectively.  Group mean 
and standard deviation are shown in older adults with T2DM.  The linear mixed 
models revealed significant time effect (p<0.001) and group × time interactions in 3MS 
(P=0.04).  I bar note the standard deviation.
575 
 
FIGURE 6.9 CHANGE IN HOMA 2 IR VS CHANGE IN MODIFIED MINI-
MENTAL STATE EXAMINATION (SCORE)  
Figure 6.9.1 Change in HOMA 2 IR vs Change in 3MS (score) in the POWER group 
 
 
Figure 6.9.2 Change in HOMA 2 IR vs Change in 3MS (score) in the SHAM group 
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FIGURE 6.10 CHANGE IN TOTAL STATIC BALANCE VS CHANGE IN 
MODIFIED MINI-MENTAL STATE EXAMINATION (SCORE) 
6.10.1 Change in Total Static Balance vs Change in 3MS (score) in the POWER group 
 
 
6.10.2 Change in Total Static Balance vs Change in 3MS (score) in the SHAM group 
  
-6
-4
-2
0
2
4
6
8
C
h
a
n
g
e
 in
 M
o
d
ifi
e
d
 M
in
i-
M
e
n
ta
l S
ta
te
 E
x
a
m
in
a
tio
n
 (
s
c
o
re
)
-20 -15 -10 -5 0 5 10 15 20 25
Change in Total Static Balance (sec)
-8
-6
-4
-2
0
2
4
6
8
10
12
14
C
h
a
n
g
e
 in
 M
o
d
ifi
e
d
 M
in
i-
M
e
n
ta
l S
ta
te
 E
x
a
m
in
a
tio
n
 (
s
c
o
re
)
-20 -15 -10 -5 0 5 10 15
Change in Total Static Balance (sec)
n=46, r =0.02, p=0.89 
n=35, r =0.27, p=0.03 
577 
 
FIGURE 6.11 CHANGE IN CHAIR STAND (SEC) VS CHANGE IN WORD LIST 
RECOGNITION (SCORE) 
Figure 6.11.1 Change in Chair Stand (sec) vs Change in Word List Recognition (score) 
in the POWER group 
 
 
Figure 6.11.2 Change in Chair Stand (sec) vs Change in Word List Recognition (score) 
in the SHAM group 
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FIGURE 6.12 CHANGE IN SKELETAL MUSCLE MASS VS CHANGE IN WORD 
LIST MEMORY (SCORE) 
Figure 6.12.1 Change in Skeletal Muscle Mass vs Change in Word List Memory (score) 
in the POWER group 
 
 
Figure 6.12.2 Change in Skeletal Muscle Mass vs Change in Word List Memory (score) 
in the SHAM group 
  
-6
-4
-2
0
2
4
6
8
10
12
C
h
a
n
g
e
 in
 W
o
rd
 L
is
t 
 M
e
m
o
ry
 (
s
c
o
re
)
-3 -2 -1 0 1 2 3 4
Change in Skeletal Muscle Mass (kg)
-8
-6
-4
-2
0
2
4
6
8
10
12
C
h
a
n
g
e
 in
 W
o
rd
 L
is
t 
 M
e
m
o
ry
 (
s
c
o
re
)
-4 -3 -2 -1 0 1 2 3 4
Change in Skeletal Muscle Mass (kg)
n=35, r=0.38, p=0.03 
n=44, r=-0.13, p=0.34 
579 
 
FIGURE 6.13 CHANGE IN THIGH MUSCLE AREA VS CHANGE IN TRAIL 
MAKING TEST A (SCORE) 
Figure 6.131 Change in Thigh Muscle Area vs Change in Trail Making Test A (score) 
in the POWER group 
 
 
Figure 6.13.2 Change in Thigh Muscle Area vs Change in Trail Making Test A (score) 
in the SHAM group 
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FIGURE 6.14 CHANGE IN SKELETAL MUSCLE MASS (KG) VS CHANGE IN 
MODIFIED MINI-MENTAL STATE EXAMINATION (SCORE) 
Figure 6.14.1 Change in Skeletal Muscle Mass (kg) vs Change in 3MS (score) in the 
POWER group 
 
 
Figure 6.14.2 Change in Skeletal Muscle Mass (kg) vs Change in 3MS score in the 
SHAM group 
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FIGURE 6.15 CHANGE IN TOTAL ABDOMINAL ADIPOSE TISSUE (CM2) VS 
CHANGE IN TRAIL MAKING TEST B (SCORE) 
Figure 6.15.1 Change in Total Abdominal Adipose Tissue (cm2) vs Change in  
Trail Making Test B (score) in the POWER group 
 
 
Figure 6.15.2 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Trail 
Making Test B (score) in the SHAM group 
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FIGURE 6.16 CHANGE IN SUBCUTANEOUS ADIPOSE TISSUE (CM2) VS 
CHANGE IN WORD LIST RECALL (SCORE) 
Figure 6.16.1 Change in Subcutaneous Adipose Tissue (cm2) vs Change in Word List 
Recall (score) in the POWER group 
 
 
Figure 6.16.2 Change in Subcutaneous Adipose Tissue (cm2) vs Change in Word List 
Recall (score) in the POWER group 
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FIGURE 6.17 CHANGE IN BODY MASS INDEX VS CHANGE IN WORD LIST 
RECALL (SCORE) 
Figure 6.17.1 Change in Body Mass Index vs Change in Word List Recall (score) in the 
POWER group 
 
 
Figure 6.17.2 Change in Body Mass Index vs Change in Word List Recall (score) in the 
SHAM group 
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FIGURE 6.18 CHANGE IN BODY WEIGHT (KG) VS CHANGE IN WORD LIST 
RECALL (SCORE) 
Figure 6.18.1 Change in Body Weight (kg) vs Change in Word List Recall (score) in 
POWER group 
 
 
Figure 6.18.2 Change in Body Weight (kg) vs Change in Word List Recall (score) in 
SHAM group 
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FIGURE 6.19 CHANGE IN TOTAL ABDOMINAL ADIPOSE TISSUE (CM2) VS 
CHANGE IN WORD LIST MEMORY (SCORE) 
Figure 6.19.1 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Word 
List Memory (score) in the POWER group 
 
Figure 6.19.2 Change in Total Abdominal Adipose Tissue (cm2) vs Change in Word 
List Memory (score) in the SHAM 
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FIGURE 6.20 CHANGE IN VISCERAL ADIPOSE TISSUE (CM2) VS CHANGE IN 
WORD LIST MEMORY (SCORE) 
Figure 6.20.1 Change in Visceral Adipose Tissue (cm2) vs Change in Word List 
Memory (score) in the POWER group 
 
 
Figure 6.20.2 Change in Visceral Adipose Tissue (cm2) vs Change in Word List 
Memory (score) in the SHAM group 
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FIGURE 6.21 CHANGE IN BODY MASS INDEX (CM2) VS CHANGE IN WORD 
LIST MEMORY (SCORE) 
Figure 6.21.1 Change in Body Mass Index vs Change in Word List Memory (score) in 
the POWER group 
 
Figure 6.21.2 Change in Body Mass Index vs Change in Word List Memory (score) in 
the SHAM group 
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FIGURE 6.22 CHANGE IN BODY WEIGHT VS CHANGE IN WORD LIST 
MEMORY (SCORE) 
Figure 6.22.1 Change in Body Weight vs Change in Word List Memory (score) in the 
POWER 
 
 
Figure 6.22.2 Change in Body Weight vs Change in Word List Memory (score) in the 
SHAM 
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FIGURE 6.23 CHANGE IN SERUM TOTAL ADIPONECTIN (NG/ML) VS 
CHANGE IN MODIFIED MINI-MENTAL STATE EXAMINATION (SCORE) 
Figure 6.23.1 Change in Serum Total Adiponectin (ng/ml) vs Change in 3MS (score) in 
the POWER group 
 
Figure 6.23.2 Change in Serum Total Adiponectin (ng/ml) vs Change in 3MS (score) in 
the SHAM group 
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FIGURE 6.24 CHANGE IN SERUM HMW ADIPONECTIN (NG/ML) VS CHANGE 
IN TRAIL MAKING TEST B (SCORE) 
Figure 6.24.1 Change in Serum HMW Adiponectin (ng/ml) vs Change in Trail Making 
Test B (score) in the POWER group 
 
 
Figure 6.24.2 Change in Serum HMW Adiponectin (ng/ml) vs Change in Trail Making 
Test B (score) in the SHAM group 
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FIGURE 6.25 CHANGE IN SERUM HMW ADIPONECTIN (NG/ML) VS CHANGE 
IN PURE EXECUTIVE FUNCTION (DIFFERENCE SCORE BETWEEN TRAIL 
MAKING TEST B MINUS TRAIL MAKING TEST A)  
Figure 6.25.1 Change in Serum HMW adiponectin (ng/ml) vs Change in Pure Executive 
Function in the POWER group (Difference score between Trail Making Test B minus 
Trail Making Test A) 
 
Figure 6.25.2 Change in Serum HMW Adiponectin (ng/ml) vs Change in Pure 
Executive Function in the SHAM group (Difference score between Trail Making Test 
B minus Trail Making Test A) 
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FIGURE 6.26 CHANGE IN SERUM HMW ADIPONECTIN/TOTAL 
ADIPONECTIN RATIO VS CHANGE IN WORD LIST MEMORY (SCORE)  
Figure 6.26.1 Change in Serum HMW Adiponectin / Total Adiponectin Ratio vs 
Change in Word List Memory (score) in the POWER group 
 
 
Figure 6.26.2 Change in Serum HMW Adiponectin / Total Adiponectin Ratio vs 
Change in Word List Memory (score) in the SHAM group 
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FIGURE 6.27 CHANGE IN C-REACTIVE PROTEIN (MG/L) VS CHANGE IN 
WORD LIST RECOGNITION (SCORE) 
Figure 6.27.1 Change in C-reactive protein (mg/L) vs Change in Word List Recognition 
(score) in the POWER group 
 
Figure 6.27.2 Change in C-reactive protein (mg/L) vs Change in Word List Recognition 
(score) 
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FIGURE 6.28 CHANGE IN TOTAL MUSCLE STRENGTH (N) VS CHANGE IN TRAIL 
MAKING TEST A (SCORE) 
Figure 6.28.1 Change in Total Muscle Strength (N) vs Change in Trail Making Test A (score) in 
the POWER group 
 
Figure 6.28.2 Change in Total Muscle Strength (N) vs Change in Trail Making Test A (score) in 
the SHAM group 
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CHAPTER 7 
DISCUSSION AND CONCLUSIONS 
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7.1 DISCUSSION 
The aims of this thesis were firstly to outline the current level of evidence for the morphological, 
biochemical, and functional adaptations in the brain to exercise training from animal models and 
human clinical trials with diabetes or insulin resistance or impaired glucose tolerance, secondly to 
investigate the correlates of cognitive function and the cognitive benefits of power training in older 
adults with T2DM; and finally to identify possible underlying mechanisms of benefit, in particular 
modulation of insulin sensitivity and glucose homeostasis, body composition, psychosocial status, 
physical activity level, systemic inflammatory cytokines, and adipokines. 
CHAPTER 2 provided a review of morphology, biochemistry, and function in the brain after any 
form of exercise intervention within animal models with diabetes or insulin resistance or 
hyperglycaemia.  The purpose of this review was to examine changes at the level of neurogenesis, 
metabolism, and function which may explain the overall benefits of exercise on brain plasticity in 
animal models.  The most consistent adaptations were in the areas of improved cell proliferation, 
synaptic plasticity, dendritic spine density, brain-derived neurotrophic factor (BDNF), 
neurotransmitter (glutamate), glucocorticoid receptor in the hippocampus, as well as memory 
testing, with inconsistent evidence for beneficial adaptations in insulin levels.  Some of those 
studies1-3 reported concomitant correlations between improved memory and adaptations to 
exercise in the areas of cell proliferation, synaptic plasticity, and nerve growth factor.  However, 
only one randomised controlled trial (RCT) reporting the concomitant relationship between new 
neuron cell and memory existed, with a small number of animals involved, so preliminary results 
reviewed here still need to be confirmed in additional larger controlled trials in animal models.  
Future studies will need to refine the design of animal studies investigating the cognitive effects 
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of exercise to increase their relevance and translatability to humans.  In particular, the use of 
animal models representative of T2DM rather than T1DM, and exercise paradigms which are 
voluntary rather than forced, and anabolic in addition to aerobic, and would advance knowledge 
in this field. 
CHAPTER 3 examined the existing literature on the cognitive adaptations to any form of exercise 
intervention or physical activity exposure within individuals with T2DM or impaired glucose 
tolerance, and investigated the relationships between glucose metabolism and cognition for an at-
risk group of older adults.  This review only identified 5 studies that assessed the effects of 
exercise or physical activity on cognitive function and explored the relationship between changes 
in indices of either insulin resistance or glucose homeostasis and change in cognition following an 
exercise intervention.  The data from these limited studies indicate that improvements in 
cognitive function, when they occur, can be partly explained by improvements in insulin resistance 
and glucose homeostasis, but the effect of exercise was inconsistent and modest across these 
cohorts.  Notably, only two of the studies were RCTs, with a small number of participants 
involved, and few potentially mechanistic factors measured.  No studies of anabolic exercise 
exposure and cognition were identified in this cohort.  Thus, given the limited data available, 
additional robust research is required to fully understand the effects of exercise/physical activity 
exposure on cognitive function in individuals with T2DM, and to determine whether exercise may 
assist in reduction of incident dementia in this vulnerable cohort. 
CHAPTER 4 described the methodology of this GREAT2DO trial.  This included an overview 
of the design, rationale, and methods of the GREAT2DO trial.  The general aim of this 
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GREAT2DO sub-study was to determine whether the resistance training treatment of diabetes, a 
major risk factor for Alzheimer disease and vascular dementia, can reduce the early decline in 
cognitive function that could later evolve into more cognitively disabling conditions.  This study 
conformed to all design and reporting requirements for randomised controlled trials recommended 
by the CONSORT group.   
CHAPTER 5 was described using baseline cognitive function measures collected in the Graded 
Resistance Exercise And Type 2 Diabetes in Older adults (GREAT2DO) sub-study.  This chapter 
also investigated important relationships between these baseline characteristics.  Specifically, the 
cross-sectional relationships between cognitive function and insulin resistance, glucose 
homeostasis, inflammatory and anti-inflammatory factors, health status, body composition, muscle 
function, quality of life and physical performance were investigated in this cohort. 
The cohort we enrolled was at least as burdened with chronic illnesses and metabolic abnormalities 
as older with diabetes in Australia and previous clinical trials of exercise in T2DM, suggesting the 
potential generalisability of our clinical trial outcomes to this cohort.  At baseline, metabolic 
dysfunction was linked to both body composition and functional capacity.  We have shown for 
the first time that poorer physical performance and exercise capacity were related to some aspects 
of poorer cognitive function, a systematic inflammatory marker and insulin resistance in older 
people with T2DM.  Thus targeting insulin resistance and inflammation may be important for 
improving physical performance and ultimately cognition in this cohort.  Insulin resistance and 
inflammatory markers have been associated with cognitive impairment and Alzheimer’s disease 
(AD) in other studies.  Thus, it is possible that an exercise intervention which could improve 
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metabolic profile may also have benefits for cognitive health as well as functional capacity.   
In addition to the above factors, body composition appears to be important in relation to cognitive 
function in this cohort.  Although many previous investigations have explored the relationship 
between body composition and cognition in healthy people, this thesis presents data that advances 
the existing literature due to the use of gold standard methods of regional adiposity assessment, 
and investigating multiple domains of cognitive performance in an at-risk group.  Most notably, 
our results have confirmed that central obesity best predicts the cognitive status of older adults 
with T2DM, particularly in men, reducing central adiposity may thus both be critical for improving 
insulin resistance, glucose control, physical performance and exercise capacity, pro- and anti-
inflammatory balance, and ultimately improved cognitive function.  Our data suggest that 
lifestyle interventions robustly targeting body composition are therefore warranted to investigate 
their benefit for the cognitive health of this vulnerable cohort.  Moreover, this was the first 
evidence that inflammatory profie (both C-reactive protein and adiponectin) is related to some 
aspects of cognition in older people with T2DM.  These data expand evidence from animal 
models and healthy individuals, showing for the first time in the same study in older adults with 
T2DM that central adiposity, C-reactive protein and adiponectin are related to body composition, 
glucose metabolism and cognitive health in this cohort. 
CHAPTER 6 described the cognitive outcomes of the first RCT of power training on in older 
adults with T2DM enrolled in the GREAT2DO study.  We hypothesised that high intensity power 
training would result in beneficial cognitive performance, and that lean tissue and peripheral 
adipose tissue adaptations, insulin sensitivity, glucose homeostasis, and systemic inflammation 
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would be associated with improved cognitive function compared to low intensity SHAM exercise.  
Contrary to our hypotheses, there were no significant benefits of power training on the cognitive 
domains tested in this study following the intervention, although both group improved significantly 
over time in most cognitive outcomes.  Unexpectedly, the SHAM group improved significantly 
more than the power training group on measures of attention/executive function and global 
cognitive function in fact.  Similarly, contrary to our hypothesis, insulin sensitivity, systemic 
inflammation, and whole body composition did not change over time or between groups.  
Glycosylated haemoglobin did improve significantly and similarly in both groups over time, 
although it was well controlled at baseline, a fact which may have attenuated any possible benefits 
of the intervention on metabolic profile. 
However, as we hypothesised, increased (higher) thigh muscle area and whole body skeletal 
muscle mass were related to improved cognition over 12 months, but only in the power training 
group, suggesting that improvements in muscle mass and cognition may share common 
mechanisms such as growth factors and inflammatory profile, both of which may be targeted by 
robust anabolic exercise.  In addition, increased adiponectin level after 12 months was associated 
with improved cognitive function, as we expected.   
There are some limitations within this thesis. 
 Chapters 2 and 3 were limited to published data and English-language literature and did not 
include studies in press or published within the 6 months prior to submission of this thesis 
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 Chapters 5 presented cross-sectional data from 103 older adults with T2DM who were enrolled 
in the GREAT2DO randomized controlled trial (RCT).  While these were the first such 
comprehensive data in this specific clinical cohort, similar investigations should be carried out 
in larger cohorts, both with T2DM and other chronic diseases, and within young and middle 
aged adults to further validate, and understand these relationships.  As these data were taken 
from the baseline characteristics of a volunteer sample of older adults enrolled in a clinical trial 
of exercise, selection bias relevant to all such volunteer samples may have limited 
generalisability to clinical cohorts.  Notably, the health status of our subjects was worse in 
most aspects than older adults with T2DM in Australia however, suggesting that this bias was 
minimal and did not invalidate our findings. 
 Chapters 6 provided primary cognitive analysis of patients with a 6-month or 12 month 
memory, information processing speed, executive function, and global cognitive scores: 49 
assigned to receive power training and 54 assigned to receive SHAM exercise.  In order to 
maximize the robustness of our hypothesis testing, and eliminate Hawthorne and other non-
specific effects of enrolling in an exercise trial, higher training intensity and velocity were the 
only differences between the POWER training and SHAM-exercise control group, and the 
subjects were blinded to our hypotheses as to which was the effective exercise modality.   
Another factor might have attenuated treatment differences in cognitive scores.  Higher 
training intensity and velocity were the only differences between the POWER training and 
SHAM-exercise control group, and not all participants in POWER training group reached the 
intended high intensity training range. Thus, the differences in training modality between the 
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two groups were not quite as distinct as planned, and adherence was high and equivalent in 
both groups.  This could have minimised the group differences observed.  Our SHAM-
exercise control design, although more robust and ethically justified than if a waitlist control 
group or advice-only control group had been used instead, may have led to an actual 
underestimation of POWER training efficacy.  Future trials may need to include a non-
exercise control group as well, although this raises ethical concerns of clinical equipoise in a 
year-long trial of T2DM, as exercise is considered part of the standard care of this cohort. 
Due to participant burden constraints, our measure of insulin resistance was restricted to the 
use of the HOMA2-IR, which is an estimate of fasting hepatic insulin sensitivity.  While this 
has been validated against the hyperinsulinaemic/euglycaemic clamp,4, 5 the use of the latter 
method may provide more specific data related to skeletal muscle insulin sensitivity and 
glucose disposal, and future studies should confirm our findings using this methodology.  
Furthermore, it has been shown that estimates of hepatic and skeletal muscle insulin resistance 
can also be derived from oral glucose tolerance tests.6  Moreover, the use of an oral glucose 
tolerance test may provide additional information that is not provided by HbA1c alone 
regarding glucose homeostasis. 
It should be noted that only C-reactive protein (CRP) was used as a marker for systemic 
inflammation.  Many other pro-inflammatory cytokines exist, and the relationships presented 
here with CRP may not reflect those of other pro-inflammatory cytokines.  While resistance 
training has been shown to reduce levels of other inflammatory cytokines in some studies,7 
future research should be directed towards their relationship with modifications to cognition, 
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body composition, and in particular skeletal muscle mass, as well as insulin resistance and 
glucose homeostasis, adiponectin, and brain-derived neurotrophic factor (BDNF).  In 
addition, CRP and adiponectin measurements were only available in a subset of the study 
participants due to funding constraints, and sample size limitations could have contributed to 
Type II errors for some relationships and outcomes.   
Tight control of glucose and lipids via medications may have limited the range of values in 
metabolic variables and blunted relationship with cognitive measures due to ceiling effects.  
Future studies including those with less well-controlled metabolic profiles at baseline are 
warranted. 
The GREAT2DO study enrolled both men and women.  While randomisation stratified by 
sex ensured that men and women were equally distributed amongst the intervention and SHAM 
groups, it is possible that sex effects may explain heterogeneity in responsiveness amongst 
those participants in the intervention (POWER) group.  Our investigation however was not 
sufficiently powered to explore any such effects.  Thus future studies should be appropriately 
designed to explore for any potential sex effects between body composition, metabolic health, 
and cognitive function in older adults with T2DM, and the subsequent effect of a high intensity 
POWER training or other intervention on this characteristic. 
Our cohort had relatively normal cognitive function at baseline.  Thus, their ability to improve 
on the cognitive outcomes chosen may have been blunted, limiting apparent effectiveness of our 
intervention at 12 months.  Thus, starting with more impaired individuals with mild cognitive 
impairment for example, may have produced more robust changes in cognition, as we have 
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published in a recent trial of resistance training in older adults with MCI.  The Study of Mental 
and Resistance Training (SMART) Study—Resistance Training and/or Cognitive Training in Mild 
Cognitive Impairment: A Randomized, Double-Blind, Double-SHAM Controlled Trial.8  In this 
study, high intensity resistance training has been shown to improve in cognitive function relative 
to sham exercise or cognitive training.8  In addition, the cognitive improvements observed over 
time in the overall cohort were predominantly in the more difficult tests such as delayed memory 
and attention/executive function, suggesting that use of neuropsychological assessments with an 
ability to identify a very early stage of cognitive dysfunction and which have a very high sensitivity 
to change over time are required to advance knowledge in this field.  Furthermore, longer term 
follow-up (which is ongoing in GREAT2DO out to 6 years post-baseline assessment) may be 
needed to discern significant cognitive decline or incident dementia, and determine whether 
exercise or any intervention can attenuate the rate of such decline.  
 
Future directions  
Our initial systematic review highlighted that only 8 RCTs examined the morphological, 
biochemical, and functional adaptation to aerobic exercise in the brain, and supported the cerebral 
neuroplasticity to learning and memory in animal models with diabetes or insulin resistance or 
hyperglycaemia.  Additional research is needed to facilitate translation to clinical trials such as 
use of animal models more analogous to T2DM, behavioural tests with relevance to humans, 
precise definition of the effects of dose and modality of exercise on cognitive function or cerebral 
morphology/biochemistry benefits, and identifying mechanisms of any exercise intervention 
effects observed.   
Our second systematic review found that only 2 RCTs have been published to date to our 
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knowledge which have assessed the efficacy of aerobic exercise on cognitive function, and 
examined the potential associations between cognitive function and insulin sensitivity in adults 
with diabetes mellitus or impaired glucose tolerance.  Our own data suggest that there is a 
potential link between anabolic adaptations to POWER training and cognitive benefits, and many 
more investigations are needed to expand these findings in this very small literature and to 
understand the mechanisms behind these relationships.   
In order to assess the full effects of our exercise program compared to a sedentary population, 
comparing our protocol (anabolic exercise) to a usual care advice-only exercise group as well as 
to an aerobic training group may be needed.  This would also provide an insight into the potential 
neuropsychological benefits gained by various modalities of exercise compared to usual care.    
Development of dissemination models allowing robust anabolic exercise (both standard PRT and 
POWER training) to be conducted in the community with minimal or remote supervision only is 
also needed if such RCT results are to be translated cost-effectively to clinical practice while 
maintaining efficacy and fidelity.  This is much more difficult for PRT or POWER training than 
it is with aerobic exercise interventions such as walking for example, due to the need for adequate 
equipment allowing for progression and high intensity, and in some individuals supervision, for 
safety.  Collaboration with exercise equipment manufacturers to produce versions of such 
anabolic exercise equipment suitable for home or community centre use would be extremely 
important in this translational work.  In addition, development of tools to monitor and provide 
feedback on anabolic exercise via Health tools such as smartphone applications, 
videoconferencing, and web-based trainers, etc. are vital to advancements in this field.  
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Dissemination should only follow demonstration of efficacy in RCTs obviously, so these efforts 
are appropriate once the primary data are sufficient to warrant their widespread recommendation 
and implementation for cognitive improvements in this cohort. 
Muscle mass (thigh muscle) is the primary site for glucose disposal, and thus it is possible that 
increases in muscle quality and quantity simply increase the available storage depot for glucose 
and improve insulin sensitivity, and thereby contribute to cognitive function.  However, more 
complex interactions are likely and may also contribute to these outcomes, as suggested below, 
which require elucidation in future studies 
Part of the hypertrophic stimulus resulting from PRT is attributable to increases in IGF-1.9  
Mechanical stimulation of skeletal muscle results in the local production of two isoforms of IGF-
1: IGF-1E, these are the principal growth factors thought to mediate the effects of exercise on brain 
plasticity, function, and health.  Administration of intra-hippocampal injection of anti-IGF-1 
prevents enhancement of spatial recall.10 Resistance training increases peripheral IGF-1, leading 
to improved insulin sensitivity,11 restored insulin–IGF-1 signaling12 and improved brain health and 
cognitive function.5 Furthermore, pro-inflammatory cytokines impair IGF-1 signal transduction in 
neurons.12, 13  Exercise might counteract the negative effects of this inflammation by acting to 
restore IGF-1 signaling, because it reduces circulating pro-inflammatory cytokines and Aβ.14 Thus, 
it is therefore possible that a potential link between augmentation of skeletal muscle mass and 
cognition exists due to the reduction in central and peripheral inflammation and increase in IGF-1 
signaling.  These pathways require many more investigations in both animal and human models 
of T2DM. 
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Previous literature suggests that sarcopenia, representing loss of muscle mass and strength, is 
associated with systemic inflammation and functional impairment.15  CRP has been shown to 
have catabolic effects on skeletal muscle, and thus may have potentially inhibitive effects on 
intended adaptations to an anabolic stimulus such as high intensity POWER training.  Our data 
extend these findings, as we have shown that lower muscle mass was associated with higher CRP 
levels at baseline, and that increased CRP expression over 12 months was correlated with cognitive 
decline in our cohort.  Therefore, given the ‘progressive’ nature of the training intervention within 
our study, increases in skeletal muscle mass may have resulted in greater IGF-1 levels from skeletal 
muscle during subsequent training bouts, resulting in greater anti-inflammatory effects (lower CRP 
and other unmeasured cytokines) over the course of the intervention.  This may explain why 
increases in muscle area and skeletal muscle mass in POWER training were associated with 
improved memory in GREAT2DO.  This line of inquiry should be confirmed and extended in 
future trials with a more expansive set of cytokines, with intramuscular measurements of growth 
factors and markers of inflammation and insulin signaling pathway components, and more precise 
whole body measures of skeletal muscle mass such as dual energy absorptiometry. 
Another potential mediating factor associated with exercise may be alterations in adiponectin 
expression and function.  We observed a positive relationship between changes in adiponectin 
and cognitive function after POWER training as well as after SHAM exercise (Chapter 6).  
Previously, only one study to our knowledge has investigated this relationship, and it was within 
individuals with cognitive impairment.16  Thus, our study is the second to investigate this 
relationship and the first to show a relationship between increases in adiponecctin in response to 
either high or low intensity exercise and cognition in T2DM.  The increase of adiponectin by 
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exercise may serve as a common mechanism to reduce the risk for both diabetes and cognitive 
decline, and although levels did not change significantly over 12 months in either group, in those 
who did increase adiponectin, this increase was related to positive cognitive outcomes.  It was 
unexpected that this would occur after low intensity exercise exposure, and further study is 
required to confirm and extend these findings, and define dose-response characteristics of this 
relationship, as well as longterm clinical implications of alterations of adiponection in relation to 
body composition, metabolic health, and cognition.  In particular, investigations should be 
directed toward the nature of the observed relationship between increases in adiponectin and 
improvements in cognition, as this could have significant impacts on future therapeutic 
interventions.  Identification of the characteristics of individuals who were able to express more 
adiponectin after exposure to exercise and thereby improve cognition is required to more robustly 
provoke this adaptation.  For example, if this relationship is driven by the catabolic effects of 
adipokines, then complementary interventions aimed at further increasing adiponectin (such as 
reducing adiposity through diet, use of anti-inflammatory agents, etc.) may improve efficacy of 
exercise in reducing insulin resistance and HbA1c, as well as associated cognitive improvements.  
Alternatively, if this relationship between cognition and adiponectin is driven by the reduced 
visceral adipose tissue and increased lean tissue itself, then interventions maximising these body 
composition changes are warranted to increase adiponectin.   
7.2 CONCLUSIONS 
This thesis investigated the effect of exercise or physical activity exposure on cognitive function 
and explored the relationship between body composition, adipokines, and the cognitive health of 
older adults with T2DM.  Furthermore, the effect of a one-year power training intervention on 
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body composition, physical performance, and adipokines, and subsequently improving the 
cognitive health within this cohort was determined.  In addition, our data addressed gaps in the 
literature by including older adults with multiple comorbidities, including a high prevalence of 
cardiovascular disease, compared to most previous studies.  Previously, trials from animal models 
and human clinical trials have not examined the effects of any form of exercise intervention the 
relationship between changes in skeletal muscle mass, adiponection, and improvements in either 
cognition or metabolic dysfunction within individuals with T2DM.  This makes our trial the first 
to investigate these relationships within older adults, and the first to show any relationship between 
increases in skeletal muscle mass, physical performance, and adiponectin levels and improvements 
in cognitive function. 
We have confirmed that abdominal adipose tissue, systemic inflammation, and serum adiponectin 
level play a significant role in cognitive impairment in this cohort, and that such impairment is 
related to physical performance, and exercise capacity.  Power training was shown to improve 
the cognitive health of older adults with T2DM, but only provided they increased muscle mass, 
decreased systemic inflammation and insulin resistance and/or increased adiponectin level, and 
these cognitive benefits were related to improved lower extremity exercise capacity and physical 
performance related to strength, power and balance.  However, even SHAM exercise 
demonstrated some relationships between improved insulin resistance and adiponectin with 
cognitive benefits, and SHAM exercise outperformed power training in terms of cognitive 
improvements n some domains, which may have been due in part to their slightly more impaired 
cognitive status at baseline.   Additional study is required to refine the elements of the exercise 
prescription in this cohort, identify the most important pathways mediating cognitive improvement, 
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optimise apparently important mediators such as muscle hypertrophy and inflammatory/anti-
inflammatory profile, and confirm that longterm clinical benefits accrue, in particular attenuation 
of the rate of cognitive decline and incident dementia in this high-risk cohort.  
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APPENDIX (MANUAL OF PROCEDURES) 
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The GREAT2DO study is a randomised, double-blind, SHAM-exercise controlled trial. 
Subjects (n=103) were randomised to the experimental (high intensity progressive 
resistance training-PRT) or control condition (SHAM resistance training with the subjects 
blinded to investigators’ hypotheses as to which is the experimental group) for 12 months, 
in addition to usual care from their GP. Blinded outcome assessments will be conducted at 
0, 6, and 12 months in all subjects regardless of adherence to the intervention. (Figure 1) 
The exercises target the majority of the large muscle groups of the arms, legs, and trunk: 
seated row, chest press, leg press, knee extension, hip flexion, hip extension and hip 
abduction. In addition, these are symmetrical muscle groups and functionally relevant to 
the activities of daily living, gait, and balance of older adults. For each exercise, subjects 
will perform 3 sets of 8 repetitions (2 sets of 8 on each leg for the three hip exercises) with 
a fast concentric and slow eccentric phase on pneumatic resistance training machines 
(approximately 6 seconds per repetition with 2 minutes of rest between sets). The intensity 
will be set at 80% of the most recently determined peak strength (1 repetition maximum or 
1RM). Resistances used will be increased as tolerated using Borg scale rating of perceived 
exertion on a continuous basis throughout the 12 months, and 1RM testing will be repeated 
at 2-week intervals to ascertain progress and regulate intensity. Where 1RM testing was 
not feasible, resistances were increased by targeting a Borg scale rating of perceived 
exertion between 15 and 18.  
SHAAM exercise subjects will be supervised by the same trainers in the same facility, but 
at different hours to avoid contamination and unblinding. These subjects will perform 3 
sets of 8 repetitions on the same machines, but with no loading beyond the bar of the 
machine, using slow concentric and eccentric contraction speed. No interim 1RM testing 
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and no progression will take place.   
Subjects recruited for the study will undergo three separate days of assessments at baseline, 
6 and 12 month re-assessment, spread over two weeks. 
 
Figure 1 – Study Design and Participant flow
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APPENDIX A. ASSESSMENT PROTOCOLS (ASSESSMENT A) 
ASSESSMENT A PROTOCOLS 
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Variables created by the C2R Macro 
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PARTICIPANT INFORMATION SHEET 
Purpose 
It is important for the participant to understand what is involved in the study if they wish 
to participate. The Participant Information Sheet describes, in detail, the testing and 
training protocols of the GREAT2DO study. By explaining each of the procedures, the 
participant is given a greater opportunity to ask questions and put to rest any concerns they 
may have. 
Protocol 
Go through each testing protocol, explaining the details thoroughly and be open to 
questions Provide a copy of the information sheet in the Participant Information Pack taken 
home by the participant later that day. 
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PARTICIPANT CONSENT FORM 
Purpose 
To gain the consent of the participant whilst informing them of all procedures to ensure 
understanding and provide an opportunity to have questions answered. 
Protocol 
Ensure that the participant has the chance to read through the statements on the sheet and 
to have any questions that arise answered clearly. Most people feel pressured to ‘sign on 
the dotted line’ so it may help to lean back and sit away from the subject so that they feel 
comfortable to read the consent form fully. 
If the participant consents to the terms of the study, they must: 
 Write their name at the top of the sheet 
 Sign the bottom of the sheet 
 Date the bottom of the sheet 
Ensure that you: 
 Witness their signature 
 Sign the bottom of the sheet 
 Date the bottom of the sheet 
 Make a photocopy of the signed consent form and place it in the Participant’s 
Information Pack that will be taken home later that day
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PROCEDURE FOR THE ADMINISTRATION OF THE CERAD 
NEUROPSYCHOLOGICAL ASSESSMENT BATTERY 
To ensure the results are reliable, it is essential that the cognitive function tests are 
administered precisely according to the instructions provided. 
 Each CERAD task should be administered in the order in which it is presented. 
 Moreover, the entire CERAD battery should always be administered before any 
other neuropsychological items. 
 RA’s should encourage the completion of the task without adding to the stress of 
the situation, and should offer neutral phrases as support when subjects cannot 
complete the tasks. 
 Feedback to the patients should be positive but should not offer information to the 
correctness of the response. Appropriate phrases include “That’s fine” and “You’re 
doing alright”. 
 The score sheets should not be placed within the patients view. 
 
J4 WORD LIST MEMORY TASK 
To assess the patients’ ability to remember newly learned information, this task asks the 
patient to recall 10 common nouns. To ensure the patient is familiar with the word, they 
are asked to read the words printed on separate cards in the CERAD flip book. The 10 
words are presented at a constant rate (1 word every 2 seconds) and then the subject is 
immediately asked to recall as many of the words shown as possible.  
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The instructions for the first trial are: 
 “I am going to show you ten printed words. Read each word out loud as I show it 
to you. Later I will ask you to recall all ten words” 
If the subject cannot read the word, say it for him/her and tick the ‘can’t read’ column on 
the score sheet. After the last word has been read, ask the patient to recall as many words 
as they can. Allow a maximum of 90secs. Continue with the second and third sets in the 
same way, changing you instructions slightly to encourage the patient. 
The subject’s score for each trial is the number of words correctly recalled. Be sure to 
record on each trial the number of words that the patient ‘recalls’ that are not on the list 
(intrusions). 
Refer to the scoring protocol for the CERAD neuropsychological Assessment Battery for 
more information. 
 
J6 WORD LIST RECALL 
This task is to determine how well subjects can remember the words presented in the J4 
form. Allow ‘distraction’ time by completing another task, such as the medications review. 
The instructions for this recall task are: 
 “A few minutes ago I asked you to learn a list of 10 words which you read one at a 
time from cards. Now I want you to try to recall as many of those 10 words as you 
can. OK, now tell me as many of those 10 words as you can remember.” 
 
Allow the patient a maximum of 90seconds. Number each word in its corresponding block 
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on the score sheet in the order it is recalled. Score the number of words correctly recalled. 
Also record and score the number of words not on the list (instrusions), that the subject 
reports. 
Refer to the scoring protocol for the CERAD neuropsychological Assessment Battery for 
more information. 
 
J7 Word List Recognition 
The instructions for this recognition test are: 
 “Now I am going to show you a set of words printed on cards. Some of the words 
are form the list you saw earlier and some are words I haven’t shown you before. I 
want you to tell me which words are from the list you saw earlier (show the first 
word). Is this one of the words you saw earlier?” 
 
Repeat the question, or say, ‘how about this one?” for each word. Record the subject’s 
response. The scores for this test include the number of correctly recognised words 
previously seen (correct ‘yes’ responses) and the number of correctly rejected new words 
(correct ‘no’ responses).  
 
Urge the patient to give ‘yes’ or ‘no’ responses, since ‘don’t know’ responses are unscorable.  
Refer to the scoring protocol for the CERAD neuropsychological Assessment Battery for 
more information.
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SCORING FOR WORD LIST MEMORY /RECALL TASKS 
 
Word List Memory 
 Task Scoring 
o Score each administration separately (i.e., 3 scores out of 10). 
o You can then decide which administration to use (some investigators use 
only the score on the third administration) or you can sum the three scores 
to get a score out of 30. 
o Score separately for number of correct responses, and for number of 
intrusions. 
 Scoring for Intrusions 
o An intrusion is any word that is not on the list of words presented. If, for 
example, a word that is given in response to the word list memory task that 
the patient has not been shown as part of the task. 
o Intrusions are scored separately, and do not affect the score obtained when 
the subject gives a correct response. 
o Repeating a word that is on the list is not considered an intrusion. The 
repetition is not counted. An intrusion is a word that is not on the list.
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Word List Recall 
 Use the same rules as the word list memory task. 
 
Word List Recognition 
 Task Scoring 
o The total score is out of 20. Score the correctly identified original words 
and the correctly identified new words.
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MEDICATION REVIEW 
Complete the Medication Review after the J4 Word List Memory Task but before the J6 
Word List Recall task. This allows ‘distraction time’ between the two memory tests. 
Complete the name, dose and regularity (compliance) information in the spaces provided 
on the form.
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THE SF-36® HEALTH SURVEY- John E. Ware, Jr., Ph.D.  
Construction of the SF-36® 
The SF-36® was constructed to satisfy minimum psychometric standards necessary for 
group comparisons involving generic health concepts — that is, concepts that are not 
specific to any age, disease, or treatment group. The eight health concepts were selected 
from 40 included in the Medical Outcomes Study (MOS) (Stewart and Ware, 1992) to 
represent those hypothesized to be most frequently measured in widely-used health surveys 
and those most affected by disease and treatment (Ware et al., 1993; Ware, 1995). They 
also represent multiple operational definitions of health, including: function and 
dysfunction, distress and well-being, objective reports and subjective ratings, and both 
favorable and unfavorable self-evaluations of general health status (Ware et al., 1993). 
Most items have their roots in instruments that have been in use for more than 20 years 
(Stewart and Ware, 1992), including: the General Psychological Well-Being Inventory 
(Dupuy, 1984), various physical and role functioning measures (Patrick, Bush, and Chen, 
1973; Hulka and Cassel, 1973; Reynolds et al., 1974; Stewart, Ware and Brook, 1981), the 
Health Perceptions Questionnaire (Ware, 1976), and other measures that proved to be 
useful during the Health Insurance Experiment (HIE) (Brook, Ware et al., 1979). MOS 
researchers selected and adapted questionnaire items from these and other sources and 
developed new measures for a 149-item Functioning and Well-Being Profile (Stewart and 
Ware, 1992), which was the source for SF-36® items.  
 
SF-36® Measurement Model 
Figure 1 illustrates the measurement model underlying the construction of the SF-36® 
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scales and summary measures.  This model has three levels: (1) items, (2) eight scales 
that aggregate 2-10 items each, and (3) two summary measures that aggregate scales. All 
but one of the 36 items (self-reported health transition) are used to score the eight SF-36® 
scales.  Each item is used in scoring only one scale.  
 
The eight scales are hypothesized to form two distinct higher-ordered clusters due to the 
physical and mental health variance that they have in common. Factor analytic studies have 
confirmed physical and mental health factors that account for 80-85% of the reliable 
variance in the eight scales in the US general population (Ware et al., 1994), among MOS 
patients (McHorney et al., 1993; Ware et al., 1994), and in general populations in Sweden 
(Sullivan et al., 1994) and the UK (Ware et al., 1994). Three scales (Physical Functioning, 
Role-Physical, Bodily Pain) correlate most highly with the physical component and 
contribute most to the scoring of the Physical Component Summary (PCS) measure (Ware 
et al., 1994). The mental component correlates most highly with the Mental Health, Role-
Emotional, and Social Functioning scales, which also contribute most to the scoring of the 
Mental Component Summary (MCS) measure.  Three of the scales (Vitality, General 
Health, and Social Functioning) have noteworthy correlations with both components.  
 
Administration Methods and Data Quality 
The SF-36® is suitable for self-administration, computerized administration, or 
administration by a trained interviewer in person or by telephone, to persons age 14 and 
older. The SF-36® has been administered successfully in general population surveys in the 
US and other countries (Ware, Keller, Gandek, et al., 1995) as well as to young and old 
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adult patients with specific diseases (Ware, Snow, Kosinski, et al., 1993; McHorney, Ware, 
Lu, et al., 1994).  It can be administered in 5-10 minutes with a high degree of 
acceptability and data quality (Ware, Know, Kosinski, et al., 1993).  Indicators of data 
quality that have yielded satisfactory results in studies to date include very high item 
completion rates and favorable results for a response consistency index based on 15 pairs 
of SF-36® items, which is scored at the individual level (Ware et al., 1993).  Computer 
administered and telephone voice recognition interactive systems of administration are 
currently being evaluated.  
 
Scaling and Scoring Assumptions 
A major objective in constructing the SF-36® was achievement of high psychometric 
standards. Guidelines for testing were derived from those recommended for use in 
validating psychological and educational measures by the American Psychological 
Association, the American Education Research Association, and the National Council on 
Measurement in Education (APA, 1984). Extensive psychometric testing has been 
conducted on the SF-36® in the United States (McHorney et al., 1994; Garratt et al., 1993; 
Jenkinson et al., 1993; Wagner et al., in press), and in numerous other countries (Sullivan, 
1994; Rampall et al., 1994; Sullivan et al., in press; Bullinger, in press; McCallum et al., 
in press).  
 
On the strength of favorable results from tests to date, nearly all studies have used the 
method of summated ratings and standardized SF-36® scoring algorithms documented 
elsewhere (MOT, 1991; Ware et al., 1993).  This method assumes that items shown in the 
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same scale in Figure 1 can be aggregated without score standardization or item weighing. 
Standardization of items within a scale was avoided by selecting or constructing items with 
roughly equivalent means and standard deviations. Weighing was avoided by using equally 
representative items (that is, items with roughly equivalent relationships to the underlying 
scale dimension).  All items have been shown to correlate substantially (greater than 0.40, 
corrected for overlap) with their hypothesized scales with rare exceptions (McHorney et 
al., 1994; Ware et al., 1993).  These results support analysis as interval-level measurement 
scales.  
 
Reliability and Confidence Intervals 
The reliability of the eight scales and two summary measures has been estimated using 
both internal consistency and test-retest methods.  With rare exceptions, published 
reliability statistics have exceeded the minimum standard of 0.70 recommended for 
measures used in group comparisons; most have exceeded 0.80 (McHorney et al., 1994; 
Ware et al., 1993). Reliability estimates for physical and mental summary scores usually 
exceed 0.90 (Ware et al., 1994). One review of 15 published studies revealed that the 
median reliability coefficients for each of the eight scales was equal or greater than 0.80 
except Social  Functioning, which had a median reliability across studies of 0.76 (Ware, 
Snow, Kosinski, et al., 1993). In addition, a reliability of 0.93 has been reported for the 
Mental Health scale using the alternate forms method, suggesting that the internal-
consistency method underestimated the reliability of that scale by about 3% (McHorney 
and Ware, 1995).  
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The trends in reliability coefficients for the SF-36® scales and summary measures 
summarized above have also been replicated across 24 patient groups differing in socio-
demographic characteristics and diagnoses (Ware et al., 1993; Ware et al., 1994; McHorney 
et al., 1994).  While studies of subgroups indicate slight declines in reliability for more 
disadvantaged respondents, reliability coefficients consistently exceeded recommended 
standards for group level analysis.  
 
Standard errors of measurement, 95% confidence intervals for individual scores, and 
distributions of change scores from test-retest and one-year stability studies have been 
published (Brazier et al., 1992; Ware et al., 1993; Ware et al., 1994).  Confidence intervals 
around individual scores are much smaller for the two summary measures than for the eight 
scales +/- 6-7 points versus +/- 13-32 points, respectively) (Ware, Kosinski, and Keller, 
1994).  Estimates of sample sizes required to detect differences in average scores of 
various magnitudes have been documented for five different study designs for each of the 
eight scales and for the two summary measures (Ware et al., 1993; Ware et al., 1994).  
 
Norms for General and Specific Populations 
The SF-36® has been normed in the general US population and for representative samples 
from Denmark, Germany, Sweden, and the UK using common translation and norming 
protocols developed by the International Quality of Life Assessment (IQOLA) Project 
(Ware, Gandek et al., 1994; Sullivan et al., in press; Bullinger, in press).  Other norming 
studies, which are underway in Australia, Denmark, France, Italy, and The Netherlands 
will be completed in 1995. From the general US population, norms for age and sex groups 
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and for 14 chronic diseases have been published along with estimates of the effect of 
telephone-relative to self-administered versions (McHorney et al., 1994; Ware et al., 1993; 
Ware et al., 1994).  
 
For patients with chronic conditions participating in the MOS, cross-sectional norms and 
average changes over a one-year follow-up period have been published for congestive heart 
failure, diabetes (Type II), hypertension, myocardial infarction (recent survivors), and for 
depressive disorder (Ware et al., 1993; Ware et al., 1994).  In addition, norms have been 
published for uncomplicated hypertensive patients with the following comorbid 
conditions: angina (recent), chronic obstructive pulmonary disease, back pain/sciatica, 
osteoarthritis, musculoskeletal complaints, benign prostatic hypertrophy, varicosities, and 
dermatitis.  
 
Validity 
Studies of validity are about the meaning of scores and whether or not they have their 
intended interpretations. Because of the widespread use of the SF-36® across a variety of 
applications, evidence of all types of validity is relevant. Studies to date have addressed 
content, concurrent, criterion, construct, and predictive validity.  
The content validity of the SF-36® has been compared to that of other widely used generic 
health surveys (Ware et al., 1993; Ware et al., 1995). Systematic comparisons indicate that 
the SF-36® includes eight of the most frequently represented health concepts. Among the 
content areas included in widely-used surveys, but not included in the SF-36®, are: sleep 
adequacy, cognitive functioning, sexual functioning, health distress, family functioning, 
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self-esteem, eating, recreation/hobbies, communication, and symptoms/problems that are 
specific to one condition. Symptoms and problems that are specific to a particular condition 
are not included in the SF-36® because the SF-36® is a generic measure. To facilitate the 
consideration of concepts not included, the SF-36® Users' Manuals include tables of 
correlations between the eight scales and the two summary measures and 32 measures of 
other general concepts (Ware et al., 1993; Ware et al., 1994) and 19 specific symptoms. 
SF-36® scales correlate substantially (r=0.40 or greater) with most of the omitted general 
health concepts and with the frequency and severity of many specific symptoms and 
problems. A noteworthy exception is sexual functioning, which correlates relatively 
weakly with SF-36® scales and is a good candidate for inclusion in questionnaires that 
supplement the SF-36®.  
 
Because most SF-36® scales were constructed to reproduce longer scales, much attention 
has been given to how well the short-form versions perform in empirical tests relative to 
the full-length versions. Relative to the longer MOS measures they were constructed to 
reproduce, SF-36® scales have been shown to perform with about 80-90% empirical 
validity in studies involving physical and mental health "criteria" (McHorney et al., 1993). 
 
The validity of each of the eight scales and the two summary measures has been shown to 
differ markedly as would be expected from factor analytic studies of construct validity 
(McHorney et al., 1993; Ware et al., 1994; Ware et al., 1995). Specifically, the Mental 
Health, Role-Emotional, and Social Functioning scales and the MCS summary measure 
have been shown to be the most valid mental health measures in both cross-cultural and 
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longitudinal tests using the method of known-groups validity. The Physical Functioning, 
Role-Physical, and Bodily Pain scales and the PCS have been shown to be the most valid 
physical health measures. Criteria used in the known-groups validation of the SF-36®, 
which include accepted clinical indicators of diagnosis and severity of depression, heart 
disease, and other conditions, are well documented in peer-reviewed publications and in 
the two users' manuals (Kravitz et al., 1992; McHorney et al., 1993; Ware et al., 1993; Ware 
et al., 1994; Ware et al., 1995). 
 
The Mental Health scale has been shown to be useful in screening for psychiatric disorders 
(Berwick et al., 1991; Ware et al., 1994), as has the MCS summary measure (Ware et al., 
1994). For example, using a cutoff score of 42, the MCS had a sensitivity of 74% and a 
specificity of 81% in detecting patients diagnosed with depressive disorder (Ware et al., 
1994). 
 
Relative to other published measures, SF-36® scales have performed well in most tests 
published to date (Weinberger et al., 1991; Brazier et al., 1992; Kantz et al., 1992; Krousel-
Wood, 1994 a & b). Predictive validity studies have linked SF-36® scales and summary 
measures to utilization of health care services (Ware et al., 1994), the clinical course of 
depression (Wells et al., 1992), loss of job within one year (Ware et al., 1994), and 5-year 
survival (Ware et al., 1994). 
 
Results from clinical studies comparing scores for patients before and after treatment have 
largely supported hypotheses about the validity of SF-36® scales based on factor analytic 
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studies. For example, clinical studies have shown that the three most valid physical scales 
(Physical Functioning, Role-Physical, and Bodily Pain) tend to be most responsive to the 
benefits of knee replacement (Kantz et al., 1992), hip replacement (Kantz et al., 1992; 
Lanky et al., 1992), and heart valve surgery (Phillips and Lanky, 1992). Likewise, the three 
most valid mental health scales (Mental Health, Role-Emotional, and Social Functioning) 
in factor analytic studies have been shown to be most responsive in comparisons of patients 
before and after recovery from depression (Ware et al., 1995). 
 
The discovery that 80-85% of the reliable variance in the eight SF-36® scales led to the 
construction of psychometrically-based physical and mental health summary measures. It 
was hoped that they would make it possible to reduce the number of statistical comparisons 
involved in analyzing the SF-36® (from eight to two) without substantial loss of 
information. In both cross-sectional and longitudinal studies reported to date, this appears 
to be the case (Ware et al., 1994; Ware et al., 1995). The advantages and disadvantages of 
analyzing the eight-scale SF-36® profile versus the two summary measures are illustrated 
and discussed elsewhere (Ware et al., 1994; Ware et al., 1995). 
 
Finally, the SF-36® self-evaluated health transition item (five levels from "much better" to 
"much worse"), which is not used in scoring the scales or summary measures, has been 
shown to be useful in estimating average changes in health status during the year prior to 
its administration. In the MOS, measured changes in health status during a 1-year follow-
up period corresponded substantially, on average, to self-evaluated transitions at the end of 
the year. Using the 0-100 GHRI scale (Davies and Ware, 1981) as a "criterion," those who 
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evaluated their health as "much better" improved an average of 13.2 points. The average 
change was 5.8 points for those who reported that they were "somewhat better." An average 
decline of -10.8 was observed for those who reported that their health was "somewhat 
worse" and 34.4 for those reporting "much worse." (It should be noted that the latter 
category had only 29 patients.) Change scores for those choosing the "about the same" 
category averaged 1.6 points.  These results are encouraging with regard to the use and 
interpretation of self-evaluated transitions at the group level. Pending results from ongoing 
studies of the reliability of responses to the SF-36® self-evaluated transition item, it should 
be interpreted with caution at the individual level. Additional results and their implications 
are discussed elsewhere (Ware et al., 1993; Ware et al., 1994).  
 
Summary of Information About SF-36® Scales & Summary Measures 
Table 1 summarizes information about the eight SF-36® scales and two summary measures 
that is important in their use and interpretation. The eight scales are ordered in terms of 
their factor content (i.e., construct validity) as they are in the SF-36® profile to facilitate 
interpretation. The first scale is Physical Functioning (PF), which has been shown to be the 
best all around measure of physical health; the last scale, Mental Health (MH) is the most 
valid measure of mental health in studies to date (McHorney et al., 1993; Ware et al., 1993; 
Ware et al., 1994). Interestingly, MH and PF are the poorest measures of the physical and 
mental components, respectively. Scales in between are ordered according to their validity 
in measuring physical and mental health. The Vitality and General Health scales have 
substantial or moderate validity for both components of health status and should be 
interpreted accordingly. 
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The number of items and levels and the range of states defined by each scale are also shown 
in Table 1. These attributes have been linked to their empirical validity (McHorney et al., 
1992). The most precise (least coarse) scales are those with 20 or more levels (PF, GH, VT, 
and MH). They also define the widest range of health states and, therefore, usually produce 
the least skewed score distributions. The relatively coarse role disability scales (RP and 
RE) each measure only four or five levels across a restricted range and, therefore, usually 
have the most problems with ceiling and floor effects. 
 
Means and standard deviations for each of the eight scales in the general US adult 
population are also presented. These can be used to determine whether a group or 
individual in question scores above or below the US average. Detailed normative data 
including frequency distributions of scores and percentile ranks are documented in the two 
users' manuals (Ware et al., 1993; Ware et al., 1994). Reliability estimates and 95% 
confidence intervals for individual scores are also presented. These estimates are based on 
internal-consistency reliability coefficients and standard deviations from the general US 
population, as documented elsewhere (Ware et al., 1993; Ware et al., 1994). 
 
Table 1 illustrates the practical implications of a number of theoretical advantages of the 
PCS and MCS summary measures as compared to the eight SF-36® scales. These 
advantages include a very large increase in the number of levels defined, much smaller 
confidence intervals for individual scores relative to each of the eight scales, as well as the 
elimination of both floor and ceiling effects. The implications for the use of the PCS and 
MCS in clinical practice and research are currently being evaluated; preliminary results are 
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encouraging (Ware, Kosinski, and Keller, 1994).  
 
Documentation and Availability 
The scoring of the eight SF-36® scales and two summary measures and detailed 
interpretation guidelines (content-based, norm-based, and criterion-based) are documented 
in two users' manuals (Ware et al., 1993; Ware et al., 1994). A third manual documents 
English-language adaptations and scoring algorithms for use in Australia, Canada, and the 
UK (MOT, 1992), and a fourth manual documents the Swedish translation and related 
norms and validations (Sultan et al., 1994). Others are forthcoming from the IQOLA 
Project. Order the manuals  
 
Permission to Use 
Permission to reproduce the SF-36® items and scoring algorithms has also been granted to 
computer software vendors and dozens of commercial survey and data processing firms 
offering a wide range of services based on standard SF-36® scoring algorithms and 
interpretation guidelines. If you would like permission to use, click here.  
 
Discussion 
The widespread adoption of the SF-36® in general population surveys, clinical trials, and 
clinical practice is evidence that more practical measurement tools are more likely to be 
used. The standardization of measurement across studies is producing considerable 
information about norms and benchmarks useful in comparing "well" and "sick" 
populations and for estimating the burden of specific conditions. At the time of writing this 
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chapter, 85 publications reporting results for the SF-36® had been identified. (Studies 
reporting results for one or more of the SF-36® scales are starred in the reference list.) 
 
The brevity of the SF-36® was achieved by focusing on only eight of 40 health concepts 
studied in the MOS and by measuring each concept with a short-form scale. The scales 
chosen (other than General Health) have been shown to explain about two-thirds of the 
reliable variance in individual evaluations of their current health status in the UK, US, and 
Sweden (Ware, Keller, Gandek et al., 1995, in press). In the US, addition of 14 multi-item 
measures (e.g., sleep problems, family and sexual functioning) added only about five 
percent to the variance explained. 
 
Although many studies appear to be relying on the SF-36® as the principal measure of 
health outcome, it may be best to rely upon it as a "generic core," pending further research. 
A generic core battery of measures serves the purpose of comparing results across studies 
and populations and greatly expands the interpretation guidelines that are essential to 
determining the clinical, economic, and human relevance of results. Because it is short, the 
SF-36® can be reproduced in a questionnaire with ample room for other more precise 
general and specific measures. Numerous studies in progress and some that have been 
published (Wagner et al., in press; Kantz et al., 1992; Nerenz et al., 1992) adopted this 
strategy and have illustrated the advantages of supplementing it.  
 
How useful is the SF-36® for purposes of comparing general and specific population 
groups, relative to longer surveys? Some SF-36® scales have been shown to have 10-20% 
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less precision than the long-form MOS measures they were constructed to reproduce 
(McHorney et al., 1992). This disadvantage of the SF-36® should be weighed against the 
fact that some of these long-form measures require 5-10 times greater respondent burden. 
Empirical studies of this tradeoff suggest that the SF-36® provides a practical alternative 
to longer measures and that the eight scales and two summary scales rarely miss a 
noteworthy difference in physical or mental health status in group level comparisons (Ware 
et al., 1993; Ware et al., 1994; Katz et al., 1992). Regardless, the fact that the SF-36® 
represents a documented compromise in measurement precision (relative to longer MOS 
measures leading to a reduction in the statistical power of hypothesis testing should be 
taken into account in planning clinical trials and other studies. To facilitate such planning, 
five tables of sample size estimates for differences in scores of various amounts for 
conventional statistical tests are published in the two SF-36® Users' Manuals (Ware et al., 
1993; Ware et al., 1994). In relation to longer non-MOS measures, such as the Sickness 
Impact Profile, the SF-36® has performed equally well or better in detecting average group 
differences or changes over time (Katz et al., 1992; Beaton et al., 1994).  
 
The value of general and specific population norms, which was demonstrated well for the 
Sickness Impact Profile (Bergner et al., 1981) and later for the MOS SF-20 (Stewart et al., 
1988; 1989) and other measures, has also been demonstrated for the SF-36®. In addition 
to the 20 medical conditions described in the MOS and 14 conditions described in the US 
population norming survey (Ware et al., 1994), other publications have reported descriptive 
data for patients with cardiac disease (Krousel-Wood et al., 1994; Jette et al., 1994), 
epilepsy (Vickrey et al., 1992; Wagner et al., in press), diabetes mellitus (Nerenz et al., 
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1992; Jacobsen et al., 1994), migraine headache (Osterhaus et al., 1994), heart transplant 
patients (Rector et al., 1993), ischemic heart disease (Phillips and Lansky, 1992), ischemic 
stroke (Kappelle et al., 1994), low back pain (Garratt et al., 1993; Lansky et al., 1992), lung 
disease (Viramontes et al., 1994), menorrhagia (Garratt et al., 1992), orthopedic conditions 
leading to knee replacement (Kantz et al., 1992), knee surgery (Katz et al, 1992), and hip 
replacement (Katz et al., 1992; Lansky et al., 1992), and for renal disease (Kurtin et al., 
1992; Meyer et al., 1994; Benedetti et al., 1994). Whereas some of the initial descriptive 
studies using the SF-36® were performed primarily to validate scale scores (McHorney et 
al., 1992), on the strength of validation studies to date, SF-36® scales appear to be 
increasingly accepted as valid health measures for purposes of documenting disease burden.  
Relatively little is known about population health in comprehensive terms, the relative 
burden of disease, or the relative benefits of alternative treatments. One reason has been 
the lack of practical measurement tools appropriate for widespread use across diverse 
populations. The SF-36® was constructed to provide a basis for such comparisons of 
results.  
 
As predicted when it was first published (Ware and Sherbourne, 1992), the SF-36® has 
been widely adopted because of its brevity and its comprehensiveness. Although these two 
measurement goals are competing, the SF-36® appears to have achieved a 
psychometrically-sound compromise between them. Population and large-group 
descriptive studies and clinical trials to date suggest that the SF-36® will prove very useful 
for descriptive purposes such as documenting differences between sick and well patients 
and for estimating the relative burden of different medical conditions. Experience to date, 
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however limited, suggests that the SF-36® may also have potential in evaluating the 
benefits of alternative treatments. Additional research is necessary before that potential and 
the features of study designs essential to success can be well understood.  
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Standard Interview Script for SF-36 HEALTH SURVEY (4-WEEK RECALL) 
SCRIPT FOR INTERVIEW ADMINISTRAION 
These first questions are about your health now and your current daily activities. 
Please try to answer every question as accurately as you can. 
1) In general, would you say your health is: [READ RESPONSE CHOICES] (Circle one 
number) 
1. Excellent 
2. Very good 
3. Good 
4. Fair 
5. Poor 
2) Compared to one year ago, how would you rate your health in general now? Would you 
say it is: [READ RESPONSE CHOICES] (Circle one number) 
1. Much better now than one year ago 
2. Somewhat better now than one year ago 
3. About the same as one year ago 
4. Somewhat worse now than one year ago 
5. Much worse now than one year ago 
3) Now I'm going to read a list of activities that you might do during a typical day. As I 
read each item, please tell me if your health now limits you a lot, limits you a little, or does 
not limit you at all in these activities. [READ RESPONSE CHOICES] [IF RESPONDENT 
SAYS S/HE DOES NOT DO ACTIVITY; PROBE: Is that because of your health?] (Circle 
one number for each question) 
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 Yes, limited a 
lot 
Yes, limited a 
little 
No, not 
limited at all 
3a) vigorous activities, such as  
running, lifting heavy objects, 
participating in strenuous sports 
1 2 3 
3b) moderate activities, such as 
moving a table, pushing a vacuum 
cleaner, bowling, or playing golf 
1 2 3 
3c) lifting or carrying groceries 1 2 3 
3d) climbing several flights of stairs 1 2 3 
3e) climbing one flight of stairs 1 2 3 
3f) bending, kneeling, or stooping 1 2 3 
3g) walking more than a mile  
(or more than 1.6 kilometres) 
1 2 3 
3h) walking several hundred yards 
(or several hundred metres) 
1 2 3 
3i) walking one hundred yards  
(or 100 metres) 
1 2 3 
3j) bathing or dressing yourself 1 2 3 
4) The following four questions ask you about your physical health and your daily activities 
as a result of your physical health during the past four weeks. [READ RESPONSE 
CHOICES] (Circle one number for each question) 
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 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of  
The time 
None of  
The time 
4a) how much of the time 
have you had to cut down on 
the amount of time you spent 
on work or other daily 
activities? 
1 2 3 4 5 
4b) how much of the time 
have you accomplished less 
than you would like? 
1 2 3 4 5 
4c) how much of the time 
were you limited in the kind 
of work or other regular daily 
activities you do? 
1 2 3 4 5 
4d) how much of the time 
have you had difficulty 
performing work or other 
regular daily activities (for 
example, it took extra effort)? 
1 2 3 4 5 
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5) The following three questions ask about your emotions and your daily activities as a 
result of any emotional problems, such as feeling depressed or anxious during the past four 
weeks. [READ RESPONSE CHOICES] (Circle one number for each question) 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of  
The time 
None of  
The time 
5a) how much of the time 
have you had to cut down the 
amount of time you spent on 
work or regular daily 
activities? 
1 2 3 4 5 
5b) how much of the time 
have you accomplished less 
than you would like? 
1 2 3 4 5 
5c) how much of the time did 
you do work or other regular 
daily activities less carefully 
than usual? 
1 2 3 4 5 
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6) During the past four weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups? Has it interfered: [READ RESPONSE CHOICES] (Circle one number)  
1. Not at all 
2. Slightly 
3. Moderately 
4. Quite a bit 
5. Extremely 
7) How much bodily pain have you had during the past four weeks? Have you had: [READ 
RESPONSE CHOICES] (Circle one number) 
1. None 
2. Very mild 
3. Mild 
4. Moderate 
5. Severe 
6. Very severe 
8) During the past four weeks, how much did pain interfere with your normal work, 
including both work outside the home and housework? Did it interfere: [READ 
RESPONSE CHOICES] (Circle one number) 
1. Not at all 
2. A little bit 
3. Moderately 
4. Quite a bit 
5. Extremely
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9) The next questions are about how you feel and how things have been with you during 
the past four weeks. As I read each statement, please give me the one answer that comes 
closest to the way you have been feeling; is it all of the time, most of the time, some of the 
time, a little of the time, or none of the time? [READ RESPONSE CHOICES] (Circle one 
number for each question) 
 All of  
the time 
Most of 
the time 
Some of 
the time 
A little of  
The time 
None of  
The time 
9a) did you feel full of life? 1 2 3 4 5 
9b) have you been very 
nervous? 
1 2 3 4 5 
9c) have you felt so down in 
the dumps that nothing could 
cheer you up? 
1 2 3 4 5 
9d) have you felt calm and 
peaceful? 
1 2 3 4 5 
9e) did you have a lot of 
energy? 
1 2 3 4 5 
9f) have you felt  
downhearted and depressed? 
1 2 3 4 5 
9g) did you feel worn out? 1 2 3 4 5 
9h) have you been happy? 1 2 3 4 5 
9i) did you feel tired? 1 2 3 4 5 
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10) During the past four weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities like visiting with friends or relatives? Has it 
interfered: [READ RESPONSE CHOICES] (Circle one number) 
1. All of the time 
2. Most of the time 
3. Some of the time 
4. A little of the time 
5. None of the time 
11) These next questions are about your health and health-related matters. Now, I'm going 
to read a list of statements. After each one, please tell me if it is definitely true, mostly true, 
mostly false, or definitely false. If you don't know, just tell me. [READ RESPONSE 
CHOICES] (Circle one number for each question) 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of  
The time 
None of  
The time 
11a) I seem to get sick a little 
easier than other people 
1 2 3 4 5 
11b) I am as healthy as 
anybody I know 
1 2 3 4 5 
11c) I expect my health to get 
worse 
1 2 3 4 5 
11d) My health is excellent 1 2 3 4 5 
 
 
760 
 
Gender: 
1. Male 
2. Female 
Age:  1. Less than 64 years 
2. 65-74 years 
3. 75-84 years 
4. 85 and older 
 
Comments: 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
Code each test using the format below in the comments column: 
1= protocol completed 
2= not completed due to death 
3= not completed due to refusal, drop-out or loss to follow up 
4= not completed due to medical illness or incapacity 
5= not completed due to equipment failure or examiner error 
6= not completed due to other cause (specify) 
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ANTHROPOMETRY 
 
MEASUREMENT OF BODY MASS (WEIGHT) 
 
Equipment: 
 Weighing Scale (AND HW-100k & SECA Wedderburn (>100 kgs) 
 Free weights of known mass (range x kgs, x kgs) 
 
Calibration of Scale 
 The site staff must ensure that calibration of the weighing scale is performed 
following the instructions outlined by the manufacturer's user manual. The 
frequency of calibration must be as recommended by the manufacturer of the scale. 
 Three objects of known weight (eg, dumbbells which have been accurately weighed 
on a force platform) are EACH placed on the weighing scale on three separate 
occasions, and the weight to the nearest 0.1kg as displayed by the weighing scale 
recorded. 
The calibration factor to be used for correcting the subject weight is then obtained by 
following the steps below: 
 The average of the three attempts for EACH of the three known weights is 
calculated 
 The ratio of the scale average to each of the known weights is calculated 
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e.g. Scale weight averages = 5.1 kg, 10.5, 20.7 kg 
Known weights= 4.9 kg, 10.1kg, 20.3 kg 
Ratios=5.1/4.9; 10.5/10.1; 20.7/20.3 
 
The average of these 3 ratios is the calibration factor. 
 Each measured weight of the subject is divided by the average calibration factor to 
obtain the TRUE WEIGHT, which is entered into the source document. 
 The calibration factor may change during the course of the study and it is important 
that site staff maintain a log of the date/time that each calibration is undertaken. It 
is strongly recommended that the calibration factors are part of the calibration log 
and kept with the weighing scale. 
 
Body Weight 
 Body weight is recorded three times while the subject is wearing only a robe (with 
a measured weight) and no shoes.  
 Any unusual conditions should be noted (e.g. presence of a cast or other non-
removable appliance such as a brace, amputation).  
 Pockets and heavy jewelry, hats, etc., should be removed prior to having the subject 
step on the weighing scale. 
 The subject should step on and off the scale for EACH of the three attempts, 
whenever possible. 
763 
 
 All three weights are recorded, corrected with the calibration factor as described 
above, and entered into the source document. 
 
Note: 
 For RMR, body mass in robe minus the weight of the robe is the entered 
measurement. 
 For max test on the treadmill, body mass is entered including the weight of the 
clothes and shoes that the subject is wearing.
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MEASUREMENT OF STRETCH STATURE (STANDING HEIGHT) 
 
Equipment: 
 Wall mounted Holtain stadiometer (Holtain Limited, Crymmych Pembs., UK), 
calibrated with steel calibration measuring stick of known length 
 Height must be measured in all subjects at baseline assessment. It is not measured 
at follow-up assessments, unless it was not recorded at baseline. In this case, a 
follow-up height is taken and used as a “baseline height”. 
Protocol 
 Subject is barefoot with the feet together and heels, buttocks, and shoulder blades 
against the wall, or as close to this position as possible (if the vertical position of 
the body is distorted it may be just the buttocks against the wall mount. 
 Head must be in Frankfort plane: 
o Orbitale (lower edge of eye socket) is in the same horizontal plane as the 
tragion (the notch superior to the tragus of the ear). 
o Vertex of skull will be at the highest point. 
o The examiner should assist the subject in the attainment of the Frankfort 
plane by gentle positioning of the head and neck to attain as fully erect a 
posture as possible, telling them to direct his/her gaze straight ahead. 
 A walking frame may be placed in front of the volunteer for security and 
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stabilisation as long as the heels and the shoulder blades remain touching the wall 
and there is no forward flexion of the spine to hold onto the walker. 
 Instruct the subject to take a deep breath in and hold it at full inspiration during 
each measurement. 
 At the end of inspiration, with the head still in the Frankfort plane, an assistant 
should lower the headboard down gently and completely on vertex of the skull, 
crushing hair as much as possible, but not so hard as to compress neck or spine. If 
there is no assistant, place the headboard down before the stretch and then read the 
measurement where the height is attained while the board travels in contact with 
the vertex. 
 Height is taken at full inspiration to the nearest mm in triplicate 
 The 3 readings (which should be within 5mm of each other) are recorded on the 
data sheet. If readings are further apart than this, take additional readings until 3 
close measures are obtained. All three measurements are entered into the data base 
to allow calculation of CV's. 
 
BODY MASS INDEX 
The body mass index (BMI) is calculated by dividing the subject's body weight in 
kilograms by the square of their height in meters.
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GAIT SPEEDS 
Habitual and Maximal gait speeds need to be reviewed during the physican screen prior to 
the maximal stress test. After timing gait as per the protocols below, use the gait speed 
calculator on the “Q-stress” system to calculate gait speeds. Change printer to “C-Block” 
printer and print. Leave on the desk in C111 with subject’s medical records and screening 
file for Professor Maria Fiatarone Singh to review. 
 
HABITUAL GAIT VELOCITY 
Equipment 
 Ultra-timer with working battery 
 
Purpose 
This test is meant to record the normal walking speed of the volunteer, as if he or she were 
not being observed. Gait velocity is a very good overall indicator of functional status, and 
it is typically slowed by both aging and disease. In the elderly, muscle weakness and poor 
balance contribute substantially to abnormal gaits. 
 
Preparing the volunteer 
 Volunteer should be wearing normal, low-heeled walking shoes, comfortable 
clothing, eye glasses and hearing aides, if any.  
 They should have been offered to use the restroom prior to starting the test. If an 
assistive device is normally used for walking, the person should use this during the 
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test, and the device used should be recorded on the worksheet.  
 The same assistive device should be used at all timepoints if possible, unless the 
person has advanced to a higher level device (e.g. walker instead of a cane) due to 
changing medical condition.  
 If the volunteer rarely uses a cane, do not use it during the testing. 
 
Environmental Considerations 
The gait speed test should be conducted in an indoor room or hallway which is entirely free 
of traffic or clutter. An open path of at least 10 meters in length is needed. Preferably, there 
should be no wall directly in front of the volunteer as they are walking forward. The path 
should be well lighted by natural or artificial lighting. A non-slip, non-carpeted surface 
such as tile or linoleum is best, but if carpeted floor must be used it should be low pile wall-
to-wall carpeting, and the same surface must be used at all timepoints. 
 
Protocol 
 Place the Ultra-timer receiver on the belt so that it is positioned in the middle of the 
subject’s back and is in a direct line with the examiner’s transmitter.   
 Fasten belt snugly around waist, and make sure no clothing or belt loops are 
covering the “eye” of the box.   
 Stand directly behind the subject and tell them to walk at a normal pace, as though 
you were not there observing them.  
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 Tell the subject this is “Not a test of their fastest walking speed”, which will come 
later on.  
 The subject is to start walking when you say “Begin” and not stop until instructed. 
 Turn on the transmitter. If no numbers appear on the dial, the battery needs to be 
replaced before continuing.  
 When the subject has moved approximately 2 meters away from you, press the 
“Start” button on the transmitter you are holding, making sure that it is pointed 
directly at the receiver and that you do not change your hand or foot position at all 
during the test. 
 As soon as the subject has moved an additional 2 meters away from you, the box 
will automatically stop timing and you can then tell the subject to stop walking. 
 Record the numbers you see on the dial. This is the number of seconds it took the 
subject to walk 2 meters. If this number is divided by 2, this is the number of 
seconds it takes to walk 1 meter. Inverting this will give you gait velocity in 
meters/second (m/sec) which are the required units. 
 
e.g.: 4.00 = Ultra-timer readout 
 2.00 = seconds to walk 1 meter 
 1/2.00 = 0.50 = gait velocity in m/sec 
 
 After recording the numbers, press the reset button on the transmitter.   
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 Repeat the entire test procedure above and record the numbers you see on the dial. 
The average of the two readings of gait velocity will be the final score which is 
used 
At the screening visit, it will be necessary to  
1) average the two reading of gait velocity from the Ultra-timer, and  
2) convert this average score to m/sec, the required units. 
 
Once the score is in m/sec, you can determine if the subject meets the inclusion criteria for 
habitual gait speed. Habitual gait speed should be between: 
 0.6 - 1.3 m/sec (inclusive) for males; and,  
 0.6 to 1.2 m/sec (inclusive) for females.   
 If a subject’s score in m/sec is .55 to .59, this can be rounded up to 6.0 and thus the 
subject would be eligible for the study.   
 Any score in m/sec above 1.3 for males and 1.2 for females makes a subject 
ineligible for the study. 
For all follow-up testing, you will only be required to enter the two readings from the Ultra-
timer onto the CRF and the computer will calculate the average and then convert the score 
to m/sec. 
 
Common problems/questions 
Make sure to let the person walk 2 meters before pressing the start button, so that 
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acceleration is not factored into the speed. Similarly, you do not want deceleration to be 
part of the measurement, so do not mark a finish line or give the subject any indication as 
to when the walk will end. The receiver and transmitter cannot be more than 7 meters apart 
to work. Therefore, do not let the person “warm-up” for more than 2-3 meters, or you will 
run out of distance before the measured 2 meter walk is over. The two readings should be 
almost identical, unless the person has not understood your directions or other errors have 
been made. If they are not in close agreement, do the test a third time and discard the 
outlying reading. 
 
Be sure to turn off the transmitter after each test or the battery will wear down quickly. 
Always have a spare battery with you in the Ultra-timer case to avoid delays in testing 
 
Maximal Gait Velocity 
Equipment 
 Ultra-timer with working battery 
Purpose 
This test is meant to record the maximal walking speed of the volunteer, as if he or she 
were exerting and covering as much ground as possible without breaking into a jog or run. 
Maximal gait velocity in healthy young people may be twice as fast as habitual gait velocity. 
The difference between habitual and maximal velocity narrows considerably with age. 
Very frail older people are able to make little or no adjustments to their customary walking 
speed, due to low endurance, muscle weakness, imbalance, arthritic pain or orthopaedic 
limitations. 
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Preparing the volunteer 
Volunteer should be wearing normal, low-heeled walking shoes, comfortable clothing, eye 
glasses and hearing aides, if any. They should have been offered to use the restroom prior 
to starting the test. If an assistive device is normally used for walking, the person should 
use this during the test, and the device used should be recorded on the worksheet. The same 
assistive device should be used at all timepoints if possible, unless the person has advanced 
to a higher level device (e.g. walker instead of a cane) due to changing medical condition. 
If the volunteer rarely uses a cane, do not use it during the testing. 
 
Environmental considerations 
The maximal gait speed test should be conducted in an indoor room or hallway which is 
entirely free of traffic or clutter. An open path of at least 10 meters in length is needed. 
Preferably, there should be no wall directly in front of the volunteer as they are walking 
forward. The path should be well lighted by natural or artificial lighting. A non-slip, non-
carpeted surface such as tile or linoleum is best, but if carpeted floor must be used it should 
be low pile wall-to-wall carpeting, and the same surface must be used at all timepoints. 
 
Protocol 
 Place the Ultra-timer receiver on the belt so that it is positioned in the middle of the 
subject’s back and is in a direct line with the examiner’s transmitter.   
 Fasten belt snugly around waist, and make sure no clothing or belt loops are 
covering the “eye” of the box.   
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 Stand directly behind the subject and tell them to walk as fast as they can, and they 
will be timed to measure their speed.   
 Tell the subject this is a test of their fastest walking speed, unlike the normal gait 
speed test they just completed.  
 The subject is to start walking when you say “1, 2, 3, GO!!!” and not stop until 
instructed. It is important to give this command to elicit maximal acceleration. 
 Turn on the transmitter. If no numbers appear on the dial, the battery needs to be 
replaced before continuing.  
 When the subject has moved approximately 2 meters away from you, press the 
“Start” button on the transmitter you are holding, making sure that it is pointed 
directly at the receiver and that you do not change your hand or foot position at all 
during the test.  
 As soon as the subject has moved an additional 2 meters away from you, the box 
will automatically stop timing and you can then tell the subject to stop walking. 
 Record the numbers you see on the dial.  This is the number of seconds it took the 
subject to walk 2 meters. If this number is divided by 2, this is the number of 
seconds it takes to walk 1 meter. Inverting this will give you gait velocity in m/sec, 
which are the required units. 
e.g.: 4.00 = Ultra-timer readout 
  2.00 = seconds to walk 1 meter 
773 
 
  1/2.00 = 0.50 = gait velocity in m/sec 
 After recording the number, press the reset button on the transmitter.  
 Repeat the entire test procedure above. Record the numbers from the Ultratimer.  
 Both of these numbers will be entered onto the CRF. The computer will then 
convert these scores to m/sec, the required units.  
 The best (highest) of the two readings of maximal gait velocity in m/sec will be 
picked by the computer as the final score which is used. It is not necessary for you 
to do any calculations to determine maximal gait velocity! 
Common problems/questions 
Make sure to let the person walk 2 meters before pressing the start button, so that 
acceleration is not factored into the speed. Similarly, you do not want deceleration to be 
part of the measurement, so do not mark a finish line or give the subject any indication as 
to when the walk will end.  The receiver and transmitter cannot be more than 7 meters 
apart to work. Therefore, do not let the person “warm-up” for more than 2-3 meters, or you 
will run out of distance before the measured 2 meter walk is over. 
The two readings should be almost identical, unless the person has not understood your 
directions or other errors have been made. If they are not in close agreement, do the test a 
third time and discard the outlying reading.   
It is good to tell the person the first result and encourage them to beat it on the second try. 
If you are concerned about balance problems, position the subject near the wall or railing 
so that they can immediately grab it if they start to fall.  Subjects will normally not walk 
faster than they feel they safely can, but you may test someone whose judgment is not good 
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in this regard, so be aware during the initial gait test of any potential problems uring this 
more stressful test and be prepared to spot them. If necessary, two examiners can be used 
for the very frail, one timer and one spotter. 
 
Be sure to turn off the transmitter after each test or the battery will wear down quickly. 
Always have a spare battery with you in the Ultra-timer case to avoid delays in testing.
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STATIC BALANCE 
 
Equipment 
 Measuring Tape  
 Stopwatch that can measure time in seconds to 0.01 seconds 
 Chair 
Purpose 
These tests are progressively more difficult tests of both static and dynamic balance, both 
of which are related to the quality of gait and risk of falling in older adults. Balance is a 
complex phenomenon with many inputs, including vision, proprioception, coordination, 
muscle strength, reaction time, and others. In static balance testing, by narrowing the base 
of support over which a person’s centre of gravity rests, the task of standing still without 
moving or falling becomes progressively more difficult.  Removing visual cues makes 
this even more difficult.  This is the purpose of the timed stands.  Dynamic stresses 
include moving through space with a narrow base of support (tandem walking), or more 
difficult versions of this kind of test. 
 
Preparing the subject 
Subject should be wearing normal, low-heeled walking shoes, comfortable clothing, eye 
glasses and hearing aides, if any.  The subject should have been offered to use the 
restroom prior to starting the test. If an assistive device is normally used for walking, the 
person cannot use this during the test, as it reduces the difficulty of the tasks greatly. If the 
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subject is unable to stand without the use of an assistive device, this should be recorded in 
the source documents, as the person being unable to do the test. 
 
Environmental considerations 
A quiet area with vinyl flooring or very low pile carpeting, good lighting, and with at least 
a 30 foot straight, unobstructed path is needed. The same flooring should be used at all 
time points. 
 
Protocol for static balance 
Be sure to demonstrate all positions to the subject one at a time as you explain that you will 
be testing balance, and “the task is to keep the feet in the desired position for 15 seconds 
while being timed”. Arms and trunk may be moved slightly during the test if needed to 
maintain balance, but the timing ends when the full 15 seconds is reached or when either 
foot moves, or if you or any object in the environment is touched by the subject, whichever 
comes first. 
 
The subject must wear comfortable, low-heal shoes for these tests; tests may not be 
conducted with the subject in bare feet as these tests are devised to ascertain balance in 
activities of daily living. Position the subject so that his/her back is about 1 ft in front of a 
chair, in case the subject begins to fall. You should be positioned just to either side, close 
enough to spot the subject and prevent a fall but not touching the subject. For each position, 
demonstrate and then allow the subject to try to assume the correct position unassisted. If 
this is not possible, assist the subject in doing so, and then let go of him/her. For the most 
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difficult tests, you may position the subject and hold onto one of his/her hands, letting go 
just when you begin to time the subject, otherwise the subject may lose his/her balance 
before the test actually begins. The person must feel secure when doing these tests. It is 
acceptable to position a subject’s walker just in front of the subject during the static balance 
tests as long as the subject doesn’t touch it during the test, as the subject may feel more 
confident to try in that case. 
 
Do not repeat tests unless it is clear directions were misunderstood, as practice makes the 
subject learn how to do the task very rapidly, and it is unfair to compare single and multiple 
attempts among different subjects. Subject must stand up as straight as possible as bending 
the knees during the balance test reduces the difficulty of the task greatly. The series of 
static balance stands are done in the following order: 
 
Static Balance Tests 
1) Wide Stance 
2) Narrow Stance 
3) Semi-tandem Stance 
4) Tandem Stance 
5) One Leg, Eyes Open 
6) One Leg, Eyes Closed 
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1) Wide stance, no hand support 
 Subject's feet are positioned so that the feet are lined up approximately hip 
width apart and in parallel.  
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds as they watch you demonstrate the next position. 
 
2) Narrow stance, no hand support 
 Subject's feet are positioned so that the feet are lined up next to each other 
pointing straight ahead and are touching all along the length of the foot.  
 If bunions or other conditions prevent this, position the feet so that the heels are 
touching each other.  
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds as they watch you demonstrate the next position. 
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3) Semi-tandem stand, no hand support 
 Subject's feet are positioned so that the toes of one foot are at the level of the 
instep of the other foot, and feet are touching.  
 Either foot may be placed ahead of the other according to preference/comfort 
as the position is tried out.  
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds as they watch you demonstrate the next position. 
 
4) Tandem stand, no hand support 
 Subject's feet are positioned so that the toes of one foot are touching the heel of 
the other foot, and feet are both pointing directly forward.   
 Either foot may be place ahead of the other according to preference/comfort as 
the position is tried out.  
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 If necessary, hold onto the subject’s hand, and start the stopwatch as soon as 
you let go.  
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 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds as they watch you demonstrate the next position. 
 
5) One leg, eyes open, no hand support 
 The subject needs to lift one foot so that it is clear of the floor. They may choose 
whichever foot they feel most comfortable with. 
 Start timing after the foot position is attained correctly.  
 If necessary, hold onto the subject’s hand, and start the stopwatch as soon as 
you let go.     
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds.  
 
6) One leg, eyes closed, no hand support 
 As above for the one leg stand, except that the eyes are closed after the foot 
position is attained correctly.  
 If necessary, hold onto the subject’s hand, and start the stopwatch as soon as 
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you let go.   
 Subjects’ eyes must be closed before the stopwatch is started.   
 Record the number of seconds to the nearest 0.01 seconds from the stopwatch, 
up to a maximum of 15 seconds.  
 Tell the person to relax (eg, widen their stand by moving the feet to be shoulder 
width apart; subject should not be allowed to sit down) at the end of the 15 
seconds. 
 
Note that all positions must be tried in the order listed, regardless of the level of 
performance on the preceding test. If a subject attempts but is unable to achieve a position 
and start the timing, even with you helping them get in position, record unable to do in the 
source documents. The time recorded in the source documents will consist of all the digits 
offered by the stopwatch; when transcribing the time to the case report forms (CRFs), the 
time should be rounded to the nearest 0.01 sec. If the subject is able to achieve the desired 
position, with or without your assistance, and the stopwatch is started, record whatever 
time is achieved, even if it is only a fraction of a second.
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Physician Screen 
BLOOD PRESSURE MEASUREMENT 
Time since last exercise, medications, hydration status, time since last meal, test room 
temperature, cuff size, sphygmomanometer angle and positioning, and arm angle upon 
standing may all affect the results of this measurement and therefore should be standardized, 
or recorded on the data sheet. 
Equipment 
 Mercury Sphygmomanometer (Enter Make, Model) 
 Stethoscope 
a. A cuff size appropriate to the size of the arm should be selected. 
b. The cuff is placed snugly over the upper arm with the bladder centred 
over the brachial artery, as indicated by the arrow on the cuff, and the lower 
edge of the cuff about 1 cm above the crease of the elbow. 
c. The patient should be seated for at least 5 minutes before the 
measurement is taken, with feet flat on floor, and no environmental 
distractions present. 
d. The patient’s arm, from which the measurement is made, is supported by 
the assessor taking the measurement at the heart level, or preferably is 
supported on a table or arm of a chair. 
e. The right arm should be used unless it is not possible (lymph node 
dissection, amputation, other). 
f. The position of the sphygmomanometer is at eye level. 
g. Blood pressures are recorded in even numbers and read to the closest 2 
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mmHg mark. 
h. The bladder should inflated quickly to 200 mmHg, and then be deflated 
slowly. 
i. The first Korotokoff sound (first of a repetitive series of sounds that are 
heard) should be recorded as systolic pressure. 
j. The pressure at the point the last sound fades out completely should be 
recorded as diastolic pressure. 
k. If the measurement needs to be repeated, one minute or longer must 
elapse between reading
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MAXIMAL TREADMILL TEST PROTOCOL 
 
Equipment 
 Ultima PFX Series, Medgraphics, (St. Paul, Minnesota, U.S.A). 
 BreezeSuite software, version 6.2a 
 Quinton 4500 Stress Test Monitor (Bothell, WA, U.S.A)  
 Quinton Automatic BP monitor  model 412 (Bothell, WA, U.S.A) 
 3M Electrodes 
 Pneumotach 
 Medgraphics mask (Pat. #6718982, Taiwan) 
 
Medgraphics Equipment and Software Preparation 
1. Turn Ultima PFX “on” via the wall switch (white cord) at least 40 min before use.  
Wait until the red light on the Ultima PFX turns from red to green. This indicates 
that it is ready for use. 
2. Select the program “Breeze” from the desktop of the computer. 
3. The window which appears in front of you when you first open the program is the 
‘Patient’ screen. Select the ‘New’ option at the bottom of the window. Enter in 
patient’s last, middle and first names, gender race and Date of Birth in the boxes 
provided. Press ‘Add visit’. This information is only entered at the first visit, and is 
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retrievable subsequent visits. To retrieve, when the ‘Patient’ screen is open, select 
the patients file from the list present, press ‘add visit’.  
4. The next screen that will appear is another patient information screen.  
5. DO NOT enter this information because you will still be waiting on some details 
(height and weight). This can be filled out after the anthropometry is assessed, prior 
to testing. This screen can be in the background as you prepare the software for 
testing. 
 
6. Select    
 
7. Wait until the red coloured numbers next to “GX Vac” turn into a green “READY”.  
This takes 10 minutes. 
 
8. Select     
 
This calibrates the pneumotach. You will need to enter the temperature, humidity 
and barometric pressure at bottom of window/screen PRIOR to calibrating. Room 
temperature (˚C) and humidity (%) are obtained from the temperature and humidity 
gauge on the shelves located on your left. The barometric pressure (hPa) is obtained 
from the Bankstown airport Website: 
 
GX Vac 
CALIBRATE 
caCA 
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http://www.bom.gov.au/products/IDN65092/IDN65092.94765.shtml  
9. Attach pneumotach to the blue end of the 3L calibration syringe. Remove the gas 
analyser from the front of the Ultima system and attach it to the pneumotach/ 
syringe configuration. (NOTE: the gas analyser is attached to the pneumotach 
correctly; the notch on the gas analyser is at opposite sides to the notch on the 
pneumotach) 
10. Select “Zero flow” (whilst holding your palm over the end of the pneumotach). If 
there a caution message that the ‘flow is out of range’, check correct configuration 
of the syringe/pneumotach/gas analyser configuration and retry. If there was no 
caution message, this mean the ‘zero flow’ was successful. 
11. When ready, you will be asked to calibrate different flow rates using the known 
volume of air in the syringe. Press ‘start’ and then pull syringe pistol in and out - at 
a speed to match the lines on the graph displayed on the screen.  Do this at five 
different speeds. (NOTE: To re-do or reset, select “Stop”, then “Start” – and try 
calibrating again) 
12. If calibration is successful, ‘calibration successful’ will appear on the screen. If the 
calibration was unsuccessful, ‘calibration unsuccessful’ will appear. You will need 
to retry until ‘calibration successful’ appears. 
13. Select “OK” when done. This will close the calibration window. 
14. To perform the ‘Calibration of gases’, turn the handles on both gas cylinders in a 
counter-clockwise direction to open cylinders (the gas cylinders are located at the 
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back of the cart). You do not need to open the knobs the all the way. They only need 
to be turned 90 degrees from the starting position. (Do not touch the knobs where 
indicated by signs ‘DO NOT TOUCH!’).  
15. Return the gas analyser into the Ultima PFX (with the 2 pins on top). 
16. Select  
A caution message ‘Calibrating Gas Analysers’ will appear while auto calibrating 
the gas cylinders. A summary window will appear once the calibration is complete, 
indicating that the calibration was successful. 
17. Select “OK”. 
18. Turn gases off completely (twist knobs clockwise) when calibration is complete. If 
left open, the gases will be depleted. 
19. Now that the anthropometry has been measured, enter the details into the patient 
page.  
20. Select  
The “Gas Exchange” tab is located at the bottom of the screen.  
21. The ‘settings’ page will be the page appearing on the screen.  
22. Enter the details of the test you will be conducting. In this case it will be a ‘treadmill 
test’. Enter physician and technician details in the appropriate places. Select the 
‘HR monitor’ in the ‘External Device’ column. This will allow the Medgraphics 
system to register heart rate reading from the Quinton ECG machine. Heart rate 
AUTO CAL 
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reading will be displayed with the other variables on the computer screen. 
23. Select the ‘Test’ tab. At this point the page displays a blank data section (located in 
the top portion of the screen with variables such as V02, VCO2 RER and HR) and 
two blank graphs. 
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WITH THE PATIENT PRESENT 
 
 Remind the patient whether they need to visit the bathroom prior to the test 
 Explain purpose of test. Illustrate how to straddle the treadmill and then begin 
walking on the moving belt. 
 Explain the electrode placement, and the purpose of having the electrodes. 
 Explain the placement of the mask and its purpose 
 Explain the placement of the BP cuff and its purpose 
 Explain that the research assistant and MD will encourage patient throughout the 
test. Explain/show ‘thumbs up’ for doing well/keep going, for the test to continue. 
 Explain/show ‘thumbs down’ if they can not go on anymore for the test to cease 
immediately followed by a 1-2 minute cool down.
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CONNECTING THE PATIENT TO THE TESTING APARATUS 
 
The patient will be attached to three pieces of testing equipment: 
 ECG 
 BP 
 MEDGRAPHICS 
 
The patient preparation will take place in three positions: 
 Supine 
 Seated 
 Standing 
 
Patient supine 
 Enclose the testing area by drawing the curtains to ensure the patients privacy 
during electrode placement. 
 Ask subjects to remove, open or lift their shirt (females are instructed to wear a 
crop-top/bikini top/singlet top). Electrodes are placed while the patient is in a 
supine position. Any body hair is shaved off with a disposable razor when necessary. 
 Electrodes are placed on subjects using the 12-lead placement and positioned as 
follows: (refer to picture of correct 12-lead placement) 
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 RA and LA: just below the right/left clavicle medial to the deltoid. 
 RL and LL: just above the right/left iliac crest along the midaxillary line. 
 V1-V6: as described in Rautaharju et al 1 
 Attach the leads to the electrodes, check correct placement of electrodes by 
selecting “Check Electrodes” on the Quinton Computer. If the signal does not look 
good, make sure the electrodes are in the right place and are properly attached. If 
the signal appears normal, select the “Exercise Test” option. 
 
Patient seated 
 Place the BP cuff snugly around the subject’s left arm, after palpating the brachial 
artery pulse.  
 Use the Blood Pressure cuff which is peripherally attached to the Quinton 4500. 
Take supine BP manually by placing the BP monitor in ‘manual’ mode. Press the 
‘Start’ button on the BP monitor until ‘systolic pressure’ is inflated to approximately 
200. 
 Ask the patient to be seated in a chair, and may re-button/readjust their shirt. 
 Resting ECG readings are viewed by Doctor, while final stages of Medgraphics 
preparation are taking place. 
 Another manual BP measurement is taken while the patient is in the seated position. 
While still in ‘manual’ mode press the ‘Start’ button on the BP monitor until 
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‘systolic pressure’ is inflated to approximately 200. 
 Provide a couple of sizes of mask for the patient to try on. The mask should be snug, 
but not to tight so that the flesh surrounding the mask is protruding. Ask the patient 
to take a few breaths so that you could feel any air escaping from around the nose 
or around the chin. 
 Ascertain the correct size mask for the patient, then remove the mask and ask the 
patient to stand on the treadmill. 
 
NOTE: Wearing the mask is uncomfortable, and this time should not be prolonged 
unnecessarily.  
 
Patient standing 
 Patient to assume the ‘straddle’ position on the treadmill. 
 Standing blood pressure measurement is taken in the standing position. 
 While still in ‘manual’ mode press the ‘Start’ button on the BP monitor until 
‘systolic pressure’ is inflated to approximately 200. 
 Replace the mask on the patients face and feed the gas analyser and tube through 
the cord which is suspended from the roof.  
 Placing the mask onto the patient, and attach the gas analyser is the last step of the 
preparation phase.  
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 Press the    button located on the top left hand corner of the  
 
screen. This will start the collection of the data from the mask into the Medgraphics 
system. The empty data screen and graphs will now have information appearing. 
 Obtain standing resting measurements for approximately one minute to ensure that 
all equipment is in working order. 
 The patient is now ready to begin the testing procedure. Simultaneously press ‘Start 
exercise’ on all machines (BP, ECG, and Metabolic cart) and begin treadmill 
protocol. 
 
TESTING PROTOCOL 
 
 Measure habitual gait speed (refer to the Ultratimer protocol). Convert this value 
from time taken to travel 2 minutes to km/hour 
 Set treadmill as close as possible to that speed. Adjust up or down to achieve a 
mechanically efficient walking motion on the treadmill. 
 For older or frailer patients, start with 80% of habitual gait speed; adjust up or down 
as needed. 
 For younger patients, start at 100% habitual gait speed; adjust up or down as needed. 
 Ask subject to very lightly grasp the handrails for balance. Record if 1 or 2 hands 
START 
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were used during the test. 
 Start the exercise test a 0% incline walking at/around habitual gait speed. Incline is 
increased by 2% per minute. 
 Blood Pressure is taken automatically at 2 minute intervals throughout the test and 
at the end of the test. 
 Encourage the subject every minute from the start of the test, until they start 
displaying signs of fatigue, then encouragement is provided more often.   
 The intention is for the test to continue for a minimum of 6 minutes but no longer 
than 10 minutes. The test will be terminated when the subject requests to 
discontinue (volitional fatigue).   
 Other reasons for terminating a test include abnormalities of pulse or ECG noted 
by physician/research assistant, failure of technical equipment, drop in SBP 
≥10mmHg despite an increase in workload, and signs of poor perfusion (light-
headedness, confusion, pallor, nausea, cold and clammy skin) The same protocol 
(including starting speed and grade) is used for each subject at baseline and follow-
up. 
 When the test is terminated because of any of the above reasons: 
o Reduce the incline to 0% and the speed to 1.1km/hr.  
o The stop button is pressed on all machines. At this point the Quinton 4500 
will automatically take the patient’s BP. 
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o Remove the mask from the patient at the earliest convenience. 
o Patient is to continue walking at the above mentioned speed, with the ECG 
and BP measurements continuing to take place. 
 At the Physician’s cue, the patient may cease walking, at this point they are 
provided with a chair and a glass of water if they like. The physician continues to 
monitor ECG, BP and HR readings. Once the Physician is satisfied with the 
measures returning almost to rest levels, the procedure is stopped at the physician’s 
cue. 
 At the earliest convenience, proceed to cleaning the mask, pneumotach and coupler 
(as described in the maintenance section) 
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PERFORMANCE BASED TESTS OF FUNCTION 
 
GENERAL GUIDELINES 
Performance-based testing is a means to quantitatively define or estimate the maximal 
physiologic capacity in a variety of domains which are thought to be relevant to functional 
status and mobility in the elderly. These tests are valid and reproducible only if the 
directions are followed meticulously, so as to avoid inter-tester differences which can 
otherwise be quite large. Although each test is simple to perform, small errors in timing, 
instructions to the volunteer, or changes in environmental conditions have large 
effects on the outcome. 
For each test, its purpose, necessary equipment, volunteer preparation, environmental 
considerations, and exact protocol and data collected are indicated in the sections which 
follow/ 
 
Because the attempt is to elicit maximal performance in each of these areas, it is essential 
that the volunteers be aware of the requirements of the test, mentally and physically capable 
of giving a maximal effort, as well as being as unfatigued as possible. The tests are meant 
to be performed in the order listed in order to reduce the possibility of fatigue interfering 
with the subsequent test.  In general a five minute rest period is given between tests during 
which time water may be offered and additional explanations given.  However, if a 
volunteer appears to need a longer break, than it should always be given. As this will not 
adversely affect test scores in any way. 
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Before beginning testing, an assessment should be made that the volunteer is competent to 
undergo testing, has signed the informed consent papers, and is medically stable.  If there 
is any doubt that the person is at their baseline medical condition, or if an acute, previously 
undiagnosed serious symptom is discovered on questioning, seek advice from medical 
personnel of coordinators before continuing with the protocols.  Always err on the side of 
safety in this regard.  If a volunteer refuses all or part of the testing in the middle of a 
session, for any reason, adhere to their wishes and stop at that point. 
 
Demonstrate all tests for the volunteer as well as giving the verbal instructions indicated, 
as this is usually far easier for most people to grasp. Encouragement to elicit maximal 
performance is an essential part of these testing procedures and should always be used. 
Record all data from each test immediately on data sheets or computers so that no 
information is lost. 
 
  
798 
 
SIT-TO-STAND 
 
Equipment 
• Standard chair 
• Stopwatch 
Purpose 
This test is used as a proxy for lower extremity power, or the ability to generate high forces 
rapidly. The hip extensor and knee extensor muscle groups are primarily used in this task, 
which may be quite difficult for frailer individuals. As frailty increases, the time taken to 
complete the task extends, and muscle endurance begins to play a role in addition to muscle 
power. 
 
Preparing the volunteer 
The volunteer should be wearing normal, low-heeled walking shoes, comfortable clothing, 
eyeglasses and hearing aides, if any. They should have been offered to use the restroom 
prior to starting the test. 
 
Environmental considerations 
The standard chair should be placed with the back directly against a wall so that it is secure 
during testing. If a walker is normally used for ambulation it may be placed 2 feet in front 
of the volunteer if they think they may need to steady themselves at the end of the test, but 
they should not touch it unless absolutely necessary. 
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Protocol 
Instruct the volunteer that the purpose of the test is to stand up and sit down as rapidly as 
possible 5 times in a row. Encouragement to achieve maximal performance is critical in 
this test, as they may otherwise forget the nature of the task in the middle. 
 
Position the volunteer in the chair so that their back is against the back of the chair, feet are 
planted on the ground (It is okay if the subject’s feet do not reach the ground), knees bent 
at 90 degrees, and arms crossed in front of chest. When you say “1,2,3, GO!” start the 
stopwatch. The subject should rise fully and sit down fully a total of 5 times in a row.  
Stop the watch when they have achieved a fully erect standing position for a 5th time. DO 
NOT WAIT until they have resumed their initial position in the chair. 
 
Tell them that they should try to do it without using their arms, but if they find at any point 
during the test that they need to use their arms to push off the chair or complete a stand, 
they should do so and continue with the test. Record the time taken to complete 5 stands to 
the nearest 0.01 second on the worksheet, as well as whether or not the volunteer used their 
arms for assistance. 
 
This test is done one time only! 
Common problems/questions 
Make sure that the subject does not begin to move forward in the chair or reposition their 
feet until you actually begin the test. On each stand, they must come to a complete erect 
posture; evaluate their standing posture before you begin so that you will know what “erect” 
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means for them. Similarly, they must return all the way back to the starting position in the 
chair between each rise; it is not sufficient to barely touch the seat and then come back up. 
If someone tries over and over to rise without their arms unsuccessfully when you start the 
test, and is clearly going to be unable to do it, stop them and tell them to start with their 
arms crossed, but as soon as you say go, uncross their arms and use them to assist for all 
of the rises if necessary. 
 
You will also need to stop the test if the person is not following the directions to rise or sit 
down fully. Since it is fatiguing to repeat this test, and will adversely affect test scores, it 
is much better to anticipate and demonstrate these common errors for the volunteer before 
they actually try it themselves.
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STAIR CLIMB  
Volunteer should be wearing normal, low-heeled walking shoes, comfortable clothing, 
eyeglasses and hearing aids, if any. Hand rails may be used if necessary. 
 
Environmental conditions 
Lighting and ventilation should be adequate. Close off the area to other traffic during 
testing. 
 
Protocol 
• Instruct the subject that the purpose of the test is to climb the stairs as rapidly as 
possible. The subject should start with hands by their sides at the foot of the stairs, close to 
one of the handrails in case they need to use it, but they should attempt the test without 
using their hands.   
• Say “1, 2, 3, GO!” and start the stopwatch, following them up the stairs as they go. 
Stop the watch when both of their feet are on the landing at the top of the stairs. 
 
Calculation 
Power (Watts) is calculated from the formula: 
 
P = (M x D) x 9.8/ t  
Where: 
P = Power (Watts) 
M = Body mass (kg) 
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D = Vertical distance (m) 
t = Time (s) 
D = vertical height of the staircase= height of 1 step in meters x number of steps (if they 
are all the same height) 
 
NOTE: Units must be in kg and meters for correct calculation of power in Watts. 
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SIX MINUTE WALK TEST 
Equipment 
• Measure Meter 
• Stopwatch 
 
Purpose 
The six minute walk is a proxy for overall cardiovascular endurance capacity (aerobic 
capacity). In addition to cardiovascular efficiency, however, in the elderly subject it may 
be determined by muscle strength and endurance, balance, orthopaedic or neurologic 
abnormalities, and other problems. It works best as an estimate of aerobic capacity in 
individuals who cannot run, so that variations in walking velocity describe most of the 
possible range of function. Therefore it is very appropriate in very frail or elderly 
volunteers as well as healthy elderly. 
 
Preparing the volunteer 
Volunteer should be wearing normal, low-heeled walking shoes, comfortable clothing, eye 
glasses and hearing aids, if any. They should have been offered to use the restroom prior to 
starting the test. If an assistive device is normally used for walking, the person should use 
this during the test, and the device used should be recorded on the data sheet. The same 
assistive device should be used at all timepoints if possible, unless the person has advanced 
to a higher level device (e.g. walker instead of a cane) due to changing medical condition. 
If the volunteer rarely uses a cane, do not use it during the testing. 
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Environmental considerations 
This test requires a long open circuit around which the volunteer can walk continuously for 
six minutes. Long circular or square corridors around the perimeter of a building without 
many turns are ideal. All testing should be done indoors rather than outdoors, as there are 
too many uncontrolled variables in outdoor areas. The path should be free of clutter and all 
other traffic should be closed off if possible during the testing. No steps, inclines, doors, or 
other obstacles should be in the path of the volunteer, and lighting and ventilation should 
be adequate. 
 
Protocol 
The person should be instructed that they are to “cover as much ground as possible in six 
minutes” by “walking as fast as they can the entire time”. They must be encouraged and 
reminded of the task at least every 30 seconds during the test or they will tend to slow 
down. Line up the Measure Meter (with the dial reset to read 000) with the volunteer’s feet 
on the starting line. Prior to beginning the test, ascertain that the volunteer’s pulse rate, 
breathing rate, and blood pressure are in their normal range. Say “1,2,3, GO!” and begin 
the stopwatch.  Follow closely behind the volunteer with the Measure Meter, attempting 
to follow their path as closely as possible without getting in their way or influencing their 
gait speed. The number of metres travelled at the end of 6 minutes is recorded to the nearest 
foot from the wheel. Use standardized statements such as: 
• “Keep Going!”  
• “You’re Doing Well!”  
• “Keep up the Good Work” 
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If the volunteer needs to stop to rest during the test, the watch continues to run, and they 
should be instructed to start back up again as soon as they are able. 
 
If they develop angina during the test, or any other symptoms which seem severe, the test 
should be terminated immediately and emergency medical help should be contacted. 
However, shortness of breath, fatigue, and slight muscle or joint pain are not unusual and 
are not an indication for stopping the test. If claudication occurs, the person may need to 
stop momentarily, but can go on as soon as they feel able. 
 
Record if an assistive device used, the number of stops made during the test, any symptoms 
which developed during the test, reason for stopping prematurely, if any, and the total 
distance covered in 6 minutes to the nearest 0.1 metre. This test is only performed once. 
 
Common problems/questions 
The volunteer should be well rested prior to beginning this test, as it requires physical 
stamina and mental alertness. The exact wording above should be used to instruct the 
volunteer so that consistency is maintained. The volunteer is not allowed to break into a 
run; if this happens, stop the test and begin again. If a chair is anticipated to be needed for 
rest stops, a second examiner can follow closely behind the timer with a wheelchair which 
can be positioned behind the volunteer as needed. If a volunteer can only ambulate by 
pushing themselves in a wheelchair, the test can be conducted in this way, but no assistance 
in moving the wheelchair from anyone else is allowed. 
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MUSCLE STRENGTH TESTING (ASSESSMENTS) 
Initial strength testing will be performed after the subject screening and before assignment 
to one of the two groups. Baseline, 6 and 12 month follow-up assessments will be 
conducted on the Keiser equipment in C-block. These assessments include both PRT and 
SHAM groups. The assessor is blind to the interim strength test results of the subject, as 
only the PRT group undergoes these tests during training. 
 
Equipment 
 Keiser pneumatic-resistance training equipment with K400 electronics (Keiser Sports 
Health Equipment, Inc., Fresno, CA) is used for muscle strength, power and endurance 
testing (in C-block).  
 The compressor should be turned on at both the power point and the distribution box 
2-3 hours prior to use. 
 For assessments, 1RM testing is carried out on the following equipment: 
o seated leg press 
o seated chest press 
o seated knee extension 
o seated row 
o seated knee flexion 
Instructions to Subjects for 1 RM testing 
 Before initiating EACH session, you should ask the subject if he/she needs to use the 
toilet. As strength testing may provoke incontinence, this is particularly important in 
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older women. 
 As applicable, distance vision corrective lenses and hearing aides must be in working 
order and in place. 
 Ensure that proper footwear, such as jogging shoes with non-slip soles, are worn by 
the subject, in addition to loose pants. It is helpful to be able to visualise the knee if 
capris or stretch pants are worn by women and sweat pants by men. 
 Prior to beginning the test, demonstrate to the subjects the correct technique for 
performing each of the exercises, which muscle group it isolates, and where this 
muscle group is located. 
 You should explain to the subject why emphasis is placed upon proper breathing 
technique and avoidance of the Valsalva manoeuvre. 
 Demonstrate proper breathing technique (i.e., breathe in before lifting/pushing the 
weight; breathe out during the “concentric” or lifting/pushing phase). 
 Reinforce correct form and breathing during the rest period between repetitions 
 Inform subjects that this is a test of maximum muscle strength. Explain that the 
objective of the exercise is to find the greatest amount of weight he/she can lift with 
good form for the whole range of motion one time only. Instruct the subject to 
push/pull against the footplate or arm of the machine until it is in the fully extended 
position, as you demonstrate the action. 
 Once the movement has been performed, the weight should be lowered carefully. 
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 Strong verbal encouragement should be given throughout the test. 
 Probe for any symptoms such as pain or other discomfort during the rest periods 
between attempts and document these in the source document. 
 
Procedure 
Muscle strength is defined as the maximal weight that can be lifted in good form, one time 
only, known as the one repetition maximum or 1RM. 
 The Keiser air compressor should be turned on at both the power point and the 
distribution box 2 hours prior to use.  
 Record the settings for each piece of equipment positioning on data sheet.  
 Allow subject to familiarise with the equipment with 2-3 unweighted repetitions.   
 
NOTE: for the leg press, add only the amount of resistance required to hold the footplates 
up against the weight of the legs, if necessary. For most subjects, the lowest available 
resistance holds the footplates up against the weight of the legs. Make sure the bar 
connecting the two footplates is engaged so that both footplates move as one. 
 
 Using the SETUP key from any mode will bring up the SETUP SCREEN. 
 Measure the unweighted range of motion twice by noting the arrow head position on 
the left side of the display panel. Ensure that good form is used during these repetitions, 
or the range will be too high and unreachable in good form once the load is increased. 
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 PRESS position mode and use the arrows to adjust the load. Add a small amount of 
weight and ask subject the level of difficulty (use Borg RPE Scale) 
 For each repetition, record the force in Newtons or Newton-metres from the BOTTOM 
of the display panel, the BORG rating and whether successful or not (i.e. the range of 
motion was full and good form was maintained). 
 Attempt to reach a BORG rating of 15 in 3-4 lifts, resting 20-30 seconds between each 
lift. 
 Ensure 1 minute rest between each repetition once the BORG rating is > 15. 
 Failure is defined as a lift short of the full range of motion (determined in the 
unweighted position) on at least 2 attempts at least 60 seconds apart. Therefore, if a 
repetition is failed, either repeat again or lower weight slightly and repeat, depending 
on the degree of failure. 
 On machines with 2 cylinders (i.e., leg press, chest press), note maximum weight for 
both limbs and write down both on the data sheet. 
 To minimise risk of injury, carefully position the subject on each piece of equipment, 
taking extra care with mounting and dismounting as well as correct exercise position. 
  
810 
 
Seated Leg Press (bilateral) 
Machine Setup 
 Assist the subject onto the machine by backing up towards the seat and sitting down 
first; then assist or observe as the legs are lifted up onto the footplates. 
 Move the seat to a position where the hips and knees are bent at approximately 90º. 
The seat may be moved while the subject is seated, as long as they are stabilised by 
you and warned that the seat is going to move slowly. 
 If subjects cannot flex hips to 90º due to hip pain or abdominal girth, move the seat 
back to a tolerable position. 
 Record the final seat position from the numbered plate in the source document. 
 
Movement Performance 
 Subjects’ feet should be placed at the bottom of each foot plate, with the heel resting 
on the rubber “lip” at the bottom of the foot plate; or if joint pain is encountered, a 
position allowing pain free movement. 
 Extra caution should be used for those subjects who have chronic lower back 
discomfort, ensuring that they are not twisting the spine and are keeping their back, 
neck, and head against the padded seat. 
 The subject may stabilise the upper body by using handgrips on each side of the seat, 
making sure that his/her thumb is not touching the force control knob accidentally. The 
subject’s shoulders and neck should be relaxed. 
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 The subject should then be instructed to push both legs forward simultaneously and to 
control the return of the weight back to a resting state. 
 It is important that you communicate to the subject that the knees travel in line with 
the toes, and that they do not drift medially (which is common in subjects with arthritis 
or weak ligaments around the knee). 
 The push should be generated through the whole foot, particularly the heel, not through 
the forefoot/toes, to ensure activation of the gluteus and hamstring muscles, not just 
the plantar flexors/quads. You may show the subject where the active muscle area. 
 The subject should push until the knees are just short of being “locked” in full 
extension; that is there should be a very slight bend at the knee. 
 Subjects who have osteoarthritis may have limited extension and may not achieve this 
full range of motion. A subject whose knees are correctly positioned (not locked) will 
have to use muscle force to keep the footplate out. When the knees are locked, no 
muscle force is being used, and the bones of the leg are keeping the footplate up. This 
should be explained and demonstrated explicitly so the subject knows what it feels like 
to perform the exercise correctly (versus incorrectly). 
 Excessive movement of the buttocks completely rising up off the seat is not considered 
good form but slight movements are tolerated. 
 
Chest Press 
Machine Setup  
  
812 
 
 Adjust the height of the seat such so the subject’s forearms run parallel with the floor.  
Record this setting in the source document.  
 Range of motion should be determined in the unweighted position. 
 Adjust arm levers to the comfort level of the subject and note position. This may 
depend on the joint limitations and ROM of the rotator cuff. The range limiter will be 
set at 3 for most subjects. 
 
Movement Performance 
 Subject should sit upright facing forward with the back pressed against the back pad.  
 The position while gripping the handles should avoid excessive extension of the wrist 
throughout the range. 
 Subject should push to full range without locking the elbows and then slowly allow 
the arms to control the return of the weight back to resting position.  
 The shoulders should not be elevated to compensate for the effort. 
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Knee Extension 
Machine Setup 
 Move backrest position so that back and upper legs of the subject are fully supported 
after the subject is assisted onto the machine. 
 The pad should rest just behind the subject’s knee in the popliteal fossa; the subject’s 
back should be securely supported by the backrest. 
 Record the final seat position number in the source document from the numbered plate 
or notches on the back rest. 
 With the subject well positioned in the seat, move the weighted bar position so that it 
sits just above the malleoli (ankle) level and the foot can still dorsiflex below the 
weighted bar. Record the position number of the bar in the source document. This may 
be recorded to the nearest 0.5 (e.g. 3.5) if it is between 2 engraved numbers on the 
machine. 
 Start position is always 90º of knee flexion, to avoid overstretching of the patellar 
tendon that may cause knee pain. Adjust by pulling out the knob on the range limiter 
until the correct number appears in the window. No limitation on extension range is 
imposed during strength testing or training however. Unscrew the range-limiting knob 
and leave it off the machine. Most subjects will have full extension short of this. 
Record the start and end positions of the range limiter in the source document. 
 
Movement Performance 
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 The subject’s hands should be resting lightly on the grips, making sure that his/her 
thumb is not touching the force control accidentally. 
 Similarly, the subject’s shoulders and neck should be as relaxed as possible. 
 The subject should then be instructed to straighten his/her legs without any ballistic 
movement as far as possible, keeping the ankle in neutral position (90º of flexion), and 
then control the return of the weight back to a resting state. 
 Failure is defined as not reaching full extension. 
 Do not allow subjects to arch their backs more than very minimally or lift their thigh 
off the seat to qualify as “good form”.
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Seated Row 
Machine Setup 
 Adjust the seat height so that xiphoid process is positioned in the middle of the chest 
pad then record this position. 
 Adjust the chest pad so that arms are comfortable at full extension and record this 
position.  
 Range of motion should be determined in the unweighted position and recorded. 
 Wide grip will be used for 1RM testing, although in training wide grip is used for the 
PRT group and narrow grip for the SHAM group. 
 
Movement Performance 
 The subject’s hands should be resting lightly on the grips, making sure that his/her 
thumbs are not touching the force control accidentally. 
 The chest should remain in contact with the pad, the back should remain straight and 
motionless and arching the back and neck should be avoided.  
 The handles should move to the level or if possible behind the chest pad while 
contracting the shoulder blades together and then slowly allow their arms to control 
the return of the weight back to resting position. 
 Failure is defined as not reaching within 50 of the recorded full extension (derived 
from the unweighted range).
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Knee Flexion 
Machine Setup 
 Move backrest position so that back and upper legs of the subject are fully supported 
after the subject is assisted onto the machine. 
 Note the lever position so that ankles just hang over the edge of the foot padding. 
 Record the position number of the bar in the source document. This may be recorded 
to the nearest 0.5 (e.g. 3.5) if it is between 2 engraved numbers on the machine. 
 Ensure that upper legs are held firmly in place by the padding and clicked into place. 
 Start position is maintained at -10º of knee flexion. Adjust by pulling out the knob on 
the range limiter until the correct number appears in the window.  
 Unscrew the range limiting knob and leave it off the machine. Record the start and end 
positions of the range limiter in the source document. 
 
Movement Performance 
 The subject’s hands should be resting lightly on the grips. 
 The subject’s shoulders and neck should be relaxed. 
 The subject should then be instructed to bend his/her legs without any ballistic 
movement as far as possible, keeping the ankle in neutral position, and then allow the 
legs to control the return of the weight back to an extended position. 
 Failure is defined as not reaching full flexion.  
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 Do not allow the subject to arch the back more than very minimally to qualify as “good 
form”. 
 The subject may need to be reminded to reposition on the seat to ensure the lower back 
is in contact with the back pad.
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ACTIGRAPH MONITORS 
Physical activity and sleep quality will be monitored using two Actigraph monitors worn 
over seven days at each timepoint (baseline, 6 and 12 months). The Actigraph used to 
measure physical activity data is worn around the waist. The Actigraph used to measure 
sleep quality is worn on the wrist. 
 
Software used to Initialize, Download and Analyse Data 
Two separate software programs are used to initialize (set the start times), download and 
analyse data from the Actigraphs, the ActiLifeGT1M (version 2.2.3) and the ActiWeb 
Client (version 4.2.2) programs. 
 
ActiLifeGT1M = This program will be used to initialize and download data from the “waist” 
Actigraph for analysis of physical activity. 
 
ActiWeb Client = This program will be used to initialize, download and upload data from 
the “wrist” Actigraph to the online ActiWeb Server for analysis of sleep quality. 
 
Actigraph Initialization (Set Up) Procedures 
Initialisation sets up the Actigraph for use and clears data from previous collection period. 
 
NOTE: Make sure that Actigraph data from the last collection period has been downloaded 
(and in the case of the “wrist” Actigraph, uploaded) prior to re-initialization. 
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“Waist” (Physical Activity) Actigraph 
 
1. Connect “Waist” Actigraph to USB on Computer 
2. Go to ‘programs’ and select ‘ActilifeGT1M.exe’ 
3. A caution window will appear, Click ‘OK’ 
4. The Main window will appear. You will see a ‘start’ and ‘download’. 
5. Click on ‘Start’ 
  
‘GT1M Driver Enumerated on COM6 (or similar) 
Click OK to continue. 
There is (1) device plugged into the System’ 
 
6. Click ‘OK’ 
7. The next screen that will appear is the ‘Initialize Data’ 
a. Enter Epoch period: 10 second (waist actigraph) 
b. Select both ‘Activity Mode’ and ‘Step Count Mode’ 
c. Enter the desired times and days to begin and end the data collection. For the 
GREAT2DO study Data is collected for 7 consecutive days. 
d. Enter Subject name, waist, timepoint in alphanumeric characters only (eg John 
Smith_waist_baseline). 
8. Once you have entered the appropriate information, click ‘OK’. 
9. A caution window saying: 
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’Sending Initialize Command and Data’  
 
will appear. This step may take a while to complete. 
 
10. A final window for the set-up phase will appear. It will say:  
 
‘Initialize: GT1M will begin taking data at (desired date and time).  
Please remove USB connector’ 
 
Remove the USB connector and click ‘OK’. The Actigraph is now ready to be worn and 
collect Data. 
 
“Wrist” (Sleep Quality) Actigraph 
 
1. Connect “Wrist” Actigraph to USB on Computer 
2. Go to ‘programs’, then ‘ActiGraph’, then select ‘ActiWeb’ 
3. The ‘ActiWeb Client’ window will appear. You will see a ‘start’ and ‘download’. 
4. Click on ‘Start’ 
 ‘GT1M Driver Enumerated on COM6 (or similar) 
Click OK to continue. 
There is (1) device plugged into the System’ 
5. Click ‘OK’ 
6. The next screen that will appear is the ‘Initialize Data’ 
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a. Enter the Start Time (from drop down menu) 
b. Enter the Start Date (from drop down menu) 
c. Enter Subject Name (eg. Surname_wrist_timepoint).  
For the GREAT2DO study Data is collected for 7 consecutive days. There is no option to 
select a Stop Time and Date. Default Epoch time is 60 sec and can not be modified. 
7. Once you have entered the appropriate information, click ‘OK’. 
8. A window saying: 
’Sending Initialize Command and Data’  
will appear. This step may take a while to complete. 
 
9. A final window for the set-up phase will appear. It will say:  
‘Initialize: GT1M will begin taking data at (desired date and time).  
Please remove USB connector’ 
Remove the USB connector and click ‘OK’. The Actigraph is now ready to be worn and 
collect Data. 
 
Placement of Actigraphs on Subject 
1. Actigraphs are normally placed on patient after Assessment A. 
2. Place the waist actigraph (activity) on the non dominant ASIS, and place the wrist 
actigraph (sleep) on the non-dominant wrist. 
 
Instructions to Subject 
1. Actigraphs are to be worn over 7 consecutive days (from Assessment A to Assessment 
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B).  
2. Both “wrist” and “waist” Actigraphs are NOT to be wet and MUST be removed during 
showering/bathing or swimming.   
3. “Waist” Actigraph is to be removed when getting into bed and put back on when 
getting out of bed. (MUST leave the “wrist” Actigraph ON while sleeping).  
4. Ensure the subject understands how to complete the ‘Actigraph Log’, recording exact 
“ON” and “OFF” times during the week.  
5. The subject should be asked to avoid sleeping with their monitored wrist across their 
chest or abdomen to minimise movement artefact due to the rise and fall of the 
chest/abdomen during breathing. (This instruction is on the log). 
6. The subject should be asked whether they sleep with an active/restless partner (“Does 
your partner toss and turn or get in and out of bed frequently during the night” - Circle 
“yes/no” on the Actigraph log). Reverberations from an active bed partner may 
overestimate the subject’s movement and number of awakenings. 
7. The subject should be asked if they sleep in a water, rocking or vibrating bed (for the 
reason stated above). Circle “yes/no” on the Actigraph log) 
8. The subject should be asked if they have a movement disorder which causes them to 
move without waking, for example restless leg syndrome, periodic limb movement 
disorder or sleep walking. Circle “yes/no” on the Actigraph log. 
9. The subject should be asked if they take any medications which disturb their sleep – 
The research assistant will have a list of relevant medications. If any of the listed 
medications are used, the subject should circle “yes/no” for use on each day monitored on 
the Actigraph log. 
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10. The subject should also be asked to circle “yes/no” for each day on the Actigraph log 
if they ingest caffeine, alcohol or nicotine within 2 hours of bed time. 
11. For participants at 6 and 12 month time points, the “Waist” Actigraph is to be removed 
(by research assistant) and placed on a table during study exercise sessions (Wed, Fri, and 
Mon) and put back on at the end of each session.  
For additional information on standards of practice and other issues on the role of 
Actigraphy for sleep study, refer to: 
 
Littner, M. et al., (2003) Practice Parameters of the Role of Actigraphy in the Study of 
Sleep and Circadian Rhythms: An Update for 2002. An American Academy of Sleep 
Medicine Report. SLEEP, 26(3); 337-341 
 
Tryon, W. (2002) 
 
Actigraph Download Procedures 
 
“Waist” (Physical Activity) Actigraph 
 
1. Connect Actigraph to USB on Computer 
2. Go to ‘programs’ and select ‘ActilifeGT1M.exe’ 
3. A caution window will appear, Click ‘OK’ 
4. The Main window will appear. You will see a ‘start’ and ‘download’. 
5. Click on ‘Download’ 
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‘GT1M Driver Enumerated on COM6 (or similar) 
Click OK to continue. 
There is (1) device plugged into the System’ 
 
6. Click ‘OK’. A ‘Downloading Data’ screen will appear for a couple of seconds.  
 
‘The ActiLife Software is initiating the downloading 
phase of the data from the Actigraph’ 
 
7. Click ‘Yes’ for the option ‘Would you like to save data to file?’. The Downloaded data 
needs to be saved on the computer for analysis. The initial file name that you used in the 
initializing/saving process will appear.  This step completes the downloading phase of this 
assessment. 
 
“Wrist” (Sleep Quality) Actigraph   
 
1. Connect “Wrist” Actigraph to USB on Computer 
2. Go to ‘programs’, then ‘ActiGraph’, then select ‘ActiWeb’ 
3. The ‘ActiWeb Client’ window will appear. You will see a ‘start’ and ‘download’. 
4. Click on ‘Download’ 
 
‘GT1M Driver Enumerated on COM6 (or similar) 
Click OK to continue. 
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There is (1) device plugged into the System’ 
5. Click ‘OK’.  
6. Next Screen will read: ‘Information required for Actigraph download process’. The 
‘Faculty and Physician Info’ should be present. 
7. Enter ‘User Data’ (i.e. Patient details) including name, age, sex, height, weight, race, 
sleep analysis. 
8. Click the position the Actigraph was worn on the diagram (i.e. left or right wrist). The 
wrist the Acitigraph was worn should have been recorded on the participants Actigraph 
diary. 
9. Click on ‘Continue’ 
10. Next Screen will read: ‘Please Enter your ActiWeb Login Info’ 
11. Type in the following: 343NAT (username); 343DEV (password) 
12. Click on ‘Login’ 
13. Messages will pop-up reading “Downloading Data”, then “Processing” 
14. Next Screen will be a web page reading “Actiweb Data Analysis File Upload”  
a. Enter Username and Password (as above) 
b. Copy and paste the text in the ‘Confirm file upload’ box into the blank text box below 
(This is the excel [.csv] file containing sleep data. It is saved by default to C:¥Program 
Files¥Actigraph¥ActiWeb¥files¥...csv) 
c. Click on ‘Login and Process’ 
15. Next Screen will read ‘File Upload’; ‘Please Wait’ 
16. Next Screen will be a web page (http://actiwebpro.com/uploadProcessDEBUG... ) You 
should see a long list of data with the following message superimposed: “Data upload 
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complete…Processing data for analysis. Based on number of days, this may take a 
moment…” This can take up to 30 mins. 
 
*** IMPORTANT *** 
Files can not be uploaded from the computer to the ActiWeb Server. Failure to complete 
the upload process at the time data is downloaded will prevent analysis of sleep data using 
the online program.  
 
Procedure for Viewing Uploaded Sleep Data 
 
Once data is uploaded to the server, ActiWeb will automatically calculate sleep quality 
variables including: 
• Sleep Efficiency 
• Sleep Latency (and time of sleep onset) 
• Minutes Asleep 
• Minutes Awake 
• Number of Awakenings 
• Average time (duration) of awakenings 
 
To view sleep variables: 
 
a.    Open the ‘ActiWeb Client” progam  
b. At the top of screen, click “Patient Management”, then “View Downloaded Patient 
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Data” 
c. In the “Patient Management” screen you should see the file you have just uploaded. 
Tick the “select” box for that file, then click the “Load Selected File(s)” button at the top 
of the window. (NOTE: You can also email patient files to others to view remotely) 
d. You may be prompted to Login to ActiWeb (use previous username and password – 
click ok).  
e. You will now be on the “ActiWeb Server” and should see the name of the file under 
“patients”. Clicking the file link will graphically display the complete 7 days data using 
ActiWeb’s online Sleep Analysis program. 
f. Click the date on the calendar for the recorded data you want to view 
g. Enter the “Time in Bed” (bed time) and “Time out of Bed” (wake up time) from the 
subject’s Actigraph Log for that particular day. Click the “Store times and refresh” button 
h. You will now see the above variables calculated for the period spent in bed. 
 
Special Section 
 
For data that were not uploaded to the ActiWeb server prior to deletion from the actigraph 
 
For data that does not display/analyse properly on the ActiWeb server (incorrect date 
convention, i.e. mm/dd/yyyy) 
 
These data need to be analysed using specially created Excel Macros 
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Sadeh Macro – for data captured with the Actigraph “Step Counter” function turned ON 
 
Zhao 1 minute Macro – for data captured with the Actigraph “Step Counter” function 
turned “OFF” 
 
Zhao 3 minute Macro – for data captured with the Actigraph “Step Counter” function 
turned “OFF” 
 
Follow the following steps: 
 
Reintegrate the .dat file: Sleep data is captured in 30 second epochs but needs to be changed 
to 60 second epochs to be ran through the macros. 
 Open ActiLife program 
 Go to “Analyze Data” => “.dat file Re-Integrator” 
 Go to “File” => “Re-integrate .dat file” 
 Find the .dat (wrist) file you need to reintegrate 
Save output file as the same name as the original file with “_reintegrated” added to the end 
of the file name. 
 
Create an excel .csv file from the reintegrated .dat file 
 Go to “Analyze Data” => “Show Data Table” 
Open the reintegrated .dat file and save the .csv file using the following naming convention: 
“Surname, first initial_wrist_Xmths” 
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Change the “Mode” in the excel csv file from 3 to 1 
Go to row 9 of the .csv file and change Mode 3 to Mode 1 (just delete “3” and type “1”) 
 
Check to see if the Step Counter function is ON or OFF 
 Step Counter is OFF if: 
  Any step count is >200 or 
  Step counts are higher than activity counts 
 
If the step count is deemed to be ON, run the .csv file using the Sadeh Macro 
 
If the step count is deemed to be OFF, run the .csv file using the Zhao 1 and 3 Macros 
 
Note: The same method of sleep analysis must be used at each time-point for an individual. 
 
Physical and Sedentary Activity Data  
 
Physical and sedentary activity during waking hours will be estimated using the Actigraph 
accelerometer and intialised using the ActiLifeGT1M (version 2.2.3) as described above. 
 
Physical and sedentary activity will be analysed using the Crouter 2 regression (C2R) 
macro in Microsoft Excel. The data analysis options from the ActiLifeGT1M software will 
NOT be used. 
The C2R macro was developed by Dr Scott Crouter and enables estimation of time spent 
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in sedentary activity and categories of light, moderate, and vigorous physical activity over 
5 days. 
 
For equation methodology and validation data refer to: 
Crouter S.E., Clowers K.C., and Bassett D.R Jr. (2006)  A Novel Method for Using 
Accelerometer Data to Predict Energy Expenditure. J Appl Physiol 100: 1324-1331 
 
For data preparation/processing refer to: 
Masse L.C., et al. (2005) Accelerometer Data Reduction: A Comparison of Four Reduction 
Algorithms on Select Outcome Variables. Med Sci Sports Exerc 37 (11): S544-S554 
 
Contact Details for Dr Scott Crouter: 
 
Scott Crouter, Ph.D 
Assistant Professor 
University of Massachusetts Boston 
Dept. of Exercise and Health Sciences 
100 Morrissey Blvd. 
Boston, MA 02125 
(w) 617-287-7509 
(fax) 617-287-7527 
Email: Scott.Crouter@umb.edu 
** All manuscripts will acknowledge Dr Crouter’s generous contribution in sharing these 
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analytic procedures with us.** 
 
Procedure for Viewing and Cleaning Physical and Sedentary Activity Data 
 
*** May need to change Mircosoft Excel security setting to “enable macros” *** 
1. Open Excel 
2. Click “Tools” from top taskbar 
3. Click “Options” from menu 
4. Click “Security” tab from options dialog box 
5. Click “Macro Security” button 
6. Click “Medium – choose whether to run potentially unsafe macros” setting 
Overview: 
 Waist” Actigraph data is downloaded as a .dat file. This .dat file must be saved as an 
excel.csv file using the ActiLifeGT1M software.  
 The excel.csv file is then cleared of erroneous data and data captured during times 
when the Actigraph was removed (i.e., during bathing/swimming, study exercise 
training sessions, and time in bed at night). Refer to the participant’s Actigraph log and 
training diary for “ON/OFF” times. The “wearing time” and “number of wearing 
interruptions” must be calculated, as well as determining whether the day was a “valid” 
day, the “number of valid days” and the “number of weekdays” 
 The “cleaned” excel.csv file is then imported to the Excel spreadsheet running the C2R 
macro for analysis of the first 5 days of data. 
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 The C2R macro must be run a second time, importing the data from the “cleaned” 
excel.csv file captured beyond day 5. 
 
Saving .dat file as an excel.csv file 
Procedure: 
 
1. Go to ‘programs’ and select ‘ActilifeGT1M.exe’ 
2. Click “Analyse Data”, then “Show Activity Table” (click “OK” when prompted to 
create an activity file) 
3. Select the Actigraph .dat file (Path: My Documents => GREAT2DO Study => 
Actigraph => Actigraph files.) you want to analyse. Files will be named by “Subject 
Name_waist_timepoint”. Click “Open”. 
4. Next you will be prompted to “Save Actigraph Activity File”. This will save the .dat 
file as an excel .csv file. Type in a file name using the same naming convention above. Eg. 
“Toovey,B_waist_6mths”. Click “Save” 
5. Click “Yes” to view file in Excel when prompted. 
 
Cleaning the excel.csv file (identifying erroneous data, removal intervals, calculation of 
wearing time, and determination of valid days) 
 
1. The Excel.csv file will show 3 columns of data: Date; Time: and Activity Count (note: 
may not be titled as such) 
2. Visually screen the Activity Count column for erroneous data. Erroneous data will be 
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identified by an activity count >/= 1600 or if the activity count is held at the same number 
(>0) for 10 minutes (ref. Masse et al, 2005). This data will be deleted and treated as missing 
data.  
3. Activity Count data will be deleted for periods when the “waist” Actigraph was 
removed (i.e. bathing/showering/swimming, study exercise training sessions, and night 
sleeping times).  
4. Use the participants ‘Actigraph Log’ (data sheet) as a guide to the approximate “waist” 
actigraph removal intervals The actual removal intervals will be denoted by a long 
succession of “0” activity counts within the .csv file beginning around the “OFF” time, and 
ending around the “ON” time, indicated on the participant’s Actigraph Log.  
5. Write these times (first and last “0” of actual removal interval) on the participant’s 
Actigraph Log beside the approximate “OFF/ON” times.  
6. Highlight and delete all “0” activity count cells within actual removal intervals. DO 
NOT DELETE THE “DATE” AND “TIME” DATA.  
7. NOTE: ‘Actigraph Log’ indicates removal intervals during bathing / showering / 
swimming and sleeping only. During follow-up testing periods (6 & 12mths), participants 
also remove the ‘waist’ actigraph during scheduled study exercise training sessions 
(Wed/Fri/Mon). To identify removal intervals during these periods, the participants 
training time and attendance must be confirmed via review of the training diary and 
communication with the RA supervising training. Write training attendance (yes/no) and 
training time for each scheduled session on the participants Actigraph Log. 
8. Calculate “Wearing Time” for each day. The Actigraphs are initialised to start at 6pm 
on the day of Assessment A.  Day 1 of activity analysis will begin the following day. 
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Determine the number of waking hours between the time the actigraph was put “ON” 
(disruption of continuous “0”’s) upon getting up in the morning and the time the actigraph 
was taken “OFF” (beginning of continuous “0”’s) around the indicated bed time. Calculate 
the summed time of all removal intervals. Wearing time (hrs) = waking hours (hrs) – total 
removal interval time (hrs). Record this time on the data sheet, as well as indicating the 
number of removal intervals. 
9. Determine if the day was a “Valid Day”: a day is considered valid if the ‘wearing time’ 
is at least 60% of ‘waking hours’(ref. Masse et al, 2005) Calculate this for each day and 
record ‘yes/no’ on the data sheet as well as the number of valid days during the week. 
10. Complete this “cleaning” procedure for all days of the week. 
11. Click “Save” 
 
 Importing “cleaned” data from .csv file into C2R Marco 
 
1. Click on column “C” (activity count data), highlighting the entire column.  
2. Click “Edit” (top task bar), then “copy” (from drop down menu) 
3. Open the “2Regression Macro-5day-3-9-07” excel file (Path: My Documents => 
GREAT2DO Study => Actigraph => Actigraph C2R Macro files) 
4. Be sure to click “enable macros” when prompted. 
5. Click on column “C”, highlighting the entire column 
6. Click “Edit” (top task bar), then “paste” (from drop down menu). This will paste the 
‘activity count’ data of the subject into the C2R macro which will calculate all the variables 
to be analysed. 
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7. Columns A (date) and B (time) from the subjects .csv file should also be copied and 
pasted into the respective columns of the C2R macro in the same way so data can be 
referenced against the participant’s “Actigraph Log” (However, dates and times do not 
effect the how data is calculated). 
8. This Macro file now needs to be saved for this participant. Click “File” (top task bar), 
then “Save As” (from drop down menu). 
9. Name the file using the same naming convention as above in addition to adding “macro” 
to denote it as such. Eg. “Toovey,B_waist_6mths_macro”. 
10. Save the file in the “Actigraph C2R Macro files” folder (Path: My Documents => 
GREAT2DO Study => Actigraph => Actigraph C2R Macro files) 
 
Variables Created By the C2R Macro 
 
The C2R Marco will automatically calculate physical activity variables including
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APPENDIX B. ASSESSMENT PROTOCOLS (CT SCAN) 
CT SCAN PROTOCOLS 
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CT Scans of Thigh and Abdomen for Soft Tissue Measurements by Digital Analysis 
EQUIPMENT: GE HIGH SPEED CTI SCANNER 
LOCATION: ROYAL PRINCE ALFRED HOSPITAL RADIOLOGY DEPARTMENT 
CONTACT PERSON FOR ADMINISTRATIVE ISSUES: CHARBEL SAADE, CT SECTION 
CHIEF, 9515-7444  
Contact Person for Appointment Scheduling: Leila, Radiology, 9515-8947 
Note: Procedures in Bold are done by CT technicians, the rest is done by the research 
assistant. 
Initial Scanning Protocol: 
1. Subject is changed into hospital gown, removing all constricting underwear, stockings, 
belts, etc and actigraphs (record time off and on). 
2. Subject lies on scanner bed with non-dominant leg flexed at the hip and flexed 90o at 
the knee. Dominant leg is used if there is a metal prosthesis in the non-dominant leg. 
NOTE the time “first supine” on the data sheet. 
3. Measure the thigh length with an anthropometric tape from the inguinal crease to the 
proximal pole of the patella.  Mark the mid-point of this distance with a black marker 
and then tape a metal ball bearing over the black mark. 
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4. Return the leg to resting position and separate the legs so that the skin is not touching 
between the thighs by abducting the leg that is not to be scanned. This may require a 
foam pad to be placed between the knees in some subjects. Keep the scanned leg 
straight (parallel to the scanner bed). 
 
5. Measure the distance between the iliac crest and the lower costal margin on the left side 
and mark the mid-point with a marker and then tape a metal ball bearing over the spot.  
 840 
 
Note that the mid-point between the hip and rib located when the patient is supine is not 
the same as the mid-point between the hip and rib located when the patient is standing. The 
“laser mark” is not representative of the IDF waist  
circumference. The addition is useful for comparing WC to other diabetes data. 
 
6. A long scout film is taken of the trunk region down to the tibia with the ball 
bearings visualised.   
 
7. The abdominal cross-sectional slice is marked with a horizontal line on the scanner. 
After the scout is checked, the ball bearing is removed from the abdomen.  
 
8. A vertical line is drawn from the femoral notch to this horizontal line
Standing 
IDF  Supine IDF  
(laser mark)  
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9. This distance at a 0 degree vector is noted on data sheet 
 
10.  A horizontal line is drawn at thigh midpoint (in line with ball bearing) 
 
11.  A vertical line is drawn from the femoral notch to this horizontal line 
 
12.  This distance at a 0 degree vector is noted on data sheet 
Scan Scout 
 
 
 
 
 
 
 
13. The CT scanner measures the distance from the notch between the femoral 
condyle and the lines indicating the position of the abdominal slice and the position 
of the thigh slice. These numbers are recorded on the header of the electronic files 
and also by the researcher or research assistant (RA) on the data sheet. IT IS 
IMPORTANT THAT THESE DETAILS ARE RECORDED FOR FOLLOW-UP 
SCANS.
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14. The scanner is set to take a 1mm thick slice at the abdominal marker. The DFOV 
should be 45 – 48 (up to 50 on the new scanner). The patient is instructed to hold 
his or her breath while the scan is being taken. Ensure that the entire abdomen is 
visible, including all skin. Note the time the CT was taken on the data sheet in the space 
provided. 
 
15. The scanner will now take a 1mm cross sectional slice of the thigh at the measured 
midpoint of the thigh. Ensure the entire cross section of the thigh is visible, including 
all the skin. Note the time the CT was taken on the data sheet in the space provided. 
DFOV will usually be 25 – 30. 
 
16. The DFOV may be different for every patient depending on his or her size. The larger 
the patient, the larger the DFOV. The DFOV does not have to be the same at all 
timepoints, although it usually is, as the subject size has not changed markedly. It must 
be correctly recorded for analysis of each scan. 
 
17. KEEP THE CENTERING LASER LIGHTS ON. The scanner bed is moved out of the 
scanner with the subject still lying in the same position as when they were scanned. 
The circumference of the thigh and abdomen at the black marks is measured in triplicate 
by the research assistant after the scans have been taken, while the subject is still lying 
supine on the scanner bed. The abdominal circumference should be taken while the 
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subject is holding his/her breath just as during the scan. Note the time girth 
measurements were taken on the data sheet in the space provided.  
 
18. Assist subject off scanner bed with consideration for back and shoulder discomfort a 
well as orthostatic hypotensive symptoms. 
 
19.  Remind the CT technician to save data on a CD. This CD will be sent to the front 
desk but may not be ready immediately. CDs can be stored for pick up at subsequent 
appointment. 
 
20. RA checks the CD’s to see that all the correct images have been transferred. If anything 
is missing, it must be retrieved from RPA CT scanner as soon as possible, or it will be 
deleted from the archived files. 
21. At the end of each scan, the radiographer must SELECT REMOTE HOST from the 
network express 100X and send to PACS as normal to RPAHANWG1. 
Instructions for repeat scans in a previously scanned subject: 
 
1. Bring the original data sheet and use the stored scout film taken at baseline to compare 
measurement lines and reproduce the position precisely.  
 
2. There is no need to measure the anthropometric sites or tape on a ball bearing. 
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3. Position the patient as in the initial scan. Use the details from the first CT scan data 
(distance from femoral notch) to find the same points where the CT was originally 
taken. Compare body position (femur) with the original and adjust if needed and 
take another scout. 
 
4. Technician will draw lines on the scout which are the exact distance as at baseline, 
and take 2 cross-sectional slices at the 2 locations; record the time each CT slice was 
taken.  RA will ensure that the lines start from the same spot on the distal femur and 
that the subject positioning is as close to the baseline scout as possible. The RA and 
technician should check where the abdominal line intersects the vertebral body or space 
to make sure the scan location is the same as the previous scan/s. 
 
5. Turn on laser light and mark spots on the skin where two cross-sections were taken. 
Then move the scanner bed out of the scanner, without changing the position of the 
subject. 
 
6. Take anthropometric measurements at both points and record time measurements are 
taken. 
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7. Remind the CT technician to save data on a CD. The CD will be sent to the front 
desk, but if it is not ready immediately, it may be stored for collection at the 
subsequent appointment. 
 
8. RA checks the CD’s to see that all the correct images have been transferred. If anything 
is missing, it must be retrieved from RPA CT scanner as soon as possible, or it will be 
deleted from the archived files.  
 
9. At the end of each scan, the radiographer must send SELECT REMOTE HOST from 
the network express 100X and send to PAX as normal to RPAHANWG1
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CT ANALYSIS PROTOCOL 
Step 1. Copying Scans onto the Computer 
Open the program named ‘Osirix’ (by double-clicking on the HD icon, opening 
‘Applications’, and then double-clicking the ‘Osirix’ icon OR by clicking on the icon in 
the “dock”). Osirix is a program that allows you to view CT films in their raw format. 
 
Scans are on a CD that must be copied onto the hard drive of a computer or a zip disc, so 
that the files on them can be renamed and analysed. (Files burned onto a CD cannot be 
renamed until they are copied onto another drive or disk).   
 
First you will need to create a main folder where all of the scans for the particular study 
will be kept. To create this folder on the desktop, click on an ‘empty space’ on the desktop 
and then go to File – New Folder. Name this folder:  
 
GREAT2DOSCANS 
If OSIRIX is open when the CD is loaded onto the computer, the file will usually show in 
the OSIRIX window. If it doesn’t appear, drag the folder from the CD to the hard drive. If 
it still does not appear in OSIRIX, click “IMPORT” from the OSIRIX file heading and 
choose the folder with 4 digits. (You may have to wait a few seconds while the program 
imports all the files). Once the participant’s files are imported, make sure you highlight that 
participant’s name (in case you have more than 1 participant’s data open). You will now be 
able to view all the participant’s images. The different thumbnails to the right of the main 
image allow you to view different ‘series’ of images of the participant (including 
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topograms).  
 
Select the thigh CT scan, and check that the details on the scan are correct (e.g. patient 
name, day, right or left leg). The time the scan was taken is also reported on the scan, 
however the research assistant should record the “real” time, at the time of the scan to avoid 
errors from hospital clocks or CT scanning equipment. Repeat for the abdominal scan.
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Step 2. Finding the Scan(s) to Analyse 
You next need to determine the filename of the thigh and abdomen scan. The easiest way 
to do this is to first export all the images for the participant into Dicom format. To do this, 
go to the pull-down menu ‘File’ and select ‘Export’ and ‘Export to Dicom’.  
Select the (GREAT2DO folder on the desktop and choose the appropriate destination: 
“baseline”, “6 month” or “12 month” folders as the location you want to export the files to, 
and click ‘Choose’. Make sure that if you have more than 1 participant’s images open that 
the correct participant’s name is highlighted in the top window before you click Export 
(otherwise you will export the wrong person’s scans). All the images that you have open 
for the participant will then be copied into a folder labelled with the participant’s name. 
The CT scans should be in a sub-folder (and all have filenames ending in the extension 
‘.dcm’). The 2 CT scans of interest (thigh and abdomen) should be in a folder named 
“GREAT2DO in the folder ‘CT abdomen, CT thigh ”.  
 
To check which file(s) correspond to the scan(s) to analyse, complete the following steps: 
 Go to the pull-down tab ‘File’ and select ‘Delete selected exam’ (make sure the correct 
participant’s name is highlighted in the top window before you do this). You will be asked 
‘Are you sure you want to delete the selected exams?’ Confirm this by clicking OK. Then 
click ‘Remove the links’ (do not ‘delete the files’). This will remove all the participant’s 
images from the OSIRIX display. Next, open the individual file to be analysed (that is, one 
of the 2 files in the scan folder). Make sure you add the filename. This scan will now be 
the only image open for the participant. Check that it is either a thigh or abdomen CT scan.
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Step 3. Renaming the CT Scan(s) 
 
To rename the thigh and abdomen scans so that they can be easily identified and then de-
identified, open the study folder on the desktop. Then work your way through the directory 
to find the particular scans that you now know are the abdomen and thigh scans. Click on 
the name of this file twice (slowly) – you will now be able to rename it. Rename the file: 
 
Participant ID_timepoint _thigh _DFOV(e.g. G2Do001(b)thigh(DFOV25).dcm) 
OR  
Participant ID_timepoint_abdo_DFOV (e.g. G2Do001(b)abdo(DFOV48).dcm) 
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Step 4. Converting the File from ‘.dcm’ to ‘.dcmx’ 
 
Before you can analyse a CT scan, it (i.e. the file) needs to be in a format which the analysis 
program (DICOM NIH Image) can understand. The analysis program will convert the 
file(s) for you. To open DICOM NIH Image, double-click on the icon labelled ‘DICOM 
NIH ImageNEW’ on the desktop, and then double-click on the file named ‘NIH Image 1.63’ 
(note: do not open the older version named ‘NIH Image 1.62’). Ensure one of the DICOM 
windows are highlighted (to do this just click on any one of the program’s windows). Next, 
go to the pull-down menu ‘Special’ and then click on ‘Load Macros’. The macros file 
(‘image macros.txt’) is located under Desktop/DICOM NIH Image NEW/NIH Image 1.63 
f/. Loading the macros is necessary for the program to recognise specific commands which 
have been set up for use with CT scans.  
 
To convert the file, press F1 on the keyboard (if using a laptop you will have to hold down 
the function ‘fn’ key as you do this; if using a G5 Macintosh running OSX, you will have to 
hold down the control or option key while pressing F1).  A directory tree of the computer 
will be displayed.  Select the options ‘Custom’ and ’16 bit unsigned’. Then ensure the 
top window (current directory) reads desktop. Using the cursor on the right hand of the 
directory tree, scroll down until you find the location of the study folder (i.e. GREAT2DO 
Scans) and double-click on this. Then work your way through the directory tree to double 
click on the particular CT scan you wish to convert (the file that you just renamed). You 
will see the CT scan ‘flash’ open and then close again. This means you have successfully 
converted the file, and a new file has been added to the participant’s folder with the same 
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filename, except the extension now reads ‘.dcmx’, and not ‘.dcm’. If you get an error 
message e.g. ‘argument out of range…’ then try repeating the process but with other options 
selected e.g. ‘16 bit signed’ or ‘8 bit’. If the scans still do not open and show an error 
message, ask RPA PACS manager to redo the scan files in compatible format. 
  
If you need to convert more than 1 file, hit F1 again (remember to hold ‘fn’ if using a laptop 
or the control or option key on a G5 computer) to take you back to the directory tree. And 
repeat as above.  You are now ready to analyse the scan(s). 
 
De-identified Scans 
As analysis is blinded, all scans are copied to the appointed research staff member to assign 
de-identified numbers to the original files from a computer generated random numbers list. 
The time-point is excluded in this title but the DFOV must be included. 
 
All files are then copied from USB to the person who is responsible for this task. 
 
A list of original file IDs and corresponding de-identified IDs should be secured. 
Each individual file is then relabelled with de-identified ID number, thigh or abdo and 
appropriate DFOV, e.g. G2Do300_Thigh_DFOV25.dcmx. When this is completed, the 
abdominal and thigh folders are returned to the person analysing the scans via USB.  
 
When analysis is completed for a specific block of scans, the data sheets are returned to 
the research assistant to be “re-identified” with original subject ID and time-point. For 
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thigh scans, the filemaker pro.dbf spreadsheet is also re-identified. 
 
All re-identified files and data analysis sheets are delivered to the appointed research 
assistant for data entry into the master data sheet. 
 
In summary, there are 3 people involved in this process: the person analysing the scans, the 
person performing the de-identification and re-identification of subject numbers and the 
person entering data into the master spreadsheet. 
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ANALYSING THIGH SCANS  
 
Read all the analysis instructions before you start analysing your first scan. 
 
1. Open DICOM NIH Image 1.63. Click on any one of the program’s windows. 
Ensure the macros are loaded by going to the pull-down menu ‘Special’ and then 
click on ‘Load Macros’. The macros file (‘image macros.txt’) is located under 
Desktop/DICOM NIH Image NEW/NIH Image 1.63 f/. Loading the macros is 
necessary for the program to recognise specific commands which have been set up 
for use with CT scans. Open a scan by holding down the space bar and pushing the 
letter O (or go to File – Open).  This will display the file directory tree on the 
screen. 
2. Select the file you wish to analyse by navigating through the directory tree of the 
hard drive. 
3. Open this file by double clicking on its name or clicking on OPEN. (File should be 
named study.de-identified number.body part.DFOV).  
4. Select the correct DFOV as indicated on folder. A cross section of the thigh will 
appear on the screen.  In order to accurately analyse the scan, ‘imperfections’ to 
the image must be corrected.  Some scans will require no correction, but most will.  
5. If the scan has the ipsilateral leg or part of the scanner bed touching the cross section 
of interest (see scan below), then this area must be edited.  For accurate editing, 
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first magnify the image using the magnifying tool located in the top left hand side 
of the tool section. (Continued on next page) 
 
 
 
6. Once the image is magnified to a suitable level (the actual amount is subjective: 
magnify until you can clearly see the pixels that need to be removed – 4x is 
generally enough). Click on the eraser tool (fourth from the top on the left hand 
side) and whilst holding the mouse button down, move the mouse over the 
‘offending’ pixels and erase them.   
a. Note:  This process can be unreliable if not done carefully.  Investigator 
has to “guess” which pixels to erase as best as possible – there is no better 
way to complete this process.  In order to increase the reliability of this 
Using the eraser tool, remove the 
scanner bed pixels that are attached to 
the thigh cross section (remember to 
magnify first!). 
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b. procedure, try to match the border around the entire thigh perimeter (e.g. 
the same no. of lighter coloured pixels).  
c. To save time note that you don’t have to erase all the pixels outside the cross 
section. As long as there is at least a 1-pixel gap between the peripheral 
thigh perimeter pixels and the pixels outside the perimeter (i.e. they are not 
touching one another), the pixels outside the perimeter will not be included 
in the cross section analysis.  
d. Note on the data sheet whether editing of the scan bed or other leg was 
required (Circle ‘Yes’ or ‘No’). If editing was required, circle one of the 
numbers to indicate the combined amount/difficulty of the editing (3 = the 
most difficult/amount of editing, whereas 1 = the least difficult/amount of 
editing). Obviously this rating is quite subjective but at least it will give you 
some indication of the amount/difficulty of editing performed at this step, 
which may be useful when analysing the data.  
 
You can restore the image at any time to its original size by double clicking on the 
magnifier tool.  
 
7. Remove the ball bearing and associated artefact if ball bearing is inadvertently left 
on during the cross-sectional scan.  (Typically, scans do not require this step as 
the protocol is to remove the barium/ball-bearing marker prior to the scan): 
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i.e. If the scan exhibits a bright white circular image (barium or ball-bearing marker) 
on the ‘top’ (periphery) of the cross section this will also have to be edited (e.g. see 
scan below). Note that this will only be present in baseline scans). 
 
 
Remove the ball bearing and associated 
artefact if the ball bearing is 
inadvertently left on during the cross-
sectional scan.   
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a. First you will need to re-create the thigh border (perimeter) by: 
 
i. Removing the pixels that are outside what you think is the ‘true’ 
thigh border. 
ii. Changing the colour (density) of the pixels that you think were 
affected by the barium/ball-bearing marker to a similar density as 
the rest of the ‘unaffected’ thigh border. 
iii. Add any pixels that you think are missing due to this artefact. (Try 
to pick roughly the same colour/density as the rest of the ‘unaffected’ 
thigh border). 
 
b. If the barium/ball bearing marker is localised to the thigh border and does 
not protrude into subcutaneous (SC) fat or muscle then this is all the editing 
that will be required in this step. However, if artefact from the barium/ball-
bearing marker does protrude (like ‘rays’) into either SC fat or both SC fat 
and muscle then further editing is required. i.e. You will need to edit the 
‘rays’ from the ball-bearing/barium marker so that: 
i. The densities of pixels in SC fat have density values that fall outside 
the range for muscle (i.e. outside the range 10-113). Any pixels that 
fall outside this range will be included as SC fat. Note: Take care 
when editing SC fat close to muscle. You do not want to change ‘real’ 
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muscle to SC fat (otherwise this will decrease the calculated muscle 
area and increase the calculated SC fat area). 
ii. The densities of pixels which are muscle have density values that 
fall within the range of muscle (10-113). Note: This step involves a 
lot of ‘guesswork’, but needs to be done (otherwise values for 
‘muscle with holes’ and ‘muscle without holes’ will be 
underestimated, and, muscle density, SC fat, and IM fat values may 
also be affected). To aid reliability try to ‘copy’ a section of the 
muscle that has not been affected by artefact (use the pencil tool). 
You will need to use a couple of different colours (density values) 
such that once you have finished editing, the ‘rays’ will hardly be 
noticeable.  
The edited thigh border.  
 
(Note that the black area just 
deep to the editing in the 
subcutaneous fat does not 
have to be edited to match 
the colour of subcutaneous 
fat. As long as the density of 
the pixels in this area are 
outside the density of muscle 
(10-113), the area will be 
included as fat). 
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8. Save the edited version of the scan (G2Do.de-identifiedID.EDIT1).  
DO NOT save over the original copy of the scan.   
 
9. Now press 1.  Most of the scan will turn red (see image below).  
  
 
10. Magnify around the femur and look at the internal (around bone marrow) and 
external femur perimeter to see if there are any red pixels that appear to be ‘missing’ 
and which you think will affect the ‘true’ perimeter values. Select the pencil tool 
and add red pixels to ‘smooth out’ either or both of these perimeters. Note: These 
perimeters are not meant to be perfect circles. Very few scans will need any editing 
at this stage (i.e. only about 1 in 10) and where editing is required only 1 or 2 red 
pixels will need to be added (In the example above no editing of these perimeters 
was required). 
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11. The next step is to calculate the area and perimeter of the total thigh and of the 
internal and external femur. Do this by selecting the ‘wand tool’ (second from the 
bottom left), and on the image, click on the bone marrow (the red section in the 
centre of the limb (1*)), then the bone (the white section surrounding the bone 
marrow (2*)), and then the muscle/fat area (the large red section surrounding the 
bone (3*)). The values will appear in the results window. Note: Make sure that 
when the thigh perimeter is selected that no pixels outside the thigh perimeter 
are included (e.g. this may have occurred if you did not leave at least a 1-pixel 
space between scanner bed pixels and thigh perimeter pixels). 
 
12. Once the whole thigh is selected, the average density (or attenuation) of the muscle 
can be calculated. 
a. Go to analyse then to show histogram 
b. Go to edit then to copy histogram (you will be copying 256 rows of data 
that contain the count for each density) 
c. Open Excel (average density template), click on the column labelled 
COUNT (cell B3) and then paste the histogram data (in rows 3-258 i.e. 
density 1 to 256). 
d. The average density value will be displayed. Record this value. 
e.  Do not save any changes to the template. 
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- The first column DENSITY already has the range of densities (1-256) 
entered into it. Do not change the entries in this column.  
f. The template has been set up to calculate the average density of muscle (using 
the density range 10 – 113). Any pixels in the selected cross section that are 
outside this range (e.g. bone and fat) will not be included in this calculation. 
Note that some skin and connective tissue in the SC fat may have density values 
that are included in this calculation. However, this should be the same at all 
time-points for a patient, so it should not affect any reported changes in average 
density over time.  
g. The template will multiply the "count" column by the "density" column 
to get a new column, called TOTAL. Then it sums the values in the density 
range of interest.  So for muscle (density range = 10 to 113), it will sum the 
rows 12 to 115 to get "sum of total" and "sum of count".  Then the template 
will divide "total" sum by "count" sum. The average density for that scan of 
muscle will be displayed on the template. This is the number that will be entered 
onto the data analysis sheets. You can also look at "low density muscle" and 
"high density muscle" using this template just by adjusting the density range 
used in the calculations.   
 
13. Now go back to the image. Press 2.  Select the eraser tool and erase the bone 
marrow in the centre of the limb (magnify first!). 
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14. Click on the wand tool and then click on the outside of the muscle border. The 
results window will display values (4*) – ‘muscle area with holes’ and ‘muscle 
perimeter with holes’ i.e. for the area you have selected. Note: You may need to re-
do this calculation if you notice that: 
a. The muscle perimeter you selected is attached to the thigh perimeter (See 
below). 
Erase the bone marrow, 
using the eraser tool (so 
that is it not included as 
muscle). 
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If this occurs you will need to edit the scan so that there is at least a 1-pixel gap 
between the thigh perimeter (skin) and ‘real’ muscle perimeter. Do this by erasing 
the most superficial skin pixels while still leaving at least a 1-pixel thigh perimeter. 
You should be able to decide which pixels are skin and which are muscle by looking 
at the ‘original’ scan.  
 
Note on the data sheet whether you needed to edit the muscle border so that it is not 
touching skin (Circle ‘Yes’ or ‘No’). If editing of the muscle border was necessary 
assign a rating of the amount of editing required from 1 (edited <5 pixels) to 3 
(edited >15 pixels).
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b. Do not include other connective tissue (‘red bundles’) that is outside what you 
think is the periosteum (see scan below). In most scans you will see a small 
circular ‘bundle’ just outside or on the periosteum. Do not include this ‘bundle’ 
(It is likely a blood vessel). It may help to look at the original scan when 
determining what should be included as muscle and what should be left out. 
 
 
Using the eraser tool, detach the small 
circular bundle from the periphery of the 
thigh muscle. It is likely a blood vessel 
and should not be included as muscle. 
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UNEDITED AND EDITED THIGH SCANS 
Due to the difficulty in determining a consistent method for re-creating the thigh muscle 
border or the fascial perimeter, GREAT 2 DO thigh scans are calculated via 2 methods: 
“UNEDITED” (including only editing from the previous steps: erasing the scanner bed, 
detaching muscle pixels from the skin or detaching muscle from the blood vessel) or 
“EDITED” (pixels are added to reconstruct the muscle border, but not the fascial 
perimeter). Up to this step (14), each method is the same. 
 
The selected muscle perimeter often runs deep into the muscle instead of going around 
(what you think is) the outside of the muscle. This will occur when parts of the muscle have 
separated. (All it takes is a 1-pixel gap. Un-edited, this results in the ‘muscle area with 
holes’ being underestimated (and perimeters for ‘muscle with holes’ and ‘muscle without 
holes’ generally being overestimated). The underestimated ‘muscle area with holes’ results 
in IMAT being recorded as SC adipose tissue. This problem cannot be completely solved. 
Therefore the accuracy of IMAT and SC adipose tissue values is compromised. It would be 
more accurate to compare changes in ‘total fat’.  
 
c.  For UNEDITED THIGH SCANS calculation,‘bundles’ of muscle that fall outside 
the selected muscle perimeter (but within what you think is the periosteum), will need 
to be selected separately by clicking on each bundle with the wand tool. The area 
value(s) displayed for the ‘extra’ muscle bundle(s) in the results window will need to 
be added to the ‘muscle with holes’ area value to get the total muscle with holes value. 
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Include all ‘muscle bundles’ that are at least 2 pixels in area.  
 
 
 
15. Press 3. As per the ‘muscle with holes’ measure above, select the muscle within the 
periosteum (by clicking just outside the muscle perimeter). The results window will 
display the area value and perimeter value(s) for ‘muscle without holes’ (5*). And, 
as for ‘muscle with holes’, you will need to select individual muscle bundles that 
fall outside the selected muscle perimeter separately (and add all the area values to 
calculate the total ‘muscle without holes’). 
 
16. The results are recorded in a window that is similar to the table below.
You will need to select ‘bundles’ of 
muscle that fall outside the selected 
muscle perimeter individually and add 
these area values to get the total area (for 
both ‘muscle with holes’, and ‘muscle 
without holes’ measures). 
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17. Record the results onto the data sheet and remember to add all the values for the 
same measure together before entering the final value into Filemaker Pro. 
Table 1. Results Window 
 Area Perimeter 
1. Internal femur    
2. External femur   
3. Total thigh   
4. Muscle with holes   Ignore this measure. 
5. Muscle area  Ignore this measure. 
Note that ‘muscle without holes’ may become 6, 7, or 8, …if ‘muscle bundles’ have to be 
selected separately.  Area measures are given in cm2 and perimeter measures in cm. 
 
18. EDITED THIGH SCANS Repeat steps 2 to13 (density calculated from step 12 
should be the same).  
 
19. If the muscle perimeter runs deep into the muscle where parts of the muscle have 
separated, the goal is to connect the muscle perimeter with minimal editing by 
adding pixels with the pencil tool to smooth out the border (see below). The number 
of pixels added should be recorded on the data sheet.
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20. After editing, SAVE AS G2Do.de-identified ID#.edit # 
 
21. EDITED values for ‘muscle with holes’ and ‘muscle without holes’ will be different 
from UNEDITED values unless the muscle border required no editing. Editing will 
increase the area of tissue included as IMAT and decrease the tissue area included 
as subcutaneous fat. This is different from IMAT and subfascial adipose area 
described by Goodpaster et al.  
 
22. Record values on data sheet under the EDITED column. 
 
23. If a scan is challenging, for reliability do another edit of the same scan (preferably 
on another day or at least after you edit a different scan first), and save this as 
‘G2DoID#.edit#’, then compare the results. If there is greater than 0.3% (e.g. 
15/100 variation for values = 50) for any of the following measures – ‘muscle area 
with holes’, ‘muscle area without holes’, ‘total thigh perimeter’, and ‘total thigh 
QuickTime?and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime?and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
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area’ - between the 2 edits, do a third edit (Note: editing the muscle border may 
result in the variation of the perimeter value for ‘muscle with holes’ and ‘muscle 
without holes’ between edits to be > 0.3%. As these values are not required in the 
final analysis this variation is ok – the important thing is area. If the variation for 
all these measures (except the muscle perimeter) is less than 0.3% between any 2 
edits (e.g. edit 1 and 2, or edit 2 and 3), use the average of these 2 particular edits 
for your final values (to be entered in FileMaker Pro). 
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Tips for analysis 
- The quickest way to re-do the last measure you did is to go to Edit – Undo 
Measurement. 
- To re-do a particular measure, go to Analyse – Redo Measurement and 
enter the particular measurement you wish to re-do. 
- To delete a particular measure, go to Analyse – Delete Measurement and 
enter the particular measurement you wish to delete. 
- To clear all measurements from the results table go to Analyse – Reset. 
- The ‘muscle with holes’ and ‘muscle without holes’ perimeter values should 
be the same. 
- When the program calculates a perimeter measure for thigh scans the 
variation of this calculation is 6/100. You can see this variation by 
repeatedly selecting e.g. the muscle area with holes (or without holes) and 
looking at the calculated perimeter value. The value should be exactly the 
same no matter how many times the program calculates the perimeter, but 
it will vary by +-6/100. 
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Scans affected by Artefact 
Artefact can appear as ‘streaks’ usually running diagonally down and across from right to 
left (see image below). It may be due to a metal prothesis (e.g. pin and plate) being in situ 
in the opposite hip. 
 
 
 
Artefact may affect the calculated value for muscle density (attenuation), and area and 
perimeter values for the internal and external femur, muscle with holes, and muscle without 
holes. Editing can limit the extent of this affect. However, generally, this type of artefact 
will not greatly alter the value you calculated for muscle density because although the 
artefact caused some areas of muscle to have non-muscle density values (meaning these 
pixels will not be included in the muscle density calculation), most of the ‘missing’ muscle 
has been relocated to the SC fat (and since the whole cross-section of the thigh is included 
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in the muscle density calculation these pixels will be included).  Similar to analysing other 
scans, you may need to smooth out the internal and/or external femur perimeter. 
 
After pushing 2 (i.e. just prior to calculating muscle area with holes), the ‘streaks’ or 
artefact will be more prominent. Importantly, ‘bits’ of muscle will be ‘missing’ (i.e. 
replaced by black pixels), and in what should be SC fat, there will be bits of muscle (i.e. 
red pixels). See image below. 
 
Depending on the degree of artefact, 
if you were to go ahead and select 
the muscle, in most cases you will 
find the perimeter of the muscle 
does not represent the ‘real’ muscle 
area, i.e., the ‘streaks’ are causing 
some parts of the muscle perimeter 
to extend into the SC fat, and other 
parts of the muscle perimeter to run 
deeper than it should. 
 
Even for UNEDITED scans, you may need to ‘smooth out’ the muscle perimeter so that 
when selected, it gives a truer representation of the actual muscle area. This process 
involves: 
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1. Erasing the red streaks/artefact attached to the muscle perimeter that should really 
be black, i.e. SC fat. Use the original scan as a guide when editing the muscle 
perimeter (i.e. deciding what is fat and what is muscle). Remember that you only 
need to leave a 1-pixel gap between the peripheral muscle perimeter pixels and the 
deepest SC fat pixels. 
2. Adding red pixels (muscle) to ‘close off’ the periphery of the muscle perimeter so 
that when the muscle perimeter is selected, it is continuous and not interrupted by 
1 or 2 missing pixels that cause the perimeter to run deep into the muscle where it 
shouldn’t. (Again, use the original scan to guide you, or scans for the same pt at 
other time-points). 
 
(However it can depend on the scan: sometimes it is better to skip step 1 above and only 
perform step 2 i.e. leave the ‘streaks’ of muscle that extend into the SC fat, because this 
may represent the muscle that is missing from where it actually should be. And thus you 
will be able to get a value for muscle area without holes that is not underestimated to the 
same degree than  it would have been had you erased all the streaks of muscle that 
extended  into the SC fat. However this may mean that the value for SC fat will be 
underestimated – can edit twice – first time concerned with ms without holes, and 2nd time 
concerned with SC fat – although the accuracy and reliability of SC is already limited). 
As a result of editing: 
To a certain extent it depends on the scan and how you choose to edit but regardless 
of editing, in nearly all cases of artefact, muscle area without holes will be 
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underestimated due to the ‘missing muscle’– so IMAT fat will be overestimated. 
(The greater the artefact the more ‘muscle area without holes’ and IMAT fat 
will be underestimated and overestimated respectively). 
 
Therefore it is important to record the extent of artefact (i.e. how much you think it affected 
your results) compared with other scans (assign a rating out of 5 - as a guide, the above 
scan was given an artefact rating of 3 out of 5). Also note how much editing you performed 
(e.g. the number of pixels added/deleted). You will then have to decide if the effect of 
artefact on your results was so great that it warrants some/all values being left out of the 
data analysis. If you do decide to include the results in your data analysis, by noting the 
degree of artefact you will be able to determine if an unexpected result may have been 
somewhat attributable to this artefact.  
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STEP 4 ANALYSIS USING FILEMARKET PRO 
 
1. Open the master template. 
 
2. Before you enter any data, you must save a copy of the template to enter your data 
into. (Do not save any changes to the original template). Go to File – Save a copy 
as and then name the file ‘GREAT2DOuneditedCTscans’. Then go to File – Open 
– and open the file you just created. Go to window and select the ‘CT analysis 
master template’. Close this file. The new file you created will now be the only 
file that the program has open and any data you enter will now be saved under this 
filename. 
 
3. Select new record from the Records menu. 
 
4. Enter study de-identified ID number. Then enter all the other data into the 
appropriate fields. 
 
5. The program will calculate the final values that will be analysed later in StatView. 
These values will be displayed under ‘Results’.  
 
6. To enter data for another patient, select new record from the Records menu again. 
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7. To print a record, go to File – print. Note that you have the option of printing only 
the ‘current record’ displayed on the screen, or all ‘records being browsed’. 
 
8. A number of files will be de-identified and analysed in groups (Part 1, 2, 3 etc) over 
the time the trial is continuing. It will save time to enter the UNEDITED data from 
a completed folder first, then duplicate the original file, then save as‘GREAT2DO 
edited CTscans’. This requires caution as all previously entered data are already in 
the cells and the edited values for ‘muscle with holes’ and ‘muscle without holes’ 
must be deleted and re-entered. This will change the results for subcutaneous fat 
and IMAT. 
 
Note:  
 At any time you can sort the records e.g. by the patient number so that if you 
have to come back to a record to enter data for the next time-point or to edit 
data that you have previously entered you can do so without searching through 
all the records. To sort records go to the Records menu and select sort. Then 
click on the field that you want to sort by (e.g. patient number) and click ‘sort’. 
 There is no ‘save’ option. When you close the program, the data just entered is 
automatically saved.
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STEP 5 STATISTICAL ANALYSIS USING STATVIEW 
 Enter the data by hand into the StatView template from the printed off 
Filemaker Pro data sheets. Other variables, such as the ‘time first supine’, 
and ‘artifact rating’ will also need to be entered from the relevant source.  
 
 The StatView dataset should be updated as additional CT results are known.  
 
 Save the StatView file as nameofstudy.ctscans in dataset transfer format (i.e. 
with extension .ssd). This allows the file to be opened by either PC or 
Macintosh computers with StatView installed. Do not save over the original 
template. 
 
 Proceed with Statistical analyses of records as desired. 
 
If required…to transfer all pt’s data from Filemaker Pro to StatView:  
a. In Filemaker Pro, open the data set that you wish to transfer to StatView. 
b. Go to File – export records. 
c. Choose DBF in pulldown menu (should already be selected). 
d. Create a filename (‘G2DoUNEDITED thighs part1) and click ‘save’. 
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e. Screen will come up showing all the possible variables in the master 
template which can be transferred. Choose the subset of variables which 
are applicable for your analyses by highlighting each one and then clicking 
on MOVE. (Unfortunately you cannot move more than 1 variable at a time). 
NOTE: Transfer multiple timepoints sequentially in order, as they are 
required to be in this order for repeated measures ANOVA in StatView.  Be 
sure to include the subject ID and Name variables or you will not know who 
the data belongs to once it is transferred! 
f. These variables will be saved as a DBF file (database format). Open Excel 
and open this file. The variables you have chosen should appear as a 
spreadsheet with the variable names as the column headings and the values 
for each subject in a row (Don’t worry about editing the number of decimal 
places, column width, variable headings, e.t.c.  because you will still have 
to do this again in StatView). 
g. Save the file as an EXCEL 3.0 worksheet. The letters .xls will be appended 
to the end of the file name you have chosen 
h. Open the Excel file you just created in StatView.  
i. A StatView version of this data file will be created. The variable names will 
have been truncated by DBF and EXCEL conversions. Edit the column 
headings (variable names) so that they are easily identifiable. Check to see 
that all the column headings have been transferred and that they are in 
sequential time-point order.  If columns are in a non-desirable order (e.g. 
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timepoints are not consecutively arranged) you can cut and paste the 
columns how you wish. 
j. Values that were left blank in Filemaker Pro will appear as 0’s in StatView. 
Delete all the 0’s, otherwise they will be used in calculations. 
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SUMMARY OF COLLECTED INFORMATION 
 Data sheets with values obtained from the analysis performed using NIH 
Image. 
 
 Printed CT scan results from FileMaker Pro. 
 
 Electronic files will consist of each patients original and edited CT scans 
(and scout films plus header file), 1 FileMaker pro file (with data for thigh 
analyses), 1 StatView file (with data for all pts). Note that the interim Excel 
file that was created when transferring from FileMaker Pro to StatView can 
be deleted once the StatView file has been created and checked for accuracy).   
 
 You or your supervisor should also have the original CDs, and CT scan data 
sheets from when the scans were performed (includes information such as 
the scan date, contrast settings, midpoint of the thigh where the scan was 
taken, DFOV).
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ANALYSING ABDOMINAL CT SCANS 
 
24. Open DICOM NIH Image 1.63. Click on any one of the program’s windows. 
Ensure the macros are loaded by going to the pull-down menu ‘Special’ and then 
click on ‘Load Macros’. The macros file (‘image macros.txt’) is located under 
Desktop/DICOM NIH Image NEW/NIH Image 1.63 f/. Loading the macros is 
necessary for the program to recognise specific commands which have been set up 
for use with CT scans.  
25. Open a scan by holding down the space bar and pushing the letter O (or go to File 
– Open).  This will display the file directory tree on the screen. Select the file 
(scan) you wish to analyse by navigating through the directory tree of the hard drive. 
Open this file by double clicking on its name or clicking on OPEN. (File should be 
named G2Do.de-identified ID#.abdo.DFOV.dcmx).  
26. Select the correct DFOV as indicated on the folder header. A cross section of the 
abdomen will appear on the screen.  In order to accurately analyse the scan, 
‘imperfections’ to the image must be corrected.   
27. If the scan has part of the scanner bed touching the cross section of interest, (see 
scan below) then the scanner bed pixels must be removed (so that there is at least a 
one-pixel gap between the peripheral abdominal skin pixels and scanner bed pixels).  
For accurate removal, first magnify the image using the magnifying tool located in 
the top left hand side of the tool section.  Click on this tool and then click on the 
image to magnify around the area that you wish to edit. (Continues on next page) 
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28. Once the image is magnified to a suitable level (the actual amount is subjective: 
magnify until you can clearly see the pixels that need to be removed – 4x is 
generally enough). Click on the eraser tool (fourth from the top on the left hand 
side) and whilst holding the mouse button down, move the mouse over the 
‘offending’ pixels and erase them.   
a. Note:  This process can be unreliable if not done carefully.  For some 
scans you may need to “guess” which pixels to erase as best as possible – 
there is no better way to complete this process.  In order to increase the 
reliability of this procedure, try to match the area of abdomen perimeter you 
Detach the scanner bed pixels from 
the abdominal skin periphery by 
using the eraser tool. 
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are editing with other areas of the abdomen perimeter unaffected by the 
scanner bed (e.g. the same no. of lighter coloured pixels).  
b. To save time note that you do not have to erase all the pixels outside the 
cross section. As long as there is at least a 1-pixel gap between the 
peripheral abdomen perimeter pixels and the pixels outside the perimeter 
(i.e. they are not touching one another), the pixels outside the perimeter will 
not be included in the cross section analysis.  
 
You can restore the image at any time to its original size by double clicking on the 
magnifier tool.  
 
29. Note on the data sheet whether editing of the scan bed was required (Circle ‘Yes’ 
or ‘No’). If editing was required, circle one of the numbers to indicate the combined 
amount/difficulty of the editing (3 = the most difficult/amount of editing, whereas 
1 = the least difficult/amount of editing. Obviously this rating is quite subjective 
but at least it will give you some indication of the amount/difficulty of editing 
performed at this step, which may be useful when analysing the data.  
 
30. Save the edited version of the scan  
(G2Do.de-identified ID#.abdo.DFOV.edit1.dcmx).  
DO NOT save over the original copy of the scan.   
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31. Now press 4.  Most of the scan will turn red (see image below).  
 
 
 
 
32. The next step is to calculate the area and perimeter of the abdomen (including skin) 
(1*). Do this by selecting the ‘wand tool’ (second from the bottom left), and on the 
image, click just outside the abdominal skin (perimeter). The values will appear in 
the results window. Note: Make sure that when the abdominal perimeter is 
selected that no pixels outside this perimeter are included (e.g. this may have 
occurred if you did not leave at least a 1-pixel space between scanner bed pixels 
and abdominal perimeter pixels).  
 
Click just outside the abdominal 
perimeter with the wand tool to 
measure the area and perimeter 
of the abdomen (including skin). 
See Step 9 on the next page. 
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33. Now go back to the image. Press 6. Click on the wand tool and then click just 
outside the abdominal perimeter. The results window will display the ‘Total 
Abdominal Fat Without Skin’ value (2*). The program calculates this measure by 
summing the area within the selected perimeter occupied by pixels with density 
values in the range of 140-240. 
 
If the program fails to select the abdominal perimeter (without skin), because the 
abdominal muscle core pixels are attached to the abdominal skin (usually by 
‘fissures’ in the subcutaneous fat, i.e. not because muscle and skin are actually 
connected), then you will need to change the colour (density) of some of the 
subcutaneous fat pixels (fissures) that are causing this to happen to red. Do this 
using the pencil tool. Re-calculate ‘Total abdominal fat without skin’ as above. On 
the data sheet, circle ‘YES’ for ‘Detached Muscle from Skin’ and rate the amount 
of editing required from 1 (<5 pixels edited) to 3 (>15 pixels edited). 
Note: it is unnecessary to smooth-out the perimeter by detaching those ‘fissures’ 
extending inward from the skin that do not reach the abdominal core of muscle, as 
the calculation of fat will not be affected. 
 
 
34. With the abdomen perimeter selected, the average density of fat for the entire 
abdomen can be calculated. 
a. Go to analyse then to show histogram 
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b. Go to edit then to copy histogram (you will be copying 256 rows of data 
that contain the count for each density) 
c. Open Excel (‘Abdomen Fat Density.xls’ located in DICOM NIH 
ImageNEW folder on the desktop under ‘Instructions’ folder), click on the 
column labelled COUNT (cell B3) and then paste the histogram data (in 
rows 3-258 i.e. density 1 to 256). 
d. The average fat density value will be displayed. Record this value. 
e.  Do not save any changes to the template. 
f. The first column DENSITY already has the range of densities (1-256) 
entered into it. Do not change the entries in this column. 
The template has been set up to calculate the average density of fat (using 
the density range 140 – 240). Any pixels in the selected cross section that 
are outside this range (e.g. bone and muscle) will not be included in this 
calculation. (Note that some skin pixels, muscle pixels, and abdominal 
viscera pixels may have density values that are included in this calculation. 
However, this should be similar across all time-points for a patient, so it 
should not affect any reported changes in average fat density over time).  
g. The template has been set up to calculate the average density of fat (using 
the density range 140 – 240). Any pixels in the selected cross section that 
are outside this range (e.g. bone and muscle) will not be included in this 
calculation. (Note that some skin pixels, muscle pixels, and abdominal 
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viscera pixels may have density values that are included in this calculation. 
However, this should be similar across all time-points for a patient, so it 
should not affect any reported changes in average fat density over time). 
h. The template will multiply the "count" column by the "density" column to 
get a new column, called TOTAL. Then it sums the values in the density 
range of interest.  So for fat (density range = 140 to 240), it will sum the 
rows 142 to 242 to get "sum of total" and "sum of count".  Then the 
template will divide "total" sum by "count" sum. The average density for 
that scan of fat will be displayed on the template. This is the number that 
will be entered onto the data analysis sheet. You can also look at "low 
density fat" and "high density fat" using this template just by adjusting the 
density range used in the calculations. 
 
35. The next step is to calculate ‘Visceral Fat’. To do this, select the wand tool and click 
just outside the abdominal muscle core area. You should now see that the abdominal 
core is selected (i.e. a complete ‘ring’ of muscle extending from the paraspinal 
muscles to the anterior abdominal muscles is selected). However, in nearly all scans 
you will find that the program cannot select this perimeter. This occurs due to the 
abdominal muscle core perimeter being incomplete (i.e. there are small pixel gaps 
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when you look closely at the perimeter – see image below). 
 
 
To overcome this problem you will need to complete the abdominal muscle core 
perimeter by adding muscle (i.e. grey) pixels. Do this using the pencil tool 
(magnify first!). Note that this step involves a fair bit of ‘guesswork’ and you may 
question whether to add pixels at more superficial or deep regions of the abdominal 
muscle core perimeter. To help you determine this, (and aid the reliability of this 
editing), only add the minimum number of pixels required to complete the border 
(e.g. if at one region of the abdominal muscle core perimeter 3 pixels are required 
to complete the border at its most superficial region, but only 1 pixel is required to 
complete the border at a deeper location, add the 1 pixel at the deeper location. If 
both deep and superficial locations require the same number of pixels to complete 
the perimeter, then add the pixels to where you think would best replicate the 
perimeter – usually this means adding the pixels superficially).
You will need to add grey 
pixels using the pencil tool 
to complete the abdominal 
muscle core perimeter. 
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On the data sheet, circle ‘YES’ for ‘Completed Abdominal Core’, and rate the amount 
of editing required from 1 (<5 pixels added), to 3 (>15 pixels added). 
 
Once selected, the abdominal muscle core perimeter should appear as a ‘ring’ of muscle 
(as stated above). This perimeter should by no means be perfectly smooth. As long as 
it is complete and not attached to abdomen skin pixels, once this perimeter is selected 
the visceral fat measure will be generated in the results window (3*). Note: it is 
unnecessary to detach those fissures extending outward into subcutaneous fat that do 
not reach the skin (see image above), as the densities of these fissures fall outside the 
density range that the program uses when summing fat area.  
 
36. With the complete abdominal muscle core selected calculate visceral fat density as 
per steps a to e above.  
37. To calculate Subcutaneous Fat subtract ‘Visceral Fat’ from ‘Total Abdominal Fat 
(without skin)’. 
 
38. To calculate the subcutaneous fat density, proceed as above to select the ‘Total 
Abdominal Area without skin’ (this time you do not need to worry about any 
fissures that may be present). Then, to avoid any tissue deep to the subcutaneous 
fat (e.g. muscle, abdominal viscera, bone, visceral fat) being included, change the 
colour (density) of any tissue deep to the subcutaneous fat to black (note you do not 
have to re-colour all the pixels, only those that fall outside the range used for fat, 
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i.e. 140-240). You can now calculate subcutaneous fat density as per previous fat 
density calculations above, i.e. with the total abdominal perimeter (without skin) 
selected,  
a. Go to the pull-down tab analyse and choose show histogram. 
b. Go to edit then to copy histogram (you will be copying 256 rows of data 
that contain the count for each density) 
c. Open Excel (average density template), click on the column labelled 
COUNT (cell B3) and then paste the histogram data (in rows 3-258 i.e. 
density 1 to 256). 
d. The average fat density value will be displayed. Record this value. 
e.  Do not save any changes to the template. 
 
39. To calculate liver density, use the rope tool to select an area of liver if it is evident 
in the scan (depending on the level of the scan, the liver may or may not be in the 
slice). The average density of fat for the selected segment can be calculated. 
a. Go to analyse then to show histogram 
b. Go to edit then to copy histogram (you will be copying 256 rows of data 
that contain the count for each density) 
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c. Open Excel (average liver density template) click on the column labelled 
COUNT (cell B3) and then paste the histogram data (in rows 3-258 i.e. 
density 1 to 256). 
d. The average liver density value will be displayed. Record this value. 
e.  Do not save any changes to the template. 
  
40. Next, measure the abdominal sagittal length. To do this, first select the ruler tool 5th 
from the top on the right-hand-side of the tool panel. Then click on the most 
peripheral trunk skin pixel posterior to the spinous process (magnify first!). This is 
easily identified in the middle of the posterior abdomen skin perimeter. While 
holding down the mouse button move the ruler perpendicularly up to the most 
peripheral anterior abdomen skin pixel – you will have to de-magnify the image 
first. Note that this line must be completely straight to aid accuracy and reliability 
of this measure. If after you let go of the mouse button you think that the line is not 
straight or that you did not draw the line far enough (or you drew it too far), simply 
move the cursor over the end of the line, hold down the left mouse button and re-
position the end of the line to where it should be. Once you are happy with the 
sagittal line you have drawn go to the pull-down tab ‘Analyse’, and select 
‘Measure’. The abdominal sagittal length value will now be displayed in the results 
table (4*). Note: sometimes the patient’s trunk appears to be rotated (by looking at 
the angle of the spinous process). This may be due to some rotation of the pt on the 
scanner bed, but may also be due to a spinal deformity, such as scoliosis. In these 
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cases, still measure the sagittal length as per above, but note the rotation on the data 
sheet (as this may affect the ‘true’ abdominal sagittal length). 
41. The results for the above measures are recorded in a window that is similar to the 
table below.   
Table 1. Results Window 
Measure Area Perimeter (or Length) 
1. Total Abdominal  
(with skin) 
  
2. Total Abdominal Fat  
(without skin) 
 Ignore this value. 
3. Visceral Fat  Ignore this value. 
4. Subcutaneous fat area (2 -  3)   
5. Abdominal Sagittal Length  Ignore this value.  
 
Total Abdomen Fat Density (w/o skin)   
Visceral Fat Density  
Subcutaneous Fat Density  
Liver Fat Density  
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42. Record the results onto the data sheet.  
Area measures are given in cm2, perimeter measures in cm, sagittal length in cm. 
 
43. It is also important to record the extent of artefact (i.e. how much you think artefact 
affected your results) compared with other scans. Artefact usually appears as 
‘streaks’ running diagonally across the scan. Artefact changes the density values of 
the areas affected. In doing so, fat values will usually be increasingly 
underestimated as artefact increases. This occurs because the density values of 
fat areas now have density values that fall outside the density range of fat and thus 
the program does not ‘recognise’ these areas as fat. This is best seen after you press 
‘6’ where you will see diagonal ‘streaks’ of pixels coloured grey (i.e. non-fat) that 
should be coloured red (i.e. as fat). Therefore it is important to assign a rating of 
the degree of artefact that can used when interpreting changes in fat values across 
time. As a gross measure, circle a rating between 0 and 5 on the data sheet. As a 
guide, the scan below was given an artefact rating of 4 out of 5. 
Artefact is present in this scan 
around the arrowhead (mainly in 
the SC fat area). It may cause all 
fat values to be underestimated – 
especially subcutaneous fat.  
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44. When a scan requires editing that is more than simply obvious editing of a few 
pixels, for reliability do another edit of the same scan (Preferably on another day or 
at least after you edit a different scan first), and save this as ‘edit 2.ID#.Abo’. Once 
you have completed both edits, compare the results. Use the table on the next page 
as an indication of an acceptable level of variation between the 1st and 2nd values 
obtained. If the level of variation of any measure between the 2 edits is outside the 
‘max variation’ noted in the table, perform a 3rd edit of the scan. If after 3 edits the 
variation of any of the measures between the 2 most reliable edits is still greater 
than the ‘max variation’ consult your supervisor. If the variation of all measures 
between 2 edits is acceptable enter the average of the 2 values from the 2 edits for 
all measures into the StatView data entry template.  
Note that if the values for a particular measure (perimeter measures only) were 
different between edits when you did not do any editing that would affect that 
measure (or measures), calculate (select) the measure a couple of times and enter 
the most recurring value and not the average of the 2 edits (this is the variation of 
the program which has been found to be up to 11/100). 
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Level of Variation (± % change) between Edit 1 and Edit 2 (Using 10 – 17 scans) 
Measure 
Area Perimeter 
Mean 
Variation 
(%) 
Max 
Variation 
(%) 
n 
Mean 
Variation 
(%) 
Max 
Variation 
(%) 
n 
1. Total Abdominal  
(with skin) 
0.005 0.025 17 0.052 0.139 17 
2. Total Abdominal Fat 
(without skin) 
0.021 0.093 11 Ignore this value. 
3. Visceral Fat 0.086 0.457 15 Ignore this value. 
4. Abdominal Sagittal 
Length  
Ignore this value. 0.117 0.697 17 
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ANTHROPOMETRY 
WAIST CIRCUMFERENCE 
 
Equipment 
 Lufkin steel tape measure (W606 PM) 
 
IDF Protocol 
 The cross hand technique (left hand under) is used for measuring all girths. The 
tape should be read at the measurer’s eye level to avoid parallax error and with 
decimal place in line with the zero. Constant tension is achieved by ensuring that 
there is no indentation of the skin or gaping of the tape. 
 The waist circumference is taken at the mid-point between the lower costal (rib) 
border and the iliac crest (measured and marked). The measurement is taken at the 
end of normal expiration with the subject’s arms relaxed at the sides. 
 
ISAK protocol (2006) 
 The ISAK waist circumference is located at the narrowest point of the abdomen 
between the lower costal border (10th rib) and the top of the iliac crest, 
perpendicular to the long axis of the trunk. If there is no obvious narrowing, the 
measurement is taken at the mid-point between the lower coastal border and the 
iliac crest (ie. IDF protocol). 
 The subject assumes a relaxed standing position with the arms folded across the 
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thorax (this also allows clothing to be positioned and held outside the measurement 
circumference as well). The anthropometrist positions the tape at the target level 
using the left hand under to read the measurement and then records the number at 
the end of normal expiration. 
 
Laser Mark Circumference 
A circumference is recorded (see CT protocol) at the location of the CT scan while the 
subject is supine, at the mid-point between the lower costal (rib) border and the iliac 
crest on the left side of the body (measured and marked). When subjects are in standing 
position, this mark does not usually correspond with the IDF circumference landmark 
(the mark on the skin at the mid-point between the lower costal border and the iliac 
crest in supine position is not usually at the same mark on the skin as the mid-point 
between the lower costal border and the iliac crest when standing). A circumference is 
also measured where the laser mark is on the skin in standing position. At the baseline 
scan, the landmark is located from palpation and marking (with ball bearing). At 6 and 
12-month scans, this mark is identified by the scanner laser lights at the location of the 
abdominal CT scan slice. 
 
Neck Circumference 
The girth around the neck is measured immediately superior to the thyroid cartilage 
(Adam’s apple). The subject should maintain the head in the Frankfort plane and may be 
seated or standing. It is important not to pull the tape tight in this region since the tissues 
are compressible. The tape is held perpendicular to the long axis of the neck, this is not in 
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a horizontal plane.  
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PASE SCORING 
PASE Score (By Brad Lloyd) 
To calculate the PASE score for each activity below, work out the average number of hours 
spent engaged in each activity per day over the 7 day period and multiply this by the PASE 
weight. 
Examples 
1. A participant engages in light sport ‘sometimes (3-4 d)’ for ‘1 but < 2 h’. 
3.5 d x 1.5 h = 5.25 h/wk. 
5.25 / 7 = 0.75 h/d over the 7 d period. 
So PASE score for light sport = 0.75 h/d x 21 = 15.75 
PASE Activity Score PASE Weight PASE Score 
Muscle strength/endurance* h/d 30  
Strenuous sports* h/d 23  
Moderate sports* h/d 23  
Light sports* h/d 21  
Job involving standing/walking* h/d 21  
Walking* h/d 20  
Lawn work or yard care  36  
Caring for another person  35  
Home repairs  30  
Heavy housework  25  
Light housework  25  
 900 
 
Outdoor-gardening  20  
PASE Total    
 
PASE scores for the activities below are calculated by multiplying the PASE weight by 1 
or 0. If the participant engaged in an activity in the last 7 d, multiply the PASE weight by 
1. If the participant did not engage in an activity in the last 7 d, multiply the 
 
PASE weight by 0. See below.* determine the average number of hours/day (h/d) over the 
7-day period 
  1= engaged in activity during the previous 7 days 
  0= did not engage in activity during the previous 7 dayS 
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Paffenbarger Score (BL) 
To calculate the kcal/wk for blocks walked multiply the total number of blocks walked in 
the previous 7 d by 8. To calculate the kcal/wk for flights climbed multiply the 
totalmnumber of flights climbed in the previous 7 d by 4. To calculate the kcal/wk for light 
sport, moderate sport, and heavy sport, multiply the total number of minutes spent engaged 
in each activity over the whole wk by the respective energy expenditure for that activity. 
From previous example: 
1. A participant engages in light sport ‘sometimes (3-4 d)’ for ‘1 but < 2 h’. 
3.5 d x 1.5 h = 5.25 h/wk. 
5.25 x 60 = 315 min/wk 
315 x 5 = 1575 kcal/wk 
NOTE for PASE 
1. Walking – has to be outdoors. 
2. Hip exercise/physiotherapy exercise/stretching exercise/seated calisthenics – do not 
count as muscle strength/endurance. If you think the exercise has a similar EE as ‘light 
sport’ then include this as ‘light sport’ (e.g. doing weights, light cycling). 
 Blocks walked X 8 kcal / block = kcal  
 Flights climbed X 4 kcal / flight = kcal 
 Minutes light sport / recreation X 5 kcal / min = kcal 
 Minutes moderate sport / 
recreation or muscle strength 
X 7.5 kcal / min = kcal 
 Minutes heavy sport / recreation x 10 kcal / min = kcal 
 Total    kcal/wk 
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3. DO NOT include study exercise in estimate of activity for any question 
4. Please remember that if you answer ‘never’ to the first part of Q2 then you should  leave 
Q’s 2a and 2b blank and move onto Q3. 
5. Q 2a. Walking To work out the average number of hours per day walked over a 7 day 
period: 
 Take the average of how many days walked (e.g 1-2) and times this by the average 
of the number of hours the patient walked per day that they walked (e.g. <1hour). 
Then divide this answer by 7. 
- E.g. Walked ‘seldom’ (1-2 days per week) for less than 1 hour per day=1.5 x 0.5 
hours/day over a 7 day period. 
 If ticked ‘more than 4 hours’ – take this as 4 hours. 
[Note: If exact values are given by RA use these values. E.g. Walked 7 days for 2 
hours each day = 2 hour/day over a 7 day period]. 
6. Q 2b. Walking The distance the patient walked given by RA is per day that the patient 
walked (unless written otherwise). 
- E.g. If ticked less than 1 mile and walked ‘seldom’ (1-2 days per week), then the patient 
walked 0.5 mile X 1.5 days = 0.75 miles per week. 
- E.g. If written 4 blocks and walked ‘sometimes’ (3-4 days per week), then the patient 
walked 4 blocks X 3.5 days = 14 blocks per week. 
 If ticked ‘more than 4 miles’ – takes this as 4 miles. 
[Note: If exact values are given by RA use these values. E.g. Walked 2 blocks per 
day, 7 day per week = 2 blocks X 7 days = 14 blocks/week.] 
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7. Q 3. Please record the total number of flights/steps climbed up in a week. Do not include 
stairs descended. 
Note: If exact value is given by RA use this value, otherwise take the average of what the 
RA has ticked. 
If ticked more than 4 flights – take this as 4 flights. 
8. Q’s 4. Light sport, 5. Moderate sport, 6. Strenuous sport, 7. Ms. 
Strength/endurance Work out the average number of hours per day over a 7 day 
period as per Q 2a. 
Do not include ROM exercise as ‘light sport’. 
Pilates = ‘light sport
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APPENDIX C. ASSESSMENT PROTOCOLS (ASSESSMENT B) 
ASSESSMENT B PROTOCOLS 
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ANTHROPOMETRY 
Equipment 
 Weighing Scale (AND HW-100k & SECA Wedderburn (>100 kgs) 
 Free weights of known mass (range x kgs, x kgs) 
 
Calibration of Scale 
 The site staff must ensure that calibration of the weighing scale is performed 
following the instructions outlined by the manufacturer's user manual. The 
frequency of calibration must be as recommended by the manufacturer of the scale. 
 Three objects of known weight (eg, dumbbells which have been accurately weighed 
on a force platform) are EACH placed on the weighing scale on three separate 
occasions, and the weight to the nearest 0.1kg as displayed by the weighing scale 
recorded. 
 
The calibration factor to be used for correcting the subject weight is then obtained by 
following the steps below: 
 The average of the three attempts for EACH of the three known weights is 
calculated 
 The ratio of the scale average to each of the known weights is calculated 
 
e.g. Scale weight averages = 5.1 kg, 10.5, 20.7 kg 
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Known weights= 4.9 kg, 10.1kg, 20.3 kg 
Ratios=5.1/4.9; 10.5/10.1; 20.7/20.3 
 
The average of these 3 ratios is the calibration factor. 
 
 Each measured weight of the subject is divided by the average calibration factor to 
obtain the TRUE WEIGHT, which is entered into the source document. 
 The calibration factor may change during the course of the study and it is important 
that site staff maintain a log of the date/time that each calibration is undertaken. It 
is strongly recommended that the calibration factors are part of the calibration log 
and kept with the weighing scale. 
 
Subject Preparation 
 When the subject arrives, ask them to go to the bathroom to relieve themselves 
whether they feel that they need to or not. They will be lying down for an extended 
period of time and won’t have the opportunity to go to the bathroom. 
 Have the subject change into the gown, removing all garments of clothing 
(including shoes and socks) and leaving their underwear on. Instruct the subject not 
to tie the gown up at the back as this will be uncomfortable to lie on for the hour. 
Leave the room while the subject changes. 
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Body Weight 
 Body weight is recorded three times while the subject is wearing only a robe (with 
a measured weight) and no shoes.  
 Any unusual conditions should be noted (e.g. presence of a cast or other non-
removable appliance such as a brace, amputation).  
 The subject should step on and off the scale for EACH of the three attempts, 
whenever possible. 
 All three weights are recorded, corrected with the calibration factor as described 
above, and entered onto the data sheet. 
 
Note: 
 For RMR, body mass in the robe minus the weight of the robe is the entered 
measurement. 
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BIOELECTRICAL IMPEDANCE ANALYSIS 
 
Equipment 
 BIA Analyzer (RJL Systems, Inc., Clinton, MI, USA) 
 
Purpose 
BIA will be used to evaluate body composition (RJL Systems, Inc., Clinton, MI). A low-
level electrical current is passed through the subject’s body via electrodes placed on the 
right hand and foot. Impedance (opposition to flow of the current) is measured by the BIA 
analyzer to estimate the individual’s total body water (TBW). Because of the relatively 
high water (73%) and electrolyte content of fat free mass (FFM), it offers less impedance 
to electrical current than fat, which is anhydrous and a poor conductor of electrical current. 
Thus, individuals with a larger FFM and TBW content will have less resistance to current 
than those with less FFM and greater body fat. 
 
Subject preparation 
 Avoid ingesting food or fluids for 12 hours prior to the test (present in a fasted state). 
 Avoid consumption of alcohol for 12 hours prior to testing. 
 Avoid exercise, strenuous exertion, or taking a sauna 8 hours prior to testing. 
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 Subject should not be wet from sweat or urine. 
 Subject should not have a fever or be in shock. 
 
Environmental considerations 
 The exam area should be comfortable and free of drafts and portable heaters. 
 
Calibration 
 Calibrate before each test using 500-ohm resistor. Resistance should be between 
495-505 ohms (usually 502 ohms). Record resistance. 
 Maximum total test time (including placement and removal of electrodes) = 5 
minutes 
 Maximum time BIA Analyser is on for = 1 minute 
 
Procedure 
1. Record the patient’s naked weight, height, age and gender. Naked weight is 
calculated by taking away the weight of the gown from the measured weight taken 
with the gown on. 
 
Example  Weight of person + gown = 80.41kg 
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Weight of gown   = 0.39kg 
Naked Weight   = 80.41kg – 0.39kg 
= 80.02kg   
2. The patient should remove their right shoe and sock. Generally the test is completed 
on the right side of the body. If for some reason the test cannot be completed on the 
right side, conduct the test on the left side. (Subsequent tests must be conducted on 
the same side as the first test). 
3. Lay the subject in a supine position with arms 30 degrees away from the body, and 
the legs not touching. 
4. Clean the electrode sites with alcohol to remove any dry skin or lotion. 
5. Place a signal electrode on the proximal interphalangeal joint of the middle finger 
of the right hand and attach the black clip with the red lead. 
6. Place the detecting electrode edge on the dorsal aspect of the wrist along an 
imaginary line bisecting the styloid process of the ulna and attach the red clip with 
the red lead. 
7. Place a signal electrode over the base of the proximal phalange of the second toe of 
the right foot and attach the black clip with the black lead. 
8. Place the detecting electrode edge on the anterior aspect of the ankle along an 
imaginary line bisecting the medial malleolus and attach the red clip with the black 
lead. 
9. Turn the analyser on and make sure the subject refrains from moving. Record the 
 913 
 
Resistance and Reactance. Do this three times. 
10. Remove and dispose of the electrodes. 
 
BIA Equation 
Fat free mass [FFM] in (kg) is calculated using the following equation: 
 
 
–4.03 + 0.734 (Ht2 / R) + 0.116 (weight) + 0.096 (Xc) + 0.984 (Sex) 
 
 
Where: 
 Ht = height in cm 
 R = resistance in  
 weight is in kg 
 Xc is reactance in  
 Sex = 0 for women or 1 for men
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RESTING METABOLIC RATE 
Equipment 
 Ultima PFX, Medgraphics, Minnesota. 
 BreezeSuite software. 
 Electrodes 
 Pnuemotach 
 Medgraphics mask 
 
RMR MEASUREMENT 
Baseline assessments are performed before initiation of resistance exercise. Two more 
measurements are done at 6 and 12 months assessments. Each subject should have been 
transported by motor vehicle to the testing site to ensure minimal activity before RMR 
determination. Subjects should have been asked to avoid exercise or the ingestion of food, 
fluids or alcohol for 12 hours prior to the test. Additionally subjects should have had the 
last training session no less than 48 hours prior to the procedure to avoid the effect of excess 
post-exercise O2 consumption (EPOC). [1, 2, 3] 
 
Room preparation 
 Place metabolic cart next to desk against wall 
 Place the foot of the bed against the southern wall of the room to allow the sample 
tube to reach from behind the head of the patient 
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 Tape the tube to the bed head if necessary to prevent pulling of the mask 
 Turn off light 
 
RMR 
After preparation of the equipment and software, RMR is measured with the participants 
lying supine for 60 min while breathing through a mask assuring an air tight seal. The 
ambient room temperature should be above 15° Celsius and the patient should be provided 
with blankets if needed to guarantee a thermo neutral state; the room should be darkened 
and noise kept to a minimum. The first 30 min of measurements should be considered a 
resting and a wash out period. The last 30 min will be considered for the actual calculation 
of the RMR. 
 
Medgraphics Equipment and Software preparation 
1. Remind the patient whether they need to visit the bathroom prior to the test. 
2. Turn Ultima PFX “on” via the wall switch (white cord) at least 40 min before use.  
Wait until the red light on the Ultima PFX turns from red to green. This indicates 
that it is ready for use. 
3. On the computer screen (desktop screen), select the program “Breeze”.  
4. The window which appears in front of you when you first open the program is the 
‘Patient’ screen. Select the ‘New’ option at the bottom of the window.  
5. Enter in patient’s last, middle and first names, gender race and Date of Birth in the 
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boxes provided.  
6. Press ‘Add visit’. This information is only entered at the first visit, and is retrievable 
subsequent visits. To retrieve, when the ‘Patient’ screen is open, select the patients 
file from the list present, press ‘add visit’.  
7. Enter in the patient’s height (from Assessment A) and weight (Assessment B). 
 
8. Select    
 
9. Wait until the red coloured numbers next to “GX Vac” turn into a green “READY”.  
This takes 10 minutes. 
 
10. Select                    
 
This calibrates the pneumotach. 
 
11. You will need to enter the temperature, humidity and barometric pressure at bottom 
of window/screen PRIOR to calibrating. Room temperature (˚C) and humidity (%) 
are obtained from the temperature and humidity gauge (placed on the table). The 
barometric pressure (hPa) is obtained from the Bankstown airport Website: 
http://www.bom.gov.au/products/IDN65092/IDN65092.94765.shtml 
 
GX Vac 
CALIBRATE 
caCA 
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12. Attach pneumotach to the blue end of the 3L calibration syringe. Remove the gas 
analyser from the front of the Ultima system and attach it to the pneumotach/ 
syringe configuration. (NOTE: the gas analyser is attached to the pneumotach 
correctly; the notch on the gas analyser is at opposite sides to the notch on the 
pneumotach). 
13. Select “Zero flow” (whilst holding your palm over the end of the pneumotach). If 
there a caution message that the ‘flow is out of range’, check correct configuration 
of the syringe/pneumotach/gas analyser configuration and retry. If there was no 
caution message, this mean the ‘zero flow’ was successful. 
14. When ready, you will be asked to calibrate different flow rates using the known 
volume of air in the syringe. Press ‘start’ and then pull syringe pistol in and out - at 
a speed to match the lines on the graph displayed on the screen. Do this at five 
different speeds. 
15. To re-do or reset (if you make a mistake): select “Stop”, then “Start” – and try 
calibrating again. 
16. If calibration is successful, ‘calibration successful’ will appear on the top right hand 
corner of the screen. If the calibration was unsuccessful, ‘calibration unsuccessful’ 
will appear in the same space. You will need to retry until ‘calibration successful’ 
appears. 
17. Select “OK” when done. This will close the calibration window. 
18. The gas cylinders are located at the back of the cart. Turn handles on both gas 
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cylinders in a counter-clockwise direction to open cylinders. You do not need to 
open the knobs the all the way. They only need to be turned 90degrees from the 
starting position. (Do not touch the knobs where indicated by signs ‘DO NOT 
TOUCH!’).  
19. Return the gas analyser into the Ultima PFX (with the 2 pins on top). 
20. Select                            This is the ‘Calibration of gases’. 
21. A caution message ‘Calibrating Gas Analysers’ will appear while auto calibrating 
the gas cylinders. A summary window will appear once the calibration is complete, 
indicating that the calibration was successful. 
22. Select “OK”. 
23. Turn gases off completely (twist knobs clockwise) when calibration is complete. If 
left open, the gases will be depleted 
24. Select        (Tab at the bottom of the screen – Gas Exchange) 
 
The ‘settings’ page will be the page appearing on the screen.  
25. Enter the details of the test you will be conducting. In this case it will be ‘Metabolic 
- DARE’. 
26. Enter physician and technician details in the appropriate places.  
27. Select the ‘Test’ tab. At this point the page displays a blank data section (located in 
the top portion of the screen with variables such as V02, VCO2 RER and HR) and 
AUTO CAL 
GX 
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two blank graphs.  
28. Explain purpose of test.  
29. Explain the placement of the mask and its purpose. 
30. Place the mask on the patients face while in the seated position. 
31. Let the patient know that the data acquisition will go for 60 minutes, where they 
are needed to stay as still and as relaxed as possible. Sleeping is not permitted; they 
will be gently woken if they are seen to be falling asleep. 
32. Press the         button located on the top left hand corner of the  
 
screen. This will start the collection of the data from the mask into the Medgraphics 
system. The empty data screen and graphs will now have information appearing. 
33. At the end of the 60 minute period, stop the test. 
NOTE: Wearing the mask is uncomfortable, and this time should not be prolonged 
unnecessarily.  
RMR calculation (use naked body weight in calculations) 
The final RMR value will be determined as follows: 
1. Using the functions available in the software, the measurement window will be 
adjusted to the last 30 min. This procedure will provide a mean value for the last 30 
min which will be used as a reference later. 
2. The data points provided by the software will be exported to a datasheet in Excel and 
the coefficient of variation CV (SD/mean) of each 3 min block will be calculated for 
START 
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VO2 and VCO2. 
3. Additionally the minute to minute variability (%) of the VO2 and VCO2 data points 
will also be calculated. 
4. The 5 min period with a min-min variability <10% and the lowest CV will be 
considered the RMR value. 
5. The values obtained at step 1 and 4 should be compared. The value in 4 should be 
lower than 1, confirming that the result corresponds to a stable period close to the basal 
activity and not a result coming from a stable peak.  
 
Steps 2 to 4 should be done in order to determine a steady state period of gas exchange 
defined by a 5-minute interval during which VO2 and VCO2 vary by < 10%. [4] A 3-minute 
interval can be considered clinically acceptable in ambulatory patients whenever the 5-min 
period is difficult to achieve. [5] The validity of the measurements 
must be verified by at least 2 essential parameters: evaluation of the RQ and documentation 
that steady state has been achieved. The RQ should be within the physiologic range of 0.67 
to 1.3. [4, 6] 
 
Fat Oxidation Calculation 
Once the RMR has been calculated (see above) the amount of fat oxidized per day (both 
absolute g/day and relative g.kg-1.day-1 or g.kg-1FFM.day-1) can be calculated. 
1. Insert the average VO2 (L.min-1) and VCO2 (L.min-1) from the calculated  
RMR period into the equation of Frayn (1983): [7] 
Fat oxidation (g/min) = 1.67(VO2) - 1.67(VCO2) 
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2. Multiply by 1440 (i.e. number of minutes in a day) to get total grams of fat oxidized 
per day. 
3. Divide by naked body weight (kg) and/or fat free mass (FFM) calculated from the 
BIA to determine the relative daily fat oxidation rate (i.e. g.kg-1.day-1). 
4. Example: Subject 1 (BM = 98kg, FFM = 68 kg) has resting VO2 = 0.283 L.min-1, 
VCO2 = 0.221 L.min-1, RER = 0.78 
Fat oxidation (g/min) = 1.67 × 0.283 – 1.67 × 0.221= 0.104 
Fat oxidation (g/day) = 0.104 × 1440= 149.8 
Fat oxidation (g.kg-1.day-1) = 149.8 ÷ 98= 1.529 
Fat oxidation (g.kgFFM-1.day-1) = 149.8 ÷ 68= 2.203  
 
Data Extraction from Medgraphics 
 Open Patient file 
 Select Patient 
 Select a visit (should be either resting or treadmill: select resting) double click 
 You are now in “ Visit Demographics” 
 Select “GX” tab (bottom of screen) 
 You are now in “Settings” 
 Select “Test” tab 
 You are now looking at the data in spreadsheet and/or graph form 
 Select the data on the spreadsheet       Right click       copy         paste 
into 
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Excel spreadsheet for further analysis. 
If further data is required that is not displayed in the columns of the spreadsheet 
� Click of “Tools” 
� Select “Options” 
� In the “Test” tab go to “configuration” 
� In the drop-down list select “RMR Analysis (Raw)” 
� In the “Averaging” box select “Unaveraged” and click “OK” 
� Click on any column heading, a drop down list will appear, scroll through the 
list and select the data you want. 
� Copy and paste into Excel. 
 
Environment data extraction from Medraphics 
All environmental data (ambient temperature, relative humidity and barometric pressure) 
typed in for each test is saved by Medgraphics. To extract this data: 
� Click on the “Calibration” button (top of screen) 
� You are now in the pneumotach calibration screen 
� Click on the “Cal Log” buttom (bottom left of sceen) 
� From the list double click on the test that is required and all environmental data will 
be there 
Possible outliers and spurious data 
Some RMR data may have RER values >1. Some possible explanations for this are: 
1. Bad calibration of Medgraphics 
2. Patient is hyperventilating resulting in CO2 being blown off. This increases 
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the RER via a non-metabolic source of CO2. Some reasons for hyperventilation are: 
i. Anxiety or stress 
ii. A reaction to wearing the mask 
iii. Obese patients lying on their back can experience dyspnoea 
iv. Patients with mild COPD who suffer from dyspnoea 
2. Patient may fall asleep. If they suffer from sleep apnoea the patient will not breathe 
for periods of 20-60s followed by a period hyperventilation. 
 
Monitor patient closely to prevent sleep. 
4. Some patients may have rapid but shallow breathing. The Medgraphics has a default 
setting for tidal volume (Vt) of 180ml. Any breathe less than this will not be shown on 
the screen resulting in gaps as large as 2 minutes. The default value can be changed 
retrospectively in the software to include all breathes. Go to the “settings” page to 
change Vt default setting before loading the file. 
5. The data output on the screen needs to be monitored in order to observe any large 
gaps between breathes. Check patient is awake and mask is properly positioned. 
 
Bland-Altmann analyses of fat oxidation methods  
Data of the first 20 subjects (55 files) in G2D study were used to look at differences 
between different equations from the literature and the Medgraphics output for fat 
oxidation rates. Equations used were Frayn (1983)7, Jequier et al. (1987) [8] and 
Consolazio et al. (1963)9. These were also compared to the Medgraphics output. 
Note: the 3 equations are very similar. The Frayn (1983) equation was therefore selected 
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as it is the most cited. 
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BLOOD TEST #1 (FASTING) 
Blood sample preparation, analysis, storage and shipment 
 Blood Insulin, Glucose, Total cholesterol, LDL, HDL, triglycerides  
 Blood should be collected on a 10 ml serum tube (gel tube or clot activated) which 
is labelled with subjects name, study ID number, sample type (Ins, Glu, Chol, etc.), 
date and visit number (ie. Baseline = Visit 1; 6 months = Visit 2; 12 months = Visit 
3). 
 Record the time sample is drawn, and the time it is spun. 
 Tubes should be left to clot at room temperature for 30 minutes. Do not allow 
clotted samples to sit for more than 1 hour (if possible). Spin the tube in a 
refrigerated centrifuge (H107, Sorvall centrifuge, 3400rpm, 10min at 4°) and leave 
it in on ice until collection. 
 
Full blood count and blood HbA1c samples (Purple top) 
 Samples should be collected in a 10 ml EDTA (purple top) tube,  
 Samples must be clearly labelled with subjects name, study ID number, sample type 
(ie. FBC + HbA1c) and identified as to which visit they represent (ie. Baseline = 
Visit 1; 6 months = Visit 2; 12 months = Visit 3) 
 Samples can be stored on ice with the previous sample until time of pickup by 
courier. 
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Shipment procedure 
 Samples will be picked up by a courier and transported on dry ice. 
 Samples must be accompanied by a spreadsheet detailing the subject initials, study 
ID 
 Number, sex, date of birth, date of collection and time of collection. The 
spreadsheet will be provided by the Laboratory. 
 
Delivery should be organized prior to the visit by contacting DHM courier on  
9855 5200 
 
Blood test results 
Blood results are available electronically and via the mail within 1-3 days of blood  
collection. To view the results electronically, visit http://www.dhm.com.au 
"Online Services for Doctors" 
"Webster" 
"Log-in here" 
Username: XXXXXX 
Password: XXXXXX 
Serum C-peptide (Red top) 
 Serum C-peptide should be collected in a 10 ml serum (red top) tube after the 
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subject has fasted for 12 hours. 
 The tube must be labelled with subjects name, study ID number, date and visit 
number (ie. Baseline = Visit 1; 6 months = Visit 2; 12 months = Visit 3). 
 The tube should be left to clot at room temperature for 30 minutes.  Do not allow 
clotted samples to sit for more than 1 hour (if possible).  
 Centrifuge in a refrigerated centrifuge (found in H107, Sorvall centrifuge, 3400rpm, 
10 min at 4°) and pipette 3ml of serum that you transfer into a 4ml plastic tube. The 
tube must be labeled with subject name, study ID number. 
 Freeze it in liquid nitrogen,and store it in the -20° freezer in H block, room H107 
until collection. 
 The rest of the serum should be transferred to 1.5ml eppendorfs  (0.5ml per 
eppendorf) and labeled with subjects name, study ID number and type of sample 
(spare sample 1, 2, etc.). These tubes should be placed inside a GREAT2DO freezer 
box, and stored in –80 freezer in H block, room H108 until analysis. 
 
CRP Analysis 
CRP analyses are performed by Bernhard Baune’s laboratory at the University of  
Adelaide, Adelaide SA. Organise 1 eppendorf containing serum from each participant, at 
each time point to be analysed for CRP, and place them inside a cryogenic box to prepare 
for shipping. Samples should be shipped with an accompanying list to help the laboratory 
identify the samples inside. Organise a courier to transport the samples. The following 
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courier is recommended http://www.worldcourier.com/locations/australia.  
Serum samples should be shipped to the following address: 
Prof. Bernhard Baune 
Psychiatric Neuroscience Laboratory 
Attention: Dr. Catharine Jawahar / Dr. Emily Jaehne 
Level 4, Medical School South 
University of Adelaide 
Frome Road 
Adelaide – 5005 
Tel: 61 8 8222 5141 
Fax: 61 8 8222 2774 
 
Human C-reactive Protein Instant ELISA (eBIOSCIENCE) 
Description 
The human C-reactive protein Instant ELISA is an enzyme-linked immunosorbent assay 
for the quantitative detection of human C-reactive protein. The human C-reactive protein 
Instant ELISA is for research use only. Not for diagnostic or therapeutic procedures. 
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Sensitivity: 3.0 pg/ml 
Sensitivity limit is comparable to other high sensitivity ones: 
hsCRP Human ELISA (BioVendor) 0.02 μg/ml 
IBL Immuno-biological laboratories CRP high sensitive ELISA 0.124 ng/ml 
 
SI unit: mg/l 
For comparison: 
1. Haider et al. C-reactive protein is expressed and secreted by peripheral blood 
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mononuclear cells. Clinical & Experimental Immunology. 2006; 146:533-539. 
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2006.03224.x/full  
2. Memoli at al. Inflammation may modulate IL-6 and C-reactive protein gene expression 
in the adipose tissue: the role of IL-6 cell membrane receptor. Endocrinology and 
Metabolism. 2007; 293:E1030-E1035.  
http://ajpendo.physiology.org/content/293/4/E1030.full (Table 1) 
3. Lekakis et al. Divergent effects of rofecoxib on endothelial function and inflammation 
in acute coronary syndromes. International Journal of Cardiology. 2006; 112:359-366. 
http://www.sciencedirect.com/science/article/pii/S0167527305012532 
 
Expected Values 
A panel of 8 sera from randomly selected healthy donors (males and females) was tested 
for human C-reactive protein. The detected human C-reactive protein levels ranged 
between 136 and 800 ng/ml with a mean level of 381 ng/ml and a standard deviation of 
214 ng/ml. (136 ng/ml = 0.136 mg/l) 
 
Coefficient of Variation 
Absorbance values from duplicates are allowed to be less than 20%. 
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Table 1: Intra- and inter-assay CV in % 
Intra-assay CV (%)    Inter-assay CV (%) 
Plate 1     6.3      24.5 
Plate     2 3.8 
Plate     3 7.5 
Plate     4 8.2 
Plate     5 6.1 
Plate     6 4.9 
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Serum adiponectin  
 
Collection and storage 
 Serum adiponectin should be collected in a 10 ml serum (red top) tube after the 
subject has fasted for 12 hours. 
 Each tube must be labelled with subjects name, study ID number, sample type (ie. 
Adiponectin), date and visit number (ie. Baseline = Visit 1; 6 months = Visit 2; 12 
months = Visit 3). 
 Tubes should be left to clot at room temperature for 30-60 minutes.  Do not allow 
clotted samples to sit for more than 1 hour (if possible).  
 Centrifuge in a refrigerated centrifuge in a refrigerated centrifuge (found in H107, 
Sorvall centrifuge, 3400rpm, 10min at 4°) and pipette 0.5ml of serum into 5 
different 1.5 ml microfuge (Eppendorf) tubes. Each tube must be labelled with 
subjects name, study ID number and type of sample (adiponectin). Pipette the rest 
of the serum in different Eppendorfs (0.5ml per Eppendorf) and label it with 
subjects name, study ID number and type of sample (spare sample 1, 2, etc.). 
 Store samples at 4oC until all samples from subject are prepared.   
 Store all samples for each subject together in -80o freezer in GREAT 2 Do Freezer 
boxes until time of analysis in batches. 
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Shipment procedure 
 Samples will be picked up by a courier and transported on dry ice.  
 Samples must be accompanied by a spreadsheet detailing the subject initials, study 
ID number, sex, date of birth, date of collection and time of collection. The 
spreadsheet will be provided by the Laboratory as a PDF file with all the 
information except the ones above that will need to be filed. 
 Samples should be shipped with an accompanying list to help the laboratory 
identify the samples inside. Organise a courier to transport the samples. The 
following courier is recommended 
http://www.worldcourier.com/locations/australia.  Serum samples should be 
shipped to the following address: 
Prof. Bernhard Baune. 
School of Medicine and Dentistry,  
James Cook University (Townsville, QLD, Australia) 
 
Human Adiponectin Immunoassay 
Introduction  
The Quantikine Human Total Adiponectin Immunoassay is a 4.5 hour solid-phase enzyme-
linked immunosorbent assay (ELISA) designed to measure total (low, middle, and high 
molecular weight) human Adiponectin in cell culture supernates, serum, and plasma. It 
contains NS0-expressed recombinant human adiponectin and has been shown to accurately 
quantitate the recombinant factor. The human adiponectin Immunoassay is for research use 
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only. Not for diagnostic or therapeutic procedures. 
Principle of the assay 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for the Adiponectin globular domain has been pre-coated 
onto a microplate. Standards and samples are pipetted into the wells and any Adiponectin 
present is bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked monoclonal antibody specific for the Adiponectin globular 
domain is added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and color develops in proportion to the 
amount of Adiponectin bound in the initial step. The color development is stopped and the 
intensity of the color is measured. 
 
Sensitivity 
Eighty assays were evaluated and the minimum detectable dose (MDD) of Adiponectin 
ranged from 0.079 - 0.891 ng/mL. The mean MDD was 0.246 ng/mL. 
 
Sample values 
Serum samples drawn from apparently healthy volunteers were evaluated for the presence 
of adiponectin in this assay. 
Sample Type Mean (ng/mL) Range (ng/mL) Standard Deviation 
(ng/mL) 
Serum (n=60) 6641 6641  865 - 21,424  3665 
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Precision 
Intra-assay Precision (Precision within an assay): Three samples of known concentration 
were tested twenty times on one plate to assess intra-assay precision. 
Inter-assay Precision (Precision between assays): Three samples of known concentration 
were tested in forty separate assays to assess 
 
Inter-assay precision. 
 Intra-assay Precision  Inter-assay Precision 
Sample 1 2 3  1 2 3 
n 20  20 20  40 40 40 
Mean (ng/mL) 19.8  69.9  143  20.5 20.5  157 
Standard Deviation 
(ng/mL) 
0.50  2.40 6.76  1.4 4.3 10.8 
CV% 2.5  3.4 4.7  6.8 5.8 6.9 
 940 
 
DEMOGRAPHICS 
Gender  Male 
 Female 
 
Race / Ethnic Background 
What is your ethnic background? 
 
 Caucasian 
 Asian 
 Aboriginal 
 Indian 
 Middle East 
 Black 
 Other ____________________ 
 
Marital Status 
Are you married, widowed, divorced, 
separated, never married? 
 
 
 Married / Defacto 
 Widowed 
 Divorced 
 Single / Never Married 
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 Separated 
 
Residence 
In what type of accommodation do you live? 
 
 
 
 
 
 
 
How long have you lived at this address? 
 
 House (own) 
 House (rented) 
 Unit (own) 
 Unit (rent) 
 Retirement Village 
 Hostel 
 Nursing Home 
 Board / Rooming House 
 
___________ Years 
___________ Months 
 
 
Living Situation 
With whom do you live? 
 
 Alone 
 Spouse / Partner 
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Total number of people in the household 
 
 Family 
 Paid Carer 
 Friend 
 Other Residents 
 
___________ People 
 
Education 
What is the highest grade or year of school 
you completed? 
 
 Never / Kindergarten 
 Primary School 
 High School 
 Tertiary / Undergraduate 
 Post Graduate 
      Year 1   2   3   4   5   6   7   
8    9   10                  
        11 12 13 14 15 16 17 18  19  20   
Work 
Do you currently work for pay either for 
yourself or someone else? 
 
 Yes (_________ hours / week) 
 No 
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Do you currently work as a volunteer? 
 
 
 Yes (_________ hours / week) 
 No 
 
Annual Income 
In what range is your annual income? 
 
 < $15,000 
 $15,000 - $30,000 
 > $30,000 
 
Private Health Insurance 
Do you have private health insurance? 
 
 Yes 
 No 
 
 
Hospital Admissions 
During the past 12 months, how many 
different times did you stay in hospital 
overnight? 
 
 
__________ Number of times 
__________ Number of days in  
                     hospital 
Smoking  
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Have you ever smoked cigarettes, cigars or 
a pipe on a daily basis? 
 
Do you currently smoke at least 1 cigarette, 
cigar or pipe per day? 
 
 Yes (__________ number / day) 
 No 
 
 Yes 
 No 
Alcohol  
During the past 30 days, about how many 
days did you drink any alcoholic beverages 
(beer, wine, spirits)? 
 
 Almost every day 
 3-4 times a week 
 Once or twice a week 
 2-3 times a month 
 Once a month 
 None 
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GERIATRIC DEPRESSION SCALE 
SCORING INSTRUCTIONS 
1. USE THE TRANSPARENCY TEMPLATE WITH ALL THE NON-DEPRESSED 
ANSWERS BLACKENED. 
2. PLACE TRANSPARENCY OVER QUESTIONNAIRE; ALL “DEPRESSED” 
ANSWERS WHICH ARE CHECKED WILL SHOW THROUGH THE CLEAR 
BOXES. 
3. COUNT THE NUMBER OF CHECKED DEPRESSED ANSWERS. 
4. THIS IS THE SCORE OF THE GDS (RANGE 0-30) 
 
TOTAL SCORE AS WELL AS CATEGORICAL SCORE SHOULD BE ENTERED INTO THE 
DATABASE: 
 0-9 = NORMAL 
 10-19 = MILD DEPRESSIVE SYMPTOMS 
 20-30 = SEVERE DEPRESSIVE SYMPTOMS
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TRAIL MAKING TEST A 
Hand the participant the “Trail Making-Sample A” Sheet and a pencil with an eraser. 
 
Say to the participant: 
“On this page are some numbers. Begin at number 1 (point to 1) and draw a line to number 
2 (point to 2), 2 to 3 (point to 3), 3 to 4 (point to 4), 4 to 5 (point to 5), and so on in order, 
until you reach the end (point to the circle marked “End”). Draw the lines as fast as you 
can. Ready? Begin.” 
 
If the participant makes a mistake point out the error and explain it. If necessary guide the 
participant’s hand through the trail, eraser end down. Then say “Now you try it,” and repeat 
the original directions starting with “Begin at number 1…” Repeat instructions with 
guidance twice. 
 
If the participant completes the sample item correctly and shows that he/she understands 
the task say, “Good! Let’s try the next one.” If the participant still does not understand, 
terminate Trail Making Test A and go on to Trail Making Test B. 
Hand the participant the “Trail Making Test A” Sheet. 
 
Start timing as soon as the instruction is given to begin. Allow a maximum of 300 seconds 
for the task. WATCH CLOSELY IN ORDER TO CATCH ANY ERRORS AS THEY ARE 
MADE. If the participant makes an error, identify it immediately, draw a perpendicular line 
through the incorrect line and tell him/her to proceed from the number where the mistake 
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occurred. DO NOT STOP TIMING. 
 
If the participant goes over the 300 seconds, stop and go to the next cognitive function test. 
Record time taken on the sheet.
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TRAIL MAKING TEST B 
Hand the participant the “Trail Making Sample B” Sheet and a pencil with an eraser. 
 
Say to the participant: 
“On this page are some numbers and letters. Begin at number 1 (point to 1) and draw a line 
to A (point to A), A to 2 (point to 2), 2 to B (point to B), 3 to C (point to C), and so on in 
order, until you reach the end (point to the circle marked “End”). Remember, first you have 
a number (point to 1), then a letter (point to A), then a number (point to 2), then a letter 
(point to B) and so on. Draw the lines as fast as you can. Ready? Begin.” 
 
If the participant makes a mistake explain the rules in exactly the same way you did for the 
previous test. 
 
Hand the participant the “Trail Making Test B” Sheet. 
 
Start timing according to the same instruction given for the previous test. If the participant 
goes over 300 seconds, stop and go to the next cognitive function test.
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TRAIL MAKING TEST A SCORING SHEET 
 
 NOT DONE 
 
Number of circles connected (maximum 25):  __________ 
 
Total time (maximum 300 seconds):   __________ 
 
Errors:       __________ 
 
TRAIL MAKING TEST B SCORING SHEET 
 
 NOT DONE 
 
Number of circles connected (maximum 25):  __________ 
Total time (maximum 300 seconds):   __________ 
Errors:       __________ 
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TRAIL MAKING Part B 
 
SAMPLE 
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MODIFIED MINI MENTAL STATUS (3MS) EXAMINATION 
ADMINISTRATION AND SCORING  
ADMINISTRATION AND SCORING 
A summary form for the administration and scoring of the 3MS is presented in the 
Appendix and can be reproduced on one side of a standard (8.5 in. x 11 in.) sheet of paper.  
3MS is a revision of the MMS that includes four additional items (date and place of birth, 
word fluency, similarities, and delayed recall of words) to sample a wider range of 
cognitive abilities an expended range of scores from 0-30 to 30-100.  On the back side of 
the same sheet, CLOSE YOUR EYES (all in capital letters, approximately 12 in. high) can 
be printed in the upper part, and two intersecting pentagons (each side 1 in, long) can be 
drawn in the lower part.  Enough blank space is left to record the participant's drawing 
and writing.   
 
Testing procedures and scoring criteria that either do not differ from the original MMS or 
are self-evident in the summary form are not repeated here.  Clarifications, important 
aspects of administration, and comments on the differences between the MMS and the 3MS 
are presented.  Instructions enclosed in quotation marks and printed in capital letters 
should be follow verbatim.   
 
Date and Place of Birth 
Assign one point each to the year, month, and date, City or town, and state of birth.  This 
item is added to provide some measure of the subject's recall of personal information that 
one can assume to have been overlearned. 
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Registration 
"I SHALL SAY THREE WORDS FOR YOU TO REMEMBER.  REPEAT THEM 
AFTER I HAVE SAID ALL THREE WORDS   SHIRT   BROWN   HONESTY."  
If a person is tested repeatedly, the alternatives of "shoes, black, modesty" and "socks, blue, 
char in." May be used in successive test sessions.  However, whether or not the three 
alternate forms are comparable has yet to be determined.   
 
The MMS procedure permits the use of the names of any three objects, thus allowing wide 
variations in item difficulty.  The 3MS procedure specifies the three words to reduce the 
variation.  The inclusion in the 3MS of a low frequency abstract word, honesty, is 
intended to broaden the range of difficulty.   
  
Mental Reversal 
First establish the subject's ability to recite in the forward direction, coaching him or her 
once if needed.  Then ask the subject to recite in the reverse direction.  Score for the 
number of elements in correct relative position.  Score 0, if after being coached, the 
subject is still unable to recite in the usual direction.   
 
The relatively easy item of counting backward from 5 to 1 is added to introduce the task 
and to extend the lower range of the test.   
 
The corresponding MMS item of "Attention and Calculation" permits two choices of 
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testing: either by spelling "world" backward or by five serial subtractions of 7.  However, 
the equivalence between the two alternatives in the composition of mental operations has 
not been demonstrated.  The serial subtractions are more difficult and are more affected 
by the subject's educational background; therefore.  This alternative is eliminated from 
the 3MS.  
  
First Recall  
First ask, "WHAT ARE THE THREE WORDS THAT I ASKED YOU TO REMEMBER?"  
 
For each word not recalled, provide a category cue (e.g., "something to wear"); if the 
subject still cannot give the correct answer, provide three choices (e.g., "shoes, shirt, 
socks").  Use only the specified cues and choices.  If the subject does not give the correct 
answer from the three choices, score 0 and provide the correct answer.   
 
The MMS gives credit only for unaided recall.  To extend the lower range of the test, the 
3MS also gives credit for correct responses after the subject has received category-cueing 
and after being given multiple choices.   
  
Temporal Orientation  
The MMS dichotomises the response to each of the five subitems as correct or incorrect.  
The 3MS assigns scores according to the closeness of the response to the correct answer.  
Graded scoring of temporal orientation has been found to be highly sensitive for detecting 
abnormal mental decline in old persons.'  
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Temporal orientation is scored in a negative manner.  For example, most nondemented 
persons know the year; assigning 8 points for the year means that not knowing the year 
will be penalised for up to 8 points.  
  
Spatial Orientation 
For the last subitem, ask, "ARE WE IN A HOSPITAL OR OFFICE BUILDING OR 
HOME?" If the correct answer is not among those three choices, substitute the correct 
answer for the second choice, office building.   
 
The MMS asks for the name of the hospital, but reporting the hospital's name has a high 
memory component and may not be applicable in some circumstances, such as when a 
subject is tested in his or her home.  The 3MS procedure simply provides three 
alternatives for the subject to choose from.  The MMS item for floor is eliminated because 
the correct identification of the floor is pan influenced by the total number of floors in a 
building,  
  
Naming  
Point to a pan of your own body and ask the subject name it.  Score 0 if the subject cannot 
name it ready gives an incorrect name.  Do not wait for the subject to mentally search for 
the name.  Body parts are used to ensure equal familiarity b, subjects.  According to the 
Kucera-Francis word count the frequencies of occurrence in approximately important 
words for "shoulder," "chin," "forehead;' bow," and "knuckle" are 61, 27, 16, 10, and 3, 
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restively.  The corresponding frequencies for the MMS w of "watch" and "pencil" are 81 
and 34, respective:  
 
Four-Legged  
Ask, "WHAT ANIMALS HAVE FOUR LEGS?" allow 30 seconds for the response.  If 
the subject gives no response in 10 seconds, the question once.   
 
The first time an incorrect answer is provided, say “I WANT FOUR-LEGGED 
ANIMALS."  Do not correct subsequent errors.  Score for the number of correct 
responses, up to 10.  This item is added because fluency of retrieval from specified 
category has been demonstrated to be sensitive in differentiating between normal and early-
dementia states.  
  
Similarities 
Ask, "IN WHAT WAY ARE AN ARM AND A LEG I ALIKE?" If the subject fails to give 
an answer that worth 2 points, assign the appropriate score of 1 or 0, do coach the subject 
by saying that an arm and a leg either limbs or parts of the body.  Do not coach for the, 
sequent two subitems.  This item is added to sample abstraction or conceptual thinking 
that is relatively unrelated to category retrial but that is impaired in dementia.  
  
Repetition 
First say, “REPEAT WHAT I SAY, 'I WOULD L TO GO HOME/OUT.”  Pronounce the 
individual word clearly but with the normal tempo of a spoken sentence (i.e., without 
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artificial slowing or pausing after forward).  Use "home" in the sentence if the subject is 
at home; otherwise, use "out.” 
 
Next say, "NOW REPEAT, 'NO IFS, ANDS, OR BUTS.' "Again, use the normal tempo of 
a spoken sentence.  Assign 1 point each for "no ifs," "ands,” "buts."  Give no credit if 
the subject misses the "s."  The first sentence is added to extend the lower rang the test 
and to help establish the subject's mental se repeating  
 
Read and Obey "Close Your Eyes"  
Hold up the piece of paper on which the command printed and say, "PLEASE DO THIS." 
If the subject not close his or her eyes within 5 seconds, prompt him or her by pointing to 
the sentence and saying, "READ AND DO WHAT THIS SAYS." If the subject has already 
read the sentence aloud spontaneously, simply say, "DO WHAT THIS SAYS." Allow 5 
seconds for the response.  Assign a score of 1 if the subject reads the sentence either 
spontaneously or after the examiner's request, but does not close the eyes. 
  
Writing 
For this and the following item, provide the subject a soft (No. 2) pencil with an eraser 
attached.  Ask the subject to write, "I would like to go home/out." Repeat the sentence, 
word by word if necessary, but a maximum of 1 minute after the first reading of the 
sentence for the response.  Either printing or cursive writing is allowed.  Assign 1 point 
for each correct word, but give no credit for "I."  Each word needs to be completely 
correct to earn 1 point.  DO not penalise self-corrected errors.  If the writing is 
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ambiguous, judge whether or not the word can be readily recognised in isolation.  The 
MMS calls for a written sentence generated by the subject and gives a score of 1 or 0 for 
the whole product.  The subject may fail because he or she is unable to generate a sentence 
or unable to write or both.  Recent reports indicate that the inability to write is the more 
limiting component for this item, and the loss of the ability to write is associated with a 
higher familial incidence of dementia.  The 3MS item more specifically measures the 
ability to write a standard dictated sentence, and it permits a range of scores from 0 to 5.   
  
Copying two Intersecting Pentagons. 
Allow 1 minute for copying.  In scoring, do not penalise for self-corrected errors, tremors, 
minor gaps, or overshoots.  For each five-sided enclosure, assign a score of 4 unless the 
longest side is more than twice the length of the shortest side, in which case assigned a 
score of 3.  A non-pentagon enclosed figure is given 2 points.  Two or more line 
segments that do not form an enclosure are given 1 point.  A four-cornered intersection is 
given 2 points.  An intersection with other than four comers receives 1 point.  The 0-10 
graded scoring for this item in the 3MS replaces the 0-1 dichotomous scoring of the MMS.  
In the MMS only this one point is given to a nonverbal task.   
  
Three-stage Command 
Hold up a piece of white paper in plain view of the Subject but out of his or her reach and 
say, "TAKE THIS PAPER WITH YOUR LEFT [for a left-handed person, Say RIGHT] 
HAND, FOLD IT IN HALF, AND HAND BACK TO ME."  
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After saying the whole command, hold the paper Within reach of the subject.  Do not 
repeat any part of the command.  Do not give visual cues for the subject to return the 
paper, such as keeping a hand in a ready- receive posture.   
 
The first part of the command asks the subject to use the nonpreferred hand in order to 
avoid crediting 1 point by default.  The third part of the command is revised from the 
MMS for ease of administration.   
  
Second Recall  
Administer this item even if the subject has a score of 0 on the first recall.  Test and score 
in the same way as with the first recall.  The second recall is added to test the subject's 
memory after a longer interval than the first recall, and it is expected to extend the ceiling 
of the test.  The second recall may also help differentiate dementia of the Alzheimer type 
from other forms of dementia.  Although the distinction between cortical dementia and 
subcortical dementia has been questioned, patients with dementia of the Alzheimer type 
show a clearly faster rate of forgetting between two recall tests than do patients with 
Huntington's disease.  
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Read and Obey "Close Your Eyes" Hold up the piece of paper on which the comma printed 
and say, "PLEASE DO THIS." If the subject (“Where were you born?”) 
1. “Where were you born?” Record responses 
Correct 
answer 
Error / 
refused 
City / town _______________ 1 0 
State / county _______________ 1 0 
    
2. “When were you born?” Record responses 
Correct 
answer 
Error / 
refused 
Day _______________ 1 0 
Month  _______________ 1 0 
Year _______________ 1 0 
3. “I am going to say three words for you to remember. Repeat them after I have said 
all three words: Socks, blue, charity.” 
Do not repeat the words for the participant until after the first trial. The participant may 
give the words in any order. If there are errors on the first trial, repeat the items up to three 
times until they are learned. 
 First trial only: 
Correct 
answer 
Error / 
refused 
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a. Socks  1 0 
b. Blue  1 0 
c. Charity  1 0 
d. number of presentations necessary for the 
participant to repeat the sequence (choose 0-
3) 
   
    
4. “Count from 1 to 5.”    
    Able to count forward    
    Unable to count forward (if unable to count forward, say “1-2-3-4-5”) 
“Now count backwards from 5 to 1.”    
Record the responses in the order given:    
 
First number        __________ 
2    Accurate Answer   
 
Second number   __________ 
1    1-2 errors   
 0    > 2 errors   
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Third number       __________ 
 
Fourth number    __________ 
   
 
Fifth number        __________ 
 
 
  
 
3MS Page 1, Score: __________ 
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5. “Spell ‘world’.”    
     Able to spell    
     Unable to spell (say “It’s spelled W-O-R-L-D”) 
“Now spell ‘world’ backwards.” Examples (not only possibilities): 
Record the letters in the order given:  5 DLROW 
 
First letter        
__________ 
4  DLORW, DLWRO, DROW, DLOW, 
DRLOW 
 
Second letter   __________ 
3    DORW, DOLW, DORLW, DRLW 
 
Third letter       __________ 
2    DOR, DL, DW 
 
Fourth letter     __________ 
1    D 
 
Fifth letter        
__________ 
0    No response 
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6. “What three words did I ask you to remember earlier?”   
The words may be repeated in any order   
If the participant cannot give the correct answer after a category cue, provide the three 
choices listed. 
If the participant still cannot give the correct answer from the 3 choices, mark 0 and provide 
the correct answer. 
a. Socks 3    spontaneous recall 
2    after “Something to wear” 
1    after “Was it shirt, shoes or socks?” 
0    still incorrect / refused (provide correct 
answer) 
b. Blue 3    spontaneous recall 
2    after “A colour” 
1    after “Was it blue, black or brown?” 
0    still incorrect / refused (provide correct 
answer) 
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c. Charity 3    spontaneous recall 
2    after “A good, personal quality” 
1    after “Was it honesty, charity or 
modesty?” 
0    still incorrect / refused (provide correct 
answer) 
3MS Page 2, Score: __________ 
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7. “What is today’s date?” Record response. Enter ‘X’ if no 
response. Probe for the month, day or year if it is not volunteered. 
  
Month __________ 
2    Accurate or within 5 days 
1    Missed by 6 days to 1 month 
0    Missed > 1 month 
Day    __________ 
3    Accurate 
2    Missed by 1-2 days 
1    Missed by 3-5 days 
0    Missed by > 5 days 
Year  __________ 
8    Accurate 
4    Missed by or within 1 year 
2    Missed by or within 2-5 years 
0    Missed by > 5 years 
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8. “What is the day of the week?” 
Record answer in error. 
Enter ‘X’ if no response 
Correct 
answer 
Error / 
refused 
 
Day of the week _______________ 
 1 0 
9. “What season of the year is it?” 
Record answer in error. 
Enter ‘X’ if no response 
Correct 
answer 
Error / 
refused 
 
Season _______________ 
 1 0 
    
10. “What state are we in?” 
Record answer in error. 
Enter ‘X’ if no response 
Correct 
answer 
Error / 
refused 
 
State _______________ 
 
 1 0 
11. “What county (suburb) are we 
in?” 
Record answer in error. 
Enter ‘X’ if no response 
Correct 
answer 
Error / 
refused 
 
County _______________ 
 1 0 
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12. “What city/town are we in?” 
Record answer in error. 
Enter ‘X’ if no response 
Correct 
answer 
Error / 
refused 
City/town _______________  1 0 
 
13. “Are we in a store, medical clinic (hospital) or home?” 
Correct 
answer 
Error / 
refused 
If the correct answer is not among the three alternatives (eg 
university), substitute is for the middle alternative.  
If the participant states that none is correct, ask them to make the best 
choice of the three options. 
1 0 
 
 
   
14. Point to the part of your own body and ask the participant to name 
it. Score 0 is the participant cannot name it within 2 seconds or gives 
an incorrect name. Do not wait for the participant to mentally search 
for the name. 
 
Correct 
answer 
Error / 
refused 
a. forehead: “What do you call this part of the face?” 1 0 
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b. chin: “… And this part?” 1 0 
c. shoulder:  “… And this part of the body?” 1 0 
d. elbow: “… And this part?” 1 0 
e. knuckle: “… And this part?” 1 0 
 
 
   
15. “What animals have four legs? Tell me as many as you can.”   
Discontinue after 30 seconds. Count all the correct response. If the participant gives no 
response in 10 seconds, and there are at least 10 seconds of remaining time, gently remind 
(once only) “What (other) animals have four legs?” The first time an incorrect answer is 
provided, say “I want four legged animals”. Do not correct subsequent errors. 
 
_______________          
_______________ 
   
 
_______________          
_______________ 
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_______________          
_______________ 
 
_______________          
_______________ 
   
 
_______________          
_______________ 
   
 
_______________          
_______________ 
   
 
_______________          
_______________ 
   
 
3MS Page 4, Score: __________ 
Introduce by saying: “An apple and a banana are alike in that they are both fruit.” 
 
 971 
 
16. “In what way are an arm and a leg 
alike?” 
Response: 
___________________________ 
If the participant fails to give an answer that is 
worth 2 points mark the appropriate score of 1 
or 0. If the answer is not worth 2 points, coach 
the participant by saying “An arm and leg are 
both limbs or extremities.” Do not coach 
questions 17 & 18. 
2    limbs, extremities, parts of the body 
1 lesser correct answer (eg both bend, 
have joint or bones, long, move) 
0 error (eg states differences, useful, 
gives unrelated answer) / refused 
    
17. “In what way are laughing and crying 
alike?” 
Response: 
___________________________ 
Do not coach. 2    (expressions of) feelings, emotions 
 
1 lesser correct answer (eg sounds, 
expressions, involve the mouth) 
 
0 error (eg produces tears, states 
differences, gives unrelated answer, 
sometime you laugh, sometimes you 
cry) / refused 
18. “In what way are eating and sleeping 
alike?” 
2 necessary bodily functions, essential 
for life 
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1 lesser correct answer (eg bodily 
functions, relaxing, “good for you”, 
refreshing, enjoyable daily activities, 
“I like both”) 
 
3 error (eg states differences, gives 
unrelated answer) “I don’t know” / 
refused 
 
19. “Repeat exactly what I say: ‘He would 
like to go home.’” 
Response: 
___________________________ 
 2    correct 
 1    1 or 2 words missed or wrong 
 
0 3 or more words missed or wrong 
words / refused 
 
20. “Now request: ‘No ifs ands or buts.’” 
correct answer error / refused  
a. no ifs 1 0  
b. ands 1 0  
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c. or buts 1 0  
3MS Page 5, Score: __________ 
 
21. Hold up Worksheet 1 and say “Please do 
this.” 
3    obeys without prompting 
 
2    closes eyes after prompting 
 1    reads aloud, but does not close eyes 
If the participant does not close his / her eyes 
within 5 seconds, prompt by pointing to the 
sentence and saying “Read and do what this 
says.” If the participant has already read the 
sentence aloud spontaneously, simply say, 
“Do what this says.” 
0 does not read aloud or close eyes / 
refused 
Allow 5 seconds, for the response. Mark 1 if the participant read the sentence aloud, either 
spontaneously or after your request, but does not close his / her eyes. As soon as the 
participant closes his / her eyes, say “Thanks, You can open your eyes now.” 
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22. I would like to have a sample of your handwriting. Write ‘He would like to go 
home.’” 
Hand the participant Worksheet 2 and a #2 pencil with eraser. If necessary, repeat the 
sentence word by word as the participant writes. Allow a maximum of 1 minute after the 
first readying of the sentence for the second response. If at the end of 1 minute the subject 
is still writing, consider allowing him / her to finish for the sake of rapport and morale, but 
mark the 1 minute point on the product using the scoring, and do not credit points finished 
after 1 minute. 
Either printing or cursive writing is allowed. Assign 1 point for each correct word, but no 
credit for “He.” For each word, mark 0 is there are spelling errors, or incorrect mixed 
capitalisations (all letter printed in uppercase is permissible). Do not penalize for self 
corrected errors.  
  
correct 
answer 
error / 
refused 
a. would  1 0 
b. like  1 0 
c. to  1 0 
d. go  1 0 
e. home  1 0 
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3MS Page 6, Score: __________ 
 
23. “Here is a drawing. Please copy the drawing onto this piece of paper.” 
Hand the participant Worksheet 3. For right-handed participants, present the sample on 
their left side. For left-handed, present the sample on their right side. Allow 1 minute for 
copying. In scoring, do not penalize for self correct errors, tremors, minor gaps or 
overshoots. If at the end of 1 minute he / she is still working on the task, consider allowing 
him / her to finish for sake of rapport and morale. Do mark the 12 minute point on the 
product during scoring, but do not credit parts finished after 1 minute. If the subject 
attempts more than 1 drawing due to dissatisfaction with the first one, score the better 
product completed within one minute. 
    
a. pentagon 1 
 
4    5 approximately equal sides 
3    5 sides, but longest : shortest side is 
>2:1 
2    nonpentagon enclosed figure 
1    2 or more lines, not an enclosure 
0    less than 2 lines / refused 
 
 976 
 
a. pentagon 2 
 
4    5 approximately equal sides 
3    5 sides, but longest : shortest side is 
>2:1 
2    nonpentagon enclosed figure 
1    2 or more lines, not an enclosure 
0    less than 2 lines / refused 
 
b. intersection 
 
2    4-cornered enclosure 
1    other than 4-cornered enclosure 
0    no enclosure / refused 
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24. Hold up Worksheet 2 in plain view of the participant but out of his / her reach, 
and say: 
 “Take this paper with you left (right for left-handed person) hand, fold it in half, and 
hand it back to me.” 
After saying the whole command, hold the paper within reach of the participant. Do not 
give visual cues for him / her to take or return the paper. He / She may hand it back with 
either hand. Do not repeat any part of the command. (“Sorry I cannot repeat. Just do 
what I think I asked you to do.”) If it is desirable to oblige for sake of maintaining a 
fragile rapport, score according to responses executed before the repat presentation of the 
command. He / She may fold the paper with both hands and may hand back the paper with 
either hand. 
  
correct 
answer 
error / 
refused 
a. takes paper in correct hand  1 0 
b. folds paper in half once  1 0 
c. hands paper back  1 0 
 
 
3MS Page 7, Score: __________ 
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25. “What three words did I ask you to remember earlier?” 
a. socks 3    spontaneous recall 
2    after “Something to wear” 
1    after “Was it shirt, shoes or socks?” 
0    still incorrect / refused (provide 
correct answer) 
b. blue 3    spontaneous recall 
2    after “A colour” 
1    after “Was it blue, black or brown?” 
0    still incorrect / refused (provide 
correct answer) 
c. charity 3    spontaneous recall 
2    after “A good, personal quality” 
1    after “Was it honesty, charity or 
modesty?” 
0    still incorrect / refused (provide 
correct answer) 
3MS Page 8, Score: __________ 
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Response scores at 
bottom of page 
 
Response scores at 
bottom of page 
 
Score Page 1 __________ Score Page 5 __________ 
 
Score Page 2 __________ Score Page 6 __________ 
 
Score Page 3 __________ Score Page 7 __________ 
 
Score Page 4 __________ Score Page 8 __________ 
    
 
Total Score (maximum 100): __________ 
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INTERVENTION AND SHAM EXERCISE GUIDELINES 
 
INTERVENTION AND SHAM EXERCISE GUIDELINES 
 
RANDOMISATION PROCEDURE 
After Assessment B is completed, a follow-up phone call is made to the patient to ascertain 
how the biopsy site is healing. Ask the patient if there is any bleeding, swelling, 
inflammation, significant redness or heat in the surrounding tissues, masses (or lumps) 
under the skin, opening of the skin edges, oozing of fluid from the incision or significant 
pain or numbness near the site. 
 
If the site is healing well, ask the patient if they are still willing to participate in the program. 
If the answer is yes, let them know that they will receive a call from Shelley to let them 
know what time on Monday they will have their first session at the Harbord Diggers. 
 
The Research Assistant (Kylie) will email Angela Lange (alan5625@mail.usyd.edu.au) 
with the following details: 
Patient’s Name, 
Gender, 
Whether or insulin dependent or non-insulin dependent 
Angela will email Shelley with the randomisation information and email the RA to advise 
that the subject has been randomised and the date of randomisation. 
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Shelley will call the patient back and let them know what time on the Monday they will 
meet at the Diggers. 
 
Subjects are randomised after the entire second baseline assessment has been completed to 
either the: 
Experimental PRT group 
OR 
SHAM exercise group 
Randomisation is at the level of the individual patient, and will be stratified by gender and 
use or non-use of insulin and carried out in blocks of 4. Written informed consent will be 
required prior to any testing or randomisation. The list will be generated and maintained 
by a research assistant not otherwise involved in the study. Assignments will be placed in 
sealed opaque envelopes and designated “Blue Group” for Experimental or “Green Group” 
for SHAM exercise. The sequential treatment assignments are based on a computer-
generated randomisation scheme (by using the Web site www.randomization.com set up 
by Dr Gerard E. Dallal). The subject will open these envelopes after completion of all 
baseline testing. Subjects who dropout prior to completion of baseline testing will not be 
randomized. 
 
Experimental PRT Group: 
Subjects in the experimental group will receive high intensity (~80% of 1 repetition 
maximum) PRT of 7 exercises for the major muscle groups, 3 days per week at Freshwater 
Rehabilitation at Harbord Diggers Memorial Club or at the STRONG Clinic, Balmain 
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Hospital for 12 months (see Progressive Resistance Training Guidelines). 
 
SHAM Group: 
Subjects in the SHAM group will receive low intensity, non-progressive training of 6 
similar exercises for the major muscle groups, 3 days per week at Freshwater Rehabilitation 
at Harbord Diggers Memorial Club for 12 months. 
 
PRT GUIDELINES 
Subjects in the experimental group will participate in high-intensity, progressive resistance 
training 3 days per week for 12 months under the supervision of an exercise physiologist. 
High intensity progressive resistance training is defined as training with 80% of the 
maximal weight (1RM) that can be lifted in good form, On the 3 days of the first week, the 
loads are 50%, 60% and 70% of the baseline 1RM. The target training intensity will then 
be maintained at approximately 80% of the most recently determined 1RM for each 
machine by progressively increasing the loads utilized as tolerated by the subject. 
 
Strength is re-tested every 4 weeks to establish a new 1RM. After the strength test, 1 set of 
exercises at the new weight can be performed to complete the training for that day. On all 
other days, 3 sets of 8 repetitions of each exercise are performed at the target load calculated 
for that day. 
 
The 1RM tests at baseline and follow-up testing (6 and 12 months) are blind to the trainer; 
therefore loads must be established by the trainer on the training equipment, independent 
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of the assessment strength tests. 
 
The Borg scale of perceived exertion should be used to rate effort during a lift. On this 
scale from 6-20, a rating of 15-18 (Hard to Very Hard) is equivalent to 80% of maximum 
lifting capacity in studies conducted in young and older adults, and is therefore an 
appropriate training goal. The technique is as follows: 
As soon as the subject performs the lift with the first weight selected, he/she should be 
asked to rate how difficult it was to lift 
If it was given a score less than 15, than the next higher weight available can be used until 
the appropriate range is reached 
If a weight that is too heavy is selected, as long as proper form, breathing and speed of 
lifting are adhered to, the only thing that can happen is that they will be unable to cover the 
full range of motion or complete a full set of repetitions 
 
Older adults, particularly older men and women, rarely, if ever, voluntarily chose weights 
that are too heavy. On the other hand, there is a great tendency to choose weights that are 
far too light to be optimally therapeutic. 
 
Warm up 
The warm up for strength training is to do 4 reps at lowest load on the machine at slow 
velocity. 
 
Cool down 
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Training sessions average 60 min and end with 5 min of stretching. 
 
PRT 
PRT is comprised of dynamic contractions of large upper and lower body muscle groups 
using pneumatic-resistance training equipment (Keiser Sports Health Equipment Inc., 
Fresno, CA) at Freshwater Health and Fitness, Harbord Diggers Memorial Club and at the 
STRONG Clinic, Balmain Hospital. 
 
With each piece of strength training equipment, the following protocol will be used:  
The subject will be placed on the piece of equipment and the settings recorded to ensure 
proper biomechanics with each training exercise and testing session. 
 
The subject will be shown how each piece of strength training equipment works, what 
muscle group it isolates and where this muscle group is located 
 
It will be explained and demonstrated to the subjects why emphasis is placed on proper 
breathing technique (exhaling on exertion, avoidance of Valsalva manoeuvre) 
 
The settings for each equipment position are recorded on the data sheet 
 
The subject performs 3 sets of 8 repetitions on each machine. Each repetition is to be as 
fast as possible for the concentric phase and approximately 4 seconds in the eccentric phase, 
with a 2-3 seconds rest between repetitions and 60-90 seconds rest between sets 
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The subject will be encouraged to discuss with the trainer any problems which arise before, 
during and after each training session regarding muscle soreness, dizziness, light 
headedness or any discomfort of any kind. 
 
The order may be dictated by: 
The set up of the room 
The number of trainers available to supervise 
The time it takes to get on and off the machines 
The general level of frailty of the group, and 
Other practical issues 
Alternating upper and lower body exercises is preferred in order to limit fatigue in 
particular muscle groups that may impair performance of subsequent exercises. 
Preferred order: 
Leg press 
Chest press 
Hip abduction 
Knee extension 
Seated row 
Hip flexion 
Hip extension 
 
SEATED LEG PRESS (BILATERAL) 
Machine set up 
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Move the seat to the recorded position 
Assist the subject onto the machine by backing up towards the seat and sitting down first; 
then assist or observe as the legs are lifted up onto the foot plates 
 
Movement performance 
The subject’s feet should be placed at the bottom of each foot plate, with the heel resting 
on the rubber “lip” at the bottom of the foot plate; or if joint pain is encountered, a position 
allowing pain free movement. 
 
Extra caution should be used for those subjects who have chronic lower back discomfort, 
ensuring that they are not twisting the spine and are keeping their back, neck, and head 
against the padded seat 
 
The subject may stabilise the upper body by using hand grips on each side of the seat, 
making sure that his/her thumbs are not touching the force control knobs The subject’s 
shoulders and neck should be relaxed 
 
The subjects should then be instructed to push both legs simultaneously so that the 
concentric phase is performed as fast as possible, hold the muscle in the contracted state 
for 1 second and then slowly allow the legs to control the return of the weight back to the 
starting position over approximately 3-4 seconds. The subject should not allow the 
footplates to snap back rapidly or move the feet off the footplates before the machine has 
completely returned to the resting position 
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It is important that you communicate to the subject that the knees travel in line with the 
toes, and that they do not drift medially (which is common in subjects with arthritis or weak 
ligaments around the knee) 
 
The push should be generated through the whole foot particularly the heel, not through the 
forefoot/toes, to ensure activation of the gluteus and hamstring muscles, not just the plantar 
flexors/quads. You may show the subject where the active muscles are, and have him/her 
place their hand on these muscle groups to feel them contracting as they are doing the 
movement correctly. 
. 
The subject should push until the knees are just short of being “locked” in full extension; 
that is there should be a very slight bend at the knee. Subjects who have osteoarthritis may 
have limited extension and may not achieve this full range of motion. A subject whose 
knees are correctly positioned (not locked) will have to use muscle force to keep the 
footplate out. When the knees are locked, no muscle force is being used, and the bones of 
the leg are keeping the footplate up. This should be explained and demonstrated explicitly 
so the subject knows what it feels like to perform the exercise correctly (versus incorrectly). 
The subject must not lift his/her buttocks off the seat excessively to accomplish a lift. 
 
CHEST PRESS 
 
Machine set up 
Adjust the height of the seat such so the subject’s forearms run parallel with the floor. 
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Record this setting in the source document. 
Adjust arm levers (if possible) to the comfort level of the subject and note position. This 
may depend on the joint limitations and ROM of the rotator cuff. 
 
Movement performance 
Subject should sit upright facing forward with lower back pressed against the back pad. 
The feet should rest in a position that does not exert pressure on the foot pedals on the older 
model Keiser equipment. 
While gripping the handles, excessive extension of the wrist should be avoided throughout 
the range. 
The subject should then be instructed to push to full range without locking the elbow so 
that the concentric phase is performed as fast as possible, hold the muscle in the contracted 
state for 1 second and then slowly allow the arms to control the return of the weight back 
to the starting position over approximately 3 - 4 seconds. 
Good form is working through full range of motion determined in the unweighted position. 
The shoulders should not be elevated to compensate for the effort. 
 
HIP ABDUCTION 
 
Machine set up 
Adjust the height of the platform. 
Set the starting dial at 2 on the side of the movement leg that is being worked as the prime 
mover. 
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Movement performance 
Subject should stand upright facing towards the dial on the machine with the hip pad resting 
just above the knee on the outside leg that will be used for the exercise. 
The support leg should be fully extended and positioned so that the forefoot is protruding 
slightly off the footplate, and the support leg is cantered in front of the machine dial. (With 
the foot completely on the footplate, the padded bar is not long enough to fully reach the 
exercising thigh and allow it to move freely out to the side without hitting the footplate. 
This is the reason the foot of the support leg must be moved forward so that the toes hang 
off the footplate). 
The subject’s hands should be both grasping the handlebars on either side of the machine 
lightly to provide balance. This may be challenging for frail subjects due to the need to 
stand on one leg, and move the foot forward as described above. The subject’s hands should 
always be on the grips for this exercise for stability. 
The subject’s back should remain straight and motionless throughout the exercise. 
The subject should move the working leg out to the side as fast as possible without bending 
at the waist or rotating the trunk, and then slowly return to the starting position. 
Toes must not be turned out during the movement; they should be positioned directly 
forward with the ankle in neutral position throughout (no dorsiflexion or extension). This 
is the most common error made in this exercise. 
Good form is working to or near full range of motion on the dial (established with an 
unloaded repetition). 
Repeat for the other leg, moving the dial to “2” on the side of the movement leg. 
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KNEE EXTENSION 
 
Machine set up 
Move backrest position, pad and range limiter. 
 
Movement Performance 
The subject’s hands should be resting lightly on the grips. 
Similarly, the subject’s shoulders and neck should be as relaxed as possible. 
The subject should then be instructed to straighten his/her legs without any ballistic 
movement as fast as possible, keeping the ankle in neutral position (90º of flexion), hold 
the muscle in the contracted state for 1 second and then slowly allow the legs to control  
the return of the weight back to the starting position over approximately 3 - 4 seconds. 
Good form is working to full extension (determined in the unweighted position) and not 
arching the back more than very minimally or lifting the thigh off the seat. 
 
SEATED ROW 
 
Machine set up 
Adjust the seat height and chest pad. 
Good form is working through full or within 50 of full range of motion determined in the 
unweighted position. 
 
Movement performance 
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The subject’s hands should be resting lightly on the grips. 
The chest should remain in contact with the pad, the back should remain straight and 
motionless and arching the back and neck should be avoided. 
Using the wide grip, the handles should move to the level or if possible behind the chest 
pad while contracting the shoulder blades together and down. The subject pulls the handles 
as fast as possible in concentric phase, holds for a second and then slowly returns the weight 
over 3 –4 seconds to resting position. 
 
HIP FLEXION 
 
Machine set up 
Adjust the height of the platform and the pad rest (if possible). 
Set the starting dial at 2. 
 
Movement performance 
Subject should stand upright facing sideways to the dial on the machine with the hip pad 
resting just above the knee on the front of the leg that will be used for the exercise  
The support leg should be fully extended, and positioned on the footplate. 
The subject’s hands should be resting on either side of the machine lightly to provide 
balance. This may be challenging for frail subjects due to the need to stand on one leg, and 
move the foot forward as described above. 
The subject’s back should remain straight and motionless throughout the exercise. 
The subject should move the working leg as fast as possible without bending at the waist 
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or rotating the trunk, and then return to the starting position. 
Good form is working through full range of motion determined during a slow unloaded 
repetition. 
Repeat for the other leg adjusting to the “2” position on the other side 
 
SHAM TRAINING GUIDELINES 
 
The SHAM training intervention consists of exercises that are modified so as to remove 
the essential elements leading to physiological adaptations. The exercise serves as an ideal 
“control” activity, because it is offered under supervision, by the same staff, and in the 
same location as the PRT. Subjects will not be told which of the two forms of exercise is 
hypothesized to be the preferred one for the outcomes being studied. Exercises are 
performed on 8 of the 9 following Keiser Pneumatic Resistance Machines and choice of 
machine may be varied. 
 
Warm-Up 
There is no warm-up for the SHAM group. 
 
Cool Down 
Training sessions end with 5 minutes of stretching. 
 
Seated Leg Press (bilateral) 
Machine Setup 
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 Assist the subject onto the machine by backing up towards the seat and sitting down 
first; then assist or observe as the legs are lifted up onto the footplates. 
 Move the seat to a position where the hips and knees are bent at approximately 90º. 
The seat may be moved while the subject is seated, as long as they are stabilised by 
you and warned that the seat is going to move slowly. 
 If subjects cannot flex hips to 90º due to hip pain or abdominal girth, move the seat 
back to a tolerable position. 
 Record the final seat position from the numbered plate in the source document. 
 
Movement Performance 
 Subjects’ feet should be placed at the bottom of each foot plate, with the heel resting 
on the rubber “lip” at the bottom of the foot plate; or if joint pain is encountered, a 
position allowing pain free movement. 
 Extra caution should be used for those subjects who have chronic lower back 
discomfort, ensuring that they are not twisting the spine and are keeping their back, 
neck, and head against the padded seat. 
 The subject may stabilise the upper body by using handgrips on each side of the 
seat, making sure that his/her thumb is not touching the force control knob 
accidentally. The subject’s shoulders and neck should be relaxed. 
 The subject should then be instructed to push both legs forward simultaneously and 
to control the return of the weight back to a resting state. 
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 It is important that you communicate to the subject that the knees travel in line with 
the toes, and that they do not drift medially (which is common in subjects with 
arthritis or weak ligaments around the knee). 
 The push should be generated through the whole foot, particularly the heel, not 
through the forefoot/toes, to ensure activation of the gluteus and hamstring muscles, 
not just the plantar flexors/quads. You may show the subject where the active 
muscle area. 
 The subject should push until the knees are just short of being “locked” in full 
extension; that is there should be a very slight bend at the knee. 
 Subjects who have osteoarthritis may have limited extension and may not achieve 
this full range of motion. A subject whose knees are correctly positioned (not 
locked) will have to use muscle force to keep the footplate out. When the knees are 
locked, no muscle force is being used, and the bones of the leg are keeping the 
footplate up. This should be explained and demonstrated explicitly so the subject 
knows what it feels like to perform the exercise correctly (versus incorrectly). 
 Excessive movement of the buttocks completely rising up off the seat is not 
considered good form but slight movements are tolerated. 
 
Chest Press 
Machine Setup  
 Adjust the height of the seat such so the subject’s forearms run parallel with the 
floor.  Record this setting in the source document. 
 Range of motion should be determined in the unweighted position 
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 Adjust arm levers to the comfort level of the subject and note position. This may 
depend on the joint limitations and ROM of the rotator cuff. The range limiter will 
be set at 3 for most subjects. 
 
Movement Performance 
 Subject should sit upright facing forward with the back pressed against the back 
pad.  
 The position while gripping the handles should avoid excessive extension of the 
wrist throughout the range.  
 Subject should push to full range without locking the elbows and then slowly allow 
the arms to control the return of the weight back to resting position.  
 The shoulders should not be elevated to compensate for the effort.  
Knee Extension 
 
Machine Setup 
 Move backrest position so that back and upper legs of the subject are fully 
supported after the subject is assisted onto the machine 
 The pad should rest just behind the subject’s knee in the popliteal fossa; the 
subject’s back should be securely supported by the backrest. 
 Record the final seat position number in the source document from the numbered 
plate or notches on the back rest. 
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 With the subject well positioned in the seat, move the weighted bar position so that 
it sits just above the malleoli (ankle) level and the foot can still dorsiflex below the 
weighted bar. Record the position number of the bar in the source document. This 
may be recorded to the nearest 0.5 (e.g. 3.5) if it is between 2 engraved numbers on 
the machine. 
 Start position is always 90º of knee flexion, to avoid overstretching of the patellar 
tendon that may cause knee pain. Adjust by pulling out the knob on the range limiter 
until the correct number appears in the window. No limitation on extension range 
is imposed during strength testing or training however. Unscrew the range-limiting 
knob and leave it off the machine. Most subjects will have full extension short of 
this. Record the start and end positions of the range limiter in the source document. 
  
Movement Performance 
 The subject’s hands should be resting lightly on the grips, making sure that his/her 
thumb is not touching the force control accidentally. 
 Similarly, the subject’s shoulders and neck should be as relaxed as possible. 
 The subject should then be instructed to straighten his/her legs without any ballistic 
movement as far as possible, keeping the ankle in neutral position (90º of flexion), 
and then control the return of the weight back to a resting state. 
 Failure is defined as not reaching full extension. 
 Do not allow subjects to arch their backs more than very minimally or lift their 
thigh off the seat to qualify as “good form”. 
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Seated Row 
Machine Setup 
 Adjust the seat height so that xiphoid process is positioned in the middle of the 
chest pad then record this position. 
 Adjust the chest pad so that arms are comfortable at full extension and record this 
position.    
 Range of motion should be determined in the unweighted position and recorded. 
 Wide grip will be used for 1RM testing, although in training wide grip is used for 
the PRT group and narrow grip for the SHAM group. 
 
Movement Performance 
 The subject’s hands should be resting lightly on the grips, making sure that his/her 
thumbs are not touching the force control accidentally.  
 The chest should remain in contact with the pad, the back should remain straight 
and motionless and arching the back and neck should be avoided.  
 The handles should move to the level or if possible behind the chest pad while 
contracting the shoulder blades together and then slowly allow their arms to control 
the return of the weight back to resting position. 
 Failure is defined as not reaching within 50 of the recorded full extension (derived 
from the unweighted range). 
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Knee Flexion 
Machine Setup 
 Move backrest position so that back and upper legs of the subject are fully 
supported after the subject is assisted onto the machine. 
 Note the lever position so that ankles just hang over the edge of the foot padding. 
 Record the position number of the bar in the source document. This may be 
recorded to the nearest 0.5 (e.g. 3.5) if it is between 2 engraved numbers on the 
machine. 
 Ensure that upper legs are held firmly in place by the padding and clicked into place. 
 Start position is maintained at -10º of knee flexion. Adjust by pulling out the knob 
on the range limiter until the correct number appears in the window.  
 Unscrew the range limiting knob and leave it off the machine. Record the start and 
end positions of the range limiter in the source document. 
 
Movement Performance 
 The subject’s hands should be resting lightly on the grips. 
 The subject’s shoulders and neck should be relaxed. 
 The subject should then be instructed to bend his/her legs without any ballistic 
movement as far as possible, keeping the ankle in neutral position, and then allow 
the legs to control the return of the weight back to an extended position. 
 Failure is defined as not reaching full flexion.  
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 Do not allow the subject to arch the back more than very minimally to qualify as 
“good form”. 
 The subject may need to be reminded to reposition on the seat to ensure the lower 
back is in contact with the back pad.
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6 MINUTE WALK TEST 
 
SIX MINUTE WALK TEST 
 
Equipment 
 Measure Meter 
 Stopwatch 
 
Purpose 
The six minute walk is a proxy for overall cardiovascular endurance capacity (aerobic 
capacity). In addition to cardiovascular efficiency, however, in the elderly subject it may 
be determined by muscle strength and endurance, balance, orthopaedic or neurologic 
abnormalities, and other problems. It works best as an estimate of aerobic capacity in 
individuals who cannot run, so that variations in walking velocity describe most of the 
possible range of function. Therefore it is very appropriate in very frail or elderly 
volunteers as well as healthy elderly. 
 
Preparing the volunteer 
Volunteer should be wearing normal, low-heeled walking shoes, comfortable clothing, eye 
glasses and hearing aides, if any. They should have been offered to use the restroom prior 
to starting the test. If an assistive device is normally used for walking, the person should 
use this during the test, and the device used should be recorded on the data sheet. The same 
assistive device should be used at all timepoints if possible, unless the person has advanced 
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to a higher level device (e.g. walker instead of a cane) due to changing medical condition. 
If the volunteer rarely uses a cane, do not use it during the testing. 
 
Environmental considerations 
This test requires a long open circuit around which the volunteer can walk continuously for 
six minutes. Long circular or square corridors around the perimeter of a building without 
many turns are ideal. All testing should be done indoors rather than outdoors, as there are 
too many uncontrolled variables in outdoor areas. The path should be free of clutter and all 
other traffic should be closed off if possible during the testing. No steps, inclines, doors, or 
other obstacles should be in the path of the volunteer, and lighting and ventilation should 
be adequate. 
 
Protocol 
The person should be instructed that they are to “cover as much ground as possible in six 
minutes” by “walking as fast as they can the entire time”. They must be encouraged and 
reminded of the task at least every 30 seconds during the test or they will tend to slow 
down. Line up the Measure Meter (with the dial reset to read 000) with the volunteer’s feet 
on the starting line. Prior to beginning the test, ascertain that the volunteer’s pulse rate, 
breathing rate, and blood pressure are in their normal range. Say “1,2,3, GO!” and begin 
the stopwatch.  Follow closely behind the volunteer with the Measure Meter, attempting 
to follow their path as closely as possible without getting in their way or influencing their 
gait speed. The number of metres travelled at the end of 6 minutes is recorded to the nearest 
foot from the wheel. Use standardized statements such as: 
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 “Keep Going!”  
 “You’re Doing Well!” 
 “Keep up the Good Work” 
 
If the volunteer needs to stop to rest during the test, the watch continues to run, and they 
should be instructed to start back up again as soon as they are able. 
 
If they develop angina during the test, or any other symptoms which seem severe, the 
test should be terminated immediately and emergency medical help should be 
contacted. However, shortness of breath, fatigue, and slight muscle or joint pain are not 
unusual and are not an indication for stopping the test. If claudication occurs, the person 
may need to stop momentarily, but can go on as soon as they feel able. 
 
Record if an assistive device used, the number of stops made during the test, any symptoms 
which developed during the test, reason for stopping prematurely, if any, and the total 
distance covered in 6 minutes to the nearest 0.1 metre. This test is only performed once. 
 
Common problems/questions 
The volunteer should be well rested prior to beginning this test, as it requires physical 
stamina and mental alertness. The exact wording above should be used to instruct the 
volunteer so that consistency is maintained. The volunteer is not allowed to break into a 
run; if this happens, stop the test and begin again. If a chair is anticipated to be needed for 
rest stops, a second examiner can follow closely behind the timer with a wheelchair which 
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can be positioned behind the volunteer as needed. If a volunteer can only ambulate by 
pushing themselves in a wheelchair, the test can be conducted in this way, but no assistance 
in moving the wheelchair from anyone else is allowed.
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POWER TESTING 
 
Equipment 
Keiser pneumatic resistance training equipment (Keiser Sports Health Equipment, Inc., 
Fresno, CA) with K400 electronics is used for muscle endurance testing (in C-Block). The 
compressor should be turned on at both the power point and the distribution box 2-3 hours 
prior to use. 
Purpose 
 This test measures the ability of muscles to generate force (movement) quickly. 
 Force, velocity, and power will be assessed using a single explosive contraction at 
20, 40, 50, 60, 70, 80, 90, and 100 % of the subject’s most recently measured 1RM 
or, at baseline, the better of the two 1RM measurements using the Keiser Leg Press 
Machine. 
 
Five exercises will be tested: bilateral horizontal leg press, seated chest press, bilateral knee 
extension, seated row, and seated bilateral knee flexion. Keiser A400 software calculates 
work and power during the concentric phase of the repetition by sampling the system 
pressure (force) and position (via ultrasonic position transducers) at a rate of 400 times per 
second. Accuracy of system pressure and position are reported by the manufacturer to be 
within 1%. Power (Watts) and velocity (cm/sec) are calculated as the average respective 
value between 5% and 95% of the concentric phase of the repetition to eliminate noisy data 
at the beginning and end points of motion. 
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The highest average power produced throughout the loads tested will be recorded as 
the peak power. 
 
Additional power testing at follow-up test periods  
 To assess potential change in peak velocity capacity the subject will perform an 
‘extra’ lift at the load during which peak velocity was demonstrated at baseline. 
 Power testing must follow 1RM testing when performed at each timepoint, as the 
loads are set based on the results of the 1RM testing. 
 Power testing should be done in an unfatigued state at each timepoint. 
 
Protocol 
 Demonstrate movement (fast concentric/slow eccentric). 
 Prior to starting the test, explain the purpose of the test to the subject and how it 
will be achieved. E.g. “The purpose of this test is to measure how powerful muscles 
are in your legs. This means how quickly your muscles can generate force, so this 
time I will ask you to push the weight as fast as you can. However, I still want you 
to slowly return the weight to the starting position. Similar to the maximum strength 
test, you will start with a light weight and then move onto heavier weights.” (Avoid 
saying something like “You should be able to push the lighter weights faster than 
you can push the heavier weights”.) 
 Subject will be instructed to push the footplate as fast as possible and slowly return 
it for one time only at each of the workloads and will be verbally cued. “1, 2, 3, 
GO!!”  
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 To improve coordination of breathing and exertion, subjects may be instructed to 
inhale on the count of “1”, exhale on the count of “2”, inhale again on the count of 
“3”, and exhale with rapid exertion on “GO!” 
 A rest period of 30-60 seconds will be taken between repetitions.  
 Ensure subject is in the correct starting position for the exercise (see 1RM testing).  
 Allow one ‘practice’ trial at 20% 1RM and record the results from the motion the 
real time display on the computer panel. The force, work, and power will be 
available on the time computer display panel. (Distance moved is also shown, but 
is not needed for the POWER test). The velocity will need to be taken from of 
motion the data file downloaded onto the computer at the conclusion of the test (see 
below for A420 software instructions), as it is not shown on the real time display 
window. 
 If the subject’s baseline 20% 1RM is less than the minimal resistance of machine, 
use the minimal resistance possible on the machine. If the subject’s 1RM was so 
low that the machine’s lowest resistance is greater than some of the lighter loads 
e.g. 20, 40% 1RM then you can only do those loads that the machine will allow. If 
the subject’s 1RM is the lowest resistance that the machine allows then the subject 
can only be tested at 100% 1RM. Allow the subject 3 trials at this load, with 1-min 
rest between each one. Record force, work, and power for each trial, (the highest 
power achieved out of the 3 attempts will be recorded as their peak power). 
 Next, set the machine resistance at 20% of the most recent 1RM and continue with 
heavier loads. 
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 Assess the subject at each %1RM (40, 50, 60, 70, 80. 90, and 100%), right up to 
100%1RM even if you think they achieved their peak power at a lighter load. For 
subjects whose power is still increasing at 100% of the 1RM, additional loads must 
be used at 10% increments (110%, 120%, etc.) until a drop in Power is seen. This 
will be a very unusual, but possible occurrence. 
 Record the force, velocity, work, and power at each % 1RM on the source document 
(record the attempt where the highest power was achieved out of the 2 attempts at 
20% 1RM as the “20%” value when the source document). 
 Allow 30 seconds rest after the trial at 20%, and 60 seconds rest after each trial at 
heavier loads (RPE scorings of 15+) 
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ENDURANCE TESTING 
 
Equipment 
Keiser pneumatic resistance training equipment (Keiser Sports Health Equipment, Inc., 
Fresno, CA) with K400 electronics is used for muscle endurance testing (in C-Block). The 
compressor should be turned on at both the power point and the distribution box 2-3 hours 
prior to use. 
 
Purpose 
 Muscle endurance is a test of sub-maximal muscle performance. Analogous to a 
sub-maximal aerobic capacity test, the same workload is used at baseline and final 
testing, and the performance relative to this fixed workload is used to determine 
adaptation to the intervention. 
 
Types of Endurance testing 
 
ABSOULTE ENDURANCE 
 90% of the subject’s best baseline 1RM will be used as the workload at all 
timepoints. If they cannot complete 1 repetition, load will be decreased to 80%1RM. 
The adjusted load will be used at all subsequent timepoints as well. 
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RELATIVE ENDURANCE 
 90% of the subjects current 1RM will be used as the workload. If they cannot 
complete 1 repetition, load will be decreased to 80%1RM. The adjusted load will 
be used at all subsequent timepoints as well.  
 
PLEASE NOTE: 
Assessors for the GREAT2DO study will measure RELATIVE ENDURANCE. 
However, ABSOULUTE ENDURANCE has been measured in a subset of participants. 
These participants will have this noted on their assessment/data testing sheets. Participants 
MUST be undergo the same type of endurance testing at ALL timepoints. Ie. If absolute 
endurance was measured at baseline or six months, absolute endurance must be measured 
at 12 months. There is provision for both relative and absolute muscle endurance data entry 
within the outcomes database. 
 
Protocol 
 Muscle endurance will be assessed on leg press, chest press, knee extension, seated 
row, and knee flexion. 
 90% of the subjects previously determined 1RM (best of 2 baseline 1 RMs) will 
be used as the workload. If they cannot complete 1 repetition, load will be 
decreased to 80%1RM. The adjusted load will be used at all subsequent timepoints 
as well. 
 Keiser Machine display should be set on “Position Mode” so that the range of 
motion bar can be seen to evaluate the completeness of lift. 
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 The examiner will perform sample continuous repetitions at the desired cadence to 
full range of motion, describing the “mistakes” of pauses, incomplete range of 
motion and bad form. 
 First the subject is asked to perform a full range of motion with the machine set to 
minimum resistance possible. For the leg press, this is the resistance which is 
necessary to keep the footplates up against gravity. This range of motion lift may 
be repeated 2 times to correctly ascertain the range of motion. 
 The subject will be instructed to perform as many consecutive repetitions as 
possible through their full range of motion using good form. 
 Repetitions will be performed at the cadence of approx. 2 seconds concentric, 3 
seconds eccentric, with no rest at the fully extended/flexed position or between 
repetitions. Rest is defined as a visual pause in the motion as assessed subjectively 
by the examiner. 
 Test is terminated when subject performs a lift  and the moving bar is short of the 
arrowhead marking the point of full range of motion or pauses at any point in the 
lifts, or uses bad form (other than minor deviations such as slight use of accessory 
muscles or arching of the back. 
 The total number of complete repetitions, the total work performed, as well as the 
velocity and power generated during the first and last complete repetitions for each 
exercise will be recorded on the data sheet. Note that if a repetition is stopped half-
way, this is not the last complete repetition. The previous full repetition is used to 
record the work, velocity and power. 
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 Post training assessment of muscle endurance at 6 and 12 months will be 
performed using 90% of the subject's baseline 1RM. If 80%1RM as used at 
baseline, 80%1RM will also be used during post training assessments.
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